From: <Saved by Blink>
Snapshot-Content-Location: https://investor.xenon-pharma.com/news-releases?38df5374f7c4fd82aa79d6fb8d12b19edb5315f510fe910f969b08452c4028fe_year%5Bvalue%5D=_none&op=Filter&38df5374f7c4fd82aa79d6fb8d12b19edb5315f510fe910f969b08452c4028fe_widget_id=38df5374f7c4fd82aa79d6fb8d12b19edb5315f510fe910f969b08452c4028fe&form_build_id=form-zwSt7FqJDol13lB9XMJ9y5Ha5rrm4y-KinVsb4ypczw&form_id=widget_form_base
Subject: Press Releases | Xenon Pharmaceuticals Inc.
Date: Sat, 22 Mar 2025 16:55:55 -0400
MIME-Version: 1.0
Content-Type: multipart/related;
	type="text/html";
	boundary="----MultipartBoundary--OyEh8n7b4Lw6tzistt7cxFCRw1zMtvVQlXOUlVtdJx----"


------MultipartBoundary--OyEh8n7b4Lw6tzistt7cxFCRw1zMtvVQlXOUlVtdJx----
Content-Type: text/html
Content-ID: <frame-EBAE77B6D318007EE191D21018FCE03E@mhtml.blink>
Content-Transfer-Encoding: quoted-printable
Content-Location: https://investor.xenon-pharma.com/news-releases?38df5374f7c4fd82aa79d6fb8d12b19edb5315f510fe910f969b08452c4028fe_year%5Bvalue%5D=_none&op=Filter&38df5374f7c4fd82aa79d6fb8d12b19edb5315f510fe910f969b08452c4028fe_widget_id=38df5374f7c4fd82aa79d6fb8d12b19edb5315f510fe910f969b08452c4028fe&form_build_id=form-zwSt7FqJDol13lB9XMJ9y5Ha5rrm4y-KinVsb4ypczw&form_id=widget_form_base

<!DOCTYPE html><html lang=3D"en" dir=3D"ltr" prefix=3D"og: https://ogp.me/n=
s#" style=3D"" class=3D"inputtypes-search inputtypes-tel inputtypes-url inp=
uttypes-email no-inputtypes-datetime inputtypes-date inputtypes-month input=
types-week inputtypes-time inputtypes-datetime-local inputtypes-number no-i=
nputtypes-range inputtypes-color details no-touchevents toolbar-loading too=
lbar-anti-flicker js whatinput-types-initial" data-once=3D"drupal-dialog-de=
precation-listener" data-whatinput=3D"initial" data-whatintent=3D"mouse"><h=
ead><meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3DUTF-8=
"><link rel=3D"stylesheet" type=3D"text/css" href=3D"cid:css-7144c8f9-7436-=
42a7-8f90-d2c6afc77f4b@mhtml.blink" /><link rel=3D"stylesheet" type=3D"text=
/css" href=3D"cid:css-9e6a5f14-919f-423f-a6e5-8c6c4e9316bf@mhtml.blink" />
   =20
<meta property=3D"og:site_name" content=3D"Xenon Pharmaceuticals Inc.">
<meta property=3D"og:type" content=3D"website">
<meta property=3D"og:url" content=3D"https://investor.xenon-pharma.com/news=
-releases">
<meta property=3D"og:title" content=3D"Press Releases | Xenon Pharmaceutica=
ls Inc.">
<meta property=3D"og:description" content=3D"The Investor Relations website=
 contains information about Xenon Pharmaceuticals Inc.'s business for stock=
holders, potential investors, and financial analysts.">
<meta name=3D"Generator" content=3D"Drupal 10 (https://www.drupal.org)">
<meta name=3D"MobileOptimized" content=3D"width">
<meta name=3D"HandheldFriendly" content=3D"true">
<meta name=3D"viewport" content=3D"width=3Ddevice-width, initial-scale=3D1.=
0">
<link rel=3D"icon" href=3D"https://investor.xenon-pharma.com/sites/g/files/=
knoqqb12671/files/favicon%20%281%29.ico" type=3D"image/vnd.microsoft.icon">
<link rel=3D"alternate" hreflang=3D"en" href=3D"https://investor.xenon-phar=
ma.com/news-releases">
<link rel=3D"canonical" href=3D"https://investor.xenon-pharma.com/news-rele=
ases">
<link rel=3D"shortlink" href=3D"https://investor.xenon-pharma.com/node/5816=
">

    <title>Press Releases | Xenon Pharmaceuticals Inc.</title>
    <link rel=3D"stylesheet" media=3D"all" href=3D"https://investor.xenon-p=
harma.com/sites/g/files/knoqqb12671/files/css/css_1BYDXkiJUITULboGN1B4U4lCf=
cXnJ5FvdU8omlFmO4s.css?delta=3D0&amp;language=3Den&amp;theme=3Dnir_pid1175&=
amp;include=3DeJyVjsEKAjEMRH-oWPYgfk5I27CGTZMljYJ_b3cvInjxNrx5DKPs0NE3CmgYC=
EWsbrkTKjhV6510cjaFekePpD99VJTXCPCp6goF_Q99QGARStWccvPHjnJpjGJrGtOingsOOqeO=
kI_A1XR8kHD57sNM5osT7tyW5XbN9iR3bvQGCmRfGw">
<link rel=3D"stylesheet" media=3D"all" href=3D"https://investor.xenon-pharm=
a.com/sites/g/files/knoqqb12671/files/css/css_V550fu0H92bP2BuXkow6log7Go8ey=
iTUB9hoqvOjNy8.css?delta=3D1&amp;language=3Den&amp;theme=3Dnir_pid1175&amp;=
include=3DeJyVjsEKAjEMRH-oWPYgfk5I27CGTZMljYJ_b3cvInjxNrx5DKPs0NE3CmgYCEWsb=
rkTKjhV6510cjaFekePpD99VJTXCPCp6goF_Q99QGARStWccvPHjnJpjGJrGtOingsOOqeOkI_A=
1XR8kHD57sNM5osT7tyW5XbN9iR3bvQGCmRfGw">
<link rel=3D"stylesheet" media=3D"print" href=3D"https://investor.xenon-pha=
rma.com/sites/g/files/knoqqb12671/files/css/css_hwNokfnlMe-cYUUnn3-6p03Kbjd=
XcTDzrGGqs4p1EqI.css?delta=3D2&amp;language=3Den&amp;theme=3Dnir_pid1175&am=
p;include=3DeJyVjsEKAjEMRH-oWPYgfk5I27CGTZMljYJ_b3cvInjxNrx5DKPs0NE3CmgYCEW=
sbrkTKjhV6510cjaFekePpD99VJTXCPCp6goF_Q99QGARStWccvPHjnJpjGJrGtOingsOOqeOkI=
_A1XR8kHD57sNM5osT7tyW5XbN9iR3bvQGCmRfGw">

   =20


    <!-- IrwinIQ Tag Manager -->=20

=20

<!-- End IrwinIQ Tag Manager -->=20
 =20
                   =20
                    </head>
  <body class=3D"body-sidebars-first nir-node nir-node--type-nir-landing-pa=
ge nir-node--5816 path-node page-node-type-nir-landing-page">
    <div id=3D"skip">
      <a class=3D"visually-hidden focusable skip-link" href=3D"https://inve=
stor.xenon-pharma.com/news-releases?38df5374f7c4fd82aa79d6fb8d12b19edb5315f=
510fe910f969b08452c4028fe_year%5Bvalue%5D=3D_none&amp;op=3DFilter&amp;38df5=
374f7c4fd82aa79d6fb8d12b19edb5315f510fe910f969b08452c4028fe_widget_id=3D38d=
f5374f7c4fd82aa79d6fb8d12b19edb5315f510fe910f969b08452c4028fe&amp;form_buil=
d_id=3Dform-zwSt7FqJDol13lB9XMJ9y5Ha5rrm4y-KinVsb4ypczw&amp;form_id=3Dwidge=
t_form_base#main-menu">
        Skip to main navigation
      </a>
    </div>
   =20
      <div class=3D"dialog-off-canvas-main-canvas" data-off-canvas-main-can=
vas=3D"">
    <header class=3D"hide-for-small-only">
        <div class=3D"grid-container ">
            <div class=3D"grid-x grid-padding-x">
                <div class=3D"large-4 small-12 cell">
                    <div class=3D"logo">
                        <a href=3D"http://www.xenon-pharma.com/"></a>
                    </div>
                </div>
                <div class=3D"large-8 small-12 cell">
                    <div class=3D"menu-sub-menu-container">
                        <ul id=3D"menu-sub-menu" class=3D"menu">
                            <li id=3D"menu-item-28" class=3D"menu-item menu=
-item-type-post_type menu-item-object-page menu-item-28"><a href=3D"http://=
www.xenon-pharma.com/careers/">Careers</a></li>
                            <li id=3D"menu-item-29" class=3D"menu-item menu=
-item-type-post_type menu-item-object-page menu-item-29"><a href=3D"http://=
www.xenon-pharma.com/contact/">Contact</a></li>
                            <li id=3D"menu-item-54" class=3D"menu-item menu=
-item-type-custom menu-item-object-custom menu-item-54"><a href=3D"https://=
investor.xenon-pharma.com/news-releases">News</a></li>
                        </ul>
                    </div>
                    <nav>
                        <div class=3D"menu-main-nav-container">
                            <ul id=3D"menu-main-nav" class=3D"menu">
                                <li id=3D"menu-item-14" class=3D"menu-item =
menu-item-type-post_type menu-item-object-page menu-item-14"><a href=3D"htt=
p://www.xenon-pharma.com/about/">About</a></li>
                                <li id=3D"menu-item-23" class=3D"menu-item =
menu-item-type-post_type menu-item-object-page menu-item-has-children menu-=
item-23"><a href=3D"http://www.xenon-pharma.com/product-pipeline/">Science =
&amp; Pipeline</a>
                                    <ul class=3D"sub-menu">
                                        <li id=3D"menu-item-68" class=3D"me=
nu-item menu-item-type-post_type menu-item-object-page menu-item-68"><a hre=
f=3D"https://www.xenon-pharma.com/product-pipeline/azetukalner-fos/">AZETUK=
ALNER (FOS)</a></li>
                                        <li id=3D"menu-item-1754" class=3D"=
menu-item menu-item-type-post_type menu-item-object-page menu-item-1754"><a=
 href=3D"https://www.xenon-pharma.com/product-pipeline/azetukalner-pgtcs/">=
AZETUKALNER (PGTCS)</a></li>
                                        <li id=3D"menu-item-1755" class=3D"=
menu-item menu-item-type-post_type menu-item-object-page menu-item-1755"><a=
 href=3D"https://www.xenon-pharma.com/product-pipeline/azetukalner-mdd/">AZ=
ETUKALNER (MDD)</a></li>
                                        <li id=3D"menu-item-65" class=3D"me=
nu-item menu-item-type-post_type menu-item-object-page menu-item-65"><a hre=
f=3D"https://www.xenon-pharma.com/product-pipeline/preclinical-programs/">P=
RECLINICAL PROGRAMS</a></li>
                                        <li id=3D"menu-item-66" class=3D"me=
nu-item menu-item-type-post_type menu-item-object-page menu-item-66"><a hre=
f=3D"https://www.xenon-pharma.com/product-pipeline/partnered-programs/">PAR=
TNERED PROGRAMS</a></li>
                                       =20
                                    </ul>
                                </li>
                                 <li id=3D"menu-item-40" class=3D"menu-item=
 menu-item-type-post_type menu-item-object-page menu-item-has-children menu=
-item-40"><a href=3D"https://investor.xenon-pharma.com/">Investors</a>
                                     =20
   =20


                       =20
    <h2 class=3D"visually-hidden" id=3D"block-headerinvestormenu-menu">Head=
er investor menu</h2>
   =20

                              <ul class=3D"sub-menu">
                  <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/" target=3D"" rel=3D"" data=
-drupal-link-system-path=3D"<front>">Investor Overview</a>
                                    <ul class=3D"sub-menu">
                  <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/stock-information/stock-quo=
te" target=3D"" rel=3D"" data-drupal-link-system-path=3D"node/5911">Stock Q=
uote</a>
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/stock-information/stock-cha=
rt" target=3D"" rel=3D"" data-drupal-link-system-path=3D"node/6126">stock c=
hart</a>
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/stock-information/historica=
l-price-lookup" target=3D"" rel=3D"" data-drupal-link-system-path=3D"node/5=
921">Historic stock lookup</a>
                  </li>
          </ul>
 =20
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/news-releases" target=3D"" =
rel=3D"" data-drupal-link-system-path=3D"node/5816">News &amp; Events</a>
                                    <ul class=3D"sub-menu">
                  <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/news-releases" target=3D"" =
rel=3D"" data-drupal-link-system-path=3D"node/5816">Press Releases</a>
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/events-and-presentations/up=
coming-events" target=3D"" rel=3D"" data-drupal-link-system-path=3D"node/58=
26">Event Calendar</a>
                  </li>
          </ul>
 =20
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/corporate-governance" targe=
t=3D"" rel=3D"" data-drupal-link-system-path=3D"node/6116">Corporate Govern=
ance</a>
                                    <ul class=3D"sub-menu">
                  <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/corporate-governance/manage=
ment" target=3D"" rel=3D"" data-drupal-link-system-path=3D"node/5846">Manag=
ement</a>
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/corporate-governance/board-=
of-directors" target=3D"" rel=3D"" data-drupal-link-system-path=3D"node/584=
1">BOARD OF DIRECTORS</a>
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/corporate-governance/commit=
tee-composition" target=3D"" rel=3D"" data-drupal-link-system-path=3D"node/=
5851">Committee Composition</a>
                  </li>
          </ul>
 =20
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/financial-information/sec-f=
ilings" target=3D"" rel=3D"" data-drupal-link-system-path=3D"node/5876">FIN=
ANCIALS &amp; FILINGS</a>
                                    <ul class=3D"sub-menu">
                  <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/financial-information/annua=
l-reports" target=3D"" rel=3D"" data-drupal-link-system-path=3D"node/5881">=
ANNUAL FINANCIAL REPORTS</a>
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/financial-information/quart=
erly-results" target=3D"" rel=3D"" data-drupal-link-system-path=3D"node/598=
6">Quarterly Results</a>
                  </li>
          </ul>
 =20
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/corporate-governance/contac=
t-the-board" target=3D"" rel=3D"" data-drupal-link-system-path=3D"node/5866=
">contact investor relations</a>
                  </li>
          </ul>
 =20


   =20

 =20

                                 </li>
                                  <li id=3D"menu-item-22" class=3D"menu-ite=
m menu-item-type-post_type menu-item-object-page menu-item-22"><a href=3D"h=
ttp://www.xenon-pharma.com/partners/">Partners</a></li>
                                <li id=3D"menu-item-21" class=3D"menu-item =
menu-item-type-post_type menu-item-object-page menu-item-has-children menu-=
item-21"><a href=3D"http://www.xenon-pharma.com/medical-affairs/">Medical A=
ffairs</a>
                                    <ul class=3D"sub-menu">
                                        <li id=3D"menu-item-2263" class=3D"=
menu-item menu-item-type-post_type menu-item-object-page menu-item-2263"><a=
 href=3D"https://www.xenon-pharma.com/medical-affairs/conferences/">Confere=
nces</a></li>
                                        <li id=3D"menu-item-92" class=3D"me=
nu-item menu-item-type-post_type menu-item-object-page menu-item-92"><a hre=
f=3D"http://www.xenon-pharma.com/medical-affairs/publications/">Publication=
s</a></li>
                                        <li id=3D"menu-item-92" class=3D"me=
nu-item menu-item-type-post_type menu-item-object-page menu-item-92"><a hre=
f=3D"https://www.xenon-pharma.com/medical-affairs/expanded-access-program/"=
>Expanded Access Program</a></li>
                                    </ul>
                                </li>
                            </ul>
                        </div>
                    </nav>
                </div>
            </div>
        </div>
    </header>
    <header class=3D"show-for-small-only">
        <div class=3D"grid-container ">
            <div class=3D"grid-x grid-padding-x">
                <div class=3D"small-8 cell">
                    <div class=3D"logo">
                        <a href=3D"http://www.xenon-pharma.com/"></a>
                    </div>
                </div>
                <div class=3D"small-4 cell">
                    <label for=3D"check"><img src=3D"https://investor.xenon=
-pharma.com/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client/images=
/hamburger.png" alt=3D""></label>
                </div>
            </div>
            <div class=3D"grid-x grid-padding-x">
                <div class=3D"small-12 cell">
                    <input id=3D"check" type=3D"checkbox">
                    <div class=3D"test" id=3D"main-nav">
                        <li><a href=3D"http://www.xenon-pharma.com/about/">=
About</a></li>
                        <li><a href=3D"http://www.xenon-pharma.com/product-=
pipeline/">Product Pipeline</a></li>
                        <li><a href=3D"https://investor.xenon-pharma.com/" =
class=3D"investors-active">Investors</a></li>
                        <li><a href=3D"http://www.xenon-pharma.com/partners=
/">Partners</a></li>
                        <li><a href=3D"http://www.xenon-pharma.com/medical-=
affairs/">Medical Affairs</a></li>
                        <li><a href=3D"http://www.xenon-pharma.com/careers/=
">Careers</a></li>
                        <li><a href=3D"http://www.xenon-pharma.com/contact/=
">Contact</a></li>
                        <li><a href=3D"https://investor.xenon-pharma.com/ne=
ws-releases">News</a></li>
                    </div>
                </div>
            </div>
        </div>
    </header>
    <div class=3D"mainContent">
        <div class=3D"grid-container">
            <div class=3D"grid-x grid-padding-x">
                <div class=3D"large-8 small-12 cell">
                                            <h1>Press Releases</h1>
                                        <hr class=3D"underLine">
                    <div class=3D"irContent lfg-printable-area">
                       =20
                          <div class=3D"region region-content">
    <div data-drupal-messages-fallback=3D"" class=3D"hidden"></div>

<div id=3D"block-nir-pid1175-content" class=3D"block--system-main-block blo=
ck--system-main-block--5816 block--content--system-main-block block--conten=
t--system-main-block--5816 block--a626eec5-f13a-4092-9f85-d217145a2a55 bloc=
k--a626eec5-f13a-4092-9f85-d217145a2a55--5816 block block-system block-syst=
em-main-block">
 =20
   =20
      <article class=3D"node node--type-nir_landing_page node--view-mode-fu=
ll clearfix">
 =20
      <h1>
              Press Releases
          </h1>
   =20

  <div>
   =20
<div class=3D"panel-display boxton clearfix">

  <div class=3D"container-fluid">
    <div class=3D"row">
      <div class=3D"col-md-12 radix-layouts-content panel-panel">
        <div class=3D"panel-panel-inner">
          <div class=3D"block-region-contentmain">
<div class=3D"block--search-form block--search-form--5816 block--contentmai=
n--search-form block--contentmain--search-form--5816 block--8f28a8b7-ab1c-4=
684-b7dd-bbda1b8d4e13 block--8f28a8b7-ab1c-4684-b7dd-bbda1b8d4e13--5816 blo=
ck block-nir-search block-search-form">
 =20
      <h2 id=3D"block-search-form">Keyword Search</h2>
   =20
      <form data-block-uuid=3D"8f28a8b7-ab1c-4684-b7dd-bbda1b8d4e13" action=
=3D"https://investor.xenon-pharma.com/search" method=3D"get" accept-charset=
=3D"UTF-8">
  <div class=3D"js-form-item form-item js-form-type-search form-item-query =
js-form-item-query form-no-label">
        <input type=3D"search" name=3D"query" size=3D"60" maxlength=3D"128"=
 placeholder=3D"" class=3D"form-search required" required=3D"required" aria=
-required=3D"true">

        </div>

<input type=3D"submit" name=3D"op" value=3D"Search" class=3D"button button-=
-primary js-form-submit form-submit">

</form>

  </div>

<div class=3D"block--newslist block--nir-news__widget block--nir-news__widg=
et--5816 block--contentmain--nir-news__widget block--contentmain--nir-news_=
_widget--5816 block--a261b7fe-5298-41e9-a793-02b269d14a16 block--a261b7fe-5=
298-41e9-a793-02b269d14a16--5816 block block-nir-news block-nir-news__widge=
t">
 =20
   =20
      <div class=3D"nir-widget">
    <div class=3D"nir-widget--content">
          <div class=3D"nir-widget--form">
        <form class=3D"nir-widget-form-base" data-drupal-selector=3D"widget=
-form-base" action=3D"https://investor.xenon-pharma.com/news-releases?38df5=
374f7c4fd82aa79d6fb8d12b19edb5315f510fe910f969b08452c4028fe_year%5Bvalue%5D=
=3D_none&amp;op=3DFilter&amp;38df5374f7c4fd82aa79d6fb8d12b19edb5315f510fe91=
0f969b08452c4028fe_widget_id=3D38df5374f7c4fd82aa79d6fb8d12b19edb5315f510fe=
910f969b08452c4028fe&amp;form_build_id=3Dform-zwSt7FqJDol13lB9XMJ9y5Ha5rrm4=
y-KinVsb4ypczw&amp;form_id=3Dwidget_form_base" method=3D"get" id=3D"widget-=
form-base" accept-charset=3D"UTF-8">
  <div class=3D"nir-widgets--field-container nir-widgets--field-container--=
yeartimezone js-form-wrapper form-wrapper" data-drupal-selector=3D"edit-38d=
f5374f7c4fd82aa79d6fb8d12b19edb5315f510fe910f969b08452c4028fe-year" id=3D"e=
dit-38df5374f7c4fd82aa79d6fb8d12b19edb5315f510fe910f969b08452c4028fe-year">=
<div class=3D"two-col-field form-item js-form-item js-form-type-select form=
-type-select form-item-38df5374f7c4fd82aa79d6fb8d12b19edb5315f510fe910f969b=
08452c4028fe-year-value form-item-_8df5374f7c4fd82aa79d6fb8d12b19edb5315f51=
0fe910f969b08452c4028fe-year-value js-form-item-_8df5374f7c4fd82aa79d6fb8d1=
2b19edb5315f510fe910f969b08452c4028fe-year-value">
      <label for=3D"edit-38df5374f7c4fd82aa79d6fb8d12b19edb5315f510fe910f96=
9b08452c4028fe-year-value">Year</label>
        <select data-drupal-selector=3D"edit-38df5374f7c4fd82aa79d6fb8d12b1=
9edb5315f510fe910f969b08452c4028fe-year-value" id=3D"edit-38df5374f7c4fd82a=
a79d6fb8d12b19edb5315f510fe910f969b08452c4028fe-year-value" name=3D"38df537=
4f7c4fd82aa79d6fb8d12b19edb5315f510fe910f969b08452c4028fe_year[value]" clas=
s=3D"form-select" style=3D"display: none;"><option value=3D"_none" selected=
=3D"selected">None</option><option value=3D"2025">2025</option><option valu=
e=3D"2024">2024</option><option value=3D"2023">2023</option><option value=
=3D"2022">2022</option><option value=3D"2021">2021</option><option value=3D=
"2020">2020</option><option value=3D"2019">2019</option><option value=3D"20=
18">2018</option><option value=3D"2017">2017</option><option value=3D"2016"=
>2016</option><option value=3D"2015">2015</option><option value=3D"2014">20=
14</option><option value=3D"2013">2013</option><option value=3D"2012">2012<=
/option><option value=3D"2011">2011</option><option value=3D"2010">2010</op=
tion><option value=3D"2009">2009</option><option value=3D"2008">2008</optio=
n></select><div class=3D"chosen-container chosen-container-single form-sele=
ct" style=3D"width: 150px;" title=3D"" id=3D"edit_38df5374f7c4fd82aa79d6fb8=
d12b19edb5315f510fe910f969b08452c4028fe_year_value_chosen"><a class=3D"chos=
en-single"><span>None</span><div><b></b></div></a><div class=3D"chosen-drop=
"><div class=3D"chosen-search"><input type=3D"text" autocomplete=3D"off" ar=
ia-label=3D"Search from list"></div><ul class=3D"chosen-results"></ul></div=
></div>
        </div>
</div>
<input data-drupal-selector=3D"edit-submit" type=3D"submit" id=3D"edit-subm=
it" name=3D"op" value=3D"Filter" class=3D"button button--primary js-form-su=
bmit form-submit">




</form>

      </div>
        <div class=3D"nir-widget--list">
             =20
<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 12, 2025
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-present-stifel-2025-virtual-cns-forum" hreflang=3D"en"=
>Xenon to Present at Stifel 2025 Virtual CNS Forum</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia and BOSTON , March 12, 2025 (GLOBE NE=
WSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focuse=
d biopharmaceutical company dedicated to discovering, developing, and deliv=
ering life-changing therapeutics for patients in need, today announced that=
 the
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-present-stifel-2025-virtual-cns-forum" hreflang=3D"en">More=
 &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 27, 2025
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-reports-fourth-quarter-full-year-2024-financial-result=
s" hreflang=3D"en">Xenon Reports Fourth Quarter &amp; Full Year 2024 Financ=
ial Results and Business Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          <p>=E2=80=93 Phase 3 topline data from azetukalner FOS epilepsy p=
rogram planned for H2 2025 in support of NDA filing and potential commercia=
l launch =E2=80=93 First of three planned Phase 3 azetukalner MDD studies u=
nderway, with second study on track to initiate mid-year =E2=80=93 Phase 3 =
azetukalner bipolar depression</p>
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-reports-fourth-quarter-full-year-2024-financial-results" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 25, 2025
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-present-45th-annual-td-cowen-healthcare-conference" hr=
eflang=3D"en">Xenon to Present at the 45th Annual TD Cowen Healthcare Confe=
rence</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia and BOSTON , Feb. 25, 2025 (GLOBE NEW=
SWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused=
 biopharmaceutical company dedicated to discovering, developing, and delive=
ring life-changing therapeutics for patients in need, today announced that =
the
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-present-45th-annual-td-cowen-healthcare-conference" hreflan=
g=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 20, 2025
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-report-q4-and-full-year-2024-financial-results-februar=
y-27" hreflang=3D"en">Xenon to Report Q4 and Full Year 2024 Financial Resul=
ts on February 27, 2025</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia and BOSTON , Feb. 20, 2025 (GLOBE NEW=
SWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused=
 biopharmaceutical company dedicated to discovering, developing, and delive=
ring life-changing therapeutics for patients in need, today announced it wi=
ll report
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-report-q4-and-full-year-2024-financial-results-february-27"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 13, 2025
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-outlines-key-corporate-milestone-opportunities-2025" h=
reflang=3D"en">Xenon Outlines Key Corporate Milestone Opportunities for 202=
5</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          =E2=80=93 Topline data from the first Phase 3 FOS study anticipat=
ed in H2 2025 representing major milestone in support of NDA filing and pot=
ential launch of azetukalner =E2=80=93 First of three planned Phase 3 MDD s=
tudies now initiated =E2=80=93 Expanding ion channel portfolio includes Kv7=
 and Nav1.7 candidates advancing
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-outlines-key-corporate-milestone-opportunities-2025" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 7, 2025
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-present-43rd-annual-jp-morgan-healthcare-conference" h=
reflang=3D"en">Xenon to Present at the 43rd Annual J.P. Morgan Healthcare C=
onference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia and BOSTON , Jan. 07, 2025 (GLOBE NEW=
SWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused=
 biopharmaceutical company dedicated to discovering, developing, and delive=
ring life-changing therapeutics for patients in need, today announced that =
the
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-present-43rd-annual-jp-morgan-healthcare-conference" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      December 6, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-showcases-new-long-term-azetukalner-data-x-tole-ole-st=
udy" hreflang=3D"en">Xenon Showcases New Long-Term Azetukalner Data from X-=
TOLE OLE Study in FOS at AES 2024</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          =E2=80=93 OLE data shows sustained monthly reduction in seizure f=
requency, impressive seizure freedom rates, and consistent AE safety profil=
e suggesting long-term efficacy and tolerability of azetukalner =E2=80=93 A=
pproximately one in three patients on drug for at least 36 months achieved =
seizure freedom for a
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-showcases-new-long-term-azetukalner-data-x-tole-ole-study" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 25, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-showcase-new-long-term-azetukalner-data-aes-2024" href=
lang=3D"en">Xenon to Showcase New Long-Term Azetukalner Data at AES 2024</a=
>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Five posters to be presented including new long-term 36-month dat=
a from the ongoing X-TOLE OLE study of azetukalner in FOS and findings arou=
nd mental health and comorbidity burdens of FOS New pre-clinical data from =
the Company=E2=80=99s Nav1.1 program VANCOUVER, British Columbia and BOSTON=
 , Nov.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-showcase-new-long-term-azetukalner-data-aes-2024" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 13, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-present-upcoming-investor-conferences" hreflang=3D"en"=
>Xenon to Present at Upcoming Investor Conferences</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia and BOSTON , Nov. 13, 2024 (GLOBE NEW=
SWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused=
 biopharmaceutical company dedicated to discovering, developing, and delive=
ring life-changing therapeutics for patients in need, today announced that =
the
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-present-upcoming-investor-conferences" hreflang=3D"en">More=
 &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 12, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-reports-q3-2024-financial-results-and-business-update"=
 hreflang=3D"en">Xenon Reports Q3 2024 Financial Results and Business Updat=
e</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          =E2=80=93 Phase 3 epilepsy program advancing with X-TOLE2 topline=
 FOS data anticipated in H2 2025 =E2=80=93 Long-term azetukalner results fr=
om X-TOLE open-label extension study in FOS to be presented at AES =E2=80=
=93 Phase 3 MDD program on track with X-NOVA2 study expected to initiate by=
 year-end =E2=80=93 Expanding ion channel
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-reports-q3-2024-financial-results-and-business-update" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 5, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-report-q3-2024-financial-results-november-12-2024" hre=
flang=3D"en">Xenon to Report Q3 2024 Financial Results on November 12, 2024=
</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia and BOSTON , Nov. 05, 2024 (GLOBE NEW=
SWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused=
 biopharmaceutical company dedicated to discovering, developing, and delive=
ring life-changing therapeutics for patients in need, today announced it wi=
ll report
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-report-q3-2024-financial-results-november-12-2024" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      October 2, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-present-bofa-securities-2024-cns-therapeutics-virtual"=
 hreflang=3D"en">Xenon to Present at BofA Securities 2024 CNS Therapeutics =
Virtual Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia and BOSTON , Oct. 02, 2024 (GLOBE NEW=
SWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused =
biopharmaceutical company dedicated to discovering, developing, and deliver=
ing life-changing therapeutics for patients in need, today announced its
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-present-bofa-securities-2024-cns-therapeutics-virtual" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 9, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-showcases-azetukalner-data-15th-european-epilepsy-cong=
ress" hreflang=3D"en">Xenon Showcases Azetukalner Data at 15th European Epi=
lepsy Congress</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Three presentations highlighting long-term data and improved qual=
ity of life outcomes in adults with focal onset seizures VANCOUVER, British=
 Columbia and BOSTON , Sept. 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuti=
cals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company d=
edicated
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-showcases-azetukalner-data-15th-european-epilepsy-congress"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 12, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-expands-leadership-team-matthew-d-ronsheim-phd-chief" =
hreflang=3D"en">Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.=
D.&nbsp;as Chief Operating Officer</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia and BOSTON , Aug. 12, 2024 (GLOBE NEW=
SWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused =
biopharmaceutical company dedicated to discovering, developing, and deliver=
ing life-changing therapeutics for patients in need, today announced the ap=
pointment
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-expands-leadership-team-matthew-d-ronsheim-phd-chief" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 8, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-reports-q2-2024-financial-results-and-business-update"=
 hreflang=3D"en">Xenon Reports Q2 2024 Financial Results and Business Updat=
e</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          =E2=80=94&nbsp; Phase 3 epilepsy program progressing with X-TOLE2=
 topline FOS data anticipated in H2 2025 =E2=80=94&nbsp;MDD program on trac=
k with Phase 3 study expected to initiate in H2 2024 =E2=80=94&nbsp; Multip=
le Kv7 and Nav1.7 candidates progressing towards development with INDs expe=
cted in 2025 =E2=80=94&nbsp; Conference call at 4:30 pm ET
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-reports-q2-2024-financial-results-and-business-update" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 1, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-report-q2-2024-financial-results-august-8-2024" hrefla=
ng=3D"en">Xenon to Report Q2 2024 Financial Results on August 8, 2024</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Conference Call and webcast scheduled at 4:30 pm ET VANCOUVER, Br=
itish Columbia , Aug. 01, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals In=
c. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicate=
d to discovering, developing, and delivering life-changing therapeutics for=
 patients
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-report-q2-2024-financial-results-august-8-2024" hreflang=3D=
"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      June 5, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-goldman-sachs-45th-annual-glob=
al" hreflang=3D"en">Xenon Pharmaceuticals to Present at the Goldman Sachs 4=
5th Annual Global Healthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , June 05, 2024 (GLOBE NEWSWIRE) -- X=
enon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmace=
utical company, today announced that the company will present at the Goldma=
n Sachs 45th Annual Global Healthcare Conference taking place June 10-13, 2=
024 in
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-goldman-sachs-45th-annual-global" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 28, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-presents-data-phase-2-x-nova-clinical"=
 hreflang=3D"en">Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Cl=
inical Trial of Azetukalner in Major Depressive Disorder at the American So=
ciety of Clinical Psychopharmacology 2024 Annual Meeting</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , May 28, 2024 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceu=
tical company, announced data presentations highlighting azetukalner (XEN11=
01) clinical data in major depressive disorder (MDD) at the American Societ=
y of
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-presents-data-phase-2-x-nova-clinical" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 9, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-first-quarter-2024-financial" =
hreflang=3D"en">Xenon Pharmaceuticals Reports First Quarter 2024 Financial =
Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Phase 3 epilepsy program continues to progress with anticipated c=
ompletion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Succe=
ssful =E2=80=9Cend-of-Phase 2=E2=80=9D interactions with FDA in MDD; Phase =
3 program on track to initiate in the second half of the year Azetukalner n=
ow the international
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-first-quarter-2024-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 8, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-bofa-securities-health-care-0"=
 hreflang=3D"en">Xenon Pharmaceuticals to Present at the BofA Securities He=
alth Care Conference 2024</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , May 08, 2024 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceu=
tical company, today announced that the company will present at the BofA Se=
curities Health Care Conference 2024 taking place May 14-16, 2024 in Las Ve=
gas, NV.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-bofa-securities-health-care-0" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 7, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-2024-rbc-capital-markets-globa=
l" hreflang=3D"en">Xenon Pharmaceuticals to Present at the 2024 RBC Capital=
 Markets Global Healthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , May 07, 2024 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceu=
tical company, today announced that the company will present at the 2024 RB=
C Capital Markets Global Healthcare Conference taking place May 14-15, 2024=
 in New
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-2024-rbc-capital-markets-global" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 2, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-=
13" hreflang=3D"en">Xenon Pharmaceuticals Announces Conference Call and Web=
cast to Discuss First Quarter 2024 Financial Results and Provide Corporate =
Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , May 02, 2024 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceu=
tical company, today announced it will report its first quarter 2024 financ=
ial and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-13" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      April 16, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-showcases-xen1101-american-academy" hr=
eflang=3D"en">Xenon Pharmaceuticals Showcases XEN1101 at the American Acade=
my of Neurology 2024 Annual Meeting</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , April 16, 2024 (GLOBE NEWSWIRE) -- =
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmac=
eutical company, announced two oral presentations highlighting XEN1101 clin=
ical data at the American Academy of Neurology (AAN) 2024 Annual Meeting in=
 Denver,
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-showcases-xen1101-american-academy" hreflan=
g=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      April 10, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-2024-bloom-burton-co-healthcar=
e" hreflang=3D"en">Xenon Pharmaceuticals to Present at the 2024 Bloom Burto=
n &amp; Co. Healthcare Investor Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , April 10, 2024 (GLOBE NEWSWIRE) -- =
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceut=
ical company, today announced that the company will present at the 2024 Blo=
om Burton &amp; Co. &nbsp; Healthcare Investor Conference taking place Apri=
l 16-17, 2024 .
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-2024-bloom-burton-co-healthcare" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      April 4, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-23rd-annual-needham-virtual" h=
reflang=3D"en">Xenon Pharmaceuticals to Present at the 23rd Annual Needham =
Virtual Healthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , April 04, 2024 (GLOBE NEWSWIRE) -- =
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceut=
ical company, today announced that the company will present at the 23 rd An=
nual Needham (Virtual) Healthcare Conference taking place April 8-11, 2024 =
.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-23rd-annual-needham-virtual" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 12, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-stifel-2024-virtual-cns-days" =
hreflang=3D"en">Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS=
 Days</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , March 12, 2024 (GLOBE NEWSWIRE) -- =
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceut=
ical company, today announced that the company will present at the Stifel 2=
024 Virtual CNS Days event. Company Fireside Chat Presentation Details: &nb=
sp; Date:
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-stifel-2024-virtual-cns-days" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 5, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-leerink-partners-global-biopha=
rma" hreflang=3D"en">Xenon Pharmaceuticals to Present at Leerink Partners G=
lobal Biopharma Conference 2024</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , March 05, 2024 (GLOBE NEWSWIRE) -- =
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceut=
ical company, today announced that the company will present at Leerink Part=
ners Global Biopharma Conference 2024 to be held in Miami, FL on March 11-1=
3, 2024 .
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-leerink-partners-global-biopharma" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 29, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-fourth-quarter-and-full-year-2=
023" hreflang=3D"en">Xenon Pharmaceuticals Reports Fourth Quarter and Full =
Year 2023 Financial Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          XEN1101 Phase 3 epilepsy program continues to progress with X-TOL=
E2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized to=
nic-clonic seizures; completion of patient enrollment&nbsp; in X-TOLE2 expe=
cted in late 2024 to early 2025 Planned =E2=80=9Cend-of-Phase 2=E2=80=9D me=
eting with the FDA in April to
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-fourth-quarter-and-full-year-2023" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 22, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-=
12" hreflang=3D"en">Xenon Pharmaceuticals Announces Conference Call and Web=
cast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Pro=
vide Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , Feb. 22, 2024 (GLOBE NEWSWIRE) -- X=
enon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceuti=
cal company, today announced it will report its fourth quarter and full yea=
r 2023 financial and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-12" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 8, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-outlines-key-milestone-opportunities-2=
024" hreflang=3D"en">Xenon Pharmaceuticals Outlines Key Milestone Opportuni=
ties for 2024</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Completion of Patient Enrollment in XEN1101 Phase 3 X-TOLE2 Clini=
cal Trial in Focal Onset Seizures Anticipated in Second Half of 2024 XEN110=
1 Phase 3 Program in Major Depressive Disorder Planned for Initiation in 20=
24 VANCOUVER, British Columbia , Jan.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-outlines-key-milestone-opportunities-2024" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 3, 2024
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-42nd-annual-jp-morgan-healthca=
re" hreflang=3D"en">Xenon Pharmaceuticals to Present at the 42nd Annual J.P=
. Morgan Healthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , Jan. 03, 2024 (GLOBE NEWSWIRE) -- X=
enon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceuti=
cal company, today announced that the company will present at the 42nd Annu=
al J.P. Morgan Healthcare Conference taking place in San Francisco, CA from=
 January
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-42nd-annual-jp-morgan-healthcare" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      December 4, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-closing-3450-million-upsized=
" hreflang=3D"en">Xenon Pharmaceuticals Announces Closing of $345.0 Million=
 Upsized Public Offering Including Full Exercise of the Underwriters=E2=80=
=99 Option to Purchase Additional Shares</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , Dec. 04, 2023 (GLOBE NEWSWIRE) -- X=
enon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceuti=
cal company, today announced the closing of its previously announced underw=
ritten public offering of 9,846,157 common shares, which includes 1,384,615=
 shares
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-closing-3450-million-upsized" hre=
flang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      December 2, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-provides-updates-neurology-pipeline-0"=
 hreflang=3D"en">Xenon Pharmaceuticals Provides Updates on Neurology Pipeli=
ne Programs at the&nbsp;Annual Meeting of the American Epilepsy Society (AE=
S 2023)</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , Dec. 02, 2023 (GLOBE NEWSWIRE) -- X=
enon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceuti=
cal company, today announced it will provide updates on its neurology progr=
ams at the Annual Meeting of the American Epilepsy Society (AES 2023). Mr.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-provides-updates-neurology-pipeline-0" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 29, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-pricing-upsized-3000-million=
" hreflang=3D"en">Xenon Pharmaceuticals Announces Pricing of Upsized $300.0=
 Million Public Offering</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , Nov. 29, 2023 (GLOBE NEWSWIRE) -- X=
enon Pharmaceuticals Inc. (Nasdaq:XENE) (=E2=80=9CXenon=E2=80=9D), a neurol=
ogy-focused biopharmaceutical company, today announced the pricing of its u=
psized underwritten public offering of 8,461,542 common shares and, in lieu=
 of common shares to
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-pricing-upsized-3000-million" hre=
flang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 29, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-proposed-public-offering-4" =
hreflang=3D"en">Xenon Pharmaceuticals Announces Proposed Public Offering</a=
>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , Nov. 29, 2023 (GLOBE NEWSWIRE) -- X=
enon Pharmaceuticals Inc. (Nasdaq:XENE) (=E2=80=9CXenon=E2=80=9D), a neurol=
ogy-focused biopharmaceutical company, today announced that it has commence=
d an underwritten public offering of $225.0 million of its common shares an=
d, in lieu of common
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-proposed-public-offering-4" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 27, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-topline-results-phase-2-proo=
f" hreflang=3D"en">Xenon Pharmaceuticals Announces Topline Results from Pha=
se 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive =
Disorder (MDD)</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Conference call today at 8:30 am ET VANCOUVER, British Columbia ,=
 Nov. 27, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE)=
, a neurology-focused biopharmaceutical company, today reported topline res=
ults from the randomized, double-blind, placebo-controlled, Phase 2 proof-o=
f-concept
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-topline-results-phase-2-proof" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 9, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-provides-update-partnered-program" hre=
flang=3D"en">Xenon Pharmaceuticals Provides Update on Partnered Program wit=
h Neurocrine Biosciences</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Foc=
al Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure Fre=
quency VANCOUVER, British Columbia , Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xeno=
n Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical=
 company,
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-provides-update-partnered-program" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 8, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-third-quarter-2023-financial" =
hreflang=3D"en">Xenon Pharmaceuticals Reports Third Quarter 2023 Financial =
Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major =
depressive disorder&nbsp; on track for late November to mid-December XEN110=
1 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 i=
n focal onset seizures and X-ACKT in primary generalized tonic-clonic seizu=
res Patient
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-third-quarter-2023-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 1, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-=
11" hreflang=3D"en">Xenon Pharmaceuticals Announces Conference Call and Web=
cast to Discuss Third Quarter 2023 Financial Results and Provide Corporate =
Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , Nov. 01, 2023 (GLOBE NEWSWIRE) -- X=
enon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceuti=
cal company, today announced it will report its third quarter 2023 financia=
l and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-11" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      October 9, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-publication-results-xen1101"=
 hreflang=3D"en">Xenon Pharmaceuticals Announces Publication of Results fro=
m XEN1101 Phase 2b =E2=80=9CX-TOLE=E2=80=9D Clinical Trial in Peer-Reviewed=
 Journal Article in JAMA Neurology</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , Oct. 09, 2023 (GLOBE NEWSWIRE) -- X=
enon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceuti=
cal company, today announced the medical journal JAMA Neurology has publish=
ed peer-reviewed efficacy and safety results from the X-TOLE Phase 2b rando=
mized
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-publication-results-xen1101" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      October 6, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-jefferies-inaugural-biotech" h=
reflang=3D"en">Xenon Pharmaceuticals to Present at Jefferies Inaugural Biot=
ech CNS/Neuro Summit</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , Oct. 06, 2023 (GLOBE NEWSWIRE) -- X=
enon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceuti=
cal company, today announced that the company will present at Jefferies Ina=
ugural Biotech CNS/Neuro Summit to be held on October 11, 2023 .
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-jefferies-inaugural-biotech" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 14, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-td-cowens-3rd-annual-novel" hr=
eflang=3D"en">Xenon Pharmaceuticals to Present at TD Cowen=E2=80=99s 3rd An=
nual Novel Mechanisms in Neuropsychiatry Summit</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , Sept. 14, 2023 (GLOBE NEWSWIRE) -- =
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceut=
ical company, today announced that the company will present at TD Cowen=E2=
=80=99s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit to be held on=
 September 20,
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-td-cowens-3rd-annual-novel" hreflan=
g=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 12, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-upcoming-investor-webinar" h=
reflang=3D"en">Xenon Pharmaceuticals Announces Upcoming Investor Webinar wi=
th Leading Key Opinion Leaders&nbsp;to Discuss XEN1101 and Major Depressive=
 Disorder</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Live broadcast of webinar on Tuesday, September 19 beginning at 1=
1:30 am ET VANCOUVER, British Columbia , Sept. 12, 2023 (GLOBE NEWSWIRE) --=
 Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceu=
tical company, today announced that the company will host an investor webin=
ar with
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-upcoming-investor-webinar" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 4, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-showcases-xen1101-epilepsy-program-35t=
h" hreflang=3D"en">Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program=
 at 35th International Epilepsy Congress</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          New interim data from ongoing Phase 2b X-TOLE open-label extensio=
n demonstrates improvement in overall quality-of-life (QoL) when compared t=
o baseline Clinically important improvements seen for all patients across i=
mportant subscales of Seizure Worry, Social Functioning and Medication Effe=
cts and
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-showcases-xen1101-epilepsy-program-35th" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 31, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-wells-fargo-2023-healthcare" h=
reflang=3D"en">Xenon Pharmaceuticals to Present at the Wells Fargo 2023 Hea=
lthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , Aug. 31, 2023 (GLOBE NEWSWIRE) -- X=
enon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceuti=
cal company, today announced that the company will present at the Wells Far=
go 2023 Healthcare Conference to be held September 6-8, 2023 .
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-wells-fargo-2023-healthcare" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 9, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-second-quarter-2023-financial"=
 hreflang=3D"en">Xenon Pharmaceuticals Reports Second Quarter 2023 Financia=
l Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Last patient enrolled in XEN1101 Phase 2 X-NOVA clinical trial in=
 major depressive disorder&nbsp; with topline data expected in late Novembe=
r to mid-December Continued progress across all XEN1101 Phase 3 epilepsy pr=
ograms including in X-TOLE2 and X-TOLE3 clinical trials in focal onset seiz=
ures and
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-second-quarter-2023-financial" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 8, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-expands-leadership-its-board-directors=
" hreflang=3D"en">Xenon Pharmaceuticals Expands Leadership on its Board of =
Directors with Appointments of Gillian M. Cannon and Justin Gover</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , Aug. 08, 2023 (GLOBE NEWSWIRE) -- X=
enon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceuti=
cal company, today announced two new appointments to its Board of Directors=
: Dr. Gillian M. Cannon and Mr. Justin Gover . Dr.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-expands-leadership-its-board-directors" hre=
flang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 2, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-=
10" hreflang=3D"en">Xenon Pharmaceuticals Announces Conference Call and Web=
cast to Discuss Second Quarter 2023 Financial Results and Provide Corporate=
 Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , Aug. 02, 2023 (GLOBE NEWSWIRE) -- X=
enon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceuti=
cal company, today announced it will report its second quarter 2023 financi=
al and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-10" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      June 6, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-goldman-sachs-44th-annual-glob=
al" hreflang=3D"en">Xenon Pharmaceuticals to Present at the Goldman Sachs 4=
4th Annual Global Healthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , June 06, 2023 (GLOBE NEWSWIRE) -- X=
enon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceuti=
cal company, today announced that the company will present at the Goldman S=
achs 44th Annual Global Healthcare Conference in Dana Point, CA.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-goldman-sachs-44th-annual-global" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 31, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-2023-jefferies-healthcare" hre=
flang=3D"en">Xenon Pharmaceuticals to Present at the 2023 Jefferies Healthc=
are Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , May 31, 2023 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutic=
al company, today announced that the company will present at the 2023 Jeffe=
ries Healthcare Conference taking place June 7-9, 2023 in New York, NY .
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-2023-jefferies-healthcare" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 11, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-2023-rbc-capital-markets-globa=
l" hreflang=3D"en">Xenon Pharmaceuticals to Present at the 2023 RBC Capital=
 Markets Global Healthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , May 11, 2023 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutic=
al company, today announced that the company will present at the 2023 RBC C=
apital Markets Global Healthcare Conference taking place May 16-17, 2023 in=
 New
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-2023-rbc-capital-markets-global" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 9, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-first-quarter-2023-financial" =
hreflang=3D"en">Xenon Pharmaceuticals Reports First Quarter 2023 Financial =
Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          XEN1101 Phase 3 epilepsy program continues to make significant pr=
ogress across all ongoing clinical trials including the recent initiation o=
f X-TOLE3 in addition to the ongoing X-TOLE2 and X-ACKT Phase 3 clinical tr=
ials Anticipate last patient to be screened next month in XEN1101 Phase 2 X=
-NOVA
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-first-quarter-2023-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 3, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-bofa-securities-health-care" h=
reflang=3D"en">Xenon Pharmaceuticals to Present at the BofA Securities Heal=
th Care Conference 2023</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , May 03, 2023 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutic=
al company, today announced that the company will present at the BofA Secur=
ities Health Care Conference&nbsp;2023 taking place May 9-11, 2023 .
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-bofa-securities-health-care" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 2, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-=
9" hreflang=3D"en">Xenon Pharmaceuticals Announces Conference Call and Webc=
ast to Discuss First Quarter 2023 Financial Results and Provide Corporate U=
pdate</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          VANCOUVER, British Columbia , May 02, 2023 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutic=
al company, today announced it will report its first quarter 2023 financial=
 and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-9" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      April 24, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-showcases-its-xen1101-epilepsy-program=
" hreflang=3D"en">Xenon Pharmaceuticals Showcases Its XEN1101 Epilepsy Prog=
ram at the 2023 American Academy of Neurology (AAN) Annual Meeting</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Oral presentation by Dr. Jacqueline French to outline sustained m=
onthly reduction in focal onset seizures during open-label extension of X-T=
OLE study Poster to present the trial design for Phase 3 X-ACKT clinical st=
udy evaluating XEN1101 in additional epilepsy indication of primary general=
ized
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-showcases-its-xen1101-epilepsy-program" hre=
flang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      April 21, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-2023-bloom-burton-co-healthcar=
e" hreflang=3D"en">Xenon Pharmaceuticals to Present at the 2023 Bloom Burto=
n &amp; Co. Healthcare Investor Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , April 21, 2023 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutic=
al company, today announced that it will host a company presentation at the=
 2023 Bloom Burton &amp; Co. &nbsp; Healthcare Investor Conference to be he=
ld in Toronto,
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-2023-bloom-burton-co-healthcare" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      April 18, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-22nd-annual-needham-virtual" h=
reflang=3D"en">Xenon Pharmaceuticals to Present at the 22nd Annual Needham =
Virtual Healthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , April 18, 2023 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutic=
al company, today announced that the company will present at the 22nd Annua=
l Needham Virtual Healthcare Conference taking place April 17-20, 2023 .
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-22nd-annual-needham-virtual" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 22, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-stifel-2023-cns-days" hreflang=
=3D"en">Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , March 22, 2023 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutic=
al company, today announced that the company will present at the virtual St=
ifel 2023 CNS Days taking place March 28-29, 2023 .
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-stifel-2023-cns-days" hreflang=3D"e=
n">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 1, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-fourth-quarter-and-full-year-2=
022" hreflang=3D"en">Xenon Pharmaceuticals Reports Fourth Quarter and Full =
Year 2022 Financial Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          XEN1101 Phase 3 epilepsy program continues to advance in focal on=
set seizures and primary generalized tonic clonic seizures Topline data fro=
m XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder expect=
ed in third quarter Conference call at 4:30 pm ET today BURNABY, British Co=
lumbia ,
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-fourth-quarter-and-full-year-2022" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 22, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-=
8" hreflang=3D"en">Xenon Pharmaceuticals Announces Conference Call and Webc=
ast to Discuss Fourth Quarter and Full Year 2022 Financial Results and Prov=
ide Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Feb. 22, 2023 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced it will report its fourth quarter and full year =
2022 financial and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-8" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 8, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-svb-securities-global-biopharm=
a" hreflang=3D"en">Xenon Pharmaceuticals to Present at the SVB Securities G=
lobal Biopharma Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Feb. 08, 2023 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced that the company will present at the virtual SVB=
 Securities Global Biopharma Conference taking place from February 14-16, 2=
023 .
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-svb-securities-global-biopharma" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 9, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-outlines-key-milestone-opportunities-2=
023" hreflang=3D"en">Xenon Pharmaceuticals Outlines Key Milestone Opportuni=
ties for 2023</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          XEN1101 Phase 3 Epilepsy Program Ongoing in Focal Onset Seizures =
and Recently Initiated in Primary Generalized Tonic Clonic Seizures Strong =
financial position expected to fully support XEN1101 Phase 3 program develo=
pment and cash runway into 2026 BURNABY, British Columbia , Jan.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-outlines-key-milestone-opportunities-2023" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 4, 2023
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-41st-annual-jp-morgan-healthca=
re" hreflang=3D"en">Xenon Pharmaceuticals to Present at the 41st Annual J.P=
. Morgan Healthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Jan. 04, 2023 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced that the company will present at the 41st Annual=
 J.P. Morgan Healthcare Conference taking place in San Francisco, CA from J=
anuary
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-41st-annual-jp-morgan-healthcare" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      December 2, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-provides-updates-proprietary-neurology=
-1" hreflang=3D"en">Xenon Pharmaceuticals Provides Updates on Proprietary N=
eurology Pipeline Programs at the&nbsp;Annual Meeting of the American Epile=
psy Society (AES 2022)</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Company Presents Additional Positive Data from Open Label Extensi=
on of Phase 2b =E2=80=98X-TOLE=E2=80=99 Clinical Trial for Focal Onset Seiz=
ures XEN1101 Phase 3 Program to be Showcased at Scientific Exhibit Taking P=
lace on Sunday, December 4, 2022 BURNABY, British Columbia , Dec.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-provides-updates-proprietary-neurology-1" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 30, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-bank-america-securities-biotec=
h" hreflang=3D"en">Xenon Pharmaceuticals to Present at the Bank of America =
Securities Biotech SMID Cap Conference 2022</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 30, 2022 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced that management will participate in one-on-one i=
nvestor meetings and a fireside chat presentation at the Bank of America Se=
curities
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-bank-america-securities-biotech" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 9, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-participate-upcoming-investor-5" hrefl=
ang=3D"en">Xenon Pharmaceuticals to Participate in Upcoming Investor Confer=
ences</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 09, 2022 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced that Ian Mortimer , Xenon=E2=80=99s President an=
d Chief Executive Officer, along with Sherry Aulin , Xenon=E2=80=99s Chief =
Financial Officer, will
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-participate-upcoming-investor-5" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 8, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-third-quarter-2022-financial" =
hreflang=3D"en">Xenon Pharmaceuticals Reports Third Quarter 2022 Financial =
Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          XEN1101 Phase 3 program launched with initiation of X-TOLE2 clini=
cal trial Strong financial position of approximately $752 million to fully =
support XEN1101 Phase 3 program development and expected cash runway into 2=
026 Conference call at 4:30 pm ET today BURNABY, British Columbia , Nov.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-third-quarter-2022-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 7, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-strengthens-leadership-team-appointmen=
t" hreflang=3D"en">Xenon Pharmaceuticals Strengthens Leadership Team with A=
ppointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary=
</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 07, 2022 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced the appointment of Andrea DiFabio as Chief Legal=
 Officer and Corporate Secretary, effective immediately. Ms.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-strengthens-leadership-team-appointment" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 3, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-launch-xen1101-phase-3-progr=
am" hreflang=3D"en">Xenon Pharmaceuticals Announces Launch of XEN1101 Phase=
 3 Program&nbsp;with Initiation of X-TOLE2 Clinical Trial in Patients with =
Focal Onset Seizures</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 03, 2022 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced the launch of its XEN1101 Phase 3 program with t=
he initiation of the X-TOLE2 clinical trial, which will examine XEN1101 adm=
inistered
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-launch-xen1101-phase-3-program" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 1, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-=
7" hreflang=3D"en">Xenon Pharmaceuticals Announces Conference Call and Webc=
ast to Discuss&nbsp;Third Quarter 2022 Financial Results and Provide Corpor=
ate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 01, 2022 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced it will report its third quarter 2022 financial =
and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-7" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 1, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-wells-fargo-2022-healthcare" h=
reflang=3D"en">Xenon Pharmaceuticals to Present at the Wells Fargo 2022 Hea=
lthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Sept. 01, 2022 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutic=
al company, today announced that management will participate in one-on-one =
investor meetings and a fireside chat presentation at the 17th Annual Wells=
 Fargo
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-wells-fargo-2022-healthcare" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 9, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-second-quarter-2022-financial"=
 hreflang=3D"en">Xenon Pharmaceuticals Reports Second Quarter 2022 Financia=
l Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Xenon remains on track to initiate the XEN1101 Phase 3 program wi=
thin second half of this year Cash runway extended into 2026 following succ=
essful completion of equity offering in June Conference Call at 4:30 pm ET =
Today BURNABY, British Columbia , Aug.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-second-quarter-2022-financial" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 8, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-13th-annual-wedbush-pacgrow" h=
reflang=3D"en">Xenon Pharmaceuticals to Present at the 13th Annual Wedbush =
PacGrow Healthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Aug. 08, 2022 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced that management will participate in virtual one-=
on-one investor meetings and a fireside chat presentation at the 13th Annua=
l Wedbush
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-13th-annual-wedbush-pacgrow" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 2, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-=
6" hreflang=3D"en">Xenon Pharmaceuticals Announces Conference Call and Webc=
ast to Discuss Second Quarter 2022 Financial Results and Provide Corporate =
Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Aug. 02, 2022 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced it will report its second quarter 2022 financial=
 and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-6" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      July 11, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-william-blair-biotech-focus" h=
reflang=3D"en">Xenon Pharmaceuticals to Present at the William Blair Biotec=
h Focus Conference 2022</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , July 11, 2022 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced that management will participate in a fireside c=
hat presentation and one-on-one investor meetings at the William Blair Biot=
ech Focus
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-william-blair-biotech-focus" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      June 27, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-closing-2875-million-public"=
 hreflang=3D"en">Xenon Pharmaceuticals Announces Closing of $287.5 Million =
Public Offering Including Full Exercise of the Underwriters=E2=80=99 Option=
 to Purchase Additional Shares</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , June 27, 2022 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical c=
ompany, today announced the closing of its previously announced underwritte=
n public offering of 9,098,362 common shares, which includes 1,229,508 shar=
es sold
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-closing-2875-million-public" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      June 22, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-pricing-2500-million-public"=
 hreflang=3D"en">Xenon Pharmaceuticals Announces Pricing of $250.0 Million =
Public Offering</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , June 22, 2022 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical c=
ompany, today announced the pricing of its underwritten public offering of =
7,868,854 common shares and, in lieu of common shares to certain investors,
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-pricing-2500-million-public" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      June 22, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-proposed-public-offering-3" =
hreflang=3D"en">Xenon Pharmaceuticals Announces Proposed Public Offering</a=
>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , June 22, 2022 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical =
company, today announced that it has commenced an underwritten public offer=
ing of its common shares and, in lieu of common shares to certain investors=
 that so
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-proposed-public-offering-3" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      June 22, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-provides-update-additional-positive-da=
ta" hreflang=3D"en">Xenon Pharmaceuticals Provides Update on Additional Pos=
itive Data from the XEN1101 Program</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          New XEN1101 Phase 2b X-TOLE sub-group analysis demonstrates stati=
stically significant efficacy results at all doses at Week&nbsp;1, differen=
tiating XEN1101 with rapid onset to seizure reduction New XEN1101 OLE data =
demonstrates continued seizure reduction exceeding 70% at 3 months in OLE a=
nd exceeding
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-provides-update-additional-positive-data" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      June 21, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-positive-outcome-end-phase-2=
" hreflang=3D"en">Xenon Pharmaceuticals Announces Positive Outcome of End-o=
f-Phase 2 Meeting with the FDA</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          XEN1101 Phase 3 program for the treatment of focal onset seizures=
 to be initiated in the second half of 2022 and New Drug Application expect=
ed to be submitted after completion of first Phase 3 clinical trial (X-TOLE=
2) along with the completed Phase 2b (X-TOLE) clinical trial Plans to initi=
ate
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-positive-outcome-end-phase-2" hre=
flang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      June 1, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-2022-jefferies-healthcare" hre=
flang=3D"en">Xenon Pharmaceuticals to Present at the 2022 Jefferies Healthc=
are Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , June 01, 2022 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced that management will participate in one-on-one i=
nvestor meetings and present at the 2022 Jefferies Healthcare Conference to=
 be held
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-2022-jefferies-healthcare" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 10, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-first-quarter-2022-financial" =
hreflang=3D"en">Xenon Pharmaceuticals Reports First Quarter 2022 Financial =
Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          XEN1101 =E2=80=9CEnd of Phase 2=E2=80=9D Meeting with FDA to take=
 Place in Second Quarter and Initiation of Phase 3 in Adult Focal Epilepsy =
Expected in the Second Half of 2022 Company-sponsored Phase 2 Clinical Tria=
l Initiated to Evaluate XEN1101 for the Treatment of MDD Conference Call at=
 4:30 pm ET Today
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-first-quarter-2022-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 3, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-=
5" hreflang=3D"en">Xenon Pharmaceuticals Announces Conference Call and Webc=
ast to Discuss&nbsp;First Quarter 2022 Financial Results and Provide Corpor=
ate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , May 03, 2022 (GLOBE NEWSWIRE) -- Xeno=
n Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical=
 company, today announced it will report its first quarter 2022 financial a=
nd operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-5" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 3, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-initiation-phase-2-clinical"=
 hreflang=3D"en">Xenon Pharmaceuticals Announces Initiation of Phase 2 Clin=
ical Trial to Evaluate XEN1101 as a Treatment for Major Depressive Disorder=
 (MDD)</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , May 03, 2022 (GLOBE NEWSWIRE) -- Xeno=
n Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical=
 company, today announced the initiation of a Phase 2 randomized, double-bl=
ind, placebo-controlled, multicenter clinical study =E2=80=93 called the =
=E2=80=9CX-NOVA=E2=80=9D clinical
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-initiation-phase-2-clinical" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      April 25, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-participate-upcoming-investor-4" hrefl=
ang=3D"en">Xenon Pharmaceuticals to Participate in Upcoming Investor Confer=
ences</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , April 25, 2022 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutic=
al company today announced that Xenon=E2=80=99s management team will partic=
ipate in the following investor conferences: Jefferies Biotech on the Bay S=
ummit &nbsp; &nbsp; &nbsp;
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-participate-upcoming-investor-4" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      April 4, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-21st-annual-needham-virtual" h=
reflang=3D"en">Xenon Pharmaceuticals to Present at the 21st Annual Needham =
Virtual Healthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , April 04, 2022 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutic=
al company, today announced that management will participate in one-on-one =
investor meetings and a fireside chat at the 21 st Annual Needham (Virtual)
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-21st-annual-needham-virtual" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 22, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-stifel-2022-cns-days" hreflang=
=3D"en">Xenon Pharmaceuticals to Present at Stifel 2022 CNS Days</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , March 22, 2022 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutic=
al company, today announced that management will participate in one-on-one =
investor meetings and a fireside chat at the Stifel 2022 CNS Days (virtual)
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-stifel-2022-cns-days" hreflang=3D"e=
n">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 1, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-2021-financial-results-and" hr=
eflang=3D"en">Xenon Pharmaceuticals Reports 2021 Financial Results and Prov=
ides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Conference Call at 4:30 pm ET Today BURNABY, British Columbia , M=
arch 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE),=
 a neurology-focused biopharmaceutical company, today reported financial re=
sults for the year ended December 31, 2021 and provided a corporate update.=
 Mr.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-2021-financial-results-and" hreflan=
g=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 22, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-=
4" hreflang=3D"en">Xenon Pharmaceuticals Announces Conference Call and Webc=
ast to Discuss Year-End 2021 Financial Results and Provide Corporate Update=
</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced it will report its financial results for the yea=
r ended December 31, 2021 and provide a corporate update after the close of=
 U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-4" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 14, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-participate-11th-annual-svb-leerink-gl=
obal" hreflang=3D"en">Xenon Pharmaceuticals to Participate in the 11th Annu=
al SVB Leerink Global Healthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Feb. 14, 2022 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced its participation in one-on-one investor meeting=
s and a virtual fireside chat at the 11th Annual SVB Leerink Global Healthc=
are
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-participate-11th-annual-svb-leerink-global"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 12, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-collaboration-neurocrine-0" =
hreflang=3D"en">Xenon Pharmaceuticals Announces Collaboration with Neurocri=
ne Biosciences  Achieves $15.0 Million Regulatory Milestone</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Jan. 12, 2022 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced that its collaboration to develop treatments for=
 epilepsy with Neurocrine Biosciences, Inc.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-collaboration-neurocrine-0" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 10, 2022
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-outlines-key-milestone-opportunities-2=
022" hreflang=3D"en">Xenon Pharmaceuticals Outlines Key Milestone Opportuni=
ties for 2022</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Jan. 10, 2022 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today outlined its key milestones for 2022. Mr. Ian Mortimer , X=
enon=E2=80=99s President and Chief Executive Officer stated, =E2=80=9CWe ar=
e entering 2022 with an
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-outlines-key-milestone-opportunities-2022" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      December 3, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-presents-additional-positive-data-phas=
e-2b" hreflang=3D"en">Xenon Pharmaceuticals Presents Additional Positive Da=
ta from Phase 2b =E2=80=98X-TOLE=E2=80=99 Clinical Trial at the Annual Meet=
ing of the American Epilepsy Society (AES 2021)</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Topline Data Showed All Primary and Secondary Seizure Reduction E=
ndpoints Statistically Significant Across All Dose Groups, with p-value of
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-presents-additional-positive-data-phase-2b"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      December 3, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-provides-updates-proprietary-neurology=
-0" hreflang=3D"en">Xenon Pharmaceuticals Provides Updates on Proprietary N=
eurology Pipeline Programs at the Annual Meeting of the American Epilepsy S=
ociety (AES 2021)</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Dec. 03, 2021 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced that it will provide updates on its proprietary,=
 neurology programs at the Annual Meeting of the American Epilepsy Society =
(AES
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-provides-updates-proprietary-neurology-0" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 12, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-participate-upcoming-investor-3" hrefl=
ang=3D"en">Xenon Pharmaceuticals to Participate in Upcoming Investor Confer=
ences</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced that Ian Mortimer , Xenon=E2=80=99s President an=
d Chief Executive Officer, along with Sherry Aulin , Xenon=E2=80=99s Chief =
Financial Officer, will
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-participate-upcoming-investor-3" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 10, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-third-quarter-2021-financial" =
hreflang=3D"en">Xenon Pharmaceuticals Reports Third Quarter 2021 Financial =
Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          XEN1101 X-TOLE Presentations Scheduled at AES 2021 with Planning =
Underway for Phase 3 Initiation in 2022 Conference Call at 4:30 pm ET Today=
 BURNABY, British Columbia , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Xenon Pharma=
ceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company=
, today
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-third-quarter-2021-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 3, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-=
3" hreflang=3D"en">Xenon Pharmaceuticals Announces Conference Call and Webc=
ast to Discuss&nbsp;Third Quarter 2021 Financial Results and Provide Corpor=
ate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 03, 2021 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced it will report its third quarter 2021 financial =
and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-3" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      October 8, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-closing-345-million-public" =
hreflang=3D"en">Xenon Pharmaceuticals Announces Closing of $345 Million Pub=
lic Offering Including Full Exercise of the Underwriters=E2=80=99 Option to=
 Purchase Additional Shares</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Oct. 08, 2021 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical c=
ompany, today announced the closing of its previously announced underwritte=
n public offering of 10,000,000 common shares, which includes 1,525,423 sha=
res sold
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-closing-345-million-public" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      October 5, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-pricing-3000-million-public"=
 hreflang=3D"en">Xenon Pharmaceuticals Announces Pricing of $300.0 Million =
Public Offering</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Oct. 05, 2021 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical c=
ompany, today announced the pricing of its underwritten public offering of =
8,474,577 common shares and, in lieu of common shares to certain investors,
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-pricing-3000-million-public" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      October 4, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-proposed-public-offering" hr=
eflang=3D"en">Xenon Pharmaceuticals Announces Proposed Public Offering</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Oct. 04, 2021 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical =
company, today announced that it has commenced an underwritten public offer=
ing of $250 million of its common shares pursuant to its existing shelf reg=
istration
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-proposed-public-offering" hreflan=
g=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      October 4, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-positive-topline-results-pha=
se" hreflang=3D"en">Xenon Pharmaceuticals Announces Positive Topline Result=
s from Phase 2b =E2=80=98X-TOLE=E2=80=99 Clinical Trial of XEN1101 for the =
Treatment of Focal Epilepsy</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          All Primary and Secondary Seizure Reduction Endpoints Statistical=
ly Significant Across All Dose Groups, with p-value of
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-positive-topline-results-phase" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      October 3, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-=
2" hreflang=3D"en">Xenon Pharmaceuticals Announces Conference Call and Webc=
ast to Discuss Topline Results from Phase 2b =E2=80=98X-TOLE=E2=80=99 Clini=
cal Trial of XEN1101</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Oct. 03, 2021 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced that Xenon management will host a conference cal=
l and webcast to discuss topline results from the XEN1101 Phase 2b =E2=80=
=9CX-TOLE=E2=80=9D clinical
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-2" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 8, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-collaboration-neurocrine" hr=
eflang=3D"en">Xenon Pharmaceuticals Announces Collaboration with Neurocrine=
 Biosciences Achieves $10.0 Million Regulatory Milestone</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Phase 2 Clinical Trial to Evaluate NBI-921352 for the Treatment o=
f Focal-Onset Seizures in Adults Anticipated in 2021 BURNABY, British Colum=
bia , Sept. 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq=
:XENE), a neurology-focused biopharmaceutical company, today announced that=
 its
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-collaboration-neurocrine" hreflan=
g=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 23, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-strengthens-leadership-team-appointmen=
t-dr" hreflang=3D"en">Xenon Pharmaceuticals Strengthens Leadership Team wit=
h Appointment of Dr. Christopher Kenney as Chief Medical Officer</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Aug. 23, 2021 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced the appointment of Christopher Kenney , M.D. as =
Chief Medical Officer, effective immediately. Dr.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-strengthens-leadership-team-appointment-dr"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 11, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-second-quarter-2021-financial"=
 hreflang=3D"en">Xenon Pharmaceuticals Reports Second Quarter 2021 Financia=
l Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Topline Data from XEN1101 Phase 2b =E2=80=9CX-TOLE=E2=80=9D Clini=
cal Trial Anticipated Late September to Mid-October 2021 Conference Call at=
 4:30 pm ET Today BURNABY, British Columbia , Aug. 11, 2021 (GLOBE NEWSWIRE=
) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharm=
aceutical company, today
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-second-quarter-2021-financial" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 10, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-participate-12th-annual-wedbush-pacgro=
w" hreflang=3D"en">Xenon Pharmaceuticals to Participate in the 12th Annual =
Wedbush PacGrow Healthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Aug. 10, 2021 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced its participation in one-on-one investor meeting=
s as well as a virtual panel discussion at the 12th Annual Wedbush PacGrow
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-participate-12th-annual-wedbush-pacgrow" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 4, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-=
1" hreflang=3D"en">Xenon Pharmaceuticals Announces Conference Call and Webc=
ast to Discuss&nbsp;Second Quarter 2021 Financial Results and Provide Corpo=
rate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Aug. 04, 2021 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced it will report its second quarter 2021 financial=
 and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-1" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      July 13, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-participate-william-blair-biotech-focu=
s" hreflang=3D"en">Xenon Pharmaceuticals to Participate at the William Blai=
r Biotech Focus Conference 2021</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , July 13, 2021 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, today announced its participation in a virtual fireside chat at =
the William Blair Biotech Focus Conference 2021.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-participate-william-blair-biotech-focus" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      July 7, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-completion-patient-randomiza=
tion" hreflang=3D"en">Xenon Pharmaceuticals Announces Completion of Patient=
 Randomization in XEN1101 Phase 2b =E2=80=9CX-TOLE=E2=80=9D Clinical Trial =
and Announces Upcoming Investor Webinar with Leading Epilepsy Key Opinion L=
eaders</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Webinar to be broadcast live on Monday, July 12, 2021 beginning a=
t 10 am ET BURNABY, British Columbia , July 07, 2021 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutic=
al company, today provided an update on its ongoing XEN1101 Phase 2b =E2=80=
=9CX-TOLE=E2=80=9D
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-completion-patient-randomization"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      June 3, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-provides-corporate-update-following-it=
s" hreflang=3D"en">Xenon Pharmaceuticals Provides Corporate Update Followin=
g its Annual Meeting of Shareholders</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , June 03, 2021 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, provided a corporate update following its 2021 Annual Meeting of=
 Shareholders (the =E2=80=9CAnnual Meeting=E2=80=9D) held today on June 3, =
2021 . Dr.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-provides-corporate-update-following-its" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 31, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-jefferies-2021-virtual-healthc=
are" hreflang=3D"en">Xenon Pharmaceuticals to Present at the Jefferies 2021=
 Virtual Healthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , May 31, 2021 (GLOBE NEWSWIRE) -- Xeno=
n Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical co=
mpany, today announced that members of its executive management team will p=
articipate in the following investor conference: Jefferies 2021 Virtual Hea=
lthcare
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-jefferies-2021-virtual-healthcare" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 11, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-first-quarter-2021-financial" =
hreflang=3D"en">Xenon Pharmaceuticals Reports First Quarter 2021 Financial =
Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Topline Data from XEN1101 Phase 2b =E2=80=9CX-TOLE=E2=80=9D Clini=
cal Trial Anticipated by End of Third Quarter of 2021 Conference Call at 4:=
30 pm ET Today BURNABY, British Columbia , May 11, 2021 (GLOBE NEWSWIRE) --=
 Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceu=
tical company, today
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-first-quarter-2021-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 4, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-=
0" hreflang=3D"en">Xenon Pharmaceuticals Announces Conference Call and Webc=
ast to Discuss First Quarter 2021 Financial Results and Provide Corporate U=
pdate</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , May 04, 2021 (GLOBE NEWSWIRE) -- Xeno=
n Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical co=
mpany, today announced it will report its first quarter 2021 financial and =
operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-conference-call-and-webcast-0" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      April 8, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-participate-upcoming-investor-2" hrefl=
ang=3D"en">Xenon Pharmaceuticals to Participate in Upcoming Investor Confer=
ences</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , April 08, 2021 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical =
company, today announced that members of its executive management team will=
 present a corporate overview and participate in the following virtual inve=
stor
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-participate-upcoming-investor-2" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 29, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-participate-stifel-3rd-annual-cns-day"=
 hreflang=3D"en">Xenon Pharmaceuticals to Participate in the Stifel 3rd Ann=
ual CNS Day</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , March 29, 2021 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical =
company, today announced that the Company will participate in a fireside ch=
at at the following virtual investor conference: Stifel 3 rd Annual CNS Day
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-participate-stifel-3rd-annual-cns-day" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 12, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-closing-115-million-public" =
hreflang=3D"en">Xenon Pharmaceuticals Announces Closing of $115 Million Pub=
lic Offering and Full Exercise of the Underwriters=E2=80=99 Option to Purch=
ase Additional Shares</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , March 12, 2021 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical =
company, today announced the closing of its previously announced underwritt=
en public offering of 5,135,135 common shares, which includes 810,810 share=
s sold
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-closing-115-million-public" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 9, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-pricing-1000-million-public"=
 hreflang=3D"en">Xenon Pharmaceuticals Announces Pricing of $100.0 Million =
Public Offering</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , March 09, 2021 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical =
company, today announced the pricing of its underwritten public offering of=
 4,324,325 common shares and, in lieu of common shares to a certain investo=
r,
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-pricing-1000-million-public" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 9, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-proposed-public-offering-2" =
hreflang=3D"en">Xenon Pharmaceuticals Announces Proposed Public Offering of=
 Common Shares</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , March 09, 2021 (GLOBE NEWSWIRE) -- &n=
bsp; Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmace=
utical company, today announced that it has commenced an underwritten publi=
c offering of its common shares and, in lieu of common shares to certain in=
vestors that
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-proposed-public-offering-2" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 8, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-collaboration-researchers-ic=
ahn" hreflang=3D"en">Xenon Pharmaceuticals Announces Collaboration with Res=
earchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 St=
udy of XEN1101 for the Treatment of Major Depressive Disorder (MDD)</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          U.S. FDA IND acceptance and IRB approval in place for investigato=
r-sponsored trial, expected to be initiated in the second quarter of 2021 B=
URNABY, British Columbia , March 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmac=
euticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, to=
day
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-collaboration-researchers-icahn" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 1, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-2020-financial-results-and" hr=
eflang=3D"en">Xenon Pharmaceuticals Reports 2020 Financial Results and Prov=
ides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          XEN1101 Phase 2b =E2=80=9CX-TOLE=E2=80=9D Clinical Trial in Adult=
 Focal Epilepsy on Track for Topline Data in&nbsp; Third Quarter of 2021 Co=
nference Call at 4:30 pm ET Today BURNABY, British Columbia , March 01, 202=
1 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology=
-focused biopharmaceutical
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-2020-financial-results-and" hreflan=
g=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 23, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-conference-call-and-webcast"=
 hreflang=3D"en">Xenon Pharmaceuticals Announces Conference Call and Webcas=
t to Discuss Year-End 2020 Financial Results</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Xenon to Participate in Fireside Discussion at SVB Leerink 10th A=
nnual Global Healthcare Conference BURNABY, British Columbia , Feb. 23, 202=
1 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical =
stage biopharmaceutical company, today announced it will report its 2020 fi=
nancial
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-conference-call-and-webcast" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 22, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-promising-new-pre-clinical-d=
ata" hreflang=3D"en">Xenon Pharmaceuticals Announces Promising New Pre-Clin=
ical Data and Provides Clinical Overview of its XEN1101 Program at ASENT 20=
21</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Pre-Clinical Data Support the Potential Benefit of XEN1101 to Tre=
at Depression and Anhedonia XEN1101, in Combination with Other Anti-Seizure=
 Medications, Provides Robust Efficacy in Animal Models Topline Data from X=
EN1101 Phase 2b X-TOLE Clinical Trial in Adult Focal Epilepsy on Track for =
Third
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-promising-new-pre-clinical-data" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 14, 2021
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-outlines-key-milestone-opportunities-a=
nd" hreflang=3D"en">Xenon Pharmaceuticals Outlines Key Milestone Opportunit=
ies and Planned Leadership Transition in 2021</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Simon Pimstone to Assume New Role as Executive Chair and Ian Mort=
imer to be Named Chief Executive Officer at Annual Meeting of Shareholders =
in June 2021 Topline Data from XEN1101 Phase 2b X-TOLE Clinical Trial in Ad=
ult Focal Epilepsy on Track for Third Quarter of 2021 Phase 3 XEN496 =E2=80=
=9CEPIK=E2=80=9D Clinical
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-outlines-key-milestone-opportunities-and" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      December 7, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-provides-updates-neurology-pipeline" h=
reflang=3D"en">Xenon Pharmaceuticals Provides Updates on Neurology Pipeline=
 Programs at AES2020, the Virtual Annual Meeting of the American Epilepsy S=
ociety</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Early, Promising Data from Physician-Led Phase 2 Open Label Clini=
cal Trial Support XEN007 as a Potential Treatment of Childhood Absence Epil=
epsy (CAE) BURNABY, British Columbia , Dec. 07, 2020 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutic=
al
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-provides-updates-neurology-pipeline" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 13, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-participate-upcoming-investor-1" hrefl=
ang=3D"en">Xenon Pharmaceuticals to Participate in Upcoming Investor Confer=
ences</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 13, 2020 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical c=
ompany, today announced that Dr. Simon Pimstone , Xenon's Chief Executive O=
fficer, will participate in the following virtual investor conferences: Gug=
genheim
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-participate-upcoming-investor-1" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 5, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-third-quarter-2020-financial" =
hreflang=3D"en">Xenon Pharmaceuticals Reports Third Quarter 2020 Financial =
Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Experienced Biotech Executive, Patrick Machado , Joins Xenon=E2=
=80=99s Board of Directors Conference Call at 4:30 pm ET Today BURNABY, Bri=
tish Columbia , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc=
. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today repor=
ted financial
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-third-quarter-2020-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 2, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-24" h=
reflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Webcast to=
 Discuss&nbsp;Third Quarter 2020 Financial Results and Provide Corporate Up=
date</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical c=
ompany, today announced that it will report its third quarter 2020 financia=
l and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-24" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      October 8, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-receives-fda-feedback-and-track-initia=
te" hreflang=3D"en">Xenon Pharmaceuticals Receives FDA Feedback and is on T=
rack to Initiate XEN496 Phase 3 Clinical Trial for the Treatment of KCNQ2-D=
EE Before Year-End</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Positive Opinion Received Supporting Orphan Medicinal Product Des=
ignation in Europe for XEN496 for the Treatment of KCNQ2-DEE BURNABY, Briti=
sh Columbia , Oct. 08, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. =
(Nasdaq:XENE), a neurology-focused biopharmaceutical company, today provide=
d
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-receives-fda-feedback-and-track-initiate" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      October 8, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/neurocrine-biosciences-and-xenon-pharmaceuticals-provide" hr=
eflang=3D"en">Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regu=
latory Update on Ongoing Collaboration  to Develop First-In-Class Treatment=
 for Epilepsy</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          U.S. Food and Drug Administration &nbsp; (FDA) Requests Additiona=
l Non-Clinical Data to Support Dose Justification Before Initiation of a Ph=
ase II Clinical Trial with NBI-921352 in Pediatric SCN8A-DEE Patients FDA G=
rants Rare Pediatric Disease Designation for NBI-921352 for the Treatment o=
f SCN8A-DEE
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/neurocrine-biosciences-and-xenon-pharmaceuticals-provide" hreflan=
g=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 17, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-appoints-dr-chris-von-seggern-chief" h=
reflang=3D"en">Xenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chie=
f Commercial Officer</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Aug. 17, 2020 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutica=
l company, announced today the appointment of Dr. Chris Von Seggern as Chie=
f Commercial Officer, effective immediately. In this newly created role, Dr=
.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-appoints-dr-chris-von-seggern-chief" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 6, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-second-quarter-2020-financial"=
 hreflang=3D"en">Xenon Pharmaceuticals Reports Second Quarter 2020 Financia=
l Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          XEN496 Phase 3 Protocol Submitted to FDA and Trial Initiation Ant=
icipated in 2020 Conference Call at 4:30 pm ET Today BURNABY, British Colum=
bia , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:=
XENE), a neurology-focused biopharmaceutical company, today reported its fi=
nancial
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-second-quarter-2020-financial" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 4, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-participate-upcoming-investor-0" hrefl=
ang=3D"en">Xenon Pharmaceuticals to Participate in Upcoming Investor Confer=
ences</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical c=
ompany, today announced that Dr. Simon Pimstone , Xenon's Chief Executive O=
fficer, will participate in the following virtual investor conferences: Wil=
liam
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-participate-upcoming-investor-0" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      July 30, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-23" h=
reflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Webcast to=
 Discuss Second Quarter 2020 Financial Results and Provide Corporate Update=
</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , July 30, 2020 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical c=
ompany, today announced that it will report its second quarter 2020 financi=
al and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-23" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      June 1, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-jefferies-2020-virtual-healthc=
are" hreflang=3D"en">Xenon Pharmaceuticals to Present at the Jefferies 2020=
 Virtual Healthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , June 01, 2020 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, announced today that Dr. Simon Pimstone , Xenon=E2=80=99s Chief Exe=
cutive Officer, will present a company overview at the Jefferies Virtual He=
althcare
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-jefferies-2020-virtual-healthcare" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 21, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-first-quarter-2020-financial" =
hreflang=3D"en">Xenon Pharmaceuticals Reports First Quarter 2020 Financial =
Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Progress Reported in Both Proprietary and Partnered Neurology Cli=
nical Programs&nbsp; Additional FDA Feedback Supports Commencement of XEN49=
6 Phase 3 Clinical Trial in 2020 Conference Call at 4:30 pm ET Today BURNAB=
Y, British Columbia , May 21, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceutical=
s Inc.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-first-quarter-2020-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 14, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-22" h=
reflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Webcast to=
 Discuss First Quarter 2020 Financial Results and Provide Corporate Update<=
/a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , May 14, 2020 (GLOBE NEWSWIRE) -- Xeno=
n Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical co=
mpany, today announced that it will report its first quarter 2020 financial=
 and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-22" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 31, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-provides-corporate-update-context-covi=
d-19" hreflang=3D"en">Xenon Pharmaceuticals Provides Corporate Update in th=
e Context of COVID-19</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , March 31, 2020 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical =
company, today provided a corporate update in the context of the developing=
 situation with the COVID-19 pandemic. Dr.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-provides-corporate-update-context-covid-19"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 26, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq=
" hreflang=3D"en">Xenon Pharmaceuticals Reports Inducement Grants Under Nas=
daq Listing Rule 5635(c)(4)</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , March 26, 2020 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical =
company, today announced equity inducement grants to eight new non-officer =
employees consisting of an aggregate of 63,200 share options.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq" hre=
flang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 9, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-2019-financial-results-and" hr=
eflang=3D"en">Xenon Pharmaceuticals Reports 2019 Financial Results and Prov=
ides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Xenon=E2=80=99s Robust Neurology Pipeline of Proprietary and Part=
nered Programs Advances with Multiple Important Milestone Opportunities Ant=
icipated in 2020 Conference Call at 4:30 pm ET Today BURNABY, British Colum=
bia , March 09, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-2019-financial-results-and" hreflan=
g=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 2, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-21" h=
reflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Webcast to=
 Discuss 2019 Financial Results and Provide Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , March 02, 2020 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical =
company, today announced that it will report its 2019 financial and operati=
ng results after the close of U.S. financial markets on Monday, March 9, 20=
20 .
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-21" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 14, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-full-exercise-and-closing" h=
reflang=3D"en">Xenon Pharmaceuticals Announces Full Exercise and Closing of=
 Underwriters=E2=80=99 Option to Purchase Additional Shares</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Feb. 14, 2020 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical c=
ompany, today announced that the underwriters of its previously announced p=
ublic offering of 3,750,000 common shares, which initially closed on Januar=
y 27,
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-full-exercise-and-closing" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 27, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-closing-its-600-million-publ=
ic" hreflang=3D"en">Xenon Pharmaceuticals Announces Closing of its $60.0 Mi=
llion Public Offering of Common Shares</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Jan. 27, 2020 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical c=
ompany, today announced the closing of its previously announced public offe=
ring of 3,750,000 common shares pursuant to its existing shelf registration
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-closing-its-600-million-public" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 22, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-pricing-600-million-public" =
hreflang=3D"en">Xenon Pharmaceuticals Announces Pricing of $60.0 Million Pu=
blic Offering of Common Shares</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Jan. 22, 2020 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical c=
ompany, today announced the pricing of its underwritten public offering of =
3,750,000 common shares pursuant to its existing shelf registration stateme=
nt at a
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-pricing-600-million-public" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 22, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-proposed-public-offering-1" =
hreflang=3D"en">Xenon Pharmaceuticals Announces Proposed Public Offering of=
 Common Shares</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Jan. 22, 2020 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical c=
ompany, today announced that it has commenced an underwritten public offeri=
ng of its common shares pursuant to its existing shelf registration stateme=
nt.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-proposed-public-offering-1" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 13, 2020
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-outlines-key-milestone-opportunities-2=
020" hreflang=3D"en">Xenon Pharmaceuticals Outlines Key Milestone Opportuni=
ties for 2020 and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Xenon =E2=80=99 s Proprietary Programs Continue to Advance with M=
ultiple Mid to Late Stage Clinical Trials&nbsp; Anticipated to be Underway =
in 2020 Xenon Eligible for Milestone Payments Based on the Advancement of P=
artnered Programs Experienced Biotech Executive, Dr.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-outlines-key-milestone-opportunities-2020" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      December 7, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-provides-updates-partnered-neurology" =
hreflang=3D"en">Xenon Pharmaceuticals Provides Updates on Partnered Neurolo=
gy Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Mee=
ting</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Overview of Clinical Stage XEN901 and Related Patient Survey to b=
e Presented in the =E2=80=9CGenetic Epilepsies =E2=80=93 Updates in the Sci=
ence and Diagnosis=E2=80=9D Exhibit in Room 318 -319 on Sunday, December 8 =
th Pre-Clinical Work Suggests Selective Sodium Channel Inhibitors that Redu=
ce Action Potential Firing in
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-provides-updates-partnered-neurology" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      December 6, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-provides-updates-proprietary-neurology=
" hreflang=3D"en">Xenon Pharmaceuticals Provides Updates on Proprietary Neu=
rology Pipeline Programs at the  2019 American Epilepsy Society (AES) Annua=
l Meeting</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Xenon=E2=80=99s Epilepsy Programs Continue to Advance Including O=
ngoing XEN1101 Phase 2b Clinical Trial in Adult Focal Epilepsy and Plans fo=
r Anticipated Pediatric XEN496 Pivotal Phase 3 Clinical Trial in KCNQ2-DEE =
Patients Promising New Pre-Clinical Data Support Precision Medicine Approac=
h to Treat Dravet
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-provides-updates-proprietary-neurology" hre=
flang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      December 3, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-31st-annual-piper-jaffray" hre=
flang=3D"en">Xenon Pharmaceuticals to Present at the 31st Annual Piper Jaff=
ray Healthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Dec. 03, 2019 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, today announced that Dr. Simon Pimstone , Xenon's Chief Executive O=
fficer, will present at the 31 st Annual Piper Jaffray Healthcare Conferenc=
e in New
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-31st-annual-piper-jaffray" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      December 2, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-provi=
de-2" hreflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Web=
cast to Provide Corporate Update on License and Collaboration Agreement wit=
h Neurocrine Biosciences</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, announced that it will host a conference call and live audio webcas=
t at 8:30 am Eastern Time ( 5:30 am Pacific Time ) today to provide a corpo=
rate
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-provide-2"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      December 2, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/neurocrine-biosciences-and-xenon-pharmaceuticals-announce" h=
reflang=3D"en">Neurocrine Biosciences and Xenon Pharmaceuticals Announce Ag=
reement to Develop First-in-Class Treatments for Epilepsy</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Neurocrine Biosciences Gains Rights to XEN901, a Clinical Stage S=
elective Nav1.6 Sodium Channel Inhibitor, Being Developed for the Treatment=
 of Epilepsy Xenon Receives $50 Million Upfront and Up to $1.7 Billion in P=
otential Development, Regulatory and Commercial Milestone Payments Across A=
ll
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/neurocrine-biosciences-and-xenon-pharmaceuticals-announce" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 15, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-participate-upcoming-investor-conferen=
ces" hreflang=3D"en">Xenon Pharmaceuticals to Participate in Upcoming Inves=
tor Conferences</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 15, 2019 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, today announced that Dr. Simon Pimstone , Xenon's Chief Executive O=
fficer, will participate in the following investor conferences and present =
a company
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-participate-upcoming-investor-conferences" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 5, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-third-quarter-2019-financial" =
hreflang=3D"en">Xenon Pharmaceuticals Reports Third Quarter 2019 Financial =
Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          In Addition to Ongoing XEN1101 Phase 2b Clinical Trial in Adult F=
ocal Epilepsy,&nbsp; Company Advances Epilepsy Programs and Anticipates Ini=
tiating Pediatric Clinical Trials in&nbsp; KCNQ2 (XEN496) and SCN8A (XEN901=
) Developmental and Epileptic Encephalopathies in 2020&nbsp; XEN007 Phase 2=
 Proof-Of-Concept,
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-third-quarter-2019-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      October 29, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-20" h=
reflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Webcast to=
 Discuss Third Quarter 2019 Financial Results and Provide Corporate Update<=
/a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, today announced that it will report its third quarter 2019 financia=
l and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-20" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 25, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-2019-cantor-global-healthcare"=
 hreflang=3D"en">Xenon Pharmaceuticals to Present at the 2019 Cantor Global=
 Healthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical =
company, today announced that Dr. Simon Pimstone , Xenon's Chief Executive =
Officer, will present a corporate update at the 2019 Cantor Global Healthca=
re
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-2019-cantor-global-healthcare" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 17, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-announces-appointment-shelley-mccloskey-senior-vice" h=
reflang=3D"en">Xenon Announces Appointment of Shelley McCloskey as Senior V=
ice President, Human Resources</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(=
c)(4) BURNABY, British Columbia , Sept. 17, 2019 (GLOBE NEWSWIRE) -- Xenon =
Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical comp=
any, announced that Shelley McCloskey has joined the company=E2=80=99s lead=
ership team as
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-announces-appointment-shelley-mccloskey-senior-vice" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 9, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/flexion-therapeutics-and-xenon-pharmaceuticals-announce-flex=
ions" hreflang=3D"en">Flexion Therapeutics and Xenon Pharmaceuticals Announ=
ce Flexion=E2=80=99s Acquisition of an Investigational NaV1.7 Inhibitor for=
 the Treatment of Post-Operative Pain</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Flexion=E2=80=99s new locally delivered product candidate, FX301,=
 will combine Xenon=E2=80=99s NaV1.7 inhibitor, XEN402, with a novel thermo=
sensitive hydrogel FX301 is a potential first-in-class therapy with the aim=
 of providing pain relief via peripheral nerve block for up to a week follo=
wing surgery while
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/flexion-therapeutics-and-xenon-pharmaceuticals-announce-flexions"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 6, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-second-quarter-2019-financial"=
 hreflang=3D"en">Xenon Pharmaceuticals Reports Second Quarter 2019 Financia=
l Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Anticipate Testing of New Pediatric Formulations of XEN496 and XE=
N901 in Adults in Third Quarter,&nbsp; Followed by IND Submissions to Initi=
ate Pediatric Clinical Trials in&nbsp;&nbsp; KCNQ2 and SCN8A Developmental =
and Epileptic Encephalopathies Conference Call at 4:30 pm ET Today BURNABY,=
 British Columbia , Aug.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-second-quarter-2019-financial" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      July 31, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-19" h=
reflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Webcast to=
 Discuss Second Quarter 2019 Financial Results and Provide Corporate Update=
</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , July 31, 2019 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, today announced that it will report its second quarter 2019 financi=
al and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-19" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      June 5, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-presents-corporate-update-neurology" h=
reflang=3D"en">Xenon Pharmaceuticals Presents Corporate Update on Neurology=
-Focused Pipeline at the Jefferies 2019 Healthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Company Highlights Recent Regulatory Feedback Guiding the Clinica=
l Development of XEN901&nbsp; into Pediatric SCN8A-EE Patients Webcast of C=
onference Presentation at 11:00 am ET Today BURNABY, British Columbia , Jun=
e 05, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-presents-corporate-update-neurology" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 29, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-jefferies-2019-healthcare" hre=
flang=3D"en">Xenon Pharmaceuticals to Present at the Jefferies 2019 Healthc=
are Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , May 29, 2019 (GLOBE NEWSWIRE) -- Xeno=
n Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical co=
mpany, today announced that Dr. Simon Pimstone , Xenon's Chief Executive Of=
ficer, will present a corporate update at the Jefferies 2019 Healthcare Con=
ference
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-jefferies-2019-healthcare" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 7, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-first-quarter-2019-financial" =
hreflang=3D"en">Xenon Pharmaceuticals Reports First Quarter 2019 Financial =
Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Company Reports Advancements in Neurology-Focused Pipeline and An=
ticipates Multiple Products in&nbsp; Phase 2 or Later Stage Development thi=
s Year Conference Call at 4:30 pm ET Today BURNABY, British Columbia , May =
07, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-first-quarter-2019-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      April 30, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-18" h=
reflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Webcast to=
 Discuss  First Quarter 2019 Financial Results and Provide Corporate Update=
</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , April 30, 2019 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical =
company, today announced that it will report its first quarter 2019 financi=
al and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-18" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      April 24, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-2019-bloom-burton-co-healthcar=
e" hreflang=3D"en">Xenon Pharmaceuticals to Present at the 2019 Bloom Burto=
n &amp; Co. Healthcare Investor Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , April 24, 2019 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical =
company, today announced that Dr. Simon Pimstone , Xenon's Chief Executive =
Officer, will present a corporate update at the Bloom Burton &amp; Co.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-2019-bloom-burton-co-healthcare" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 6, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-2018-financial-results-and" hr=
eflang=3D"en">Xenon Pharmaceuticals Reports 2018 Financial Results and Prov=
ides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Multiple Neurology-Focused Products Anticipated to be in Phase 2 =
or Later Stage Development in 2019 Global XEN1101 Phase 2b Clinical Trial U=
nderway with Data Anticipated in Second Half of 2020 Conference Call at 4:3=
0 pm ET Today BURNABY, British Columbia , March 06, 2019 (GLOBE NEWSWIRE) -=
- Xenon
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-2018-financial-results-and" hreflan=
g=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 27, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-17" h=
reflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Webcast to=
 Discuss 2018 Financial Results and Provide Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, today announced that it will report its 2018 financial and operatin=
g results after the close of U.S. financial markets on Wednesday, March 6, =
2019 .
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-17" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 26, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/behind-seizuretm-program-expansion-helps-speed-diagnosis-gen=
etic" hreflang=3D"en">Behind the Seizure=E2=84=A2 Program Expansion Helps S=
peed the Diagnosis  of Genetic Epilepsy in Younger Children Experiencing Un=
provoked Seizures </a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Behind the Seizure=E2=84=A2 Program Expansion Helps Speed the Dia=
gnosis &nbsp;of Genetic Epilepsy in Younger Children Experiencing Unprovoke=
d Seizures =E2=80=94 Stoke Therapeutics and Xenon Pharmaceuticals Join &nbs=
p;Founders BioMarin and Invitae to Offer a No-Cost Epilepsy Gene Panel Test=
ing &nbsp;Program for Children Up to 60
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/behind-seizuretm-program-expansion-helps-speed-diagnosis-genetic"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 28, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-provides-key-regulatory-updates-xen007-and-xen1101" hr=
eflang=3D"en">Xenon Provides Key Regulatory Updates on XEN007 and XEN1101</=
a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          FDA Grants Rare Pediatric Disease Designation to XEN007 for Alter=
nating Hemiplegia of Childhood (AHC); Xenon Eligible to Apply for Priority =
Review Voucher IND for XEN1101 Accepted; Site Selection and Patient Enrollm=
ent Underway in Canada and the United States for XEN1101 Phase 2b Clinical =
Trial
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-provides-key-regulatory-updates-xen007-and-xen1101" hreflan=
g=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 6, 2019
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-outlines-2019-key-milestones" hreflang=
=3D"en">Xenon Pharmaceuticals Outlines 2019 Key Milestones</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Innovative Product Pipeline Includes Multiple Neurology-Focused P=
roducts Anticipated to be in Phase 2 or Later Stage Development in 2019 BUR=
NABY, British Columbia , Jan. 06, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceut=
icals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today=
 provided
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-outlines-2019-key-milestones" hreflang=3D"e=
n">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      December 3, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-announces-final-results-xen1101-phase-1-clinical-trial=
-and" hreflang=3D"en">Xenon Announces Final Results of XEN1101 Phase 1 Clin=
ical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epil=
epsy Society (AES) Annual Meeting</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          XEN1101 CTA Accepted by Health Canada for Initiation of Phase 2 C=
linical Trial in Adult Focal Epilepsy; U.S. IND Filing Targeted in Q1 2019 =
Conference Call to Discuss Xenon=E2=80=99s Epilepsy Programs at 9 am ET Tod=
ay BURNABY, British Columbia , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Xenon Phar=
maceuticals Inc.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-announces-final-results-xen1101-phase-1-clinical-trial-and"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 30, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-provi=
de-1" hreflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Web=
cast to Provide Corporate Update and Overview of Presentations at the 2018 =
American Epilepsy Society (AES) Meeting</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 30, 2018 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, today announced that it will host a conference call and live audio =
webcast on Monday, December 3, 2018 at 9:00 am Eastern Time ( 6:00 am Pacif=
ic Time )
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-provide-1"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 7, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-stifel-2018-healthcare-confere=
nce" hreflang=3D"en">Xenon Pharmaceuticals to Present at the Stifel 2018 He=
althcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, today announced that Dr. Simon Pimstone , Xenon's Chief Executive O=
fficer, will present a corporate update at the Stifel 2018 Healthcare Confe=
rence in
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-stifel-2018-healthcare-conference" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 6, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-third-quarter-2018-financial" =
hreflang=3D"en">Xenon Pharmaceuticals Reports Third Quarter 2018 Financial =
Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Robust, Novel Pipeline of Neurology Candidates Advancing in Clini=
cal Development Conference Call at 4:30 pm ET Today BURNABY, British Columb=
ia , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:X=
ENE), a clinical stage biopharmaceutical company, today reported its financ=
ial
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-third-quarter-2018-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      October 30, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-16" h=
reflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Webcast to=
 Discuss Third Quarter 2018 Financial Results and Provide Corporate Update<=
/a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, today announced that it will report its third quarter 2018 financia=
l and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-16" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 17, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-closing-its-630-million-publ=
ic" hreflang=3D"en">Xenon Pharmaceuticals Announces Closing of its $63.0 Mi=
llion Public Offering of Common Shares</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical stage, neurology-f=
ocused biopharmaceutical company, today announced the closing of its previo=
usly announced public offering of 4,500,000 common shares pursuant to its e=
xisting shelf
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-closing-its-630-million-public" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 12, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-pricing-630-million-public" =
hreflang=3D"en">Xenon Pharmaceuticals Announces Pricing of $63.0 Million Pu=
blic Offering of Common Shares</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Sept. 12, 2018 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical stage, neurology-f=
ocused biopharmaceutical company, today announced the pricing of its underw=
ritten public offering of 4,500,000 common shares pursuant to its existing =
shelf
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-pricing-630-million-public" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 12, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-proposed-public-offering-0" =
hreflang=3D"en">Xenon Pharmaceuticals Announces Proposed Public Offering of=
 Common Shares</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Sept. 12, 2018 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical stage, neurology-f=
ocused biopharmaceutical company, today announced that it has commenced an =
underwritten public offering of its common shares pursuant to its existing =
shelf
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-proposed-public-offering-0" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 10, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-enters-agreement-buy-out-milestones-and-royalties-rela=
ted" hreflang=3D"en">Xenon Enters into Agreement to Buy Out Milestones and =
Royalties Related to its XEN1101 Program</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Sept. 10, 2018 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical stage, neurology-f=
ocused biopharmaceutical company, today announced it has signed an agreemen=
t with Valeant Pharmaceuticals Luxembourg S.a.r.l.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-enters-agreement-buy-out-milestones-and-royalties-related" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 6, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-expands-ion-channel-neurology-pipeline-addition-xen496=
" hreflang=3D"en">Xenon Expands Ion Channel Neurology Pipeline with Additio=
n of XEN496, a =E2=80=9CPhase 3 Ready=E2=80=9D Potassium Channel Modulator =
for the Treatment of Epilepsy</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Single, Pivotal Phase 3 Clinical Trial in Approximately 20 KCNQ2-=
EE Patients Expected to be&nbsp; Initiated in Mid-2019 Conference Call Toda=
y at 8:00 am ET Xenon to Webcast Update on Epilepsy Pipeline from Biocentur=
y NewsMakers Conference on September 7, 2018 BURNABY, British Columbia , Se=
pt.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-expands-ion-channel-neurology-pipeline-addition-xen496" hre=
flang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 29, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-announces-positive-xen1101-pharmacodynamic-data-phase-=
1b" hreflang=3D"en">Xenon Announces Positive XEN1101 Pharmacodynamic Data f=
rom Phase 1b TMS Study</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          XEN1101 Demonstrates Statistically Significant Reduction in Corti=
cospinal and Cortical Excitability as Measured by TMS-EMG and TMS-EEG XEN11=
01 Demonstrates Greater Effect on TMS-EMG Resting Motor Threshold at Signif=
icantly Lower Dose When Compared to Historical Ezogabine Data XEN1101 Phase=
 2
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-announces-positive-xen1101-pharmacodynamic-data-phase-1b" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 7, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-second-quarter-2018-financial"=
 hreflang=3D"en">Xenon Pharmaceuticals Reports Second Quarter 2018 Financia=
l Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Novel Epilepsy Product Candidates =E2=80=93 XEN1101 and XEN901 =
=E2=80=93 Continue to Advance in the Clinic New XEN1101 Phase 1b TMS Pharma=
codynamic Data to be Presented at upcoming European Congress on Epileptolog=
y BURNABY, British Columbia , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Xenon Pharm=
aceuticals Inc.&nbsp;
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-second-quarter-2018-financial" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 3, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-15" h=
reflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Webcast to=
 Discuss  Second Quarter 2018 Financial Results and Provide Corporate Updat=
e</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, today announced that it will report its second quarter 2018 financi=
al and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-15" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      July 12, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-market-equity-offering" href=
lang=3D"en">Xenon Pharmaceuticals Announces At-The-Market Equity Offering</=
a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , July 12, 2018 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical stage biopharmaceut=
ical company, announced today that it has entered into an at-the-market equ=
ity offering sales agreement with Jefferies and Stifel, effective as of Jul=
y 11, 2018 ,
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-market-equity-offering" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      June 1, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-jefferies-2018-healthcare" hre=
flang=3D"en">Xenon Pharmaceuticals to Present at the Jefferies 2018 Healthc=
are Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          <p>BURNABY, British Columbia , June 01, 2018 (GLOBE NEWSWIRE) -- =
Xenon Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmac=
eutical company, today announced that Dr. Simon Pimstone , Xenon's Chief Ex=
ecutive Officer, will present a corporate update at the Jefferies 2018 Heal=
thcare Conference</p>

		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-jefferies-2018-healthcare" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 15, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-presents-positive-xen1101-tms-pharmacodynamic-phase-1-=
data" hreflang=3D"en">Xenon Presents Positive XEN1101 TMS Pharmacodynamic P=
hase 1 Data at 14th Eilat Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          <p>Company to Hold Conference Call at 8:00 am ET Today XEN1101 Pi=
lot TMS-EEG Data Demonstrates Statistically Significant Effect of 20mg Dose=
 versus Baseline (p</p>

		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-presents-positive-xen1101-tms-pharmacodynamic-phase-1-data"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 15, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-presents-xen901-phase-1-clinical-update-and-supporting=
-pre" hreflang=3D"en">Xenon Presents XEN901 Phase 1 Clinical Update and Sup=
porting Pre-clinical Data at 14th Eilat Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          <p>Company to Hold Conference Call at 8:00 am ET Today Preliminar=
y Phase 1 Clinical Data Support Drug Exposure Levels Higher than Required i=
n Pre-clinical Efficacy Models with Excellent Tolerability and Safety New P=
re-clinical Data Support Selective Nav1.6 Mechanism of Action and XEN901 Ef=
ficacy</p>

		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-presents-xen901-phase-1-clinical-update-and-supporting-pre"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 14, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-provi=
de" hreflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Webca=
st to Provide Corporate Update and  Overview of XEN1101 and XEN901 Presenta=
tions at 14th Eilat Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          <p>BURNABY, British Columbia , May 14, 2018 (GLOBE NEWSWIRE) -- X=
enon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical=
 company, today announced that it will provide a corporate update and overv=
iew of the presentations on its proprietary epilepsy products, XEN1101 and =
XEN901, at</p>

		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-provide" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 8, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-first-quarter-2018-financial" =
hreflang=3D"en">Xenon Pharmaceuticals Reports First Quarter 2018 Financial =
Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          <p>Xenon=E2=80=99s novel clinical stage epilepsy candidates, XEN1=
101 and XEN901, to be presented at upcoming&nbsp; 14th Eilat Conference on =
New Antiepileptic Drugs and Devices on May 15, 2018 BURNABY, British Columb=
ia , May 08, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc.&nbsp; (Nas=
daq:XENE), a clinical stage</p>

		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-first-quarter-2018-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 1, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-13" h=
reflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Webcast to=
 Discuss  First Quarter 2018 Financial Results and Provide Corporate Update=
</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          <p>BURNABY, British Columbia , May 01, 2018 (GLOBE NEWSWIRE) -- X=
enon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical=
 company, today announced that it will report its first quarter 2018 financ=
ial and operating results after the close of U.S.</p>

		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-13" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      April 25, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-2018-bloom-burton-co-healthcar=
e" hreflang=3D"en">Xenon Pharmaceuticals to Present at the 2018 Bloom Burto=
n &amp; Co. Healthcare Investor Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          <p>BURNABY, British Columbia , April 25, 2018 (GLOBE NEWSWIRE) --=
 Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutic=
al company, today announced that Dr. Simon Pimstone , Xenon's Chief Executi=
ve Officer, will present a corporate update at the Bloom Burton &amp;amp; C=
o.</p>

		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-2018-bloom-burton-co-healthcare" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 28, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-confirms-closing-transaction-teva-and"=
 hreflang=3D"en">Xenon Pharmaceuticals Confirms Closing of Transaction with=
 Teva and Announces Preferred Share Exchange Agreement with BVF Partners L.=
P.</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          <p>BURNABY, British Columbia , March 28, 2018 (GLOBE NEWSWIRE) --=
 Xenon Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical stage biopharma=
ceutical company, today reported the closing of the previously announced tr=
ansaction with Teva Pharmaceuticals International GmbH , along with Teva Ca=
nada Limited</p>

		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-confirms-closing-transaction-teva-and" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 13, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/dr-ernesto-aycardi-joins-xenon-pharmaceuticals-chief-medical=
" hreflang=3D"en">Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief =
Medical Officer</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Changes to Senior Leadership Support Expanding Neurology Pipeline=
 BURNABY, British Columbia , March 13, 2018 (GLOBE NEWSWIRE) -- Xenon Pharm=
aceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical stage biopharmaceutical com=
pany, today announced that Dr. Ernesto Aycardi will join the company as its=
 Chief Medical
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/dr-ernesto-aycardi-joins-xenon-pharmaceuticals-chief-medical" hre=
flang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 7, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-2017-financial-results-and" hr=
eflang=3D"en">Xenon Pharmaceuticals Reports 2017 Financial Results and Prov=
ides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Two novel anti-epileptic drugs advancing in clinical development;=
 Interim XEN1101 Phase 1 data expected to be released in May 2018 at scient=
ific symposium; Xenon announces new clinical stage ion channel product to e=
xpand its neurology pipeline BURNABY, British Columbia , March 07, 2018 (GL=
OBE
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-2017-financial-results-and" hreflan=
g=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 28, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-12" h=
reflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Webcast to=
 Discuss 2017 Financial Results and Provide Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, today announced that it will report its 2017 financial and operatin=
g results after the close of U.S. financial markets on Wednesday, March 7, =
2018 .
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-12" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 20, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-advances-second-proprietary-epilepsy" =
hreflang=3D"en">Xenon Pharmaceuticals Advances Second Proprietary Epilepsy =
Product into the Clinic with  Initiation of XEN901 Phase 1 Clinical Trial</=
a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Feb. 20, 2018 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceut=
ical company, today announced the initiation of a Phase 1 clinical trial of=
 its proprietary epilepsy product candidate, XEN901, which is an orally adm=
inistered,
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-advances-second-proprietary-epilepsy" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 8, 2018
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-outlines-key-milestones-2018" hreflang=
=3D"en">Xenon Pharmaceuticals Outlines Key Milestones for 2018</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceut=
ical company, today provided a corporate update and outlined its anticipate=
d key corporate milestones for 2018. Dr. Simon Pimstone , Xenon's President=
 and Chief
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-outlines-key-milestones-2018" hreflang=3D"e=
n">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      December 4, 2017
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/positive-preclinical-data-xenons-xen901-epilepsy-program-be"=
 hreflang=3D"en">Positive Preclinical Data from Xenon=E2=80=99s XEN901 Epil=
epsy Program to be Presented at the 71st American Epilepsy Society Annual M=
eeting</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Data Suggest Xenon=E2=80=99s Selective Nav1.6 Sodium Channel Inhi=
bitor, XEN901, Provides Efficacy with a Potentially Improved Safety Profile=
 over Other Non-Selective, Sodium Channel Blocker Anti-Epileptic Drugs (AED=
s) BURNABY, British Columbia , Dec. 04, 2017 (GLOBE NEWSWIRE) -- Xenon Phar=
maceuticals Inc.&nbsp;
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/positive-preclinical-data-xenons-xen901-epilepsy-program-be" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 8, 2017
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-stifel-2017-healthcare-confere=
nce" hreflang=3D"en">Xenon Pharmaceuticals to Present at the Stifel 2017 He=
althcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 08, 2017 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceut=
ical company, today announced that Dr. Simon Pimstone , Xenon's President a=
nd Chief Executive Officer, will present a corporate update at the Stifel 2=
017 Healthcare
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-stifel-2017-healthcare-conference" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 7, 2017
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-third-quarter-2017-financial" =
hreflang=3D"en">Xenon Pharmaceuticals Reports Third Quarter 2017 Financial =
Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceut=
ical company, today reported its financial results for the quarter ended Se=
ptember 30, 2017 , and provided a corporate update. Dr.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-third-quarter-2017-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 1, 2017
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-10" h=
reflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Webcast to=
 Discuss Third Quarter 2017 Financial Results and Provide Corporate Update<=
/a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, today announced that it will report its 2017 third quarter financia=
l and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-10" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      October 17, 2017
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-initiation-xen1101-phase-1" =
hreflang=3D"en">Xenon Pharmaceuticals Announces Initiation of XEN1101 Phase=
 1 Clinical Trial</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Xenon=E2=80=99s innovative, proprietary epilepsy programs continu=
e to advance in development Pharmacodynamic read-out expected in Q1 2018 an=
d XEN1101 Phase 2 proof-of-concept clinical trial anticipated to begin in Q=
3 2018 BURNABY, British Columbia , Oct. 17, 2017 (GLOBE NEWSWIRE) -- Xenon =
Pharmaceuticals
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-initiation-xen1101-phase-1" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 3, 2017
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-second-quarter-2017-financial"=
 hreflang=3D"en">Xenon Pharmaceuticals Reports Second Quarter 2017 Financia=
l Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Aug. 03, 2017 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceut=
ical company, today reported its financial results for the quarter ended Ju=
ne 30, 2017 , and provided a corporate update for 2017. Dr.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-second-quarter-2017-financial" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      July 27, 2017
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discu=
ss-9" hreflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Web=
cast to Discuss Second Quarter 2017 Financial Results and Provide Corporate=
 Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , July 27, 2017 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, today announced that it will report its 2017 second quarter financi=
al and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discuss-9"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      June 27, 2017
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-today=
-0" hreflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Webca=
st Today at 9:00 a.m. Eastern Time to Discuss Topline Results from TV-45070=
 Phase 2b Clinical Trial in PHN</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , June 27, 2017 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, announced that it will host a conference call and live audio webcas=
t at 9:00 a.m. Eastern Time ( 6:00 a.m.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-today-0" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      June 27, 2017
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/teva-and-xenon-announce-phase-ii-study-topical-tv-45070-pati=
ents" hreflang=3D"en">Teva and Xenon Announce Phase II Study of Topical TV-=
45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary E=
ndpoint</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          JERUSALEM and BURNABY, British Columbia , June 27, 2017 (GLOBE NE=
WSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and =
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announce top-line results in a Pha=
se II study of topical TV-45070 in patients with post-herpetic neuralgia (P=
HN).
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/teva-and-xenon-announce-phase-ii-study-topical-tv-45070-patients"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      June 2, 2017
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-jefferies-2017-healthcare" hre=
flang=3D"en">Xenon Pharmaceuticals to Present at the Jefferies 2017 Healthc=
are Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , June 02, 2017 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceut=
ical company, today announced that Dr. Simon Pimstone , Xenon's President a=
nd Chief Executive Officer, will present a corporate update at the Jefferie=
s 2017
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-jefferies-2017-healthcare" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 9, 2017
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-first-quarter-2017-financial" =
hreflang=3D"en">Xenon Pharmaceuticals Reports First Quarter 2017 Financial =
Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , May 09, 2017 (GLOBE NEWSWIRE) -- Xeno=
n Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceuti=
cal company today, reported its financial results for the quarter ended Mar=
ch 31, 2017 , and provided a corporate update for 2017. Dr.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-first-quarter-2017-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 4, 2017
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discu=
ss-8" hreflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Web=
cast to Discuss First Quarter 2017  Financial Results and Provide Corporate=
 Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , May 04, 2017 (GLOBE NEWSWIRE) -- Xeno=
n Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical co=
mpany, today announced that it will report its 2017 first quarter financial=
 and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discuss-8"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      April 28, 2017
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-2017-bloom-burton-co-healthcar=
e" hreflang=3D"en">Xenon Pharmaceuticals to Present at the 2017 Bloom Burto=
n &amp; Co. Healthcare Investor Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , April 28, 2017 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceu=
tical company, today announced that Dr. Simon Pimstone , Xenon's President =
and Chief Executive Officer, will present a corporate update at the Bloom B=
urton &amp;
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-2017-bloom-burton-co-healthcare" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      April 26, 2017
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-expands-ion-channel-neurology-pipeline-acquisition-new=
" hreflang=3D"en">Xenon Expands Ion Channel Neurology Pipeline with Acquisi=
tion of New Potassium Channel Modulator  for the Treatment of Epilepsy</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Phase 1 expected to begin in Q4 2017, with pharmacodynamic read-o=
ut in Q1 2018 and&nbsp; Phase 2 proof-of-concept clinical trial beginning i=
n mid-2018 Conference call to be held today at 9:00 am ET BURNABY, British =
Columbia , April 26, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc.&nb=
sp; (Nasdaq:XENE),
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-expands-ion-channel-neurology-pipeline-acquisition-new" hre=
flang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 24, 2017
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-xen801-did-not-meet-efficacy=
" hreflang=3D"en">Xenon Pharmaceuticals Announces XEN801 Did Not Meet Effic=
acy Endpoints in Phase 2 Clinical Trial in Patients with Moderate to Severe=
 Acne</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Company to Hold Conference Call at 8:30 am ET Today BURNABY, Brit=
ish Columbia , March 24, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc=
.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today re=
ported topline efficacy results from the double-blind, multi-center, vehicl=
e-controlled,
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-xen801-did-not-meet-efficacy" hre=
flang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 8, 2017
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-2016-financial-results-and" hr=
eflang=3D"en">Xenon Pharmaceuticals Reports 2016 Financial Results and Prov=
ides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , March 08, 2017 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceu=
tical company, today reported its financial results for the year ended Dece=
mber 31, 2016 , and provided a corporate update for 2017. Dr.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-2016-financial-results-and" hreflan=
g=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 1, 2017
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discu=
ss-7" hreflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Web=
cast to Discuss 2016 Financial Results  and Provide Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , March 01, 2017 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical =
company, today announced that it will report its 2016 financial and operati=
ng results after the close of U.S. financial markets on Wednesday, March 8,=
 2017 .
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discuss-7"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 8, 2017
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-outlines-key-milestones-2017" hreflang=
=3D"en">Xenon Pharmaceuticals Outlines Key Milestones for 2017</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Jan. 08, 2017 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceut=
ical company, today outlined its anticipated key corporate milestones for 2=
017. Dr. Simon Pimstone , Xenon's President and Chief Executive Officer, sa=
id, =E2=80=9CAs we
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-outlines-key-milestones-2017" hreflang=3D"e=
n">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 8, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-stifel-2016-healthcare-confere=
nce" hreflang=3D"en">Xenon Pharmaceuticals to Present at the Stifel 2016 He=
althcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 08, 2016 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceut=
ical company, today announced that Dr. Simon Pimstone , Xenon's President a=
nd Chief Executive Officer, will present a corporate update at the Stifel 2=
016 Healthcare
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-stifel-2016-healthcare-conference" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 3, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-third-quarter-2016-financial" =
hreflang=3D"en">Xenon Pharmaceuticals Reports Third Quarter 2016 Financial =
Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 03, 2016 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceut=
ical company, today reported its financial results for the quarter ended Se=
ptember 30, 2016 and provided a corporate update. Dr.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-third-quarter-2016-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      October 27, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discu=
ss-6" hreflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Web=
cast to Discuss Third Quarter 2016 Financial Results and Provide Corporate =
Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Oct. 27, 2016 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceut=
ical company, today announced that it will report its 2016 third quarter fi=
nancial and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discuss-6"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 27, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-appoints-dawn-svoronos-its-board-direc=
tors" hreflang=3D"en">Xenon Pharmaceuticals Appoints Dawn Svoronos to Its B=
oard of Directors</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Sept. 27, 2016 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical =
company, today announced that Dawn Svoronos has been appointed to its Board=
 of Directors. Ms. Svoronos is a pharmaceutical industry executive whose ex=
perience
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-appoints-dawn-svoronos-its-board-directors"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 13, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-exercise-full-option-purchas=
e" hreflang=3D"en">Xenon Pharmaceuticals Announces Exercise in Full of Opti=
on to Purchase Additional Shares and Closing of $34.5 Million Public Offeri=
ng</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Sept. 13, 2016 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceu=
tical company, today announced that the underwriters of the previously anno=
unced public offering of its common shares have exercised in full their opt=
ion to
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-exercise-full-option-purchase" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 8, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-pricing-30-million-public" h=
reflang=3D"en">Xenon Pharmaceuticals Announces Pricing of $30 Million Publi=
c Offering of Common Shares</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Sept. 08, 2016 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceu=
tical company, today announced the pricing of a $30 million underwritten pu=
blic offering of its common shares pursuant to its existing shelf registrat=
ion statement
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-pricing-30-million-public" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 7, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-proposed-public-offering-com=
mon" hreflang=3D"en">Xenon Pharmaceuticals Announces Proposed Public Offeri=
ng of Common Shares</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Sept. 07, 2016 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc.&nbsp;(Nasdaq:XENE), a clinical-stage biopharmaceut=
ical company, today announced that it has commenced an underwritten public =
offering of its common shares pursuant to its existing shelf registration s=
tatement and
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-proposed-public-offering-common" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 3, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-second-quarter-2016-financial"=
 hreflang=3D"en">Xenon Pharmaceuticals Reports Second Quarter 2016 Financia=
l Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Aug. 03, 2016 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceut=
ical company, today reported its financial results for the quarter ended Ju=
ne 30, 2016 and provided a corporate update.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-second-quarter-2016-financial" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 2, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-canaccord-genuity-36th-annual"=
 hreflang=3D"en">Xenon Pharmaceuticals to Present at the Canaccord Genuity =
36th Annual Growth Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Aug. 02, 2016 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceut=
ical company, today announced that Dr. Simon Pimstone , Xenon's President a=
nd Chief Executive Officer, will present a corporate update at the Canaccor=
d Genuity 36th
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-canaccord-genuity-36th-annual" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      July 25, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discu=
ss-5" hreflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Web=
cast to Discuss Second Quarter 2016 Financial Results and Provide Corporate=
 Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , July 25, 2016 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceut=
ical company, today announced that it will report its 2016 second quarter f=
inancial and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discuss-5"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      June 8, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-presents-corporate-update-and-highligh=
ts" hreflang=3D"en">Xenon Pharmaceuticals Presents Corporate Update and Hig=
hlights Its Proprietary Therapeutic Programs  at the Jefferies 2016 Healthc=
are Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , June 08, 2016 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceut=
ical company, announced that Dr. Simon Pimstone , Xenon's President and Chi=
ef Executive Officer, will present today at the Jefferies 2016 Healthcare C=
onference in
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-presents-corporate-update-and-highlights" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      June 2, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-jefferies-2016-healthcare" hre=
flang=3D"en">Xenon Pharmaceuticals to Present at the Jefferies 2016 Healthc=
are Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , June 02, 2016 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceut=
ical company, today announced that Dr. Simon Pimstone , Xenon's President a=
nd Chief Executive Officer, will present a corporate update at the Jefferie=
s 2016
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-jefferies-2016-healthcare" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 10, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-first-quarter-2016-financial" =
hreflang=3D"en">Xenon Pharmaceuticals Reports First Quarter 2016 Financial =
Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , May 10, 2016 (GLOBE NEWSWIRE) -- Xeno=
n Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceuti=
cal company, today reported its financial results for the quarter ended Mar=
ch 31, 2016 and provided a corporate update.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-first-quarter-2016-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 2, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discu=
ss-4" hreflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Web=
cast to Discuss First Quarter 2016  Financial Results and Provide Corporate=
 Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , May 02, 2016 (GLOBE NEWSWIRE) -- Xeno=
n Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceuti=
cal company, today announced that it will report its 2016 first quarter fin=
ancial and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discuss-4"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      April 4, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-names-dr-raymond-j-winquist-head-translational-researc=
h" hreflang=3D"en">Xenon Names Dr. Raymond J. Winquist as Head, Translation=
al Research</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , April 04, 2016 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical =
company, today announced that Dr. Raymond J. Winquist has been named as its=
 Head, Translational Research , effective immediately. Reporting to the CEO=
, Dr.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-names-dr-raymond-j-winquist-head-translational-research" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 31, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-provide-business-and-milestone-update-=
0" hreflang=3D"en">Xenon Pharmaceuticals to Provide Business and Milestone =
Update at Needham Healthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , March 31, 2016 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceu=
tical company, today announced that Dr. Simon Pimstone , Xenon's President =
and Chief Executive Officer, will present a business update, including prog=
ress toward
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-provide-business-and-milestone-update-0" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 15, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-and-genentech-extend-collaborations-focused-pain" href=
lang=3D"en">Xenon and Genentech Extend Collaborations Focused on Pain</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , March 15, 2016 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical =
company, today provided an update on its two ongoing collaborations focused=
 on identifying and developing novel pain targets and therapeutics with Gen=
entech, a
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-and-genentech-extend-collaborations-focused-pain" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 8, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-2015-financial-results-and" hr=
eflang=3D"en">Xenon Pharmaceuticals Reports 2015 Financial Results and Prov=
ides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Significant Progress&nbsp;in Proprietary Development Pipeline and=
 Partnered Programs Initiated Phase 2 Trial of XEN801 in Moderate to Severe=
 Acne; Results Anticipated in Fourth Quarter of 2016 BURNABY, British Colum=
bia , March 08, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc.&nbsp; (=
Nasdaq:XENE), a
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-2015-financial-results-and" hreflan=
g=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 1, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discu=
ss-3" hreflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Web=
cast to Discuss 2015 Financial Results and Provide Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , March 01, 2016 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc.&nbsp; (Nasdaq:XENE), a clinical-stage biopharmaceu=
tical company, today announced that it will report its 2015 financial and o=
perating results after the close of U.S. financial markets on Tuesday, Marc=
h 8, 2016 .
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discuss-3"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 10, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-initiates-phase-2-clinical-trial-xen801-treat-moderate=
" hreflang=3D"en">Xenon Initiates Phase 2 Clinical Trial of XEN801 to Treat=
 Moderate to Severe Acne</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Feb. 10, 2016 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, today announced that it has commenced dosing patients in a Phase 2 =
clinical trial of XEN801, which is a stearoyl Co-A desaturase-1, or SCD1, i=
nhibitor
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-initiates-phase-2-clinical-trial-xen801-treat-moderate" hre=
flang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 9, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-names-dr-james-r-empfield-senior-vice-president-drug" =
hreflang=3D"en">Xenon Names Dr. James R. Empfield Senior Vice President, Dr=
ug Discovery</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Feb. 09, 2016 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, today announced that Dr. James R. Empfield has been named as Senior=
 Vice President, Drug Discovery, effective immediately. Reporting to Dr.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-names-dr-james-r-empfield-senior-vice-president-drug" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 11, 2016
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-outlines-key-milestones-2016" hreflang=3D"en">Xenon Ou=
tlines Key Milestones for 2016</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Jan. 11, 2016 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, today outlined its anticipated key corporate milestones for 2016. D=
r. Simon Pimstone , Xenon=E2=80=99s President and Chief Executive Officer, =
stated: =E2=80=9COverall,
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-outlines-key-milestones-2016" hreflang=3D"en">More &gt;&gt;=
</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      December 17, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-and-genentech-publish-science-3-d-crystal-structure-no=
vel" hreflang=3D"en">Xenon and Genentech Publish in Science the 3-D Crystal=
 Structure of a Novel Nav1.7 Compound Binding Site Enabling the Development=
 of Potent Selective Inhibitors to Treat Pain</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Dec. 17, 2015 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical c=
ompany, today announced publication of a key article in Science by research=
ers at Xenon and Genentech describing for the first time the X-ray crystal =
structure
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-and-genentech-publish-science-3-d-crystal-structure-novel" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 12, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-stifel-2015-healthcare-confere=
nce" hreflang=3D"en">Xenon Pharmaceuticals to Present at the Stifel 2015 He=
althcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 12, 2015 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical c=
ompany, today announced that Dr. Simon Pimstone , Xenon's President and Chi=
ef Executive Officer, will present a corporate update at the Stifel 2015 He=
althcare
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-stifel-2015-healthcare-conference" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 10, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-third-quarter-2015-financial" =
hreflang=3D"en">Xenon Pharmaceuticals Reports Third Quarter 2015 Financial =
Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Progress Includes Initiation of XEN801 Phase 1 Clinical Trial and=
 Achievement of Milestones in Genentech Nav1.7 Clinical Program and Pain Ge=
netics Collaboration Conference Call/Webcast Today at 5:00 p.m. Eastern Tim=
e BURNABY, British Columbia , Nov. 10, 2015 (GLOBE NEWSWIRE) -- Xenon
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-third-quarter-2015-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 5, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discu=
ss-2" hreflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Web=
cast to Discuss Third Quarter 2015 Financial Results and Provide Corporate =
Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 5, 2015 (GLOBE NEWSWIRE) -- Xeno=
n Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical co=
mpany, today announced that it will report its 2015 third quarter financial=
 and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discuss-2"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      October 22, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-announces-its-partner-genentech-has-advanced-gdc-0310"=
 hreflang=3D"en">Xenon Announces Its Partner Genentech Has Advanced GDC-031=
0, a Second Nav1.7 Inhibitor for Pain, Into Clinical Development</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Oct. 22, 2015 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, today announced that the Company's partner Genentech, a member of t=
he Roche Group , has advanced a second Nav1.7 inhibitor into clinical devel=
opment.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-announces-its-partner-genentech-has-advanced-gdc-0310" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 24, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-initiation-xen801-phase-1" h=
reflang=3D"en">Xenon Pharmaceuticals Announces Initiation of XEN801 Phase 1=
 Clinical Trial</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Phase 2 in Acne Patients Expected to be Initiated by Year-End BUR=
NABY, British Columbia , Sept. 24, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceu=
ticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, toda=
y announced the initiation of a Phase 1 clinical trial of its lead propriet=
ary
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-initiation-xen801-phase-1" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 21, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-achieves-milestone-genentech-collabora=
tion" hreflang=3D"en">Xenon Pharmaceuticals Achieves Milestone in Genentech=
 Collaboration to Discover Novel Pain Targets</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Sept. 21, 2015 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical =
company, today announced that the Company has achieved a milestone in its p=
ain genetics discovery collaboration with Genentech, a member of the Roche =
Group ,
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-achieves-milestone-genentech-collaboration"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 3, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-10th-annual-wells-fargo-health=
care" hreflang=3D"en">Xenon Pharmaceuticals to Present at the 10th Annual W=
ells Fargo Healthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Sept. 3, 2015 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical c=
ompany, today announced that Dr. Simon Pimstone , Xenon's President and Chi=
ef Executive Officer, will present a corporate update at the 10 th Annual W=
ells
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-10th-annual-wells-fargo-healthcare"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 10, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-second-quarter-2015-financial"=
 hreflang=3D"en">Xenon Pharmaceuticals Reports Second Quarter 2015 Financia=
l Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Continued Pipeline Progress in Partnered and Proprietary Programs=
; Conference Call/Webcast Today at 4:30 p.m. Eastern Time BURNABY, British =
Columbia , Aug. 10, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Na=
sdaq: XENE), a clinical-stage biopharmaceutical company, today reported its
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-second-quarter-2015-financial" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 6, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-present-canaccord-genuity-35th-annual"=
 hreflang=3D"en">Xenon Pharmaceuticals to Present at the Canaccord Genuity =
35th Annual Growth Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Aug. 6, 2015 (GLOBE NEWSWIRE) -- Xeno=
n Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical co=
mpany, today announced that Dr. Simon Pimstone , Xenon's President and Chie=
f Executive Officer, will present a corporate update at the Canaccord Genui=
ty 35 th
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-present-canaccord-genuity-35th-annual" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 5, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discu=
ss-1" hreflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Web=
cast to Discuss Second Quarter 2015 Financial Results and Provide Corporate=
 Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Aug. 5, 2015 (GLOBE NEWSWIRE) -- Xeno=
n Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical co=
mpany, today announced that it will report its 2015 second quarter financia=
l and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discuss-1"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      July 1, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-today=
-900" hreflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Web=
cast Today at 9:00 a.m. Eastern Time to Discuss TV-45070 Phase 2b Study in =
Osteoarthritis Pain</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , July 1, 2015 (GLOBE NEWSWIRE) -- Xeno=
n Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical co=
mpany, announced that it will host a conference call and live audio webcast=
 at 9:00 a.m. Eastern Time ( 6:00 a.m.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-today-900"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      July 1, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/teva-and-xenon-provide-update-tv-45070-phase-2b-study" hrefl=
ang=3D"en">Teva and Xenon Provide Update on TV-45070 Phase 2b Study in Oste=
oarthritis Pain</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          TV-45070 4% and 8% did not demonstrate statistically significant =
difference from placebo in efficacy endpoints in Phase 2b study in pain due=
 to osteoarthritis of the knee. TV-45070 demonstrated a favorable safety an=
d tolerability profile, with no drug-related serious adverse events.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/teva-and-xenon-provide-update-tv-45070-phase-2b-study" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 28, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-provide-business-and-milestone-update"=
 hreflang=3D"en">Xenon Pharmaceuticals to Provide Business and Milestone Up=
date at Jefferies 2015 Global Healthcare Conference</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , May 28, 2015 (GLOBE NEWSWIRE) -- Xeno=
n Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical co=
mpany, today announced that Dr. Simon Pimstone , Xenon's President and Chie=
f Executive Officer, will present a business update, including progress tow=
ard
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-provide-business-and-milestone-update" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 22, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-appoints-steven-gannon-its-board-direc=
tors" hreflang=3D"en">Xenon Pharmaceuticals Appoints Steven Gannon to Its B=
oard of Directors</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , May 22, 2015 (GLOBE NEWSWIRE) -- Xeno=
n Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical co=
mpany, today announced that Steven Gannon has been appointed to its Board o=
f Directors, where he will also serve on the Company's Audit Committee. Mr.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-appoints-steven-gannon-its-board-directors"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 12, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-first-quarter-2015-financial" =
hreflang=3D"en">Xenon Pharmaceuticals Reports First Quarter 2015 Financial =
Results and Provides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Continued Pipeline Progress in Partnered and Proprietary Programs=
 Conference Call/Webcast Today at 4:30 p.m. Eastern Time BURNABY, British C=
olumbia , May 12, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasd=
aq:XENE), a clinical-stage biopharmaceutical company, today reported its fi=
nancial
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-first-quarter-2015-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 7, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discu=
ss-0" hreflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Web=
cast to Discuss First Quarter 2015 Financial Results and Provide Corporate =
Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , May 7, 2015 (GLOBE NEWSWIRE) -- Xenon=
 Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical com=
pany, today announced that it will report its 2015 first quarter financial =
and operating results after the close of U.S.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discuss-0"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      April 2, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/teva-and-xenon-announce-enrollment-first-patient-phase-2b-st=
udy" hreflang=3D"en">Teva and Xenon Announce Enrollment of First Patient in=
 a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia (PHN)</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          JERUSALEM and BURNABY, British Columbia , April 2, 2015 (GLOBE NE=
WSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and =
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) today announced that the first pat=
ient has been enrolled into the Phase 2b study designed to evaluate the saf=
ety and
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/teva-and-xenon-announce-enrollment-first-patient-phase-2b-study" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 16, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-appoints-dr-richard-h-scheller-its-boa=
rd" hreflang=3D"en">Xenon Pharmaceuticals Appoints Dr. Richard H. Scheller =
to Its Board of Directors</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , March 16, 2015 (GLOBE NEWSWIRE) -- Xe=
non Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical =
company, today announced that Richard H. Scheller , Ph.D., has been appoint=
ed to its Board of Directors. Dr. Scheller is a globally recognized leader =
in
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-appoints-dr-richard-h-scheller-its-board" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 12, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-2014-financial-results-and" hr=
eflang=3D"en">Xenon Pharmaceuticals Reports 2014 Financial Results and Prov=
ides Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Progress in Partnered Programs and Proprietary Development Pipeli=
ne Conference Call/Webcast Today at 4:30 p.m. Eastern Time BURNABY, British=
 Columbia , March 12, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (=
Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported it=
s
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-2014-financial-results-and" hreflan=
g=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 9, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discu=
ss" hreflang=3D"en">Xenon Pharmaceuticals to Host Conference Call and Webca=
st to Discuss 2014 Financial Results and Provide Corporate Update</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , March 9, 2015 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, today announced that it will report its 2014 financial and operatin=
g results after the close of U.S. financial markets on Thursday, March 12, =
2015 .
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-host-conference-call-and-webcast-discuss" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 19, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-partner-teva-initiate-phase-2b-clinica=
l" hreflang=3D"en">Xenon Pharmaceuticals' Partner Teva to Initiate Phase 2b=
 Clinical Trial of TV-45070 in Post-Herpetic Neuralgia</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Clinical Program in Post-Herpetic Neuralgia Broadens Opportunity =
of TV-45070 Into Neuropathic Pain BURNABY, British Columbia , Feb. 19, 2015=
 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-s=
tage biopharmaceutical company, announced today that its development and
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-partner-teva-initiate-phase-2b-clinical" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 8, 2015
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-outlines-key-anticipated-milestones-20=
15" hreflang=3D"en">Xenon Pharmaceuticals Outlines Key Anticipated Mileston=
es for 2015</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Partnered Programs on Track; Proprietary Development Pipeline Pro=
gressing; Multiple Potential Near-Term Milestones BURNABY, British Columbia=
 , Jan. 8, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE=
), a clinical-stage biopharmaceutical company, today outlined its anticipat=
ed 2015
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-outlines-key-anticipated-milestones-2015" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      December 15, 2014
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-reports-third-quarter-2014-financial" =
hreflang=3D"en">Xenon Pharmaceuticals Reports Third Quarter 2014 Financial =
Results</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia, Dec. 15, 2014 (GLOBE NEWSWIRE) -- Xeno=
n Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical co=
mpany, today reported its financial results for the third quarter ended Sep=
tember 30, 2014 and provided a corporate update. Dr.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-reports-third-quarter-2014-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 10, 2014
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-closing-initial-public-offer=
ing" hreflang=3D"en">Xenon Pharmaceuticals Announces Closing of Initial Pub=
lic Offering and Full Exercise of the Underwriters' Option to Purchase Addi=
tional Shares</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 10, 2014 (GLOBE NEWSWIRE) -- Xen=
on Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical c=
ompany, today announced the closing of its previously announced initial pub=
lic offering of 4,600,000 of its common shares at a price to the public of =
$9.00 per
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-closing-initial-public-offering" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      November 4, 2014
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-announces-pricing-initial-public-offer=
ing" hreflang=3D"en">Xenon Pharmaceuticals Announces Pricing of Initial Pub=
lic Offering</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          BURNABY, British Columbia , Nov. 4, 2014 (GLOBE NEWSWIRE) -- Xeno=
n Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical co=
mpany, today announced the pricing of its initial public offering of 4,000,=
000 of its common shares at a price to the public of $9.00 per share.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-announces-pricing-initial-public-offering" =
hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      March 26, 2014
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-and-genentech-establish-new-pain-discovery-collaborati=
on" hreflang=3D"en">Xenon and Genentech Establish New Pain Discovery Collab=
oration</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Vancouver, Canada (March 26, 2014) =E2=80=93 Xenon Pharmaceutical=
s Inc. today announced the establishment of a new collaboration with Genent=
ech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for pain gen=
etics, with the goal of discovering and validating new therapeutic targets =
and mechanisms
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-and-genentech-establish-new-pain-discovery-collaboration" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      September 10, 2013
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-announces-appointment-ian-c-mortimer-chief-financial" =
hreflang=3D"en">Xenon Announces Appointment of Ian C. Mortimer as Chief Fin=
ancial Officer</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Vancouver, Canada (September 10th, 2013) =E2=80=93 Xenon Pharmace=
uticals Inc. is pleased to announce the appointment of Mr. Ian C. Mortimer =
as Chief Financial Officer. =E2=80=9CWe are delighted to welcome Ian to the=
 Xenon team,=E2=80=9D said Dr. Simon Pimstone, Xenon=E2=80=99s President an=
d CEO.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-announces-appointment-ian-c-mortimer-chief-financial" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      June 10, 2013
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-licenses-antisense-drug-xen701-isis-and-initiates" hre=
flang=3D"en">Xenon Licenses Antisense Drug XEN701 from Isis and Initiates P=
reclinical Toxicology Studies</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Carlsbad, Calif. and Vancouver, Canada, (June 10, 2013) =E2=80=93=
 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and Xenon Pharmaceuticals Inc. a=
nnounced today that Xenon has exercised its option to an exclusive worldwid=
e license to XEN701, an antisense drug discovered in a collaboration betwee=
n Isis and Xenon.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-licenses-antisense-drug-xen701-isis-and-initiates" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      April 23, 2013
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/teva-and-xenon-announce-fda-orphan-drug-designation-pain-dru=
g" hreflang=3D"en">Teva and Xenon Announce FDA Orphan Drug Designation for =
Pain Drug XEN402</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Jerusalem, Israel, and Burnaby, British Columbia, (April 23, 2013=
) =E2=80=93 Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Xenon Phar=
maceuticals Inc. (Xenon) announced today that the US Food and Drug Administ=
ration (FDA) has granted orphan-drug designation to the investigational dru=
g XEN402 being
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/teva-and-xenon-announce-fda-orphan-drug-designation-pain-drug" hr=
eflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      April 22, 2013
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-named-company-year-biotecanada" hreflang=3D"en">Xenon =
Named Company of the Year by BIOTECanada</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Vancouver, Canada (April 22, 2013) =E2=80=93 Xenon Pharmaceutical=
s Inc. is pleased to announce that it has been awarded BIOTECanada=E2=80=99=
s Gold Leaf Company of the Year Award for 2013. The prestigious Gold Leaf A=
wards ceremony will take place on Tuesday, April 23 at the BIO Internationa=
l Convention in Chicago.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-named-company-year-biotecanada" hreflang=3D"en">More &gt;&g=
t;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      April 18, 2013
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-named-life-sciences-company-year-lifesciences-british"=
 hreflang=3D"en">Xenon Named Life Sciences Company of the Year by LifeScien=
ces British Columbia</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Vancouver, Canada (April 8th, 2013) =E2=80=93 Xenon Pharmaceutica=
ls Inc. is pleased to announce that it has been awarded the LifeSciences Br=
itish Columbia Life Sciences Company of the Year Award for 2013. The LifeSc=
iences British Columbia Awards took place on Thursday, April 4 at the Vanco=
uver Convention
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-named-life-sciences-company-year-lifesciences-british" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      April 17, 2013
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-exclusively-licenses-merck-compounds-novel-target" hre=
flang=3D"en">Xenon Exclusively Licenses to Merck Compounds for a Novel Targ=
et for Cardiovascular Disease</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Vancouver, Canada (April 17, 2013) =E2=80=93 Xenon announced that=
 Merck, known as MSD outside the United States and Canada, through an affil=
iate, has exercised its option to exclusively license small molecule compou=
nds for a novel target for the potential treatment of cardiovascular diseas=
e.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-exclusively-licenses-merck-compounds-novel-target" hreflang=
=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 13, 2013
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-announces-appointment-evp-research-development" hrefla=
ng=3D"en">Xenon Announces Appointment of EVP, Research &amp; Development</a=
>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Vancouver, Canada (February 13th, 2013) =E2=80=93 Xenon Pharmaceu=
ticals Inc. is pleased to announce the appointment of Gary J. Bridger PhD a=
s Executive Vice President, Research and Development. =E2=80=9CWe are delig=
hted to welcome Gary to the Xenon team=E2=80=9D commented Simon Pimstone, X=
enon=E2=80=99s President and CEO.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-announces-appointment-evp-research-development" hreflang=3D=
"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      February 5, 2013
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-receives-milestone-payment-marketing-approval-glyberar=
" hreflang=3D"en">Xenon Receives a Milestone Payment for Marketing Approval=
 of Glybera=C2=AE in Europe</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Vancouver, Canada, (February 5, 2013) =E2=80=93 Xenon, a clinical=
 stage biopharmaceutical company developing novel therapeutics for rare dis=
eases, today announced that it has received a milestone payment from uniQur=
e BV for the European Commission marketing approval of Glybera=C2=AE, a nov=
el gene therapy
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-receives-milestone-payment-marketing-approval-glyberar" hre=
flang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      December 11, 2012
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/teva-and-xenon-announce-tevas-world-wide-license-xenons-pain=
" hreflang=3D"en">Teva and Xenon Announce Teva=E2=80=99s World Wide License=
 of Xenon=E2=80=99s Pain Drug XEN402</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          XEN402 is a Strategic Fit for Teva=E2=80=99s Commercial, R&amp;D =
and Technology focus in CNS and Pain Jerusalem, and Burnaby, British Columb=
ia (December 11, 2012) =E2=80=94 Teva Pharmaceutical Industries Ltd (NYSE: =
TEVA) and Xenon Pharmaceuticals Inc. (Xenon) announced today that they have=
 entered into a
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/teva-and-xenon-announce-tevas-world-wide-license-xenons-pain" hre=
flang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 9, 2012
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-collaborate-genentech-discovery-novel-targeted-pain" h=
reflang=3D"en">Xenon to Collaborate with Genentech on Discovery of Novel Ta=
rgeted Pain Therapeutics</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Vancouver, Canada (January 9, 2012) =E2=80=93 Xenon Pharmaceutica=
ls Inc. (Xenon) today announced a strategic alliance with Genentech, a memb=
er of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to discover and develop=
 compounds and companion diagnostics for the potential treatment of pain.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-collaborate-genentech-discovery-novel-targeted-pain" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      January 6, 2012
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-publishes-new-research-papers" hreflang=3D"en">Xenon p=
ublishes new research papers</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Vancouver, Canada (Jan 6, 2012) =E2=80=93 Xenon Pharmaceuticals I=
nc. (Xenon) authors publish new articles in Pain and Current Pharmaceutical=
 Biotechnology. See PubMed for abstracts and links to full text. Treatment =
of Na V 1.7-mediated pain in inherited erythromelalgia using a novel sodium=
 channel blocker.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-publishes-new-research-papers" hreflang=3D"en">More &gt;&gt=
;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 23, 2011
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-chief-scientific-officer-dr-michael-hayden-receives" h=
reflang=3D"en">Xenon Chief Scientific Officer, Dr. Michael Hayden Receives =
Prestigious Award for Leadership in Medicine</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Vancouver, Canada (March 23rd, 2011) =E2=80=93 Dr. Michael Hayden=
, a Xenon founder and Chief Scientific Officer, has received the Canada Gai=
rdner Wightman Award for leadership in medical science in Canada. The Wight=
man Award is another major honour for Dr. Hayden, having previously been aw=
arded the Order
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-chief-scientific-officer-dr-michael-hayden-receives" hrefla=
ng=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 2, 2011
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenons-xen402-ointment-significantly-relieves-pain-patients-=
post" hreflang=3D"en">Xenon=E2=80=99s XEN402 Ointment Significantly Relieve=
s Pain in Patients with Post Herpetic Neuralgia</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Vancouver, Canada (May 2, 2011) =E2=80=93 Xenon Pharmaceuticals I=
nc. (Xenon) announced today that its novel ointment XEN402 demonstrated sig=
nificant and clinically meaningful reductions in pain in patients with Post=
 Herpetic Neuralgia (PHN). Xenon is developing XEN402 as a topical treatmen=
t for a variety
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenons-xen402-ointment-significantly-relieves-pain-patients-post"=
 hreflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      August 17, 2010
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-pharmaceuticals-initiates-phase-2-clinical-trial-post"=
 hreflang=3D"en">Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial i=
n Post Herpetic Neuralgia (PHN) for Topical XEN402</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Vancouver, Canada (August 17, 2010) - Xenon Pharmaceuticals Inc. =
announced today that it has initiated a phase 2 clinical trial evaluating i=
ts novel topical XEN402 therapy for the treatment of PHN. XEN402 has been d=
eveloped by Xenon as a topical ointment formulation and recently concluded =
a 21-day
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-pharmaceuticals-initiates-phase-2-clinical-trial-post" href=
lang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      May 16, 2010
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/isis-and-xenon-collaborate-develop-antisense-drugs-against" =
hreflang=3D"en">Isis and Xenon Collaborate to Develop Antisense Drugs Again=
st Hemojuvelin and Hepcidin</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Carlsbad, Calif. and Vancouver, Canada (Nov. 16, 2010) =E2=80=93 =
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Xenon Pharmaceuticals Inc. an=
nounced today a new collaboration to discover and develop antisense drugs a=
s novel treatments for the common disease anemia of inflammation (AI).
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/isis-and-xenon-collaborate-develop-antisense-drugs-against" hrefl=
ang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      June 11, 2009
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-enters-cardiovascular-disease-collaboration-merck-co-i=
nc" hreflang=3D"en">Xenon Enters Cardiovascular Disease Collaboration with =
Merck &amp; Co., Inc.</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Vancouver, Canada (June 11, 2009) - Xenon Pharmaceuticals Inc. to=
day announced a strategic alliance with Merck &amp; Co., Inc., through an a=
ffiliate, to discover and develop novel small molecule candidates for the p=
otential treatment of cardiovascular disease.
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-enters-cardiovascular-disease-collaboration-merck-co-inc" h=
reflang=3D"en">More &gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

<article class=3D"clearfix node node--nir-news--nir-widget-list node--type-=
nir-news node--view-mode-nir-widget-list node--promoted">

 =20
      <div class=3D"nir-widget--field nir-widget--news--date-time">
      June 17, 2008
    </div>
 =20
            <div class=3D"nir-widget--field nir-widget--news--headline">
          <a href=3D"https://investor.xenon-pharma.com/news-releases/news-r=
elease-details/xenon-receives-biotecanada-gold-leaf-award" hreflang=3D"en">=
Xenon Receives BIOTECanada Gold Leaf Award</a>
      </div>
     =20
      <div>
      <div class=3D"nir-widget--field nir-widget--news--teaser">
          Vancouver, Canada (June 17, 2008) - Xenon Pharmaceuticals Inc. is=
 pleased to announce today that it has been awarded the Promising Early Sta=
ge Company of the Year Award by BIOTECanada in the Health category for 2008=
. =E2=80=9CWe are delighted to have received this prestigious award, one of=
 BIOTECanada=E2=80=99s
		  <span class=3D"dotsNews">...</span>=20
		  			<div class=3D"nir-widget--field nir-widget--news--read-more">
			  <a href=3D"https://investor.xenon-pharma.com/news-releases/news-releas=
e-details/xenon-receives-biotecanada-gold-leaf-award" hreflang=3D"en">More =
&gt;&gt;</a>
			</div>
		        </div>
    </div>
 =20
 =20
 =20
 =20
 =20
</article>

          </div>
    <div class=3D"nir-widget--pager">
     =20
    </div>
    <div class=3D"nir-widget--total-results">
     =20
    </div>
  </div>
</div>
  </div>
</div>
        </div>
      </div>
    </div>
  </div>

</div><!-- /.boxton -->

  </div>
</article>

  </div>

  </div>

                    </div>
                </div>
                <div class=3D"large-3 large-offset-1 small-12 cell">
                    <div class=3D"sidebarNav">
                          <div class=3D"region region-sidebar-first">
   =20

<nav role=3D"navigation" aria-labelledby=3D"block-nir-pid1175-investorrelat=
ions-menu" id=3D"block-nir-pid1175-investorrelations" class=3D"block--syste=
m-menu-blockir block--system-menu-blockir--5816 block--sidebar-first--syste=
m-menu-block--ir block--sidebar-first--system-menu-block--ir--5816 block--8=
284cda6-bf40-48d8-956a-1c76629f0180 block--8284cda6-bf40-48d8-956a-1c76629f=
0180--5816 block block-menu navigation block-system-menublock menu--ir">
                       =20
    <h2 class=3D"visually-hidden" id=3D"block-nir-pid1175-investorrelations=
-menu">Investor Relations</h2>
   =20

                              <ul>
                  <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/" target=3D"" rel=3D"" titl=
e=3D"Main Investor Relations Page" data-drupal-link-system-path=3D"<front>"=
>investor overview</a>
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/stock-information/stock-quo=
te" target=3D"" rel=3D"" data-drupal-link-system-path=3D"node/5911">stock q=
uote</a>
                                    <ul>
                  <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/stock-information/stock-cha=
rt" target=3D"" rel=3D"" data-drupal-link-system-path=3D"node/6126">stock c=
hart</a>
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/stock-information/historica=
l-price-lookup" target=3D"" rel=3D"" data-drupal-link-system-path=3D"node/5=
921">historic stock lookup</a>
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/stock-information/analyst-c=
overage" data-drupal-link-system-path=3D"node/5896">Analyst Coverage</a>
                  </li>
          </ul>
 =20
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/news-releases" target=3D"" =
rel=3D"" data-drupal-link-system-path=3D"node/5816">news &amp; events</a>
                                    <ul>
                  <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/news-releases" target=3D"" =
rel=3D"" data-drupal-link-system-path=3D"node/5816">press releases</a>
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/events-and-presentations/up=
coming-events" target=3D"" rel=3D"" data-drupal-link-system-path=3D"node/58=
26">events calendar</a>
                  </li>
          </ul>
 =20
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/corporate-governance" targe=
t=3D"" rel=3D"" data-drupal-link-system-path=3D"node/6116">Corporate Govern=
ance</a>
                                    <ul>
                  <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/corporate-governance/manage=
ment" data-drupal-link-system-path=3D"node/5846">Management</a>
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/corporate-governance/board-=
of-directors" data-drupal-link-system-path=3D"node/5841">Board of Directors=
</a>
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/corporate-governance/commit=
tee-composition" data-drupal-link-system-path=3D"node/5851">Committee Compo=
sition</a>
                  </li>
          </ul>
 =20
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/financial-information/sec-f=
ilings" target=3D"" rel=3D"" data-drupal-link-system-path=3D"node/5876">fin=
ancials &amp; filings</a>
                                    <ul>
                  <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/financial-information/annua=
l-reports" target=3D"" rel=3D"" data-drupal-link-system-path=3D"node/5881">=
annual financial reports</a>
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/financial-information/quart=
erly-results" data-drupal-link-system-path=3D"node/5986">Quarterly Results<=
/a>
                  </li>
          </ul>
 =20
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/corporate-governance/contac=
t-the-board" target=3D"" rel=3D"" data-drupal-link-system-path=3D"node/5866=
">contact investor relations</a>
                  </li>
          </ul>
 =20


    </nav>


<nav role=3D"navigation" aria-labelledby=3D"block-nir-pid1175-tools-menu" i=
d=3D"block-nir-pid1175-tools" class=3D"block--system-menu-blocktools block-=
-system-menu-blocktools--5826 block--sidebar-first--system-menu-block--tool=
s block--sidebar-first--system-menu-block--tools--5826 block--621edd4b-ec51=
-4dcb-a6ed-1dcff90043dd block--621edd4b-ec51-4dcb-a6ed-1dcff90043dd--5826 b=
lock block-menu navigation block-system-menublock menu--tools">
                       =20
    <h2 class=3D"visually-hidden" id=3D"block-nir-pid1175-tools-menu">Tools=
</h2>
   =20

                              <ul data-block-uuid=3D"621edd4b-ec51-4dcb-a6e=
d-1dcff90043dd" class=3D"menu side-menu">
                  <li class=3D"side-menu__item">
          <a href=3D"https://investor.xenon-pharma.com/news-releases?38df53=
74f7c4fd82aa79d6fb8d12b19edb5315f510fe910f969b08452c4028fe_year%5Bvalue%5D=
=3D_none&amp;op=3DFilter&amp;38df5374f7c4fd82aa79d6fb8d12b19edb5315f510fe91=
0f969b08452c4028fe_widget_id=3D38df5374f7c4fd82aa79d6fb8d12b19edb5315f510fe=
910f969b08452c4028fe&amp;form_build_id=3Dform-zwSt7FqJDol13lB9XMJ9y5Ha5rrm4=
y-KinVsb4ypczw&amp;form_id=3Dwidget_form_base" target=3D"" rel=3D"" class=
=3D"print">print page</a>
                  </li>
              <li class=3D"side-menu__item">
          <a href=3D"https://investor.xenon-pharma.com/rss-feeds" target=3D=
"" rel=3D"" class=3D"rss" data-drupal-link-system-path=3D"node/5951">RSS Fe=
eds</a>
                  </li>
              <li class=3D"side-menu__item">
          <a href=3D"https://investor.xenon-pharma.com/shareholder-services=
/email-alerts" target=3D"" rel=3D"" class=3D"mail" data-drupal-link-system-=
path=3D"node/5946">e-mail alerts</a>
                  </li>
          </ul>
 =20


    </nav>

  </div>

                    </div>
                    <div class=3D"sidebarUtility">
                       =20
                    </div>
                </div>
            </div>
        </div>
    </div>
    <footer>
        <div class=3D"grid-container">
            <div class=3D"grid-x grid-padding-x">
                <div class=3D"large-4 small-12 cell">
                    <h4>Explore the site</h4>
                    <hr class=3D"underLine">
                          <div class=3D"region region-footer-menu">
   =20

<nav role=3D"navigation" aria-labelledby=3D"block-footer-menu" id=3D"block-=
footer" class=3D"block--system-menu-blockfooter block--system-menu-blockfoo=
ter--5816 block--footer-menu--system-menu-block--footer block--footer-menu-=
-system-menu-block--footer--5816 block--6d7ba30a-3eea-4541-a897-257f9ef2596=
0 block--6d7ba30a-3eea-4541-a897-257f9ef25960--5816 block block-menu naviga=
tion block-system-menublock menu--footer">
                       =20
    <h2 class=3D"visually-hidden" id=3D"block-footer-menu">Footer</h2>
   =20

                              <ul class=3D"footerNav">
                  <li class=3D"side-menu__item">
       =20
		 <a href=3D"http://www.xenon-pharma.com/about/" target=3D"" rel=3D"">Abou=
t</a>
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"http://www.xenon-pharma.com/product-pipeline/" target=3D"" re=
l=3D"">Product Pipeline</a>
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/" target=3D"" rel=3D"" data=
-drupal-link-system-path=3D"<front>">Investors</a>
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"http://www.xenon-pharma.com/partners/" target=3D"" rel=3D"">P=
artners</a>
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"http://www.xenon-pharma.com/medical-affairs/" target=3D"" rel=
=3D"">Medical Affairs</a>
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"http://www.xenon-pharma.com/careers/" target=3D"" rel=3D"">Ca=
reers</a>
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"http://www.xenon-pharma.com/contact/" target=3D"" rel=3D"">Co=
ntact</a>
                  </li>
              <li class=3D"side-menu__item">
       =20
		 <a href=3D"https://investor.xenon-pharma.com/news-releases" target=3D"" =
rel=3D"" data-drupal-link-system-path=3D"node/5816">News</a>
                  </li>
          </ul>
 =20


    </nav>

  </div>

                </div>
<div class=3D"large-4 small-12 cell">
                    <h4>Contact Xenon</h4>
                    <hr class=3D"underLine">
                    <p>Xenon Pharmaceuticals Inc.
                        <br> 3650 Gilmore Way
                        <br> Burnaby, BC V5G 4W8</p>
                    <p>Tel: 604.484.3300
                        <br> Fax: 604.484.3450
                        <br><a href=3D"mailto:info@xenon-pharma.com">info@x=
enon-pharma.com</a></p>
                </div>
                <div class=3D"large-4 small-12 cell legalText">
                    <div class=3D"logoFooter">
                        <a href=3D"https://investor.xenon-pharma.com/"></a>
                    </div>
                    <p>"Xenon" and the Xenon logo are trademarks of Xenon P=
harmaceuticals Inc. They are registered in the United States and used or re=
gistered in various other jurisdictions.</p>
                    <p>Copyright =C2=A9 2001 =E2=80=93 2025 Xenon<sup>=C2=
=AE</sup> All rights reserved.</p>
                    <p><a href=3D"http://www.xenon-pharma.com/legal-notice/=
">Legal Terms of Site Use</a></p>
             <p><a href=3D"https://www.xenon-pharma.com/privacy-policy/">Pr=
ivacy Notice</a></p>
                </div>
            </div>
            <div class=3D"grid-x grid-padding-x">
                <div class=3D"large-12 small-12 cell socialMedia">
                    <hr>
                    <ul>
                        <li class=3D"twitter">
                            <a href=3D"https://twitter.com/XenonPharma" tar=
get=3D"_blank"></a>
                        </li>
                        <li class=3D"linkedin">
                            <a href=3D"https://www.linkedin.com/company/xen=
on-pharmaceuticals-inc-/" target=3D"_blank"></a>
                        </li>
                        <li class=3D"facebook">
                            <a href=3D"https://www.facebook.com/xenonpharma=
/" target=3D"_blank"></a>
                        </li>
                    </ul>
                </div>
            </div>
        </div>
    </footer>

  </div>

   =20
         =20
       =20






   =20
 =20

<div id=3D"drupal-live-announce" class=3D"visually-hidden" aria-live=3D"pol=
ite" aria-busy=3D"false"></div><div id=3D"drupal-modal" class=3D"ui-front" =
style=3D"display: none;"></div></body></html>
------MultipartBoundary--OyEh8n7b4Lw6tzistt7cxFCRw1zMtvVQlXOUlVtdJx----
Content-Type: image/png
Content-Transfer-Encoding: base64
Content-Location: https://investor.xenon-pharma.com/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client/images/hamburger.png
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------MultipartBoundary--OyEh8n7b4Lw6tzistt7cxFCRw1zMtvVQlXOUlVtdJx----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://investor.xenon-pharma.com/sites/g/files/knoqqb12671/files/css/css_hwNokfnlMe-cYUUnn3-6p03KbjdXcTDzrGGqs4p1EqI.css?delta=2&language=en&theme=nir_pid1175&include=eJyVjsEKAjEMRH-oWPYgfk5I27CGTZMljYJ_b3cvInjxNrx5DKPs0NE3CmgYCEWsbrkTKjhV6510cjaFekePpD99VJTXCPCp6goF_Q99QGARStWccvPHjnJpjGJrGtOingsOOqeOkI_A1XR8kHD57sNM5osT7tyW5XbN9iR3bvQGCmRfGw

@charset "utf-8";

a[href]::after { content: ""; }

table.nirtable.collapse-table-wide tbody tr td[data-before] { padding-left:=
 50% !important; }

body * { visibility: hidden; }

footer, .lfg-noprint { display: none; }

.lfg-printable-area, .lfg-printable-area * { visibility: visible; }

.lfg-printable-area { position: absolute; left: 0px; top: 0px; padding: 20p=
x; }

.lfg-printable-area::before { content: url("/sites/g/files/knoqqb12671/them=
es/site/nir_pid1175/client/images/xenon-logo.jpg"); }

.block--nir-news__widget--5806 .nir-widget--label { margin-bottom: 22px; }

.nir-widget--label { display: inline-block; margin-bottom: 2px; padding-bot=
tom: 8px; font-size: 30px; font-style: normal; font-weight: normal; text-re=
ndering: optimizelegibility; font-family: Montserrat, sans-serif; color: rg=
b(137, 140, 141) !important; }
------MultipartBoundary--OyEh8n7b4Lw6tzistt7cxFCRw1zMtvVQlXOUlVtdJx----
Content-Type: image/png
Content-Transfer-Encoding: base64
Content-Location: https://investor.xenon-pharma.com/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client/images/alertIcon_2x.png
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------MultipartBoundary--OyEh8n7b4Lw6tzistt7cxFCRw1zMtvVQlXOUlVtdJx----
Content-Type: image/png
Content-Transfer-Encoding: base64
Content-Location: https://investor.xenon-pharma.com/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client/images/rssIcon_2x.png
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------MultipartBoundary--OyEh8n7b4Lw6tzistt7cxFCRw1zMtvVQlXOUlVtdJx----
Content-Type: image/png
Content-Transfer-Encoding: base64
Content-Location: https://investor.xenon-pharma.com/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client/images/printIcon_2x.png
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------MultipartBoundary--OyEh8n7b4Lw6tzistt7cxFCRw1zMtvVQlXOUlVtdJx----
Content-Type: image/png
Content-Transfer-Encoding: base64
Content-Location: https://investor.xenon-pharma.com/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client/images/logo.png
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------MultipartBoundary--OyEh8n7b4Lw6tzistt7cxFCRw1zMtvVQlXOUlVtdJx----
Content-Type: image/png
Content-Transfer-Encoding: base64
Content-Location: https://investor.xenon-pharma.com/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client/images/facebookIcon.png
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------MultipartBoundary--OyEh8n7b4Lw6tzistt7cxFCRw1zMtvVQlXOUlVtdJx----
Content-Type: image/png
Content-Transfer-Encoding: base64
Content-Location: https://investor.xenon-pharma.com/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client/images/linkedinIcon.png
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------MultipartBoundary--OyEh8n7b4Lw6tzistt7cxFCRw1zMtvVQlXOUlVtdJx----
Content-Type: image/png
Content-Transfer-Encoding: base64
Content-Location: https://investor.xenon-pharma.com/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client/images/twitterIcon.png
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------MultipartBoundary--OyEh8n7b4Lw6tzistt7cxFCRw1zMtvVQlXOUlVtdJx----
Content-Type: image/png
Content-Transfer-Encoding: base64
Content-Location: https://investor.xenon-pharma.com/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client/images/logoFooter.png
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------MultipartBoundary--OyEh8n7b4Lw6tzistt7cxFCRw1zMtvVQlXOUlVtdJx----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://fonts.googleapis.com/css?family=Montserrat:300,700

@charset "utf-8";

@font-face { font-family: Montserrat; font-style: normal; font-weight: 300;=
 src: url("https://fonts.gstatic.com/s/montserrat/v29/JTUSjIg1_i6t8kCHKm459=
WRhyyTh89ZNpQ.woff2") format("woff2"); unicode-range: U+460-52F, U+1C80-1C8=
A, U+20B4, U+2DE0-2DFF, U+A640-A69F, U+FE2E-FE2F; }

@font-face { font-family: Montserrat; font-style: normal; font-weight: 300;=
 src: url("https://fonts.gstatic.com/s/montserrat/v29/JTUSjIg1_i6t8kCHKm459=
W1hyyTh89ZNpQ.woff2") format("woff2"); unicode-range: U+301, U+400-45F, U+4=
90-491, U+4B0-4B1, U+2116; }

@font-face { font-family: Montserrat; font-style: normal; font-weight: 300;=
 src: url("https://fonts.gstatic.com/s/montserrat/v29/JTUSjIg1_i6t8kCHKm459=
WZhyyTh89ZNpQ.woff2") format("woff2"); unicode-range: U+102-103, U+110-111,=
 U+128-129, U+168-169, U+1A0-1A1, U+1AF-1B0, U+300-301, U+303-304, U+308-30=
9, U+323, U+329, U+1EA0-1EF9, U+20AB; }

@font-face { font-family: Montserrat; font-style: normal; font-weight: 300;=
 src: url("https://fonts.gstatic.com/s/montserrat/v29/JTUSjIg1_i6t8kCHKm459=
WdhyyTh89ZNpQ.woff2") format("woff2"); unicode-range: U+100-2BA, U+2BD-2C5,=
 U+2C7-2CC, U+2CE-2D7, U+2DD-2FF, U+304, U+308, U+329, U+1D00-1DBF, U+1E00-=
1E9F, U+1EF2-1EFF, U+2020, U+20A0-20AB, U+20AD-20C0, U+2113, U+2C60-2C7F, U=
+A720-A7FF; }

@font-face { font-family: Montserrat; font-style: normal; font-weight: 300;=
 src: url("https://fonts.gstatic.com/s/montserrat/v29/JTUSjIg1_i6t8kCHKm459=
WlhyyTh89Y.woff2") format("woff2"); unicode-range: U+0-FF, U+131, U+152-153=
, U+2BB-2BC, U+2C6, U+2DA, U+2DC, U+304, U+308, U+329, U+2000-206F, U+20AC,=
 U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; }

@font-face { font-family: Montserrat; font-style: normal; font-weight: 700;=
 src: url("https://fonts.gstatic.com/s/montserrat/v29/JTUSjIg1_i6t8kCHKm459=
WRhyyTh89ZNpQ.woff2") format("woff2"); unicode-range: U+460-52F, U+1C80-1C8=
A, U+20B4, U+2DE0-2DFF, U+A640-A69F, U+FE2E-FE2F; }

@font-face { font-family: Montserrat; font-style: normal; font-weight: 700;=
 src: url("https://fonts.gstatic.com/s/montserrat/v29/JTUSjIg1_i6t8kCHKm459=
W1hyyTh89ZNpQ.woff2") format("woff2"); unicode-range: U+301, U+400-45F, U+4=
90-491, U+4B0-4B1, U+2116; }

@font-face { font-family: Montserrat; font-style: normal; font-weight: 700;=
 src: url("https://fonts.gstatic.com/s/montserrat/v29/JTUSjIg1_i6t8kCHKm459=
WZhyyTh89ZNpQ.woff2") format("woff2"); unicode-range: U+102-103, U+110-111,=
 U+128-129, U+168-169, U+1A0-1A1, U+1AF-1B0, U+300-301, U+303-304, U+308-30=
9, U+323, U+329, U+1EA0-1EF9, U+20AB; }

@font-face { font-family: Montserrat; font-style: normal; font-weight: 700;=
 src: url("https://fonts.gstatic.com/s/montserrat/v29/JTUSjIg1_i6t8kCHKm459=
WdhyyTh89ZNpQ.woff2") format("woff2"); unicode-range: U+100-2BA, U+2BD-2C5,=
 U+2C7-2CC, U+2CE-2D7, U+2DD-2FF, U+304, U+308, U+329, U+1D00-1DBF, U+1E00-=
1E9F, U+1EF2-1EFF, U+2020, U+20A0-20AB, U+20AD-20C0, U+2113, U+2C60-2C7F, U=
+A720-A7FF; }

@font-face { font-family: Montserrat; font-style: normal; font-weight: 700;=
 src: url("https://fonts.gstatic.com/s/montserrat/v29/JTUSjIg1_i6t8kCHKm459=
WlhyyTh89Y.woff2") format("woff2"); unicode-range: U+0-FF, U+131, U+152-153=
, U+2BB-2BC, U+2C6, U+2DA, U+2DC, U+304, U+308, U+329, U+2000-206F, U+20AC,=
 U+2122, U+2191, U+2193, U+2212, U+2215, U+FEFF, U+FFFD; }
------MultipartBoundary--OyEh8n7b4Lw6tzistt7cxFCRw1zMtvVQlXOUlVtdJx----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://fonts.googleapis.com/css?family=Roboto

@charset "utf-8";

@font-face { font-family: Roboto; font-style: normal; font-weight: 400; fon=
t-stretch: 100%; src: url("https://fonts.gstatic.com/s/roboto/v47/KFOMCnqEu=
92Fr1ME7kSn66aGLdTylUAMQXC89YmC2DPNWubEbVmZiAr0klQmz24O0g.woff2") format("w=
off2"); unicode-range: U+460-52F, U+1C80-1C8A, U+20B4, U+2DE0-2DFF, U+A640-=
A69F, U+FE2E-FE2F; }

@font-face { font-family: Roboto; font-style: normal; font-weight: 400; fon=
t-stretch: 100%; src: url("https://fonts.gstatic.com/s/roboto/v47/KFOMCnqEu=
92Fr1ME7kSn66aGLdTylUAMQXC89YmC2DPNWubEbVmQiAr0klQmz24O0g.woff2") format("w=
off2"); unicode-range: U+301, U+400-45F, U+490-491, U+4B0-4B1, U+2116; }

@font-face { font-family: Roboto; font-style: normal; font-weight: 400; fon=
t-stretch: 100%; src: url("https://fonts.gstatic.com/s/roboto/v47/KFOMCnqEu=
92Fr1ME7kSn66aGLdTylUAMQXC89YmC2DPNWubEbVmYiAr0klQmz24O0g.woff2") format("w=
off2"); unicode-range: U+1F00-1FFF; }

@font-face { font-family: Roboto; font-style: normal; font-weight: 400; fon=
t-stretch: 100%; src: url("https://fonts.gstatic.com/s/roboto/v47/KFOMCnqEu=
92Fr1ME7kSn66aGLdTylUAMQXC89YmC2DPNWubEbVmXiAr0klQmz24O0g.woff2") format("w=
off2"); unicode-range: U+370-377, U+37A-37F, U+384-38A, U+38C, U+38E-3A1, U=
+3A3-3FF; }

@font-face { font-family: Roboto; font-style: normal; font-weight: 400; fon=
t-stretch: 100%; src: url("https://fonts.gstatic.com/s/roboto/v47/KFOMCnqEu=
92Fr1ME7kSn66aGLdTylUAMQXC89YmC2DPNWubEbVnoiAr0klQmz24O0g.woff2") format("w=
off2"); unicode-range: U+302-303, U+305, U+307-308, U+310, U+312, U+315, U+=
31A, U+326-327, U+32C, U+32F-330, U+332-333, U+338, U+33A, U+346, U+34D, U+=
391-3A1, U+3A3-3A9, U+3B1-3C9, U+3D1, U+3D5-3D6, U+3F0-3F1, U+3F4-3F5, U+20=
16-2017, U+2034-2038, U+203C, U+2040, U+2043, U+2047, U+2050, U+2057, U+205=
F, U+2070-2071, U+2074-208E, U+2090-209C, U+20D0-20DC, U+20E1, U+20E5-20EF,=
 U+2100-2112, U+2114-2115, U+2117-2121, U+2123-214F, U+2190, U+2192, U+2194=
-21AE, U+21B0-21E5, U+21F1-21F2, U+21F4-2211, U+2213-2214, U+2216-22FF, U+2=
308-230B, U+2310, U+2319, U+231C-2321, U+2336-237A, U+237C, U+2395, U+239B-=
23B7, U+23D0, U+23DC-23E1, U+2474-2475, U+25AF, U+25B3, U+25B7, U+25BD, U+2=
5C1, U+25CA, U+25CC, U+25FB, U+266D-266F, U+27C0-27FF, U+2900-2AFF, U+2B0E-=
2B11, U+2B30-2B4C, U+2BFE, U+3030, U+FF5B, U+FF5D, U+1D400-1D7FF, U+1EE00-1=
EEFF; }

@font-face { font-family: Roboto; font-style: normal; font-weight: 400; fon=
t-stretch: 100%; src: url("https://fonts.gstatic.com/s/roboto/v47/KFOMCnqEu=
92Fr1ME7kSn66aGLdTylUAMQXC89YmC2DPNWubEbVn6iAr0klQmz24O0g.woff2") format("w=
off2"); unicode-range: U+1-C, U+E-1F, U+7F-9F, U+20DD-20E0, U+20E2-20E4, U+=
2150-218F, U+2190, U+2192, U+2194-2199, U+21AF, U+21E6-21F0, U+21F3, U+2218=
-2219, U+2299, U+22C4-22C6, U+2300-243F, U+2440-244A, U+2460-24FF, U+25A0-2=
7BF, U+2800-28FF, U+2921-2922, U+2981, U+29BF, U+29EB, U+2B00-2BFF, U+4DC0-=
4DFF, U+FFF9-FFFB, U+10140-1018E, U+10190-1019C, U+101A0, U+101D0-101FD, U+=
102E0-102FB, U+10E60-10E7E, U+1D2C0-1D2D3, U+1D2E0-1D37F, U+1F000-1F0FF, U+=
1F100-1F1AD, U+1F1E6-1F1FF, U+1F30D-1F30F, U+1F315, U+1F31C, U+1F31E, U+1F3=
20-1F32C, U+1F336, U+1F378, U+1F37D, U+1F382, U+1F393-1F39F, U+1F3A7-1F3A8,=
 U+1F3AC-1F3AF, U+1F3C2, U+1F3C4-1F3C6, U+1F3CA-1F3CE, U+1F3D4-1F3E0, U+1F3=
ED, U+1F3F1-1F3F3, U+1F3F5-1F3F7, U+1F408, U+1F415, U+1F41F, U+1F426, U+1F4=
3F, U+1F441-1F442, U+1F444, U+1F446-1F449, U+1F44C-1F44E, U+1F453, U+1F46A,=
 U+1F47D, U+1F4A3, U+1F4B0, U+1F4B3, U+1F4B9, U+1F4BB, U+1F4BF, U+1F4C8-1F4=
CB, U+1F4D6, U+1F4DA, U+1F4DF, U+1F4E3-1F4E6, U+1F4EA-1F4ED, U+1F4F7, U+1F4=
F9-1F4FB, U+1F4FD-1F4FE, U+1F503, U+1F507-1F50B, U+1F50D, U+1F512-1F513, U+=
1F53E-1F54A, U+1F54F-1F5FA, U+1F610, U+1F650-1F67F, U+1F687, U+1F68D, U+1F6=
91, U+1F694, U+1F698, U+1F6AD, U+1F6B2, U+1F6B9-1F6BA, U+1F6BC, U+1F6C6-1F6=
CF, U+1F6D3-1F6D7, U+1F6E0-1F6EA, U+1F6F0-1F6F3, U+1F6F7-1F6FC, U+1F700-1F7=
FF, U+1F800-1F80B, U+1F810-1F847, U+1F850-1F859, U+1F860-1F887, U+1F890-1F8=
AD, U+1F8B0-1F8BB, U+1F8C0-1F8C1, U+1F900-1F90B, U+1F93B, U+1F946, U+1F984,=
 U+1F996, U+1F9E9, U+1FA00-1FA6F, U+1FA70-1FA7C, U+1FA80-1FA89, U+1FA8F-1FA=
C6, U+1FACE-1FADC, U+1FADF-1FAE9, U+1FAF0-1FAF8, U+1FB00-1FBFF; }

@font-face { font-family: Roboto; font-style: normal; font-weight: 400; fon=
t-stretch: 100%; src: url("https://fonts.gstatic.com/s/roboto/v47/KFOMCnqEu=
92Fr1ME7kSn66aGLdTylUAMQXC89YmC2DPNWubEbVmbiAr0klQmz24O0g.woff2") format("w=
off2"); unicode-range: U+102-103, U+110-111, U+128-129, U+168-169, U+1A0-1A=
1, U+1AF-1B0, U+300-301, U+303-304, U+308-309, U+323, U+329, U+1EA0-1EF9, U=
+20AB; }

@font-face { font-family: Roboto; font-style: normal; font-weight: 400; fon=
t-stretch: 100%; src: url("https://fonts.gstatic.com/s/roboto/v47/KFOMCnqEu=
92Fr1ME7kSn66aGLdTylUAMQXC89YmC2DPNWubEbVmaiAr0klQmz24O0g.woff2") format("w=
off2"); unicode-range: U+100-2BA, U+2BD-2C5, U+2C7-2CC, U+2CE-2D7, U+2DD-2F=
F, U+304, U+308, U+329, U+1D00-1DBF, U+1E00-1E9F, U+1EF2-1EFF, U+2020, U+20=
A0-20AB, U+20AD-20C0, U+2113, U+2C60-2C7F, U+A720-A7FF; }

@font-face { font-family: Roboto; font-style: normal; font-weight: 400; fon=
t-stretch: 100%; src: url("https://fonts.gstatic.com/s/roboto/v47/KFOMCnqEu=
92Fr1ME7kSn66aGLdTylUAMQXC89YmC2DPNWubEbVmUiAr0klQmz24.woff2") format("woff=
2"); unicode-range: U+0-FF, U+131, U+152-153, U+2BB-2BC, U+2C6, U+2DA, U+2D=
C, U+304, U+308, U+329, U+2000-206F, U+20AC, U+2122, U+2191, U+2193, U+2212=
, U+2215, U+FEFF, U+FFFD; }
------MultipartBoundary--OyEh8n7b4Lw6tzistt7cxFCRw1zMtvVQlXOUlVtdJx----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://investor.xenon-pharma.com/sites/g/files/knoqqb12671/files/css/css_V550fu0H92bP2BuXkow6log7Go8eyiTUB9hoqvOjNy8.css?delta=1&language=en&theme=nir_pid1175&include=eJyVjsEKAjEMRH-oWPYgfk5I27CGTZMljYJ_b3cvInjxNrx5DKPs0NE3CmgYCEWsbrkTKjhV6510cjaFekePpD99VJTXCPCp6goF_Q99QGARStWccvPHjnJpjGJrGtOingsOOqeOkI_A1XR8kHD57sNM5osT7tyW5XbN9iR3bvQGCmRfGw

@charset "utf-8";

@import url("https://fonts.googleapis.com/css?family=3DRoboto");

@import url("https://fonts.googleapis.com/css?family=3DMontserrat:300,700")=
;

@font-face { font-family: ndqfonticons; src: url("/profiles/nasdaqir/themes=
/custom/nir_base/dist/fonts/ndqfonticons.woff2") format("woff2"), url("/pro=
files/nasdaqir/themes/custom/nir_base/dist/fonts/ndqfonticons.woff") format=
("woff"), url("/profiles/nasdaqir/themes/custom/nir_base/dist/fonts/ndqfont=
icons.ttf") format("truetype"); font-weight: normal; font-style: normal; }

.select2-container { box-sizing: border-box; display: inline-block; margin:=
 0px; position: relative; vertical-align: middle; }

.select2-container .select2-selection--single { box-sizing: border-box; cur=
sor: pointer; display: block; height: 28px; user-select: none; }

.select2-container .select2-selection--single .select2-selection__rendered =
{ display: block; padding-left: 8px; padding-right: 20px; overflow: hidden;=
 text-overflow: ellipsis; white-space: nowrap; }

.select2-container .select2-selection--single .select2-selection__clear { p=
osition: relative; }

.select2-container[dir=3D"rtl"] .select2-selection--single .select2-selecti=
on__rendered { padding-right: 8px; padding-left: 20px; }

.select2-container .select2-selection--multiple { box-sizing: border-box; c=
ursor: pointer; display: block; min-height: 32px; user-select: none; }

.select2-container .select2-selection--multiple .select2-selection__rendere=
d { display: inline-block; overflow: hidden; padding-left: 8px; text-overfl=
ow: ellipsis; white-space: nowrap; }

.select2-container .select2-search--inline { float: left; }

.select2-container .select2-search--inline .select2-search__field { box-siz=
ing: border-box; border: none; font-size: 100%; margin-top: 5px; padding: 0=
px; }

.select2-container .select2-search--inline .select2-search__field::-webkit-=
search-cancel-button { appearance: none; }

.select2-dropdown { background-color: white; border: 1px solid rgb(170, 170=
, 170); border-radius: 4px; box-sizing: border-box; display: block; positio=
n: absolute; left: -100000px; width: 100%; z-index: 1051; }

.select2-results { display: block; }

.select2-results__options { list-style: none; margin: 0px; padding: 0px; }

.select2-results__option { padding: 6px; user-select: none; }

.select2-results__option[aria-selected] { cursor: pointer; }

.select2-container--open .select2-dropdown { left: 0px; }

.select2-container--open .select2-dropdown--above { border-bottom: none; bo=
rder-bottom-left-radius: 0px; border-bottom-right-radius: 0px; }

.select2-container--open .select2-dropdown--below { border-top: none; borde=
r-top-left-radius: 0px; border-top-right-radius: 0px; }

.select2-search--dropdown { display: block; padding: 4px; }

.select2-search--dropdown .select2-search__field { padding: 4px; width: 100=
%; box-sizing: border-box; }

.select2-search--dropdown .select2-search__field::-webkit-search-cancel-but=
ton { appearance: none; }

.select2-search--dropdown.select2-search--hide { display: none; }

.select2-close-mask { border: 0px; margin: 0px; padding: 0px; display: bloc=
k; position: fixed; left: 0px; top: 0px; min-height: 100%; min-width: 100%;=
 height: auto; width: auto; opacity: 0; z-index: 99; background-color: rgb(=
255, 255, 255); }

.select2-hidden-accessible { border: 0px !important; clip: rect(0px, 0px, 0=
px, 0px) !important; clip-path: inset(50%) !important; height: 1px !importa=
nt; overflow: hidden !important; padding: 0px !important; position: absolut=
e !important; width: 1px !important; white-space: nowrap !important; }

.select2-container--default .select2-selection--single { background-color: =
rgb(255, 255, 255); border: 1px solid rgb(170, 170, 170); border-radius: 4p=
x; }

.select2-container--default .select2-selection--single .select2-selection__=
rendered { color: rgb(68, 68, 68); line-height: 28px; }

.select2-container--default .select2-selection--single .select2-selection__=
clear { cursor: pointer; float: right; font-weight: bold; }

.select2-container--default .select2-selection--single .select2-selection__=
placeholder { color: rgb(153, 153, 153); }

.select2-container--default .select2-selection--single .select2-selection__=
arrow { height: 26px; position: absolute; top: 1px; right: 1px; width: 20px=
; }

.select2-container--default .select2-selection--single .select2-selection__=
arrow b { border-color: rgb(136, 136, 136) transparent transparent; border-=
style: solid; border-width: 5px 4px 0px; height: 0px; left: 50%; margin-lef=
t: -4px; margin-top: -2px; position: absolute; top: 50%; width: 0px; }

.select2-container--default[dir=3D"rtl"] .select2-selection--single .select=
2-selection__clear { float: left; }

.select2-container--default[dir=3D"rtl"] .select2-selection--single .select=
2-selection__arrow { left: 1px; right: auto; }

.select2-container--default.select2-container--disabled .select2-selection-=
-single { background-color: rgb(238, 238, 238); cursor: default; }

.select2-container--default.select2-container--disabled .select2-selection-=
-single .select2-selection__clear { display: none; }

.select2-container--default.select2-container--open .select2-selection--sin=
gle .select2-selection__arrow b { border-color: transparent transparent rgb=
(136, 136, 136); border-width: 0px 4px 5px; }

.select2-container--default .select2-selection--multiple { background-color=
: white; border: 1px solid rgb(170, 170, 170); border-radius: 4px; cursor: =
text; }

.select2-container--default .select2-selection--multiple .select2-selection=
__rendered { box-sizing: border-box; list-style: none; margin: 0px; padding=
: 0px 5px; width: 100%; }

.select2-container--default .select2-selection--multiple .select2-selection=
__rendered li { list-style: none; }

.select2-container--default .select2-selection--multiple .select2-selection=
__clear { cursor: pointer; float: right; font-weight: bold; margin-top: 5px=
; margin-right: 10px; padding: 1px; }

.select2-container--default .select2-selection--multiple .select2-selection=
__choice { background-color: rgb(228, 228, 228); border: 1px solid rgb(170,=
 170, 170); border-radius: 4px; cursor: default; float: left; margin-right:=
 5px; margin-top: 5px; padding: 0px 5px; }

.select2-container--default .select2-selection--multiple .select2-selection=
__choice__remove { color: rgb(153, 153, 153); cursor: pointer; display: inl=
ine-block; font-weight: bold; margin-right: 2px; }

.select2-container--default .select2-selection--multiple .select2-selection=
__choice__remove:hover { color: rgb(51, 51, 51); }

.select2-container--default[dir=3D"rtl"] .select2-selection--multiple .sele=
ct2-selection__choice, .select2-container--default[dir=3D"rtl"] .select2-se=
lection--multiple .select2-search--inline { float: right; }

.select2-container--default[dir=3D"rtl"] .select2-selection--multiple .sele=
ct2-selection__choice { margin-left: 5px; margin-right: auto; }

.select2-container--default[dir=3D"rtl"] .select2-selection--multiple .sele=
ct2-selection__choice__remove { margin-left: 2px; margin-right: auto; }

.select2-container--default.select2-container--focus .select2-selection--mu=
ltiple { border: 1px solid black; outline: 0px; }

.select2-container--default.select2-container--disabled .select2-selection-=
-multiple { background-color: rgb(238, 238, 238); cursor: default; }

.select2-container--default.select2-container--disabled .select2-selection_=
_choice__remove { display: none; }

.select2-container--default.select2-container--open.select2-container--abov=
e .select2-selection--single, .select2-container--default.select2-container=
--open.select2-container--above .select2-selection--multiple { border-top-l=
eft-radius: 0px; border-top-right-radius: 0px; }

.select2-container--default.select2-container--open.select2-container--belo=
w .select2-selection--single, .select2-container--default.select2-container=
--open.select2-container--below .select2-selection--multiple { border-botto=
m-left-radius: 0px; border-bottom-right-radius: 0px; }

.select2-container--default .select2-search--dropdown .select2-search__fiel=
d { border: 1px solid rgb(170, 170, 170); }

.select2-container--default .select2-search--inline .select2-search__field =
{ background: transparent; border: none; outline: 0px; box-shadow: none; ap=
pearance: textfield; }

.select2-container--default .select2-results > .select2-results__options { =
max-height: 200px; overflow-y: auto; }

.select2-container--default .select2-results__option[role=3D"group"] { padd=
ing: 0px; }

.select2-container--default .select2-results__option[aria-disabled=3D"true"=
] { color: rgb(153, 153, 153); }

.select2-container--default .select2-results__option[aria-selected=3D"true"=
] { background-color: rgb(221, 221, 221); }

.select2-container--default .select2-results__option .select2-results__opti=
on { padding-left: 1em; }

.select2-container--default .select2-results__option .select2-results__opti=
on .select2-results__group { padding-left: 0px; }

.select2-container--default .select2-results__option .select2-results__opti=
on .select2-results__option { margin-left: -1em; padding-left: 2em; }

.select2-container--default .select2-results__option .select2-results__opti=
on .select2-results__option .select2-results__option { margin-left: -2em; p=
adding-left: 3em; }

.select2-container--default .select2-results__option .select2-results__opti=
on .select2-results__option .select2-results__option .select2-results__opti=
on { margin-left: -3em; padding-left: 4em; }

.select2-container--default .select2-results__option .select2-results__opti=
on .select2-results__option .select2-results__option .select2-results__opti=
on .select2-results__option { margin-left: -4em; padding-left: 5em; }

.select2-container--default .select2-results__option .select2-results__opti=
on .select2-results__option .select2-results__option .select2-results__opti=
on .select2-results__option .select2-results__option { margin-left: -5em; p=
adding-left: 6em; }

.select2-container--default .select2-results__option--highlighted[aria-sele=
cted] { background-color: rgb(88, 151, 251); color: white; }

.select2-container--default .select2-results__group { cursor: default; disp=
lay: block; padding: 6px; }

.select2-container--classic .select2-selection--single { background-color: =
rgb(247, 247, 247); border: 1px solid rgb(170, 170, 170); border-radius: 4p=
x; outline: 0px; background-image: linear-gradient(rgb(255, 255, 255) 50%, =
rgb(238, 238, 238) 100%); background-repeat: repeat-x; }

.select2-container--classic .select2-selection--single:focus { border: 1px =
solid rgb(88, 151, 251); }

.select2-container--classic .select2-selection--single .select2-selection__=
rendered { color: rgb(68, 68, 68); line-height: 28px; }

.select2-container--classic .select2-selection--single .select2-selection__=
clear { cursor: pointer; float: right; font-weight: bold; margin-right: 10p=
x; }

.select2-container--classic .select2-selection--single .select2-selection__=
placeholder { color: rgb(153, 153, 153); }

.select2-container--classic .select2-selection--single .select2-selection__=
arrow { background-color: rgb(221, 221, 221); border-top: none; border-righ=
t: none; border-bottom: none; border-image: initial; border-left: 1px solid=
 rgb(170, 170, 170); border-top-right-radius: 4px; border-bottom-right-radi=
us: 4px; height: 26px; position: absolute; top: 1px; right: 1px; width: 20p=
x; background-image: linear-gradient(rgb(238, 238, 238) 50%, rgb(204, 204, =
204) 100%); background-repeat: repeat-x; }

.select2-container--classic .select2-selection--single .select2-selection__=
arrow b { border-color: rgb(136, 136, 136) transparent transparent; border-=
style: solid; border-width: 5px 4px 0px; height: 0px; left: 50%; margin-lef=
t: -4px; margin-top: -2px; position: absolute; top: 50%; width: 0px; }

.select2-container--classic[dir=3D"rtl"] .select2-selection--single .select=
2-selection__clear { float: left; }

.select2-container--classic[dir=3D"rtl"] .select2-selection--single .select=
2-selection__arrow { border-top: none; border-bottom: none; border-left: no=
ne; border-image: initial; border-right: 1px solid rgb(170, 170, 170); bord=
er-radius: 4px 0px 0px 4px; left: 1px; right: auto; }

.select2-container--classic.select2-container--open .select2-selection--sin=
gle { border: 1px solid rgb(88, 151, 251); }

.select2-container--classic.select2-container--open .select2-selection--sin=
gle .select2-selection__arrow { background: transparent; border: none; }

.select2-container--classic.select2-container--open .select2-selection--sin=
gle .select2-selection__arrow b { border-color: transparent transparent rgb=
(136, 136, 136); border-width: 0px 4px 5px; }

.select2-container--classic.select2-container--open.select2-container--abov=
e .select2-selection--single { border-top: none; border-top-left-radius: 0p=
x; border-top-right-radius: 0px; background-image: linear-gradient(rgb(255,=
 255, 255) 0%, rgb(238, 238, 238) 50%); background-repeat: repeat-x; }

.select2-container--classic.select2-container--open.select2-container--belo=
w .select2-selection--single { border-bottom: none; border-bottom-left-radi=
us: 0px; border-bottom-right-radius: 0px; background-image: linear-gradient=
(rgb(238, 238, 238) 50%, rgb(255, 255, 255) 100%); background-repeat: repea=
t-x; }

.select2-container--classic .select2-selection--multiple { background-color=
: white; border: 1px solid rgb(170, 170, 170); border-radius: 4px; cursor: =
text; outline: 0px; }

.select2-container--classic .select2-selection--multiple:focus { border: 1p=
x solid rgb(88, 151, 251); }

.select2-container--classic .select2-selection--multiple .select2-selection=
__rendered { list-style: none; margin: 0px; padding: 0px 5px; }

.select2-container--classic .select2-selection--multiple .select2-selection=
__clear { display: none; }

.select2-container--classic .select2-selection--multiple .select2-selection=
__choice { background-color: rgb(228, 228, 228); border: 1px solid rgb(170,=
 170, 170); border-radius: 4px; cursor: default; float: left; margin-right:=
 5px; margin-top: 5px; padding: 0px 5px; }

.select2-container--classic .select2-selection--multiple .select2-selection=
__choice__remove { color: rgb(136, 136, 136); cursor: pointer; display: inl=
ine-block; font-weight: bold; margin-right: 2px; }

.select2-container--classic .select2-selection--multiple .select2-selection=
__choice__remove:hover { color: rgb(85, 85, 85); }

.select2-container--classic[dir=3D"rtl"] .select2-selection--multiple .sele=
ct2-selection__choice { float: right; margin-left: 5px; margin-right: auto;=
 }

.select2-container--classic[dir=3D"rtl"] .select2-selection--multiple .sele=
ct2-selection__choice__remove { margin-left: 2px; margin-right: auto; }

.select2-container--classic.select2-container--open .select2-selection--mul=
tiple { border: 1px solid rgb(88, 151, 251); }

.select2-container--classic.select2-container--open.select2-container--abov=
e .select2-selection--multiple { border-top: none; border-top-left-radius: =
0px; border-top-right-radius: 0px; }

.select2-container--classic.select2-container--open.select2-container--belo=
w .select2-selection--multiple { border-bottom: none; border-bottom-left-ra=
dius: 0px; border-bottom-right-radius: 0px; }

.select2-container--classic .select2-search--dropdown .select2-search__fiel=
d { border: 1px solid rgb(170, 170, 170); outline: 0px; }

.select2-container--classic .select2-search--inline .select2-search__field =
{ outline: 0px; box-shadow: none; }

.select2-container--classic .select2-dropdown { background-color: rgb(255, =
255, 255); border: 1px solid transparent; }

.select2-container--classic .select2-dropdown--above { border-bottom: none;=
 }

.select2-container--classic .select2-dropdown--below { border-top: none; }

.select2-container--classic .select2-results > .select2-results__options { =
max-height: 200px; overflow-y: auto; }

.select2-container--classic .select2-results__option[role=3D"group"] { padd=
ing: 0px; }

.select2-container--classic .select2-results__option[aria-disabled=3D"true"=
] { color: grey; }

.select2-container--classic .select2-results__option--highlighted[aria-sele=
cted] { background-color: rgb(56, 117, 215); color: rgb(255, 255, 255); }

.select2-container--classic .select2-results__group { cursor: default; disp=
lay: block; padding: 6px; }

.select2-container--classic.select2-container--open .select2-dropdown { bor=
der-color: rgb(88, 151, 251); }

.sidr { display: block; position: fixed; top: 0px; height: 100%; z-index: 9=
99999; width: 260px; overflow: hidden auto; font-family: "lucida grande", t=
ahoma, verdana, arial, sans-serif; font-size: 15px; background: rgb(51, 51,=
 51); color: rgb(255, 255, 255); box-shadow: rgb(34, 34, 34) 0px 0px 5px 5p=
x inset; }

.sidr .sidr-inner { padding: 0px 0px 15px; }

.sidr .sidr-inner > p { margin-left: 15px; margin-right: 15px; }

.sidr.right { left: auto; right: -260px; }

.sidr.left { left: -260px; right: auto; }

.sidr h1, .sidr h2, .sidr h3, .sidr h4, .sidr h5, .sidr h6 { background-siz=
e: 100%; background-image: linear-gradient(rgb(77, 77, 77), rgb(26, 26, 26)=
); font-size: 11px; font-weight: normal; padding: 0px 15px; margin: 0px 0px=
 5px; color: rgb(255, 255, 255); line-height: 24px; box-shadow: rgba(0, 0, =
0, 0.2) 0px 5px 5px 3px; }

.sidr p { font-size: 13px; margin: 0px 0px 12px; }

.sidr p a { color: rgba(255, 255, 255, 0.9); }

.sidr > p { margin-left: 15px; margin-right: 15px; }

.sidr ul { display: block; margin: 0px 0px 15px; padding: 0px; border-top: =
1px solid rgb(26, 26, 26); border-bottom: 1px solid rgb(77, 77, 77); }

.sidr ul li { display: block; margin: 0px; line-height: 48px; border-top: 1=
px solid rgb(77, 77, 77); border-bottom: 1px solid rgb(26, 26, 26); }

.sidr ul li:hover, .sidr ul li.active, .sidr ul li.sidr-class-active { bord=
er-top: 0px; line-height: 49px; }

.sidr ul li:hover > a, .sidr ul li:hover > span, .sidr ul li.active > a, .s=
idr ul li.active > span, .sidr ul li.sidr-class-active > a, .sidr ul li.sid=
r-class-active > span { box-shadow: rgb(34, 34, 34) 0px 0px 15px 3px inset;=
 }

.sidr ul li a, .sidr ul li span { padding: 0px 15px; display: block; text-d=
ecoration: none; color: rgb(255, 255, 255); }

.sidr ul li ul { border-bottom: 0px; margin: 0px; }

.sidr ul li ul li { line-height: 40px; font-size: 13px; }

.sidr ul li ul li:last-child { border-bottom: 0px; }

.sidr ul li ul li:hover, .sidr ul li ul li.active, .sidr ul li ul li.sidr-c=
lass-active { border-top: 0px; line-height: 41px; }

.sidr ul li ul li:hover > a, .sidr ul li ul li:hover > span, .sidr ul li ul=
 li.active > a, .sidr ul li ul li.active > span, .sidr ul li ul li.sidr-cla=
ss-active > a, .sidr ul li ul li.sidr-class-active > span { box-shadow: rgb=
(34, 34, 34) 0px 0px 15px 3px inset; }

.sidr ul li ul li a, .sidr ul li ul li span { color: rgba(255, 255, 255, 0.=
8); padding-left: 30px; }

.sidr form { margin: 0px 15px; }

.sidr label { font-size: 13px; }

.sidr input[type=3D"text"], .sidr input[type=3D"password"], .sidr input[typ=
e=3D"date"], .sidr input[type=3D"datetime"], .sidr input[type=3D"email"], .=
sidr input[type=3D"number"], .sidr input[type=3D"search"], .sidr input[type=
=3D"tel"], .sidr input[type=3D"time"], .sidr input[type=3D"url"], .sidr tex=
tarea, .sidr select { width: 100%; font-size: 13px; padding: 5px; box-sizin=
g: border-box; margin: 0px 0px 10px; border-radius: 2px; border: 0px; backg=
round: rgba(0, 0, 0, 0.1); color: rgba(255, 255, 255, 0.6); display: block;=
 clear: both; }

.sidr input[type=3D"checkbox"] { width: auto; display: inline; clear: none;=
 }

.sidr input[type=3D"button"], .sidr input[type=3D"submit"] { color: rgb(51,=
 51, 51); background: rgb(255, 255, 255); }

.sidr input[type=3D"button"]:hover, .sidr input[type=3D"submit"]:hover { ba=
ckground: rgba(255, 255, 255, 0.9); }

.select2-container--default .select2-results__option.select2-results__optio=
n--highlighted[aria-selected] { background-color: rgb(45, 114, 225); }

.select2-container--default .select2-selection--multiple .select2-selection=
__choice .select2-selection__choice__remove { color: inherit; }

.select2-container--default .select2-selection--multiple .select2-selection=
__rendered .select2-selection__choice { border-color: rgb(148, 148, 148); }

.chosen-container { position: relative; display: inline-block; vertical-ali=
gn: middle; font-size: 13px; user-select: none; }

.chosen-container * { box-sizing: border-box; }

.chosen-container .chosen-drop { position: absolute; top: 100%; left: -9999=
px; z-index: 1010; width: 100%; border-width: 0px 1px 1px; border-right-sty=
le: solid; border-bottom-style: solid; border-left-style: solid; border-rig=
ht-color: rgb(170, 170, 170); border-bottom-color: rgb(170, 170, 170); bord=
er-left-color: rgb(170, 170, 170); border-image: initial; border-top-style:=
 initial; border-top-color: initial; background: rgb(255, 255, 255); box-sh=
adow: rgba(0, 0, 0, 0.15) 0px 4px 5px; }

.chosen-container.chosen-with-drop .chosen-drop { left: 0px; }

.chosen-container a { cursor: pointer; }

.chosen-container .search-choice .group-name, .chosen-container .chosen-sin=
gle .group-name { margin-right: 4px; overflow: hidden; white-space: nowrap;=
 text-overflow: ellipsis; font-weight: normal; color: rgb(153, 153, 153); }

.chosen-container .search-choice .group-name::after, .chosen-container .cho=
sen-single .group-name::after { content: ":"; padding-left: 2px; vertical-a=
lign: top; }

.chosen-container-single .chosen-single { position: relative; display: bloc=
k; overflow: hidden; padding: 0px 0px 0px 8px; height: 25px; border: 1px so=
lid rgb(170, 170, 170); border-radius: 5px; background: linear-gradient(rgb=
(255, 255, 255) 20%, rgb(246, 246, 246) 50%, rgb(238, 238, 238) 52%, rgb(24=
4, 244, 244) 100%) padding-box; box-shadow: white 0px 0px 3px inset, rgba(0=
, 0, 0, 0.1) 0px 1px 1px; color: rgb(68, 68, 68); text-decoration: none; wh=
ite-space: nowrap; line-height: 24px; }

.chosen-container-single .chosen-default { color: rgb(153, 153, 153); }

.chosen-container-single .chosen-single span { display: block; overflow: hi=
dden; margin-right: 26px; text-overflow: ellipsis; white-space: nowrap; }

.chosen-container-single .chosen-single-with-deselect span { margin-right: =
38px; }

.chosen-container-single .chosen-single abbr { position: absolute; top: 6px=
; right: 26px; display: block; width: 12px; height: 12px; background: url("=
/profiles/nasdaqir/themes/custom/nir_base/bower_components/chosen/chosen-sp=
rite.png") -42px 1px no-repeat; font-size: 1px; }

.chosen-container-single .chosen-single abbr:hover { background-position: -=
42px -10px; }

.chosen-container-single.chosen-disabled .chosen-single abbr:hover { backgr=
ound-position: -42px -10px; }

.chosen-container-single .chosen-single div { position: absolute; top: 0px;=
 right: 0px; display: block; width: 18px; height: 100%; }

.chosen-container-single .chosen-single div b { display: block; width: 100%=
; height: 100%; background: url("/profiles/nasdaqir/themes/custom/nir_base/=
bower_components/chosen/chosen-sprite.png") 0px 2px no-repeat; }

.chosen-container-single .chosen-search { position: relative; z-index: 1010=
; margin: 0px; padding: 3px 4px; white-space: nowrap; }

.chosen-container-single .chosen-search input[type=3D"text"] { margin: 1px =
0px; padding: 4px 20px 4px 5px; width: 100%; height: auto; outline: 0px; bo=
rder: 1px solid rgb(170, 170, 170); background: url("/profiles/nasdaqir/the=
mes/custom/nir_base/bower_components/chosen/chosen-sprite.png") 100% -20px =
no-repeat; font-size: 1em; font-family: sans-serif; line-height: normal; bo=
rder-radius: 0px; }

.chosen-container-single .chosen-drop { margin-top: -1px; border-radius: 0p=
x 0px 4px 4px; background-clip: padding-box; }

.chosen-container-single.chosen-container-single-nosearch .chosen-search { =
position: absolute; left: -9999px; }

.chosen-container .chosen-results { color: rgb(68, 68, 68); position: relat=
ive; overflow: hidden auto; margin: 0px 4px 4px 0px; padding: 0px 0px 0px 4=
px; max-height: 240px; }

.chosen-container .chosen-results li { display: none; margin: 0px; padding:=
 5px 6px; list-style: none; line-height: 15px; overflow-wrap: break-word; }

.chosen-container .chosen-results li.active-result { display: list-item; cu=
rsor: pointer; }

.chosen-container .chosen-results li.disabled-result { display: list-item; =
color: rgb(204, 204, 204); cursor: default; }

.chosen-container .chosen-results li.highlighted { background-color: rgb(56=
, 117, 215); background-image: linear-gradient(rgb(56, 117, 215) 20%, rgb(4=
2, 98, 188) 90%); color: rgb(255, 255, 255); }

.chosen-container .chosen-results li.no-results { color: rgb(119, 119, 119)=
; display: list-item; background: rgb(244, 244, 244); }

.chosen-container .chosen-results li.group-result { display: list-item; fon=
t-weight: bold; cursor: default; }

.chosen-container .chosen-results li.group-option { padding-left: 15px; }

.chosen-container .chosen-results li em { font-style: normal; text-decorati=
on: underline; }

.chosen-container-multi .chosen-choices { position: relative; overflow: hid=
den; margin: 0px; padding: 0px 5px; width: 100%; border: 1px solid rgb(170,=
 170, 170); background-color: rgb(255, 255, 255); background-image: linear-=
gradient(rgb(238, 238, 238) 1%, rgb(255, 255, 255) 15%); cursor: text; heig=
ht: auto !important; }

.chosen-container-multi .chosen-choices li { float: left; list-style: none;=
 }

.chosen-container-multi .chosen-choices li.search-field { margin: 0px; padd=
ing: 0px; white-space: nowrap; }

.chosen-container-multi .chosen-choices li.search-field input[type=3D"text"=
] { margin: 1px 0px; padding: 0px; height: 25px; outline: 0px; box-shadow: =
none; color: rgb(121, 118, 118); font-size: 100%; font-family: sans-serif; =
line-height: normal; border-radius: 0px; border: 0px !important; background=
: transparent !important; }

.chosen-container-multi .chosen-choices li.search-choice { position: relati=
ve; margin: 3px 5px 3px 0px; padding: 3px 20px 3px 5px; border: 1px solid r=
gb(170, 170, 170); max-width: 100%; border-radius: 3px; background-color: r=
gb(238, 238, 238); background-image: linear-gradient(rgb(244, 244, 244) 20%=
, rgb(240, 240, 240) 50%, rgb(232, 232, 232) 52%, rgb(238, 238, 238) 100%);=
 background-size: 100% 19px; background-repeat: repeat-x; background-clip: =
padding-box; box-shadow: white 0px 0px 2px inset, rgba(0, 0, 0, 0.05) 0px 1=
px 0px; color: rgb(51, 51, 51); line-height: 13px; cursor: default; }

.chosen-container-multi .chosen-choices li.search-choice span { overflow-wr=
ap: break-word; }

.chosen-container-multi .chosen-choices li.search-choice .search-choice-clo=
se { position: absolute; top: 4px; right: 3px; display: block; width: 12px;=
 height: 12px; background: url("/profiles/nasdaqir/themes/custom/nir_base/b=
ower_components/chosen/chosen-sprite.png") -42px 1px no-repeat; font-size: =
1px; }

.chosen-container-multi .chosen-choices li.search-choice .search-choice-clo=
se:hover { background-position: -42px -10px; }

.chosen-container-multi .chosen-choices li.search-choice-disabled { padding=
-right: 5px; border: 1px solid rgb(204, 204, 204); background-color: rgb(22=
8, 228, 228); background-image: linear-gradient(rgb(244, 244, 244) 20%, rgb=
(240, 240, 240) 50%, rgb(232, 232, 232) 52%, rgb(238, 238, 238) 100%); colo=
r: rgb(102, 102, 102); }

.chosen-container-multi .chosen-choices li.search-choice-focus { background=
: rgb(212, 212, 212); }

.chosen-container-multi .chosen-choices li.search-choice-focus .search-choi=
ce-close { background-position: -42px -10px; }

.chosen-container-multi .chosen-results { margin: 0px; padding: 0px; }

.chosen-container-multi .chosen-drop .result-selected { display: list-item;=
 color: rgb(204, 204, 204); cursor: default; }

.chosen-container-active .chosen-single { border: 1px solid rgb(88, 151, 25=
1); box-shadow: rgba(0, 0, 0, 0.3) 0px 0px 5px; }

.chosen-container-active.chosen-with-drop .chosen-single { border: 1px soli=
d rgb(170, 170, 170); border-bottom-right-radius: 0px; border-bottom-left-r=
adius: 0px; background-image: linear-gradient(rgb(238, 238, 238) 20%, rgb(2=
55, 255, 255) 80%); box-shadow: rgb(255, 255, 255) 0px 1px 0px inset; }

.chosen-container-active.chosen-with-drop .chosen-single div { border-left:=
 none; background: transparent; }

.chosen-container-active.chosen-with-drop .chosen-single div b { background=
-position: -18px 2px; }

.chosen-container-active .chosen-choices { border: 1px solid rgb(88, 151, 2=
51); box-shadow: rgba(0, 0, 0, 0.3) 0px 0px 5px; }

.chosen-container-active .chosen-choices li.search-field input[type=3D"text=
"] { color: rgb(34, 34, 34) !important; }

.chosen-disabled { opacity: 0.5 !important; cursor: default; }

.chosen-disabled .chosen-single { cursor: default; }

.chosen-disabled .chosen-choices .search-choice .search-choice-close { curs=
or: default; }

.chosen-rtl { text-align: right; }

.chosen-rtl .chosen-single { overflow: visible; padding: 0px 8px 0px 0px; }

.chosen-rtl .chosen-single span { margin-right: 0px; margin-left: 26px; dir=
ection: rtl; }

.chosen-rtl .chosen-single-with-deselect span { margin-left: 38px; }

.chosen-rtl .chosen-single div { right: auto; left: 3px; }

.chosen-rtl .chosen-single abbr { right: auto; left: 26px; }

.chosen-rtl .chosen-choices li { float: right; }

.chosen-rtl .chosen-choices li.search-field input[type=3D"text"] { directio=
n: rtl; }

.chosen-rtl .chosen-choices li.search-choice { margin: 3px 5px 3px 0px; pad=
ding: 3px 5px 3px 19px; }

.chosen-rtl .chosen-choices li.search-choice .search-choice-close { right: =
auto; left: 4px; }

.chosen-rtl.chosen-container-single-nosearch .chosen-search, .chosen-rtl .c=
hosen-drop { left: 9999px; }

.chosen-rtl.chosen-container-single .chosen-results { margin: 0px 0px 4px 4=
px; padding: 0px 4px 0px 0px; }

.chosen-rtl .chosen-results li.group-option { padding-right: 15px; padding-=
left: 0px; }

.chosen-rtl.chosen-container-active.chosen-with-drop .chosen-single div { b=
order-right: none; }

.chosen-rtl .chosen-search input[type=3D"text"] { padding: 4px 5px 4px 20px=
; background: url("/profiles/nasdaqir/themes/custom/nir_base/bower_componen=
ts/chosen/chosen-sprite.png") -30px -20px no-repeat; direction: rtl; }

.chosen-rtl.chosen-container-single .chosen-single div b { background-posit=
ion: 6px 2px; }

.chosen-rtl.chosen-container-single.chosen-with-drop .chosen-single div b {=
 background-position: -12px 2px; }

@media only screen and (-webkit-min-device-pixel-ratio: 1.5), only screen a=
nd (min-resolution: 144dpi), only screen and (min-resolution: 1.5dppx) {
  .chosen-rtl .chosen-search input[type=3D"text"], .chosen-container-single=
 .chosen-single abbr, .chosen-container-single .chosen-single div b, .chose=
n-container-single .chosen-search input[type=3D"text"], .chosen-container-m=
ulti .chosen-choices .search-choice .search-choice-close, .chosen-container=
 .chosen-results-scroll-down span, .chosen-container .chosen-results-scroll=
-up span { background-image: url("/profiles/nasdaqir/themes/custom/nir_base=
/bower_components/chosen/chosen-sprite%402x.png") !important; background-si=
ze: 52px 37px !important; background-repeat: no-repeat !important; }
}

.float-left { float: left; }

.clear-both { clear: both; }

img, legend { border: 0px; }

legend, td, th { padding: 0px; }

html { font-family: sans-serif; text-size-adjust: 100%; }

body { margin: 0px; }

article, aside, details, figcaption, figure, footer, header, hgroup, main, =
menu, nav, section, summary { display: block; }

audio, canvas, progress, video { display: inline-block; vertical-align: bas=
eline; }

audio:not([controls]) { display: none; height: 0px; }

[hidden], template { display: none; }

a { background-color: rgba(0, 0, 0, 0); }

a:active, a:hover { outline: 0px; }

abbr[title] { border-bottom: 1px dotted; }

b, optgroup, strong { font-weight: 700; }

dfn { font-style: italic; }

h1 { font-size: 2em; margin: 0.67em 0px; }

mark { background: rgb(255, 255, 0); color: rgb(0, 0, 0); }

small { font-size: 80%; }

sub, sup { font-size: 75%; line-height: 0; position: relative; vertical-ali=
gn: baseline; }

sup { top: -0.5em; }

sub { bottom: -0.25em; }

svg:not(:root) { overflow: hidden; }

figure { margin: 1em 40px; }

hr { box-sizing: content-box; height: 0px; }

pre, textarea { overflow: auto; }

code, kbd, pre, samp { font-family: monospace, monospace; font-size: 1em; }

button, input, optgroup, select, textarea { color: inherit; font: inherit; =
margin: 0px; }

button { overflow: visible; }

button, select { text-transform: none; }

button, html input[type=3D"button"], input[type=3D"reset"], input[type=3D"s=
ubmit"] { appearance: button; cursor: pointer; }

button[disabled], html input[disabled] { cursor: default; }

input { line-height: normal; }

input[type=3D"checkbox"], input[type=3D"radio"] { box-sizing: border-box; p=
adding: 0px; }

input[type=3D"number"]::-webkit-inner-spin-button, input[type=3D"number"]::=
-webkit-outer-spin-button { height: auto; }

input[type=3D"search"] { appearance: textfield; box-sizing: content-box; }

input[type=3D"search"]::-webkit-search-cancel-button, input[type=3D"search"=
]::-webkit-search-decoration { appearance: none; }

fieldset { border: 1px solid silver; margin: 0px 2px; padding: 0.35em 0.625=
em 0.75em; }

table { border-collapse: collapse; border-spacing: 0px; }

.icon { background-image: url("/profiles/nasdaqir/themes/custom/nir_base/di=
st/images/sprite.png"); }

html { font-size: 87.5%; line-height: 1.42857em; font-family: Verdana, Taho=
ma, "DejaVu Sans", sans-serif; text-size-adjust: 100%; min-height: 100%; }

@media print {
  html { font-size: 12pt; }
}

body { margin: 0px; padding: 0px; }

* { box-sizing: border-box; }

article, aside, details, figcaption, figure, footer, header, hgroup, main, =
menu, nav, section, summary { display: block; }

audio, canvas, progress, video { display: inline-block; vertical-align: bas=
eline; }

audio:not([controls]) { display: none; height: 0px; }

[hidden] { display: none; }

template { display: none; }

html, body { font-size: 87.5%; line-height: 1.42857em; min-height: 100%; he=
ight: 100%; padding: 0px; margin: 0px; }

@media print {
  html, body { font-size: 12pt; }
}

body { background: rgb(245, 245, 245); font-family: "Helvetica Neue", Helve=
tica, Arial, sans-serif; font-size: 14px; overflow-wrap: break-word; color:=
 rgb(51, 51, 51); }

body .container { background: rgba(255, 255, 255, 0.9); }

h1, h2, h3, h4 { font-weight: bold; font-family: "Helvetica Neue", Helvetic=
a, Arial, sans-serif; }

body .menu-item { padding-top: 0px; margin: 0px; }

a#logo { width: 100px; display: block; padding: 5px; float: left; margin-bo=
ttom: 15px; }

:link { color: rgb(3, 124, 165); text-decoration: none; }

:visited { color: rgb(3, 124, 165); }

a:hover, a:focus { text-decoration: underline; }

a:active { color: rgb(1, 49, 65); background-color: rgba(0, 0, 0, 0); }

a:active, a:hover { outline: 0px; }

@media print {
  :link, :visited { text-decoration: underline; }
  a[href]::after { content: " (" attr(href) ")"; font-weight: normal; font-=
size: 14px; text-decoration: none; }
  a[href^=3D"javascript:"]::after, a[href^=3D"#"]::after { content: ""; }
}

img { border: 0px; }

img, svg { max-width: 100%; height: auto; width: auto; }

svg:not(:root) { overflow: hidden; }

form { margin: 0px; }

button, input, optgroup, select, textarea { box-sizing: border-box; max-wid=
th: 100%; color: inherit; font: inherit; margin: 0px; }

button { overflow: visible; }

button, select { text-transform: none; }

html input[type=3D"button"], [type=3D"reset"], [type=3D"submit"] { appearan=
ce: button; }

input[type=3D"number"]::-webkit-inner-spin-button, input[type=3D"number"]::=
-webkit-outer-spin-button { height: auto; }

input[type=3D"search"] { appearance: textfield; }

input[type=3D"search"]::-webkit-search-cancel-button, input[type=3D"search"=
]::-webkit-search-decoration { appearance: none; }

textarea, input[type=3D"text"], input[type=3D"search"], input[type=3D"tel"]=
, input[type=3D"url"], input[type=3D"email"], input[type=3D"password"], inp=
ut[type=3D"date"], input[type=3D"time"], input[type=3D"number"], input[type=
=3D"datalist"] { display: block; width: auto; padding: 10px 15px; font-size=
: 14px; line-height: 1.42857; margin-top: 5px; color: rgb(121, 118, 118); b=
order: 1px solid rgb(156, 146, 146); border-radius: 4px; outline: 0px; }

input[type=3D"checkbox"], input[type=3D"radio"] { box-sizing: border-box; p=
adding: 0px; }

fieldset { padding: 0.5em 0.892857em 0.928571em; border: 1px solid rgb(204,=
 204, 204); margin: 0px 2px; }

fieldset::before { content: ""; display: table; }

fieldset::after { content: ""; display: table; clear: both; }

legend { border: 0px; margin-left: -5px; padding: 0px 5px; }

[dir=3D"rtl"] legend { }

label { display: block; font-weight: bold; }

select { appearance: none; padding-right: 30px; }

optgroup { font-weight: bold; }

textarea { overflow: auto; }

blockquote { margin: 0px 2em 1.42857em; }

figure { margin: 0px 0px 1.42857em; }

hr { box-sizing: content-box; height: 0px; }

p { margin: 1em 0px; }

pre { font-family: monospace; font-size: 0.8em; line-height: 1.45; }

pre { overflow: auto; }

dl, menu, ol, ul { margin: 1em 0px; }

ol ol, ol ul, ul ol, ul ul { margin: 0px; }

dd { margin: 0px 0px 0px 28px; }

[dir=3D"rtl"] dd { margin: 0px 28px 0px 0px; }

menu, ol, ul { padding: 0px 0px 0px 28px; }

[dir=3D"rtl"] menu, [dir=3D"rtl"] ol, [dir=3D"rtl"] ul { padding: 0px 28px =
0px 0px; }

nav ul, nav ol { list-style: none none; }

h1, #nir-header__site-name { font-size: 1.5em; line-height: 1.42857em; marg=
in-top: 0.666571em; margin-bottom: 0.476143em; }

h2, .block-market-data-block__estimates__all .js-form-type-select label, ta=
ble.nirtable caption, table.dataTable caption { font-size: 1.3em; line-heig=
ht: 1.42857em; margin-top: 0.357143em; margin-bottom: 0.357143em; border-bo=
ttom: 1px solid rgb(225, 225, 225); }

h3 { font-size: 1.2em; line-height: 1.42857em; margin-top: 1em; margin-bott=
om: 1em; }

h4, h5, h6, .node--view-mode-nir-media-gallery-viewmode .field--name-field-=
nir-media-gallery-title, .view-nir-media-gallery-items-grid .views-row h2 {=
 font-size: 1.1em; line-height: 1.42857em; margin-top: 1.42857em; margin-bo=
ttom: 1.42857em; }

table.nirtable, table.dataTable { margin: 0px 0px 15px; border-collapse: se=
parate; border-spacing: 0px; border: 0px; table-layout: fixed; width: 100%;=
 overflow-wrap: normal; }

table.nirtable caption, table.dataTable caption { font-weight: bold; text-a=
lign: left; padding: 5px 0px; }

table.nirtable tbody tr:nth-child(2n+1), table.dataTable tbody tr:nth-child=
(2n+1) { background-color: rgb(245, 250, 250); }

table.nirtable td, table.nirtable th, table.dataTable td, table.dataTable t=
h { padding: 15px; border: 0px; }

table.nirtable th, table.nirtable thead td, table.dataTable th, table.dataT=
able thead td { background-color: rgb(102, 102, 102); color: rgb(255, 255, =
255); text-align: left; position: relative; }

.container { max-width: 80em; margin-left: auto; margin-right: auto; paddin=
g-bottom: 1em; }

.container::after { content: " "; display: block; clear: both; }

.two-col-node .node-left { width: 100%; float: right; margin-right: 0px; }

@media (min-width: 480px) {
  .two-col-node .node-left { width: 36.7089%; float: left; margin-right: 1.=
26582%; }
}

.two-col-node .node-right { width: 100%; float: right; margin-right: 0px; }

@media (min-width: 480px) {
  .two-col-node .node-right { width: 62.0253%; float: right; margin-right: =
0px; }
}

.two-col-node-alt1 .node-left { width: 100%; float: right; margin-right: 0p=
x; }

@media (min-width: 480px) {
  .two-col-node-alt1 .node-left { width: 24.0506%; float: left; margin-righ=
t: 1.26582%; }
}

.two-col-node-alt1 .node-right { width: 100%; float: right; margin-right: 0=
px; }

@media (min-width: 480px) {
  .two-col-node-alt1 .node-right { width: 74.6835%; float: right; margin-ri=
ght: 0px; }
}

.two-col-node-alt2 .node-left { width: 100%; float: right; margin-right: 0p=
x; }

@media (min-width: 480px) {
  .two-col-node-alt2 .node-left { width: 36.7089%; float: left; margin-righ=
t: 1.26582%; }
}

.two-col-node-alt2 .node-right { width: 100%; float: right; margin-right: 0=
px; }

@media (min-width: 480px) {
  .two-col-node-alt2 .node-right { width: 62.0253%; float: right; margin-ri=
ght: 0px; }
}

.two-col-node-alt3 .node-left { width: 100%; float: right; margin-right: 0p=
x; }

@media (min-width: 480px) {
  .two-col-node-alt3 .node-left { width: 17.7215%; float: left; margin-righ=
t: 1.26582%; }
}

.two-col-node-alt3 .node-right { width: 100%; float: right; margin-right: 0=
px; }

@media (min-width: 480px) {
  .two-col-node-alt3 .node-right { width: 81.0127%; float: right; margin-ri=
ght: 0px; }
}

.two-col-half .left-half { width: 100%; float: right; margin-right: 0px; }

@media (min-width: 480px) {
  .two-col-half .left-half { width: 49.3671%; float: left; margin-right: 1.=
26582%; }
}

.two-col-half .right-half { width: 100%; float: right; margin-right: 0px; }

@media (min-width: 480px) {
  .two-col-half .right-half { width: 49.3671%; float: right; margin-right: =
0px; }
}

.modal-content .node-left { width: 100%; float: right; margin-right: 0px; }

@media (min-width: 480px) {
  .modal-content .node-left { width: 17.7215%; float: left; margin-right: 1=
.26582%; }
}

.modal-content .node-right { width: 100%; float: right; margin-right: 0px; =
}

@media (min-width: 480px) {
  .modal-content .node-right { width: 81.0127%; float: right; margin-right:=
 0px; }
}

.split-half { float: left; margin-bottom: 1em; width: 100%; }

.split-half .left-half { width: 100%; float: right; margin-right: 0px; }

@media (min-width: 480px) {
  .split-half .left-half { width: 49.3671%; float: left; margin-right: 1.26=
582%; }
}

.split-half .right-half { width: 100%; float: right; margin-right: 0px; }

@media (min-width: 480px) {
  .split-half .right-half { width: 49.3671%; margin-right: 0px; float: left=
; }
}

.full-width { width: 100%; float: right; margin-right: 0px; }

.container-fluid { width: 100%; float: left; margin-left: 0px; margin-right=
: 0px; }

.row::before { content: ""; display: table; }

.row::after { content: ""; display: table; clear: both; }

@media (min-width: 768px) {
  .col-md-12 { width: 100%; float: left; margin-left: 0px; margin-right: 0p=
x; }
  .col-md-11 { width: 91.5254%; float: left; margin-right: 1.69492%; }
  .col-md-10 { width: 83.0508%; float: left; margin-right: 1.69492%; }
  .col-md-9 { width: 74.5763%; float: left; margin-right: 1.69492%; }
  .col-md-8 { width: 66.1017%; float: left; margin-right: 1.69492%; }
  .col-md-7 { width: 57.6271%; float: left; margin-right: 1.69492%; }
  .col-md-6 { width: 49.1525%; float: left; margin-right: 1.69492%; }
  .col-md-5 { width: 40.678%; float: left; margin-right: 1.69492%; }
  .col-md-4 { width: 32.2034%; float: left; margin-right: 1.69492%; }
  .col-md-3 { width: 23.7288%; float: left; margin-right: 1.69492%; }
  .col-md-2 { width: 15.2542%; float: left; margin-right: 1.69492%; }
  .col-md-1 { width: 6.77966%; float: left; margin-right: 1.69492%; }
  .col-md-pull-12 { margin-left: -101.695%; }
  .col-md-pull-11 { margin-left: -93.2203%; }
  .col-md-pull-10 { margin-left: -84.7458%; }
  .col-md-pull-9 { margin-left: -76.2712%; }
  .col-md-pull-8 { margin-left: -67.7966%; }
  .col-md-pull-7 { margin-left: -59.322%; }
  .col-md-pull-6 { margin-left: -50.8475%; }
  .col-md-pull-5 { margin-left: -42.3729%; }
  .col-md-pull-4 { margin-left: -33.8983%; }
  .col-md-pull-3 { margin-left: -25.4237%; }
  .col-md-pull-2 { margin-left: -16.9492%; }
  .col-md-pull-1 { margin-left: -8.47458%; }
  .col-md-pull-0 { margin-left: 0%; }
  .col-md-push-12 { margin-left: 101.695%; }
  .col-md-push-11 { margin-left: 93.2203%; }
  .col-md-push-10 { margin-left: 84.7458%; }
  .col-md-push-9 { margin-left: 76.2712%; }
  .col-md-push-8 { margin-left: 67.7966%; }
  .col-md-push-7 { margin-left: 59.322%; }
  .col-md-push-6 { margin-left: 50.8475%; }
  .col-md-push-5 { margin-left: 42.3729%; }
  .col-md-push-4 { margin-left: 33.8983%; }
  .col-md-push-3 { margin-left: 25.4237%; }
  .col-md-push-2 { margin-left: 16.9492%; }
  .col-md-push-1 { margin-left: 8.47458%; }
  .col-md-push-0 { margin-left: 0%; }
}

.row [class^=3D"col-md-"]:last-child { margin-right: 0px; }

.tabledrag-handle .handle, .mceToolbar table td a { box-sizing: content-box=
; }

.container-fluid .container-fluid { width: auto; margin-left: -1.69492%; ma=
rgin-right: -1.69492%; }

@media (min-width: 320px) {
  body.body-sidebars-first aside.sidebar-first { width: 100%; float: left; =
margin-left: 0px; margin-right: 0px; }
  body.body-sidebars-first aside.sidebar-first > * { padding-left: 0.5em; p=
adding-right: 0.5em; }
  body.body-sidebars-first section#content { width: 100%; float: left; marg=
in-left: 0px; margin-right: 0px; }
  body.body-sidebars-first section#content > * { padding-left: 0.5em; paddi=
ng-right: 0.5em; }
}

@media (min-width: 768px) {
  body.body-sidebars-first aside.sidebar-first { width: 24.0506%; float: le=
ft; margin-right: 1.26582%; }
  body.body-sidebars-first aside.sidebar-first > * { padding-left: 1em; }
  body.body-sidebars-first section#content { width: 74.6835%; float: right;=
 margin-right: 0px; }
  body.body-sidebars-first section#content > * { padding-right: 1em; }
}

@media (min-width: 320px) {
  body.body-sidebars-last aside.sidebar-last { width: 100%; float: left; ma=
rgin-left: 0px; margin-right: 0px; }
  body.body-sidebars-last aside.sidebar-last > * { padding-left: 0.5em; pad=
ding-right: 0.5em; }
  body.body-sidebars-last section#content { width: 100%; float: left; margi=
n-left: 0px; margin-right: 0px; }
  body.body-sidebars-last section#content > * { padding-left: 0.5em; paddin=
g-right: 0.5em; }
}

@media (min-width: 768px) {
  body.body-sidebars-last aside.sidebar-last { width: 24.0506%; float: righ=
t; margin-right: 0px; }
  body.body-sidebars-last aside.sidebar-last > * { padding-right: 1em; }
  body.body-sidebars-last section#content { width: 74.6835%; float: left; m=
argin-right: 1.26582%; }
  body.body-sidebars-last section#content > * { padding-left: 1em; }
}

@media (min-width: 320px) {
  body.body-sidebars-both aside.sidebar-first { width: 100%; float: left; m=
argin-left: 0px; margin-right: 0px; }
  body.body-sidebars-both aside.sidebar-first > * { padding-left: 0.5em; pa=
dding-right: 0.5em; }
  body.body-sidebars-both aside.sidebar-last { width: 100%; float: left; ma=
rgin-left: 0px; margin-right: 0px; }
  body.body-sidebars-both aside.sidebar-last > * { padding-left: 0.5em; pad=
ding-right: 0.5em; }
  body.body-sidebars-both section#content { width: 100%; float: left; margi=
n-left: 0px; margin-right: 0px; }
  body.body-sidebars-both section#content > * { padding-left: 0.5em; paddin=
g-right: 0.5em; }
}

@media (min-width: 768px) {
  body.body-sidebars-both aside.sidebar-first { width: 24.0506%; float: lef=
t; margin-right: 1.26582%; }
  body.body-sidebars-both aside.sidebar-first > * { padding-left: 1em; }
  body.body-sidebars-both section#content { width: 49.3671%; float: left; m=
argin-right: 1.26582%; }
  body.body-sidebars-both aside.sidebar-last { width: 24.0506%; float: righ=
t; margin-right: 0px; }
  body.body-sidebars-both aside.sidebar-last > * { padding-right: 1em; }
}

@media (min-width: 320px) {
  body.body-sidebars-none section#content { width: 100%; float: left; margi=
n-left: 0px; margin-right: 0px; }
  body.body-sidebars-none section#content > * { padding-left: 0.5em; paddin=
g-right: 0.5em; }
}

@media (min-width: 768px) {
  body.body-sidebars-none section#content { width: 100%; float: left; margi=
n-left: 0px; margin-right: 0px; }
  body.body-sidebars-none section#content > * { padding-left: 1em; padding-=
right: 1em; }
}

aside.sidebar { overflow: hidden; }

@media (max-width: 768px) {
  body.search #main .container { display: flex; flex-direction: column; }
  body.search #main .container #content { order: 2; }
  body.search #main .container .sidebar-last { order: 1; }
}

.views-view-grid.cols-3 .views-col { width: 100%; float: left; margin-left:=
 0px; margin-right: 0px; }

.views-view-grid.cols-3 .col-1 { width: 100%; float: left; margin-right: 1.=
69492%; }

.views-view-grid.cols-3 .col-3 { width: 100%; float: right; margin-right: 0=
px; }

@media (min-width: 768px) {
  .views-view-grid.cols-3 .views-col { width: 32.2034%; float: left; margin=
-right: 1.69492%; }
  .views-view-grid.cols-3 .col-1 { width: 32.2034%; float: left; margin-rig=
ht: 1.69492%; }
  .views-view-grid.cols-3 .col-3 { width: 32.2034%; float: right; margin-ri=
ght: 0px; }
}

.hidden, html.js .js-hidden, html.js .js-hide, html.js .element-hidden { di=
splay: none; }

.visually-hidden, .main-navigation .block-menu .block__title, .main-navigat=
ion .block-menu-block .block__title, .breadcrumb__title, .element-invisible=
, .visually-hidden--focusable, .element-focusable { height: 1px; width: 1px=
; overflow: hidden; clip: rect(1px, 1px, 1px, 1px); position: absolute !imp=
ortant; }

.visually-hidden--off, .visually-hidden--focusable:active, .visually-hidden=
--focusable:focus, .element-focusable:active, .element-focusable:focus { cl=
ip: auto; height: auto; width: auto; overflow: auto; position: static !impo=
rtant; }

.clearfix::before, #nir-header::before, div[class*=3D"view-widget-"]::befor=
e, .tabs::before, .tabs--secondary::before { content: ""; display: table; }

.clearfix::after, #nir-header::after, div[class*=3D"view-widget-"]::after, =
.tabs::after, .tabs--secondary::after { content: ""; display: table; clear:=
 both; }

.market-data-filter-form .form-item.form-item-period-compare-one::before, .=
field--name-field-nir-committee-link a::before, .view-search .inline-asset =
span.file--application-pdf::before, .block-search-form form::after, .view-s=
earch form::after, .nir-mean-value-rating .rating-arrow::after, .top-link::=
after, .faq-acc-dl dt.opened::before, .faq-acc-dl .acc-title.opened::before=
, .acc-wrap dt.opened::before, .acc-wrap .acc-title.opened::before, .faq-ac=
c-dl dt::before, .faq-acc-dl .acc-title::before, .acc-wrap dt::before, .acc=
-wrap .acc-title::before, a.show-all.hide-all::after, a.show-all::after, .n=
dqicon-check-circle::before, .thank-you-page h1::before, .up-arrow::before,=
 .right-arrow::before, .add-gcal a::before, .add-outlook a::before, .html-l=
ink a::before, .asset-link a::before, .ndqicon__calculator1::before, span.n=
dqicon__calculator_after::after, .ndqicon__calculator_after::after, .ndqico=
n__calculator::before, .ndqicon__independent_italic::before, .ndqicon__inde=
pendent::before, .ndqicon__download::before, .ndqicon__member a::before, sp=
an.ndqicon__member::before, .ndqicon__chair3::before, .ndqicon__chair2::bef=
ore, .ndqicon__chair1::before, .ndqicon__chair::before, span.ndqicon__leadd=
ir_after::after, .ndqicon__leaddir_after::after, .ndqicon__leaddir::before,=
 span.ndqicon__vicechair_after::after, .ndqicon__vicechair_after::after, .n=
dqicon__vicechair::before, span.ndqicon__cob_after::after, .ndqicon__cob a_=
after::after, .ndqicon__cob a::before, span.ndqicon__cob::before, span.ndqi=
con__chairperson_after::after, .ndqicon__chairperson a_after::after, .ndqic=
on__chairperson a::before, span.ndqicon__chairperson::before, .widget-file-=
-mime-application-zip::before, .file--mime-application-zip a::before, .widg=
et-file--mime-application-octet-stream::before, .file--mime-application-oct=
et-stream a::before, .widget-file--mime-application-xml::before, .file--mim=
e-application-xml a::before, .widget-file--mime-application-vnd-openxmlform=
ats-officedocument-spreadsheetml-sheet::before, .file--mime-application-vnd=
-openxmlformats-officedocument-spreadsheetml-sheet a::before, .widget-file-=
-mime-application-vnd-ms-excel-sheet-macroEnabled-12::before, .file--mime-a=
pplication-vnd-ms-excel-sheet-macroEnabled-12 a::before, .widget-file--xls:=
:before, .file--xls a::before, .widget-file--x-office-spreadsheet::before, =
.file--x-office-spreadsheet a::before, .market-data-file-download-xls::befo=
re, .widget-file--mime-video-x-ms-wmv::before, .file--mime-video-x-ms-wmv a=
::before, .widget-file--mime-audio-x-ms-wma::before, .file--mime-audio-x-ms=
-wma a::before, .widget-file--mime-audio-x-wav::before, .file--mime-audio-x=
-wav a::before, .widget-file--text::before, .file--text a::before, .widget-=
file--mime-image-tiff::before, .file--mime-image-tiff a::before, .widget-fi=
le--swf::before, .file--swf a::before, .widget-file--rtx::before, .file--rt=
x a::before, .widget-file--mime-application-rtf::before, .file--mime-applic=
ation-rtf a::before, .widget-file--mime-application-rar::before, .file--mim=
e-application-rar a::before, .widget-file--mime-application-vnd-ms-powerpoi=
nt-presentation-macroEnabled-12::before, .file--mime-application-vnd-ms-pow=
erpoint-presentation-macroEnabled-12 a::before, .widget-file--mime-applicat=
ion-vnd-openxmlformats-officedocument-presentationml-slideshow::before, .fi=
le--mime-application-vnd-openxmlformats-officedocument-presentationml-slide=
show a::before, .widget-file--mime-application-vnd-openxmlformats-officedoc=
ument-presentationml-presentation::before, .file--mime-application-vnd-open=
xmlformats-officedocument-presentationml-presentation a::before, .widget-fi=
le--mime-application-vnd-ms-powerpoint::before, .file--mime-application-vnd=
-ms-powerpoint a::before, .widget-file--mime-image-png::before, .file--mime=
-image-png a::before, .widget-file--application-pdf::before, .file--applica=
tion-pdf a::before, .widget-file--odt::before, .file--odt a::before, .widge=
t-file--mpg::before, .file--mpg a::before, .widget-file--mime-audio-mpeg::b=
efore, .file--mime-audio-mpeg a::before, .widget-file--mime-video-quicktime=
::before, .file--mime-video-quicktime a::before, .widget-file--mime-applica=
tion-x-mobipocket-ebook::before, .file--mime-application-x-mobipocket-ebook=
 a::before, .widget-file--mime-application-pgp-keys::before, .file--mime-ap=
plication-pgp-keys a::before, .widget-file--mime-image-jpeg::before, .widge=
t-file--mime-image-jpg::before, .file--mime-image-jpeg a::before, .file--mi=
me-image-jpg a::before, .widget-file--ics::before, .file--ics a::before, .w=
idget-file--mime-image-gif::before, .file--mime-image-gif a::before, .widge=
t-file--mime-video-x-flv::before, .file--mime-video-x-flv a::before, .widge=
t-file--fla::before, .file--fla a::before, .widget-file--mime-application-e=
pub::before, .file--mime-application-epub a::before, .widget-file--mime-app=
lication-postscript::before, .file--mime-application-postscript a::before, =
.widget-file--mime-application-vnd-openxmlformats-officedocument-wordproces=
singml-document::before, .file--mime-application-vnd-openxmlformats-officed=
ocument-wordprocessingml-document a::before, .widget-file--mime-application=
-msword::before, .file--mime-application-msword a::before, .widget-file--mi=
me-text-csv::before, .file--mime-text-csv a::before, .file--mime-text-csv.f=
ile--text a::before, .market-data-file-download-csv::before, .widget-file--=
mime-image-x-ms-bmp::before, .file--mime-image-x-ms-bmp a::before, .widget-=
file--mime-video-x-ms-asf::before, .file--mime-video-x-ms-asf a::before, .w=
idget-file--html::before, .field--name-field-nir-ext-document a::before, .f=
ield--name-field-nir-news-supp-ext-url a::before, .external-link::before, .=
webcast-link a::before, .normal-webcast-link a::before, a.nir-widget--news-=
-accordion-toggle.open:hover::before, a.nir-widget--news--accordion-toggle.=
open::before, a.nir-widget--news--accordion-toggle:hover::before, a.nir-wid=
get--news--accordion-toggle::before, a.nir-widget--person--accordion-toggle=
.open:hover::before, a.nir-widget--person--accordion-toggle.open::before, a=
.nir-widget--person--accordion-toggle:hover::before, a.nir-widget--person--=
accordion-toggle::before, a.summary-toggle.open:hover::before, a.summary-to=
ggle.open::before, a.summary-toggle:hover::before, a.summary-toggle::before=
, .ui-dialog-titlebar-close::before { font-family: ndqfonticons; font-size:=
 26px; vertical-align: middle; padding-right: 5px; font-weight: normal; tex=
t-decoration: none; }

.ui-dialog-titlebar-close::before { content: "=EE=80=93"; display: inline-b=
lock; text-decoration: none; color: rgb(0, 96, 126); }

.ui-dialog-titlebar-close::before { color: rgb(102, 102, 102); font-size: 2=
0px; }

a.summary-toggle { font-weight: normal; cursor: pointer; }

a.summary-toggle::before { content: "=EE=81=8D"; display: inline-block; tex=
t-decoration: none; color: rgb(0, 96, 126); }

a.summary-toggle:hover::before { content: "=EE=81=8F"; display: inline-bloc=
k; text-decoration: none; color: rgb(0, 96, 126); }

a.summary-toggle::before, a.summary-toggle:hover::before { font-size: 15px;=
 line-height: 0; }

a.summary-toggle span { height: 1px; width: 1px; overflow: hidden; clip: re=
ct(1px, 1px, 1px, 1px); position: absolute !important; }

a.summary-toggle.open::before { content: "=EE=81=90"; display: inline-block=
; text-decoration: none; color: rgb(0, 96, 126); }

a.summary-toggle.open:hover::before { content: "=EE=81=8E"; display: inline=
-block; text-decoration: none; color: rgb(0, 96, 126); }

a.summary-toggle.open::before, a.summary-toggle.open:hover::before { font-s=
ize: 15px; line-height: 0; }

a.nir-widget--person--accordion-toggle { font-weight: normal; cursor: point=
er; }

a.nir-widget--person--accordion-toggle::before { content: "=EE=81=8D"; disp=
lay: inline-block; text-decoration: none; color: rgb(0, 96, 126); }

a.nir-widget--person--accordion-toggle:hover::before { content: "=EE=81=8F"=
; display: inline-block; text-decoration: none; color: rgb(0, 96, 126); }

a.nir-widget--person--accordion-toggle::before, a.nir-widget--person--accor=
dion-toggle:hover::before { font-size: 15px; line-height: 0; }

a.nir-widget--person--accordion-toggle span { height: 1px; width: 1px; over=
flow: hidden; clip: rect(1px, 1px, 1px, 1px); position: absolute !important=
; }

a.nir-widget--person--accordion-toggle.open::before { content: "=EE=81=90";=
 display: inline-block; text-decoration: none; color: rgb(0, 96, 126); }

a.nir-widget--person--accordion-toggle.open:hover::before { content: "=EE=
=81=8E"; display: inline-block; text-decoration: none; color: rgb(0, 96, 12=
6); }

a.nir-widget--person--accordion-toggle.open::before, a.nir-widget--person--=
accordion-toggle.open:hover::before { font-size: 15px; line-height: 0; }

a.nir-widget--person--accordion-toggle + div { display: inline; }

a.nir-widget--news--accordion-toggle { font-weight: normal; cursor: pointer=
; }

a.nir-widget--news--accordion-toggle::before { content: "=EE=81=8D"; displa=
y: inline-block; text-decoration: none; color: rgb(0, 96, 126); }

a.nir-widget--news--accordion-toggle:hover::before { content: "=EE=81=8F"; =
display: inline-block; text-decoration: none; color: rgb(0, 96, 126); }

a.nir-widget--news--accordion-toggle::before, a.nir-widget--news--accordion=
-toggle:hover::before { font-size: 15px; line-height: 0; }

a.nir-widget--news--accordion-toggle span { height: 1px; width: 1px; overfl=
ow: hidden; clip: rect(1px, 1px, 1px, 1px); position: absolute !important; =
}

a.nir-widget--news--accordion-toggle.open::before { content: "=EE=81=90"; d=
isplay: inline-block; text-decoration: none; color: rgb(0, 96, 126); }

a.nir-widget--news--accordion-toggle.open:hover::before { content: "=EE=81=
=8E"; display: inline-block; text-decoration: none; color: rgb(0, 96, 126);=
 }

a.nir-widget--news--accordion-toggle.open::before, a.nir-widget--news--acco=
rdion-toggle.open:hover::before { font-size: 15px; line-height: 0; }

.ndqicon-disable-link { margin-left: 30px; }

.ndqicon-disable-link a::before { margin-left: -30px; cursor: default !impo=
rtant; pointer-events: none !important; }

.ndqicon-hide-icon a::before { display: none !important; }

.summary-hidden { display: none; }

.webcast-link a::before, .normal-webcast-link a::before { content: "=EE=80=
=9C"; display: inline-block; text-decoration: none; color: rgb(0, 96, 126);=
 }

.widget-file--html::before, .field--name-field-nir-ext-document a::before, =
.field--name-field-nir-news-supp-ext-url a::before, .external-link::before =
{ content: "=EE=81=B7"; display: inline-block; text-decoration: none; color=
: rgb(0, 96, 126); }

.widget-file--mime-video-x-ms-asf::before, .file--mime-video-x-ms-asf a::be=
fore { content: "=EE=84=83"; display: inline-block; text-decoration: none; =
color: rgb(0, 96, 126); }

.widget-file--mime-image-x-ms-bmp::before, .file--mime-image-x-ms-bmp a::be=
fore { content: "=EE=84=84"; display: inline-block; text-decoration: none; =
color: rgb(0, 96, 126); }

.widget-file--mime-text-csv::before, .file--mime-text-csv a::before, .file-=
-mime-text-csv.file--text a::before, .market-data-file-download-csv::before=
 { content: "=EE=81=B0"; display: inline-block; text-decoration: none; colo=
r: rgb(0, 96, 126); }

.widget-file--mime-application-msword::before, .file--mime-application-mswo=
rd a::before { content: "=EE=81=B2"; display: inline-block; text-decoration=
: none; color: rgb(0, 96, 126); }

.widget-file--mime-application-vnd-openxmlformats-officedocument-wordproces=
singml-document::before, .file--mime-application-vnd-openxmlformats-officed=
ocument-wordprocessingml-document a::before { content: "=EE=81=B3"; display=
: inline-block; text-decoration: none; color: rgb(0, 96, 126); }

.widget-file--mime-application-postscript::before, .file--mime-application-=
postscript a::before { content: "=EE=83=B5"; display: inline-block; text-de=
coration: none; color: rgb(0, 96, 126); }

.widget-file--mime-application-epub::before, .file--mime-application-epub a=
::before { content: "=EE=83=B6"; display: inline-block; text-decoration: no=
ne; color: rgb(0, 96, 126); }

.widget-file--fla::before, .file--fla a::before { content: "=EE=81=B4"; dis=
play: inline-block; text-decoration: none; color: rgb(204, 0, 0); }

.widget-file--mime-video-x-flv::before, .file--mime-video-x-flv a::before {=
 content: "=EE=81=B5"; display: inline-block; text-decoration: none; color:=
 rgb(204, 0, 0); }

.widget-file--mime-image-gif::before, .file--mime-image-gif a::before { con=
tent: "=EE=82=80"; display: inline-block; text-decoration: none; color: rgb=
(0, 96, 126); }

.widget-file--ics::before, .file--ics a::before { content: "=EE=83=BE"; dis=
play: inline-block; text-decoration: none; color: rgb(0, 96, 126); }

.widget-file--mime-image-jpeg::before, .widget-file--mime-image-jpg::before=
, .file--mime-image-jpeg a::before, .file--mime-image-jpg a::before { conte=
nt: "=EE=81=BF"; display: inline-block; text-decoration: none; color: rgb(0=
, 96, 126); }

.widget-file--mime-application-pgp-keys::before, .file--mime-application-pg=
p-keys a::before { content: "=EE=83=BF"; display: inline-block; text-decora=
tion: none; color: rgb(0, 96, 126); }

.widget-file--mime-application-x-mobipocket-ebook::before, .file--mime-appl=
ication-x-mobipocket-ebook a::before { content: "=EE=83=B7"; display: inlin=
e-block; text-decoration: none; color: rgb(0, 96, 126); }

.widget-file--mime-video-quicktime::before, .file--mime-video-quicktime a::=
before { content: "=EE=83=B8"; display: inline-block; text-decoration: none=
; color: rgb(0, 96, 126); }

.widget-file--mime-audio-mpeg::before, .file--mime-audio-mpeg a::before { c=
ontent: "=EE=82=85"; display: inline-block; text-decoration: none; color: r=
gb(0, 96, 126); }

.widget-file--mpg::before, .file--mpg a::before { content: "=EE=83=B9"; dis=
play: inline-block; text-decoration: none; color: rgb(0, 96, 126); }

.widget-file--odt::before, .file--odt a::before { content: "=EE=83=BB"; dis=
play: inline-block; text-decoration: none; color: rgb(0, 96, 126); }

.widget-file--application-pdf::before, .file--application-pdf a::before { c=
ontent: "=EE=82=88"; display: inline-block; text-decoration: none; color: r=
gb(204, 0, 0); }

.widget-file--mime-image-png::before, .file--mime-image-png a::before { con=
tent: "=EE=82=82"; display: inline-block; text-decoration: none; color: rgb=
(0, 96, 126); }

.widget-file--mime-application-vnd-ms-powerpoint::before, .file--mime-appli=
cation-vnd-ms-powerpoint a::before { content: "=EE=82=89"; display: inline-=
block; text-decoration: none; color: rgb(0, 96, 126); }

.widget-file--mime-application-vnd-openxmlformats-officedocument-presentati=
onml-presentation::before, .file--mime-application-vnd-openxmlformats-offic=
edocument-presentationml-presentation a::before { content: "=EE=82=8B"; dis=
play: inline-block; text-decoration: none; color: rgb(0, 96, 126); }

.widget-file--mime-application-vnd-openxmlformats-officedocument-presentati=
onml-slideshow::before, .file--mime-application-vnd-openxmlformats-officedo=
cument-presentationml-slideshow a::before { content: "=EE=83=BC"; display: =
inline-block; text-decoration: none; color: rgb(0, 96, 126); }

.widget-file--mime-application-vnd-ms-powerpoint::before, .file--mime-appli=
cation-vnd-ms-powerpoint a::before { content: "=EE=82=8A"; display: inline-=
block; text-decoration: none; color: rgb(0, 96, 126); }

.widget-file--mime-application-vnd-ms-powerpoint-presentation-macroEnabled-=
12::before, .file--mime-application-vnd-ms-powerpoint-presentation-macroEna=
bled-12 a::before { content: "=EE=83=BD"; display: inline-block; text-decor=
ation: none; color: rgb(0, 96, 126); }

.widget-file--mime-application-rar::before, .file--mime-application-rar a::=
before { content: "=EE=84=82"; display: inline-block; text-decoration: none=
; color: rgb(0, 96, 126); }

.widget-file--mime-application-rtf::before, .file--mime-application-rtf a::=
before { content: "=EE=84=80"; display: inline-block; text-decoration: none=
; color: rgb(0, 96, 126); }

.widget-file--rtx::before, .file--rtx a::before { content: "=EE=84=81"; dis=
play: inline-block; text-decoration: none; color: rgb(0, 96, 126); }

.widget-file--swf::before, .file--swf a::before { content: "=EE=81=B6"; dis=
play: inline-block; text-decoration: none; color: rgb(204, 0, 0); }

.widget-file--mime-image-tiff::before, .file--mime-image-tiff a::before { c=
ontent: "=EE=82=81"; display: inline-block; text-decoration: none; color: r=
gb(0, 96, 126); }

.widget-file--text::before, .file--text a::before { content: "=EE=82=8C"; d=
isplay: inline-block; text-decoration: none; color: rgb(0, 96, 126); }

.widget-file--mime-audio-x-wav::before, .file--mime-audio-x-wav a::before {=
 content: "=EE=84=88"; display: inline-block; text-decoration: none; color:=
 rgb(0, 96, 126); }

.widget-file--mime-audio-x-ms-wma::before, .file--mime-audio-x-ms-wma a::be=
fore { content: "=EE=84=85"; display: inline-block; text-decoration: none; =
color: rgb(0, 96, 126); }

.widget-file--mime-video-x-ms-wmv::before, .file--mime-video-x-ms-wmv a::be=
fore { content: "=EE=84=86"; display: inline-block; text-decoration: none; =
color: rgb(0, 96, 126); }

.widget-file--xls::before, .file--xls a::before, .widget-file--x-office-spr=
eadsheet::before, .file--x-office-spreadsheet a::before, .market-data-file-=
download-xls::before { content: "=EE=81=B9"; display: inline-block; text-de=
coration: none; color: rgb(112, 168, 31); }

.widget-file--mime-application-vnd-ms-excel-sheet-macroEnabled-12::before, =
.file--mime-application-vnd-ms-excel-sheet-macroEnabled-12 a::before { cont=
ent: "=EE=80=9F"; display: inline-block; text-decoration: none; color: rgb(=
112, 168, 31); }

.widget-file--mime-application-vnd-openxmlformats-officedocument-spreadshee=
tml-sheet::before, .file--mime-application-vnd-openxmlformats-officedocumen=
t-spreadsheetml-sheet a::before { content: "=EE=81=BB"; display: inline-blo=
ck; text-decoration: none; color: rgb(112, 168, 31); }

.widget-file--mime-application-xml::before, .file--mime-application-xml a::=
before { content: "=EE=81=BE"; display: inline-block; text-decoration: none=
; color: rgb(0, 96, 126); }

.node--type-nir-sec-filing .file--mime-application-xsd a::before, .node--ty=
pe-nir-sec-filing .file--mime-application-xml a::before { content: "=EE=81=
=BD"; color: rgb(123, 65, 189); }

.widget-file--mime-application-octet-stream::before, .file--mime-applicatio=
n-octet-stream a::before { content: "=EE=84=87"; display: inline-block; tex=
t-decoration: none; color: rgb(0, 96, 126); }

.widget-file--mime-application-zip::before, .file--mime-application-zip a::=
before { content: "=EE=82=8D"; display: inline-block; text-decoration: none=
; color: rgb(0, 96, 126); }

[class^=3D"ndqicon__"] a::before { font-size: 20px; }

.ndqicon__chairperson a::before, span.ndqicon__chairperson::before { conten=
t: "=EE=80=8B"; display: inline-block; text-decoration: none; color: rgb(0,=
 96, 126); }

.ndqicon__chairperson a_after::after { content: "=EE=80=8B"; display: inlin=
e-block; text-decoration: none; color: rgb(0, 96, 126); }

span.ndqicon__chairperson_after::after { content: "=EE=80=8B"; display: inl=
ine-block; text-decoration: none; color: rgb(0, 96, 126); }

.ndqicon__cob a::before, span.ndqicon__cob::before { content: "=EE=80=A8"; =
display: inline-block; text-decoration: none; color: rgb(0, 96, 126); }

.ndqicon__cob a_after::after { content: "=EE=80=A8"; display: inline-block;=
 text-decoration: none; color: rgb(0, 96, 126); }

span.ndqicon__cob_after::after { content: "=EE=80=A8"; display: inline-bloc=
k; text-decoration: none; color: rgb(0, 96, 126); }

.ndqicon__vicechair::before { content: "=EE=80=A7"; display: inline-block; =
text-decoration: none; color: rgb(0, 96, 126); }

.ndqicon__vicechair_after::after { content: "=EE=80=A7"; display: inline-bl=
ock; text-decoration: none; color: rgb(0, 96, 126); }

span.ndqicon__vicechair_after::after { content: "=EE=80=A7"; display: inlin=
e-block; text-decoration: none; color: rgb(0, 96, 126); }

.ndqicon__leaddir::before { content: "=EE=81=AA"; display: inline-block; te=
xt-decoration: none; color: rgb(0, 96, 126); }

.ndqicon__leaddir_after::after { content: "=EE=81=AA"; display: inline-bloc=
k; text-decoration: none; color: rgb(0, 96, 126); }

span.ndqicon__leaddir_after::after { content: "=EE=81=AA"; display: inline-=
block; text-decoration: none; color: rgb(0, 96, 126); }

.ndqicon__chair::before { content: "=EE=80=A8"; display: inline-block; text=
-decoration: none; color: rgb(0, 96, 126); }

.ndqicon__chair1::before { content: "=EE=81=AA"; display: inline-block; tex=
t-decoration: none; color: rgb(0, 96, 126); }

.ndqicon__chair2::before { content: "=EE=81=AB"; display: inline-block; tex=
t-decoration: none; color: rgb(0, 96, 126); }

.ndqicon__chair3::before { content: "=EE=81=AC"; display: inline-block; tex=
t-decoration: none; color: rgb(0, 96, 126); }

.ndqicon__member a::before, span.ndqicon__member::before { content: "=EE=80=
=8A"; display: inline-block; text-decoration: none; color: rgb(0, 96, 126);=
 }

.ndqicon__download::before { content: "=EE=81=93"; display: inline-block; t=
ext-decoration: none; color: rgb(0, 96, 126); }

.ndqicon__independent::before { content: "=EE=80=8D"; display: inline-block=
; text-decoration: none; color: rgb(0, 96, 126); }

.ndqicon__independent_italic::before { content: "=EE=80=8E"; display: inlin=
e-block; text-decoration: none; color: rgb(0, 96, 126); }

.ndqicon__calculator::before { content: "=EE=80=B2"; display: inline-block;=
 text-decoration: none; color: rgb(0, 96, 126); }

.ndqicon__calculator_after::after { content: "=EE=80=B2"; display: inline-b=
lock; text-decoration: none; color: rgb(0, 96, 126); }

span.ndqicon__calculator_after::after { content: "=EE=80=B2"; display: inli=
ne-block; text-decoration: none; color: rgb(0, 96, 126); }

.ndqicon__calculator1::before { content: "=EE=80=AF"; display: inline-block=
; text-decoration: none; color: rgb(0, 96, 126); }

.icon-key { float: left; margin-top: 0px; }

.key-item { margin: 1em 0px; }

.key-item span::before { font-size: 20px; }

.html-link a::before, .asset-link a::before { content: "=EE=81=B7"; display=
: inline-block; text-decoration: none; color: rgb(4, 114, 189); }

.add-outlook a { font-size: 0px; }

.add-outlook a::before { content: "=EE=80=BF"; display: inline-block; text-=
decoration: none; color: rgb(0, 96, 126); }

.add-outlook a::before { background: rgb(255, 188, 0); color: rgb(255, 255,=
 255); font-size: 20px; width: 21px; height: 21px; text-align: center; padd=
ing-top: 5px; margin-right: 5px; padding-left: 5px; }

.add-gcal a { font-size: 0px; }

.add-gcal a::before { content: "=EE=80=9E"; display: inline-block; text-dec=
oration: none; color: rgb(0, 96, 126); }

.add-gcal a::before { background: rgb(221, 75, 57); color: rgb(255, 255, 25=
5); font-size: 20px; width: 21px; height: 21px; text-align: center; padding=
-top: 5px; margin-right: 5px; padding-left: 5px; }

.right-arrow::before { content: "=EE=84=8C"; display: inline-block; text-de=
coration: none; color: rgb(102, 102, 102); }

.right-arrow::before { font-size: 14px; }

.up-arrow::before { content: "=EE=81=92"; display: inline-block; text-decor=
ation: none; color: rgb(0, 96, 126); }

.up-arrow::before { font-size: 14px; }

.ndqicon-check-circle::before, .thank-you-page h1::before { content: "=EE=
=84=96"; display: inline-block; text-decoration: none; color: rgb(0, 96, 12=
6); }

.ndqicon-check-circle::before, .thank-you-page h1::before { font-size: 22px=
; }

a.show-all::after { content: "=EE=80=92"; display: inline-block; text-decor=
ation: none; color: rgb(0, 96, 126); }

a.show-all::after { font-size: 14px; }

a.show-all.hide-all::after { content: "=EE=80=91"; display: inline-block; t=
ext-decoration: none; color: rgb(0, 96, 126); }

a.show-all.hide-all::after { font-size: 14px; }

.faq-acc-dl dt::before, .faq-acc-dl .acc-title::before, .acc-wrap dt::befor=
e, .acc-wrap .acc-title::before { content: "=EE=81=8D"; display: inline-blo=
ck; text-decoration: none; color: rgb(0, 96, 126); }

.faq-acc-dl dt::before, .faq-acc-dl .acc-title::before, .acc-wrap dt::befor=
e, .acc-wrap .acc-title::before { color: rgb(255, 255, 255); font-size: 14p=
x; }

.faq-acc-dl dt.opened::before, .faq-acc-dl .acc-title.opened::before, .acc-=
wrap dt.opened::before, .acc-wrap .acc-title.opened::before { content: "=EE=
=81=90"; display: inline-block; text-decoration: none; color: rgb(0, 96, 12=
6); }

.faq-acc-dl dt.opened::before, .faq-acc-dl .acc-title.opened::before, .acc-=
wrap dt.opened::before, .acc-wrap .acc-title.opened::before { color: rgb(25=
5, 255, 255); font-size: 14px; }

.top-link::after { content: "=EE=81=92"; display: inline-block; text-decora=
tion: none; color: rgb(0, 96, 126); }

.top-link::after { font-size: 14px; margin-top: -4px; }

.file--mime-application-pdf a, .webcast-link a, .file--mime-application-rtf=
 a, .file--mime-application-vnd-ms-excel a, .html-link a::before, .file--mi=
me-application-xml a, .field--name-field-nir-ext-document a, .file--mime-te=
xt-csv a { text-decoration: none !important; }

.file--mime-application-pdf a:hover, .webcast-link a:hover, .file--mime-app=
lication-rtf a:hover, .file--mime-application-vnd-ms-excel a:hover, .html-l=
ink a:hover, .file--mime-application-xml a:hover, .field--name-field-nir-ex=
t-document a:hover, .file--mime-text-csv a:hover { text-decoration: none !i=
mportant; }

.file--mime-application-pdf a span, .webcast-link a span, .file--mime-appli=
cation-rtf a span, .file--mime-application-vnd-ms-excel a span, .html-link =
a span, .file--mime-application-xml a span, .field--name-field-nir-ext-docu=
ment a span, .file--mime-text-csv a span, .file--mime-application-pdf a:hov=
er span, .webcast-link a:hover span, .file--mime-application-rtf a:hover sp=
an, .file--mime-application-vnd-ms-excel a:hover span, .html-link a:hover s=
pan, .file--mime-application-xml a:hover span, .field--name-field-nir-ext-d=
ocument a:hover span, .file--mime-text-csv a:hover span { text-decoration: =
none; }

.autocomplete, html.js input.form-autocomplete { background-image: url("/pr=
ofiles/nasdaqir/themes/custom/nir_base/dist/img/throbber.gif"); background-=
position: 100% 2px; background-repeat: no-repeat; }

[dir=3D"rtl"] .autocomplete, [dir=3D"rtl"] html.js input.form-autocomplete,=
 html.js [dir=3D"rtl"] input.form-autocomplete { background-position: 0% 2p=
x; }

.autocomplete.is-throbbing, .autocomplete--is-throbbing, html.js input.is-t=
hrobbing.form-autocomplete, html.js input.throbbing { background-position: =
100% -18px; }

[dir=3D"rtl"] .autocomplete.is-throbbing, [dir=3D"rtl"] .autocomplete--is-t=
hrobbing, [dir=3D"rtl"] html.js input.is-throbbing.form-autocomplete, html.=
js [dir=3D"rtl"] input.is-throbbing.form-autocomplete, [dir=3D"rtl"] html.j=
s input.throbbing, html.js [dir=3D"rtl"] input.throbbing { background-posit=
ion: 0% -18px; }

.autocomplete__list-wrapper, #autocomplete { border: 1px solid; overflow: h=
idden; position: absolute; z-index: 100; }

.autocomplete__list, #autocomplete ul { list-style: none none; margin: 0px;=
 padding: 0px; }

.autocomplete__list-item, #autocomplete li { background: rgb(255, 255, 255)=
; color: rgb(0, 0, 0); cursor: default; white-space: pre; zoom: 1; }

.autocomplete__list-item--is-selected, #autocomplete .selected { background=
: rgb(0, 96, 126); color: rgb(255, 255, 255); }

.box, .box__right { border: 1px solid rgb(204, 204, 204); padding: 1em; }

.box__title { margin: 0px; }

.box--highlight { border-color: rgb(3, 124, 165); }

.box__right { margin-bottom: 1em; width: 100%; float: left; margin-right: 0=
px; margin-left: 1.5em !important; }

@media (min-width: 1024px) {
  .box__right { width: 30.3797%; margin-right: 0px; float: right; }
}

@media print {
  .breadcrumb { display: none; }
}

.breadcrumb__list { margin: 0px; padding: 0px; }

.breadcrumb__item { display: inline; list-style-type: none; margin: 0px; pa=
dding: 0px; }

.nir-chart { margin: 15px; }

.collapsible-fieldset, .collapsible { position: relative; }

.collapsible-fieldset.is-collapsed, .collapsible-fieldset--is-collapsed, .i=
s-collapsed.collapsible, .collapsible.collapsed { border-bottom-width: 0px;=
 border-left-width: 0px; border-right-width: 0px; height: 1em; }

.is-collapsed .collapsible-fieldset__wrapper, .collapsible-fieldset--is-col=
lapsed__wrapper, .collapsible.collapsed .fieldset-wrapper { display: none; =
}

.collapsible-fieldset__legend, .collapsible .fieldset-legend { display: blo=
ck; padding-left: 15px; background-image: url("/profiles/nasdaqir/themes/cu=
stom/nir_base/dist/img/expanded.png"); background-position: 5px 65%; backgr=
ound-repeat: no-repeat; }

[dir=3D"rtl"] .collapsible-fieldset__legend, [dir=3D"rtl"] .collapsible .fi=
eldset-legend, .collapsible [dir=3D"rtl"] .fieldset-legend { padding-left: =
0px; padding-right: 15px; background-position: 98% 75%; }

.is-collapsed .collapsible-fieldset__legend, .collapsible-fieldset--is-coll=
apsed__legend, .is-collapsed .collapsible .fieldset-legend, .collapsible .i=
s-collapsed .fieldset-legend, .collapsible.collapsed .fieldset-legend { bac=
kground-image: url("/profiles/nasdaqir/themes/custom/nir_base/dist/img/coll=
apsed.png"); background-position: 5px 50%; }

[dir=3D"rtl"] .is-collapsed .collapsible-fieldset__legend, [dir=3D"rtl"] .c=
ollapsible-fieldset--is-collapsed__legend, [dir=3D"rtl"] .is-collapsed .col=
lapsible .fieldset-legend, .collapsible [dir=3D"rtl"] .is-collapsed .fields=
et-legend, [dir=3D"rtl"] .collapsible.collapsed .fieldset-legend, .collapsi=
ble.collapsed [dir=3D"rtl"] .fieldset-legend { background-image: url("/prof=
iles/nasdaqir/themes/custom/nir_base/dist/img/collapsed-rtl.png"); backgrou=
nd-position: 98% 50%; }

.collapsible-fieldset__summary, .collapsible .fieldset-legend .summary { co=
lor: rgb(153, 153, 153); font-size: 0.9em; margin-left: 0.5em; }

.comment__section, .comments { margin: 1.42857em 0px; }

.comment__title { margin: 0px; }

.comment__permalink { text-transform: uppercase; font-size: 75%; }

.comment--preview, .comment-preview { background-color: rgb(255, 250, 219);=
 }

.comment--nested, .indented { margin-left: 28px; }

[dir=3D"rtl"] .comment--nested, [dir=3D"rtl"] .indented { margin-left: 0px;=
 margin-right: 28px; }

table.dataTable { table-layout: auto; }

table.dataTable thead th, table.dataTable tfoot th { font-weight: bold; }

table.dataTable thead th:active, table.dataTable thead td:active { outline:=
 none; }

table.dataTable thead .sorting, table.dataTable thead .sorting_asc, table.d=
ataTable thead .sorting_desc { cursor: pointer; }

table.dataTable thead .sorting, table.dataTable thead .sorting_asc, table.d=
ataTable thead .sorting_desc, table.dataTable thead .sorting_asc_disabled, =
table.dataTable thead .sorting_desc_disabled { background-repeat: no-repeat=
; background-position: right center; }

table.dataTable thead .sorting { background-image: url("/profiles/nasdaqir/=
themes/custom/nir_base/dist/img/sort_both.png"); }

table.dataTable thead .sorting_asc { background-image: url("/profiles/nasda=
qir/themes/custom/nir_base/dist/img/sort_asc.png"); }

table.dataTable thead .sorting_desc { background-image: url("/profiles/nasd=
aqir/themes/custom/nir_base/dist/img/sort_desc.png"); }

table.dataTable thead .sorting_asc_disabled { background-image: url("/profi=
les/nasdaqir/themes/custom/nir_base/dist/img/sort_asc_disabled.png"); }

table.dataTable thead .sorting_desc_disabled { background-image: url("/prof=
iles/nasdaqir/themes/custom/nir_base/dist/img/sort_desc_disabled.png"); }

table.dataTable tbody tr.selected { background-color: rgb(176, 190, 217); }

table.dataTable.stripe tbody tr.odd, table.dataTable.display tbody tr.odd {=
 background-color: rgb(249, 249, 249); }

table.dataTable.stripe tbody tr.odd.selected, table.dataTable.display tbody=
 tr.odd.selected { background-color: rgb(172, 186, 212); }

table.dataTable.hover tbody tr:hover, table.dataTable.display tbody tr:hove=
r { background-color: rgb(246, 246, 246); }

table.dataTable.hover tbody tr:hover.selected, table.dataTable.display tbod=
y tr:hover.selected { background-color: rgb(170, 183, 209); }

table.dataTable.order-column tbody tr > .sorting_1, table.dataTable.order-c=
olumn tbody tr > .sorting_2, table.dataTable.order-column tbody tr > .sorti=
ng_3, table.dataTable.display tbody tr > .sorting_1, table.dataTable.displa=
y tbody tr > .sorting_2, table.dataTable.display tbody tr > .sorting_3 { ba=
ckground-color: rgb(250, 250, 250); }

table.dataTable.order-column tbody tr.selected > .sorting_1, table.dataTabl=
e.order-column tbody tr.selected > .sorting_2, table.dataTable.order-column=
 tbody tr.selected > .sorting_3, table.dataTable.display tbody tr.selected =
> .sorting_1, table.dataTable.display tbody tr.selected > .sorting_2, table=
.dataTable.display tbody tr.selected > .sorting_3 { background-color: rgb(1=
72, 186, 213); }

table.dataTable.display tbody tr.odd > .sorting_1, table.dataTable.order-co=
lumn.stripe tbody tr.odd > .sorting_1 { background-color: rgb(241, 241, 241=
); }

table.dataTable.display tbody tr.odd > .sorting_2, table.dataTable.order-co=
lumn.stripe tbody tr.odd > .sorting_2 { background-color: rgb(243, 243, 243=
); }

table.dataTable.display tbody tr.odd > .sorting_3, table.dataTable.order-co=
lumn.stripe tbody tr.odd > .sorting_3 { background-color: rgb(245, 245, 245=
); }

table.dataTable.display tbody tr.odd.selected > .sorting_1, table.dataTable=
.order-column.stripe tbody tr.odd.selected > .sorting_1 { background-color:=
 rgb(166, 180, 205); }

table.dataTable.display tbody tr.odd.selected > .sorting_2, table.dataTable=
.order-column.stripe tbody tr.odd.selected > .sorting_2 { background-color:=
 rgb(168, 181, 207); }

table.dataTable.display tbody tr.odd.selected > .sorting_3, table.dataTable=
.order-column.stripe tbody tr.odd.selected > .sorting_3 { background-color:=
 rgb(169, 183, 209); }

table.dataTable.display tbody tr.even > .sorting_1, table.dataTable.order-c=
olumn.stripe tbody tr.even > .sorting_1 { background-color: rgb(250, 250, 2=
50); }

table.dataTable.display tbody tr.even > .sorting_2, table.dataTable.order-c=
olumn.stripe tbody tr.even > .sorting_2 { background-color: rgb(252, 252, 2=
52); }

table.dataTable.display tbody tr.even > .sorting_3, table.dataTable.order-c=
olumn.stripe tbody tr.even > .sorting_3 { background-color: rgb(254, 254, 2=
54); }

table.dataTable.display tbody tr.even.selected > .sorting_1, table.dataTabl=
e.order-column.stripe tbody tr.even.selected > .sorting_1 { background-colo=
r: rgb(172, 186, 213); }

table.dataTable.display tbody tr.even.selected > .sorting_2, table.dataTabl=
e.order-column.stripe tbody tr.even.selected > .sorting_2 { background-colo=
r: rgb(174, 188, 214); }

table.dataTable.display tbody tr.even.selected > .sorting_3, table.dataTabl=
e.order-column.stripe tbody tr.even.selected > .sorting_3 { background-colo=
r: rgb(175, 189, 216); }

table.dataTable.display tbody tr:hover > .sorting_1, table.dataTable.order-=
column.hover tbody tr:hover > .sorting_1 { background-color: rgb(234, 234, =
234); }

table.dataTable.display tbody tr:hover > .sorting_2, table.dataTable.order-=
column.hover tbody tr:hover > .sorting_2 { background-color: rgb(236, 236, =
236); }

table.dataTable.display tbody tr:hover > .sorting_3, table.dataTable.order-=
column.hover tbody tr:hover > .sorting_3 { background-color: rgb(239, 239, =
239); }

table.dataTable.display tbody tr:hover.selected > .sorting_1, table.dataTab=
le.order-column.hover tbody tr:hover.selected > .sorting_1 { background-col=
or: rgb(162, 174, 199); }

table.dataTable.display tbody tr:hover.selected > .sorting_2, table.dataTab=
le.order-column.hover tbody tr:hover.selected > .sorting_2 { background-col=
or: rgb(163, 176, 201); }

table.dataTable.display tbody tr:hover.selected > .sorting_3, table.dataTab=
le.order-column.hover tbody tr:hover.selected > .sorting_3 { background-col=
or: rgb(165, 178, 203); }

table.dataTable.nowrap th, table.dataTable.nowrap td { white-space: nowrap;=
 }

table.dataTable.compact thead th, table.dataTable.compact thead td { paddin=
g: 4px 17px 4px 4px; }

table.dataTable.compact tfoot th, table.dataTable.compact tfoot td { paddin=
g: 4px; }

table.dataTable.compact tbody th, table.dataTable.compact tbody td { paddin=
g: 4px; }

table.dataTable th.dt-left, table.dataTable td.dt-left { text-align: left; =
}

table.dataTable th.dt-center, table.dataTable td.dt-center, table.dataTable=
 td.dataTables_empty { text-align: center; }

table.dataTable th.dt-right, table.dataTable td.dt-right { text-align: righ=
t; }

table.dataTable th.dt-justify, table.dataTable td.dt-justify { text-align: =
justify; }

table.dataTable th.dt-nowrap, table.dataTable td.dt-nowrap { white-space: n=
owrap; }

table.dataTable thead th.dt-head-left, table.dataTable thead td.dt-head-lef=
t, table.dataTable tfoot th.dt-head-left, table.dataTable tfoot td.dt-head-=
left { text-align: left; }

table.dataTable thead th.dt-head-center, table.dataTable thead td.dt-head-c=
enter, table.dataTable tfoot th.dt-head-center, table.dataTable tfoot td.dt=
-head-center { text-align: center; }

table.dataTable thead th.dt-head-right, table.dataTable thead td.dt-head-ri=
ght, table.dataTable tfoot th.dt-head-right, table.dataTable tfoot td.dt-he=
ad-right { text-align: right; }

table.dataTable thead th.dt-head-justify, table.dataTable thead td.dt-head-=
justify, table.dataTable tfoot th.dt-head-justify, table.dataTable tfoot td=
.dt-head-justify { text-align: justify; }

table.dataTable thead th.dt-head-nowrap, table.dataTable thead td.dt-head-n=
owrap, table.dataTable tfoot th.dt-head-nowrap, table.dataTable tfoot td.dt=
-head-nowrap { white-space: nowrap; }

table.dataTable tbody th.dt-body-left, table.dataTable tbody td.dt-body-lef=
t { text-align: left; }

table.dataTable tbody th.dt-body-center, table.dataTable tbody td.dt-body-c=
enter { text-align: center; }

table.dataTable tbody th.dt-body-right, table.dataTable tbody td.dt-body-ri=
ght { text-align: right; }

table.dataTable tbody th.dt-body-justify, table.dataTable tbody td.dt-body-=
justify { text-align: justify; }

table.dataTable tbody th.dt-body-nowrap, table.dataTable tbody td.dt-body-n=
owrap { white-space: nowrap; }

table.dataTable, table.dataTable th, table.dataTable td { box-sizing: conte=
nt-box; }

.dataTables_wrapper { position: relative; clear: both; zoom: 1; }

.dataTables_wrapper .dataTables_length { float: left; }

.dataTables_wrapper .dataTables_filter { float: right; text-align: left; }

.dataTables_wrapper .dataTables_filter input { margin-bottom: 0.5em; }

.dataTables_wrapper .dataTables_info { clear: both; float: left; padding-to=
p: 0.755em; }

.dataTables_wrapper .dataTables_paginate { float: right; text-align: right;=
 padding-top: 0.25em; }

.dataTables_wrapper .dataTables_paginate .paginate_button { box-sizing: bor=
der-box; display: inline-block; min-width: 1.5em; padding: 10px 15px; margi=
n-left: 2px; text-align: center; cursor: pointer; color: rgb(51, 51, 51); b=
order: 1px solid rgba(0, 0, 0, 0); border-radius: 2px; text-decoration: non=
e !important; }

.dataTables_wrapper .dataTables_paginate .paginate_button.current, .dataTab=
les_wrapper .dataTables_paginate .paginate_button.current:hover { backgroun=
d-color: rgb(4, 128, 169); border-radius: 4px; padding: 10px 15px; color: r=
gb(255, 255, 255); }

.dataTables_wrapper .dataTables_paginate .paginate_button.disabled, .dataTa=
bles_wrapper .dataTables_paginate .paginate_button.disabled:hover, .dataTab=
les_wrapper .dataTables_paginate .paginate_button.disabled:active { cursor:=
 default; border: 1px solid rgba(0, 0, 0, 0); background: rgba(0, 0, 0, 0);=
 box-shadow: none; color: rgb(102, 102, 102) !important; }

.dataTables_wrapper .dataTables_paginate .paginate_button:hover { backgroun=
d-color: rgb(1, 49, 65); border-radius: 4px; padding: 10px 15px; color: rgb=
(255, 255, 255); }

.dataTables_wrapper .dataTables_paginate .paginate_button:active { outline:=
 none; background: linear-gradient(rgb(43, 43, 43) 0%, rgb(12, 12, 12) 100%=
); box-shadow: rgb(17, 17, 17) 0px 0px 3px inset; }

.dataTables_wrapper .dataTables_paginate .ellipsis { padding: 0px 1em; }

.dataTables_wrapper .dataTables_processing { position: absolute; top: 50%; =
left: 50%; width: 100%; height: 40px; margin-left: -50%; margin-top: -25px;=
 padding-top: 20px; text-align: center; font-size: 1.2em; background: linea=
r-gradient(to right, rgba(255, 255, 255, 0) 0%, rgba(255, 255, 255, 0.9) 25=
%, rgba(255, 255, 255, 0.9) 75%, rgba(255, 255, 255, 0) 100%); }

.dataTables_wrapper .dataTables_length, .dataTables_wrapper .dataTables_fil=
ter, .dataTables_wrapper .dataTables_info, .dataTables_wrapper .dataTables_=
processing, .dataTables_wrapper .dataTables_paginate { color: rgb(51, 51, 5=
1); }

.dataTables_wrapper .dataTables_scroll { clear: both; }

.dataTables_wrapper .dataTables_scroll div.dataTables_scrollBody { }

.dataTables_wrapper .dataTables_scroll div.dataTables_scrollBody th > div.d=
ataTables_sizing, .dataTables_wrapper .dataTables_scroll div.dataTables_scr=
ollBody td > div.dataTables_sizing { height: 0px; overflow: hidden; margin:=
 0px !important; padding: 0px !important; }

.dataTables_wrapper::after { visibility: hidden; display: block; content: "=
"; clear: both; height: 0px; }

@media screen and (max-width: 767px) {
  .nir-datatables thead td { display: none; }
  .dataTables_wrapper .dataTables_info, .dataTables_wrapper .dataTables_pag=
inate { float: none; text-align: center; }
  .dataTables_wrapper .dataTables_paginate { margin-top: 0.5em; }
}

@media screen and (max-width: 640px) {
  .dataTables_wrapper .dataTables_filter { margin-top: 0.5em; }
}

.dataTables_length select { display: inline; margin-bottom: 5px; }

.block-nir-attribution-block { float: left; padding: 0px 1em; }

.block-nir-attribution-block > p { margin-top: 20px; }

hr, .divider { margin: 1.42857em 0px; border-width: 0px 0px 3px; border-top=
-style: initial; border-right-style: initial; border-left-style: initial; b=
order-top-color: initial; border-right-color: initial; border-left-color: i=
nitial; border-image: initial; border-bottom-style: solid; border-bottom-co=
lor: rgb(0, 96, 126); }

hr > :first-child, .divider > :first-child { margin-top: 1.42857em; }

form.views-exposed-form .form-item { margin-bottom: 1em; float: left; margi=
n-right: 12px; }

form.views-exposed-form .form-actions { float: left; margin: 25px 0px 0px; =
}

@media (max-width: 481px) {
  form.views-exposed-form .form-actions { clear: both; }
}

form.views-exposed-form .form-item-items-per-page label::after { content: "=
:"; }

.region .block.block-facets { padding: 0px; margin: 0px; }

.region .block.block-facets h2 { display: inline-block; font-size: 14px; li=
ne-height: 1.42857; margin: 0px; border-bottom: 0px; }

.region .block.block-facets ul { padding: 0px; margin: 0px; }

.region .block.block-facets ul li { margin: 0.4em 0px 0.4em 2em; }

.field--label-inline { display: block; }

.field--label-inline * { display: inline; }

.field--label-inline .field__label::after { content: ":"; }

.full-name { font-weight: bold; }

.field__centered { width: 100%; text-align: center; }

.field__light-italic { font-style: italic; color: rgb(132, 114, 113); }

.small-inline-label { font-size: 11px; float: left; margin-right: 0.5em; }

.form-item { margin: 1.42857em 0px; }

.form-item__required::after, .form-required::after { content: "*"; color: r=
gb(204, 0, 0); display: inline; margin: 0px 0px 0px 5px; }

.form-item__description, .form-item .description { font-size: 1.1em; }

.form-item--inline div, .form-item--inline label, .container-inline .form-i=
tem div, .container-inline .form-item label { display: inline; }

.form-item--inline__exception, .container-inline .fieldset-wrapper { displa=
y: block; }

.form-item--tight, table .form-item, .password-parent, .confirm-parent, .fo=
rm-item--radio, .form-type-radio, .form-type-checkbox { margin: 0px; }

.form-item--radio__label, .form-item--radio .form-item__label, label.option=
, .form-type-radio .form-item__label, .form-type-checkbox .form-item__label=
 { display: inline; font-weight: normal; }

.form-item--radio__description, .form-item--radio .form-item__description, =
.form-type-radio .description, .form-type-checkbox .description, .form-item=
--radio .form-item .description, .form-item .form-item--radio .description,=
 .form-type-radio .form-item__description, .form-type-checkbox .form-item__=
description, .form-type-radio .form-item .description, .form-type-checkbox =
.form-item .description, .form-item .form-type-radio .description, .form-it=
em .form-type-checkbox .description { margin-left: 1.4em; }

.form-item.is-error .form-item__widget, .form-item--is-error__widget, .form=
-item input.error, .form-item textarea.error, .form-item select.error, .for=
m-item.is-error input, .form-item.is-error textarea, .form-item.is-error se=
lect, .form-item--is-error input, .form-item--is-error textarea, .form-item=
--is-error select { border: 1px solid rgb(204, 0, 0); }

.form-note .form-required::after { margin: 0px; }

.captcha { margin-bottom: 1em; }

.view-nir-glossary .views-row { margin-bottom: 20px; }

.highlight-mark, .new, .update { color: rgb(204, 0, 0); background-color: r=
gba(0, 0, 0, 0); }

.inline-links, .inline.links { padding: 0px; }

.inline-links__item, .inline.links li { display: inline; list-style-type: n=
one; padding: 0px 1em 0px 0px; }

[dir=3D"rtl"] .inline-links__item, [dir=3D"rtl"] .inline.links li, .inline.=
links [dir=3D"rtl"] li { display: inline-block; padding: 0px 0px 0px 1em; }

.inline-sibling, .field__label-inline, span.field-label { display: inline; =
margin-right: 10px; }

[dir=3D"rtl"] .inline-sibling, [dir=3D"rtl"] .field__label-inline, [dir=3D"=
rtl"] span.field-label { margin-right: 0px; margin-left: 10px; }

.inline-sibling__child, .inline-sibling *, .field__label-inline *, span.fie=
ld-label * { display: inline; }

.inline-sibling__adjacent, .inline-sibling + *, .inline-sibling + * > :firs=
t-child, .field__items-inline, .field__label-inline + *, span.field-label +=
 *, .field__label-inline + * > :first-child, span.field-label + * > :first-=
child { display: inline; }

.ipe-category-picker-search input[type=3D"text"] { display: inline; width: =
183px; }

#panels-ipe-tray .ipe-tab-wrapper ul.ipe-tabs li { margin: 0px !important; =
padding: 0px !important; }

#panels-ipe-tray .ipe-tab-wrapper ul.ipe-tabs li.ipe-tab > a:link { text-de=
coration: none !important; color: rgb(0, 0, 0) !important; }

.ipe-block-plugin-info p { padding: 0px 10px 10px; }

.ipe-block-form .front, .ipe-block-form .back { overflow: visible; }

.dcsns-content *, .dcsns-toolbar * { box-sizing: content-box; }

.dcsns-content blockquote { margin: 0px; }

.stream li.dcsns-tumblr .section-text img { max-width: 99%; }

.dcsns-flickr .stream li .section-title { width: 100%; }

.light_1 .stream li .section-title, .light_2 .stream li .section-title { co=
lor: rgb(102, 102, 102); }

.dark_2 .stream li .icon { position: absolute; left: 4px; bottom: 2px; z-in=
dex: 2; width: 22px; }

.language-switcher-language-url ul { float: right; }

.language-switcher-language-url ul .is-active { color: rgb(0, 0, 0); }

.ui-dialog { background: rgba(0, 0, 0, 0); border: 0px; position: absolute;=
 z-index: 1260; padding: 0px; }

@media (max-width: 48em) {
  .ui-dialog { min-width: 92%; max-width: 92%; }
}

.ui-dialog { box-shadow: rgb(153, 153, 153) 0px 0px 5px; }

.ui-dialog:focus { outline: none; }

.ui-icon, .ui-widget-content .ui-icon { background: none; }

.ui-button .ui-icon-closethick { background-image: url("/profiles/nasdaqir/=
themes/custom/nir_base/dist/img/ui-icons_777777_256x240.png"); background-p=
osition: -96px -128px; }

.ui-widget-content { border: 0px; }

.ui-widget-header { border: 0px; }

.ui-widget { font-family: inherit; font-size: inherit; }

.ui-dialog .ui-dialog-titlebar { background: rgb(255, 255, 255); border-rad=
ius: 0px; padding: 0px; height: 0px; }

[dir=3D"rtl"] .ui-dialog .ui-dialog-titlebar { padding-left: 49px; padding-=
right: 15px; }

.ui-dialog .ui-dialog-title { font-size: 1.231em; font-weight: 600; margin:=
 0px; color: rgb(255, 255, 255); -webkit-font-smoothing: antialiased; }

.ui-dialog .ui-dialog-titlebar-close { border: 0px; background: none; right=
: 10px; top: 10px; margin: 0px; height: 16px; width: 16px; position: absolu=
te; }

.ui-dialog .ui-dialog-titlebar-close::before { font-size: 35px; position: a=
bsolute; }

[dir=3D"rtl"] .ui-dialog .ui-dialog-titlebar-close { right: auto; left: 20p=
x; }

.ui-dialog .ui-icon.ui-icon-closethick { margin-top: -12px; }

.ui-dialog .ui-widget-content.ui-dialog-content { border-top: 0px; backgrou=
nd: rgb(255, 255, 255); overflow: auto; padding: 20px; font-size: 15px; }

.views-ui-dialog .ui-widget-content.ui-dialog-content { padding: 0px; }

.ui-dialog .ui-widget-content.ui-dialog-buttonpane { color: rgb(255, 255, 2=
55); padding: 0px; width: 100%; appearance: none; }

.ui-dialog .ui-widget-content.ui-dialog-buttonpane .ui-button { background:=
 rgb(0, 96, 126); border: inherit; border-radius: 4px; color: rgb(255, 255,=
 255); margin: 0px; padding: 10px 15px; }

.ui-dialog .ui-widget-content.ui-dialog-buttonpane .ui-button:hover, .ui-di=
alog .ui-widget-content.ui-dialog-buttonpane .ui-button:focus { background:=
 rgb(1, 132, 162); color: rgb(255, 255, 255); }

.ui-dialog .ui-dialog-buttonpane .ui-dialog-buttonset { margin: 0px 20px 20=
px; padding: 0px; text-align: center; float: none; }

.ui-dialog .ui-dialog-buttonpane .ui-button-text-only .ui-button-text { pad=
ding: 0px; }

.ui-dialog .ui-dialog-content { position: static; }

.ui-dialog .ui-dialog-content .form-actions { padding: 0px; margin: 0px; }

.ui-dialog .ajax-progress-throbber { left: 49%; position: fixed; top: 48.5%=
; z-index: 1000; background-color: rgb(35, 35, 35); background-image: url("=
/core/misc/loading-small.gif"); background-position: center center; backgro=
und-repeat: no-repeat; border-radius: 7px; height: 24px; opacity: 0.9; padd=
ing: 4px; width: 24px; }

[dir=3D"rtl"] .ui-dialog .ajax-progress-throbber { left: auto; right: 49%; =
}

.ui-dialog .ajax-progress-throbber .throbber, .ui-dialog .ajax-progress-thr=
obber .message { display: none; }

.more-link, .more-help-link { text-align: right; }

[dir=3D"rtl"] .more-link, [dir=3D"rtl"] .more-help-link { text-align: left;=
 }

.more-link__help-icon, .more-help-link a { padding: 1px 0px 1px 20px; backg=
round-image: url("/profiles/nasdaqir/themes/custom/nir_base/dist/img/more-l=
ink__help-icon.png"); background-position: 0px 50%; background-repeat: no-r=
epeat; }

[dir=3D"rtl"] .more-link__help-icon, [dir=3D"rtl"] .more-help-link a, .more=
-help-link [dir=3D"rtl"] a { padding: 1px 20px 1px 0px; background-position=
: 100% 50%; }

#mobile-header { position: absolute; right: 10px; top: 10px; }

#responsive-menu-button:hover, #responsive-menu-button:focus { text-decorat=
ion: none; }

.menu--irhorizontal { height: 1px; width: 1px; overflow: hidden; clip: rect=
(1px, 1px, 1px, 1px); position: absolute !important; }

@media (min-width: 768px) {
  #mobile-header { height: 1px; width: 1px; overflow: hidden; clip: rect(1p=
x, 1px, 1px, 1px); position: absolute !important; }
  .menu--irhorizontal { clip: auto; height: auto; width: auto; overflow: au=
to; position: static !important; }
}

.sidr-class-visually-hidden { height: 1px; width: 1px; overflow: hidden; cl=
ip: rect(1px, 1px, 1px, 1px); position: absolute !important; }

#header-region { position: relative; }

.toolbar-vertical { padding-top: 39px; }

.navbar, .main-navigation .links, .main-navigation .menu { margin: 1em 0px;=
 padding: 0px; text-align: left; }

[dir=3D"rtl"] .navbar, [dir=3D"rtl"] .main-navigation .links, .main-navigat=
ion [dir=3D"rtl"] .links, [dir=3D"rtl"] .main-navigation .menu, .main-navig=
ation [dir=3D"rtl"] .menu { text-align: right; }

.navbar__item, .navbar li, .main-navigation .links li, .main-navigation .me=
nu li { float: left; margin: 0.4em 2em; list-style-type: none; list-style-i=
mage: none; }

.navbar__item:hover > ul, .navbar li:hover > ul, .main-navigation .links li=
:hover > ul, .main-navigation .menu li:hover > ul { display: block; positio=
n: absolute; background: rgba(255, 255, 255, 0.9); }

[dir=3D"rtl"] .navbar__item, [dir=3D"rtl"] .navbar li, [dir=3D"rtl"] .main-=
navigation .links li, .main-navigation [dir=3D"rtl"] .links li, [dir=3D"rtl=
"] .main-navigation .menu li, .main-navigation [dir=3D"rtl"] .menu li { flo=
at: right; padding: 0px 0px 0px 10px; }

.navbar__item .menu, .navbar li .menu, .main-navigation .links li .menu, .m=
ain-navigation .menu li .menu { display: none; }

.navbar__item .menu li, .navbar li .menu li, .main-navigation .links li .me=
nu li, .main-navigation .menu li .menu li { float: none; margin-left: 15px;=
 font-size: 0.8em; line-height: 1.7em; }

.block-nir-website-notices { display: none; }

.notification-modal .ui-dialog { font-size: 1.1em; line-height: 1.5em; }

.pager { clear: both; padding: 0px; text-align: center; }

@media print {
  .pager { display: none; }
}

.pager__item, .pager-item, .pager-first, .pager-previous, .pager-next, .pag=
er-last, .pager-ellipsis, .pager__current-item, .pager .is-active, .pager-c=
urrent { display: inline-block; padding: 5px 8px; list-style-type: none; ba=
ckground-image: none; }

.pager__current-item, .pager .is-active, .pager-current { font-weight: bold=
; background-color: rgb(4, 128, 169); border-radius: 4px; padding: 10px 15p=
x; color: rgb(255, 255, 255); }

.pager__current-item a, .pager .is-active a, .pager-current a { color: rgb(=
255, 255, 255); }

.pager__items { float: left; width: 100%; padding: 0px; }

.results-summary { text-align: center; }

.progress-bar, .progress { font-weight: bold; }

.progress-bar__bar, .progress .bar { border-radius: 3px; margin: 0px 0.2em;=
 border: 1px solid rgb(102, 102, 102); background-color: rgb(204, 204, 204)=
; }

.progress-bar__fill, .progress .filled { height: 1.5em; width: 5px; backgro=
und: url("/profiles/nasdaqir/themes/custom/nir_base/dist/img/progress-bar.g=
if") 0px 0px repeat rgb(0, 96, 126); }

.progress-bar__percentage, .progress .percentage { float: right; }

[dir=3D"rtl"] .progress-bar__percentage, [dir=3D"rtl"] .progress .percentag=
e, .progress [dir=3D"rtl"] .percentage { float: left; }

.progress-bar--inline, .ajax-progress-bar { width: 16em; display: inline-bl=
ock; }

[dir=3D"rtl"] .progress-bar--inline, [dir=3D"rtl"] .ajax-progress-bar { flo=
at: right; }

.progress-throbber, .ajax-progress { display: inline-block; }

[dir=3D"rtl"] .progress-throbber, [dir=3D"rtl"] .ajax-progress { float: rig=
ht; }

.progress-throbber__widget, .ajax-progress .throbber { background: url("/pr=
ofiles/nasdaqir/themes/custom/nir_base/dist/img/progress-throbber.gif") 0px=
 -18px no-repeat rgba(0, 0, 0, 0); float: left; height: 15px; margin: 2px; =
width: 15px; }

[dir=3D"rtl"] .progress-throbber__widget, [dir=3D"rtl"] .ajax-progress .thr=
obber, .ajax-progress [dir=3D"rtl"] .throbber { float: right; }

.progress-throbber__widget-in-tr, tr .ajax-progress .throbber { margin: 0px=
 2px; }

.progress-throbber__message, .ajax-progress .message { padding-left: 20px; =
}

.nir-mean-value-rating { width: 100%; padding-top: 70px; }

.nir-mean-value-rating .rating-box { width: 20%; height: 16px; float: left;=
 }

.nir-mean-value-rating .sell { float: left; }

.nir-mean-value-rating .strongbuy { float: right; }

.nir-mean-value-rating h3 { text-align: center; }

.nir-mean-value-rating .mean-recommendation { text-align: center; font-weig=
ht: bold; }

.nir-mean-value-rating .rating { position: relative; padding: 10px 0px 35px=
; width: 85%; margin: 0px auto; max-width: 135px; }

.nir-mean-value-rating .rating-arrow { display: block; height: 10px; width:=
 10px; top: -8px; position: absolute; }

.nir-mean-value-rating .rating-arrow::after { content: "=EE=80=92"; display=
: inline-block; text-decoration: none; color: rgb(0, 0, 0); }

.nir-mean-value-rating .rating-arrow::after { font-size: 16px; margin-left:=
 5px; }

.nir-mean-value-rating .clearfix { clear: both; max-width: 230px; margin: 0=
px auto; }

.block-market-data-block__estimates__analyst-ratings { float: left; width: =
100%; }

@media (min-width: 1024px) {
  .block-market-data-block__estimates__analyst-ratings > div { float: left;=
 max-width: 50%; margin: 0px; }
}

.resizable-textarea { width: 100%; vertical-align: bottom; }

.resizable-textarea__grippie, .resizable-textarea .grippie { background: ur=
l("/profiles/nasdaqir/themes/custom/nir_base/dist/img/grippie.png") center =
2px no-repeat rgb(238, 238, 238); border-width: 0px 1px 1px; border-style: =
solid; border-color: rgb(204, 204, 204); border-image: initial; cursor: s-r=
esize; height: 9px; overflow: hidden; }

.responsive-video, .media-youtube-video, .media-vimeo-preview-wrapper { pos=
ition: relative; padding-bottom: 56.25%; padding-top: 25px; height: 0px; }

.responsive-video__embed, .responsive-video iframe, .media-youtube-video if=
rame, .media-vimeo-preview-wrapper iframe { position: absolute; top: 0px; l=
eft: 0px; width: 100%; height: 100%; }

.responsive-video--4-3 { padding-bottom: 75%; }

.block-search-form form, .view-search form { position: relative; }

.block-search-form form input[type=3D"search"], .block-search-form form inp=
ut[type=3D"text"], .view-search form input[type=3D"search"], .view-search f=
orm input[type=3D"text"] { width: 100%; box-sizing: border-box; margin: 0px=
; }

.block-search-form form input[type=3D"submit"], .view-search form input[typ=
e=3D"submit"] { border: 0px; background: rgba(0, 0, 0, 0); position: absolu=
te; text-indent: -9999px; padding: 10px 25px; top: 0px; right: 0px; margin:=
 0px; z-index: 100; }

.block-search-form form .form-type-textfield, .view-search form .form-type-=
textfield { width: 100%; margin: 0px; }

.block-search-form form::after, .view-search form::after { content: "=EE=80=
=B9"; display: inline-block; text-decoration: none; color: rgb(0, 96, 126);=
 }

.block-search-form form::after, .view-search form::after { position: absolu=
te; top: 0px; right: 0px; z-index: 99; font-size: 33px; padding: 11px 9px; =
}

.block-search-form .view-content, .view-search .view-content { margin-top: =
25px; }

.search-result { margin-bottom: 20px; }

.search-result::before { content: ""; display: table; }

.search-result::after { content: ""; display: table; clear: both; }

.search-result-contenttype { display: block; color: rgb(102, 102, 102); fon=
t-size: 12px; }

.search-result-title { font-size: 1.2em; margin-bottom: 5px; margin-top: 0p=
x; }

.search-result-thumbnail { float: left; width: 24%; position: relative; ove=
rflow: hidden; margin-right: 10px; margin-top: 4px; margin-bottom: 0px; }

.search-result-thumbnail img { max-width: 100%; }

.search-result .external-link h3 { display: inline; }

.search-result h3 { margin-bottom: 5px; margin-top: 0px; }

.search-result-snippet-wrapper { float: left; width: 73%; }

.search-result-snippet-wrapper-full { width: 100%; }

.search-result .item-list { display: inline; }

.search-result .item-list ul { margin-top: 0px; padding: 0px; }

.search-result .item-list ul li { list-style-type: none; }

.search-result-tags { font-size: 11px; margin-top: 8px; }

.search-result-tags ul { margin: 0px; padding: 0px; display: inline; }

.search-result-tags .item-list { display: inline; }

.search-result-tags li { margin: 0px 2px 5px 0px; padding: 0px; list-style-=
type: none; display: inline-block; font-weight: normal; color: rgb(255, 255=
, 255); }

.search-result-tags li a { background: rgb(221, 221, 221); padding: 2px 6px=
; border-radius: 3px; color: rgb(51, 51, 51); }

.search-result-tags li a:link, .search-result-tags li a:visited, .search-re=
sult-tags li a:hover, .search-result-tags li a:active { color: rgb(51, 51, =
51); }

.search-result .file a::before { line-height: 26px; }

.view-search .views-exposed-form label { height: 1px; width: 1px; overflow:=
 hidden; clip: rect(1px, 1px, 1px, 1px); position: absolute !important; }

.view-search .inline-asset { display: inline-block; float: left; }

.view-search .inline-asset .field__item { margin: 0px; padding: 0px; }

.view-search .inline-asset .filesize { display: none; }

.view-search .inline-asset span.file--application-pdf::before { content: "=
=EE=82=88"; display: inline-block; text-decoration: none; color: rgb(204, 0=
, 0); }

.view-search .inline-asset span.file--application-pdf a { display: none; }

.view-search .inline-asset span.file--application-pdf a:hover { text-decora=
tion: none; }

.view-search .inline-asset span.file--application-pdf::before { padding: 0p=
x; }

.search-result-snippet-wrapper p:first-child { padding-top: 0px; margin-top=
: 0px; }

.nir-sec-header { font-size: 14px; font-family: "Helvetica Neue", Helvetica=
, Arial, sans-serif; float: left; width: 100%; background-color: rgb(255, 2=
55, 255); border-bottom: 1px dotted rgb(204, 204, 204); padding: 10px; marg=
in-bottom: 10px; }

.nir-sec-header h1 { color: rgb(0, 0, 0); font-size: 1.5em; font-weight: bo=
ld; float: left; line-height: 1.42857em; margin: 0px; padding: 0px; }

.nir-sec-header .logo { width: 30px; float: left; margin-right: 5px; }

.nir-sec-header .logo img { height: 30px; }

.nir-sec-header .sec-docs { float: right; }

.nir-sec-header .file a { font-size: 0px; text-decoration: none; }

.nir-sec-header .file a:hover { text-decoration: none; }

.ixbrl-link a::before, #ndq-content .ixbrl-link a::before { font-family: nd=
qfonticons; font-size: 26px; vertical-align: middle; padding-right: 5px; fo=
nt-weight: normal; text-decoration: none; }

.ixbrl-link a::before, #ndq-content .ixbrl-link a::before { content: "=EE=
=81=BD"; display: inline-block; text-decoration: none; color: rgb(0, 0, 0);=
 }

.nir-sec-header .sec-docs .file-link, .nir-sec-header .sec-docs .field.ixbr=
l-link, #ndq-content .nir-sec-header .sec-docs .file-link, #ndq-content .ni=
r-sec-header .sec-docs .field.ixbrl-link { display: inline-block; }

.nir-sec-header .sec-docs .ixbrl-link a, #ndq-content .nir-sec-header .sec-=
docs .ixbrl-link a { font-size: 0px; }

.nir-sec-header, #ndq-content .nir-sec-header { box-sizing: border-box; }

.menu, .side-menu { margin: 0px; padding: 0px; line-height: 23.8px; }

.menu__item, .side-menu__item { list-style-type: none; }

.menu__item.is-expanded, .menu__item--is-expanded, .side-menu__item.is-expa=
nded, .side-menu__item--is-expanded { list-style-type: none; }

.menu__item.is-collapsed, .menu__item--is-collapsed, .side-menu__item.is-co=
llapsed, .side-menu__item--is-collapsed { list-style-type: none; }

.menu__item .side-menu, .side-menu__item .side-menu { margin-bottom: 10px; =
}

.menu__item .side-menu__item, .side-menu__item .side-menu__item { margin-le=
ft: 15px; font-size: 0.8em; line-height: 1.7em; }

.menu__link.is-active, .menu__link--is-active, .side-menu__link.is-active, =
.side-menu__link--is-active, .menu a.active { color: rgb(0, 0, 0); }

.skip-link { display: block; padding: 2px 0px 3px; text-align: center; }

.skip-link:link, .skip-link:visited { background-color: rgb(102, 102, 102);=
 color: rgb(255, 255, 255); }

.skip-link__wrapper { margin: 0px; }

@media print {
  .skip-link__wrapper { display: none; }
}

.block-jquery-social-media-tabs * { box-sizing: content-box; }

.sliding { z-index: 1000; }

.quote-wrap { border: 1px solid rgb(204, 204, 204); float: left; position: =
relative; width: 100%; }

.quote-wrap select { color: rgb(51, 51, 51); position: absolute; padding: 1=
px 5px; appearance: menulist; top: 15px; left: 10px; }

[class^=3D"stock-quote"] { float: left; width: 100%; }

.stock-quote { padding: 1em; margin-bottom: 1em; }

.stock-quote dd, .stock-quote dt { margin: 0px; display: inline-block; }

.stock-quote dd { width: 60%; }

.stock-quote dt { width: 40%; }

.stock-quote .left { float: left; }

.stock-quote .center { float: left; }

.stock-quote .right { float: left; }

.stock-quote time { font-size: 0.75em; }

.stock-quote__short select { display: inline; }

.stock-quote__featured .stock-quote { margin-bottom: 0px; }

.stock-quote__featured time { float: left; margin-top: 0.5em; }

.stock-quote__featured .quote-price { margin-bottom: 1em; }

.quote-price { font-size: 2em; line-height: 100%; }

.price-down { color: rgb(214, 53, 58); }

.price-up { color: rgb(34, 130, 96); }

.user-toggle-on .stock-quote:nth-of-type(1) { display: block; }

.user-toggle-on .stock-quote, .user-toggle-on .exchange { display: none; }

.user-toggle-on .quote-price { margin-top: 35px; }

@media (max-width: 768px) {
  .stock-quote { padding-bottom: 2em; position: relative; }
}

.stock-quote .left-stock { width: 100%; float: right; margin-right: 0px; }

@media (min-width: 480px) {
  .stock-quote .left-stock { width: 100%; float: right; margin-right: 0px; =
}
}

@media (min-width: 768px) {
  .stock-quote .left-stock { width: 24.0506%; float: left; margin-right: 1.=
26582%; }
}

@media (max-width: 768px) {
  .stock-quote .left-stock time { position: absolute; bottom: 0em; left: 1e=
m; }
}

.stock-quote .center-stock { width: 100%; float: right; margin-right: 0px; =
}

@media (min-width: 480px) {
  .stock-quote .center-stock { width: 49.3671%; float: left; margin-right: =
1.26582%; }
}

@media (min-width: 768px) {
  .stock-quote .center-stock { width: 36.7089%; float: left; margin-right: =
1.26582%; }
}

.stock-quote .right-stock { width: 100%; float: right; margin-right: 0px; }

@media (min-width: 480px) {
  .stock-quote .right-stock { width: 49.3671%; float: right; margin-right: =
0px; }
}

@media (min-width: 768px) {
  .stock-quote .right-stock { width: 36.7089%; float: right; margin-right: =
0px; }
}

.table-drag__wrapper, body.drag { cursor: move; }

.table-drag__item, tr.drag { background-color: rgb(255, 250, 219); }

.table-drag__item-previous, tr.drag-previous { background-color: rgb(255, 2=
47, 194); }

.table-drag__handle, .tabledrag-handle { cursor: move; float: left; height:=
 1.7em; margin-left: -1em; overflow: hidden; text-decoration: none; }

[dir=3D"rtl"] .table-drag__handle, [dir=3D"rtl"] .tabledrag-handle { float:=
 right; margin-right: -1em; margin-left: 0px; }

.table-drag__handle:focus, .table-drag__handle:hover, .tabledrag-handle:foc=
us, .tabledrag-handle:hover { text-decoration: none; }

.table-drag__handle-icon, .tabledrag-handle .handle { background: url("/pro=
files/nasdaqir/themes/custom/nir_base/dist/img/table-drag__handle-icon.png"=
) 6px 9px no-repeat; height: 13px; margin: -0.4em 0.5em; padding: 0.42em 0.=
5em; width: 13px; }

.table-drag__handle-icon--is-hover, .tabledrag-handle-hover .handle { backg=
round-position: 6px -11px; }

.table-drag__toggle-weight-wrapper, .tabledrag-toggle-weight-wrapper { text=
-align: right; }

[dir=3D"rtl"] .table-drag__toggle-weight-wrapper, [dir=3D"rtl"] .tabledrag-=
toggle-weight-wrapper { text-align: left; }

.table-drag__toggle-weight, .tabledrag-toggle-weight { font-size: 0.9em; }

.table-drag__indentation, .indentation { float: left; height: 1.7em; margin=
: -0.4em 0.2em -0.4em -0.4em; padding: 0.42em 0px 0.42em 0.6em; width: 20px=
; }

[dir=3D"rtl"] .table-drag__indentation, [dir=3D"rtl"] .indentation { float:=
 right; margin: -0.4em -0.4em -0.4em 0.2em; padding: 0.42em 0.6em 0.42em 0p=
x; }

.table-drag__tree-child, .tree-child, .table-drag__tree-child-horizontal, .=
tree-child-horizontal, .table-drag__tree-child-last, .tree-child-last { bac=
kground: url("/profiles/nasdaqir/themes/custom/nir_base/dist/img/table-drag=
__tree-child.png") 11px center no-repeat; }

[dir=3D"rtl"] .table-drag__tree-child, [dir=3D"rtl"] .tree-child, [dir=3D"r=
tl"] .table-drag__tree-child-horizontal, [dir=3D"rtl"] .tree-child-horizont=
al, [dir=3D"rtl"] .table-drag__tree-child-last, [dir=3D"rtl"] .tree-child-l=
ast { background-position: -65px center; }

.table-drag__tree-child-last, .tree-child-last { background-image: url("/pr=
ofiles/nasdaqir/themes/custom/nir_base/dist/img/table-drag__tree-child-last=
.png"); }

.table-drag__tree-child-horizontal, .tree-child-horizontal { background-pos=
ition: -11px center; }

.tablesort { background-image: url("/profiles/nasdaqir/themes/custom/nir_ba=
se/dist/img/unsorted.gif"); background-position: center center; background-=
repeat: no-repeat; background-attachment: initial; background-origin: initi=
al; background-clip: initial; background-color: initial; position: absolute=
; top: 40%; right: 0px; width: 16px; height: 16px; display: inline-block; b=
ackground-size: inherit; }

.tablesort--asc { background: url("/profiles/nasdaqir/themes/custom/nir_bas=
e/dist/img/asc.gif") center center no-repeat; }

.tablesort--desc { background: url("/profiles/nasdaqir/themes/custom/nir_ba=
se/dist/img/desc.gif") center center no-repeat; }

.clearfix::before, #nir-header::before, div[class*=3D"view-widget-"]::befor=
e, .tabs::before, .tabs--secondary::before { content: ""; display: table; }

.clearfix::after, #nir-header::after, div[class*=3D"view-widget-"]::after, =
.tabs::after, .tabs--secondary::after { content: ""; display: table; clear:=
 both; }

.tabs, .tabs--secondary { margin: 1.42857em 0px; padding: 0px 2px; list-sty=
le: none; white-space: nowrap; }

@media print {
  .tabs, .tabs--secondary { display: none; }
}

.tabs__tab { border-top-left-radius: 4px; border-top-right-radius: 4px; flo=
at: left; margin: 0px 3px; border-width: 1px; border-style: solid; border-c=
olor: rgb(204, 204, 204) rgb(204, 204, 204) rgba(0, 0, 0, 0); border-image:=
 initial; }

[dir=3D"rtl"] .tabs__tab { float: right; }

.tabs__tab.is-active { border-bottom-color: rgb(255, 255, 255); }

.tabs__tab-link-common, .tabs--secondary__tab-link, .tabs__tab-link, .tabs =
a, .tabs--secondary a { border-width: 1px 0px 0px 1px; border-top-style: so=
lid; border-left-style: solid; border-top-color: rgb(234, 234, 234); border=
-left-color: rgb(234, 234, 234); border-image: initial; border-right-style:=
 initial; border-right-color: initial; border-bottom-style: initial; border=
-bottom-color: initial; display: block; text-decoration: none; }

.tabs__tab-link, .tabs a, .tabs--secondary a { border-top-left-radius: 4px;=
 border-top-right-radius: 4px; color: rgb(0, 0, 0); background-color: rgb(2=
21, 221, 221); letter-spacing: 1px; padding: 0px 1em; text-align: center; }

.tabs__tab-link:focus, .tabs__tab-link:hover, .tabs a:focus, .tabs a:hover,=
 .tabs--secondary a:focus, .tabs--secondary a:hover { background-color: rgb=
(234, 234, 234); border-color: rgb(241, 241, 241); }

.tabs__tab-link.is-active, .tabs__tab-link--is-active, .tabs a.is-active, .=
tabs a--is-active, .tabs__tab-link:active, .tabs a:active, .tabs--secondary=
 a:active, .tabs--secondary a.is-active, .tabs--secondary a--is-active { bo=
rder-color: rgb(246, 246, 246); }

.tabs--secondary { font-size: 0.9em; background-image: none; }

.tabs + .tabs--secondary, .tabs--secondary + .tabs--secondary { margin-top:=
 -1.42857em; }

.tabs--secondary__tab { margin: 0.714286em 0.214286em; float: left; }

[dir=3D"rtl"] .tabs--secondary__tab { float: right; }

.tabs--secondary__tab-link { border-radius: 0.75em; color: rgb(102, 102, 10=
2); background-color: rgb(241, 241, 241); padding: 0px 0.5em; }

.tabs--secondary__tab-link:focus, .tabs--secondary__tab-link:hover { color:=
 rgb(51, 51, 51); background-color: rgb(221, 221, 221); border-color: rgb(1=
53, 153, 153); }

.tabs--secondary__tab-link.is-active, .tabs--secondary__tab-link--is-active=
, .tabs--secondary__tab-link:active { color: rgb(255, 255, 255); background=
-color: rgb(102, 102, 102); border-color: rgb(0, 0, 0); }

.styled-tag { background-color: rgb(0, 96, 126); border-radius: 3px; color:=
 rgb(255, 255, 255); float: left; padding: 5px 10px; margin: 0px 2px 5px 0p=
x; }

.styled-tag::before { content: "#"; }

.styled-tag__small { background-color: rgb(204, 204, 204); border-radius: 3=
px; color: rgb(51, 51, 51); float: left; font-size: 11px; line-height: 15px=
; padding: 2px 6px 4px; margin: 0px 2px 5px 0px; }

.styled-tag__small a { color: rgb(255, 255, 255); }

.styled-tag a { color: rgb(255, 255, 255); }

.views-field-field-nir-tags a { background-color: rgb(204, 204, 204); borde=
r-radius: 3px; color: rgb(51, 51, 51); float: left; font-size: 0.8em; line-=
height: 1.33929em; padding: 4px 6px; }

.views-field-field-nir-tags .views-label { float: left; }

.field--name-field-nir-media-gallery-tags .field__label, .field--name-field=
-nir-multimedia-tags .field__label { float: left; font-size: 11px; padding-=
right: 3px; }

.field--name-field-nir-media-gallery-tags a, .field--name-field-nir-multime=
dia-tags a { background-color: rgb(204, 204, 204); color: rgb(51, 51, 51); =
}

[role=3D"tooltip"] { background: rgb(0, 158, 194); opacity: 0; font-weight:=
 normal; position: absolute; margin-right: 20px; left: 0px; top: -1px; colo=
r: rgb(255, 255, 255); padding: 10px; z-index: -1; font-size: 12px; border-=
radius: 3px; max-width: 800px; }

[role=3D"tooltip"]::after { position: absolute; bottom: -4px; left: 20px; m=
argin: 0px auto; content: ""; width: 0px; height: 0px; border-top: 4px soli=
d rgb(0, 158, 194); border-left: 4px solid rgba(0, 0, 0, 0); border-right: =
4px solid rgba(0, 0, 0, 0); }

.tool-hide { display: none; }

.tool-show { display: block; }

.watermark { display: block; height: 0px; overflow: visible; background-col=
or: rgba(0, 0, 0, 0); color: rgb(238, 238, 238); font-size: 75px; line-heig=
ht: 1; font-family: Impact, "Arial Narrow", Helvetica, sans-serif; font-wei=
ght: bold; text-transform: uppercase; text-align: center; text-shadow: rgba=
(0, 0, 0, 0.1) 0px 0px 1px; overflow-wrap: break-word; }

.node--view-mode-nir-grid h3 { color: rgb(102, 102, 102); font-size: 1.1em;=
 }

.node--view-mode-nir-grid img { padding-right: 15px; }

@media (max-width: 481px) {
  .block-views-blockwidget-assets-widget-assets-grid .views-col { width: 10=
0% !important; }
}

.block-views-blockwidget-assets-widget-assets-ul img { margin: 0px 2% 2% 0p=
x; }

.block-views-blockwidget-assets-widget-assets-ul .file a:hover { text-decor=
ation: underline; }

div[class*=3D"view-widget-"] .pager { float: left; }

div[class*=3D"view-widget-"] .results-summary { float: right; padding: 10px=
 0px; margin: 1em 0px; }

.nir-widget .field--label-hidden h4 { display: none; }

.nir-widget .nir-widget--field { margin: 10px 0px; }

.nir-widget .nir-widgets--file-list--hide-filesize .filesize { display: non=
e; }

.nir-widget .nir-widgets--file-list--hide-title a { height: 0px; overflow: =
hidden; display: block; }

.nir-widget .nir-widgets--file-list--hide-title a::before { position: absol=
ute; margin-top: -10px; }

.nir-widget .nir-widget--labeled-field .nir-widget--label, .nir-widget .nir=
-widget--labeled-field .nir-widget--field { display: inline-block; }

.striped-odd tbody tr:nth-child(2n+1) { background-color: rgb(245, 250, 250=
); }

.striped-even tbody tr:nth-child(2n) { background-color: rgb(245, 250, 250)=
; }

.fundamentals tr td:nth-child(2) { text-align: right; }

.earnings-estimates { table-layout: auto; }

.earnings-estimates tr td:not(:first-child) { text-align: right; }

.earnings-estimates caption { text-align: right; border-bottom: 0px; font-s=
ize: 1em; padding: 15px; margin: 0px; background-color: rgb(102, 102, 102);=
 color: rgb(255, 255, 255); }

@media (max-width: 768px) {
  .earnings-estimates.estimates-analyst-forecasts thead tr:first-child { di=
splay: none; }
}

.earnings-estimates.estimates-analyst-forecasts thead td { background-color=
: rgb(102, 102, 102); color: rgb(255, 255, 255); font-weight: bold; text-al=
ign: left; }

.earnings-estimates.estimates-analyst-forecasts caption { display: none; }

.earnings-estimates th { text-align: right; }

.earnings-estimates th:first-child, .earnings-estimates th.caption { text-a=
lign: left; }

.block-widget-committee-composition table th a { color: rgb(255, 255, 255);=
 }

.block-widget-committee-composition table tbody tr td { text-align: center;=
 }

.block-widget-committee-composition table tbody tr td:first-child { text-al=
ign: left; }

.block-widget-committee-composition table tbody tr a::before { content: non=
e; }

.block-widget-committee-composition table tbody tr span::before { font-size=
: 20px; padding-right: 0px; }

.commitee-key span::before { font-size: 20px; padding-right: 0px; }

.collapse-table { border-collapse: collapse; }

@media (max-width: 481px) {
  .collapse-table th { height: 1px; width: 1px; overflow: hidden; clip: rec=
t(1px, 1px, 1px, 1px); position: absolute !important; }
  .collapse-table tr { border: 1px dotted rgb(204, 204, 204); margin-bottom=
: 25px; display: block; float: left; width: 100%; }
  .collapse-table tbody tr td, .collapse-table tfoot tr td { box-sizing: bo=
rder-box; float: left; width: 100%; text-align: left !important; }
  .collapse-table tbody tr td:empty, .collapse-table tfoot tr td:empty { di=
splay: none; }
  .collapse-table tbody tr td::before, .collapse-table tfoot tr td::before =
{ content: attr(data-before); font-weight: bold; padding-bottom: 7px; borde=
r-bottom: 1px dotted rgb(204, 204, 204); width: 100%; float: left; margin-b=
ottom: 5px; }
  .collapse-table tbody tr td:first-child::before, .collapse-table tfoot tr=
 td:first-child::before { border-bottom: 0px; }
  .collapse-table .table-indent { padding-left: 15px; }
}

.field--name-field-nir-committee-body { float: left; }

.commiteetable thead span { display: none; }

@media (max-width: 481px) {
  .commiteetable td::before { display: none; }
  .commiteetable tr { border: 0px; margin-bottom: 0px; }
  .commiteetable thead { display: none; }
  .commiteetable thead span { display: none; }
  .commiteetable tbody a { font-weight: bold; }
}

.collapse-table-wide { border-collapse: collapse; }

.collapse-table-wide .desk-absolute { position: absolute; }

@media (max-width: 768px) {
  .collapse-table-wide .total-row .views-field-field-nir-div-rec-date, .col=
lapse-table-wide .total-row .views-field-field-nir-div-pay-date, .collapse-=
table-wide .total-row .views-field-field-nir-div-dec-date, .collapse-table-=
wide .total-row .views-field-field-nir-div-type, .collapse-table-wide .tota=
l-row .views-field-field-nir-split-numerator { display: none; }
  .collapse-table-wide .desk-absolute { position: relative; }
  .collapse-table-wide th { height: 1px; width: 1px; overflow: hidden; clip=
: rect(1px, 1px, 1px, 1px); position: absolute !important; }
  .collapse-table-wide tbody tr { border-bottom: 1px solid rgb(204, 204, 20=
4); margin-bottom: 25px; display: block; float: left; width: 100%; }
  .collapse-table-wide caption { background-color: rgba(0, 0, 0, 0); color:=
 rgb(51, 51, 51); text-align: left; padding-left: 0px; }
  .collapse-table-wide tbody tr td, .collapse-table-wide tfoot tr td { box-=
sizing: border-box; float: left; width: 100%; position: relative; padding-l=
eft: 60%; white-space: normal; text-align: left !important; }
  .collapse-table-wide tbody tr td:empty, .collapse-table-wide tfoot tr td:=
empty { display: none; }
  .collapse-table-wide tbody tr td::before, .collapse-table-wide tfoot tr t=
d::before { content: attr(data-before); font-weight: bold; padding: 0px 10p=
x 7px 0px; margin-bottom: 5px; position: absolute; left: 6px; width: 55%; v=
ertical-align: middle; white-space: nowrap; text-align: left; }
  .collapse-table-wide tbody tr td:first-child::before, .collapse-table-wid=
e tfoot tr td:first-child::before { border-bottom: 0px; }
  .collapse-table-wide .table-indent { padding-left: 15px; }
}

.mobile-show { height: 1px; width: 1px; overflow: hidden; clip: rect(1px, 1=
px, 1px, 1px); position: absolute !important; }

@media (max-width: 481px) {
  .mobile-show { clip: auto; height: auto; width: auto; overflow: auto; pos=
ition: static !important; }
}

td.views-field-field-nir-asset-source { color: rgb(51, 51, 51); }

.ndq-source p { font-size: 12px; }

.table-indent { padding-left: 30px; }

tr.detail-level-1 { font-weight: bold; }

table.cash-flow td, table.income-statment td { text-align: right; }

table.cash-flow td:first-child, table.income-statment td:first-child { text=
-align: left; }

table.cash-flow th, table.income-statment th { text-align: right; }

table.historical-lookup td:nth-child(n+2), table.historical-lookup th:nth-c=
hild(n+2), table.ownership td:nth-child(n+2), table.ownership th:nth-child(=
n+2) { text-align: right; }

table.historical-lookup tr:first-child { font-weight: bold; }

@media (max-width: 768px) {
  table.estimates-reference-information tr { margin-bottom: 0px; }
  table.estimates-reference-information td:first-child { padding-left: 10px=
; width: 60%; }
  table.estimates-reference-information td:last-child { padding-left: 0px; =
width: 40%; float: right; }
}

#block-facetbreadbox.block-facet-select-breadbox { background-color: rgb(22=
1, 221, 221); padding: 10px; border-radius: 5px; margin-bottom: 20px; }

#block-facetbreadbox.block-facet-select-breadbox h2 { display: inline-block=
; font-size: 14px; line-height: 1.42857; margin: 0px; border-bottom: 0px; }

#block-facetbreadbox.block-facet-select-breadbox a { font-size: 11px; margi=
n-left: 5px; }

#block-facetbreadbox.block-facet-select-breadbox ul { padding: 0px; margin:=
 0px; }

#block-facetbreadbox.block-facet-select-breadbox ul li { margin: 0.4em 0px =
0.4em 2em; }

.view-widget-bundled-content .views-field-field-nir-bundle-thumbnail { widt=
h: 100%; float: right; margin-right: 0px; }

@media (min-width: 480px) {
  .view-widget-bundled-content .views-field-field-nir-bundle-thumbnail { wi=
dth: 30.3797%; float: left; margin-right: 1.26582%; }
}

.view-widget-bundled-content .views-field-field-nir-bundle-body, .view-widg=
et-bundled-content .views-field-field-nir-bundle-content, .view-widget-bund=
led-content .views-field-field-nir-tags { width: 100%; float: right; margin=
-right: 0px; }

@media (min-width: 480px) {
  .view-widget-bundled-content .views-field-field-nir-bundle-body, .view-wi=
dget-bundled-content .views-field-field-nir-bundle-content, .view-widget-bu=
ndled-content .views-field-field-nir-tags { width: 68.3544%; float: right; =
margin-right: 0px; }
}

.view-widget-bundled-content .views-field-field-nir-tags { font-size: 11px;=
 line-height: 16px; margin-top: 1.5em; }

.view-widget-bundled-content .views-field-field-nir-tags .views-label { mar=
gin: 0px 10px 0px 0px; }

.view-widget-bundled-content .views-field-field-nir-bundle-content { float:=
 left; }

.view-widget-bundled-content .views-field-field-nir-bundle-content ul { pad=
ding: 0px; margin: 0px; list-style-type: none; }

.view-widget-bundled-content .views-field-field-nir-bundle-content ul div {=
 margin: 0px; line-height: 1; }

.view-widget-bundled-content .views-field-field-nir-bundle-content .webcast=
-link { font-weight: normal; }

.view-widget-bundled-content .views-field-field-nir-bundle-body p { margin-=
top: 0px; }

.acc-title, .view-grouping, .acc-body { float: left; width: 100%; }

.acc-body { margin-top: 1em; margin-bottom: 15px; }

.block-views-blockwidget-bundled-content-block-1 { position: relative; }

.block-views-blockwidget-bundled-content-block-1 .show-all { margin-top: 0p=
x; }

.button, .market-data-filter-form input, button, [type=3D"button"], [type=
=3D"reset"], [type=3D"submit"], .ui-dialog .ui-widget-content.ui-dialog-but=
tonpane .ui-button { appearance: button; display: inline-block; text-decora=
tion: none; color: rgb(255, 255, 255); padding: 10px 15px; margin: 5px 0px =
0px; text-align: center; vertical-align: middle; cursor: pointer; backgroun=
d-image: none; background-color: rgb(0, 96, 126); border: 1px solid rgba(0,=
 0, 0, 0); border-radius: 4px; white-space: nowrap; font-size: 14px; font-w=
eight: normal; line-height: 1.42857; user-select: none; transition: 1s; }

.button:hover, .button:focus, .button:active, .market-data-filter-form inpu=
t:hover, button:hover, [type=3D"button"]:hover, [type=3D"reset"]:hover, [ty=
pe=3D"submit"]:hover, .ui-dialog .ui-widget-content.ui-dialog-buttonpane .u=
i-button:hover, .market-data-filter-form input:focus, button:focus, [type=
=3D"button"]:focus, [type=3D"reset"]:focus, [type=3D"submit"]:focus, .ui-di=
alog .ui-widget-content.ui-dialog-buttonpane .ui-button:focus, .market-data=
-filter-form input:active, button:active, [type=3D"button"]:active, [type=
=3D"reset"]:active, [type=3D"submit"]:active, .ui-dialog .ui-widget-content=
.ui-dialog-buttonpane .ui-button:active { background-color: rgb(1, 132, 162=
); text-decoration: none; color: rgb(255, 255, 255); }

.button[disabled], .market-data-filter-form input[disabled], button[disable=
d], [disabled][type=3D"button"], [disabled][type=3D"reset"], [disabled][typ=
e=3D"submit"], .ui-dialog .ui-widget-content.ui-dialog-buttonpane [disabled=
].ui-button { cursor: default; color: rgb(153, 153, 153); }

.button[disabled]:hover, .button[disabled]:focus, .button[disabled]:active,=
 .market-data-filter-form input[disabled]:hover, button[disabled]:hover, [d=
isabled][type=3D"button"]:hover, [disabled][type=3D"reset"]:hover, [disable=
d][type=3D"submit"]:hover, .ui-dialog .ui-widget-content.ui-dialog-buttonpa=
ne [disabled].ui-button:hover, .market-data-filter-form input[disabled]:foc=
us, button[disabled]:focus, [disabled][type=3D"button"]:focus, [disabled][t=
ype=3D"reset"]:focus, [disabled][type=3D"submit"]:focus, .ui-dialog .ui-wid=
get-content.ui-dialog-buttonpane [disabled].ui-button:focus, .market-data-f=
ilter-form input[disabled]:active, button[disabled]:active, [disabled][type=
=3D"button"]:active, [disabled][type=3D"reset"]:active, [disabled][type=3D"=
submit"]:active, .ui-dialog .ui-widget-content.ui-dialog-buttonpane [disabl=
ed].ui-button:active { color: rgb(153, 153, 153); }

ul.no-list-style, .view-widget-events .item-list ul, .view-widget-people .i=
tem-list > ul, .view-widget-assets .item-list ul { list-style-type: none; p=
adding: 0px; }

.field--name-field-nir-asset-source { margin: 1em 0px; font-size: 12px; }

.field--name-field-nir-asset-source .field__label { font-weight: bold; }

.view-widget-assets .item-list ul { margin: 0px; }

.view-widget-assets .item-list ul li { border-bottom: 1px solid rgb(238, 23=
8, 238); float: left; margin: 10px 0px; padding-bottom: 15px; width: 100%; =
}

.view-widget-assets table td { vertical-align: top; }

.view-widget-assets table td h4 { margin: 0px 0px 8px; }

.view-widget-assets table .field--name-field-nir-ext-document a, .view-widg=
et-assets table .field--name-field-nir-document a { line-height: 30px; }

.view-widget-assets table .item-list ul { margin: 5px 0px; }

.view-widget-assets table .item-list ul li { border: 0px; margin: 0px; padd=
ing: 0px; }

.view-widget-assets table .field__label { display: none; }

.view-widget-assets table tbody .views-field-field-nir-asset-date { font-st=
yle: italic; color: rgb(153, 153, 153); font-size: 12px; }

@media (max-width: 481px) {
  .view-widget-assets table tbody .views-field-field-nir-asset-date { font-=
style: normal; font-size: 14px; color: rgb(51, 51, 51); }
  .view-widget-assets table tbody .views-field-field-nir-asset-date time { =
font-size: 12px; }
}

.view-widget-assets .views-col { padding: 1%; }

.view-widget-assets .views-col article { border: 1px solid rgb(153, 153, 15=
3); float: left; padding: 4%; width: 100%; }

.view-widget-assets .views-col h3 { margin: 0px; }

.view-widget-sec-filings table th a { color: rgb(255, 255, 255); }

.view-widget-sec-filings table td { vertical-align: top; }

.view-widget-sec-filings table td p { margin: 0px; }

.view-widget-sec-filings .html-link, .view-widget-sec-filings .file-link { =
float: left; }

.view-widget-sec-filings .html-link .filesize, .view-widget-sec-filings .fi=
le-link .filesize { display: none; }

.view-widget-sec-filings .html-link a, .view-widget-sec-filings .file-link =
a { font-size: 0px; }

.view-widget-sec-filings .html-link a::before, .view-widget-sec-filings .fi=
le-link a::before { font-size: 30px; line-height: 1em; }

.view-widget-sec-filings .views-field-field-nir-sec-pdf .filesize { display=
: none; }

.view-widget-sec-filings .views-field-field-nir-sec-pdf .file--mime-applica=
tion-xml a::before, .view-widget-sec-filings .views-field-field-nir-sec-pdf=
 .file--mime-application-xsd a::before { content: "=EE=81=BD"; color: rgb(1=
23, 65, 189); }

.view-widget-sec-filings .views-field-field-nir-sec-pdf a { font-size: 0px;=
 }

.view-widget-sec-filings .views-field-field-nir-sec-pdf a::before { font-si=
ze: 30px; line-height: 1em; }

.field--name-field-nir-asset-source, .asset-date { color: rgb(132, 114, 113=
); font-style: italic; }

.asset-date { font-size: 12px; }

.nir-docs { margin: 20px 0px; }

.nir-docs a { line-height: 30px; }

.nir-docs a:hover, .nir-docs a:focus { text-decoration: none; }

.field--name-field-nir-ext-document, .field--name-field-nir-document, .fiel=
d--name-field-nir-ext-document { font-weight: bold; }

.asset-link { font-size: 14px; font-weight: bold; margin: 1em 0px; }

.view-empty { margin: 1em 0px; }

.filesize { font-style: italic; font-weight: normal; color: rgb(132, 114, 1=
13); }

.file-link .file { display: inline-block; vertical-align: middle; }

.view-widget-people .item-list > ul > li { border-bottom: 1px solid rgb(238=
, 238, 238); float: left; margin: 10px 0px; padding-bottom: 15px; width: 10=
0%; }

.block-views-blockwidget-people-widget-assets-ul { float: left; width: 100%=
; }

.view-widget-news.view-display-id-widget_news_ul .item-list { margin-bottom=
: 2em; float: left; width: 100%; }

.view-widget-news.view-display-id-widget_news_ul .item-list ul { list-style=
-type: none; padding: 0px; }

.view-widget-news.view-display-id-widget_news_ul .item-list ul li { float: =
left; width: 100%; border-bottom: 1px dotted rgb(204, 204, 204); list-style=
-type: none; padding: 2em 0px; }

.view-widget-news.view-display-id-widget_news_ul .item-list ul li:first-chi=
ld { border-top: 1px dotted rgb(204, 204, 204); }

.view-widget-news.view-display-id-widget_news_ul .views-field-field-nir-new=
s-teaser .field-content { margin: 1em 0px; }

.view-widget-news.view-display-id-widget_news_ul .views-field-field-nir-new=
s-teaser p { margin: 0px; }

.view-widget-news.view-display-id-widget_news_ul .views-field-title h3 { ma=
rgin: 0px; }

.view-widget-news.view-display-id-widget_news_ul .views-field-field-nir-new=
s-date { width: 100%; }

.view-widget-news.view-display-id-widget_news_ul .field--name-field-nir-doc=
ument { font-weight: normal; }

.view-widget-news.view-display-id-widget_news_ul .field--name-field-nir-doc=
ument .field__item { margin-top: 0px; }

.view-widget-news.view-display-id-widget_news_ul .views-field-title, .view-=
widget-news.view-display-id-widget_news_ul .views-field-field-nir-news-titl=
e { font-weight: bold; font-size: 16px; }

.view-widget-news.view-display-id-widget_news_ul .field--name-field-nir-tag=
s .field__label { font-size: 11px; float: left; margin-right: 0.5em; }

.view-widget-news.view-display-id-widget_news_ul .views-field-field-nir-new=
s-thumbnail { float: left; }

.view-widget-news.view-display-id-widget_news_ul .views-field-field-nir-new=
s-thumbnail img { border-left: 8px solid rgb(0, 96, 126); }

.view-widget-news.view-display-id-widget_news_ul .col { width: 100%; float:=
 left; margin-left: 0px; margin-right: 0px; }

.view-widget-news.view-display-id-widget_news_ul .has-news-supp .col:nth-ch=
ild(1) { width: 100%; float: left; margin-left: 0px; margin-right: 0px; }

@media (min-width: 1024px) {
  .view-widget-news.view-display-id-widget_news_ul .has-news-supp .col:nth-=
child(1) { width: 62.0253%; float: left; margin-right: 1.26582%; }
}

.view-widget-news.view-display-id-widget_news_ul .has-news-supp .col:nth-ch=
ild(2) { width: 100%; float: left; margin-left: 0px; margin-right: 0px; mar=
gin-top: 20px; }

@media (min-width: 768px) {
  .view-widget-news.view-display-id-widget_news_ul .has-news-supp .col:nth-=
child(2) { width: 81.0127%; float: right; margin-right: 0px; }
}

@media (min-width: 1024px) {
  .view-widget-news.view-display-id-widget_news_ul .has-news-supp .col:nth-=
child(2) { width: 36.7089%; float: right; margin-right: 0px; }
}

.view-widget-news.view-display-id-widget_news_ul .has-thumbnail .col:nth-ch=
ild(1) { width: 100%; float: left; margin-left: 0px; margin-right: 0px; }

@media (min-width: 768px) {
  .view-widget-news.view-display-id-widget_news_ul .has-thumbnail .col:nth-=
child(1) { width: 17.7215%; float: left; margin-right: 1.26582%; }
}

@media (min-width: 768px) {
  .view-widget-news.view-display-id-widget_news_ul .has-thumbnail .col:nth-=
child(2) { width: 81.0127%; float: right; margin-right: 0px; }
}

.view-widget-news.view-display-id-widget_news_ul .has-thumbnail.has-news-su=
pp .col:nth-child(1) { width: 100%; float: left; margin-left: 0px; margin-r=
ight: 0px; }

@media (min-width: 768px) {
  .view-widget-news.view-display-id-widget_news_ul .has-thumbnail.has-news-=
supp .col:nth-child(1) { width: 17.7215%; float: left; margin-right: 1.2658=
2%; }
}

.view-widget-news.view-display-id-widget_news_ul .has-thumbnail.has-news-su=
pp .col:nth-child(2) { margin-top: 0px; }

@media (min-width: 768px) {
  .view-widget-news.view-display-id-widget_news_ul .has-thumbnail.has-news-=
supp .col:nth-child(2) { width: 81.0127%; float: right; margin-right: 0px; =
}
}

@media (min-width: 1024px) {
  .view-widget-news.view-display-id-widget_news_ul .has-thumbnail.has-news-=
supp .col:nth-child(2) { width: 43.038%; float: left; margin-right: 1.26582=
%; }
}

.view-widget-news.view-display-id-widget_news_ul .has-thumbnail.has-news-su=
pp .col:nth-child(3) { width: 100%; float: left; margin-left: 0px; margin-r=
ight: 0px; margin-top: 20px; }

@media (min-width: 768px) {
  .view-widget-news.view-display-id-widget_news_ul .has-thumbnail.has-news-=
supp .col:nth-child(3) { width: 81.0127%; float: right; margin-right: 0px; =
}
}

@media (min-width: 1024px) {
  .view-widget-news.view-display-id-widget_news_ul .has-thumbnail.has-news-=
supp .col:nth-child(3) { width: 36.7089%; float: right; margin-right: 0px; =
}
}

@media (min-width: 1024px) {
  .view-widget-news.view-display-id-widget_news_ul .has-thumbnail.has-news-=
supp .views-field-field-nir-news-title { margin-bottom: 5px; }
}

.view-widget-news.view-display-id-table .field--name-field-nir-document .fi=
eld__item { margin-top: 0px; margin-bottom: 0px; }

.view-widget-news.view-display-id-table .html-link, .view-widget-news.view-=
display-id-table .file-link { float: left; }

.view-widget-news.view-display-id-table .html-link .filesize, .view-widget-=
news.view-display-id-table .file-link .filesize { display: none; }

.view-widget-news.view-display-id-table .html-link a, .view-widget-news.vie=
w-display-id-table .file-link a { font-size: 0px; }

.view-widget-news.view-display-id-table .html-link a::before, .view-widget-=
news.view-display-id-table .file-link a::before { font-size: 30px; line-hei=
ght: 1em; }

.view-widget-news.view-display-id-table table { table-layout: initial; }

.view-widget-news.view-display-id-table table td { vertical-align: top; }

.view-widget-news.view-display-id-table table td.views-field-field-nir-news=
-date { width: 200px; }

@media screen and (max-width: 480px) {
  .view-widget-news.view-display-id-table table td.views-field-field-nir-ne=
ws-date { width: initial; }
}

.view-widget-news.view-display-id-table table td.views-field-field-nir-news=
-supp-format { width: 180px; }

@media screen and (max-width: 480px) {
  .view-widget-news.view-display-id-table table td.views-field-field-nir-ne=
ws-supp-format { width: initial; }
}

.block-views { float: left; width: 100%; }

.view-widget-events .item-list ul li { border-bottom: 1px solid rgb(238, 23=
8, 238); float: left; margin: 10px 0px; padding-bottom: 15px; width: 100%; =
}

.view-widget-events .field--name-field-nir-event-thumbnail img { padding-ri=
ght: 0px; }

.view-widget-events h3 { margin-top: 0px; font-size: 16px; }

.view-widget-events .field--name-field-nir-event-summary { margin-bottom: 1=
em; }

.view-widget-events .two-col-half:empty { display: none; }

.view-widget-events .full-width { float: none; clear: both; }

.view-widget-events .full-width > div { margin-top: 1em; }

.view-widget-events .left-half, .view-widget-events .right-half { margin-bo=
ttom: 1em; }

.view-widget-events .webcast-link { margin-top: 0px; }

.view-widget-events.view-display-id-table table { table-layout: initial; }

.view-widget-events.view-display-id-table table td { vertical-align: top; }

.view-widget-events.view-display-id-table table td.views-field-field-nir-ev=
ent-start-date { width: 200px; }

@media screen and (max-width: 480px) {
  .view-widget-events.view-display-id-table table td.views-field-field-nir-=
event-start-date { width: initial; }
}

.view-widget-events.view-display-id-table table td.views-field-field-nir-ev=
ent-add-calender { width: 130px; }

@media screen and (max-width: 480px) {
  .view-widget-events.view-display-id-table table td.views-field-field-nir-=
event-add-calender { width: initial; }
}

.view-nir-media-gallery-items-grid .views-row { margin-bottom: 30px; }

.view-nir-media-gallery-items-grid .views-row h2 { border-bottom: 0px; marg=
in: 0px; }

.view-nir-media-gallery-items-grid form.views-exposed-form .form-actions { =
margin: 0px; }

.view-nir-media-gallery-items-grid form.views-exposed-form .form-item { mar=
gin: 6px 0px 16px; }

.view-nir-media-gallery-items-grid form.views-exposed-form input { display:=
 none; }

.gallery-title { padding: 5px 0px; margin-bottom: 20px; }

.view-nir-media-galleries-widget-grid .view-footer { margin: 1em 0px; width=
: 100%; float: left; text-align: left; padding: 25px 0px; }

.view-nir-media-galleries-widget-grid .pager { margin: 1em 0px; width: 100%=
; float: left; text-align: left; }

@media (min-width: 480px) {
  .view-nir-media-galleries-widget-grid .view-footer { width: 50%; float: r=
ight; text-align: right; }
  .view-nir-media-galleries-widget-grid .pager { width: 50%; float: left; t=
ext-align: left; }
}

.faq-dl { counter-reset: faq-counter 0; }

.faq-dl dt::before { content: counter(faq-counter) "."; counter-increment: =
faq-counter 1; padding-right: 0.75em; padding-left: 0.5em; }

.faq-dl dt { margin: 1.4em 0px 1em; font-weight: bold; }

.faq-dl dd { margin: 1em 0px; padding-left: 2.1em; }

.faq-dl .top-link { padding-left: 2.1em; }

.faq-acc-dl dt, .faq-acc-dl .acc-title, .acc-wrap dt, .acc-wrap .acc-title =
{ cursor: pointer; line-height: 1.5em; border-radius: 3px; background: rgb(=
102, 102, 102); color: rgb(255, 255, 255); border-bottom: 1px solid rgb(255=
, 255, 255); padding: 15px; transition: 1s; }

.faq-acc-dl dt:hover, .faq-acc-dl .acc-title:hover, .acc-wrap dt:hover, .ac=
c-wrap .acc-title:hover { background-color: rgb(4, 128, 169); }

.faq-acc-dl dt.opened, .faq-acc-dl .acc-title.opened, .acc-wrap dt.opened, =
.acc-wrap .acc-title.opened { background-color: rgb(4, 128, 169); }

.faq-acc-dl dd, .acc-wrap dd { margin: 1em 0px; }

.show-all { float: left; text-align: right; width: 100%; margin-top: -25px;=
 }

.view-grouping { }

.form-table__sticky-header, .sticky-header { position: fixed; visibility: h=
idden; margin-top: 0px; background-color: rgb(255, 255, 255); }

.form-table__sticky-header.is-sticky, .form-table__sticky-header--is-sticky=
, .is-sticky.sticky-header { visibility: visible; }

.form-table__header, .form-table th, form table th { border-bottom: 3px sol=
id rgb(204, 204, 204); padding-right: 1em; text-align: left; }

[dir=3D"rtl"] .form-table__header, [dir=3D"rtl"] .form-table th, .form-tabl=
e [dir=3D"rtl"] th, [dir=3D"rtl"] form table th, form [dir=3D"rtl"] table t=
h, form table [dir=3D"rtl"] th { text-align: right; padding-left: 1em; padd=
ing-right: 0px; }

.form-table__body, .form-table tbody, form table tbody { border-top: 1px so=
lid rgb(204, 204, 204); }

.form-table__row, .form-table tbody tr, form table tbody tr { padding: 0.1e=
m 0.6em; border-bottom: 1px solid rgb(204, 204, 204); background-color: rgb=
(238, 238, 238); }

.form-table__row-even, .form-table tbody tr:nth-child(2n), form table tbody=
 tr:nth-child(2n) { background-color: rgb(255, 255, 255); }

.form-table__list, .form-table ul, form table ul { margin: 0px; }

.form-table__narrow-column, td .checkbox, th .checkbox, .form-table th.form=
-table__narrow-column, form table th.form-table__narrow-column { width: -we=
bkit-min-content; text-align: center; }

td.active { background-color: rgb(221, 221, 221); }

td.menu-disabled { background: rgb(204, 204, 204); }

tr.selected td { background: rgb(255, 250, 219); }

#nir-header__logo { float: left; margin: 0px 10px 0px 0px; padding: 0px; }

[dir=3D"rtl"] #nir-header__logo { float: right; margin: 0px 0px 0px 10px; }

#nir-header__logo-image { vertical-align: bottom; }

#nir-header__name-and-slogan { float: left; }

#nir-header__site-name { margin: 0px; }

#nir-header__site-link:link, #nir-header__site-link:visited { color: rgb(0,=
 0, 0); text-decoration: none; }

#nir-header__site-link:hover, #nir-header__site-link:focus { text-decoratio=
n: underline; }

#nir-header__site-slogan { margin: 0px; }

#nir-header__secondary-menu { float: right; }

[dir=3D"rtl"] #nir-header__secondary-menu { float: left; }

#nir-header__region { clear: both; }

.messages, .messages--error, .messages.error, .messages--warning, .messages=
.warning, .messages--status { margin: 1.42857em 0px; position: relative; pa=
dding: 10px 10px 10px 44px; border: 1px solid rgb(0, 96, 126); width: 100%;=
 float: left; }

[dir=3D"rtl"] .messages, [dir=3D"rtl"] .messages--error, [dir=3D"rtl"] .mes=
sages--warning, [dir=3D"rtl"] .messages--status { padding: 10px 44px 10px 1=
0px; background-position: 99% 8px; }

.messages__icon { position: absolute; top: 50%; left: 10px; height: 24px; w=
idth: 24px; margin-top: -12px; line-height: 1; }

[dir=3D"rtl"] .messages__icon { left: auto; right: 0px; }

.messages__icon path { fill: rgb(0, 96, 126); }

.messages__list { margin: 0px; }

.messages__item { list-style-image: none; }

.messages--ok-color, .revision-current, .ok, .messages, .messages--error, .=
messages.error, .messages--warning, .messages.warning, .messages--status { =
background-color: rgb(187, 239, 255); color: rgb(0, 96, 126); }

.messages--warning-color, .warning, .messages--warning, .messages.warning {=
 background-color: rgb(255, 252, 230); color: rgb(0, 0, 0); }

.messages--error-color, .error, .messages--error, .messages.error { backgro=
und-color: rgb(255, 240, 240); color: rgb(204, 0, 0); }

.messages--warning, .messages.warning { border-color: rgb(255, 221, 0); }

.messages--warning path, .messages.warning path { fill: rgb(255, 221, 0); }

.messages--error, .messages.error { border-color: rgb(204, 0, 0); }

.messages--error path, .messages.error path { fill: rgb(204, 0, 0); }

.messages--error__highlighted-text, .messages--error .error, .messages.erro=
r .error { color: rgb(0, 0, 0); }

@media print {
  .print-none, .toolbar, .action-links, .links, .book-navigation, .forum-to=
pic-navigation, .feed-icons { display: none; }
}

.sidebars .block { margin: 10px 0px; padding: 10px 0px; }

#content .block-system-main-block { margin: 10px 0px; clear: both; }

.node--type-person h3 { margin-top: 0px; }

.node--type-person .field--name-field-nir-person-company { margin-bottom: 1=
em; }

.node--type-person .field--name-field-nir-person-dir-details { margin-top: =
1em; }

.node--type-person .field--name-field-nir-person-dir-details .field-item { =
margin-bottom: 5px; }

.centered-header { border-bottom: 1px solid rgb(153, 153, 153); margin-bott=
om: 10px; width: 100%; float: right; margin-right: 0px; }

.centered-header .field--name-field-nir-committee-charter-date { font-weigh=
t: bold; font-size: smaller; }

.centered-header .field--name-field-nir-committee-document, .centered-heade=
r .field--name-field-nir-asset, .centered-header .field--name-field-nir-com=
mittee-link { text-align: right; }

.centered-header .field--name-field-nir-committee-document span a::before, =
.centered-header .field--name-field-nir-asset span a::before, .centered-hea=
der .field--name-field-nir-committee-link span a::before { font-size: 20px;=
 }

.centered-header .field--name-field-nir-asset a { font-weight: normal; }

.field--name-field-nir-committee-link a::before { content: "=EE=81=B7"; dis=
play: inline-block; text-decoration: none; color: rgb(0, 96, 126); }

.field--name-field-nir-committee-member { border-top: 1px solid rgb(153, 15=
3, 153); border-bottom: 1px solid rgb(153, 153, 153); float: left; width: 1=
00%; padding: 8px 0px; margin: 10px 0px 0px; }

.field--name-field-nir-committee-member span::before { font-size: 20px; pad=
ding-right: 0px; }

.commitee_member { border-right: 1px solid rgb(204, 204, 204); padding-righ=
t: 5px; margin-right: 5px; }

.commitee_member:last-child { border-right: 0px; }

.commitee_member span::before { font-size: 20px; padding-right: 0px; }

.add-event { margin-bottom: 15px; }

.field--name-field-nir-event-thumbnail img { border-left: 8px solid rgb(0, =
96, 126); padding-right: 15px; }

.field--name-field-nir-person-company { font-style: italic; }

.node--view-mode-full .field--name-field-nir-event-summary { font-weight: b=
old; color: rgb(102, 102, 102); }

.node--view-mode-full .field--name-field-nir-event-summary p:first-child { =
margin-top: 0px; }

.node--type-nir-event .node--type-nir-asset .field--name-field-nir-document=
 .field__item, .node--type-nir-event .node--type-nir-asset .field--name-fie=
ld-nir-ext-document .field__item { margin: 1em 0px; }

.node--type-nir-event h4 { margin: 0px 0px 5px; }

.node--type-nir-event .field--label-inline .field__label::after { content: =
""; }

.node--type-nir-event .field--name-field-nir-event-speaker-name { font-weig=
ht: bold; font-style: italic; float: left; width: 100%; }

.node--type-nir-event .field--name-field-nir-event-speaker-title { display:=
 inline-block; float: left; }

.node--type-nir-event .field--name-field-nir-event-speaker-co { display: in=
line-block; float: left; font-style: italic; }

.node--type-nir-event .field--name-field-nir-event-speaker-co { float: left=
; }

.node--type-nir-event p.address { margin: 0px; }

.node--type-nir-event .location-info { font-style: italic; color: rgb(102, =
102, 102); }

.node--type-nir-event .field--name-field-nir-event-loc-desc p, .node--type-=
nir-event .field--name-field-nir-event-rep-dial-notes p { margin: 0px; }

.node--type-nir-event .field__item > p { margin: 0px; }

.webcast-link { font-weight: bold; margin: 1em 0px; }

.speaker-name { font-weight: bold; font-style: italic; }

.speaker-title .field { display: inline-block; }

.speaker-group { float: left; margin-bottom: 1em; width: 100%; }

.field--name-field-nir-news-document a { font-weight: bold; }

.field--name-field-nir-document, .field--name-field-nir-news-document, .fie=
ld--name-field-nir-news-supp-format, .field--name-field-nir-news-supp-refer=
ences { font-weight: bold; }

.field--name-field-nir-document .field__item, .field--name-field-nir-news-d=
ocument .field__item, .field--name-field-nir-news-supp-format .field__item,=
 .field--name-field-nir-news-supp-references .field__item { margin-top: 5px=
; margin-bottom: 1em; }

.box__right .field__label { margin-bottom: 0.5em; }

.box__right .field--name-field-nir-tags .field__label { font-size: 11px; fl=
oat: left; margin-right: 0.5em; }

.field--name-field-nir-sec-form { font-size: 20px; line-height: 150%; }

.detail-group { line-height: 175%; }

.doc-group, .xbrl-group { line-height: 200%; }

.node--type-nir-sec-filing .field--name-field-nir-tags { margin: 0.5em 0px;=
 }

.node--type-nir-sec-filing .field--name-field-nir-tags a { color: rgb(51, 5=
1, 51); }

.add-outlook, .add-gcal { float: left; margin-top: 1em; }

.media-meta div { display: inline-block; }

.field--name-field-nir-multimedia-tags { float: left; width: 100%; margin-t=
op: 10px; }

.field--name-field-nir-multimedia-tags .field__label { font-size: 11px; flo=
at: left; margin-right: 0.5em; }

.field--name-field-nir-multimedia-item .file-link, .field--name-field-nir-m=
ultimedia-item .media-meta { float: left; display: inline-block; }

.field--name-field-nir-multimedia-item .filesize { padding-right: 5px; }

.field--name-field-nir-multimedia-item .media-meta { font-style: italic; fo=
nt-weight: normal; color: rgb(132, 114, 113); }

.field.field--name-field-nir-multimedia-item { margin: 1em 0px; }

.field.field--name-field-nir-multimedia-item a::before { font-size: 30px; m=
argin-bottom: 5px; float: left; }

.node--nir-multimedia--full h2 { margin-bottom: 0.75em; }

.node--nir-multimedia--full .two-col-node .node-left { max-width: 300px; fl=
oat: left; }

.node--nir-multimedia--full .two-col-node .node-right { float: left; }

.node--nir-multimedia--full .styled-tag__small a { color: rgb(51, 51, 51); =
}

.node--view-mode-nir-media-gallery-viewmode .field--name-field-nir-media-ga=
llery-tags { padding: 1em 0px; }

.node--view-mode-nir-media-gallery-viewmode .field--name-field-nir-media-ga=
llery-title { font-weight: bold; margin: 12px 0px; }

.node--view-mode-nir-media-gallery-viewmode .field--name-field-nir-media-ga=
llery-desc p:first-child { margin-top: 0px; }

.node--view-mode-nir-media-gallery-viewmode .field--name-field-nir-media-ga=
llery-desc p:last-child { margin-top: 0px; }

.field--name-field-nir-multimedia-item .filesize { display: none; }

.field--name-field-nir-multimedia-item .file-link { padding-right: 5px; }

.node--type-nir-multimedia .filesize { display: none; }

.view-search .filesize { display: none; }

.field--name-field-nir-multimedia-item .field__label { display: none; }

.historical-price-lookup-form .form-item, .stock-price-calculator-form .for=
m-item { float: left; display: inline-block; margin-right: 20px; position: =
relative; }

.historical-price-lookup-form .form-item label::after, .stock-price-calcula=
tor-form .form-item label::after { content: ":"; }

.historical-price-lookup-form .form-item label.option::after, .stock-price-=
calculator-form .form-item label.option::after { content: ""; }

.market-data-filter-form .form-item { float: left; display: inline-block; m=
argin-right: 20px; position: relative; }

.market-data-filter-form .form-item label::after { content: ":"; }

.market-data-filter-form .form-item.form-item-period-compare-one { padding-=
left: 25px; }

.market-data-filter-form .form-item.form-item-period-compare-one::before { =
content: "=EE=82=BA"; display: inline-block; text-decoration: none; color: =
rgb(0, 96, 126); }

.market-data-filter-form .form-item.form-item-period-compare-one::before { =
color: rgb(102, 102, 102); position: absolute; left: 0px; bottom: 0px; }

.market-data-filter-form .form-item.form-item-period-compare-one label { fo=
nt-size: 75%; color: rgb(102, 102, 102); }

.market-data-filter-form .form-item.form-item-period-compare-two { padding-=
left: 25px; }

.market-data-filter-form .form-item.form-item-period-compare-two::before { =
color: rgb(102, 102, 102); content: "to"; font-weight: bold; position: abso=
lute; left: 0px; bottom: 0px; }

.market-data-filter-form .form-item.form-item-period-compare-two label { fo=
nt-size: 75%; color: rgb(102, 102, 102); }

.market-data-filter-form input { margin: 2.8em 0em 1.42857em; }

.md-download { float: left; width: 100%; margin: 1em 0px; }

.md-download .filesize { margin-left: 0.5em; }

.historical-price-lookup-form .form-submit, .stock-price-calculator-form .f=
orm-submit { margin-top: 3.1em; }

@media (max-width: 481px) {
  .historical-price-lookup-form .form-wrapper { display: block; clear: both=
; }
  .historical-price-lookup-form .form-item { margin-right: 5px; margin-bott=
om: 0px; }
  .historical-price-lookup-form .form-submit { margin-top: 10px; }
}

.form-item-symbols-historical { max-width: 120px; }

.form-item-symbols-historical .form-select { max-width: 120px; }

.form-no-label { margin-top: 2.8em; }

.filter-row { float: left; width: 100%; }

.captcha-admin-links { float: left; width: 100%; }

.form-select { width: auto; }

.contact-form input[type=3D"text"], .contact-form input[type=3D"search"], .=
contact-form input[type=3D"tel"], .contact-form input[type=3D"url"], .conta=
ct-form input[type=3D"email"], .contact-form input[type=3D"password"], .con=
tact-form input[type=3D"date"], .contact-form input[type=3D"time"], .contac=
t-form input[type=3D"number"], .contact-form input[type=3D"datalist"] { wid=
th: 100%; }

.contact-form textarea, .contact-form select, .contact-form fieldset, .cont=
act-form .form-select { width: 100%; }

.asterisk::after { content: "*"; color: rgb(204, 0, 0); display: inline; ma=
rgin: 0px; }

.nir-email-alerts-signup-form input[type=3D"text"], .nir-email-alerts-signu=
p-form input[type=3D"search"], .nir-email-alerts-signup-form input[type=3D"=
tel"], .nir-email-alerts-signup-form input[type=3D"url"], .nir-email-alerts=
-signup-form input[type=3D"email"], .nir-email-alerts-signup-form input[typ=
e=3D"password"], .nir-email-alerts-signup-form input[type=3D"date"], .nir-e=
mail-alerts-signup-form input[type=3D"time"], .nir-email-alerts-signup-form=
 input[type=3D"number"], .nir-email-alerts-signup-form input[type=3D"datali=
st"] { width: 100%; }

.nir-email-alerts-signup-form .form-select { width: 100%; }

.nir-email-alerts-signup-form table { table-layout: fixed; }

.nir-email-alerts-signup-form table th { border-bottom: 0px; color: rgb(51,=
 51, 51); background: rgb(255, 255, 255); }

.nir-email-alerts-signup-form table th:first-child::after { content: "*"; c=
olor: rgb(204, 0, 0); display: inline; margin: 0px 0px 0px 5px; }

.nir-email-alerts-signup-form table th, .nir-email-alerts-signup-form table=
 td { padding: 5px 0px; }

.ipe-block-plugin-form select { color: rgb(51, 51, 51); padding: 1px 5px; m=
argin-bottom: 0.5em; appearance: menulist; }

.form-item-nir-email-alerts-unsubscribe-from-all { margin: 1em 0px; }

.form-item-nir-email-alerts-unsubscribe-from-all label { font-weight: bold;=
 }

.modal-content .field--name-field-nir-person-company, .modal-content .field=
--name-field-nir-person-dir-since { margin-bottom: 1em; }

.modal-content .field--name-field-nir-person-dir-details .field__item { mar=
gin: 0.4em 0px; }

.modal-content .field--name-field-nir-person-dir-details .field__item::befo=
re { font-size: 22px; }

.modal-content h3.full-name { margin-top: 0px; }

.modal-content a { color: rgb(0, 96, 126); }

.ui-dialog button, .ui-dialog button:hover { background: none; }

.bold-row { font-weight: bold; }

.table-title { float: left; width: 100%; }

.form-table, form table { table-layout: auto; }

.form-table tr, form table tr { vertical-align: top; }

.form-table tr:nth-child(2n+1), .form-table tr:nth-child(2n), form table tr=
:nth-child(2n+1), form table tr:nth-child(2n) { background-color: rgba(0, 0=
, 0, 0); }

.form-table tr.field-multiple-drag, form table tr.field-multiple-drag { pad=
ding: 15px 0px 0px; }

.form-table td.field-multiple-drag, form table td.field-multiple-drag { pad=
ding: 15px 0px 0px; }

.form-table__header, .form-table th, form table th { background-color: rgba=
(0, 0, 0, 0); }

.ipe-category-picker-top.active h4 { width: 100%; }

.ixbrl-link a::before, #ndq-content .ixbrl-link a::before { font-family: nd=
qfonticons; font-size: 26px; vertical-align: middle; padding-right: 5px; fo=
nt-weight: normal; text-decoration: none; }

.ixbrl-link a::before, #ndq-content .ixbrl-link a::before { content: "=EE=
=81=BD"; display: inline-block; text-decoration: none; color: rgb(0, 0, 0);=
 }

.nir-sec-header .sec-docs .file-link, .nir-sec-header .sec-docs .field.ixbr=
l-link, #ndq-content .nir-sec-header .sec-docs .file-link, #ndq-content .ni=
r-sec-header .sec-docs .field.ixbrl-link { display: inline-block; }

.nir-sec-header .sec-docs .ixbrl-link a, #ndq-content .nir-sec-header .sec-=
docs .ixbrl-link a { font-size: 0px; }

.nir-sec-header, #ndq-content .nir-sec-header { box-sizing: border-box; }

.toolbar--toggle--closed a::after, .toolbar--toggle--open a::after, .image-=
style-nir-toolbar-profile.empty-image::after, .nir-toolbar .site-name-tab >=
 a::after, .nir-toolbar .toolbar-item.local-tasks-tab > a > span::after, .n=
ir-toolbar .toolbar-item.help-tab > a > span::after, .toolbar-bar .nir-menu=
 > li.nir-menu-item--expanded > a::after, .top-link::after, .faq-acc-dl dt.=
opened::before, .faq-acc-dl .acc-title.opened::before, .acc-wrap dt.opened:=
:before, .acc-wrap .acc-title.opened::before, .faq-acc-dl dt::before, .faq-=
acc-dl .acc-title::before, .acc-wrap dt::before, .acc-wrap .acc-title::befo=
re, a.show-all.hide-all::after, a.show-all::after, .ndqicon-check-circle::b=
efore, .thank-you-page h1::before, .up-arrow::before, .right-arrow::before,=
 .add-gcal a::before, .add-outlook a::before, .html-link a::before, .asset-=
link a::before, .ndqicon__calculator1::before, span.ndqicon__calculator_aft=
er::after, .ndqicon__calculator_after::after, .ndqicon__calculator::before,=
 .ndqicon__independent_italic::before, .ndqicon__independent::before, .ndqi=
con__download::before, .ndqicon__member a::before, span.ndqicon__member::be=
fore, .ndqicon__chair3::before, .ndqicon__chair2::before, .ndqicon__chair1:=
:before, .ndqicon__chair::before, span.ndqicon__leaddir_after::after, .ndqi=
con__leaddir_after::after, .ndqicon__leaddir::before, span.ndqicon__vicecha=
ir_after::after, .ndqicon__vicechair_after::after, .ndqicon__vicechair::bef=
ore, span.ndqicon__cob_after::after, .ndqicon__cob a_after::after, .ndqicon=
__cob a::before, span.ndqicon__cob::before, span.ndqicon__chairperson_after=
::after, .ndqicon__chairperson a_after::after, .ndqicon__chairperson a::bef=
ore, span.ndqicon__chairperson::before, .widget-file--mime-application-zip:=
:before, .file--mime-application-zip a::before, .widget-file--mime-applicat=
ion-octet-stream::before, .file--mime-application-octet-stream a::before, .=
widget-file--mime-application-xml::before, .file--mime-application-xml a::b=
efore, .widget-file--mime-application-vnd-openxmlformats-officedocument-spr=
eadsheetml-sheet::before, .file--mime-application-vnd-openxmlformats-office=
document-spreadsheetml-sheet a::before, .widget-file--mime-application-vnd-=
ms-excel-sheet-macroEnabled-12::before, .file--mime-application-vnd-ms-exce=
l-sheet-macroEnabled-12 a::before, .widget-file--xls::before, .file--xls a:=
:before, .widget-file--x-office-spreadsheet::before, .file--x-office-spread=
sheet a::before, .market-data-file-download-xls::before, .widget-file--mime=
-video-x-ms-wmv::before, .file--mime-video-x-ms-wmv a::before, .widget-file=
--mime-audio-x-ms-wma::before, .file--mime-audio-x-ms-wma a::before, .widge=
t-file--mime-audio-x-wav::before, .file--mime-audio-x-wav a::before, .widge=
t-file--text::before, .file--text a::before, .widget-file--mime-image-tiff:=
:before, .file--mime-image-tiff a::before, .widget-file--swf::before, .file=
--swf a::before, .widget-file--rtx::before, .file--rtx a::before, .widget-f=
ile--mime-application-rtf::before, .file--mime-application-rtf a::before, .=
widget-file--mime-application-rar::before, .file--mime-application-rar a::b=
efore, .widget-file--mime-application-vnd-ms-powerpoint-presentation-macroE=
nabled-12::before, .file--mime-application-vnd-ms-powerpoint-presentation-m=
acroEnabled-12 a::before, .widget-file--mime-application-vnd-openxmlformats=
-officedocument-presentationml-slideshow::before, .file--mime-application-v=
nd-openxmlformats-officedocument-presentationml-slideshow a::before, .widge=
t-file--mime-application-vnd-openxmlformats-officedocument-presentationml-p=
resentation::before, .file--mime-application-vnd-openxmlformats-officedocum=
ent-presentationml-presentation a::before, .widget-file--mime-application-v=
nd-ms-powerpoint::before, .file--mime-application-vnd-ms-powerpoint a::befo=
re, .widget-file--mime-image-png::before, .file--mime-image-png a::before, =
.widget-file--application-pdf::before, .file--application-pdf a::before, .w=
idget-file--odt::before, .file--odt a::before, .widget-file--mpg::before, .=
file--mpg a::before, .widget-file--mime-audio-mpeg::before, .file--mime-aud=
io-mpeg a::before, .widget-file--mime-video-quicktime::before, .file--mime-=
video-quicktime a::before, .widget-file--mime-application-x-mobipocket-eboo=
k::before, .file--mime-application-x-mobipocket-ebook a::before, .widget-fi=
le--mime-application-pgp-keys::before, .file--mime-application-pgp-keys a::=
before, .widget-file--mime-image-jpeg::before, .widget-file--mime-image-jpg=
::before, .file--mime-image-jpeg a::before, .file--mime-image-jpg a::before=
, .widget-file--ics::before, .file--ics a::before, .widget-file--mime-image=
-gif::before, .file--mime-image-gif a::before, .widget-file--mime-video-x-f=
lv::before, .file--mime-video-x-flv a::before, .widget-file--fla::before, .=
file--fla a::before, .widget-file--mime-application-epub::before, .file--mi=
me-application-epub a::before, .widget-file--mime-application-postscript::b=
efore, .file--mime-application-postscript a::before, .widget-file--mime-app=
lication-vnd-openxmlformats-officedocument-wordprocessingml-document::befor=
e, .file--mime-application-vnd-openxmlformats-officedocument-wordprocessing=
ml-document a::before, .widget-file--mime-application-msword::before, .file=
--mime-application-msword a::before, .widget-file--mime-text-csv::before, .=
file--mime-text-csv a::before, .file--mime-text-csv.file--text a::before, .=
market-data-file-download-csv::before, .widget-file--mime-image-x-ms-bmp::b=
efore, .file--mime-image-x-ms-bmp a::before, .widget-file--mime-video-x-ms-=
asf::before, .file--mime-video-x-ms-asf a::before, .widget-file--html::befo=
re, .field--name-field-nir-ext-document a::before, .field--name-field-nir-n=
ews-supp-ext-url a::before, .external-link::before, .webcast-link a::before=
, .normal-webcast-link a::before, a.nir-widget--news--accordion-toggle.open=
:hover::before, a.nir-widget--news--accordion-toggle.open::before, a.nir-wi=
dget--news--accordion-toggle:hover::before, a.nir-widget--news--accordion-t=
oggle::before, a.nir-widget--person--accordion-toggle.open:hover::before, a=
.nir-widget--person--accordion-toggle.open::before, a.nir-widget--person--a=
ccordion-toggle:hover::before, a.nir-widget--person--accordion-toggle::befo=
re, a.summary-toggle.open:hover::before, a.summary-toggle.open::before, a.s=
ummary-toggle:hover::before, a.summary-toggle::before, .ui-dialog-titlebar-=
close::before { font-family: ndqfonticons; font-size: 26px; vertical-align:=
 middle; padding-right: 5px; font-weight: normal; text-decoration: none; }

.ui-dialog-titlebar-close::before { content: "=EE=80=93"; display: inline-b=
lock; text-decoration: none; }

.ui-dialog-titlebar-close::before { font-size: 20px; }

a.summary-toggle { font-weight: normal; cursor: pointer; }

a.summary-toggle::before { content: "=EE=81=8D"; display: inline-block; tex=
t-decoration: none; }

a.summary-toggle:hover::before { content: "=EE=81=8F"; display: inline-bloc=
k; text-decoration: none; }

a.summary-toggle::before, a.summary-toggle:hover::before { font-size: 15px;=
 line-height: 0; }

a.summary-toggle span { height: 1px; width: 1px; overflow: hidden; clip: re=
ct(1px, 1px, 1px, 1px); position: absolute !important; }

a.summary-toggle.open::before { content: "=EE=81=90"; display: inline-block=
; text-decoration: none; }

a.summary-toggle.open:hover::before { content: "=EE=81=8E"; display: inline=
-block; text-decoration: none; }

a.summary-toggle.open::before, a.summary-toggle.open:hover::before { font-s=
ize: 15px; line-height: 0; }

a.nir-widget--person--accordion-toggle { font-weight: normal; cursor: point=
er; }

a.nir-widget--person--accordion-toggle::before { content: "=EE=81=8D"; disp=
lay: inline-block; text-decoration: none; }

a.nir-widget--person--accordion-toggle:hover::before { content: "=EE=81=8F"=
; display: inline-block; text-decoration: none; }

a.nir-widget--person--accordion-toggle::before, a.nir-widget--person--accor=
dion-toggle:hover::before { font-size: 15px; line-height: 0; }

a.nir-widget--person--accordion-toggle span { height: 1px; width: 1px; over=
flow: hidden; clip: rect(1px, 1px, 1px, 1px); position: absolute !important=
; }

a.nir-widget--person--accordion-toggle.open::before { content: "=EE=81=90";=
 display: inline-block; text-decoration: none; }

a.nir-widget--person--accordion-toggle.open:hover::before { content: "=EE=
=81=8E"; display: inline-block; text-decoration: none; }

a.nir-widget--person--accordion-toggle.open::before, a.nir-widget--person--=
accordion-toggle.open:hover::before { font-size: 15px; line-height: 0; }

a.nir-widget--person--accordion-toggle + div { display: inline; }

a.nir-widget--news--accordion-toggle { font-weight: normal; cursor: pointer=
; }

a.nir-widget--news--accordion-toggle::before { content: "=EE=81=8D"; displa=
y: inline-block; text-decoration: none; }

a.nir-widget--news--accordion-toggle:hover::before { content: "=EE=81=8F"; =
display: inline-block; text-decoration: none; }

a.nir-widget--news--accordion-toggle::before, a.nir-widget--news--accordion=
-toggle:hover::before { font-size: 15px; line-height: 0; }

a.nir-widget--news--accordion-toggle span { height: 1px; width: 1px; overfl=
ow: hidden; clip: rect(1px, 1px, 1px, 1px); position: absolute !important; =
}

a.nir-widget--news--accordion-toggle.open::before { content: "=EE=81=90"; d=
isplay: inline-block; text-decoration: none; }

a.nir-widget--news--accordion-toggle.open:hover::before { content: "=EE=81=
=8E"; display: inline-block; text-decoration: none; }

a.nir-widget--news--accordion-toggle.open::before, a.nir-widget--news--acco=
rdion-toggle.open:hover::before { font-size: 15px; line-height: 0; }

.ndqicon-disable-link { margin-left: 30px; }

.ndqicon-disable-link a::before { margin-left: -30px; cursor: default !impo=
rtant; pointer-events: none !important; }

.ndqicon-hide-icon a::before { display: none !important; }

.summary-hidden { display: none; }

.webcast-link a::before, .normal-webcast-link a::before { content: "=EE=80=
=9C"; display: inline-block; text-decoration: none; }

.widget-file--html::before, .field--name-field-nir-ext-document a::before, =
.field--name-field-nir-news-supp-ext-url a::before, .external-link::before =
{ content: "=EE=81=B7"; display: inline-block; text-decoration: none; }

.widget-file--mime-video-x-ms-asf::before, .file--mime-video-x-ms-asf a::be=
fore { content: "=EE=84=83"; display: inline-block; text-decoration: none; =
}

.widget-file--mime-image-x-ms-bmp::before, .file--mime-image-x-ms-bmp a::be=
fore { content: "=EE=84=84"; display: inline-block; text-decoration: none; =
}

.widget-file--mime-text-csv::before, .file--mime-text-csv a::before, .file-=
-mime-text-csv.file--text a::before, .market-data-file-download-csv::before=
 { content: "=EE=81=B0"; display: inline-block; text-decoration: none; }

.widget-file--mime-application-msword::before, .file--mime-application-mswo=
rd a::before { content: "=EE=81=B2"; display: inline-block; text-decoration=
: none; }

.widget-file--mime-application-vnd-openxmlformats-officedocument-wordproces=
singml-document::before, .file--mime-application-vnd-openxmlformats-officed=
ocument-wordprocessingml-document a::before { content: "=EE=81=B3"; display=
: inline-block; text-decoration: none; }

.widget-file--mime-application-postscript::before, .file--mime-application-=
postscript a::before { content: "=EE=83=B5"; display: inline-block; text-de=
coration: none; }

.widget-file--mime-application-epub::before, .file--mime-application-epub a=
::before { content: "=EE=83=B6"; display: inline-block; text-decoration: no=
ne; }

.widget-file--fla::before, .file--fla a::before { content: "=EE=81=B4"; dis=
play: inline-block; text-decoration: none; }

.widget-file--mime-video-x-flv::before, .file--mime-video-x-flv a::before {=
 content: "=EE=81=B5"; display: inline-block; text-decoration: none; }

.widget-file--mime-image-gif::before, .file--mime-image-gif a::before { con=
tent: "=EE=82=80"; display: inline-block; text-decoration: none; }

.widget-file--ics::before, .file--ics a::before { content: "=EE=83=BE"; dis=
play: inline-block; text-decoration: none; }

.widget-file--mime-image-jpeg::before, .widget-file--mime-image-jpg::before=
, .file--mime-image-jpeg a::before, .file--mime-image-jpg a::before { conte=
nt: "=EE=81=BF"; display: inline-block; text-decoration: none; }

.widget-file--mime-application-pgp-keys::before, .file--mime-application-pg=
p-keys a::before { content: "=EE=83=BF"; display: inline-block; text-decora=
tion: none; }

.widget-file--mime-application-x-mobipocket-ebook::before, .file--mime-appl=
ication-x-mobipocket-ebook a::before { content: "=EE=83=B7"; display: inlin=
e-block; text-decoration: none; }

.widget-file--mime-video-quicktime::before, .file--mime-video-quicktime a::=
before { content: "=EE=83=B8"; display: inline-block; text-decoration: none=
; }

.widget-file--mime-audio-mpeg::before, .file--mime-audio-mpeg a::before { c=
ontent: "=EE=82=85"; display: inline-block; text-decoration: none; }

.widget-file--mpg::before, .file--mpg a::before { content: "=EE=83=B9"; dis=
play: inline-block; text-decoration: none; }

.widget-file--odt::before, .file--odt a::before { content: "=EE=83=BB"; dis=
play: inline-block; text-decoration: none; }

.widget-file--application-pdf::before, .file--application-pdf a::before { c=
ontent: "=EE=82=88"; display: inline-block; text-decoration: none; }

.widget-file--mime-image-png::before, .file--mime-image-png a::before { con=
tent: "=EE=82=82"; display: inline-block; text-decoration: none; }

.widget-file--mime-application-vnd-ms-powerpoint::before, .file--mime-appli=
cation-vnd-ms-powerpoint a::before { content: "=EE=82=89"; display: inline-=
block; text-decoration: none; }

.widget-file--mime-application-vnd-openxmlformats-officedocument-presentati=
onml-presentation::before, .file--mime-application-vnd-openxmlformats-offic=
edocument-presentationml-presentation a::before { content: "=EE=82=8B"; dis=
play: inline-block; text-decoration: none; }

.widget-file--mime-application-vnd-openxmlformats-officedocument-presentati=
onml-slideshow::before, .file--mime-application-vnd-openxmlformats-officedo=
cument-presentationml-slideshow a::before { content: "=EE=83=BC"; display: =
inline-block; text-decoration: none; }

.widget-file--mime-application-vnd-ms-powerpoint::before, .file--mime-appli=
cation-vnd-ms-powerpoint a::before { content: "=EE=82=8A"; display: inline-=
block; text-decoration: none; }

.widget-file--mime-application-vnd-ms-powerpoint-presentation-macroEnabled-=
12::before, .file--mime-application-vnd-ms-powerpoint-presentation-macroEna=
bled-12 a::before { content: "=EE=83=BD"; display: inline-block; text-decor=
ation: none; }

.widget-file--mime-application-rar::before, .file--mime-application-rar a::=
before { content: "=EE=84=82"; display: inline-block; text-decoration: none=
; }

.widget-file--mime-application-rtf::before, .file--mime-application-rtf a::=
before { content: "=EE=84=80"; display: inline-block; text-decoration: none=
; }

.widget-file--rtx::before, .file--rtx a::before { content: "=EE=84=81"; dis=
play: inline-block; text-decoration: none; }

.widget-file--swf::before, .file--swf a::before { content: "=EE=81=B6"; dis=
play: inline-block; text-decoration: none; }

.widget-file--mime-image-tiff::before, .file--mime-image-tiff a::before { c=
ontent: "=EE=82=81"; display: inline-block; text-decoration: none; }

.widget-file--text::before, .file--text a::before { content: "=EE=82=8C"; d=
isplay: inline-block; text-decoration: none; }

.widget-file--mime-audio-x-wav::before, .file--mime-audio-x-wav a::before {=
 content: "=EE=84=88"; display: inline-block; text-decoration: none; }

.widget-file--mime-audio-x-ms-wma::before, .file--mime-audio-x-ms-wma a::be=
fore { content: "=EE=84=85"; display: inline-block; text-decoration: none; =
}

.widget-file--mime-video-x-ms-wmv::before, .file--mime-video-x-ms-wmv a::be=
fore { content: "=EE=84=86"; display: inline-block; text-decoration: none; =
}

.widget-file--xls::before, .file--xls a::before, .widget-file--x-office-spr=
eadsheet::before, .file--x-office-spreadsheet a::before, .market-data-file-=
download-xls::before { content: "=EE=81=B9"; display: inline-block; text-de=
coration: none; }

.widget-file--mime-application-vnd-ms-excel-sheet-macroEnabled-12::before, =
.file--mime-application-vnd-ms-excel-sheet-macroEnabled-12 a::before { cont=
ent: "=EE=80=9F"; display: inline-block; text-decoration: none; }

.widget-file--mime-application-vnd-openxmlformats-officedocument-spreadshee=
tml-sheet::before, .file--mime-application-vnd-openxmlformats-officedocumen=
t-spreadsheetml-sheet a::before { content: "=EE=81=BB"; display: inline-blo=
ck; text-decoration: none; }

.widget-file--mime-application-xml::before, .file--mime-application-xml a::=
before { content: "=EE=81=BE"; display: inline-block; text-decoration: none=
; }

.node--type-nir-sec-filing .file--mime-application-xsd a::before, .node--ty=
pe-nir-sec-filing .file--mime-application-xml a::before { content: "=EE=81=
=BD"; color: rgb(123, 65, 189); }

.widget-file--mime-application-octet-stream::before, .file--mime-applicatio=
n-octet-stream a::before { content: "=EE=84=87"; display: inline-block; tex=
t-decoration: none; }

.widget-file--mime-application-zip::before, .file--mime-application-zip a::=
before { content: "=EE=82=8D"; display: inline-block; text-decoration: none=
; }

[class^=3D"ndqicon__"] a::before { font-size: 20px; }

.ndqicon__chairperson a::before, span.ndqicon__chairperson::before { conten=
t: "=EE=80=8B"; display: inline-block; text-decoration: none; }

.ndqicon__chairperson a_after::after { content: "=EE=80=8B"; display: inlin=
e-block; text-decoration: none; }

span.ndqicon__chairperson_after::after { content: "=EE=80=8B"; display: inl=
ine-block; text-decoration: none; }

.ndqicon__cob a::before, span.ndqicon__cob::before { content: "=EE=80=A8"; =
display: inline-block; text-decoration: none; }

.ndqicon__cob a_after::after { content: "=EE=80=A8"; display: inline-block;=
 text-decoration: none; }

span.ndqicon__cob_after::after { content: "=EE=80=A8"; display: inline-bloc=
k; text-decoration: none; }

.ndqicon__vicechair::before { content: "=EE=80=A7"; display: inline-block; =
text-decoration: none; }

.ndqicon__vicechair_after::after { content: "=EE=80=A7"; display: inline-bl=
ock; text-decoration: none; }

span.ndqicon__vicechair_after::after { content: "=EE=80=A7"; display: inlin=
e-block; text-decoration: none; }

.ndqicon__leaddir::before { content: "=EE=81=AA"; display: inline-block; te=
xt-decoration: none; }

.ndqicon__leaddir_after::after { content: "=EE=81=AA"; display: inline-bloc=
k; text-decoration: none; }

span.ndqicon__leaddir_after::after { content: "=EE=81=AA"; display: inline-=
block; text-decoration: none; }

.ndqicon__chair::before { content: "=EE=80=A8"; display: inline-block; text=
-decoration: none; }

.ndqicon__chair1::before { content: "=EE=81=AA"; display: inline-block; tex=
t-decoration: none; }

.ndqicon__chair2::before { content: "=EE=81=AB"; display: inline-block; tex=
t-decoration: none; }

.ndqicon__chair3::before { content: "=EE=81=AC"; display: inline-block; tex=
t-decoration: none; }

.ndqicon__member a::before, span.ndqicon__member::before { content: "=EE=80=
=8A"; display: inline-block; text-decoration: none; }

.ndqicon__download::before { content: "=EE=81=93"; display: inline-block; t=
ext-decoration: none; }

.ndqicon__independent::before { content: "=EE=80=8D"; display: inline-block=
; text-decoration: none; }

.ndqicon__independent_italic::before { content: "=EE=80=8E"; display: inlin=
e-block; text-decoration: none; }

.ndqicon__calculator::before { content: "=EE=80=B2"; display: inline-block;=
 text-decoration: none; }

.ndqicon__calculator_after::after { content: "=EE=80=B2"; display: inline-b=
lock; text-decoration: none; }

span.ndqicon__calculator_after::after { content: "=EE=80=B2"; display: inli=
ne-block; text-decoration: none; }

.ndqicon__calculator1::before { content: "=EE=80=AF"; display: inline-block=
; text-decoration: none; }

.icon-key { float: left; margin-top: 0px; }

.key-item { margin: 1em 0px; }

.key-item span::before { font-size: 20px; }

.html-link a::before, .asset-link a::before { content: "=EE=81=B7"; display=
: inline-block; text-decoration: none; }

.add-outlook a { font-size: 0px; }

.add-outlook a::before { content: "=EE=80=BF"; display: inline-block; text-=
decoration: none; }

.add-outlook a::before { background: rgb(255, 188, 0); color: rgb(255, 255,=
 255); font-size: 20px; width: 21px; height: 21px; text-align: center; padd=
ing-top: 5px; margin-right: 5px; padding-left: 5px; }

.add-gcal a { font-size: 0px; }

.add-gcal a::before { content: "=EE=80=9E"; display: inline-block; text-dec=
oration: none; }

.add-gcal a::before { background: rgb(221, 75, 57); color: rgb(255, 255, 25=
5); font-size: 20px; width: 21px; height: 21px; text-align: center; padding=
-top: 5px; margin-right: 5px; padding-left: 5px; }

.right-arrow::before { content: "=EE=84=8C"; display: inline-block; text-de=
coration: none; }

.right-arrow::before { font-size: 14px; }

.up-arrow::before { content: "=EE=81=92"; display: inline-block; text-decor=
ation: none; }

.up-arrow::before { font-size: 14px; }

.ndqicon-check-circle::before, .thank-you-page h1::before { content: "=EE=
=84=96"; display: inline-block; text-decoration: none; }

.ndqicon-check-circle::before, .thank-you-page h1::before { font-size: 22px=
; }

a.show-all::after { content: "=EE=80=92"; display: inline-block; text-decor=
ation: none; }

a.show-all::after { font-size: 14px; }

a.show-all.hide-all::after { content: "=EE=80=91"; display: inline-block; t=
ext-decoration: none; }

a.show-all.hide-all::after { font-size: 14px; }

.faq-acc-dl dt::before, .faq-acc-dl .acc-title::before, .acc-wrap dt::befor=
e, .acc-wrap .acc-title::before { content: "=EE=81=8D"; display: inline-blo=
ck; text-decoration: none; }

.faq-acc-dl dt::before, .faq-acc-dl .acc-title::before, .acc-wrap dt::befor=
e, .acc-wrap .acc-title::before { color: rgb(255, 255, 255); font-size: 14p=
x; }

.faq-acc-dl dt.opened::before, .faq-acc-dl .acc-title.opened::before, .acc-=
wrap dt.opened::before, .acc-wrap .acc-title.opened::before { content: "=EE=
=81=90"; display: inline-block; text-decoration: none; }

.faq-acc-dl dt.opened::before, .faq-acc-dl .acc-title.opened::before, .acc-=
wrap dt.opened::before, .acc-wrap .acc-title.opened::before { color: rgb(25=
5, 255, 255); font-size: 14px; }

.top-link::after { content: "=EE=81=92"; display: inline-block; text-decora=
tion: none; }

.top-link::after { font-size: 14px; margin-top: -4px; }

.file--mime-application-pdf a, .webcast-link a, .file--mime-application-rtf=
 a, .file--mime-application-vnd-ms-excel a, .html-link a::before, .file--mi=
me-application-xml a, .field--name-field-nir-ext-document a, .file--mime-te=
xt-csv a { text-decoration: none !important; }

.file--mime-application-pdf a:hover, .webcast-link a:hover, .file--mime-app=
lication-rtf a:hover, .file--mime-application-vnd-ms-excel a:hover, .html-l=
ink a:hover, .file--mime-application-xml a:hover, .field--name-field-nir-ex=
t-document a:hover, .file--mime-text-csv a:hover { text-decoration: none !i=
mportant; }

.file--mime-application-pdf a span, .webcast-link a span, .file--mime-appli=
cation-rtf a span, .file--mime-application-vnd-ms-excel a span, .html-link =
a span, .file--mime-application-xml a span, .field--name-field-nir-ext-docu=
ment a span, .file--mime-text-csv a span, .file--mime-application-pdf a:hov=
er span, .webcast-link a:hover span, .file--mime-application-rtf a:hover sp=
an, .file--mime-application-vnd-ms-excel a:hover span, .html-link a:hover s=
pan, .file--mime-application-xml a:hover span, .field--name-field-nir-ext-d=
ocument a:hover span, .file--mime-text-csv a:hover span { text-decoration: =
none; }

.visually-hidden, .toolbar-bar li > ul, .toolbar-item > ul { height: 1px; w=
idth: 1px; overflow: hidden; clip: rect(1px, 1px, 1px, 1px); }

.visually-hidden--off, .toolbar-bar li > ul--off, .toolbar-item > ul--off {=
 clip: auto; height: auto; width: auto; overflow: auto; }

.toolbar-bar li > ul.visually-hidden--off, .toolbar-item > ul.visually-hidd=
en--off { clip: auto; height: auto; width: auto; overflow: auto; }

.toolbar--wrapper div, .toolbar--wrapper ul, .toolbar--wrapper li, .toolbar=
--wrapper a { font-size: 14px; font-family: "Helvetica Neue", Helvetica, Ar=
ial, sans-serif !important; }

.toolbar--wrapper a:link, .toolbar--wrapper a:visited { color: rgb(0, 158, =
194); font-weight: normal; }

.toolbar--wrapper a:link.bold-link, .toolbar--wrapper a:visited.bold-link {=
 font-weight: bold; }

.toolbar-bar { background: rgb(29, 30, 37) !important; height: 56px !import=
ant; }

.toolbar-bar a:focus { text-decoration: none !important; }

.toolbar-bar .nir-menu > li { display: inline-block !important; float: left=
 !important; padding: 0px !important; text-align: left !important; margin: =
0px !important; }

.toolbar-bar .nir-menu > li.nir-menu-item--expanded > a::after { content: "=
=EE=81=90"; display: inline-block; text-decoration: none; }

.toolbar-bar .nir-menu > li.nir-menu-item--expanded > a::after { font-size:=
 16px !important; }

.toolbar-bar .nir-menu > li.nir-menu-item--expanded > a:hover::after { colo=
r: rgb(0, 188, 227) !important; }

.toolbar-bar .nir-menu > li a { color: rgb(255, 255, 255) !important; font-=
size: 1.15em !important; line-height: 1 !important; padding: 19px 7px !impo=
rtant; transition: 0.15s ease-in-out !important; text-decoration: none !imp=
ortant; display: block !important; text-align: left !important; font-family=
: "Helvetica Neue", Helvetica, Arial, sans-serif !important; margin: 0px !i=
mportant; }

.toolbar-bar .nir-menu > li a:hover { color: rgb(0, 188, 227) !important; t=
ext-decoration: none !important; }

.toolbar-bar .nir-menu > li a.menu-open { background-color: rgb(17, 18, 23)=
 !important; color: rgb(0, 188, 227) !important; text-decoration: none !imp=
ortant; }

.toolbar-bar .nir-menu > li a.menu-open::after { color: rgb(0, 188, 227) !i=
mportant; }

.toolbar-bar .nir-menu > li ul { box-shadow: rgba(0, 0, 0, 0.2) 0px 5px 10p=
x !important; background: rgb(255, 255, 255) !important; position: absolute=
 !important; padding-top: 3px !important; margin: 0px !important; width: 20=
0px !important; padding-left: 0px !important; }

.toolbar-bar .nir-menu > li ul li { float: left !important; width: 100% !im=
portant; margin: 0px !important; }

.toolbar-bar .nir-menu > li ul li:hover { background: rgb(69, 150, 153) !im=
portant; }

.toolbar-bar .nir-menu > li ul li:hover a { color: rgb(255, 255, 255) !impo=
rtant; transition: none !important; }

.toolbar-bar .nir-menu > li ul a { color: rgb(51, 51, 51) !important; font-=
size: 14px !important; padding: 10px 20px !important; }

.toolbar-bar .nir-menu > li.nir-menu-item--site-status a:hover { color: rgb=
(255, 255, 255) !important; }

.toolbar-bar .nir-menu > li.nir-menu-item--site-status--secondary a { color=
: rgb(0, 0, 0) !important; }

.toolbar-bar > .nir-menu { display: inline !important; font-size: 14px !imp=
ortant; font-family: "Helvetica Neue", Helvetica, Arial, sans-serif !import=
ant; margin: 0px !important; line-height: 56px !important; float: left !imp=
ortant; padding-left: 0px !important; }

.toolbar-bar > .nir-menu > li:first-child a { padding-left: 15px !important=
; }

.nir-toolbar { -webkit-font-smoothing: antialiased !important; position: re=
lative !important; z-index: 2147483647 !important; box-shadow: rgba(0, 0, 0=
, 0.333) -1px 0px 3px 1px !important; font-family: "Helvetica Neue", Helvet=
ica, Arial, sans-serif !important; }

.nir-toolbar a.menu-open { background-color: rgb(17, 18, 23) !important; co=
lor: rgb(0, 188, 227) !important; text-decoration: none !important; }

.nir-toolbar a.menu-open::after { color: rgb(0, 188, 227) !important; }

.nir-toolbar .toolbar-item { position: relative !important; font-family: "H=
elvetica Neue", Helvetica, Arial, sans-serif !important; float: left !impor=
tant; height: 56px !important; padding: 0px !important; }

.nir-toolbar .toolbar-item h2, .nir-toolbar .toolbar-item h3 { display: inl=
ine-block !important; margin: 10px 0px !important; }

.nir-toolbar .toolbar-item > a { display: inline-block !important; padding:=
 20px 14px !important; color: rgb(255, 255, 255) !important; font-size: 1.1=
5em !important; font-weight: normal !important; line-height: 1 !important; =
transition: 0.15s ease-in-out !important; }

.nir-toolbar .toolbar-item > a:hover { color: rgb(0, 188, 227) !important; =
text-decoration: none !important; }

.nir-toolbar .toolbar-item ul { font-size: 12px !important; font-weight: no=
rmal !important; box-shadow: rgba(0, 0, 0, 0.2) 0px 5px 10px !important; ba=
ckground: rgb(255, 255, 255) !important; position: absolute !important; rig=
ht: 0px !important; padding-top: 0px !important; padding-left: 0px !importa=
nt; margin-top: 1px !important; width: 200px !important; overflow: hidden !=
important; }

.nir-toolbar .toolbar-item ul li { float: left !important; width: 100% !imp=
ortant; color: rgb(51, 51, 51) !important; }

.nir-toolbar .toolbar-item ul li .image-style-nir-toolbar-profile { float: =
left !important; margin-left: 20px !important; }

.nir-toolbar .toolbar-item ul li .profile-info { float: left !important; wi=
dth: 145px !important; }

.nir-toolbar .toolbar-item ul li .profile-info .menu-email { font-size: 12p=
x !important; }

.nir-toolbar .toolbar-item ul li .profile-info .user-name { font-size: 14px=
 !important; margin-bottom: 5px !important; }

.nir-toolbar .toolbar-item ul li a { color: rgb(51, 51, 51) !important; pad=
ding: 10px 20px !important; display: block !important; }

.nir-toolbar .toolbar-item ul li:hover { background: rgb(69, 150, 153) !imp=
ortant; }

.nir-toolbar .toolbar-item ul li:hover a { color: rgb(255, 255, 255) !impor=
tant; transition: none !important; text-decoration: none !important; }

.nir-toolbar .toolbar-item ul .user-profile-item { background-color: rgb(23=
8, 238, 238); padding: 20px 0px !important; }

.nir-toolbar .toolbar-item ul .user-profile-item a { padding: 0px !importan=
t; line-height: 13px !important; }

.nir-toolbar .toolbar-item ul .user-profile-item:hover { background-color: =
rgb(238, 238, 238) !important; cursor: default !important; }

.nir-toolbar .toolbar-item.user-tab > a { padding: 10px 14px !important; }

.nir-toolbar .toolbar-item.user-tab > a .user-name-tab { text-indent: -9999=
px !important; }

.nir-toolbar .toolbar-item.user-tab ul { width: 250px !important; }

.nir-toolbar .toolbar-item.user-tab div { display: inline-block !important;=
 }

.nir-toolbar .toolbar-item.help-tab > a { color: rgb(29, 30, 37) !important=
; padding: 16px 14px !important; border-right: 1px solid rgb(71, 74, 83) !i=
mportant; border-left: 1px solid rgb(71, 74, 83) !important; }

.nir-toolbar .toolbar-item.help-tab > a:hover { color: rgb(63, 135, 138) !i=
mportant; }

.nir-toolbar .toolbar-item.help-tab > a > span { border-radius: 50% !import=
ant; background: rgb(255, 255, 255) !important; height: 24px !important; wi=
dth: 24px !important; display: block !important; padding-left: 2px !importa=
nt; padding-top: 2px !important; }

.nir-toolbar .toolbar-item.help-tab > a > span::after { content: "=EE=82=B3=
"; display: inline-block; text-decoration: none; }

.nir-toolbar .toolbar-item.help-tab > a > span:hover::after { color: rgb(69=
, 150, 153) !important; }

.nir-toolbar .toolbar-item.help-tab > a > span::after { font-size: 20px !im=
portant; }

.nir-toolbar .toolbar-item.help-tab > a > span span { display: none; }

.nir-toolbar .toolbar-item.local-tasks-tab > a { color: rgb(29, 30, 37) !im=
portant; padding: 0px !important; border-right: 1px solid rgb(71, 74, 83) !=
important; border-left: 1px solid rgb(71, 74, 83) !important; }

.nir-toolbar .toolbar-item.local-tasks-tab > a:hover { color: rgb(69, 150, =
153) !important; }

.nir-toolbar .toolbar-item.local-tasks-tab > a.menu-open > span::after { co=
lor: rgb(63, 135, 138) !important; transform: rotate(45deg) !important; }

.nir-toolbar .toolbar-item.local-tasks-tab > a > span { height: 46px !impor=
tant; width: 54px !important; display: block !important; }

.nir-toolbar .toolbar-item.local-tasks-tab > a > span::after { content: "=
=E2=9C=8F"; display: inline-block; text-decoration: none; }

.nir-toolbar .toolbar-item.local-tasks-tab > a > span:hover::after { color:=
 rgb(63, 135, 138) !important; }

.nir-toolbar .toolbar-item.local-tasks-tab > a > span::after { transition: =
transform 0.5s; line-height: 21px; text-align: center; align-items: center;=
 display: block; font-size: 40px !important; color: rgb(255, 255, 255) !imp=
ortant; transform: rotate(-45deg) !important; margin: 10px 8px 11px !import=
ant; height: 35px !important; width: 35px !important; padding: 0px !importa=
nt; }

.nir-toolbar .toolbar-item.local-tasks-tab > a > span span { display: none =
!important; }

.nir-toolbar .toolbar-bar .nir-toolbar-tab > .toolbar-item:hover, .nir-tool=
bar .toolbar-bar .nir-toolbar-tab > .toolbar-item:hover { background-color:=
 rgb(17, 18, 23) !important; background-image: none !important; }

.nir-toolbar .site-name-tab { border-top-style: solid !important; border-to=
p-width: 4px !important; }

.nir-toolbar .site-name-tab.secondary { border-top-color: rgb(255, 221, 0) =
!important; }

.nir-toolbar .site-name-tab.primary { border-top-color: rgb(25, 183, 114) !=
important; }

.nir-toolbar .site-name-tab.local { border-top-color: rgb(218, 53, 59); }

.nir-toolbar .site-name-tab > a { padding: 16px 4px 19px 10px !important; f=
ont-size: 1em !important; }

.nir-toolbar .site-name-tab > a::after { content: "=EE=80=92"; display: inl=
ine-block; text-decoration: none; }

.nir-toolbar .site-name-tab > a::after { font-size: 14px !important; }

.nir-toolbar .site-name-tab > a:hover::after { color: rgb(63, 135, 138) !im=
portant; }

.local-tasks-sidebar--wrapper { position: absolute; right: 0px; width: 200p=
x; background: rgb(238, 238, 238); z-index: 100; transition-property: width=
; transition-delay: 0.4s; bottom: 0px; top: 93px; }

.local-tasks-sidebar--wrapper.toolbar--closed { top: 0px; }

.local-tasks-sidebar--wrapper--closed { width: 0px; }

.local-tasks-sidebar--wrapper--open { box-shadow: rgba(0, 0, 0, 0.333) -3px=
 0px 3px 1px !important; }

.local-tasks-sidebar--wrapper .menu-local-tasks--nir { padding: 15px; }

.local-tasks-sidebar--wrapper .tabs.primary { margin-top: 15px; }

.local-tasks-sidebar--wrapper .tabs.primary a { background: none; }

.local-tasks-sidebar--wrapper .tabs.primary .tabs__tab.is-active { border-r=
adius: 0px; }

.local-tasks-sidebar--wrapper .tabs.primary .tabs__tab.is-active a { color:=
 rgb(17, 18, 23); }

.local-tasks-sidebar--wrapper .tabs.primary .tabs__tab { background: rgb(25=
4, 254, 254); border: 0px; margin: 5px 0px; text-align: center; }

.nir-logo { background: url("/profiles/nasdaqir/themes/custom/nir_base/src/=
img/west_logo.png") center center / 44px no-repeat !important; text-indent:=
 -9999px !important; display: inline-block !important; width: 82px !importa=
nt; height: 56px !important; float: left !important; border-right: 1px soli=
d rgb(71, 74, 83) !important; }

#toolbar-item-administration { margin-left: 4px !important; border-left: 1p=
x solid rgb(102, 102, 102) !important; }

.image-style-nir-toolbar-profile { display: inline-block !important; height=
: 35px !important; width: 35px !important; margin: 0px 4px !important; over=
flow: hidden !important; border-radius: 50% !important; vertical-align: mid=
dle !important; }

.image-style-nir-toolbar-profile.empty-image { border: 1px solid rgb(255, 2=
55, 255) !important; }

.image-style-nir-toolbar-profile.empty-image::after { content: "=EE=80=8B";=
 display: inline-block; text-decoration: none; }

.image-style-nir-toolbar-profile.empty-image::after { color: rgb(255, 255, =
255) !important; font-size: 50px !important; margin-left: -9px !important; =
margin-top: -6px !important; }

.user-profile-item .image-style-nir-toolbar-profile.empty-image { border: 1=
px solid rgb(204, 204, 204) !important; }

.user-profile-item .image-style-nir-toolbar-profile::after { color: rgb(204=
, 204, 204) !important; margin-left: -9px !important; margin-top: 13px !imp=
ortant; }

.secondary-toolbar { padding: 10px !important; font-size: 16px !important; =
width: 100% !important; position: relative !important; right: 0px !importan=
t; left: 0px !important; top: 0px !important; z-index: 500 !important; heig=
ht: 37px !important; }

.secondary-toolbar div, .secondary-toolbar span, .secondary-toolbar a { fon=
t-family: "Helvetica Neue", Helvetica, Arial, sans-serif !important; font-s=
ize: 1em !important; }

.secondary-toolbar .environment { float: left !important; font-size: 1em !i=
mportant; }

.secondary-toolbar--local { background: rgb(240, 91, 91) !important; color:=
 rgb(255, 255, 255) !important; }

.secondary-toolbar--uat { background: rgb(55, 183, 119) !important; color: =
rgb(255, 255, 255) !important; }

.secondary-toolbar--test { background: rgb(69, 150, 153) !important; color:=
 rgb(255, 255, 255) !important; }

.secondary-toolbar--dev { background: rgb(192, 66, 248) !important; color: =
rgb(255, 255, 255) !important; }

.secondary-toolbar--nasdaqbeta { background: rgb(254, 203, 36) !important; =
}

@media only screen and (max-width: 500px) {
  .secondary-toolbar .environment { display: none !important; }
}

.nir-menu-item--site-status { pointer-events: none !important; cursor: defa=
ult !important; }

.nir-menu-item--site-status--secondary { background: rgb(254, 203, 36) !imp=
ortant; }

.nir-menu-item--site-status--primary { background: rgb(55, 183, 119) !impor=
tant; }

.nir-notification { float: right !important; margin-left: 5px !important; b=
ackground: rgb(255, 255, 255) !important; line-height: 1.2 !important; bord=
er-radius: 3px !important; color: rgb(0, 0, 0) !important; display: inline-=
block !important; font-size: 0.8em !important; padding: 0px 3px 0px 0px !im=
portant; }

.nir-notification a { line-height: inherit !important; }

.secondary-toolbar .nir-notification--text { margin-left: 3px !important; f=
ont-size: 0.8em !important; }

.nir-notification--text { margin-left: 3px !important; }

.nir-notification--status { border-radius: 50% !important; display: inline-=
block !important; width: 10px !important; height: 10px !important; border: =
1px solid rgb(255, 255, 255) !important; margin-left: 3px !important; }

.nir-notification--status--off { background: rgb(240, 91, 91) !important; }

.nir-notification--status--on { background: rgb(55, 183, 119) !important; }

.toolbar--toggle { right: 30px; position: absolute !important; display: blo=
ck !important; width: 20px !important; height: 20px !important; background:=
 rgb(0, 0, 0) !important; margin: 0px 5px !important; border-radius: 0px 0p=
x 3px 3px !important; }

.toolbar--toggle--open a::after { content: "=EE=81=92"; display: inline-blo=
ck; text-decoration: none; }

.toolbar--toggle--closed a::after { content: "=EE=81=90"; display: inline-b=
lock; text-decoration: none; }

.toolbar--toggle a::after { color: rgb(255, 255, 255) !important; font-size=
: 20px !important; }

.toolbar--toggle--text { display: none !important; }

.local-tasks-sidebar--toggle--text { display: none !important; }

@media only screen and (max-width: 363px) {
  .toolbar-item.help-tab { display: none !important; }
}

@media (min-width: 16.5em) {
  .nir-toolbar .toolbar-bar .nir-toolbar-tab, .nir-toolbar .toolbar-tray-ho=
rizontal li { float: right !important; }
}

@media only screen and (max-width: 64em) {
  .toolbar-bar .nir-logo { background-size: 30px !important; width: 50px !i=
mportant; }
  .toolbar-bar > .nir-menu > li > a { background-size: 27px !important; bac=
kground-repeat: no-repeat !important; background-position: center center !i=
mportant; text-indent: -9999px !important; padding: 19px 21px !important; }
  .toolbar-bar > .nir-menu > li:nth-child(1) > a { background-image: url("/=
profiles/nasdaqir/themes/custom/nir_base/src/img/file.svg") !important; }
  .toolbar-bar > .nir-menu > li:nth-child(2) > a { background-image: url("/=
profiles/nasdaqir/themes/custom/nir_base/src/img/orgchart.svg") !important;=
 }
  .toolbar-bar > .nir-menu > li:nth-child(3) > a { background-image: url("/=
profiles/nasdaqir/themes/custom/nir_base/src/img/wrench.svg") !important; }
  .toolbar-bar > .nir-menu > li:nth-child(4) > a { background-image: url("/=
profiles/nasdaqir/themes/custom/nir_base/src/img/barchart.svg") !important;=
 }
  .toolbar-bar .nir-menu > li ul { box-shadow: rgba(0, 0, 0, 0.2) 0px 5px 1=
0px !important; background: rgb(255, 255, 255) !important; position: fixed =
!important; padding-top: 3px !important; margin-top: 0px !important; margin=
-left: 0px !important; width: 200px !important; left: 0px !important; top: =
56px !important; }
  .toolbar-bar .nir-menu .nir-menu-item--site-status::before { display: blo=
ck !important; color: rgb(255, 255, 255) !important; font-size: 36px !impor=
tant; margin: 0px !important; padding: 0px 10px !important; }
  .toolbar-bar .nir-menu .nir-menu-item--site-status--primary::before { con=
tent: "P" !important; }
  .toolbar-bar .nir-menu .nir-menu-item--site-status--secondary::before { c=
ontent: "S" !important; color: rgb(0, 0, 0) !important; }
  .toolbar-bar .nir-menu .nir-menu-item--site-status a { display: none !imp=
ortant; }
  .nir-toolbar .toolbar-item.user-tab > a { padding: 10px 5px !important; }
  .nir-toolbar .toolbar-item.site-name-tab > a { background: url("/profiles=
/nasdaqir/themes/custom/nir_base/src/img/chevron-disc-left.svg") center cen=
ter / 27px no-repeat !important; width: 36px !important; text-indent: -9999=
px !important; }
  .nir-toolbar .toolbar-item.site-name-tab > ul { position: fixed !importan=
t; right: 0px !important; top: 56px !important; }
}

@media print, screen and (min-width: 40em) {
  .reveal, .reveal.tiny, .reveal.small, .reveal.large { right: auto; left: =
auto; margin: 0px auto; }
}

html { font-family: sans-serif; line-height: 1.15; text-size-adjust: 100%; =
}

body { margin: 0px; }

article, aside, footer, header, nav, section { display: block; }

h1 { font-size: 2em; margin: 0.67em 0px; }

figcaption, figure { display: block; }

figure { margin: 1em 40px; }

hr { box-sizing: content-box; height: 0px; overflow: visible; }

main { display: block; }

pre { font-family: monospace, monospace; font-size: 1em; }

a { background-color: transparent; }

a:active, a:hover { outline-width: 0px; }

abbr[title] { border-bottom: none; text-decoration: underline dotted; }

b, strong { font-weight: inherit; }

b, strong { font-weight: bolder; }

code, kbd, samp { font-family: monospace, monospace; font-size: 1em; }

dfn { font-style: italic; }

mark { background-color: rgb(255, 255, 0); color: rgb(0, 0, 0); }

small { font-size: 80%; }

sub, sup { font-size: 75%; line-height: 0; position: relative; vertical-ali=
gn: baseline; }

sub { bottom: -0.25em; }

sup { top: -0.5em; }

audio, video { display: inline-block; }

audio:not([controls]) { display: none; height: 0px; }

img { border-style: none; }

svg:not(:root) { overflow: hidden; }

button, input, optgroup, select, textarea { font-family: sans-serif; font-s=
ize: 100%; line-height: 1.15; margin: 0px; }

button { overflow: visible; }

button, select { text-transform: none; }

button, html [type=3D"button"], [type=3D"reset"], [type=3D"submit"] { appea=
rance: button; }

button, [type=3D"button"], [type=3D"reset"], [type=3D"submit"] { }

input { overflow: visible; }

[type=3D"checkbox"], [type=3D"radio"] { box-sizing: border-box; padding: 0p=
x; }

[type=3D"number"]::-webkit-inner-spin-button, [type=3D"number"]::-webkit-ou=
ter-spin-button { height: auto; }

[type=3D"search"] { appearance: textfield; outline-offset: -2px; }

[type=3D"search"]::-webkit-search-cancel-button, [type=3D"search"]::-webkit=
-search-decoration { appearance: none; }

::-webkit-file-upload-button { appearance: button; font: inherit; }

fieldset { border: 1px solid rgb(192, 192, 192); margin: 0px 2px; padding: =
0.35em 0.625em 0.75em; }

legend { box-sizing: border-box; display: table; max-width: 100%; padding: =
0px; color: inherit; white-space: normal; }

progress { display: inline-block; vertical-align: baseline; }

textarea { overflow: auto; }

details { display: block; }

summary { display: list-item; }

menu { display: block; }

canvas { display: inline-block; }

template { display: none; }

[hidden] { display: none; }

.foundation-mq { font-family: "small=3D0em&medium=3D40em&large=3D64em&xlarg=
e=3D75em&xxlarge=3D90em"; }

html { box-sizing: border-box; font-size: 100%; }

*, ::before, ::after { box-sizing: inherit; }

body { margin: 0px; padding: 0px; background: rgb(254, 254, 254); font-fami=
ly: "Helvetica Neue", Helvetica, Roboto, Arial, sans-serif; font-weight: no=
rmal; line-height: 1.5; color: rgb(10, 10, 10); -webkit-font-smoothing: ant=
ialiased; }

img { display: inline-block; vertical-align: middle; max-width: 100%; heigh=
t: auto; }

textarea { height: auto; min-height: 50px; border-radius: 0px; }

select { box-sizing: border-box; width: 100%; border-radius: 0px; }

.map_canvas img, .map_canvas embed, .map_canvas object, .mqa-display img, .=
mqa-display embed, .mqa-display object { max-width: none !important; }

button { padding: 0px; appearance: none; border: 0px; border-radius: 0px; b=
ackground: transparent; line-height: 1; cursor: auto; }

[data-whatinput=3D"mouse"] button { outline: 0px; }

pre { overflow: auto; }

button, input, optgroup, select, textarea { font-family: inherit; }

.is-visible { display: block !important; }

.is-hidden { display: none !important; }

.grid-container { padding-right: 0.625rem; padding-left: 0.625rem; max-widt=
h: 75rem; margin: 0px auto; }

@media print, screen and (min-width: 40em) {
  .grid-container { padding-right: 0.9375rem; padding-left: 0.9375rem; }
}

.grid-container.fluid { padding-right: 0.625rem; padding-left: 0.625rem; ma=
x-width: 100%; margin: 0px auto; }

@media print, screen and (min-width: 40em) {
  .grid-container.fluid { padding-right: 0.9375rem; padding-left: 0.9375rem=
; }
}

.grid-container.full { padding-right: 0px; padding-left: 0px; max-width: 10=
0%; margin: 0px auto; }

.grid-x { display: flex; flex-flow: wrap; }

.cell { flex: 0 0 auto; min-height: 0px; min-width: 0px; width: 100%; }

.cell.auto { flex: 1 1 0px; }

.cell.shrink { flex: 0 0 auto; }

.grid-x > .auto { width: auto; }

.grid-x > .shrink { width: auto; }

.grid-x > .small-shrink, .grid-x > .small-full, .grid-x > .small-1, .grid-x=
 > .small-2, .grid-x > .small-3, .grid-x > .small-4, .grid-x > .small-5, .g=
rid-x > .small-6, .grid-x > .small-7, .grid-x > .small-8, .grid-x > .small-=
9, .grid-x > .small-10, .grid-x > .small-11, .grid-x > .small-12 { flex-bas=
is: auto; }

@media print, screen and (min-width: 40em) {
  .grid-x > .medium-shrink, .grid-x > .medium-full, .grid-x > .medium-1, .g=
rid-x > .medium-2, .grid-x > .medium-3, .grid-x > .medium-4, .grid-x > .med=
ium-5, .grid-x > .medium-6, .grid-x > .medium-7, .grid-x > .medium-8, .grid=
-x > .medium-9, .grid-x > .medium-10, .grid-x > .medium-11, .grid-x > .medi=
um-12 { flex-basis: auto; }
}

@media print, screen and (min-width: 64em) {
  .grid-x > .large-shrink, .grid-x > .large-full, .grid-x > .large-1, .grid=
-x > .large-2, .grid-x > .large-3, .grid-x > .large-4, .grid-x > .large-5, =
.grid-x > .large-6, .grid-x > .large-7, .grid-x > .large-8, .grid-x > .larg=
e-9, .grid-x > .large-10, .grid-x > .large-11, .grid-x > .large-12 { flex-b=
asis: auto; }
}

.grid-x > .small-1 { width: 8.33333%; }

.grid-x > .small-2 { width: 16.6667%; }

.grid-x > .small-3 { width: 25%; }

.grid-x > .small-4 { width: 33.3333%; }

.grid-x > .small-5 { width: 41.6667%; }

.grid-x > .small-6 { width: 50%; }

.grid-x > .small-7 { width: 58.3333%; }

.grid-x > .small-8 { width: 66.6667%; }

.grid-x > .small-9 { width: 75%; }

.grid-x > .small-10 { width: 83.3333%; }

.grid-x > .small-11 { width: 91.6667%; }

.grid-x > .small-12 { width: 100%; }

@media print, screen and (min-width: 40em) {
  .grid-x > .medium-auto { flex: 1 1 0px; width: auto; }
  .grid-x > .medium-shrink { flex: 0 0 auto; width: auto; }
  .grid-x > .medium-1 { width: 8.33333%; }
  .grid-x > .medium-2 { width: 16.6667%; }
  .grid-x > .medium-3 { width: 25%; }
  .grid-x > .medium-4 { width: 33.3333%; }
  .grid-x > .medium-5 { width: 41.6667%; }
  .grid-x > .medium-6 { width: 50%; }
  .grid-x > .medium-7 { width: 58.3333%; }
  .grid-x > .medium-8 { width: 66.6667%; }
  .grid-x > .medium-9 { width: 75%; }
  .grid-x > .medium-10 { width: 83.3333%; }
  .grid-x > .medium-11 { width: 91.6667%; }
  .grid-x > .medium-12 { width: 100%; }
}

@media print, screen and (min-width: 64em) {
  .grid-x > .large-auto { flex: 1 1 0px; width: auto; }
  .grid-x > .large-shrink { flex: 0 0 auto; width: auto; }
  .grid-x > .large-1 { width: 8.33333%; }
  .grid-x > .large-2 { width: 16.6667%; }
  .grid-x > .large-3 { width: 25%; }
  .grid-x > .large-4 { width: 33.3333%; }
  .grid-x > .large-5 { width: 41.6667%; }
  .grid-x > .large-6 { width: 50%; }
  .grid-x > .large-7 { width: 58.3333%; }
  .grid-x > .large-8 { width: 66.6667%; }
  .grid-x > .large-9 { width: 75%; }
  .grid-x > .large-10 { width: 83.3333%; }
  .grid-x > .large-11 { width: 91.6667%; }
  .grid-x > .large-12 { width: 100%; }
}

.grid-margin-x:not(.grid-x) > .cell { width: auto; }

.grid-margin-y:not(.grid-y) > .cell { height: auto; }

.grid-margin-x { margin-left: -0.625rem; margin-right: -0.625rem; }

@media print, screen and (min-width: 40em) {
  .grid-margin-x { margin-left: -0.9375rem; margin-right: -0.9375rem; }
}

.grid-margin-x > .cell { width: calc(100% - 1.25rem); margin-left: 0.625rem=
; margin-right: 0.625rem; }

@media print, screen and (min-width: 40em) {
  .grid-margin-x > .cell { width: calc(100% - 1.875rem); margin-left: 0.937=
5rem; margin-right: 0.9375rem; }
}

.grid-margin-x > .auto { width: auto; }

.grid-margin-x > .shrink { width: auto; }

.grid-margin-x > .small-1 { width: calc(8.33333% - 1.25rem); }

.grid-margin-x > .small-2 { width: calc(16.6667% - 1.25rem); }

.grid-margin-x > .small-3 { width: calc(25% - 1.25rem); }

.grid-margin-x > .small-4 { width: calc(33.3333% - 1.25rem); }

.grid-margin-x > .small-5 { width: calc(41.6667% - 1.25rem); }

.grid-margin-x > .small-6 { width: calc(50% - 1.25rem); }

.grid-margin-x > .small-7 { width: calc(58.3333% - 1.25rem); }

.grid-margin-x > .small-8 { width: calc(66.6667% - 1.25rem); }

.grid-margin-x > .small-9 { width: calc(75% - 1.25rem); }

.grid-margin-x > .small-10 { width: calc(83.3333% - 1.25rem); }

.grid-margin-x > .small-11 { width: calc(91.6667% - 1.25rem); }

.grid-margin-x > .small-12 { width: calc(100% - 1.25rem); }

@media print, screen and (min-width: 40em) {
  .grid-margin-x > .auto { width: auto; }
  .grid-margin-x > .shrink { width: auto; }
  .grid-margin-x > .small-1 { width: calc(8.33333% - 1.875rem); }
  .grid-margin-x > .small-2 { width: calc(16.6667% - 1.875rem); }
  .grid-margin-x > .small-3 { width: calc(25% - 1.875rem); }
  .grid-margin-x > .small-4 { width: calc(33.3333% - 1.875rem); }
  .grid-margin-x > .small-5 { width: calc(41.6667% - 1.875rem); }
  .grid-margin-x > .small-6 { width: calc(50% - 1.875rem); }
  .grid-margin-x > .small-7 { width: calc(58.3333% - 1.875rem); }
  .grid-margin-x > .small-8 { width: calc(66.6667% - 1.875rem); }
  .grid-margin-x > .small-9 { width: calc(75% - 1.875rem); }
  .grid-margin-x > .small-10 { width: calc(83.3333% - 1.875rem); }
  .grid-margin-x > .small-11 { width: calc(91.6667% - 1.875rem); }
  .grid-margin-x > .small-12 { width: calc(100% - 1.875rem); }
  .grid-margin-x > .medium-auto { width: auto; }
  .grid-margin-x > .medium-shrink { width: auto; }
  .grid-margin-x > .medium-1 { width: calc(8.33333% - 1.875rem); }
  .grid-margin-x > .medium-2 { width: calc(16.6667% - 1.875rem); }
  .grid-margin-x > .medium-3 { width: calc(25% - 1.875rem); }
  .grid-margin-x > .medium-4 { width: calc(33.3333% - 1.875rem); }
  .grid-margin-x > .medium-5 { width: calc(41.6667% - 1.875rem); }
  .grid-margin-x > .medium-6 { width: calc(50% - 1.875rem); }
  .grid-margin-x > .medium-7 { width: calc(58.3333% - 1.875rem); }
  .grid-margin-x > .medium-8 { width: calc(66.6667% - 1.875rem); }
  .grid-margin-x > .medium-9 { width: calc(75% - 1.875rem); }
  .grid-margin-x > .medium-10 { width: calc(83.3333% - 1.875rem); }
  .grid-margin-x > .medium-11 { width: calc(91.6667% - 1.875rem); }
  .grid-margin-x > .medium-12 { width: calc(100% - 1.875rem); }
}

@media print, screen and (min-width: 64em) {
  .grid-margin-x > .large-auto { width: auto; }
  .grid-margin-x > .large-shrink { width: auto; }
  .grid-margin-x > .large-1 { width: calc(8.33333% - 1.875rem); }
  .grid-margin-x > .large-2 { width: calc(16.6667% - 1.875rem); }
  .grid-margin-x > .large-3 { width: calc(25% - 1.875rem); }
  .grid-margin-x > .large-4 { width: calc(33.3333% - 1.875rem); }
  .grid-margin-x > .large-5 { width: calc(41.6667% - 1.875rem); }
  .grid-margin-x > .large-6 { width: calc(50% - 1.875rem); }
  .grid-margin-x > .large-7 { width: calc(58.3333% - 1.875rem); }
  .grid-margin-x > .large-8 { width: calc(66.6667% - 1.875rem); }
  .grid-margin-x > .large-9 { width: calc(75% - 1.875rem); }
  .grid-margin-x > .large-10 { width: calc(83.3333% - 1.875rem); }
  .grid-margin-x > .large-11 { width: calc(91.6667% - 1.875rem); }
  .grid-margin-x > .large-12 { width: calc(100% - 1.875rem); }
}

.grid-padding-x .grid-padding-x { margin-right: -0.625rem; margin-left: -0.=
625rem; }

@media print, screen and (min-width: 40em) {
  .grid-padding-x .grid-padding-x { margin-right: -0.9375rem; margin-left: =
-0.9375rem; }
}

.grid-container:not(.full) > .grid-padding-x { margin-right: -0.625rem; mar=
gin-left: -0.625rem; }

@media print, screen and (min-width: 40em) {
  .grid-container:not(.full) > .grid-padding-x { margin-right: -0.9375rem; =
margin-left: -0.9375rem; }
}

.grid-padding-x > .cell { padding-right: 0.625rem; padding-left: 0.625rem; =
}

@media print, screen and (min-width: 40em) {
  .grid-padding-x > .cell { padding-right: 0.9375rem; padding-left: 0.9375r=
em; }
}

.small-up-1 > .cell { width: 100%; }

.small-up-2 > .cell { width: 50%; }

.small-up-3 > .cell { width: 33.3333%; }

.small-up-4 > .cell { width: 25%; }

.small-up-5 > .cell { width: 20%; }

.small-up-6 > .cell { width: 16.6667%; }

.small-up-7 > .cell { width: 14.2857%; }

.small-up-8 > .cell { width: 12.5%; }

@media print, screen and (min-width: 40em) {
  .medium-up-1 > .cell { width: 100%; }
  .medium-up-2 > .cell { width: 50%; }
  .medium-up-3 > .cell { width: 33.3333%; }
  .medium-up-4 > .cell { width: 25%; }
  .medium-up-5 > .cell { width: 20%; }
  .medium-up-6 > .cell { width: 16.6667%; }
  .medium-up-7 > .cell { width: 14.2857%; }
  .medium-up-8 > .cell { width: 12.5%; }
}

@media print, screen and (min-width: 64em) {
  .large-up-1 > .cell { width: 100%; }
  .large-up-2 > .cell { width: 50%; }
  .large-up-3 > .cell { width: 33.3333%; }
  .large-up-4 > .cell { width: 25%; }
  .large-up-5 > .cell { width: 20%; }
  .large-up-6 > .cell { width: 16.6667%; }
  .large-up-7 > .cell { width: 14.2857%; }
  .large-up-8 > .cell { width: 12.5%; }
}

.grid-margin-x.small-up-1 > .cell { width: calc(100% - 1.25rem); }

.grid-margin-x.small-up-2 > .cell { width: calc(50% - 1.25rem); }

.grid-margin-x.small-up-3 > .cell { width: calc(33.3333% - 1.25rem); }

.grid-margin-x.small-up-4 > .cell { width: calc(25% - 1.25rem); }

.grid-margin-x.small-up-5 > .cell { width: calc(20% - 1.25rem); }

.grid-margin-x.small-up-6 > .cell { width: calc(16.6667% - 1.25rem); }

.grid-margin-x.small-up-7 > .cell { width: calc(14.2857% - 1.25rem); }

.grid-margin-x.small-up-8 > .cell { width: calc(12.5% - 1.25rem); }

@media print, screen and (min-width: 40em) {
  .grid-margin-x.small-up-1 > .cell { width: calc(100% - 1.25rem); }
  .grid-margin-x.small-up-2 > .cell { width: calc(50% - 1.25rem); }
  .grid-margin-x.small-up-3 > .cell { width: calc(33.3333% - 1.25rem); }
  .grid-margin-x.small-up-4 > .cell { width: calc(25% - 1.25rem); }
  .grid-margin-x.small-up-5 > .cell { width: calc(20% - 1.25rem); }
  .grid-margin-x.small-up-6 > .cell { width: calc(16.6667% - 1.25rem); }
  .grid-margin-x.small-up-7 > .cell { width: calc(14.2857% - 1.25rem); }
  .grid-margin-x.small-up-8 > .cell { width: calc(12.5% - 1.25rem); }
  .grid-margin-x.medium-up-1 > .cell { width: calc(100% - 1.875rem); }
  .grid-margin-x.medium-up-2 > .cell { width: calc(50% - 1.875rem); }
  .grid-margin-x.medium-up-3 > .cell { width: calc(33.3333% - 1.875rem); }
  .grid-margin-x.medium-up-4 > .cell { width: calc(25% - 1.875rem); }
  .grid-margin-x.medium-up-5 > .cell { width: calc(20% - 1.875rem); }
  .grid-margin-x.medium-up-6 > .cell { width: calc(16.6667% - 1.875rem); }
  .grid-margin-x.medium-up-7 > .cell { width: calc(14.2857% - 1.875rem); }
  .grid-margin-x.medium-up-8 > .cell { width: calc(12.5% - 1.875rem); }
}

@media print, screen and (min-width: 64em) {
  .grid-margin-x.large-up-1 > .cell { width: calc(100% - 1.875rem); }
  .grid-margin-x.large-up-2 > .cell { width: calc(50% - 1.875rem); }
  .grid-margin-x.large-up-3 > .cell { width: calc(33.3333% - 1.875rem); }
  .grid-margin-x.large-up-4 > .cell { width: calc(25% - 1.875rem); }
  .grid-margin-x.large-up-5 > .cell { width: calc(20% - 1.875rem); }
  .grid-margin-x.large-up-6 > .cell { width: calc(16.6667% - 1.875rem); }
  .grid-margin-x.large-up-7 > .cell { width: calc(14.2857% - 1.875rem); }
  .grid-margin-x.large-up-8 > .cell { width: calc(12.5% - 1.875rem); }
}

.small-margin-collapse { margin-right: 0px; margin-left: 0px; }

.small-margin-collapse > .cell { margin-right: 0px; margin-left: 0px; }

.small-margin-collapse > .small-1 { width: 8.33333%; }

.small-margin-collapse > .small-2 { width: 16.6667%; }

.small-margin-collapse > .small-3 { width: 25%; }

.small-margin-collapse > .small-4 { width: 33.3333%; }

.small-margin-collapse > .small-5 { width: 41.6667%; }

.small-margin-collapse > .small-6 { width: 50%; }

.small-margin-collapse > .small-7 { width: 58.3333%; }

.small-margin-collapse > .small-8 { width: 66.6667%; }

.small-margin-collapse > .small-9 { width: 75%; }

.small-margin-collapse > .small-10 { width: 83.3333%; }

.small-margin-collapse > .small-11 { width: 91.6667%; }

.small-margin-collapse > .small-12 { width: 100%; }

@media print, screen and (min-width: 40em) {
  .small-margin-collapse > .medium-1 { width: 8.33333%; }
  .small-margin-collapse > .medium-2 { width: 16.6667%; }
  .small-margin-collapse > .medium-3 { width: 25%; }
  .small-margin-collapse > .medium-4 { width: 33.3333%; }
  .small-margin-collapse > .medium-5 { width: 41.6667%; }
  .small-margin-collapse > .medium-6 { width: 50%; }
  .small-margin-collapse > .medium-7 { width: 58.3333%; }
  .small-margin-collapse > .medium-8 { width: 66.6667%; }
  .small-margin-collapse > .medium-9 { width: 75%; }
  .small-margin-collapse > .medium-10 { width: 83.3333%; }
  .small-margin-collapse > .medium-11 { width: 91.6667%; }
  .small-margin-collapse > .medium-12 { width: 100%; }
}

@media print, screen and (min-width: 64em) {
  .small-margin-collapse > .large-1 { width: 8.33333%; }
  .small-margin-collapse > .large-2 { width: 16.6667%; }
  .small-margin-collapse > .large-3 { width: 25%; }
  .small-margin-collapse > .large-4 { width: 33.3333%; }
  .small-margin-collapse > .large-5 { width: 41.6667%; }
  .small-margin-collapse > .large-6 { width: 50%; }
  .small-margin-collapse > .large-7 { width: 58.3333%; }
  .small-margin-collapse > .large-8 { width: 66.6667%; }
  .small-margin-collapse > .large-9 { width: 75%; }
  .small-margin-collapse > .large-10 { width: 83.3333%; }
  .small-margin-collapse > .large-11 { width: 91.6667%; }
  .small-margin-collapse > .large-12 { width: 100%; }
}

.small-padding-collapse { margin-right: 0px; margin-left: 0px; }

.small-padding-collapse > .cell { padding-right: 0px; padding-left: 0px; }

@media print, screen and (min-width: 40em) {
  .medium-margin-collapse { margin-right: 0px; margin-left: 0px; }
  .medium-margin-collapse > .cell { margin-right: 0px; margin-left: 0px; }
}

@media print, screen and (min-width: 40em) {
  .medium-margin-collapse > .small-1 { width: 8.33333%; }
  .medium-margin-collapse > .small-2 { width: 16.6667%; }
  .medium-margin-collapse > .small-3 { width: 25%; }
  .medium-margin-collapse > .small-4 { width: 33.3333%; }
  .medium-margin-collapse > .small-5 { width: 41.6667%; }
  .medium-margin-collapse > .small-6 { width: 50%; }
  .medium-margin-collapse > .small-7 { width: 58.3333%; }
  .medium-margin-collapse > .small-8 { width: 66.6667%; }
  .medium-margin-collapse > .small-9 { width: 75%; }
  .medium-margin-collapse > .small-10 { width: 83.3333%; }
  .medium-margin-collapse > .small-11 { width: 91.6667%; }
  .medium-margin-collapse > .small-12 { width: 100%; }
}

@media print, screen and (min-width: 40em) {
  .medium-margin-collapse > .medium-1 { width: 8.33333%; }
  .medium-margin-collapse > .medium-2 { width: 16.6667%; }
  .medium-margin-collapse > .medium-3 { width: 25%; }
  .medium-margin-collapse > .medium-4 { width: 33.3333%; }
  .medium-margin-collapse > .medium-5 { width: 41.6667%; }
  .medium-margin-collapse > .medium-6 { width: 50%; }
  .medium-margin-collapse > .medium-7 { width: 58.3333%; }
  .medium-margin-collapse > .medium-8 { width: 66.6667%; }
  .medium-margin-collapse > .medium-9 { width: 75%; }
  .medium-margin-collapse > .medium-10 { width: 83.3333%; }
  .medium-margin-collapse > .medium-11 { width: 91.6667%; }
  .medium-margin-collapse > .medium-12 { width: 100%; }
}

@media print, screen and (min-width: 64em) {
  .medium-margin-collapse > .large-1 { width: 8.33333%; }
  .medium-margin-collapse > .large-2 { width: 16.6667%; }
  .medium-margin-collapse > .large-3 { width: 25%; }
  .medium-margin-collapse > .large-4 { width: 33.3333%; }
  .medium-margin-collapse > .large-5 { width: 41.6667%; }
  .medium-margin-collapse > .large-6 { width: 50%; }
  .medium-margin-collapse > .large-7 { width: 58.3333%; }
  .medium-margin-collapse > .large-8 { width: 66.6667%; }
  .medium-margin-collapse > .large-9 { width: 75%; }
  .medium-margin-collapse > .large-10 { width: 83.3333%; }
  .medium-margin-collapse > .large-11 { width: 91.6667%; }
  .medium-margin-collapse > .large-12 { width: 100%; }
}

@media print, screen and (min-width: 40em) {
  .medium-padding-collapse { margin-right: 0px; margin-left: 0px; }
  .medium-padding-collapse > .cell { padding-right: 0px; padding-left: 0px;=
 }
}

@media print, screen and (min-width: 64em) {
  .large-margin-collapse { margin-right: 0px; margin-left: 0px; }
  .large-margin-collapse > .cell { margin-right: 0px; margin-left: 0px; }
}

@media print, screen and (min-width: 64em) {
  .large-margin-collapse > .small-1 { width: 8.33333%; }
  .large-margin-collapse > .small-2 { width: 16.6667%; }
  .large-margin-collapse > .small-3 { width: 25%; }
  .large-margin-collapse > .small-4 { width: 33.3333%; }
  .large-margin-collapse > .small-5 { width: 41.6667%; }
  .large-margin-collapse > .small-6 { width: 50%; }
  .large-margin-collapse > .small-7 { width: 58.3333%; }
  .large-margin-collapse > .small-8 { width: 66.6667%; }
  .large-margin-collapse > .small-9 { width: 75%; }
  .large-margin-collapse > .small-10 { width: 83.3333%; }
  .large-margin-collapse > .small-11 { width: 91.6667%; }
  .large-margin-collapse > .small-12 { width: 100%; }
}

@media print, screen and (min-width: 64em) {
  .large-margin-collapse > .medium-1 { width: 8.33333%; }
  .large-margin-collapse > .medium-2 { width: 16.6667%; }
  .large-margin-collapse > .medium-3 { width: 25%; }
  .large-margin-collapse > .medium-4 { width: 33.3333%; }
  .large-margin-collapse > .medium-5 { width: 41.6667%; }
  .large-margin-collapse > .medium-6 { width: 50%; }
  .large-margin-collapse > .medium-7 { width: 58.3333%; }
  .large-margin-collapse > .medium-8 { width: 66.6667%; }
  .large-margin-collapse > .medium-9 { width: 75%; }
  .large-margin-collapse > .medium-10 { width: 83.3333%; }
  .large-margin-collapse > .medium-11 { width: 91.6667%; }
  .large-margin-collapse > .medium-12 { width: 100%; }
}

@media print, screen and (min-width: 64em) {
  .large-margin-collapse > .large-1 { width: 8.33333%; }
  .large-margin-collapse > .large-2 { width: 16.6667%; }
  .large-margin-collapse > .large-3 { width: 25%; }
  .large-margin-collapse > .large-4 { width: 33.3333%; }
  .large-margin-collapse > .large-5 { width: 41.6667%; }
  .large-margin-collapse > .large-6 { width: 50%; }
  .large-margin-collapse > .large-7 { width: 58.3333%; }
  .large-margin-collapse > .large-8 { width: 66.6667%; }
  .large-margin-collapse > .large-9 { width: 75%; }
  .large-margin-collapse > .large-10 { width: 83.3333%; }
  .large-margin-collapse > .large-11 { width: 91.6667%; }
  .large-margin-collapse > .large-12 { width: 100%; }
}

@media print, screen and (min-width: 64em) {
  .large-padding-collapse { margin-right: 0px; margin-left: 0px; }
  .large-padding-collapse > .cell { padding-right: 0px; padding-left: 0px; =
}
}

.small-offset-0 { margin-left: 0%; }

.grid-margin-x > .small-offset-0 { margin-left: calc(0% + 0.625rem); }

.small-offset-1 { margin-left: 8.33333%; }

.grid-margin-x > .small-offset-1 { margin-left: calc(8.33333% + 0.625rem); =
}

.small-offset-2 { margin-left: 16.6667%; }

.grid-margin-x > .small-offset-2 { margin-left: calc(16.6667% + 0.625rem); =
}

.small-offset-3 { margin-left: 25%; }

.grid-margin-x > .small-offset-3 { margin-left: calc(25% + 0.625rem); }

.small-offset-4 { margin-left: 33.3333%; }

.grid-margin-x > .small-offset-4 { margin-left: calc(33.3333% + 0.625rem); =
}

.small-offset-5 { margin-left: 41.6667%; }

.grid-margin-x > .small-offset-5 { margin-left: calc(41.6667% + 0.625rem); =
}

.small-offset-6 { margin-left: 50%; }

.grid-margin-x > .small-offset-6 { margin-left: calc(50% + 0.625rem); }

.small-offset-7 { margin-left: 58.3333%; }

.grid-margin-x > .small-offset-7 { margin-left: calc(58.3333% + 0.625rem); =
}

.small-offset-8 { margin-left: 66.6667%; }

.grid-margin-x > .small-offset-8 { margin-left: calc(66.6667% + 0.625rem); =
}

.small-offset-9 { margin-left: 75%; }

.grid-margin-x > .small-offset-9 { margin-left: calc(75% + 0.625rem); }

.small-offset-10 { margin-left: 83.3333%; }

.grid-margin-x > .small-offset-10 { margin-left: calc(83.3333% + 0.625rem);=
 }

.small-offset-11 { margin-left: 91.6667%; }

.grid-margin-x > .small-offset-11 { margin-left: calc(91.6667% + 0.625rem);=
 }

@media print, screen and (min-width: 40em) {
  .medium-offset-0 { margin-left: 0%; }
  .grid-margin-x > .medium-offset-0 { margin-left: calc(0% + 0.9375rem); }
  .medium-offset-1 { margin-left: 8.33333%; }
  .grid-margin-x > .medium-offset-1 { margin-left: calc(8.33333% + 0.9375re=
m); }
  .medium-offset-2 { margin-left: 16.6667%; }
  .grid-margin-x > .medium-offset-2 { margin-left: calc(16.6667% + 0.9375re=
m); }
  .medium-offset-3 { margin-left: 25%; }
  .grid-margin-x > .medium-offset-3 { margin-left: calc(25% + 0.9375rem); }
  .medium-offset-4 { margin-left: 33.3333%; }
  .grid-margin-x > .medium-offset-4 { margin-left: calc(33.3333% + 0.9375re=
m); }
  .medium-offset-5 { margin-left: 41.6667%; }
  .grid-margin-x > .medium-offset-5 { margin-left: calc(41.6667% + 0.9375re=
m); }
  .medium-offset-6 { margin-left: 50%; }
  .grid-margin-x > .medium-offset-6 { margin-left: calc(50% + 0.9375rem); }
  .medium-offset-7 { margin-left: 58.3333%; }
  .grid-margin-x > .medium-offset-7 { margin-left: calc(58.3333% + 0.9375re=
m); }
  .medium-offset-8 { margin-left: 66.6667%; }
  .grid-margin-x > .medium-offset-8 { margin-left: calc(66.6667% + 0.9375re=
m); }
  .medium-offset-9 { margin-left: 75%; }
  .grid-margin-x > .medium-offset-9 { margin-left: calc(75% + 0.9375rem); }
  .medium-offset-10 { margin-left: 83.3333%; }
  .grid-margin-x > .medium-offset-10 { margin-left: calc(83.3333% + 0.9375r=
em); }
  .medium-offset-11 { margin-left: 91.6667%; }
  .grid-margin-x > .medium-offset-11 { margin-left: calc(91.6667% + 0.9375r=
em); }
}

@media print, screen and (min-width: 64em) {
  .large-offset-0 { margin-left: 0%; }
  .grid-margin-x > .large-offset-0 { margin-left: calc(0% + 0.9375rem); }
  .large-offset-1 { margin-left: 8.33333%; }
  .grid-margin-x > .large-offset-1 { margin-left: calc(8.33333% + 0.9375rem=
); }
  .large-offset-2 { margin-left: 16.6667%; }
  .grid-margin-x > .large-offset-2 { margin-left: calc(16.6667% + 0.9375rem=
); }
  .large-offset-3 { margin-left: 25%; }
  .grid-margin-x > .large-offset-3 { margin-left: calc(25% + 0.9375rem); }
  .large-offset-4 { margin-left: 33.3333%; }
  .grid-margin-x > .large-offset-4 { margin-left: calc(33.3333% + 0.9375rem=
); }
  .large-offset-5 { margin-left: 41.6667%; }
  .grid-margin-x > .large-offset-5 { margin-left: calc(41.6667% + 0.9375rem=
); }
  .large-offset-6 { margin-left: 50%; }
  .grid-margin-x > .large-offset-6 { margin-left: calc(50% + 0.9375rem); }
  .large-offset-7 { margin-left: 58.3333%; }
  .grid-margin-x > .large-offset-7 { margin-left: calc(58.3333% + 0.9375rem=
); }
  .large-offset-8 { margin-left: 66.6667%; }
  .grid-margin-x > .large-offset-8 { margin-left: calc(66.6667% + 0.9375rem=
); }
  .large-offset-9 { margin-left: 75%; }
  .grid-margin-x > .large-offset-9 { margin-left: calc(75% + 0.9375rem); }
  .large-offset-10 { margin-left: 83.3333%; }
  .grid-margin-x > .large-offset-10 { margin-left: calc(83.3333% + 0.9375re=
m); }
  .large-offset-11 { margin-left: 91.6667%; }
  .grid-margin-x > .large-offset-11 { margin-left: calc(91.6667% + 0.9375re=
m); }
}

.grid-y { display: flex; flex-flow: column; }

.grid-y > .cell { width: auto; }

.grid-y > .auto { height: auto; }

.grid-y > .shrink { height: auto; }

.grid-y > .small-shrink, .grid-y > .small-full, .grid-y > .small-1, .grid-y=
 > .small-2, .grid-y > .small-3, .grid-y > .small-4, .grid-y > .small-5, .g=
rid-y > .small-6, .grid-y > .small-7, .grid-y > .small-8, .grid-y > .small-=
9, .grid-y > .small-10, .grid-y > .small-11, .grid-y > .small-12 { flex-bas=
is: auto; }

@media print, screen and (min-width: 40em) {
  .grid-y > .medium-shrink, .grid-y > .medium-full, .grid-y > .medium-1, .g=
rid-y > .medium-2, .grid-y > .medium-3, .grid-y > .medium-4, .grid-y > .med=
ium-5, .grid-y > .medium-6, .grid-y > .medium-7, .grid-y > .medium-8, .grid=
-y > .medium-9, .grid-y > .medium-10, .grid-y > .medium-11, .grid-y > .medi=
um-12 { flex-basis: auto; }
}

@media print, screen and (min-width: 64em) {
  .grid-y > .large-shrink, .grid-y > .large-full, .grid-y > .large-1, .grid=
-y > .large-2, .grid-y > .large-3, .grid-y > .large-4, .grid-y > .large-5, =
.grid-y > .large-6, .grid-y > .large-7, .grid-y > .large-8, .grid-y > .larg=
e-9, .grid-y > .large-10, .grid-y > .large-11, .grid-y > .large-12 { flex-b=
asis: auto; }
}

.grid-y > .small-1 { height: 8.33333%; }

.grid-y > .small-2 { height: 16.6667%; }

.grid-y > .small-3 { height: 25%; }

.grid-y > .small-4 { height: 33.3333%; }

.grid-y > .small-5 { height: 41.6667%; }

.grid-y > .small-6 { height: 50%; }

.grid-y > .small-7 { height: 58.3333%; }

.grid-y > .small-8 { height: 66.6667%; }

.grid-y > .small-9 { height: 75%; }

.grid-y > .small-10 { height: 83.3333%; }

.grid-y > .small-11 { height: 91.6667%; }

.grid-y > .small-12 { height: 100%; }

@media print, screen and (min-width: 40em) {
  .grid-y > .medium-auto { flex: 1 1 0px; height: auto; }
  .grid-y > .medium-shrink { height: auto; }
  .grid-y > .medium-1 { height: 8.33333%; }
  .grid-y > .medium-2 { height: 16.6667%; }
  .grid-y > .medium-3 { height: 25%; }
  .grid-y > .medium-4 { height: 33.3333%; }
  .grid-y > .medium-5 { height: 41.6667%; }
  .grid-y > .medium-6 { height: 50%; }
  .grid-y > .medium-7 { height: 58.3333%; }
  .grid-y > .medium-8 { height: 66.6667%; }
  .grid-y > .medium-9 { height: 75%; }
  .grid-y > .medium-10 { height: 83.3333%; }
  .grid-y > .medium-11 { height: 91.6667%; }
  .grid-y > .medium-12 { height: 100%; }
}

@media print, screen and (min-width: 64em) {
  .grid-y > .large-auto { flex: 1 1 0px; height: auto; }
  .grid-y > .large-shrink { height: auto; }
  .grid-y > .large-1 { height: 8.33333%; }
  .grid-y > .large-2 { height: 16.6667%; }
  .grid-y > .large-3 { height: 25%; }
  .grid-y > .large-4 { height: 33.3333%; }
  .grid-y > .large-5 { height: 41.6667%; }
  .grid-y > .large-6 { height: 50%; }
  .grid-y > .large-7 { height: 58.3333%; }
  .grid-y > .large-8 { height: 66.6667%; }
  .grid-y > .large-9 { height: 75%; }
  .grid-y > .large-10 { height: 83.3333%; }
  .grid-y > .large-11 { height: 91.6667%; }
  .grid-y > .large-12 { height: 100%; }
}

.grid-padding-y .grid-padding-y { margin-top: -0.625rem; margin-bottom: -0.=
625rem; }

@media print, screen and (min-width: 40em) {
  .grid-padding-y .grid-padding-y { margin-top: -0.9375rem; margin-bottom: =
-0.9375rem; }
}

.grid-padding-y > .cell { padding-top: 0.625rem; padding-bottom: 0.625rem; =
}

@media print, screen and (min-width: 40em) {
  .grid-padding-y > .cell { padding-top: 0.9375rem; padding-bottom: 0.9375r=
em; }
}

.grid-margin-y { margin-top: -0.625rem; margin-bottom: -0.625rem; }

@media print, screen and (min-width: 40em) {
  .grid-margin-y { margin-top: -0.9375rem; margin-bottom: -0.9375rem; }
}

.grid-margin-y > .cell { height: calc(100% - 1.25rem); margin-top: 0.625rem=
; margin-bottom: 0.625rem; }

@media print, screen and (min-width: 40em) {
  .grid-margin-y > .cell { height: calc(100% - 1.875rem); margin-top: 0.937=
5rem; margin-bottom: 0.9375rem; }
}

.grid-margin-y > .auto { height: auto; }

.grid-margin-y > .shrink { height: auto; }

.grid-margin-y > .small-1 { height: calc(8.33333% - 1.25rem); }

.grid-margin-y > .small-2 { height: calc(16.6667% - 1.25rem); }

.grid-margin-y > .small-3 { height: calc(25% - 1.25rem); }

.grid-margin-y > .small-4 { height: calc(33.3333% - 1.25rem); }

.grid-margin-y > .small-5 { height: calc(41.6667% - 1.25rem); }

.grid-margin-y > .small-6 { height: calc(50% - 1.25rem); }

.grid-margin-y > .small-7 { height: calc(58.3333% - 1.25rem); }

.grid-margin-y > .small-8 { height: calc(66.6667% - 1.25rem); }

.grid-margin-y > .small-9 { height: calc(75% - 1.25rem); }

.grid-margin-y > .small-10 { height: calc(83.3333% - 1.25rem); }

.grid-margin-y > .small-11 { height: calc(91.6667% - 1.25rem); }

.grid-margin-y > .small-12 { height: calc(100% - 1.25rem); }

@media print, screen and (min-width: 40em) {
  .grid-margin-y > .auto { height: auto; }
  .grid-margin-y > .shrink { height: auto; }
  .grid-margin-y > .small-1 { height: calc(8.33333% - 1.875rem); }
  .grid-margin-y > .small-2 { height: calc(16.6667% - 1.875rem); }
  .grid-margin-y > .small-3 { height: calc(25% - 1.875rem); }
  .grid-margin-y > .small-4 { height: calc(33.3333% - 1.875rem); }
  .grid-margin-y > .small-5 { height: calc(41.6667% - 1.875rem); }
  .grid-margin-y > .small-6 { height: calc(50% - 1.875rem); }
  .grid-margin-y > .small-7 { height: calc(58.3333% - 1.875rem); }
  .grid-margin-y > .small-8 { height: calc(66.6667% - 1.875rem); }
  .grid-margin-y > .small-9 { height: calc(75% - 1.875rem); }
  .grid-margin-y > .small-10 { height: calc(83.3333% - 1.875rem); }
  .grid-margin-y > .small-11 { height: calc(91.6667% - 1.875rem); }
  .grid-margin-y > .small-12 { height: calc(100% - 1.875rem); }
  .grid-margin-y > .medium-auto { height: auto; }
  .grid-margin-y > .medium-shrink { height: auto; }
  .grid-margin-y > .medium-1 { height: calc(8.33333% - 1.875rem); }
  .grid-margin-y > .medium-2 { height: calc(16.6667% - 1.875rem); }
  .grid-margin-y > .medium-3 { height: calc(25% - 1.875rem); }
  .grid-margin-y > .medium-4 { height: calc(33.3333% - 1.875rem); }
  .grid-margin-y > .medium-5 { height: calc(41.6667% - 1.875rem); }
  .grid-margin-y > .medium-6 { height: calc(50% - 1.875rem); }
  .grid-margin-y > .medium-7 { height: calc(58.3333% - 1.875rem); }
  .grid-margin-y > .medium-8 { height: calc(66.6667% - 1.875rem); }
  .grid-margin-y > .medium-9 { height: calc(75% - 1.875rem); }
  .grid-margin-y > .medium-10 { height: calc(83.3333% - 1.875rem); }
  .grid-margin-y > .medium-11 { height: calc(91.6667% - 1.875rem); }
  .grid-margin-y > .medium-12 { height: calc(100% - 1.875rem); }
}

@media print, screen and (min-width: 64em) {
  .grid-margin-y > .large-auto { height: auto; }
  .grid-margin-y > .large-shrink { height: auto; }
  .grid-margin-y > .large-1 { height: calc(8.33333% - 1.875rem); }
  .grid-margin-y > .large-2 { height: calc(16.6667% - 1.875rem); }
  .grid-margin-y > .large-3 { height: calc(25% - 1.875rem); }
  .grid-margin-y > .large-4 { height: calc(33.3333% - 1.875rem); }
  .grid-margin-y > .large-5 { height: calc(41.6667% - 1.875rem); }
  .grid-margin-y > .large-6 { height: calc(50% - 1.875rem); }
  .grid-margin-y > .large-7 { height: calc(58.3333% - 1.875rem); }
  .grid-margin-y > .large-8 { height: calc(66.6667% - 1.875rem); }
  .grid-margin-y > .large-9 { height: calc(75% - 1.875rem); }
  .grid-margin-y > .large-10 { height: calc(83.3333% - 1.875rem); }
  .grid-margin-y > .large-11 { height: calc(91.6667% - 1.875rem); }
  .grid-margin-y > .large-12 { height: calc(100% - 1.875rem); }
}

.grid-frame { overflow: hidden; position: relative; flex-wrap: nowrap; alig=
n-items: stretch; width: 100vw; }

.cell .grid-frame { width: 100%; }

.cell-block { overflow-x: auto; max-width: 100%; }

.cell-block-y { overflow-y: auto; max-height: 100%; }

.cell-block-container { display: flex; flex-direction: column; max-height: =
100%; }

.cell-block-container > .grid-x { max-height: 100%; flex-wrap: nowrap; }

@media print, screen and (min-width: 40em) {
  .medium-grid-frame { overflow: hidden; position: relative; flex-wrap: now=
rap; align-items: stretch; width: 100vw; }
  .cell .medium-grid-frame { width: 100%; }
  .medium-cell-block { overflow-x: auto; max-width: 100%; }
  .medium-cell-block-container { display: flex; flex-direction: column; max=
-height: 100%; }
  .medium-cell-block-container > .grid-x { max-height: 100%; flex-wrap: now=
rap; }
  .medium-cell-block-y { overflow-y: auto; max-height: 100%; }
}

@media print, screen and (min-width: 64em) {
  .large-grid-frame { overflow: hidden; position: relative; flex-wrap: nowr=
ap; align-items: stretch; width: 100vw; }
  .cell .large-grid-frame { width: 100%; }
  .large-cell-block { overflow-x: auto; max-width: 100%; }
  .large-cell-block-container { display: flex; flex-direction: column; max-=
height: 100%; }
  .large-cell-block-container > .grid-x { max-height: 100%; flex-wrap: nowr=
ap; }
  .large-cell-block-y { overflow-y: auto; max-height: 100%; }
}

.grid-y.grid-frame { width: auto; overflow: hidden; position: relative; fle=
x-wrap: nowrap; align-items: stretch; height: 100vh; }

@media print, screen and (min-width: 40em) {
  .grid-y.medium-grid-frame { width: auto; overflow: hidden; position: rela=
tive; flex-wrap: nowrap; align-items: stretch; height: 100vh; }
}

@media print, screen and (min-width: 64em) {
  .grid-y.large-grid-frame { width: auto; overflow: hidden; position: relat=
ive; flex-wrap: nowrap; align-items: stretch; height: 100vh; }
}

.cell .grid-y.grid-frame { height: 100%; }

@media print, screen and (min-width: 40em) {
  .cell .grid-y.medium-grid-frame { height: 100%; }
}

@media print, screen and (min-width: 64em) {
  .cell .grid-y.large-grid-frame { height: 100%; }
}

.grid-margin-y { margin-top: -0.625rem; margin-bottom: -0.625rem; }

@media print, screen and (min-width: 40em) {
  .grid-margin-y { margin-top: -0.9375rem; margin-bottom: -0.9375rem; }
}

.grid-margin-y > .cell { height: calc(100% - 1.25rem); margin-top: 0.625rem=
; margin-bottom: 0.625rem; }

@media print, screen and (min-width: 40em) {
  .grid-margin-y > .cell { height: calc(100% - 1.875rem); margin-top: 0.937=
5rem; margin-bottom: 0.9375rem; }
}

.grid-margin-y > .auto { height: auto; }

.grid-margin-y > .shrink { height: auto; }

.grid-margin-y > .small-1 { height: calc(8.33333% - 1.25rem); }

.grid-margin-y > .small-2 { height: calc(16.6667% - 1.25rem); }

.grid-margin-y > .small-3 { height: calc(25% - 1.25rem); }

.grid-margin-y > .small-4 { height: calc(33.3333% - 1.25rem); }

.grid-margin-y > .small-5 { height: calc(41.6667% - 1.25rem); }

.grid-margin-y > .small-6 { height: calc(50% - 1.25rem); }

.grid-margin-y > .small-7 { height: calc(58.3333% - 1.25rem); }

.grid-margin-y > .small-8 { height: calc(66.6667% - 1.25rem); }

.grid-margin-y > .small-9 { height: calc(75% - 1.25rem); }

.grid-margin-y > .small-10 { height: calc(83.3333% - 1.25rem); }

.grid-margin-y > .small-11 { height: calc(91.6667% - 1.25rem); }

.grid-margin-y > .small-12 { height: calc(100% - 1.25rem); }

@media print, screen and (min-width: 40em) {
  .grid-margin-y > .auto { height: auto; }
  .grid-margin-y > .shrink { height: auto; }
  .grid-margin-y > .small-1 { height: calc(8.33333% - 1.875rem); }
  .grid-margin-y > .small-2 { height: calc(16.6667% - 1.875rem); }
  .grid-margin-y > .small-3 { height: calc(25% - 1.875rem); }
  .grid-margin-y > .small-4 { height: calc(33.3333% - 1.875rem); }
  .grid-margin-y > .small-5 { height: calc(41.6667% - 1.875rem); }
  .grid-margin-y > .small-6 { height: calc(50% - 1.875rem); }
  .grid-margin-y > .small-7 { height: calc(58.3333% - 1.875rem); }
  .grid-margin-y > .small-8 { height: calc(66.6667% - 1.875rem); }
  .grid-margin-y > .small-9 { height: calc(75% - 1.875rem); }
  .grid-margin-y > .small-10 { height: calc(83.3333% - 1.875rem); }
  .grid-margin-y > .small-11 { height: calc(91.6667% - 1.875rem); }
  .grid-margin-y > .small-12 { height: calc(100% - 1.875rem); }
  .grid-margin-y > .medium-auto { height: auto; }
  .grid-margin-y > .medium-shrink { height: auto; }
  .grid-margin-y > .medium-1 { height: calc(8.33333% - 1.875rem); }
  .grid-margin-y > .medium-2 { height: calc(16.6667% - 1.875rem); }
  .grid-margin-y > .medium-3 { height: calc(25% - 1.875rem); }
  .grid-margin-y > .medium-4 { height: calc(33.3333% - 1.875rem); }
  .grid-margin-y > .medium-5 { height: calc(41.6667% - 1.875rem); }
  .grid-margin-y > .medium-6 { height: calc(50% - 1.875rem); }
  .grid-margin-y > .medium-7 { height: calc(58.3333% - 1.875rem); }
  .grid-margin-y > .medium-8 { height: calc(66.6667% - 1.875rem); }
  .grid-margin-y > .medium-9 { height: calc(75% - 1.875rem); }
  .grid-margin-y > .medium-10 { height: calc(83.3333% - 1.875rem); }
  .grid-margin-y > .medium-11 { height: calc(91.6667% - 1.875rem); }
  .grid-margin-y > .medium-12 { height: calc(100% - 1.875rem); }
}

@media print, screen and (min-width: 64em) {
  .grid-margin-y > .large-auto { height: auto; }
  .grid-margin-y > .large-shrink { height: auto; }
  .grid-margin-y > .large-1 { height: calc(8.33333% - 1.875rem); }
  .grid-margin-y > .large-2 { height: calc(16.6667% - 1.875rem); }
  .grid-margin-y > .large-3 { height: calc(25% - 1.875rem); }
  .grid-margin-y > .large-4 { height: calc(33.3333% - 1.875rem); }
  .grid-margin-y > .large-5 { height: calc(41.6667% - 1.875rem); }
  .grid-margin-y > .large-6 { height: calc(50% - 1.875rem); }
  .grid-margin-y > .large-7 { height: calc(58.3333% - 1.875rem); }
  .grid-margin-y > .large-8 { height: calc(66.6667% - 1.875rem); }
  .grid-margin-y > .large-9 { height: calc(75% - 1.875rem); }
  .grid-margin-y > .large-10 { height: calc(83.3333% - 1.875rem); }
  .grid-margin-y > .large-11 { height: calc(91.6667% - 1.875rem); }
  .grid-margin-y > .large-12 { height: calc(100% - 1.875rem); }
}

.grid-frame.grid-margin-y { height: calc(1.25rem + 100vh); }

@media print, screen and (min-width: 40em) {
  .grid-frame.grid-margin-y { height: calc(1.875rem + 100vh); }
}

@media print, screen and (min-width: 64em) {
  .grid-frame.grid-margin-y { height: calc(1.875rem + 100vh); }
}

@media print, screen and (min-width: 40em) {
  .grid-margin-y.medium-grid-frame { height: calc(1.875rem + 100vh); }
}

@media print, screen and (min-width: 64em) {
  .grid-margin-y.large-grid-frame { height: calc(1.875rem + 100vh); }
}

.align-right { justify-content: flex-end; }

.align-center { justify-content: center; }

.align-justify { justify-content: space-between; }

.align-spaced { justify-content: space-around; }

.align-right.vertical.menu > li > a { justify-content: flex-end; }

.align-center.vertical.menu > li > a { justify-content: center; }

.align-top { align-items: flex-start; }

.align-self-top { align-self: flex-start; }

.align-bottom { align-items: flex-end; }

.align-self-bottom { align-self: flex-end; }

.align-middle { align-items: center; }

.align-self-middle { align-self: center; }

.align-stretch { align-items: stretch; }

.align-self-stretch { align-self: stretch; }

.align-center-middle { place-content: center; align-items: center; }

.small-order-1 { order: 1; }

.small-order-2 { order: 2; }

.small-order-3 { order: 3; }

.small-order-4 { order: 4; }

.small-order-5 { order: 5; }

.small-order-6 { order: 6; }

@media print, screen and (min-width: 40em) {
  .medium-order-1 { order: 1; }
  .medium-order-2 { order: 2; }
  .medium-order-3 { order: 3; }
  .medium-order-4 { order: 4; }
  .medium-order-5 { order: 5; }
  .medium-order-6 { order: 6; }
}

@media print, screen and (min-width: 64em) {
  .large-order-1 { order: 1; }
  .large-order-2 { order: 2; }
  .large-order-3 { order: 3; }
  .large-order-4 { order: 4; }
  .large-order-5 { order: 5; }
  .large-order-6 { order: 6; }
}

.flex-container { display: flex; }

.flex-child-auto { flex: 1 1 auto; }

.flex-child-grow { flex: 1 0 auto; }

.flex-child-shrink { flex: 0 1 auto; }

.flex-dir-row { flex-direction: row; }

.flex-dir-row-reverse { flex-direction: row-reverse; }

.flex-dir-column { flex-direction: column; }

.flex-dir-column-reverse { flex-direction: column-reverse; }

@media print, screen and (min-width: 40em) {
  .medium-flex-container { display: flex; }
  .medium-flex-child-auto { flex: 1 1 auto; }
  .medium-flex-child-grow { flex: 1 0 auto; }
  .medium-flex-child-shrink { flex: 0 1 auto; }
  .medium-flex-dir-row { flex-direction: row; }
  .medium-flex-dir-row-reverse { flex-direction: row-reverse; }
  .medium-flex-dir-column { flex-direction: column; }
  .medium-flex-dir-column-reverse { flex-direction: column-reverse; }
}

@media print, screen and (min-width: 64em) {
  .large-flex-container { display: flex; }
  .large-flex-child-auto { flex: 1 1 auto; }
  .large-flex-child-grow { flex: 1 0 auto; }
  .large-flex-child-shrink { flex: 0 1 auto; }
  .large-flex-dir-row { flex-direction: row; }
  .large-flex-dir-row-reverse { flex-direction: row-reverse; }
  .large-flex-dir-column { flex-direction: column; }
  .large-flex-dir-column-reverse { flex-direction: column-reverse; }
}

div, dl, dt, dd, ul, ol, li, h1, h2, h3, h4, h5, h6, pre, form, p, blockquo=
te, th, td { margin: 0px; padding: 0px; }

p { margin-bottom: 1rem; font-size: inherit; line-height: 1.6; text-renderi=
ng: optimizelegibility; }

em, i { font-style: italic; line-height: inherit; }

strong, b { font-weight: bold; line-height: inherit; }

small { font-size: 80%; line-height: inherit; }

h1, .h1, h2, .h2, h3, .h3, h4, .h4, h5, .h5, h6, .h6 { font-family: "Helvet=
ica Neue", Helvetica, Roboto, Arial, sans-serif; font-style: normal; font-w=
eight: normal; color: inherit; text-rendering: optimizelegibility; }

h1 small, .h1 small, h2 small, .h2 small, h3 small, .h3 small, h4 small, .h=
4 small, h5 small, .h5 small, h6 small, .h6 small { line-height: 0; color: =
rgb(202, 202, 202); }

h1, .h1 { font-size: 1.5rem; line-height: 1.4; margin-top: 0px; margin-bott=
om: 0.5rem; }

h2, .h2 { font-size: 1.25rem; line-height: 1.4; margin-top: 0px; margin-bot=
tom: 0.5rem; }

h3, .h3 { font-size: 1.1875rem; line-height: 1.4; margin-top: 0px; margin-b=
ottom: 0.5rem; }

h4, .h4 { font-size: 1.125rem; line-height: 1.4; margin-top: 0px; margin-bo=
ttom: 0.5rem; }

h5, .h5 { font-size: 1.0625rem; line-height: 1.4; margin-top: 0px; margin-b=
ottom: 0.5rem; }

h6, .h6 { font-size: 1rem; line-height: 1.4; margin-top: 0px; margin-bottom=
: 0.5rem; }

@media print, screen and (min-width: 40em) {
  h1, .h1 { font-size: 3rem; }
  h2, .h2 { font-size: 2.5rem; }
  h3, .h3 { font-size: 1.9375rem; }
  h4, .h4 { font-size: 1.5625rem; }
  h5, .h5 { font-size: 1.25rem; }
  h6, .h6 { font-size: 1rem; }
}

a { line-height: inherit; color: rgb(23, 121, 186); text-decoration: none; =
cursor: pointer; }

a:hover, a:focus { color: rgb(20, 104, 160); }

a img { border: 0px; }

hr { clear: both; max-width: 75rem; height: 0px; margin: 1.25rem auto; bord=
er-width: 0px 0px 1px; border-top-style: initial; border-top-color: initial=
; border-right-style: initial; border-right-color: initial; border-bottom-s=
tyle: solid; border-bottom-color: rgb(202, 202, 202); border-left-style: in=
itial; border-left-color: initial; }

ul, ol, dl { margin-bottom: 1rem; list-style-position: outside; line-height=
: 1.6; }

li { font-size: inherit; }

ul { margin-left: 1.25rem; list-style-type: disc; }

ol { margin-left: 1.25rem; }

ul ul, ol ul, ul ol, ol ol { margin-left: 1.25rem; margin-bottom: 0px; }

dl { margin-bottom: 1rem; }

dl dt { margin-bottom: 0.3rem; font-weight: bold; }

blockquote { margin: 0px 0px 1rem; padding: 0.5625rem 1.25rem 0px 1.1875rem=
; border-left: 1px solid rgb(202, 202, 202); }

blockquote, blockquote p { line-height: 1.6; color: rgb(138, 138, 138); }

cite { display: block; font-size: 0.8125rem; color: rgb(138, 138, 138); }

cite::before { content: "=E2=80=94 "; }

abbr, abbr[title] { border-bottom: 1px dotted rgb(10, 10, 10); cursor: help=
; text-decoration: none; }

figure { margin: 0px; }

code { padding: 0.125rem 0.3125rem 0.0625rem; border: 1px solid rgb(202, 20=
2, 202); background-color: rgb(230, 230, 230); font-family: Consolas, "Libe=
ration Mono", Courier, monospace; font-weight: normal; color: rgb(10, 10, 1=
0); }

kbd { margin: 0px; padding: 0.125rem 0.25rem 0px; background-color: rgb(230=
, 230, 230); font-family: Consolas, "Liberation Mono", Courier, monospace; =
color: rgb(10, 10, 10); }

.subheader { margin-top: 0.2rem; margin-bottom: 0.5rem; font-weight: normal=
; line-height: 1.4; color: rgb(138, 138, 138); }

.lead { font-size: 125%; line-height: 1.6; }

.stat { font-size: 2.5rem; line-height: 1; }

p + .stat { margin-top: -1rem; }

ul.no-bullet, ol.no-bullet { margin-left: 0px; list-style: none; }

.text-left { text-align: left; }

.text-right { text-align: right; }

.text-center { text-align: center; }

.text-justify { text-align: justify; }

@media print, screen and (min-width: 40em) {
  .medium-text-left { text-align: left; }
  .medium-text-right { text-align: right; }
  .medium-text-center { text-align: center; }
  .medium-text-justify { text-align: justify; }
}

@media print, screen and (min-width: 64em) {
  .large-text-left { text-align: left; }
  .large-text-right { text-align: right; }
  .large-text-center { text-align: center; }
  .large-text-justify { text-align: justify; }
}

.show-for-print { display: none !important; }

@media print {
  * { background: transparent !important; box-shadow: none !important; colo=
r: black !important; text-shadow: none !important; }
  .show-for-print { display: block !important; }
  .hide-for-print { display: none !important; }
  table.show-for-print { display: table !important; }
  thead.show-for-print { display: table-header-group !important; }
  tbody.show-for-print { display: table-row-group !important; }
  tr.show-for-print { display: table-row !important; }
  td.show-for-print { display: table-cell !important; }
  th.show-for-print { display: table-cell !important; }
  a, a:visited { text-decoration: underline; }
  a[href]::after { content: " (" attr(href) ")"; }
  .ir a::after, a[href^=3D"javascript:"]::after, a[href^=3D"#"]::after { co=
ntent: ""; }
  abbr[title]::after { content: " (" attr(title) ")"; }
  pre, blockquote { border: 1px solid rgb(138, 138, 138); break-inside: avo=
id; }
  thead { display: table-header-group; }
  tr, img { break-inside: avoid; }
  img { max-width: 100% !important; }
  @page { margin: 0.5cm; }
  p, h2, h3 { orphans: 3; widows: 3; }
  h2, h3 { break-after: avoid; }
  .print-break-inside { break-inside: auto; }
}

.button { display: inline-block; vertical-align: middle; margin: 0px 0px 1r=
em; font-family: inherit; padding: 0.85em 1em; appearance: none; border: 1p=
x solid transparent; border-radius: 0px; transition: background-color 0.25s=
 ease-out, color 0.25s ease-out; font-size: 0.9rem; line-height: 1; text-al=
ign: center; cursor: pointer; background-color: rgb(23, 121, 186); color: r=
gb(254, 254, 254); }

[data-whatinput=3D"mouse"] .button { outline: 0px; }

.button:hover, .button:focus { background-color: rgb(20, 103, 158); color: =
rgb(254, 254, 254); }

.button.tiny { font-size: 0.6rem; }

.button.small { font-size: 0.75rem; }

.button.large { font-size: 1.25rem; }

.button.expanded { display: block; width: 100%; margin-right: 0px; margin-l=
eft: 0px; }

.button.primary { background-color: rgb(23, 121, 186); color: rgb(254, 254,=
 254); }

.button.primary:hover, .button.primary:focus { background-color: rgb(18, 97=
, 149); color: rgb(254, 254, 254); }

.button.secondary { background-color: rgb(118, 118, 118); color: rgb(254, 2=
54, 254); }

.button.secondary:hover, .button.secondary:focus { background-color: rgb(94=
, 94, 94); color: rgb(254, 254, 254); }

.button.success { background-color: rgb(58, 219, 118); color: rgb(10, 10, 1=
0); }

.button.success:hover, .button.success:focus { background-color: rgb(34, 18=
7, 91); color: rgb(10, 10, 10); }

.button.warning { background-color: rgb(255, 174, 0); color: rgb(10, 10, 10=
); }

.button.warning:hover, .button.warning:focus { background-color: rgb(204, 1=
39, 0); color: rgb(10, 10, 10); }

.button.alert { background-color: rgb(204, 75, 55); color: rgb(254, 254, 25=
4); }

.button.alert:hover, .button.alert:focus { background-color: rgb(165, 59, 4=
2); color: rgb(254, 254, 254); }

.button.disabled, .button[disabled] { opacity: 0.25; cursor: not-allowed; }

.button.disabled, .button.disabled:hover, .button.disabled:focus, .button[d=
isabled], .button[disabled]:hover, .button[disabled]:focus { background-col=
or: rgb(23, 121, 186); color: rgb(254, 254, 254); }

.button.disabled.primary, .button[disabled].primary { opacity: 0.25; cursor=
: not-allowed; }

.button.disabled.primary, .button.disabled.primary:hover, .button.disabled.=
primary:focus, .button[disabled].primary, .button[disabled].primary:hover, =
.button[disabled].primary:focus { background-color: rgb(23, 121, 186); colo=
r: rgb(254, 254, 254); }

.button.disabled.secondary, .button[disabled].secondary { opacity: 0.25; cu=
rsor: not-allowed; }

.button.disabled.secondary, .button.disabled.secondary:hover, .button.disab=
led.secondary:focus, .button[disabled].secondary, .button[disabled].seconda=
ry:hover, .button[disabled].secondary:focus { background-color: rgb(118, 11=
8, 118); color: rgb(254, 254, 254); }

.button.disabled.success, .button[disabled].success { opacity: 0.25; cursor=
: not-allowed; }

.button.disabled.success, .button.disabled.success:hover, .button.disabled.=
success:focus, .button[disabled].success, .button[disabled].success:hover, =
.button[disabled].success:focus { background-color: rgb(58, 219, 118); colo=
r: rgb(10, 10, 10); }

.button.disabled.warning, .button[disabled].warning { opacity: 0.25; cursor=
: not-allowed; }

.button.disabled.warning, .button.disabled.warning:hover, .button.disabled.=
warning:focus, .button[disabled].warning, .button[disabled].warning:hover, =
.button[disabled].warning:focus { background-color: rgb(255, 174, 0); color=
: rgb(10, 10, 10); }

.button.disabled.alert, .button[disabled].alert { opacity: 0.25; cursor: no=
t-allowed; }

.button.disabled.alert, .button.disabled.alert:hover, .button.disabled.aler=
t:focus, .button[disabled].alert, .button[disabled].alert:hover, .button[di=
sabled].alert:focus { background-color: rgb(204, 75, 55); color: rgb(254, 2=
54, 254); }

.button.hollow { border: 1px solid rgb(23, 121, 186); color: rgb(23, 121, 1=
86); }

.button.hollow, .button.hollow:hover, .button.hollow:focus { background-col=
or: transparent; }

.button.hollow.disabled, .button.hollow.disabled:hover, .button.hollow.disa=
bled:focus, .button.hollow[disabled], .button.hollow[disabled]:hover, .butt=
on.hollow[disabled]:focus { background-color: transparent; }

.button.hollow:hover, .button.hollow:focus { border-color: rgb(12, 61, 93);=
 color: rgb(12, 61, 93); }

.button.hollow:hover.disabled, .button.hollow:hover[disabled], .button.holl=
ow:focus.disabled, .button.hollow:focus[disabled] { border: 1px solid rgb(2=
3, 121, 186); color: rgb(23, 121, 186); }

.button.hollow.primary { border: 1px solid rgb(23, 121, 186); color: rgb(23=
, 121, 186); }

.button.hollow.primary:hover, .button.hollow.primary:focus { border-color: =
rgb(12, 61, 93); color: rgb(12, 61, 93); }

.button.hollow.primary:hover.disabled, .button.hollow.primary:hover[disable=
d], .button.hollow.primary:focus.disabled, .button.hollow.primary:focus[dis=
abled] { border: 1px solid rgb(23, 121, 186); color: rgb(23, 121, 186); }

.button.hollow.secondary { border: 1px solid rgb(118, 118, 118); color: rgb=
(118, 118, 118); }

.button.hollow.secondary:hover, .button.hollow.secondary:focus { border-col=
or: rgb(59, 59, 59); color: rgb(59, 59, 59); }

.button.hollow.secondary:hover.disabled, .button.hollow.secondary:hover[dis=
abled], .button.hollow.secondary:focus.disabled, .button.hollow.secondary:f=
ocus[disabled] { border: 1px solid rgb(118, 118, 118); color: rgb(118, 118,=
 118); }

.button.hollow.success { border: 1px solid rgb(58, 219, 118); color: rgb(58=
, 219, 118); }

.button.hollow.success:hover, .button.hollow.success:focus { border-color: =
rgb(21, 117, 57); color: rgb(21, 117, 57); }

.button.hollow.success:hover.disabled, .button.hollow.success:hover[disable=
d], .button.hollow.success:focus.disabled, .button.hollow.success:focus[dis=
abled] { border: 1px solid rgb(58, 219, 118); color: rgb(58, 219, 118); }

.button.hollow.warning { border: 1px solid rgb(255, 174, 0); color: rgb(255=
, 174, 0); }

.button.hollow.warning:hover, .button.hollow.warning:focus { border-color: =
rgb(128, 87, 0); color: rgb(128, 87, 0); }

.button.hollow.warning:hover.disabled, .button.hollow.warning:hover[disable=
d], .button.hollow.warning:focus.disabled, .button.hollow.warning:focus[dis=
abled] { border: 1px solid rgb(255, 174, 0); color: rgb(255, 174, 0); }

.button.hollow.alert { border: 1px solid rgb(204, 75, 55); color: rgb(204, =
75, 55); }

.button.hollow.alert:hover, .button.hollow.alert:focus { border-color: rgb(=
103, 37, 26); color: rgb(103, 37, 26); }

.button.hollow.alert:hover.disabled, .button.hollow.alert:hover[disabled], =
.button.hollow.alert:focus.disabled, .button.hollow.alert:focus[disabled] {=
 border: 1px solid rgb(204, 75, 55); color: rgb(204, 75, 55); }

.button.clear { border: 1px solid rgb(23, 121, 186); color: rgb(23, 121, 18=
6); }

.button.clear, .button.clear:hover, .button.clear:focus { background-color:=
 transparent; }

.button.clear.disabled, .button.clear.disabled:hover, .button.clear.disable=
d:focus, .button.clear[disabled], .button.clear[disabled]:hover, .button.cl=
ear[disabled]:focus { background-color: transparent; }

.button.clear:hover, .button.clear:focus { border-color: rgb(12, 61, 93); c=
olor: rgb(12, 61, 93); }

.button.clear:hover.disabled, .button.clear:hover[disabled], .button.clear:=
focus.disabled, .button.clear:focus[disabled] { border: 1px solid rgb(23, 1=
21, 186); color: rgb(23, 121, 186); }

.button.clear, .button.clear.disabled, .button.clear[disabled], .button.cle=
ar:hover, .button.clear:hover.disabled, .button.clear:hover[disabled], .but=
ton.clear:focus, .button.clear:focus.disabled, .button.clear:focus[disabled=
] { border-color: transparent; }

.button.clear.primary { border: 1px solid rgb(23, 121, 186); color: rgb(23,=
 121, 186); }

.button.clear.primary:hover, .button.clear.primary:focus { border-color: rg=
b(12, 61, 93); color: rgb(12, 61, 93); }

.button.clear.primary:hover.disabled, .button.clear.primary:hover[disabled]=
, .button.clear.primary:focus.disabled, .button.clear.primary:focus[disable=
d] { border: 1px solid rgb(23, 121, 186); color: rgb(23, 121, 186); }

.button.clear.primary, .button.clear.primary.disabled, .button.clear.primar=
y[disabled], .button.clear.primary:hover, .button.clear.primary:hover.disab=
led, .button.clear.primary:hover[disabled], .button.clear.primary:focus, .b=
utton.clear.primary:focus.disabled, .button.clear.primary:focus[disabled] {=
 border-color: transparent; }

.button.clear.secondary { border: 1px solid rgb(118, 118, 118); color: rgb(=
118, 118, 118); }

.button.clear.secondary:hover, .button.clear.secondary:focus { border-color=
: rgb(59, 59, 59); color: rgb(59, 59, 59); }

.button.clear.secondary:hover.disabled, .button.clear.secondary:hover[disab=
led], .button.clear.secondary:focus.disabled, .button.clear.secondary:focus=
[disabled] { border: 1px solid rgb(118, 118, 118); color: rgb(118, 118, 118=
); }

.button.clear.secondary, .button.clear.secondary.disabled, .button.clear.se=
condary[disabled], .button.clear.secondary:hover, .button.clear.secondary:h=
over.disabled, .button.clear.secondary:hover[disabled], .button.clear.secon=
dary:focus, .button.clear.secondary:focus.disabled, .button.clear.secondary=
:focus[disabled] { border-color: transparent; }

.button.clear.success { border: 1px solid rgb(58, 219, 118); color: rgb(58,=
 219, 118); }

.button.clear.success:hover, .button.clear.success:focus { border-color: rg=
b(21, 117, 57); color: rgb(21, 117, 57); }

.button.clear.success:hover.disabled, .button.clear.success:hover[disabled]=
, .button.clear.success:focus.disabled, .button.clear.success:focus[disable=
d] { border: 1px solid rgb(58, 219, 118); color: rgb(58, 219, 118); }

.button.clear.success, .button.clear.success.disabled, .button.clear.succes=
s[disabled], .button.clear.success:hover, .button.clear.success:hover.disab=
led, .button.clear.success:hover[disabled], .button.clear.success:focus, .b=
utton.clear.success:focus.disabled, .button.clear.success:focus[disabled] {=
 border-color: transparent; }

.button.clear.warning { border: 1px solid rgb(255, 174, 0); color: rgb(255,=
 174, 0); }

.button.clear.warning:hover, .button.clear.warning:focus { border-color: rg=
b(128, 87, 0); color: rgb(128, 87, 0); }

.button.clear.warning:hover.disabled, .button.clear.warning:hover[disabled]=
, .button.clear.warning:focus.disabled, .button.clear.warning:focus[disable=
d] { border: 1px solid rgb(255, 174, 0); color: rgb(255, 174, 0); }

.button.clear.warning, .button.clear.warning.disabled, .button.clear.warnin=
g[disabled], .button.clear.warning:hover, .button.clear.warning:hover.disab=
led, .button.clear.warning:hover[disabled], .button.clear.warning:focus, .b=
utton.clear.warning:focus.disabled, .button.clear.warning:focus[disabled] {=
 border-color: transparent; }

.button.clear.alert { border: 1px solid rgb(204, 75, 55); color: rgb(204, 7=
5, 55); }

.button.clear.alert:hover, .button.clear.alert:focus { border-color: rgb(10=
3, 37, 26); color: rgb(103, 37, 26); }

.button.clear.alert:hover.disabled, .button.clear.alert:hover[disabled], .b=
utton.clear.alert:focus.disabled, .button.clear.alert:focus[disabled] { bor=
der: 1px solid rgb(204, 75, 55); color: rgb(204, 75, 55); }

.button.clear.alert, .button.clear.alert.disabled, .button.clear.alert[disa=
bled], .button.clear.alert:hover, .button.clear.alert:hover.disabled, .butt=
on.clear.alert:hover[disabled], .button.clear.alert:focus, .button.clear.al=
ert:focus.disabled, .button.clear.alert:focus[disabled] { border-color: tra=
nsparent; }

.button.dropdown::after { width: 0px; height: 0px; border-width: 0.4em 0.4e=
m 0px; border-style: solid inset inset; border-image: initial; content: "";=
 border-color: rgb(254, 254, 254) transparent transparent; position: relati=
ve; top: 0.4em; display: inline-block; float: right; margin-left: 1em; }

.button.dropdown.hollow::after { border-top-color: rgb(23, 121, 186); }

.button.dropdown.hollow.primary::after { border-top-color: rgb(23, 121, 186=
); }

.button.dropdown.hollow.secondary::after { border-top-color: rgb(118, 118, =
118); }

.button.dropdown.hollow.success::after { border-top-color: rgb(58, 219, 118=
); }

.button.dropdown.hollow.warning::after { border-top-color: rgb(255, 174, 0)=
; }

.button.dropdown.hollow.alert::after { border-top-color: rgb(204, 75, 55); =
}

.button.arrow-only::after { top: -0.1em; float: none; margin-left: 0px; }

a.button:hover, a.button:focus { text-decoration: none; }

[type=3D"text"], [type=3D"password"], [type=3D"date"], [type=3D"datetime"],=
 [type=3D"datetime-local"], [type=3D"month"], [type=3D"week"], [type=3D"ema=
il"], [type=3D"number"], [type=3D"search"], [type=3D"tel"], [type=3D"time"]=
, [type=3D"url"], [type=3D"color"], textarea { display: block; box-sizing: =
border-box; width: 100%; height: 2.4375rem; margin: 0px 0px 1rem; padding: =
0.5rem; border: 1px solid rgb(202, 202, 202); border-radius: 0px; backgroun=
d-color: rgb(254, 254, 254); box-shadow: rgba(10, 10, 10, 0.1) 0px 1px 2px =
inset; font-family: inherit; font-size: 1rem; font-weight: normal; line-hei=
ght: 1.5; color: rgb(10, 10, 10); transition: box-shadow 0.5s, border-color=
 0.25s ease-in-out; appearance: none; }

[type=3D"text"]:focus, [type=3D"password"]:focus, [type=3D"date"]:focus, [t=
ype=3D"datetime"]:focus, [type=3D"datetime-local"]:focus, [type=3D"month"]:=
focus, [type=3D"week"]:focus, [type=3D"email"]:focus, [type=3D"number"]:foc=
us, [type=3D"search"]:focus, [type=3D"tel"]:focus, [type=3D"time"]:focus, [=
type=3D"url"]:focus, [type=3D"color"]:focus, textarea:focus { outline: none=
; border: 1px solid rgb(138, 138, 138); background-color: rgb(254, 254, 254=
); box-shadow: rgb(202, 202, 202) 0px 0px 5px; transition: box-shadow 0.5s,=
 border-color 0.25s ease-in-out; }

textarea { max-width: 100%; }

textarea[rows] { height: auto; }

input::-webkit-input-placeholder, textarea::-webkit-input-placeholder { col=
or: rgb(202, 202, 202); }

input::placeholder, textarea::placeholder { color: rgb(202, 202, 202); }

input:disabled, input[readonly], textarea:disabled, textarea[readonly] { ba=
ckground-color: rgb(230, 230, 230); cursor: not-allowed; }

[type=3D"submit"], [type=3D"button"] { appearance: none; border-radius: 0px=
; }

input[type=3D"search"] { box-sizing: border-box; }

[type=3D"file"], [type=3D"checkbox"], [type=3D"radio"] { margin: 0px 0px 1r=
em; }

[type=3D"checkbox"] + label, [type=3D"radio"] + label { display: inline-blo=
ck; vertical-align: baseline; margin-left: 0.5rem; margin-right: 1rem; marg=
in-bottom: 0px; }

[type=3D"checkbox"] + label[for], [type=3D"radio"] + label[for] { cursor: p=
ointer; }

label > [type=3D"checkbox"], label > [type=3D"radio"] { margin-right: 0.5re=
m; }

[type=3D"file"] { width: 100%; }

label { display: block; margin: 0px; font-size: 0.875rem; font-weight: norm=
al; line-height: 1.8; color: rgb(10, 10, 10); }

label.middle { margin: 0px 0px 1rem; padding: 0.5625rem 0px; }

.help-text { margin-top: -0.5rem; font-size: 0.8125rem; font-style: italic;=
 color: rgb(10, 10, 10); }

.input-group { display: flex; width: 100%; margin-bottom: 1rem; align-items=
: stretch; }

.input-group > :first-child { border-radius: 0px; }

.input-group > :last-child > * { border-radius: 0px; }

.input-group-label, .input-group-field, .input-group-button, .input-group-b=
utton a, .input-group-button input, .input-group-button button, .input-grou=
p-button label { margin: 0px; white-space: nowrap; }

.input-group-label { padding: 0px 1rem; border: 1px solid rgb(202, 202, 202=
); background: rgb(230, 230, 230); color: rgb(10, 10, 10); text-align: cent=
er; white-space: nowrap; display: flex; flex: 0 0 auto; align-items: center=
; }

.input-group-label:first-child { border-right: 0px; }

.input-group-label:last-child { border-left: 0px; }

.input-group-field { border-radius: 0px; flex: 1 1 0px; height: auto; min-w=
idth: 0px; }

.input-group-button { padding-top: 0px; padding-bottom: 0px; text-align: ce=
nter; display: flex; flex: 0 0 auto; }

.input-group-button a, .input-group-button input, .input-group-button butto=
n, .input-group-button label { height: auto; align-self: stretch; padding-t=
op: 0px; padding-bottom: 0px; font-size: 1rem; }

fieldset { margin: 0px; padding: 0px; border: 0px; }

legend { max-width: 100%; margin-bottom: 0.5rem; }

.fieldset { margin: 1.125rem 0px; padding: 1.25rem; border: 1px solid rgb(2=
02, 202, 202); }

.fieldset legend { margin: 0px 0px 0px -0.1875rem; padding: 0px 0.1875rem; =
}

select { height: 2.4375rem; margin: 0px 0px 1rem; padding: 0.5rem 1.5rem 0.=
5rem 0.5rem; appearance: none; border: 1px solid rgb(202, 202, 202); border=
-radius: 0px; background-color: rgb(254, 254, 254); font-family: inherit; f=
ont-size: 1rem; font-weight: normal; line-height: 1.5; color: rgb(10, 10, 1=
0); background-image: url("data:image/svg+xml;utf8,<svg xmlns=3D'http://www=
.w3.org/2000/svg' version=3D'1.1' width=3D'32' height=3D'24' viewBox=3D'0 0=
 32 24'><polygon points=3D'0,0 32,0 16,24' style=3D'fill: rgb%28138, 138, 1=
38%29'></polygon></svg>"); background-origin: content-box; background-posit=
ion: right -1rem center; background-repeat: no-repeat; background-size: 9px=
 6px; transition: box-shadow 0.5s, border-color 0.25s ease-in-out; }

@media screen and (min-width:0\0) {
  select { background-image: url("data:image/png;base64,iVBORw0KGgoAAAANSUh=
EUgAAACAAAAAYCAYAAACbU/80AAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPA=
AAAIpJREFUeNrEkckNgDAMBBfRkEt0ObRBBdsGXUDgmQfK4XhH2m8czQAAy27R3tsw4Qfe2x8uO=
O6oYLb6GlOor3GF+swURAOmUJ+RwtEJs9WvTGEYxBXqI1MQAZhCfUQKRzDMVj+TwrAIV6jvSUEk=
YAr1LSkcyTBb/V+KYfX7xAeusq3sLDtGH3kEGACPWIflNZfhRQAAAABJRU5ErkJggg=3D=3D");=
 }
}

select:focus { outline: none; border: 1px solid rgb(138, 138, 138); backgro=
und-color: rgb(254, 254, 254); box-shadow: rgb(202, 202, 202) 0px 0px 5px; =
transition: box-shadow 0.5s, border-color 0.25s ease-in-out; }

select:disabled { background-color: rgb(230, 230, 230); cursor: not-allowed=
; }

select[multiple] { height: auto; background-image: none; }

.is-invalid-input:not(:focus) { border-color: rgb(204, 75, 55); background-=
color: rgb(249, 236, 234); }

.is-invalid-input:not(:focus)::-webkit-input-placeholder { color: rgb(204, =
75, 55); }

.is-invalid-input:not(:focus)::placeholder { color: rgb(204, 75, 55); }

.is-invalid-label { color: rgb(204, 75, 55); }

.form-error { display: none; margin-top: -0.5rem; margin-bottom: 1rem; font=
-size: 0.75rem; font-weight: bold; color: rgb(204, 75, 55); }

.form-error.is-visible { display: block; }

.accordion { margin-left: 0px; background: rgb(254, 254, 254); list-style-t=
ype: none; }

.accordion[disabled] .accordion-title { cursor: not-allowed; }

.accordion-item:first-child > :first-child { border-radius: 0px; }

.accordion-item:last-child > :last-child { border-radius: 0px; }

.accordion-title { position: relative; display: block; padding: 1.25rem 1re=
m; border-width: 1px 1px 0px; border-top-style: solid; border-right-style: =
solid; border-left-style: solid; border-top-color: rgb(230, 230, 230); bord=
er-right-color: rgb(230, 230, 230); border-left-color: rgb(230, 230, 230); =
border-image: initial; border-bottom-style: initial; border-bottom-color: i=
nitial; font-size: 0.75rem; line-height: 1; color: rgb(23, 121, 186); }

:last-child:not(.is-active) > .accordion-title { border-bottom: 1px solid r=
gb(230, 230, 230); border-radius: 0px; }

.accordion-title:hover, .accordion-title:focus { background-color: rgb(230,=
 230, 230); }

.accordion-title::before { position: absolute; top: 50%; right: 1rem; margi=
n-top: -0.5rem; content: "+"; }

.is-active > .accordion-title::before { content: "=E2=80=93"; }

.accordion-content { display: none; padding: 1rem; border-width: 1px 1px 0p=
x; border-top-style: solid; border-right-style: solid; border-left-style: s=
olid; border-top-color: rgb(230, 230, 230); border-right-color: rgb(230, 23=
0, 230); border-left-color: rgb(230, 230, 230); border-image: initial; bord=
er-bottom-style: initial; border-bottom-color: initial; background-color: r=
gb(254, 254, 254); color: rgb(10, 10, 10); }

:last-child > .accordion-content:last-child { border-bottom: 1px solid rgb(=
230, 230, 230); }

.accordion-menu li { width: 100%; }

.accordion-menu a { padding: 0.7rem 1rem; }

.accordion-menu .is-accordion-submenu a { padding: 0.7rem 1rem; }

.accordion-menu .nested.is-accordion-submenu { margin-right: 0px; margin-le=
ft: 1rem; }

.accordion-menu.align-right .nested.is-accordion-submenu { margin-right: 1r=
em; margin-left: 0px; }

.accordion-menu .is-accordion-submenu-parent:not(.has-submenu-toggle) > a {=
 position: relative; }

.accordion-menu .is-accordion-submenu-parent:not(.has-submenu-toggle) > a::=
after { display: block; width: 0px; height: 0px; border-width: 6px 6px 0px;=
 border-style: solid inset inset; border-image: initial; content: ""; borde=
r-color: rgb(23, 121, 186) transparent transparent; position: absolute; top=
: 50%; margin-top: -3px; right: 1rem; }

.accordion-menu.align-left .is-accordion-submenu-parent > a::after { left: =
auto; right: 1rem; }

.accordion-menu.align-right .is-accordion-submenu-parent > a::after { right=
: auto; left: 1rem; }

.accordion-menu .is-accordion-submenu-parent[aria-expanded=3D"true"] > a::a=
fter { transform: rotate(180deg); transform-origin: 50% 50%; }

.is-accordion-submenu-parent { position: relative; }

.has-submenu-toggle > a { margin-right: 40px; }

.submenu-toggle { position: absolute; top: 0px; right: 0px; cursor: pointer=
; width: 40px; height: 40px; }

.submenu-toggle::after { display: block; width: 0px; height: 0px; border-wi=
dth: 6px 6px 0px; border-style: solid inset inset; border-image: initial; c=
ontent: ""; border-color: rgb(23, 121, 186) transparent transparent; top: 0=
px; bottom: 0px; margin: auto; }

.submenu-toggle[aria-expanded=3D"true"]::after { transform: scaleY(-1); tra=
nsform-origin: 50% 50%; }

.submenu-toggle-text { width: 1px; height: 1px; padding: 0px; overflow: hid=
den; clip: rect(0px, 0px, 0px, 0px); white-space: nowrap; clip-path: inset(=
50%); border: 0px; position: absolute !important; }

.badge { display: inline-block; min-width: 2.1em; padding: 0.3em; border-ra=
dius: 50%; font-size: 0.6rem; text-align: center; background: rgb(23, 121, =
186); color: rgb(254, 254, 254); }

.badge.primary { background: rgb(23, 121, 186); color: rgb(254, 254, 254); =
}

.badge.secondary { background: rgb(118, 118, 118); color: rgb(254, 254, 254=
); }

.badge.success { background: rgb(58, 219, 118); color: rgb(10, 10, 10); }

.badge.warning { background: rgb(255, 174, 0); color: rgb(10, 10, 10); }

.badge.alert { background: rgb(204, 75, 55); color: rgb(254, 254, 254); }

.breadcrumbs { margin: 0px 0px 1rem; list-style: none; }

.breadcrumbs::before, .breadcrumbs::after { display: table; content: " "; f=
lex-basis: 0px; order: 1; }

.breadcrumbs::after { clear: both; }

.breadcrumbs li { float: left; font-size: 0.6875rem; color: rgb(10, 10, 10)=
; cursor: default; text-transform: uppercase; }

.breadcrumbs li:not(:last-child)::after { position: relative; margin: 0px 0=
.75rem; opacity: 1; content: "/"; color: rgb(202, 202, 202); }

.breadcrumbs a { color: rgb(23, 121, 186); }

.breadcrumbs a:hover { text-decoration: underline; }

.breadcrumbs .disabled { color: rgb(202, 202, 202); cursor: not-allowed; }

.button-group { margin-bottom: 1rem; display: flex; flex-wrap: nowrap; alig=
n-items: stretch; }

.button-group::before, .button-group::after { display: table; content: " ";=
 flex-basis: 0px; order: 1; }

.button-group::after { clear: both; }

.button-group .button { margin: 0px 1px 1px 0px; font-size: 0.9rem; flex: 0=
 0 auto; }

.button-group .button:last-child { margin-right: 0px; }

.button-group.tiny .button { font-size: 0.6rem; }

.button-group.small .button { font-size: 0.75rem; }

.button-group.large .button { font-size: 1.25rem; }

.button-group.expanded .button { flex: 1 1 0px; }

.button-group.primary .button { background-color: rgb(23, 121, 186); color:=
 rgb(254, 254, 254); }

.button-group.primary .button:hover, .button-group.primary .button:focus { =
background-color: rgb(18, 97, 149); color: rgb(254, 254, 254); }

.button-group.secondary .button { background-color: rgb(118, 118, 118); col=
or: rgb(254, 254, 254); }

.button-group.secondary .button:hover, .button-group.secondary .button:focu=
s { background-color: rgb(94, 94, 94); color: rgb(254, 254, 254); }

.button-group.success .button { background-color: rgb(58, 219, 118); color:=
 rgb(10, 10, 10); }

.button-group.success .button:hover, .button-group.success .button:focus { =
background-color: rgb(34, 187, 91); color: rgb(10, 10, 10); }

.button-group.warning .button { background-color: rgb(255, 174, 0); color: =
rgb(10, 10, 10); }

.button-group.warning .button:hover, .button-group.warning .button:focus { =
background-color: rgb(204, 139, 0); color: rgb(10, 10, 10); }

.button-group.alert .button { background-color: rgb(204, 75, 55); color: rg=
b(254, 254, 254); }

.button-group.alert .button:hover, .button-group.alert .button:focus { back=
ground-color: rgb(165, 59, 42); color: rgb(254, 254, 254); }

.button-group.stacked, .button-group.stacked-for-small, .button-group.stack=
ed-for-medium { flex-wrap: wrap; }

.button-group.stacked .button, .button-group.stacked-for-small .button, .bu=
tton-group.stacked-for-medium .button { flex: 0 0 100%; }

.button-group.stacked .button:last-child, .button-group.stacked-for-small .=
button:last-child, .button-group.stacked-for-medium .button:last-child { ma=
rgin-bottom: 0px; }

@media print, screen and (min-width: 40em) {
  .button-group.stacked-for-small .button { flex: 1 1 0px; margin-bottom: 0=
px; }
}

@media print, screen and (min-width: 64em) {
  .button-group.stacked-for-medium .button { flex: 1 1 0px; margin-bottom: =
0px; }
}

@media screen and (max-width: 39.9375em) {
  .button-group.stacked-for-small.expanded { display: block; }
  .button-group.stacked-for-small.expanded .button { display: block; margin=
-right: 0px; }
}

.card { display: flex; flex-direction: column; flex-grow: 1; margin-bottom:=
 1rem; border: 1px solid rgb(230, 230, 230); border-radius: 0px; background=
: rgb(254, 254, 254); box-shadow: none; overflow: hidden; color: rgb(10, 10=
, 10); }

.card > :last-child { margin-bottom: 0px; }

.card-divider { flex: 0 1 auto; display: flex; padding: 1rem; background: r=
gb(230, 230, 230); }

.card-divider > :last-child { margin-bottom: 0px; }

.card-section { flex: 1 0 auto; padding: 1rem; }

.card-section > :last-child { margin-bottom: 0px; }

.card-image { min-height: 1px; }

.callout { position: relative; margin: 0px 0px 1rem; padding: 1rem; border:=
 1px solid rgba(10, 10, 10, 0.25); border-radius: 0px; background-color: wh=
ite; color: rgb(10, 10, 10); }

.callout > :first-child { margin-top: 0px; }

.callout > :last-child { margin-bottom: 0px; }

.callout.primary { background-color: rgb(215, 236, 250); color: rgb(10, 10,=
 10); }

.callout.secondary { background-color: rgb(234, 234, 234); color: rgb(10, 1=
0, 10); }

.callout.success { background-color: rgb(225, 250, 234); color: rgb(10, 10,=
 10); }

.callout.warning { background-color: rgb(255, 243, 217); color: rgb(10, 10,=
 10); }

.callout.alert { background-color: rgb(247, 228, 225); color: rgb(10, 10, 1=
0); }

.callout.small { padding: 0.5rem; }

.callout.large { padding: 3rem; }

.close-button { position: absolute; color: rgb(138, 138, 138); cursor: poin=
ter; }

[data-whatinput=3D"mouse"] .close-button { outline: 0px; }

.close-button:hover, .close-button:focus { color: rgb(10, 10, 10); }

.close-button.small { right: 0.66rem; top: 0.33em; font-size: 1.5em; line-h=
eight: 1; }

.close-button, .close-button.medium { right: 1rem; top: 0.5rem; font-size: =
2em; line-height: 1; }

.menu { padding: 0px; margin: 0px; list-style: none; position: relative; di=
splay: flex; flex-wrap: wrap; }

[data-whatinput=3D"mouse"] .menu li { outline: 0px; }

.menu a, .menu .button { line-height: 1; text-decoration: none; display: bl=
ock; padding: 0.7rem 1rem; }

.menu input, .menu select, .menu a, .menu button { margin-bottom: 0px; }

.menu input { display: inline-block; }

.menu, .menu.horizontal { flex-flow: wrap; }

.menu.vertical { flex-flow: column; }

.menu.expanded li { flex: 1 1 0px; }

.menu.simple { align-items: center; }

.menu.simple li + li { margin-left: 1rem; }

.menu.simple a { padding: 0px; }

@media print, screen and (min-width: 40em) {
  .menu.medium-horizontal { flex-flow: wrap; }
  .menu.medium-vertical { flex-flow: column; }
  .menu.medium-expanded li { flex: 1 1 0px; }
  .menu.medium-simple li { flex: 1 1 0px; }
}

@media print, screen and (min-width: 64em) {
  .menu.large-horizontal { flex-flow: wrap; }
  .menu.large-vertical { flex-flow: column; }
  .menu.large-expanded li { flex: 1 1 0px; }
  .menu.large-simple li { flex: 1 1 0px; }
}

.menu.nested { margin-right: 0px; margin-left: 1rem; }

.menu.icons a { display: flex; }

.menu.icon-top a, .menu.icon-right a, .menu.icon-bottom a, .menu.icon-left =
a { display: flex; }

.menu.icon-left li a { flex-flow: row; }

.menu.icon-left li a img, .menu.icon-left li a i, .menu.icon-left li a svg =
{ margin-right: 0.25rem; }

.menu.icon-right li a { flex-flow: row; }

.menu.icon-right li a img, .menu.icon-right li a i, .menu.icon-right li a s=
vg { margin-left: 0.25rem; }

.menu.icon-top li a { flex-flow: column; }

.menu.icon-top li a img, .menu.icon-top li a i, .menu.icon-top li a svg { a=
lign-self: stretch; margin-bottom: 0.25rem; text-align: center; }

.menu.icon-bottom li a { flex-flow: column; }

.menu.icon-bottom li a img, .menu.icon-bottom li a i, .menu.icon-bottom li =
a svg { align-self: stretch; margin-bottom: 0.25rem; text-align: center; }

.menu .is-active > a { background: rgb(23, 121, 186); color: rgb(254, 254, =
254); }

.menu .active > a { background: rgb(23, 121, 186); color: rgb(254, 254, 254=
); }

.menu.align-left { justify-content: flex-start; }

.menu.align-right li { display: flex; justify-content: flex-end; }

.menu.align-right li .submenu li { justify-content: flex-start; }

.menu.align-right.vertical li { display: block; text-align: right; }

.menu.align-right.vertical li .submenu li { text-align: right; }

.menu.align-right .nested { margin-right: 1rem; margin-left: 0px; }

.menu.align-center li { display: flex; justify-content: center; }

.menu.align-center li .submenu li { justify-content: flex-start; }

.menu .menu-text { padding: 0.7rem 1rem; font-weight: bold; line-height: 1;=
 color: inherit; }

.menu-centered > .menu { justify-content: center; }

.menu-centered > .menu li { display: flex; justify-content: center; }

.menu-centered > .menu li .submenu li { justify-content: flex-start; }

.no-js [data-responsive-menu] ul { display: none; }

.menu-icon { position: relative; display: inline-block; vertical-align: mid=
dle; width: 20px; height: 16px; cursor: pointer; }

.menu-icon::after { position: absolute; top: 0px; left: 0px; display: block=
; width: 100%; height: 2px; background: rgb(254, 254, 254); box-shadow: rgb=
(254, 254, 254) 0px 7px 0px, rgb(254, 254, 254) 0px 14px 0px; content: ""; =
}

.menu-icon:hover::after { background: rgb(202, 202, 202); box-shadow: rgb(2=
02, 202, 202) 0px 7px 0px, rgb(202, 202, 202) 0px 14px 0px; }

.menu-icon.dark { position: relative; display: inline-block; vertical-align=
: middle; width: 20px; height: 16px; cursor: pointer; }

.menu-icon.dark::after { position: absolute; top: 0px; left: 0px; display: =
block; width: 100%; height: 2px; background: rgb(10, 10, 10); box-shadow: r=
gb(10, 10, 10) 0px 7px 0px, rgb(10, 10, 10) 0px 14px 0px; content: ""; }

.menu-icon.dark:hover::after { background: rgb(138, 138, 138); box-shadow: =
rgb(138, 138, 138) 0px 7px 0px, rgb(138, 138, 138) 0px 14px 0px; }

.is-drilldown { position: relative; overflow: hidden; }

.is-drilldown li { display: block; }

.is-drilldown.animate-height { transition: height 0.5s; }

.drilldown a { padding: 0.7rem 1rem; background: rgb(254, 254, 254); }

.drilldown .is-drilldown-submenu { position: absolute; top: 0px; left: 100%=
; z-index: -1; width: 100%; background: rgb(254, 254, 254); transition: tra=
nsform 0.15s linear; }

.drilldown .is-drilldown-submenu.is-active { z-index: 1; display: block; tr=
ansform: translateX(-100%); }

.drilldown .is-drilldown-submenu.is-closing { transform: translateX(100%); =
}

.drilldown .is-drilldown-submenu a { padding: 0.7rem 1rem; }

.drilldown .nested.is-drilldown-submenu { margin-right: 0px; margin-left: 0=
px; }

.drilldown .drilldown-submenu-cover-previous { min-height: 100%; }

.drilldown .is-drilldown-submenu-parent > a { position: relative; }

.drilldown .is-drilldown-submenu-parent > a::after { position: absolute; to=
p: 50%; margin-top: -6px; right: 1rem; display: block; width: 0px; height: =
0px; border-width: 6px 0px 6px 6px; border-style: inset inset inset solid; =
border-image: initial; content: ""; border-color: transparent transparent t=
ransparent rgb(23, 121, 186); }

.drilldown.align-left .is-drilldown-submenu-parent > a::after { left: auto;=
 right: 1rem; display: block; width: 0px; height: 0px; border-width: 6px 0p=
x 6px 6px; border-style: inset inset inset solid; border-image: initial; co=
ntent: ""; border-color: transparent transparent transparent rgb(23, 121, 1=
86); }

.drilldown.align-right .is-drilldown-submenu-parent > a::after { right: aut=
o; left: 1rem; display: block; width: 0px; height: 0px; border-width: 6px 6=
px 6px 0px; border-style: inset solid inset inset; border-image: initial; c=
ontent: ""; border-color: transparent rgb(23, 121, 186) transparent transpa=
rent; }

.drilldown .js-drilldown-back > a::before { width: 0px; height: 0px; border=
-width: 6px 6px 6px 0px; border-style: inset solid inset inset; border-imag=
e: initial; content: ""; border-color: transparent rgb(23, 121, 186) transp=
arent transparent; display: inline-block; vertical-align: middle; margin-ri=
ght: 0.75rem; }

.dropdown-pane { position: absolute; z-index: 10; width: 300px; padding: 1r=
em; visibility: hidden; display: none; border: 1px solid rgb(202, 202, 202)=
; border-radius: 0px; background-color: rgb(254, 254, 254); font-size: 1rem=
; }

.dropdown-pane.is-opening { display: block; }

.dropdown-pane.is-open { visibility: visible; display: block; }

.dropdown-pane.tiny { width: 100px; }

.dropdown-pane.small { width: 200px; }

.dropdown-pane.large { width: 400px; }

.dropdown.menu > li.opens-left > .is-dropdown-submenu { top: 100%; right: 0=
px; left: auto; }

.dropdown.menu > li.opens-right > .is-dropdown-submenu { top: 100%; right: =
auto; left: 0px; }

.dropdown.menu > li.is-dropdown-submenu-parent > a { position: relative; pa=
dding-right: 1.5rem; }

.dropdown.menu > li.is-dropdown-submenu-parent > a::after { display: block;=
 width: 0px; height: 0px; border-width: 6px 6px 0px; border-style: solid in=
set inset; border-image: initial; content: ""; border-color: rgb(23, 121, 1=
86) transparent transparent; right: 5px; left: auto; margin-top: -3px; }

.dropdown.menu a { padding: 0.7rem 1rem; }

[data-whatinput=3D"mouse"] .dropdown.menu a { outline: 0px; }

.dropdown.menu .is-active > a { background: transparent; color: rgb(23, 121=
, 186); }

.no-js .dropdown.menu ul { display: none; }

.dropdown.menu .nested.is-dropdown-submenu { margin-right: 0px; margin-left=
: 0px; }

.dropdown.menu.vertical > li .is-dropdown-submenu { top: 0px; }

.dropdown.menu.vertical > li.opens-left > .is-dropdown-submenu { right: 100=
%; left: auto; top: 0px; }

.dropdown.menu.vertical > li.opens-right > .is-dropdown-submenu { right: au=
to; left: 100%; }

.dropdown.menu.vertical > li > a::after { right: 14px; }

.dropdown.menu.vertical > li.opens-left > a::after { right: auto; left: 5px=
; display: block; width: 0px; height: 0px; border-width: 6px 6px 6px 0px; b=
order-style: inset solid inset inset; border-image: initial; content: ""; b=
order-color: transparent rgb(23, 121, 186) transparent transparent; }

.dropdown.menu.vertical > li.opens-right > a::after { display: block; width=
: 0px; height: 0px; border-width: 6px 0px 6px 6px; border-style: inset inse=
t inset solid; border-image: initial; content: ""; border-color: transparen=
t transparent transparent rgb(23, 121, 186); }

@media print, screen and (min-width: 40em) {
  .dropdown.menu.medium-horizontal > li.opens-left > .is-dropdown-submenu {=
 top: 100%; right: 0px; left: auto; }
  .dropdown.menu.medium-horizontal > li.opens-right > .is-dropdown-submenu =
{ top: 100%; right: auto; left: 0px; }
  .dropdown.menu.medium-horizontal > li.is-dropdown-submenu-parent > a { po=
sition: relative; padding-right: 1.5rem; }
  .dropdown.menu.medium-horizontal > li.is-dropdown-submenu-parent > a::aft=
er { display: block; width: 0px; height: 0px; border-width: 6px 6px 0px; bo=
rder-style: solid inset inset; border-image: initial; content: ""; border-c=
olor: rgb(23, 121, 186) transparent transparent; right: 5px; left: auto; ma=
rgin-top: -3px; }
  .dropdown.menu.medium-vertical > li .is-dropdown-submenu { top: 0px; }
  .dropdown.menu.medium-vertical > li.opens-left > .is-dropdown-submenu { r=
ight: 100%; left: auto; top: 0px; }
  .dropdown.menu.medium-vertical > li.opens-right > .is-dropdown-submenu { =
right: auto; left: 100%; }
  .dropdown.menu.medium-vertical > li > a::after { right: 14px; }
  .dropdown.menu.medium-vertical > li.opens-left > a::after { right: auto; =
left: 5px; display: block; width: 0px; height: 0px; border-width: 6px 6px 6=
px 0px; border-style: inset solid inset inset; border-image: initial; conte=
nt: ""; border-color: transparent rgb(23, 121, 186) transparent transparent=
; }
  .dropdown.menu.medium-vertical > li.opens-right > a::after { display: blo=
ck; width: 0px; height: 0px; border-width: 6px 0px 6px 6px; border-style: i=
nset inset inset solid; border-image: initial; content: ""; border-color: t=
ransparent transparent transparent rgb(23, 121, 186); }
}

@media print, screen and (min-width: 64em) {
  .dropdown.menu.large-horizontal > li.opens-left > .is-dropdown-submenu { =
top: 100%; right: 0px; left: auto; }
  .dropdown.menu.large-horizontal > li.opens-right > .is-dropdown-submenu {=
 top: 100%; right: auto; left: 0px; }
  .dropdown.menu.large-horizontal > li.is-dropdown-submenu-parent > a { pos=
ition: relative; padding-right: 1.5rem; }
  .dropdown.menu.large-horizontal > li.is-dropdown-submenu-parent > a::afte=
r { display: block; width: 0px; height: 0px; border-width: 6px 6px 0px; bor=
der-style: solid inset inset; border-image: initial; content: ""; border-co=
lor: rgb(23, 121, 186) transparent transparent; right: 5px; left: auto; mar=
gin-top: -3px; }
  .dropdown.menu.large-vertical > li .is-dropdown-submenu { top: 0px; }
  .dropdown.menu.large-vertical > li.opens-left > .is-dropdown-submenu { ri=
ght: 100%; left: auto; top: 0px; }
  .dropdown.menu.large-vertical > li.opens-right > .is-dropdown-submenu { r=
ight: auto; left: 100%; }
  .dropdown.menu.large-vertical > li > a::after { right: 14px; }
  .dropdown.menu.large-vertical > li.opens-left > a::after { right: auto; l=
eft: 5px; display: block; width: 0px; height: 0px; border-width: 6px 6px 6p=
x 0px; border-style: inset solid inset inset; border-image: initial; conten=
t: ""; border-color: transparent rgb(23, 121, 186) transparent transparent;=
 }
  .dropdown.menu.large-vertical > li.opens-right > a::after { display: bloc=
k; width: 0px; height: 0px; border-width: 6px 0px 6px 6px; border-style: in=
set inset inset solid; border-image: initial; content: ""; border-color: tr=
ansparent transparent transparent rgb(23, 121, 186); }
}

.dropdown.menu.align-right .is-dropdown-submenu.first-sub { top: 100%; righ=
t: 0px; left: auto; }

.is-dropdown-menu.vertical { width: 100px; }

.is-dropdown-menu.vertical.align-right { float: right; }

.is-dropdown-submenu-parent { position: relative; }

.is-dropdown-submenu-parent a::after { position: absolute; top: 50%; right:=
 5px; left: auto; margin-top: -6px; }

.is-dropdown-submenu-parent.opens-inner > .is-dropdown-submenu { top: 100%;=
 left: auto; }

.is-dropdown-submenu-parent.opens-left > .is-dropdown-submenu { right: 100%=
; left: auto; }

.is-dropdown-submenu-parent.opens-right > .is-dropdown-submenu { right: aut=
o; left: 100%; }

.is-dropdown-submenu { position: absolute; top: 0px; left: 100%; z-index: 1=
; display: none; min-width: 200px; border: 1px solid rgb(202, 202, 202); ba=
ckground: rgb(254, 254, 254); }

.dropdown .is-dropdown-submenu a { padding: 0.7rem 1rem; }

.is-dropdown-submenu .is-dropdown-submenu-parent > a::after { right: 14px; =
}

.is-dropdown-submenu .is-dropdown-submenu-parent.opens-left > a::after { ri=
ght: auto; left: 5px; display: block; width: 0px; height: 0px; border-width=
: 6px 6px 6px 0px; border-style: inset solid inset inset; border-image: ini=
tial; content: ""; border-color: transparent rgb(23, 121, 186) transparent =
transparent; }

.is-dropdown-submenu .is-dropdown-submenu-parent.opens-right > a::after { d=
isplay: block; width: 0px; height: 0px; border-width: 6px 0px 6px 6px; bord=
er-style: inset inset inset solid; border-image: initial; content: ""; bord=
er-color: transparent transparent transparent rgb(23, 121, 186); }

.is-dropdown-submenu .is-dropdown-submenu { margin-top: -1px; }

.is-dropdown-submenu > li { width: 100%; }

.is-dropdown-submenu.js-dropdown-active { display: block; }

.responsive-embed, .flex-video { position: relative; height: 0px; margin-bo=
ttom: 1rem; padding-bottom: 75%; overflow: hidden; }

.responsive-embed iframe, .responsive-embed object, .responsive-embed embed=
, .responsive-embed video, .flex-video iframe, .flex-video object, .flex-vi=
deo embed, .flex-video video { position: absolute; top: 0px; left: 0px; wid=
th: 100%; height: 100%; }

.responsive-embed.widescreen, .flex-video.widescreen { padding-bottom: 56.2=
5%; }

.label { display: inline-block; padding: 0.33333rem 0.5rem; border-radius: =
0px; font-size: 0.8rem; line-height: 1; white-space: nowrap; cursor: defaul=
t; background: rgb(23, 121, 186); color: rgb(254, 254, 254); }

.label.primary { background: rgb(23, 121, 186); color: rgb(254, 254, 254); =
}

.label.secondary { background: rgb(118, 118, 118); color: rgb(254, 254, 254=
); }

.label.success { background: rgb(58, 219, 118); color: rgb(10, 10, 10); }

.label.warning { background: rgb(255, 174, 0); color: rgb(10, 10, 10); }

.label.alert { background: rgb(204, 75, 55); color: rgb(254, 254, 254); }

.media-object { display: flex; margin-bottom: 1rem; flex-wrap: nowrap; }

.media-object img { max-width: none; }

@media screen and (max-width: 39.9375em) {
  .media-object.stack-for-small { flex-wrap: wrap; }
}

@media screen and (max-width: 39.9375em) {
  .media-object.stack-for-small .media-object-section { padding: 0px 0px 1r=
em; flex-basis: 100%; max-width: 100%; }
  .media-object.stack-for-small .media-object-section img { width: 100%; }
}

.media-object-section { flex: 0 1 auto; }

.media-object-section:first-child { padding-right: 1rem; }

.media-object-section:last-child:not(:nth-child(2)) { padding-left: 1rem; }

.media-object-section > :last-child { margin-bottom: 0px; }

.media-object-section.main-section { flex: 1 1 0px; }

.is-off-canvas-open { overflow: hidden; }

.js-off-canvas-overlay { position: absolute; top: 0px; left: 0px; z-index: =
11; width: 100%; height: 100%; transition: opacity 0.5s, visibility 0.5s; b=
ackground: rgba(254, 254, 254, 0.25); opacity: 0; visibility: hidden; overf=
low: hidden; }

.js-off-canvas-overlay.is-visible { opacity: 1; visibility: visible; }

.js-off-canvas-overlay.is-closable { cursor: pointer; }

.js-off-canvas-overlay.is-overlay-absolute { position: absolute; }

.js-off-canvas-overlay.is-overlay-fixed { position: fixed; }

.off-canvas-wrapper { position: relative; overflow: hidden; }

.off-canvas { position: fixed; z-index: 12; transition: transform 0.5s; bac=
kface-visibility: hidden; background: rgb(230, 230, 230); }

[data-whatinput=3D"mouse"] .off-canvas { outline: 0px; }

.off-canvas.is-transition-push { z-index: 12; }

.off-canvas.is-closed { visibility: hidden; }

.off-canvas.is-transition-overlap { z-index: 13; }

.off-canvas.is-transition-overlap.is-open { box-shadow: rgba(10, 10, 10, 0.=
7) 0px 0px 10px; }

.off-canvas.is-open { transform: translate(0px, 0px); }

.off-canvas-absolute { position: absolute; z-index: 12; transition: transfo=
rm 0.5s; backface-visibility: hidden; background: rgb(230, 230, 230); }

[data-whatinput=3D"mouse"] .off-canvas-absolute { outline: 0px; }

.off-canvas-absolute.is-transition-push { z-index: 12; }

.off-canvas-absolute.is-closed { visibility: hidden; }

.off-canvas-absolute.is-transition-overlap { z-index: 13; }

.off-canvas-absolute.is-transition-overlap.is-open { box-shadow: rgba(10, 1=
0, 10, 0.7) 0px 0px 10px; }

.off-canvas-absolute.is-open { transform: translate(0px, 0px); }

.position-left { top: 0px; left: 0px; height: 100%; overflow-y: auto; width=
: 250px; transform: translateX(-250px); }

.off-canvas-content .off-canvas.position-left { transform: translateX(-250p=
x); }

.off-canvas-content .off-canvas.position-left.is-transition-overlap.is-open=
 { transform: translate(0px, 0px); }

.off-canvas-content.is-open-left.has-transition-push { transform: translate=
X(250px); }

.position-left.is-transition-push { box-shadow: rgba(10, 10, 10, 0.25) -13p=
x 0px 20px -13px inset; }

.position-right { top: 0px; right: 0px; height: 100%; overflow-y: auto; wid=
th: 250px; transform: translateX(250px); }

.off-canvas-content .off-canvas.position-right { transform: translateX(250p=
x); }

.off-canvas-content .off-canvas.position-right.is-transition-overlap.is-ope=
n { transform: translate(0px, 0px); }

.off-canvas-content.is-open-right.has-transition-push { transform: translat=
eX(-250px); }

.position-right.is-transition-push { box-shadow: rgba(10, 10, 10, 0.25) 13p=
x 0px 20px -13px inset; }

.position-top { top: 0px; left: 0px; width: 100%; overflow-x: auto; height:=
 250px; transform: translateY(-250px); }

.off-canvas-content .off-canvas.position-top { transform: translateY(-250px=
); }

.off-canvas-content .off-canvas.position-top.is-transition-overlap.is-open =
{ transform: translate(0px, 0px); }

.off-canvas-content.is-open-top.has-transition-push { transform: translateY=
(250px); }

.position-top.is-transition-push { box-shadow: rgba(10, 10, 10, 0.25) 0px -=
13px 20px -13px inset; }

.position-bottom { bottom: 0px; left: 0px; width: 100%; overflow-x: auto; h=
eight: 250px; transform: translateY(250px); }

.off-canvas-content .off-canvas.position-bottom { transform: translateY(250=
px); }

.off-canvas-content .off-canvas.position-bottom.is-transition-overlap.is-op=
en { transform: translate(0px, 0px); }

.off-canvas-content.is-open-bottom.has-transition-push { transform: transla=
teY(-250px); }

.position-bottom.is-transition-push { box-shadow: rgba(10, 10, 10, 0.25) 0p=
x 13px 20px -13px inset; }

.off-canvas-content { transform: none; transition: transform 0.5s; backface=
-visibility: hidden; }

.off-canvas-content.has-transition-push { transform: translate(0px, 0px); }

.off-canvas-content .off-canvas.is-open { transform: translate(0px, 0px); }

@media print, screen and (min-width: 40em) {
  .position-left.reveal-for-medium { transform: none; z-index: 12; transiti=
on: none; visibility: visible; }
  .position-left.reveal-for-medium .close-button { display: none; }
  .off-canvas-content .position-left.reveal-for-medium { transform: none; }
  .off-canvas-content.has-reveal-left { margin-left: 250px; }
  .position-left.reveal-for-medium ~ .off-canvas-content { margin-left: 250=
px; }
  .position-right.reveal-for-medium { transform: none; z-index: 12; transit=
ion: none; visibility: visible; }
  .position-right.reveal-for-medium .close-button { display: none; }
  .off-canvas-content .position-right.reveal-for-medium { transform: none; =
}
  .off-canvas-content.has-reveal-right { margin-right: 250px; }
  .position-right.reveal-for-medium ~ .off-canvas-content { margin-right: 2=
50px; }
  .position-top.reveal-for-medium { transform: none; z-index: 12; transitio=
n: none; visibility: visible; }
  .position-top.reveal-for-medium .close-button { display: none; }
  .off-canvas-content .position-top.reveal-for-medium { transform: none; }
  .off-canvas-content.has-reveal-top { margin-top: 250px; }
  .position-top.reveal-for-medium ~ .off-canvas-content { margin-top: 250px=
; }
  .position-bottom.reveal-for-medium { transform: none; z-index: 12; transi=
tion: none; visibility: visible; }
  .position-bottom.reveal-for-medium .close-button { display: none; }
  .off-canvas-content .position-bottom.reveal-for-medium { transform: none;=
 }
  .off-canvas-content.has-reveal-bottom { margin-bottom: 250px; }
  .position-bottom.reveal-for-medium ~ .off-canvas-content { margin-bottom:=
 250px; }
}

@media print, screen and (min-width: 64em) {
  .position-left.reveal-for-large { transform: none; z-index: 12; transitio=
n: none; visibility: visible; }
  .position-left.reveal-for-large .close-button { display: none; }
  .off-canvas-content .position-left.reveal-for-large { transform: none; }
  .off-canvas-content.has-reveal-left { margin-left: 250px; }
  .position-left.reveal-for-large ~ .off-canvas-content { margin-left: 250p=
x; }
  .position-right.reveal-for-large { transform: none; z-index: 12; transiti=
on: none; visibility: visible; }
  .position-right.reveal-for-large .close-button { display: none; }
  .off-canvas-content .position-right.reveal-for-large { transform: none; }
  .off-canvas-content.has-reveal-right { margin-right: 250px; }
  .position-right.reveal-for-large ~ .off-canvas-content { margin-right: 25=
0px; }
  .position-top.reveal-for-large { transform: none; z-index: 12; transition=
: none; visibility: visible; }
  .position-top.reveal-for-large .close-button { display: none; }
  .off-canvas-content .position-top.reveal-for-large { transform: none; }
  .off-canvas-content.has-reveal-top { margin-top: 250px; }
  .position-top.reveal-for-large ~ .off-canvas-content { margin-top: 250px;=
 }
  .position-bottom.reveal-for-large { transform: none; z-index: 12; transit=
ion: none; visibility: visible; }
  .position-bottom.reveal-for-large .close-button { display: none; }
  .off-canvas-content .position-bottom.reveal-for-large { transform: none; =
}
  .off-canvas-content.has-reveal-bottom { margin-bottom: 250px; }
  .position-bottom.reveal-for-large ~ .off-canvas-content { margin-bottom: =
250px; }
}

@media print, screen and (min-width: 40em) {
  .off-canvas.in-canvas-for-medium { visibility: visible; height: auto; pos=
ition: static; background: inherit; width: inherit; overflow: inherit; tran=
sition: inherit; }
  .off-canvas.in-canvas-for-medium.position-left, .off-canvas.in-canvas-for=
-medium.position-right, .off-canvas.in-canvas-for-medium.position-top, .off=
-canvas.in-canvas-for-medium.position-bottom { box-shadow: none; transform:=
 none; }
  .off-canvas.in-canvas-for-medium .close-button { display: none; }
}

@media print, screen and (min-width: 64em) {
  .off-canvas.in-canvas-for-large { visibility: visible; height: auto; posi=
tion: static; background: inherit; width: inherit; overflow: inherit; trans=
ition: inherit; }
  .off-canvas.in-canvas-for-large.position-left, .off-canvas.in-canvas-for-=
large.position-right, .off-canvas.in-canvas-for-large.position-top, .off-ca=
nvas.in-canvas-for-large.position-bottom { box-shadow: none; transform: non=
e; }
  .off-canvas.in-canvas-for-large .close-button { display: none; }
}

.orbit { position: relative; }

.orbit-container { position: relative; height: 0px; margin: 0px; list-style=
: none; overflow: hidden; }

.orbit-slide { width: 100%; }

.orbit-slide.no-motionui.is-active { top: 0px; left: 0px; }

.orbit-figure { margin: 0px; }

.orbit-image { width: 100%; max-width: 100%; margin: 0px; }

.orbit-caption { position: absolute; bottom: 0px; width: 100%; margin-botto=
m: 0px; padding: 1rem; background-color: rgba(10, 10, 10, 0.5); color: rgb(=
254, 254, 254); }

.orbit-previous, .orbit-next { position: absolute; top: 50%; transform: tra=
nslateY(-50%); z-index: 10; padding: 1rem; color: rgb(254, 254, 254); }

[data-whatinput=3D"mouse"] .orbit-previous, [data-whatinput=3D"mouse"] .orb=
it-next { outline: 0px; }

.orbit-previous:hover, .orbit-next:hover, .orbit-previous:active, .orbit-ne=
xt:active, .orbit-previous:focus, .orbit-next:focus { background-color: rgb=
a(10, 10, 10, 0.5); }

.orbit-previous { left: 0px; }

.orbit-next { left: auto; right: 0px; }

.orbit-bullets { position: relative; margin-top: 0.8rem; margin-bottom: 0.8=
rem; text-align: center; }

[data-whatinput=3D"mouse"] .orbit-bullets { outline: 0px; }

.orbit-bullets button { width: 1.2rem; height: 1.2rem; margin: 0.1rem; bord=
er-radius: 50%; background-color: rgb(202, 202, 202); }

.orbit-bullets button:hover { background-color: rgb(138, 138, 138); }

.orbit-bullets button.is-active { background-color: rgb(138, 138, 138); }

.pagination { margin-left: 0px; margin-bottom: 1rem; }

.pagination::before, .pagination::after { display: table; content: " "; fle=
x-basis: 0px; order: 1; }

.pagination::after { clear: both; }

.pagination li { margin-right: 0.0625rem; border-radius: 0px; font-size: 0.=
875rem; display: none; }

.pagination li:last-child, .pagination li:first-child { display: inline-blo=
ck; }

@media print, screen and (min-width: 40em) {
  .pagination li { display: inline-block; }
}

.pagination a, .pagination button { display: block; padding: 0.1875rem 0.62=
5rem; border-radius: 0px; color: rgb(10, 10, 10); }

.pagination a:hover, .pagination button:hover { background: rgb(230, 230, 2=
30); }

.pagination .current { padding: 0.1875rem 0.625rem; background: rgb(23, 121=
, 186); color: rgb(254, 254, 254); cursor: default; }

.pagination .disabled { padding: 0.1875rem 0.625rem; color: rgb(202, 202, 2=
02); cursor: not-allowed; }

.pagination .disabled:hover { background: transparent; }

.pagination .ellipsis::after { padding: 0.1875rem 0.625rem; content: "=E2=
=80=A6"; color: rgb(10, 10, 10); }

.pagination-previous a::before, .pagination-previous.disabled::before { dis=
play: inline-block; margin-right: 0.5rem; content: "=C2=AB"; }

.pagination-next a::after, .pagination-next.disabled::after { display: inli=
ne-block; margin-left: 0.5rem; content: "=C2=BB"; }

.progress { height: 1rem; margin-bottom: 1rem; border-radius: 0px; backgrou=
nd-color: rgb(202, 202, 202); }

.progress.primary .progress-meter { background-color: rgb(23, 121, 186); }

.progress.secondary .progress-meter { background-color: rgb(118, 118, 118);=
 }

.progress.success .progress-meter { background-color: rgb(58, 219, 118); }

.progress.warning .progress-meter { background-color: rgb(255, 174, 0); }

.progress.alert .progress-meter { background-color: rgb(204, 75, 55); }

.progress-meter { position: relative; display: block; width: 0%; height: 10=
0%; background-color: rgb(23, 121, 186); }

.progress-meter-text { top: 50%; left: 50%; transform: translate(-50%, -50%=
); position: absolute; margin: 0px; font-size: 0.75rem; font-weight: bold; =
color: rgb(254, 254, 254); white-space: nowrap; }

body.is-reveal-open { overflow: hidden; }

html.is-reveal-open, html.is-reveal-open body { min-height: 100%; overflow:=
 hidden; position: fixed; user-select: none; }

.reveal-overlay { position: fixed; inset: 0px; z-index: 1005; display: none=
; background-color: rgba(10, 10, 10, 0.45); overflow-y: scroll; }

.reveal { z-index: 1006; backface-visibility: hidden; display: none; paddin=
g: 1rem; border: 1px solid rgb(202, 202, 202); border-radius: 0px; backgrou=
nd-color: rgb(254, 254, 254); position: relative; top: 100px; margin-right:=
 auto; margin-left: auto; overflow-y: auto; }

[data-whatinput=3D"mouse"] .reveal { outline: 0px; }

@media print, screen and (min-width: 40em) {
  .reveal { min-height: 0px; }
}

.reveal .column { min-width: 0px; }

.reveal > :last-child { margin-bottom: 0px; }

@media print, screen and (min-width: 40em) {
  .reveal { width: 600px; max-width: 75rem; }
}

.reveal.collapse { padding: 0px; }

@media print, screen and (min-width: 40em) {
  .reveal.tiny { width: 30%; max-width: 75rem; }
}

@media print, screen and (min-width: 40em) {
  .reveal.small { width: 50%; max-width: 75rem; }
}

@media print, screen and (min-width: 40em) {
  .reveal.large { width: 90%; max-width: 75rem; }
}

.reveal.full { top: 0px; left: 0px; width: 100%; max-width: none; height: 1=
00vh; min-height: 100vh; margin-left: 0px; border: 0px; border-radius: 0px;=
 }

@media screen and (max-width: 39.9375em) {
  .reveal { top: 0px; left: 0px; width: 100%; max-width: none; height: 100v=
h; min-height: 100vh; margin-left: 0px; border: 0px; border-radius: 0px; }
}

.reveal.without-overlay { position: fixed; }

.slider { position: relative; height: 0.5rem; margin-top: 1.25rem; margin-b=
ottom: 2.25rem; background-color: rgb(230, 230, 230); cursor: pointer; user=
-select: none; touch-action: none; }

.slider-fill { position: absolute; top: 0px; left: 0px; display: inline-blo=
ck; max-width: 100%; height: 0.5rem; background-color: rgb(202, 202, 202); =
transition: 0.2s ease-in-out; }

.slider-fill.is-dragging { transition: linear; }

.slider-handle { position: absolute; top: 50%; transform: translateY(-50%);=
 left: 0px; z-index: 1; display: inline-block; width: 1.4rem; height: 1.4re=
m; border-radius: 0px; background-color: rgb(23, 121, 186); transition: 0.2=
s ease-in-out; touch-action: manipulation; }

[data-whatinput=3D"mouse"] .slider-handle { outline: 0px; }

.slider-handle:hover { background-color: rgb(20, 103, 158); }

.slider-handle.is-dragging { transition: linear; }

.slider.disabled, .slider[disabled] { opacity: 0.25; cursor: not-allowed; }

.slider.vertical { display: inline-block; width: 0.5rem; height: 12.5rem; m=
argin: 0px 1.25rem; transform: scale(1, -1); }

.slider.vertical .slider-fill { top: 0px; width: 0.5rem; max-height: 100%; =
}

.slider.vertical .slider-handle { position: absolute; top: 0px; left: 50%; =
width: 1.4rem; height: 1.4rem; transform: translateX(-50%); }

.sticky-container { position: relative; }

.sticky { position: relative; z-index: 0; transform: translate3d(0px, 0px, =
0px); }

.sticky.is-stuck { position: fixed; z-index: 5; width: 100%; }

.sticky.is-stuck.is-at-top { top: 0px; }

.sticky.is-stuck.is-at-bottom { bottom: 0px; }

.sticky.is-anchored { position: relative; right: auto; left: auto; }

.sticky.is-anchored.is-at-bottom { bottom: 0px; }

.switch { height: 2rem; position: relative; margin-bottom: 1rem; outline: 0=
px; font-size: 0.875rem; font-weight: bold; color: rgb(254, 254, 254); user=
-select: none; }

.switch-input { position: absolute; margin-bottom: 0px; opacity: 0; }

.switch-paddle { position: relative; display: block; width: 4rem; height: 2=
rem; border-radius: 0px; background: rgb(202, 202, 202); transition: 0.25s =
ease-out; font-weight: inherit; color: inherit; cursor: pointer; }

input + .switch-paddle { margin: 0px; }

.switch-paddle::after { position: absolute; top: 0.25rem; left: 0.25rem; di=
splay: block; width: 1.5rem; height: 1.5rem; transform: translate3d(0px, 0p=
x, 0px); border-radius: 0px; background: rgb(254, 254, 254); transition: 0.=
25s ease-out; content: ""; }

input:checked ~ .switch-paddle { background: rgb(23, 121, 186); }

input:checked ~ .switch-paddle::after { left: 2.25rem; }

[data-whatinput=3D"mouse"] input:focus ~ .switch-paddle { outline: 0px; }

.switch-active, .switch-inactive { position: absolute; top: 50%; transform:=
 translateY(-50%); }

.switch-active { left: 8%; display: none; }

input:checked + label > .switch-active { display: block; }

.switch-inactive { right: 15%; }

input:checked + label > .switch-inactive { display: none; }

.switch.tiny { height: 1.5rem; }

.switch.tiny .switch-paddle { width: 3rem; height: 1.5rem; font-size: 0.625=
rem; }

.switch.tiny .switch-paddle::after { top: 0.25rem; left: 0.25rem; width: 1r=
em; height: 1rem; }

.switch.tiny input:checked ~ .switch-paddle::after { left: 1.75rem; }

.switch.small { height: 1.75rem; }

.switch.small .switch-paddle { width: 3.5rem; height: 1.75rem; font-size: 0=
.75rem; }

.switch.small .switch-paddle::after { top: 0.25rem; left: 0.25rem; width: 1=
.25rem; height: 1.25rem; }

.switch.small input:checked ~ .switch-paddle::after { left: 2rem; }

.switch.large { height: 2.5rem; }

.switch.large .switch-paddle { width: 5rem; height: 2.5rem; font-size: 1rem=
; }

.switch.large .switch-paddle::after { top: 0.25rem; left: 0.25rem; width: 2=
rem; height: 2rem; }

.switch.large input:checked ~ .switch-paddle::after { left: 2.75rem; }

table { border-collapse: collapse; width: 100%; margin-bottom: 1rem; border=
-radius: 0px; }

table thead, table tbody, table tfoot { border: 1px solid rgb(241, 241, 241=
); background-color: rgb(254, 254, 254); }

table caption { padding: 0.5rem 0.625rem 0.625rem; font-weight: bold; }

table thead { background: rgb(248, 248, 248); color: rgb(10, 10, 10); }

table tfoot { background: rgb(241, 241, 241); color: rgb(10, 10, 10); }

table thead tr, table tfoot tr { background: transparent; }

table thead th, table thead td, table tfoot th, table tfoot td { padding: 0=
.5rem 0.625rem 0.625rem; font-weight: bold; text-align: left; }

table tbody th, table tbody td { padding: 0.5rem 0.625rem 0.625rem; }

table tbody tr:nth-child(2n) { border-bottom: 0px; background-color: rgb(24=
1, 241, 241); }

table.unstriped tbody { background-color: rgb(254, 254, 254); }

table.unstriped tbody tr { border-bottom: 1px solid rgb(241, 241, 241); bac=
kground-color: rgb(254, 254, 254); }

@media screen and (max-width: 63.9375em) {
  table.stack thead { display: none; }
  table.stack tfoot { display: none; }
  table.stack tr, table.stack th, table.stack td { display: block; }
  table.stack td { border-top: 0px; }
}

table.scroll { display: block; width: 100%; overflow-x: auto; }

table.hover thead tr:hover { background-color: rgb(243, 243, 243); }

table.hover tfoot tr:hover { background-color: rgb(236, 236, 236); }

table.hover tbody tr:hover { background-color: rgb(249, 249, 249); }

table.hover:not(.unstriped) tr:nth-of-type(2n):hover { background-color: rg=
b(236, 236, 236); }

.table-scroll { overflow-x: auto; }

.table-scroll table { width: auto; }

.tabs { margin: 0px; border: 1px solid rgb(230, 230, 230); background: rgb(=
254, 254, 254); list-style-type: none; }

.tabs::before, .tabs::after { display: table; content: " "; flex-basis: 0px=
; order: 1; }

.tabs::after { clear: both; }

.tabs.vertical > li { display: block; float: none; width: auto; }

.tabs.simple > li > a { padding: 0px; }

.tabs.simple > li > a:hover { background: transparent; }

.tabs.primary { background: rgb(23, 121, 186); }

.tabs.primary > li > a { color: rgb(254, 254, 254); }

.tabs.primary > li > a:hover, .tabs.primary > li > a:focus { background: rg=
b(22, 115, 177); }

.tabs-title { float: left; }

.tabs-title > a { display: block; padding: 1.25rem 1.5rem; font-size: 0.75r=
em; line-height: 1; color: rgb(23, 121, 186); }

.tabs-title > a:hover { background: rgb(254, 254, 254); color: rgb(20, 104,=
 160); }

.tabs-title > a:focus, .tabs-title > a[aria-selected=3D"true"] { background=
: rgb(230, 230, 230); color: rgb(23, 121, 186); }

.tabs-content { border-width: 0px 1px 1px; border-right-style: solid; borde=
r-bottom-style: solid; border-left-style: solid; border-right-color: rgb(23=
0, 230, 230); border-bottom-color: rgb(230, 230, 230); border-left-color: r=
gb(230, 230, 230); border-image: initial; border-top-style: initial; border=
-top-color: initial; background: rgb(254, 254, 254); color: rgb(10, 10, 10)=
; transition: 0.5s; }

.tabs-content.vertical { border-width: 1px 1px 1px 0px; border-top-style: s=
olid; border-right-style: solid; border-bottom-style: solid; border-top-col=
or: rgb(230, 230, 230); border-right-color: rgb(230, 230, 230); border-bott=
om-color: rgb(230, 230, 230); border-image: initial; border-left-style: ini=
tial; border-left-color: initial; }

.tabs-panel { display: none; padding: 1rem; }

.tabs-panel.is-active { display: block; }

.thumbnail { display: inline-block; max-width: 100%; margin-bottom: 1rem; b=
order: 4px solid rgb(254, 254, 254); border-radius: 0px; box-shadow: rgba(1=
0, 10, 10, 0.2) 0px 0px 0px 1px; line-height: 0; }

a.thumbnail { transition: box-shadow 200ms ease-out; }

a.thumbnail:hover, a.thumbnail:focus { box-shadow: rgba(23, 121, 186, 0.5) =
0px 0px 6px 1px; }

a.thumbnail image { box-shadow: none; }

.title-bar { padding: 0.5rem; background: rgb(10, 10, 10); color: rgb(254, =
254, 254); display: flex; justify-content: flex-start; align-items: center;=
 }

.title-bar .menu-icon { margin-left: 0.25rem; margin-right: 0.25rem; }

.title-bar-left, .title-bar-right { flex: 1 1 0px; }

.title-bar-right { text-align: right; }

.title-bar-title { display: inline-block; vertical-align: middle; font-weig=
ht: bold; }

.has-tip { position: relative; display: inline-block; border-bottom: 1px do=
tted rgb(138, 138, 138); font-weight: bold; cursor: help; }

.tooltip { position: absolute; top: calc(100% + 0.6495rem); z-index: 1200; =
max-width: 10rem; padding: 0.75rem; border-radius: 0px; background-color: r=
gb(10, 10, 10); font-size: 80%; color: rgb(254, 254, 254); }

.tooltip::before { position: absolute; }

.tooltip.bottom::before { display: block; width: 0px; height: 0px; border-w=
idth: 0px 0.75rem 0.75rem; border-style: inset inset solid; border-image: i=
nitial; content: ""; border-color: transparent transparent rgb(10, 10, 10);=
 bottom: 100%; }

.tooltip.bottom.align-center::before { left: 50%; transform: translateX(-50=
%); }

.tooltip.top::before { display: block; width: 0px; height: 0px; border-widt=
h: 0.75rem 0.75rem 0px; border-style: solid inset inset; border-image: init=
ial; content: ""; border-color: rgb(10, 10, 10) transparent transparent; to=
p: 100%; bottom: auto; }

.tooltip.top.align-center::before { left: 50%; transform: translateX(-50%);=
 }

.tooltip.left::before { display: block; width: 0px; height: 0px; border-wid=
th: 0.75rem 0px 0.75rem 0.75rem; border-style: inset inset inset solid; bor=
der-image: initial; content: ""; border-color: transparent transparent tran=
sparent rgb(10, 10, 10); left: 100%; }

.tooltip.left.align-center::before { bottom: auto; top: 50%; transform: tra=
nslateY(-50%); }

.tooltip.right::before { display: block; width: 0px; height: 0px; border-wi=
dth: 0.75rem 0.75rem 0.75rem 0px; border-style: inset solid inset inset; bo=
rder-image: initial; content: ""; border-color: transparent rgb(10, 10, 10)=
 transparent transparent; right: 100%; left: auto; }

.tooltip.right.align-center::before { bottom: auto; top: 50%; transform: tr=
anslateY(-50%); }

.tooltip.align-top::before { bottom: auto; top: 10%; }

.tooltip.align-bottom::before { bottom: 10%; top: auto; }

.tooltip.align-left::before { left: 10%; right: auto; }

.tooltip.align-right::before { left: auto; right: 10%; }

.top-bar { display: flex; justify-content: space-between; align-items: cent=
er; padding: 0.5rem; flex-wrap: wrap; }

.top-bar, .top-bar ul { background-color: rgb(230, 230, 230); }

.top-bar input { max-width: 200px; margin-right: 1rem; }

.top-bar .input-group-field { width: 100%; margin-right: 0px; }

.top-bar input.button { width: auto; }

.top-bar .top-bar-left, .top-bar .top-bar-right { flex: 0 0 100%; max-width=
: 100%; }

@media print, screen and (min-width: 40em) {
  .top-bar { flex-wrap: nowrap; }
  .top-bar .top-bar-left { flex: 1 1 auto; margin-right: auto; }
  .top-bar .top-bar-right { flex: 0 1 auto; margin-left: auto; }
}

@media screen and (max-width: 63.9375em) {
  .top-bar.stacked-for-medium { flex-wrap: wrap; }
  .top-bar.stacked-for-medium .top-bar-left, .top-bar.stacked-for-medium .t=
op-bar-right { flex: 0 0 100%; max-width: 100%; }
}

@media screen and (max-width: 74.9375em) {
  .top-bar.stacked-for-large { flex-wrap: wrap; }
  .top-bar.stacked-for-large .top-bar-left, .top-bar.stacked-for-large .top=
-bar-right { flex: 0 0 100%; max-width: 100%; }
}

.top-bar-title { flex: 0 0 auto; margin: 0.5rem 1rem 0.5rem 0px; }

.top-bar-left, .top-bar-right { flex: 0 0 auto; }

.hide { display: none !important; }

.invisible { visibility: hidden; }

@media screen and (max-width: 39.9375em) {
  .hide-for-small-only { display: none !important; }
}

@media screen and (max-width: 0em), screen and (min-width: 40em) {
  .show-for-small-only { display: none !important; }
}

@media print, screen and (min-width: 40em) {
  .hide-for-medium { display: none !important; }
}

@media screen and (max-width: 39.9375em) {
  .show-for-medium { display: none !important; }
}

@media screen and (min-width: 40em) and (max-width: 63.9375em) {
  .hide-for-medium-only { display: none !important; }
}

@media screen and (max-width: 39.9375em), screen and (min-width: 64em) {
  .show-for-medium-only { display: none !important; }
}

@media print, screen and (min-width: 64em) {
  .hide-for-large { display: none !important; }
}

@media screen and (max-width: 63.9375em) {
  .show-for-large { display: none !important; }
}

@media screen and (min-width: 64em) and (max-width: 74.9375em) {
  .hide-for-large-only { display: none !important; }
}

@media screen and (max-width: 63.9375em), screen and (min-width: 75em) {
  .show-for-large-only { display: none !important; }
}

.show-for-sr, .show-on-focus { width: 1px; height: 1px; padding: 0px; overf=
low: hidden; clip: rect(0px, 0px, 0px, 0px); white-space: nowrap; clip-path=
: inset(50%); border: 0px; position: absolute !important; }

.show-on-focus:active, .show-on-focus:focus { width: auto; height: auto; ov=
erflow: visible; clip: auto; white-space: normal; clip-path: none; position=
: static !important; }

.show-for-landscape, .hide-for-portrait { display: block !important; }

@media screen and (orientation: landscape) {
  .show-for-landscape, .hide-for-portrait { display: block !important; }
}

@media screen and (orientation: portrait) {
  .show-for-landscape, .hide-for-portrait { display: none !important; }
}

.hide-for-landscape, .show-for-portrait { display: none !important; }

@media screen and (orientation: landscape) {
  .hide-for-landscape, .show-for-portrait { display: none !important; }
}

@media screen and (orientation: portrait) {
  .hide-for-landscape, .show-for-portrait { display: block !important; }
}

.float-left { float: left !important; }

.float-right { float: right !important; }

.float-center { display: block; margin-right: auto; margin-left: auto; }

.clearfix::before, .clearfix::after { display: table; content: " "; flex-ba=
sis: 0px; order: 1; }

.clearfix::after { clear: both; }

.slide-in-down.mui-enter { transition-duration: 500ms; transition-timing-fu=
nction: linear; transform: translateY(-100%); transition-property: transfor=
m, opacity; backface-visibility: hidden; }

.slide-in-down.mui-enter.mui-enter-active { transform: translateY(0px); }

.slide-in-left.mui-enter { transition-duration: 500ms; transition-timing-fu=
nction: linear; transform: translateX(-100%); transition-property: transfor=
m, opacity; backface-visibility: hidden; }

.slide-in-left.mui-enter.mui-enter-active { transform: translateX(0px); }

.slide-in-up.mui-enter { transition-duration: 500ms; transition-timing-func=
tion: linear; transform: translateY(100%); transition-property: transform, =
opacity; backface-visibility: hidden; }

.slide-in-up.mui-enter.mui-enter-active { transform: translateY(0px); }

.slide-in-right.mui-enter { transition-duration: 500ms; transition-timing-f=
unction: linear; transform: translateX(100%); transition-property: transfor=
m, opacity; backface-visibility: hidden; }

.slide-in-right.mui-enter.mui-enter-active { transform: translateX(0px); }

.slide-out-down.mui-leave { transition-duration: 500ms; transition-timing-f=
unction: linear; transform: translateY(0px); transition-property: transform=
, opacity; backface-visibility: hidden; }

.slide-out-down.mui-leave.mui-leave-active { transform: translateY(100%); }

.slide-out-right.mui-leave { transition-duration: 500ms; transition-timing-=
function: linear; transform: translateX(0px); transition-property: transfor=
m, opacity; backface-visibility: hidden; }

.slide-out-right.mui-leave.mui-leave-active { transform: translateX(100%); =
}

.slide-out-up.mui-leave { transition-duration: 500ms; transition-timing-fun=
ction: linear; transform: translateY(0px); transition-property: transform, =
opacity; backface-visibility: hidden; }

.slide-out-up.mui-leave.mui-leave-active { transform: translateY(-100%); }

.slide-out-left.mui-leave { transition-duration: 500ms; transition-timing-f=
unction: linear; transform: translateX(0px); transition-property: transform=
, opacity; backface-visibility: hidden; }

.slide-out-left.mui-leave.mui-leave-active { transform: translateX(-100%); =
}

.fade-in.mui-enter { transition-duration: 500ms; transition-timing-function=
: linear; opacity: 0; transition-property: opacity; }

.fade-in.mui-enter.mui-enter-active { opacity: 1; }

.fade-out.mui-leave { transition-duration: 500ms; transition-timing-functio=
n: linear; opacity: 1; transition-property: opacity; }

.fade-out.mui-leave.mui-leave-active { opacity: 0; }

.hinge-in-from-top.mui-enter { transition-duration: 500ms; transition-timin=
g-function: linear; transform: perspective(2000px) rotateX(-90deg); transfo=
rm-origin: center top; transition-property: transform, opacity; opacity: 0;=
 }

.hinge-in-from-top.mui-enter.mui-enter-active { transform: perspective(2000=
px) rotate(0deg); opacity: 1; }

.hinge-in-from-right.mui-enter { transition-duration: 500ms; transition-tim=
ing-function: linear; transform: perspective(2000px) rotateY(-90deg); trans=
form-origin: right center; transition-property: transform, opacity; opacity=
: 0; }

.hinge-in-from-right.mui-enter.mui-enter-active { transform: perspective(20=
00px) rotate(0deg); opacity: 1; }

.hinge-in-from-bottom.mui-enter { transition-duration: 500ms; transition-ti=
ming-function: linear; transform: perspective(2000px) rotateX(90deg); trans=
form-origin: center bottom; transition-property: transform, opacity; opacit=
y: 0; }

.hinge-in-from-bottom.mui-enter.mui-enter-active { transform: perspective(2=
000px) rotate(0deg); opacity: 1; }

.hinge-in-from-left.mui-enter { transition-duration: 500ms; transition-timi=
ng-function: linear; transform: perspective(2000px) rotateY(90deg); transfo=
rm-origin: left center; transition-property: transform, opacity; opacity: 0=
; }

.hinge-in-from-left.mui-enter.mui-enter-active { transform: perspective(200=
0px) rotate(0deg); opacity: 1; }

.hinge-in-from-middle-x.mui-enter { transition-duration: 500ms; transition-=
timing-function: linear; transform: perspective(2000px) rotateX(-90deg); tr=
ansform-origin: center center; transition-property: transform, opacity; opa=
city: 0; }

.hinge-in-from-middle-x.mui-enter.mui-enter-active { transform: perspective=
(2000px) rotate(0deg); opacity: 1; }

.hinge-in-from-middle-y.mui-enter { transition-duration: 500ms; transition-=
timing-function: linear; transform: perspective(2000px) rotateY(-90deg); tr=
ansform-origin: center center; transition-property: transform, opacity; opa=
city: 0; }

.hinge-in-from-middle-y.mui-enter.mui-enter-active { transform: perspective=
(2000px) rotate(0deg); opacity: 1; }

.hinge-out-from-top.mui-leave { transition-duration: 500ms; transition-timi=
ng-function: linear; transform: perspective(2000px) rotate(0deg); transform=
-origin: center top; transition-property: transform, opacity; opacity: 1; }

.hinge-out-from-top.mui-leave.mui-leave-active { transform: perspective(200=
0px) rotateX(-90deg); opacity: 0; }

.hinge-out-from-right.mui-leave { transition-duration: 500ms; transition-ti=
ming-function: linear; transform: perspective(2000px) rotate(0deg); transfo=
rm-origin: right center; transition-property: transform, opacity; opacity: =
1; }

.hinge-out-from-right.mui-leave.mui-leave-active { transform: perspective(2=
000px) rotateY(-90deg); opacity: 0; }

.hinge-out-from-bottom.mui-leave { transition-duration: 500ms; transition-t=
iming-function: linear; transform: perspective(2000px) rotate(0deg); transf=
orm-origin: center bottom; transition-property: transform, opacity; opacity=
: 1; }

.hinge-out-from-bottom.mui-leave.mui-leave-active { transform: perspective(=
2000px) rotateX(90deg); opacity: 0; }

.hinge-out-from-left.mui-leave { transition-duration: 500ms; transition-tim=
ing-function: linear; transform: perspective(2000px) rotate(0deg); transfor=
m-origin: left center; transition-property: transform, opacity; opacity: 1;=
 }

.hinge-out-from-left.mui-leave.mui-leave-active { transform: perspective(20=
00px) rotateY(90deg); opacity: 0; }

.hinge-out-from-middle-x.mui-leave { transition-duration: 500ms; transition=
-timing-function: linear; transform: perspective(2000px) rotate(0deg); tran=
sform-origin: center center; transition-property: transform, opacity; opaci=
ty: 1; }

.hinge-out-from-middle-x.mui-leave.mui-leave-active { transform: perspectiv=
e(2000px) rotateX(-90deg); opacity: 0; }

.hinge-out-from-middle-y.mui-leave { transition-duration: 500ms; transition=
-timing-function: linear; transform: perspective(2000px) rotate(0deg); tran=
sform-origin: center center; transition-property: transform, opacity; opaci=
ty: 1; }

.hinge-out-from-middle-y.mui-leave.mui-leave-active { transform: perspectiv=
e(2000px) rotateY(-90deg); opacity: 0; }

.scale-in-up.mui-enter { transition-duration: 500ms; transition-timing-func=
tion: linear; transform: scale(0.5); transition-property: transform, opacit=
y; opacity: 0; }

.scale-in-up.mui-enter.mui-enter-active { transform: scale(1); opacity: 1; =
}

.scale-in-down.mui-enter { transition-duration: 500ms; transition-timing-fu=
nction: linear; transform: scale(1.5); transition-property: transform, opac=
ity; opacity: 0; }

.scale-in-down.mui-enter.mui-enter-active { transform: scale(1); opacity: 1=
; }

.scale-out-up.mui-leave { transition-duration: 500ms; transition-timing-fun=
ction: linear; transform: scale(1); transition-property: transform, opacity=
; opacity: 1; }

.scale-out-up.mui-leave.mui-leave-active { transform: scale(1.5); opacity: =
0; }

.scale-out-down.mui-leave { transition-duration: 500ms; transition-timing-f=
unction: linear; transform: scale(1); transition-property: transform, opaci=
ty; opacity: 1; }

.scale-out-down.mui-leave.mui-leave-active { transform: scale(0.5); opacity=
: 0; }

.spin-in.mui-enter { transition-duration: 500ms; transition-timing-function=
: linear; transform: rotate(-0.75turn); transition-property: transform, opa=
city; opacity: 0; }

.spin-in.mui-enter.mui-enter-active { transform: rotate(0deg); opacity: 1; =
}

.spin-out.mui-leave { transition-duration: 500ms; transition-timing-functio=
n: linear; transform: rotate(0deg); transition-property: transform, opacity=
; opacity: 1; }

.spin-out.mui-leave.mui-leave-active { transform: rotate(0.75turn); opacity=
: 0; }

.spin-in-ccw.mui-enter { transition-duration: 500ms; transition-timing-func=
tion: linear; transform: rotate(0.75turn); transition-property: transform, =
opacity; opacity: 0; }

.spin-in-ccw.mui-enter.mui-enter-active { transform: rotate(0deg); opacity:=
 1; }

.spin-out-ccw.mui-leave { transition-duration: 500ms; transition-timing-fun=
ction: linear; transform: rotate(0deg); transition-property: transform, opa=
city; opacity: 1; }

.spin-out-ccw.mui-leave.mui-leave-active { transform: rotate(-0.75turn); op=
acity: 0; }

.slow { transition-duration: 750ms !important; }

.fast { transition-duration: 250ms !important; }

.linear { transition-timing-function: linear !important; }

.ease { transition-timing-function: ease !important; }

.ease-in { transition-timing-function: ease-in !important; }

.ease-out { transition-timing-function: ease-out !important; }

.ease-in-out { transition-timing-function: ease-in-out !important; }

.bounce-in { transition-timing-function: cubic-bezier(0.485, 0.155, 0.24, 1=
.245) !important; }

.bounce-out { transition-timing-function: cubic-bezier(0.485, 0.155, 0.515,=
 0.845) !important; }

.bounce-in-out { transition-timing-function: cubic-bezier(0.76, -0.245, 0.2=
4, 1.245) !important; }

.short-delay { transition-delay: 300ms !important; }

.long-delay { transition-delay: 700ms !important; }

.shake { animation-name: shake-7; }

@keyframes shake-7 {=20
  0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% { transform: translateX(7=
%); }
  5%, 15%, 25%, 35%, 45%, 55%, 65%, 75%, 85%, 95% { transform: translateX(-=
7%); }
}

.spin-cw { animation-name: spin-cw-1turn; }

@keyframes spin-cw-1turn {=20
  0% { transform: rotate(-1turn); }
  100% { transform: rotate(0deg); }
}

.spin-ccw { animation-name: spin-cw-1turn; }

@keyframes spin-cw-1turn {=20
  0% { transform: rotate(0deg); }
  100% { transform: rotate(1turn); }
}

.wiggle { animation-name: wiggle-7deg; }

@keyframes wiggle-7deg {=20
  40%, 50%, 60% { transform: rotate(7deg); }
  35%, 45%, 55%, 65% { transform: rotate(-7deg); }
  0%, 30%, 70%, 100% { transform: rotate(0deg); }
}

.shake, .spin-cw, .spin-ccw, .wiggle { animation-duration: 500ms; }

.infinite { animation-iteration-count: infinite; }

.slow { animation-duration: 750ms !important; }

.fast { animation-duration: 250ms !important; }

.linear { animation-timing-function: linear !important; }

.ease { animation-timing-function: ease !important; }

.ease-in { animation-timing-function: ease-in !important; }

.ease-out { animation-timing-function: ease-out !important; }

.ease-in-out { animation-timing-function: ease-in-out !important; }

.bounce-in { animation-timing-function: cubic-bezier(0.485, 0.155, 0.24, 1.=
245) !important; }

.bounce-out { animation-timing-function: cubic-bezier(0.485, 0.155, 0.515, =
0.845) !important; }

.bounce-in-out { animation-timing-function: cubic-bezier(0.76, -0.245, 0.24=
, 1.245) !important; }

.short-delay { animation-delay: 300ms !important; }

.long-delay { animation-delay: 700ms !important; }

body { font-family: Roboto, sans-serif; color: rgb(68, 68, 68); }

.mainContent { padding-bottom: 80px; }

a.custombutton:link, a.custombutton:visited { background-color: rgb(0, 169,=
 183); padding: 8px 22px 8px 25px; font-weight: 600; text-transform: upperc=
ase; letter-spacing: 3px; font-size: 15px; color: rgb(255, 255, 255) !impor=
tant; }

a.custombutton:hover { background-color: rgb(21, 196, 211); padding: 8px 22=
px 8px 25px; font-weight: 600; text-transform: uppercase; letter-spacing: 3=
px; font-size: 15px; color: rgb(255, 255, 255) !important; }

ul.contentAreaUL { padding-left: 30px; }

ol.contentAreaOL { padding-left: 30px; }

h1, h2, h3, h4, h5, h6 { font-family: Montserrat, sans-serif; }

h1 { text-transform: uppercase; letter-spacing: -2px; font-weight: 700; col=
or: rgb(137, 140, 141); font-size: 48px; }

h3 { color: rgb(137, 140, 141); font-size: 30px; letter-spacing: -1px; }

hr.underLine { width: 100px; border-top: 4px solid rgb(0, 169, 183); border=
-bottom: none !important; margin: 0px 0px 40px !important; }

.mainContent a:link, a:visited { color: rgb(0, 169, 183); }

.mainContent a:hover { color: rgb(21, 196, 211); }

header { background-color: rgb(0, 169, 183); padding: 20px 0px 30px; margin=
-bottom: 60px; color: rgb(255, 255, 255); }

header ul { float: right; }

header ul li a:link, header ul li a:visited { color: rgb(255, 255, 255); te=
xt-transform: uppercase; }

header ul#menu-main-nav { margin-top: 30px; }

header ul#menu-sub-menu li { font-size: 14px; }

header ul#menu-main-nav li { font-size: 18px; }

.logo a { float: left; min-height: 40px; width: 230px; margin-top: 55px; ba=
ckground: url("/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client/im=
ages/logo.png") left top / 230px 40px no-repeat !important; }

nav { }

nav ul { padding: 0px; margin: 0px; list-style: none; position: relative; }

nav ul li { display: inline-block; background-color: rgb(0, 169, 183); }

nav a { display: block; padding: 0px 10px; color: rgb(255, 255, 255); line-=
height: 60px; text-decoration: none; }

nav a:hover { background-color: rgb(2, 151, 163); }

nav ul ul { display: none; position: absolute; top: 41px; }

nav ul li:hover > ul { display: inherit; }

nav ul ul li { width: 230px; float: none; display: list-item; position: rel=
ative; background-color: rgb(2, 151, 163); font-size: 15px !important; }

nav ul ul li a:hover, nav ul ul ul li a:hover { background-color: rgb(0, 16=
9, 183); }

nav ul ul ul li { position: relative; top: -40px; left: 230px; background-c=
olor: rgb(2, 151, 163); font-size: 15px !important; }

nav li > a::after { content: ""; }

nav li > a:only-child::after { content: ""; }

.sidebarNav { border-top: 4px solid rgb(0, 169, 183); margin-top: 120px; ma=
rgin-bottom: 50px; }

.sidebarNav li, .sidebarNav a { font-family: Roboto, sans-serif; color: rgb=
(137, 140, 141); text-transform: uppercase; list-style: none; padding: 3px =
0px 3px 5px; }

.sidebarNav a:link, .sidebarNav a:visited { color: rgb(137, 140, 141); }

.sidebarNav a:hover { color: rgb(0, 169, 183); text-decoration: none; }

.sidebarNav a.active { font-weight: 600; color: rgb(0, 169, 183); }

.sidebarNav ul { margin: 0px; }

.sidebarNav ul ul { margin-left: 20px; }

.sidebarNav ul li { border-top: 1px solid rgb(203, 203, 203); }

.sidebarNav ul li:first-child { border-top: none !important; }

.sidebarNav ul li:last-child { border-bottom: 1px solid rgb(203, 203, 203) =
!important; }

.sidebarNav ul ul li:last-child { border-bottom: none !important; }

.sidebarNav ul ul li { border-top: none !important; padding-top: 0px !impor=
tant; }

.sidebarUtility ul { margin-left: 30px; }

.sidebarUtility ul li { list-style: none; padding: 10px 0px 10px 40px; }

.sidebarUtility a:link, .sidebarUtility a:visited { color: rgb(137, 140, 14=
1); }

.sidebarUtility a:hover { color: rgb(0, 169, 183); }

.sidebarUtility ul li.printIcon { background-image: url("/sites/g/files/kno=
qqb12671/themes/site/nir_pid1175/client/images/printIcon_2x.png"); backgrou=
nd-repeat: no-repeat; background-position: left center; background-size: 30=
px; }

.sidebarUtility ul li.emailIcon { background-image: url("/sites/g/files/kno=
qqb12671/themes/site/nir_pid1175/client/images/emailIcon_2x.png"); backgrou=
nd-repeat: no-repeat; background-position: left center; background-size: 30=
px; }

.sidebarUtility ul li.rssIcon { background-image: url("/sites/g/files/knoqq=
b12671/themes/site/nir_pid1175/client/images/rssIcon_2x.png"); background-r=
epeat: no-repeat; background-position: left center; background-size: 30px; =
}

.sidebarUtility ul li.alertIcon { background-image: url("/sites/g/files/kno=
qqb12671/themes/site/nir_pid1175/client/images/alertIcon_2x.png"); backgrou=
nd-repeat: no-repeat; background-position: left center; background-size: 30=
px; }

.sidebarUtility ul li.sheetIcon { background-image: url("/sites/g/files/kno=
qqb12671/themes/site/nir_pid1175/client/images/sheetIcon_2x.png"); backgrou=
nd-repeat: no-repeat; background-position: left center; background-size: 30=
px; }

footer { background-color: rgb(137, 140, 141); padding: 60px 0px 100px; col=
or: rgb(255, 255, 255); }

footer h4 { text-transform: uppercase; letter-spacing: -1px; font-weight: 7=
00; color: rgb(255, 255, 255); font-size: 21px; }

ul.footerNav { padding: 0px; margin: 0px; }

ul.footerNav li { list-style: none; padding: 0px; margin: 0px; }

footer a:link, footer a:visited { color: rgb(255, 255, 255); }

footer a:hover { color: rgb(21, 196, 211); }

footer hr.underLine { margin: 10px 0px 20px !important; }

footer .legalText { font-size: 14px; }

footer .logoFooter a { display: block; min-height: 30px; width: 180px; marg=
in-bottom: 55px; background: url("/sites/g/files/knoqqb12671/themes/site/ni=
r_pid1175/client/images/logoFooter.png") left top / 180px 30px no-repeat !i=
mportant; }

.socialMedia { margin: 40px auto 0px; text-align: center; }

.socialMedia ul { margin-top: 30px; }

.socialMedia ul li { list-style: none; display: inline-block; }

.socialMedia ul li.twitter a { float: left; min-height: 40px; width: 40px; =
background: url("/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client/=
images/twitterIcon.png") left top / 40px 40px no-repeat !important; }

.socialMedia ul li.linkedin a { float: left; min-height: 40px; width: 40px;=
 background: url("/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client=
/images/linkedinIcon.png") left top / 40px 40px no-repeat !important; }

.socialMedia ul li.facebook a { float: left; min-height: 40px; width: 40px;=
 background: url("/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client=
/images/facebookIcon.png") left top / 40px 40px no-repeat !important; }

.contactGroupGrid div { padding-bottom: 40px; }

@media screen and (max-width: 39.9375em) {
  .logo a { float: left; min-height: 40px; width: 230px; margin-top: 15px; =
background: url("/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client/=
images/logo.png") left top / 230px 40px no-repeat !important; }
  input { display: none; }
  label { cursor: pointer; display: inline-block; padding: 0px; float: righ=
t; margin-top: 23px; margin-right: 10px; }
  label:hover { }
  .test { transition: height 0.3s; height: 0px; overflow: hidden; width: 10=
0%; margin-top: 30px; }
  input:checked + .test { height: 330px; }
  .test li { list-style: none; padding: 3px 0px 3px 30px; font-size: 21px; =
border-bottom: 1px solid rgb(156, 212, 218); text-transform: uppercase; }
  .test li:first-child { border-top: 1px solid rgb(156, 212, 218); }
  .test li a:link, .test li a:visited, .test li a:hover { color: rgb(255, 2=
55, 255) !important; }
  header { padding: 20px 0px 10px; }
}

@font-face { font-family: ndqfonticons; src: url("/sites/g/files/knoqqb1267=
1/themes/site/nir_pid1175/client/fonts/ndqfonticons.woff") format("woff"), =
url("/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client/fonts/ndqfon=
ticons.ttf") format("truetype"); font-weight: normal; font-style: normal; }

[ndq-data-icon]::before { content: attr(ndq-data-icon); speak: none; line-h=
eight: 1; -webkit-font-smoothing: antialiased; font-size: 30px; vertical-al=
ign: bottom; padding-right: 5px; font-family: ndqfonticons !important; font=
-style: normal !important; font-weight: normal !important; font-variant: no=
rmal !important; text-transform: none !important; }

[class^=3D"ndqicon-"]::before, [class*=3D" ndqicon-"]::before { speak: none=
; line-height: 1; -webkit-font-smoothing: antialiased; font-size: 22px; ver=
tical-align: middle; font-family: ndqfonticons !important; font-style: norm=
al !important; font-weight: normal !important; font-variant: normal !import=
ant; text-transform: none !important; }

.ndq-icon svg { fill: rgb(0, 0, 0); }

.ndqicon-briefcase-1::before { content: "=EE=81=A8"; }

.ndqicon-briefcase-2::before { content: "=EE=81=A9"; color: rgb(69, 69, 69)=
; }

.ndqicon-briefcase::before { content: "=EE=80=AA"; color: rgb(69, 69, 69); =
}

.ndqicon-briefcase-add::before { content: "=EE=80=AB"; color: rgb(69, 69, 6=
9); }

.ndqicon-briefcase-remove::before { content: "=EE=80=AC"; color: rgb(69, 69=
, 69); }

.ndqicon-briefcase-added::before { content: "=EE=80=AD"; color: rgb(69, 69,=
 69); }

.ndqicon-printed-materials::before { content: "=EE=80=98"; }

.ndqicon-printed-materials-1::before { content: "=EE=81=94"; }

.ndqicon-printed-materials-2::before { content: "=EE=81=97"; }

.ndqicon-alerts::before { content: "=EE=80=80"; }

.ndqicon-downloads::before { content: "=EE=80=82"; }

.ndqicon-downloads-1::before { content: "=EE=80=8F"; }

.ndqicon-downloads-2::before { content: "=EE=80=AE"; }

.ndqicon-downloads-3::before { content: "=EE=81=93"; }

.ndqicon-rss::before { content: "=EE=80=99"; }

.ndqicon-rss-1::before { content: "=EE=81=9A"; }

.ndqicon-snapshot::before { content: "=EE=80=9B"; }

.ndqicon-snapshot-1::before { content: "=EE=80=90"; }

.ndqicon-snapshot-2::before { content: "=EE=82=AC"; }

.ndqicon-mobile::before { content: "=EE=80=81"; }

.ndqicon-iphone::before { content: "=EE=80=8C"; }

.ndqicon-mail::before { content: "=EE=80=83"; }

.ndqicon-mail-1::before { content: "=EE=82=AD"; }

.ndqicon-mail-2::before { content: "=EE=82=AE"; }

.ndqicon-mail-3::before { content: "=EE=82=AF"; }

.ndqicon-print::before { content: "=EE=80=97"; }

.ndqicon-print-1::before { content: "=EE=82=A9"; }

.ndqicon-print-2::before { content: "=EE=82=AA"; }

.ndqicon-share::before { content: "=EE=80=9A"; }

.ndqicon-share-1::before { content: "=EE=81=AF"; }

.ndqicon-search::before { content: "=EE=80=B9"; }

.ndqicon-fb::before { content: "=EE=80=85"; background: rgb(59, 89, 152); c=
olor: rgb(255, 255, 255); }

.ndqicon-tw::before { content: "=EE=82=A7"; color: rgb(255, 255, 255); back=
ground: rgb(4, 152, 214); }

.ndqicon-tw-1::before { content: "=EE=80=9D"; color: rgb(4, 152, 214); }

.ndqicon-tw-2::before { content: "=EE=82=A8"; color: rgb(4, 152, 214); }

.ndqicon-linkedin::before { content: "=EE=80=87"; background: rgb(14, 118, =
168); color: rgb(255, 255, 255); }

.ndqicon-google::before { content: "=EE=80=9E"; background: rgb(221, 75, 57=
); color: rgb(255, 255, 255); }

.ndqicon-google-plus::before { content: "=EE=80=94"; background: rgb(221, 7=
5, 57); color: rgb(255, 255, 255); }

.ndqicon-outlook::before { content: "=EE=80=BF"; background: rgb(255, 188, =
0); color: rgb(255, 255, 255); }

.ndqicon-pinterest::before { content: "=EE=81=AD"; background: rgb(225, 65,=
 7); color: rgb(255, 255, 255); }

.ndqicon-youtube::before { content: "=EE=81=AE"; background: rgb(207, 52, 3=
9); color: rgb(255, 255, 255); }

.ndqicon-tumbler::before { content: "=EE=80=86"; background: rgb(44, 71, 98=
); color: rgb(255, 255, 255); }

.ndqicon-instagram::before { content: "=EE=82=B0"; color: rgb(192, 141, 100=
); }

.ndqicon-chairman::before { content: "=EE=80=A8"; }

.ndqicon-chairman-1::before { content: "=EE=80=A7"; }

.ndqicon-member::before { content: "=EE=80=8A"; }

.ndqicon-chair::before { content: "=EE=80=8B"; }

.ndqicon-chair-1::before { content: "=EE=81=AA"; }

.ndqicon-chair-2::before { content: "=EE=81=AB"; }

.ndqicon-chair-3::before { content: "=EE=81=AC"; }

.ndqicon-independent::before { content: "=EE=80=8D"; }

.ndqicon-independent-italic::before { content: "=EE=80=8E"; }

.ndqicon-calculator::before { content: "=EE=80=B2"; }

.ndqicon-calculator-1::before { content: "=EE=80=AF"; }

.ndqicon-pdf::before { content: "=EE=80=88"; color: rgb(223, 0, 0); }

.ndqicon-pdf-1::before { content: "=EE=81=9C"; color: rgb(223, 0, 0); }

.ndqicon-pdf-2::before { content: "=EE=82=88"; color: rgb(223, 0, 0); }

.ndqicon-pdf-3::before { content: "=EE=82=A0"; color: rgb(223, 0, 0); }

.ndqicon-html::before { content: "=EE=80=A9"; color: rgb(4, 114, 189); }

.ndqicon-html-1::before { content: "=EE=81=95"; color: rgb(4, 114, 189); }

.ndqicon-html-2::before { content: "=EE=81=B7"; color: rgb(4, 114, 189); }

.ndqicon-html-3::before { content: "=EE=81=A5"; color: rgb(4, 114, 189); }

.ndqicon-htm::before { content: "=EE=81=B8"; color: rgb(4, 114, 189); }

.ndqicon-htm-1::before { content: "=EE=82=93"; color: rgb(4, 114, 189); }

.ndqicon-word::before { content: "=EE=80=89"; color: rgb(0, 81, 148); }

.ndqicon-word-1::before { content: "=EE=81=98"; color: rgb(0, 81, 148); }

.ndqicon-doc::before { content: "=EE=81=B2"; color: rgb(0, 81, 148); }

.ndqicon-doc-1::before { content: "=EE=82=8E"; color: rgb(0, 81, 148); }

.ndqicon-docx::before { content: "=EE=81=B3"; color: rgb(0, 81, 148); }

.ndqicon-docx-1::before { content: "=EE=82=8F"; color: rgb(0, 81, 148); }

.ndqicon-xls::before { content: "=EE=80=9F"; color: rgb(112, 168, 31); }

.ndqicon-xls-1::before { content: "=EE=80=A2"; color: rgb(112, 168, 31); }

.ndqicon-xls-2::before { content: "=EE=81=99"; color: rgb(112, 168, 31); }

.ndqicon-xls-3::before { content: "=EE=81=9B"; color: rgb(112, 168, 31); }

.ndqicon-xls-4::before { content: "=EE=81=B9"; color: rgb(112, 168, 31); }

.ndqicon-xls-5::before { content: "=EE=81=BA"; color: rgb(112, 168, 31); }

.ndqicon-xls-6::before { content: "=EE=82=94"; color: rgb(112, 168, 31); }

.ndqicon-xlsx::before { content: "=EE=81=BB"; color: rgb(112, 168, 31); }

.ndqicon-xlsx-1::before { content: "=EE=81=BC"; color: rgb(112, 168, 31); }

.ndqicon-xlsx-2::before { content: "=EE=82=95"; color: rgb(112, 168, 31); }

.ndqicon-xbrl::before { content: "=EE=80=A0"; color: rgb(123, 65, 189); }

.ndqicon-xbrl-1::before { content: "=EE=81=9D"; color: rgb(123, 65, 189); }

.ndqicon-xbrl-2::before { content: "=EE=81=BD"; color: rgb(123, 65, 189); }

.ndqicon-xbrl-3::before { content: "=EE=82=96"; color: rgb(123, 65, 189); }

.ndqicon-xbrl-xml::before { content: "=EE=80=A1"; color: rgb(123, 65, 189);=
 }

.ndqicon-xml::before { content: "=EE=81=BE"; }

.ndqicon-xml-1::before { content: "=EE=82=97"; }

.ndqicon-pps::before { content: "=EE=82=89"; }

.ndqicon-pps-1::before { content: "=EE=82=9F"; }

.ndqicon-ppt::before { content: "=EE=82=8A"; }

.ndqicon-ppt-1::before { content: "=EE=82=9E"; }

.ndqicon-pptx::before { content: "=EE=82=8B"; }

.ndqicon-pptx-1::before { content: "=EE=82=9D"; }

.ndqicon-pptx-3::before { content: "=EE=82=A5"; }

.ndqicon-txt::before { content: "=EE=82=8C"; }

.ndqicon-txt-1::before { content: "=EE=82=9C"; }

.ndqicon-zip::before { content: "=EE=80=A3"; }

.ndqicon-zip-1::before { content: "=EE=82=8D"; }

.ndqicon-zip-2::before { content: "=EE=82=A2"; }

.ndqicon-fla::before { content: "=EE=81=B4"; color: rgb(207, 11, 13); }

.ndqicon-fla-1::before { content: "=EE=82=90"; color: rgb(207, 11, 13); }

.ndqicon-flash::before { content: "=EE=81=B5"; color: rgb(207, 11, 13); }

.ndqicon-flash-1::before { content: "=EE=82=91"; color: rgb(207, 11, 13); }

.ndqicon-swf::before { content: "=EE=81=B6"; color: rgb(207, 11, 13); }

.ndqicon-swf-1::before { content: "=EE=82=92"; color: rgb(207, 11, 13); }

.ndqicon-video-flash::before { content: "=EE=80=A4"; color: rgb(207, 11, 13=
); }

.ndqicon-video::before { content: "=EE=80=A5"; }

.ndqicon-video-play-btn::before { content: "=EE=80=B7"; }

.ndqicon-video-play-btn-1::before { content: "=EE=80=B8"; }

.ndqicon-avi::before { content: "=EE=82=86"; }

.ndqicon-avi-1::before { content: "=EE=82=A3"; }

.ndqicon-mp4::before { content: "=EE=82=87"; }

.ndqicon-mp4-1::before { content: "=EE=82=A1"; }

.ndqicon-audio::before { content: "=EE=80=9C"; }

.ndqicon-mp3::before { content: "=EE=80=A6"; }

.ndqicon-mp3-1::before { content: "=EE=82=83"; }

.ndqicon-mp3-2::before { content: "=EE=82=84"; }

.ndqicon-mp3-3::before { content: "=EE=82=85"; }

.ndqicon-mp3-4::before { content: "=EE=82=A4"; }

.ndqicon-mic::before { content: "=EE=80=BD"; }

.ndqicon-mic-1::before { content: "=EE=80=BE"; }

.ndqicon-csv::before { content: "=EE=81=B0"; }

.ndqicon-csv-1::before { content: "=EE=81=B1"; }

.ndqicon-jpg::before { content: "=EE=81=BF"; }

.ndqicon-gif::before { content: "=EE=82=80"; }

.ndqicon-tiff::before { content: "=EE=82=81"; }

.ndqicon-png::before { content: "=EE=82=82"; }

.ndqicon-empty-file::before { content: "=EE=80=95"; }

.ndqicon-empty-file-1::before { content: "=EE=80=96"; }

.ndqicon-plus::before { content: "=EE=80=B0"; }

.ndqicon-minus::before { content: "=EE=80=B1"; }

.ndqicon-plus-1::before { content: "=EE=81=9E"; }

.ndqicon-minus-1::before { content: "=EE=81=9F"; }

.ndqicon-plus-2::before { content: "=EE=81=A0"; }

.ndqicon-minus-2::before { content: "=EE=81=A1"; }

.ndqicon-plus-3::before { content: "=EE=81=A2"; }

.ndqicon-minus-3::before { content: "=EE=81=A3"; }

.ndqicon-plus-4::before { content: "=EE=81=A4"; }

.ndqicon-minus-4::before { content: "=EE=81=A5"; }

.ndqicon-plus-5::before { content: "=EE=81=A6"; }

.ndqicon-minus-5::before { content: "=EE=81=A7"; }

.ndqicon-close::before { content: "=EE=80=93"; }

.ndqicon-close-1::before { content: "=EE=81=86"; }

.ndqicon-close-2::before { content: "=EE=83=AE"; }

.ndqicon-close-3::before { content: "=EE=83=AF"; }

.ndqicon-close-4::before { content: "=EE=83=B0"; }

.ndqicon-close-5::before { content: "=EE=83=B1"; }

.ndqicon-close-6::before { content: "=EE=83=B2"; }

.ndqicon-arrow-up::before { content: "=EE=80=91"; }

.ndqicon-arrow-down::before { content: "=EE=80=92"; }

.ndqicon-arrow-right::before { content: "=EE=81=81"; }

.ndqicon-arrow-up-1::before { content: "=EE=81=82"; }

.ndqicon-arrow-left::before { content: "=EE=81=83"; }

.ndqicon-arrow-down-1::before { content: "=EE=81=84"; }

.ndqicon-arrow-45::before { content: "=EE=81=85"; }

.ndqicon-arrow-right-dots-long::before { content: "=EE=80=B3"; }

.ndqicon-arrow-left-dots-long::before { content: "=EE=80=B4"; }

.ndqicon-arrow-left-dots::before { content: "=EE=80=B5"; }

.ndqicon-arrow-right-dots::before { content: "=EE=80=B6"; }

.ndqicon-arrow-left-1::before { content: "=EE=81=87"; }

.ndqicon-arrow-up-45::before { content: "=EE=81=88"; }

.ndqicon-arrow-up-2::before { content: "=EE=81=89"; }

.ndqicon-arrow-down-2::before { content: "=EE=81=8A"; }

.ndqicon-arrow-right-1::before { content: "=EE=81=8B"; }

.ndqicon-arrow-down-45::before { content: "=EE=81=8C"; }

.ndqicon-arrow-right-2::before { content: "=EE=81=8D"; }

.ndqicon-arrow-up-45-1::before { content: "=EE=81=8E"; }

.ndqicon-arrow-down-45-1::before { content: "=EE=81=8F"; }

.ndqicon-arrow-down-3::before { content: "=EE=81=90"; }

.ndqicon-arrow-left-2::before { content: "=EE=81=91"; }

.ndqicon-arrow-up-3::before { content: "=EE=81=92"; }

.ndqicon-arw-r::before { content: "=EE=83=88"; }

.ndqicon-arw-u::before { content: "=EE=83=8B"; }

.ndqicon-arw-u45::before { content: "=EE=83=8D"; }

.ndqicon-arw-l::before { content: "=EE=83=85"; }

.ndqicon-arw-d::before { content: "=EE=83=8C"; }

.ndqicon-arw-d45::before { content: "=EE=83=80"; }

.ndqicon-arw-arw-r::before { content: "=EE=82=BA"; }

.ndqicon-arw-arw-u::before { content: "=EE=82=BC"; }

.ndqicon-arw-arw-u45::before { content: "=EE=82=BD"; }

.ndqicon-arw-arw-l::before { content: "=EE=82=B8"; }

.ndqicon-arw-arw-d::before { content: "=EE=82=B4"; }

.ndqicon-arw-arw-d45::before { content: "=EE=82=B5"; }

.ndqicon-arw-r-1::before { content: "=EE=83=89"; }

.ndqicon-arw-u-1::before { content: "=EE=83=90"; }

.ndqicon-arw-u45-1::before { content: "=EE=83=8E"; }

.ndqicon-arw-l-1::before { content: "=EE=83=86"; }

.ndqicon-arw-d-1::before { content: "=EE=83=83"; }

.ndqicon-arw-d45-1::before { content: "=EE=83=81"; }

.ndqicon-arw-arw-r-1::before { content: "=EE=82=BB"; }

.ndqicon-arw-arw-u-1::before { content: "=EE=82=BF"; }

.ndqicon-arw-arw-u45-1::before { content: "=EE=82=BE"; }

.ndqicon-arw-arw-l-1::before { content: "=EE=82=B9"; }

.ndqicon-arw-arw-d-1::before { content: "=EE=82=B7"; }

.ndqicon-arw-arw-d45-1::before { content: "=EE=82=B6"; }

.ndqicon-arw-r-2::before { content: "=EE=83=8A"; }

.ndqicon-arw-u-2::before { content: "=EE=83=91"; }

.ndqicon-arw-u45-2::before { content: "=EE=83=8F"; }

.ndqicon-arw-l-2::before { content: "=EE=83=87"; }

.ndqicon-arw-d-2::before { content: "=EE=83=84"; }

.ndqicon-arw-d45-2::before { content: "=EE=83=82"; }

.ndqicon-arw-arw-r-2::before { content: "=EE=83=98"; }

.ndqicon-arw-arw-u-2::before { content: "=EE=83=9C"; }

.ndqicon-arw-arw-u45-2::before { content: "=EE=83=9A"; }

.ndqicon-arw-arw-l-2::before { content: "=EE=83=96"; }

.ndqicon-arw-arw-d-2::before { content: "=EE=83=94"; }

.ndqicon-arw-arw-d45-2::before { content: "=EE=83=92"; }

.ndqicon-arw-r-3::before { content: "=EE=83=AC"; }

.ndqicon-arw-u-3::before { content: "=EE=83=AB"; }

.ndqicon-arw-u45-3::before { content: "=EE=83=AA"; }

.ndqicon-arw-l-3::before { content: "=EE=83=AD"; }

.ndqicon-arw-d-3::before { content: "=EE=83=A4"; }

.ndqicon-arw-d45-3::before { content: "=EE=83=A5"; }

.ndqicon-arw-arw-r-3::before { content: "=EE=83=99"; }

.ndqicon-arw-arw-u-3::before { content: "=EE=83=9D"; }

.ndqicon-arw-arw-u45-3::before { content: "=EE=83=9B"; }

.ndqicon-arw-arw-l-3::before { content: "=EE=83=97"; }

.ndqicon-arw-arw-d-3::before { content: "=EE=83=95"; }

.ndqicon-arw-arw-d45-3::before { content: "=EE=83=93"; }

.ndqicon-arw-dot-r::before { content: "=EE=83=A0"; }

.ndqicon-arw-dot-u::before { content: "=EE=83=A8"; }

.ndqicon-arw-dot-u45::before { content: "=EE=83=A9"; }

.ndqicon-arw-dot-l::before { content: "=EE=83=A1"; }

.ndqicon-arw-dot-d::before { content: "=EE=83=A3"; }

.ndqicon-arw-dot-d45::before { content: "=EE=83=A2"; }

.ndqicon-arw-dots-r::before { content: "=EE=83=A6"; }

.ndqicon-arw-dots-u::before { content: "=EE=83=A7"; }

.ndqicon-arw-dots-l::before { content: "=EE=83=9E"; }

.ndqicon-arw-dots-d::before { content: "=EE=83=9F"; }

.ndqicon-feedback::before { content: "=EE=80=84"; }

.ndqicon-feedback-1::before { content: "=EE=80=BA"; }

.ndqicon-calendar::before { content: "=EE=80=BB"; }

.ndqicon-calendar-1::before { content: "=EE=80=BC"; }

.ndqicon-reminder::before { content: "=EE=81=80"; }

.ndqicon-reminder-1::before { content: "=EE=81=96"; }

.ndqicon-faq::before { content: "=EE=82=B3"; }

.ndqicon-faq-1::before { content: "=EE=82=B1"; }

.ndqicon-faq-2::before { content: "=EE=82=B2"; }

.ndqicon-windows::before { content: "=EE=82=AB"; }

.ndqicon-xlsb::before { content: "=EE=83=B4"; }

.ndqicon-eps::before { content: "=EE=83=B5"; }

.ndqicon-epub::before { content: "=EE=83=B6"; }

.ndqicon-mobi::before { content: "=EE=83=B7"; }

.ndqicon-mov::before { content: "=EE=83=B8"; }

.ndqicon-mpg::before { content: "=EE=83=B9"; }

.ndqicon-ndaqicons-b::before { content: "=EE=83=BA"; }

.ndqicon-odt::before { content: "=EE=83=BB"; }

.ndqicon-ppsx::before { content: "=EE=83=BC"; }

.ndqicon-pptm::before { content: "=EE=83=BD"; }

.ndqicon-ics::before { content: "=EE=83=BE"; }

.ndqicon-key::before { content: "=EE=83=BF"; }

.ndqicon-rtf::before { content: "=EE=84=80"; }

.ndqicon-rtx::before { content: "=EE=84=81"; }

.ndqicon-rar::before { content: "=EE=84=82"; }

.ndqicon-asf::before { content: "=EE=84=83"; }

.ndqicon-bmp::before { content: "=EE=84=84"; }

.ndqicon-wma::before { content: "=EE=84=85"; }

.ndqicon-wmv::before { content: "=EE=84=86"; }

.ndqicon-xsd::before { content: "=EE=84=87"; }

.ndqicon-wav::before { content: "=EE=84=88"; }

.ndqicon-xlsm::before { content: "=EE=84=89"; }

table.govdocs { border: 1px solid rgb(241, 241, 241); }

table.govdocs tr:nth-child(2n+1) { border-bottom: 0px; background-color: rg=
b(241, 241, 241); }

table.govdocs td { padding: 0.5rem 0.625rem 0.625rem; }

select { width: auto; }

body.irEmail { padding: 0px; margin: 0px; }

input#control_SearchBox { width: 50%; }

input#control_AlertEmail { width: 100%; max-width: 300px; }

table.ndq-contact input#control_zipText { width: 95%; }

table.ndq-contact input#control_emailText { width: 95%; }

table.ndq-contact select, table.ndq-contact textarea { width: 95%; }

table.ndq-contact input.ccbnButton { width: auto !important; }

table tbody th, table tbody td { padding: 0px; }

table tbody tr:nth-child(2n) { border-bottom: 0px; background-color: transp=
arent; }

.ccbnOutline table { border-bottom: 1px solid rgb(241, 241, 241); }

.ccbnOutline table tbody tr:nth-child(2n+1) { border-bottom: 0px; backgroun=
d-color: rgb(241, 241, 241) !important; }

.ccbnOutline table tbody tr:nth-child(2n) { border-bottom: 0px; background-=
color: rgb(255, 255, 255) !important; }

td.ccbnBgSubmit { vertical-align: top; padding: 0px !important; }

.irContent .grid-padding-x { margin-bottom: 70px; }

.ccbn-stock-chart-image img { width: 100%; }

span.data-price { font-size: 4em; font-family: Montserrat, sans-serif; line=
-height: 1.2; color: rgb(255, 255, 255); }

span.data-change { font-size: 2.25em; font-family: Montserrat, sans-serif; =
}

.box-stock-exchange { color: rgb(255, 255, 255); font-family: Montserrat, s=
ans-serif; font-weight: 300; line-height: 1.6; font-size: 1em; }

span.ndq-disclaimer { font-size: 14px; font-style: italic; display: block; =
margin-top: 20px; font-family: Montserrat, sans-serif; font-weight: 300; }

.home-stock { margin: 20px -23px; }

.home-quote { background: rgb(0, 169, 183); color: rgb(255, 255, 255); padd=
ing: 35px; }

.home-chart { border: 1px solid rgb(221, 221, 221); padding: 10px; }

.upcoming table { margin-bottom: 0px; }

.upcoming span.ccbnTxtBold { font-weight: normal; }

.whats-new table tr td { border: 0px; background: rgb(255, 255, 255) !impor=
tant; }

.whats-new .ccbnOutline table { border-bottom: 1px solid rgb(255, 255, 255)=
; }

.whats-new tr.ccbnBgTblTxt td:nth-child(1) { width: 8%; }

.whats-new tr.ccbnBgTblTxt table { margin-bottom: 0px; }

.pfheader td { background: rgb(0, 169, 183); color: rgb(255, 255, 255); pad=
ding: 35px; }

.pfheader td a { color: rgb(255, 255, 255); }

.pfheader img.logo { min-height: 40px; width: 230px; }

span.ccbnTxt label { display: inline; }

.ccbn-event-summary-heading h2 { background: none; padding-left: 0px; }

.ccbn-doc-pdf a { background-image: none; background-position: 0px 0px; }

.sup-mat .ccbnBgTblLabelLeft { width: 20%; }

tr.ccbnBgInput td.ccbnBgSubmit { padding-left: 10px !important; }

table.quaterly td:nth-child(2) { width: 100% !important; }

.socialMedia ul li { margin-right: 5px; }

table.ndq-contact input { width: 90%; }

.sidebarUtility table { border-collapse: inherit; margin-left: 30px; border=
-color: rgb(255, 255, 255) !important; }

.sidebarUtility span.icon.ndqicon-print { background-image: url("/sites/g/f=
iles/knoqqb12671/themes/site/nir_pid1175/client/images/printIcon_2x.png"); =
background-repeat: no-repeat; background-position: left center; background-=
size: 30px; padding: 15px 0px 15px 40px; display: inline-block !important; =
}

.sidebarUtility span.icon.ndqicon-print { background-image: url("/sites/g/f=
iles/knoqqb12671/themes/site/nir_pid1175/client/images/printIcon_2x.png"); =
background-repeat: no-repeat; background-position: left center; background-=
size: 30px; padding: 15px 0px 15px 40px; display: inline-block !important; =
}

.sidebarUtility span.icon.ndqicon-mail { background-image: url("/sites/g/fi=
les/knoqqb12671/themes/site/nir_pid1175/client/images/emailIcon_2x.png"); b=
ackground-repeat: no-repeat; background-position: left center; background-s=
ize: 30px; padding: 15px 0px 15px 40px; display: inline-block !important; }

.sidebarUtility span.icon.ndqicon-rss { background-image: url("/sites/g/fil=
es/knoqqb12671/themes/site/nir_pid1175/client/images/rssIcon_2x.png"); back=
ground-repeat: no-repeat; background-position: left center; background-size=
: 30px; padding: 15px 0px 15px 40px; display: inline-block !important; }

.sidebarUtility span.ndqicon-mail-2.icon { background-image: url("/sites/g/=
files/knoqqb12671/themes/site/nir_pid1175/client/images/alertIcon_2x.png");=
 background-repeat: no-repeat; background-position: left center; background=
-size: 30px; padding: 15px 0px 15px 40px; display: inline-block !important;=
 }

.sidebarUtility span.icon.ndqicon-snapshot { background-image: url("/sites/=
g/files/knoqqb12671/themes/site/nir_pid1175/client/images/sheetIcon_2x.png"=
); background-repeat: no-repeat; background-position: left center; backgrou=
nd-size: 30px; padding: 15px 0px 15px 40px; display: inline-block !importan=
t; }

.sidebarUtility span.icon.ndqicon-print::before { display: none; }

.sidebarUtility span.icon.ndqicon-mail::before { display: none; }

.sidebarUtility span.icon.ndqicon-rss::before { display: none; }

.sidebarUtility span.ndqicon-mail-2.icon::before { display: none; }

.sidebarUtility span.icon.ndqicon-snapshot::before { display: none; }

@media screen and (max-width: 767px) {
  span.ccbnTxt label { display: inline; float: none !important; }
  table.ndq-contact select { width: 95%; }
  .whats-new tr.ccbnBgTblTxt td:nth-child(1) { padding-left: 0px; }
  .whats-new { margin-top: 70px; }
  .home-quote { margin-bottom: 20px; }
  input#control_SearchBox { width: 100%; margin: 0px; }
  .ndq-sec table { margin-bottom: 20px; }
  .ndq-sec table tr, .ndq-sec table tr td { display: block; }
  .ndq-sec .ccbnBgTblTtl { display: none; }
  .ndq-sec td { display: block; position: relative; text-align: left; backg=
round-color: transparent; border: none !important; }
  .ndq-sec td span { display: block; padding: 0px 0px 5px 35%; text-align: =
left; }
  .ndq-sec tr td { border-bottom: none; }
  .ndq-sec tr.ccbnBgTblEven, table.ndq-sec tr.ccbnBgTblOdd { display: block=
; border-bottom: 1px solid rgb(204, 204, 204); border-top: none; padding: 1=
0px 5px; }
  .ndq-sec tr.ccbnBgTblEven { background: rgb(252, 252, 252); }
  .ndq-sec tr.ccbnBgTblOdd:nth-child(2) { border-top: 1px solid rgb(204, 20=
4, 204); }
  .ndq-sec tr:last-child { margin-bottom: 0px !important; }
  .ndq-sec tr.ccbnBgTblEven td:nth-of-type(5), .ndq-sec tr.ccbnBgTblOdd td:=
nth-of-type(5) { padding-left: 34% !important; }
  .ndq-sec tr.ccbnBgTblEven td:nth-of-type(5), .ndq-sec tr.ccbnBgTblEven td=
:nth-of-type(6), .ndq-sec tr.ccbnBgTblEven td:nth-of-type(7), .ndq-sec tr.c=
cbnBgTblEven td:nth-of-type(8), .ndq-sec tr.ccbnBgTblOdd td:nth-of-type(5),=
 .ndq-sec tr.ccbnBgTblOdd td:nth-of-type(6), .ndq-sec tr.ccbnBgTblOdd td:nt=
h-of-type(7), .ndq-sec tr.ccbnBgTblOdd td:nth-of-type(8) { display: inline-=
block; padding-left: 0px; margin-left: 0px; }
  .ndq-sec td::before { position: absolute; top: -1px; left: 0px; padding: =
10px 5px; font-weight: bold; width: 35%; }
  .ndq-sec td:nth-of-type(1)::before { content: "Filing Date"; }
  .ndq-sec td:nth-of-type(2)::before { content: "Form"; }
  .ndq-sec td:nth-of-type(3)::before { content: "Description"; }
  .ndq-sec td:nth-of-type(4)::before { content: "Filing Group"; }
  .ndq-sec td:nth-of-type(5)::before { content: "Downloads"; min-width: 68.=
6%; max-width: 75.5%; padding-right: 50px !important; }
  .ndq-secform td { padding: 3px !important; }
  .ndq-govhead { margin-bottom: 20px; }
  .ndq-govhead td { display: block; width: 100%; }
  .ndq-govcom table, .ndq-govcom tbody, .ndq-govcom thead, .ndq-govcom th, =
.ndq-govcom tr, .ndq-govcom td { display: block; }
  .ndq-govcom .ccbnBgTblTtl { position: absolute; top: -9999px; left: -9999=
px; }
  .ndq-govcom tr { height: auto !important; }
  .ndq-govcom td { border: none; position: relative; text-align: left; }
  .ndq-govcom td::before { left: 2px; padding-right: 10px; color: rgb(0, 0,=
 0); overflow-wrap: break-word; width: 40%; }
  .ndq-govcom tr.ccbnBgTblSubTtl { display: none; }
  .ndq-govcom td:nth-of-type(1)::before { content: ""; display: none; }
  .ndq-govcom td:nth-of-type(2)::before { content: "Audit Committee"; }
  .ndq-govcom td:nth-of-type(3)::before { content: "Compensation Committee"=
; }
  .ndq-govcom td:nth-of-type(4)::before { content: "Nominating and Corporat=
e Governance Committee"; }
}

@media only screen and (min-device-width: 768px) and (max-device-width: 102=
4px) and (orientation: landscape) {
  span.data-price { font-size: 3em; }
  span.ndq-disclaimer { font-size: 11px; }
  .box-stock-exchange { font-size: 0.8em; }
}

@media only screen and (min-device-width: 375px) and (max-device-width: 667=
px) and (orientation: landscape) {
  span.data-price { font-size: 3em; }
  span.ndq-disclaimer { font-size: 11px; }
  .box-stock-exchange { font-size: 0.8em; }
  .whats-new { margin-top: 0px; }
}

@media only screen and (min-device-width: 768px) and (max-device-width: 102=
4px) and (orientation: portrait) {
  span.ndq-disclaimer { font-size: 11px; }
}

@media screen and (max-width: 39.9375em) {
  .irContent input { display: inherit; }
}

.qrtest { border: 1px solid rgb(230, 230, 230); }

.qrtest td { background: rgb(255, 255, 255) !important; }

.qrtest table td img { padding-right: 10px !important; }

.irPrint .irContent img[src*=3D"29981.jpg"] { display: none; }

.sociable { margin-top: 20px; }

.irContent img { max-width: none; }

.leftnavigation a { text-transform: lowercase; }

.leftnavigation a.sub { margin-left: 15px; }

.newsList br, .newsTime { display: none; }

.newsList { padding-bottom: 30px !important; }

.newsDate { font-weight: normal; }

.ccbnTtl > img { padding-left: 5px !important; vertical-align: baseline; }

.ccbnBgTblSubTxt > td { background: rgb(255, 255, 255) !important; }

.quoteLong tr td:nth-child(2n+1) { font-weight: bold; }

.ccbnError > li { margin-left: 15px; }

.ccbnError > br { display: block; margin-bottom: 5px; }

.sm td { padding-right: 5px; vertical-align: top; }

.rssFeeds img { padding-right: 5px !important; vertical-align: top; }

.alertsLong table .ccbnBgLabel td { padding: 6px; }

.alertsLong table td { margin: 0px; padding: 0px; vertical-align: baseline;=
 }

.faqQuestion { cursor: pointer; }

.faqContent td { padding: 0px; }

.faqContent .faqAnswer td { padding-top: 10px; }

.expandAll, .collapseAll { cursor: pointer; font-weight: bold; margin-botto=
m: 10px !important; }

.leftnavigation img { height: 0px; padding: 16px !important; }

.leftnavigation img[src*=3D"toolkit_print_t.gif"] { background: url("/sites=
/g/files/knoqqb12671/themes/site/nir_pid1175/client/images/presskit.png") 0=
px 0px no-repeat scroll transparent; }

.leftnavigation img[src*=3D"toolkit_emailPg_t.gif"] { background: url("/sit=
es/g/files/knoqqb12671/themes/site/nir_pid1175/client/images/email.png") 0p=
x 0px no-repeat scroll transparent; }

.leftnavigation img[src*=3D"toolkit_rss_t.gif"] { background: url("/sites/g=
/files/knoqqb12671/themes/site/nir_pid1175/client/images/rss.png") 0px 0px =
no-repeat scroll transparent; }

.leftnavigation img[src*=3D"toolkit_alert_t.gif"] { background: url("/sites=
/g/files/knoqqb12671/themes/site/nir_pid1175/client/images/email.png") 0px =
0px no-repeat scroll transparent; }

.leftnavigation img[src*=3D"toolkit_tearSht_t.gif"] { background: url("/sit=
es/g/files/knoqqb12671/themes/site/nir_pid1175/client/images/snapshot.png")=
 0px 0px no-repeat scroll transparent; }

.leftnavigation table td { vertical-align: middle; }

.leftnavigation td a { font-weight: bold; }

.padR5, .padR5 td { padding-right: 5px !important; }

.padB5, .padB5 td { padding-bottom: 5px !important; }

.padB10, .padB10 td { padding-bottom: 10px !important; }

.padR10, .padR10 td { padding-right: 10px !important; }

.irContent table { border-collapse: separate; border-spacing: 1px; }

.ccbnOutline td td { padding: 0.5rem 0.625rem 0.625rem; }

.ccbnOutline td td td { padding: 0px; background: none; }

.ccbnTable td { padding: 5px; background: rgb(241, 241, 241); }

.ccbnTable td td { padding: 0px; background: none; }

.ccbnRowHoverTbl td { padding: 5px; background: rgb(241, 241, 241); }

.newsLong td { padding: 0px; }

.ccbnCalendarHelpDiv .ccbnSubTtl { font-weight: bold; }

.ccbnCalendar .ccbnTblLabelTop { font-size: 10px; font-weight: bold; }

body.irPrint, body.irEmail { background: none; }

@media print {
  .irPrint, .irPrint p, .irPrint a, .irPrint li, .irPrint span, .irPrint di=
v, .irPrint td, .irPrint h1, .irPrint h2, .irEmail, .irEmail p, .irEmail a,=
 .irEmail li, .irEmail span, .irEmail div, .irEmail td, .irEmail h1, .irEma=
il h2 { background: rgb(255, 255, 255); color: rgb(0, 0, 0) !important; fon=
t-family: Arial, sans-serif !important; }
  a[href]::after { content: ""; }
  .irPrint .irContent a, .irEmail .irContent a { color: rgb(0, 0, 0) !impor=
tant; }
  .irContent table td { background: rgb(255, 255, 255); }
}

.ccbnTblTtl { font-weight: bold; }

.ccbnBgTblTtl td, .ccbnOutline .ccbnBgTblTtl td, .ccbnTable .ccbnBgTblTtl t=
d, .ccbnRowHoverTbl .ccbnBgTblTtl td { background: rgb(248, 248, 248); colo=
r: rgb(10, 10, 10); }

.ccbnTblSubTtl { font-weight: bold; }

.ccbnBgTblSubTtl { }

.ccbnTblOdd { }

.ccbnBgTblOdd { }

.ccbnTblEven { }

.ccbnBgTblEven { }

.ccbnTblTxt { }

.ccbnBgTblTxt { }

.ccbnTblTxtBold { font-weight: bold; }

.ccbnBgTblTxtBold { }

.ccbnTblHighlight { }

.ccbnBgTblHighlight { }

.ccbnTblSubTxt { color: rgb(153, 153, 153); font-size: 11px; }

.ccbnBgTblSubTxt { }

.ccbnTblLnk { }

.ccbnBgTblLnk { background-color: rgb(255, 255, 255); }

.ccbnTblHighlightLnk { font-weight: bold; }

.ccbnBgTblHighlightLnk { background-color: rgb(255, 255, 255); }

.ccbnTblLabelLnk { font-weight: bold; }

.ccbnBgTblLabelLnk { background-color: rgb(255, 255, 255); }

.ccbnTtl { display: inline-block; margin-bottom: 2px; padding-bottom: 8px; =
font-size: 30px; font-style: normal; font-weight: normal; text-rendering: o=
ptimizelegibility; font-family: Montserrat, sans-serif; color: rgb(137, 140=
, 141) !important; }

.ccbnBgTtl { }

.ccbnSubTtl { }

.ccbnBgSubTtl { }

.ccbnTxt { }

.ccbnBgTxt { }

.ccbnTxtBold { font-weight: bold; }

.ccbnBgTxtBold { }

.ccbnTxtBoldSub { }

.ccbnBgTxtBoldSub { }

.ccbnSubTxt { }

.ccbnBgSubTxt { }

.ccbnRequired { color: rgb(255, 0, 0); }

.ccbnBgRequired { }

.ccbnError { color: rgb(255, 0, 0); }

.ccbnBgError { }

.ccbnConfirmBold { font-weight: bold; }

.ccbnBgConfirmBold { }

.ccbnNeg { color: rgb(255, 0, 0); }

.ccbnBgNeg { background-color: rgb(255, 0, 0); }

.ccbnPos { color: rgb(0, 176, 0); }

.ccbnBgPos { background-color: rgb(0, 176, 0); }

.ccbnPrice { font-weight: bold; }

.ccbnBgPrice { background-color: rgb(255, 255, 255); }

.ccbnLnk { }

.ccbnBgLnk { }

.ccbnSubLnk { }

.ccbnBgSubLnk { }

.ccbnTblSubLnk { }

.ccbnBgTblSubLnk { }

.modDisclaimer { color: rgb(153, 153, 153); font-size: 11px; }

.ccbnDisclaimer { color: rgb(153, 153, 153); font-size: 11px; }

.ccbnBgDisclaimer { background-color: rgb(255, 255, 255); }

.ccbnLabel { font-weight: bold; }

.ccbnBgLabel { background-color: rgb(255, 255, 255); }

.ccbnTblLabelLeft { font-weight: bold; }

.ccbnBgTblLabelLeft { }

.ccbnTblLabelTop { }

.ccbnBgTblLabelTop { }

.ccbnNav { }

.ccbnSelect { }

.ccbnBgSelect { }

.ccbnInput { }

.ccbnBgInput { }

.ccbnButton, .view-more { background-color: rgb(0, 169, 183); padding: 10px=
 22px 10px 25px; font-weight: 600; text-transform: uppercase; letter-spacin=
g: 3px; font-size: 15px; border: 1px solid rgb(255, 255, 255); color: rgb(2=
55, 255, 255) !important; }

.ccbnButton:hover, .view-more:hover { background-color: rgb(21, 196, 211); =
}

.ccbnBgButton { }

.ccbnOutline { background-color: rgb(255, 255, 255); }

.ccbnOutlineChart { background-color: rgb(255, 255, 255); }

.ccbnOutlineQuote { background-color: rgb(255, 255, 255); }

.ccbnBgChart { background-color: rgb(255, 255, 255); }

.ccbnBgLine { background-color: rgb(0, 0, 0); }

.ccbnBgSpacer { background-color: rgb(255, 255, 255); }

#CCBNSECRes { }

.ccbnEnumBodyBg { }

.ccbnEnumBg { background-color: rgb(204, 204, 204); }

.ccbnEnumBgLogo { background-color: rgb(255, 255, 255); }

.ccbnEnumHighlightLt { background-color: rgb(255, 255, 255); }

.ccbnEnumHighlight { background-color: rgb(239, 239, 239); }

.ccbnEnumShadow { background-color: rgb(153, 153, 153); }

.ccbnEnumShadowDk { background-color: rgb(102, 102, 102); }

.ccbnEnumTabLnk { font-family: arial, helvetica, sans-serif; font-size: 10p=
x; color: rgb(0, 0, 0); text-transform: uppercase; }

a.ccbnEnumTabLnk:link { font-family: arial, helvetica, sans-serif; font-siz=
e: 10px; color: rgb(0, 0, 0); text-transform: uppercase; text-decoration: u=
nderline; }

a.ccbnEnumTabLnk:hover { text-decoration: none; }

a.ccbnEnumTabLnk:active { text-decoration: none; }

a.ccbnEnumTabLnk:visited { font-family: arial, helvetica, sans-serif; font-=
size: 10px; color: rgb(0, 0, 0); text-transform: uppercase; text-decoration=
: underline; }

.ccbnEnumPeerListLnk { font-size: 11px; }

.ccbnEnumTxtEven { font-family: arial, verdana, helvetica, sans-serif; font=
-size: 11px; }

.ccbnEnumTxtOdd { font-family: arial, verdana, helvetica, sans-serif; font-=
size: 11px; }

.ccbnBgEnumTblEven { background-color: rgb(239, 239, 239); }

.ccbnBgEnumTblOdd { background-color: rgb(255, 255, 255); }

.ccbnPopover { position: absolute; visibility: hidden; overflow: auto; widt=
h: 300px; height: auto; background: rgb(255, 255, 255); text-align: left; b=
order: 1px solid rgb(0, 0, 0); top: 0px; left: 0px; padding: 5px; }

.ccbnDefinitionHover { }

.ccbnEventHeaderHover { }

.ccbnBioHover { }

.ccbnNewsHover { }

.ccbnRowHoverTbl tr:hover td, .ccbnRowHoverTbl tr.ccbnIE6Over td { }

.ccbnRowHoverTbl tr.ccbnBgTblTtl:hover td { }

.ccbnScroll { position: relative; overflow: hidden; height: 160px; }

.ccbnCalendarTable tbody td.ccbnEvent:hover, .ccbnCalendarTable tbody td.cc=
bnIE6Over { cursor: pointer; }

.ccbnCalendarTable thead td.ccbnCalButton:hover, .ccbnCalendarTable thead t=
d.ccbnCalButton.ccbnIE6Over { cursor: pointer; }

.ccbnCalendarDiv { height: auto; max-height: 100px; }

.ccbnCalendarHelpDiv { max-height: 500px; }

.ccbnCalendarDivClick { overflow: auto; margin-left: 10px; height: 230px; }

.ccbnWeekend { }

.ccbnEvent { background: rgb(176, 176, 178) !important; }

.ccbnCalButton { cursor: pointer; }

.ccbnDay { }

.ccbnName { }

.ccbnCalendar { cursor: default; width: 100%; }

.ccbnCalendarTable { }

.ccbnCalCenterTitle { padding-left: 2.5em; }

.ccbnCalIconAnalyst { background: url("/sites/g/files/knoqqb12671/themes/si=
te/nir_pid1175/client/images/icon_am.gif") no-repeat; }

.ccbnCalIconConference { background: url("/sites/g/files/knoqqb12671/themes=
/site/nir_pid1175/client/images/icon_cf.gif") no-repeat; }

.ccbnCalIconConferencePres { background: url("/sites/g/files/knoqqb12671/th=
emes/site/nir_pid1175/client/images/icon_cp.gif") no-repeat; }

.ccbnCalIconConferenceCall { background: url("/sites/g/files/knoqqb12671/th=
emes/site/nir_pid1175/client/images/icon_cc-ne.gif") no-repeat; }

.ccbnCalIconCustom { background: url("/sites/g/files/knoqqb12671/themes/sit=
e/nir_pid1175/client/images/icon_custom.gif") no-repeat; }

.ccbnCalIconEarningsConfCall { background: url("/sites/g/files/knoqqb12671/=
themes/site/nir_pid1175/client/images/icon_cc-er.gif") no-repeat; }

.ccbnCalIconEarnings { background: url("/sites/g/files/knoqqb12671/themes/s=
ite/nir_pid1175/client/images/icon_er.gif") no-repeat; }

.ccbnCalIconReports { background: url("/sites/g/files/knoqqb12671/themes/si=
te/nir_pid1175/client/images/icon_fin_rpt.gif") no-repeat; }

.ccbnCalIconMA { background: url("/sites/g/files/knoqqb12671/themes/site/ni=
r_pid1175/client/images/icon_ma.gif") no-repeat; }

.ccbnCalIconGuidance { background: url("/sites/g/files/knoqqb12671/themes/s=
ite/nir_pid1175/client/images/icon_ga.gif") no-repeat; }

.ccbnCalIconOther { background: url("/sites/g/files/knoqqb12671/themes/site=
/nir_pid1175/client/images/icon_oc.gif") no-repeat; }

.ccbnCalIconSalesCall { background: url("/sites/g/files/knoqqb12671/themes/=
site/nir_pid1175/client/images/icon_sc.gif") no-repeat; }

.ccbnCalIconSalesRelease { background: url("/sites/g/files/knoqqb12671/them=
es/site/nir_pid1175/client/images/icon_sar.gif") no-repeat; }

.ccbnCalIconShareholders { background: url("/sites/g/files/knoqqb12671/them=
es/site/nir_pid1175/client/images/icon_sm.gif") no-repeat; }

.ccbnCalIconNewsRelease { background: url("/sites/g/files/knoqqb12671/theme=
s/site/nir_pid1175/client/images/icon_news.gif") no-repeat; }

.ccbnCalIconSEC { background: url("/sites/g/files/knoqqb12671/themes/site/n=
ir_pid1175/client/images/icon_sec.gif") no-repeat; }

.ccbnCalIconPresentations { background: url("/sites/g/files/knoqqb12671/the=
mes/site/nir_pid1175/client/images/icon_pres.gif") no-repeat; }

.ccbnCalIcon52WeekHigh { background: url("/sites/g/files/knoqqb12671/themes=
/site/nir_pid1175/client/images/icon_52wkh.gif") no-repeat; }

.ccbnCalIconAnalyst, .ccbnCalIconConference, .ccbnCalIconConferencePres, .c=
cbnCalIconConferenceCall, .ccbnCalIconCustom, .ccbnCalIconEarningsConfCall,=
 .ccbnCalIconEarnings, .ccbnCalIconReports, .ccbnCalIconMA, .ccbnCalIconGui=
dance, .ccbnCalIconOther, .ccbnCalIconSalesCall, .ccbnCalIconSalesRelease, =
.ccbnCalIconShareholders, .ccbnCalIconNewsRelease, .ccbnCalIconSEC, .ccbnCa=
lIconPresentations, .ccbnCalIcon52WeekHigh { padding-left: 20px; }

.ccbnEmpty span { visibility: hidden; }

td.ccbnCalButton:hover div.ccbnCalendarHelpDiv, .ccbnCalendarTable thead td=
.ccbnIE6Over div.ccbnCalendarHelpDiv { visibility: visible; z-index: 100; }

td.ccbnEvent:hover div.ccbnCalendarDiv, .ccbnCalendarTable tbody td.ccbnIE6=
Over div.ccbnCalendarDiv { visibility: visible; z-index: 100; }

.bwcellpaddingbottom1 { padding-bottom: 2px; font: 100% arial; }

.bwcellpaddingbottom3 { padding-bottom: 4px; font: 100% arial; }

.bwcellpaddingleft0 { padding-left: 0px; font: 100% arial; }

.bwcellpaddingleft1 { padding-left: 5px; font: 100% arial; }

.bwcellpaddingleft2 { padding-left: 10px; font: 100% arial; }

.bwcellpaddingleft4 { padding-left: 20px; font: 100% arial; }

.bwcellpaddingleft5 { padding-left: 25px; font: 100% arial; }

.bwcellpaddingleft6 { padding-left: 30px; font: 100% arial; }

.bwcellpaddingleft7 { padding-left: 35px; font: 100% arial; }

.bwcellpaddingleft8 { padding-left: 40px; font: 100% arial; }

.bwcellpaddingright0 { padding-right: 0px; font: 100% arial; }

.bwcellparagraphmargin { margin-bottom: 0px; margin-top: 0px; font: 100% ar=
ial; }

.bwdoublebottomborder { border-bottom: 2.25pt double black; font: 100% aria=
l; }

.bwlistitemmarginbottom { margin-bottom: 10px; font: 100% arial; }

.bwsinglebottomborder { border-bottom: 1pt solid black; font: 100% arial; }

.bwtablebottommargin { margin-bottom: 10px; font: 100% arial; }

.bwtextaligncenter { text-align: center; font: 100% arial; }

.bwtextalignleft { text-align: left; font: 100% arial; }

.bwtextalignright { text-align: right; font: 100% arial; }

.bwunderlinestyle { text-decoration: underline; font: 100% arial; }

.bwverticalalignbottom { vertical-align: bottom; font: 100% arial; }

.bwverticalaligntop { vertical-align: top; font: 100% arial; }

.bwwhitespacenowrap { white-space: nowrap; font: 100% arial; }

.bwbodyimg { float: left; padding-left: 0px; padding-right: 20px; padding-t=
op: 0px; padding-bottom: 0px !important; }

.bwbodyimgcaption { font-size: 85% !important; }

.bwtextaligncenter, .bwalignc { text-align: center !important; }

.bwtextalignleft, .bwalignl { text-align: left !important; }

.bwtextalignright, .bwalignr { text-align: right !important; }

.bwverticalaligntop, .bwvertalignt { vertical-align: top !important; }

.bwverticalalignmiddle, .bwvertalignm { vertical-align: middle !important; =
}

.bwverticalalignbottom, .bwvertalignb { vertical-align: bottom !important; =
}

.bwtablefigurealign, .bwfigurealign { text-align: right; vertical-align: bo=
ttom !important; }

.bwtabletextalign, .bwtxtalign { text-align: left; vertical-align: bottom !=
important; }

.bwwhitespacenowrap, .bwnowrap { white-space: normal !important; }

.bwsinglebottomborder, .bwsinglebottom { border-bottom: 1pt solid black !im=
portant; }

.bwdoublebottomborder, .bwdoublebottom { border-bottom: 2.25pt double black=
 !important; }

.bwsingletopborder, .bwsingletop { border-top: 1pt solid black !important; =
}

.bwdoubletopborder, .bwdoubletop { border-top: 2.25pt double black !importa=
nt; }

.bwcellpaddingleft0, .bwpadl0 { padding-left: 0px !important; }

.bwcellpaddingleft1, .bwpadl1 { padding-left: 5px !important; }

.bwcellpaddingleft2, .bwpadl2 { padding-left: 10px !important; }

.bwcellpaddingleft3, .bwpadl3 { padding-left: 15px !important; }

.bwcellpaddingleft4, .bwpadl4 { padding-left: 20px !important; }

.bwcellpaddingleft5, .bwpadl5 { padding-left: 25px !important; }

.bwcellpaddingleft6, .bwpadl6 { padding-left: 30px !important; }

.bwcellpaddingleft7, .bwpadl7 { padding-left: 35px !important; }

.bwcellpaddingleft8, .bwpadl8 { padding-left: 40px !important; }

.bwcellpaddingleft9, .bwpadl9 { padding-left: 45px !important; }

.bwcellpaddingleft10, .bwpadl10 { padding-left: 50px !important; }

.bwcellpaddingleft11, .bwpadl11 { padding-left: 55px !important; }

.bwcellpaddingleft12, .bwpadl12 { padding-left: 60px !important; }

.bwcellpaddingleft13, .bwpadl13 { padding-left: 65px !important; }

.bwcellpaddingleft14, .bwpadl14 { padding-left: 70px !important; }

.bwcellpaddingleft15, .bwpadl15 { padding-left: 75px !important; }

.bwcellpaddingleft16, .bwpadl16 { padding-left: 80px !important; }

.bwcellpaddingleft17, .bwpadl17 { padding-left: 85px !important; }

.bwcellpaddingleft18, .bwpadl18 { padding-left: 90px !important; }

.bwcellpaddingleft19, .bwpadl19 { padding-left: 95px !important; }

.bwcellpaddingleft20, .bwpadl20 { padding-left: 100px !important; }

.bwcellpaddingright0, .bwpadr0 { padding-right: 0px !important; }

.bwcellpaddingright1, .bwpadr1 { padding-right: 5px !important; }

.bwcellpaddingright2, .bwpadr2 { padding-right: 10px !important; }

.bwcellpaddingright3, .bwpadr3 { padding-right: 15px !important; }

.bwcellpaddingright4, .bwpadr4 { padding-right: 20px !important; }

.bwcellpaddingright5, .bwpadr5 { padding-right: 25px !important; }

.bwcellpaddingright6, .bwpadr6 { padding-right: 30px !important; }

.bwcellpaddingright7, .bwpadr7 { padding-right: 35px !important; }

.bwcellpaddingright8, .bwpadr8 { padding-right: 40px !important; }

.bwcellpaddingright9, .bwpadr9 { padding-right: 45px !important; }

.bwcellpaddingright10, .bwpadr10 { padding-right: 50px !important; }

.bwcellpaddingtop1, .bwpadt1 { padding-top: 10px !important; }

.bwcellpaddingtop2, .bwpadt2 { padding-top: 20px !important; }

.bwcellpaddingtop3, .bwpadt3 { padding-top: 30px !important; }

.bwcellpaddingtop4, .bwpadt4 { padding-top: 40px !important; }

.bwcellpaddingtop5, .bwpadt5 { padding-top: 50px !important; }

.bwcellpaddingtop6, .bwpadt6 { padding-top: 60px !important; }

.bwcellpaddingtop7, .bwpadt7 { padding-top: 70px !important; }

.bwcellpaddingtop8, .bwpadt8 { padding-top: 80px !important; }

.bwcellpaddingtop9, .bwpadt9 { padding-top: 90px !important; }

.bwcellpaddingtop10, .bwpadt10 { padding-top: 100px !important; }

.bwcellpaddingtop11, .bwpadt11 { padding-top: 110px !important; }

.bwcellpaddingtop12, .bwpadt12 { padding-top: 120px !important; }

.bwcellpaddingtop13, .bwpadt13 { padding-top: 130px !important; }

.bwcellpaddingtop14, .bwpadt14 { padding-top: 140px !important; }

.bwcellpaddingtop15, .bwpadt15 { padding-top: 150px !important; }

.bwcellpaddingtop16, .bwpadt16 { padding-top: 160px !important; }

.bwcellpaddingtop17, .bwpadt17 { padding-top: 170px !important; }

.bwcellpaddingtop18, .bwpadt18 { padding-top: 180px !important; }

.bwcellpaddingtop19, .bwpadt19 { padding-top: 190px !important; }

.bwcellpaddingtop20, .bwpadt20 { padding-top: 200px !important; }

.bwcellpaddingbottom1, .bwpadb1 { padding-bottom: 2px !important; }

.bwcellpaddingbottom2, .bwpadb2 { padding-bottom: 3px !important; }

.bwcellpaddingbottom3, .bwpadb3 { padding-bottom: 4px !important; }

.bwunderlinestyle, .bwuline { text-decoration: underline !important; }

.bwdoubleunderlinestyle, .bwdbluline { text-decoration: underline; border-b=
ottom: 1px solid black !important; }

.bwcolorred, .bwred { color: red !important; }

.bwcolorblack, .bwblack { color: black !important; }

.bwmarginleft1, .bwmarginl1 { margin-left: 30px !important; }

.bwmarginleft2, .bwmarginl2 { margin-left: 60px !important; }

.bwmarginleft3, .bwmarginl3 { margin-left: 90px !important; }

.bwmarginleft4, .bwmarginl4 { margin-left: 120px !important; }

.bwmarginleft5, .bwmarginl5 { margin-left: 150px !important; }

.bwmarginleft6, .bwmarginl6 { margin-left: 180px !important; }

.bwmarginleft7, .bwmarginl7 { margin-left: 210px !important; }

.bwmarginleft8, .bwmarginl8 { margin-left: 240px !important; }

.bwmarginleft9, .bwmarginl9 { margin-left: 270px !important; }

.bwmarginleft10, .bwmarginl10 { margin-left: 300px !important; }

.bwhangingindent, .bwhangindent { text-indent: -30px !important; }

.bwparagraphindent, .bwpindent { text-indent: 30px !important; }

.bwliststylenone, .bwlistnone { list-style-image: none; list-style-type: no=
ne !important; }

.bwliststyledisc, .bwlistdisc { list-style-type: disc !important; }

.bwliststylesquare, .bwlistsquare { list-style-type: square !important; }

.bwliststylecircle, .bwlistcircle { list-style-type: circle !important; }

.bwliststyledecimal, .bwlistdecimal { list-style-type: decimal !important; =
}

.bwliststyleloweralpha, .bwlistlowalpha { list-style-type: lower-alpha !imp=
ortant; }

.bwliststyleupperalpha, .bwlistupalpha { list-style-type: upper-alpha !impo=
rtant; }

.bwliststylelowerroman, .bwlistlowroman { list-style-type: lower-roman !imp=
ortant; }

.bwliststyleupperroman, .bwlistuproman { list-style-type: upper-roman !impo=
rtant; }

.bwlistitemmarginbottom, .bwlistitemmargb { margin-bottom: 10px !important;=
 }

.bwcellparagraphmargin, .bwcellpmargin { margin-bottom: 0px; margin-top: 0p=
x !important; }

.bwtablebottommargin, .bwtablemarginb { margin-bottom: 10px !important; }

.bwblockaligncenter, .bwblockalignc { margin-left: auto; margin-right: auto=
 !important; }

.bwblockalignleft, .bwblockalignl { margin-left: 0px; margin-right: auto !i=
mportant; }

.bwblockalignright, .bwblockalignr { margin-left: auto; margin-right: 0px !=
important; }

.bwwidthpercent1, .bwwidth1 { width: 1% !important; }

.bwwidthpercent2, .bwwidth2 { width: 2% !important; }

.bwwidthpercent3, .bwwidth3 { width: 3% !important; }

.bwwidthpercent4, .bwwidth4 { width: 4% !important; }

.bwwidthpercent5, .bwwidth5 { width: 5% !important; }

.bwwidthpercent6, .bwwidth6 { width: 6% !important; }

.bwwidthpercent7, .bwwidth7 { width: 7% !important; }

.bwwidthpercent8, .bwwidth8 { width: 8% !important; }

.bwwidthpercent9, .bwwidth9 { width: 9% !important; }

.bwwidthpercent10, .bwwidth10 { width: 10% !important; }

.bwwidthpercent11, .bwwidth11 { width: 11% !important; }

.bwwidthpercent12, .bwwidth12 { width: 12% !important; }

.bwwidthpercent13, .bwwidth13 { width: 13% !important; }

.bwwidthpercent14, .bwwidth14 { width: 14% !important; }

.bwwidthpercent15, .bwwidth15 { width: 15% !important; }

.bwwidthpercent16, .bwwidth16 { width: 16% !important; }

.bwwidthpercent17, .bwwidth17 { width: 17% !important; }

.bwwidthpercent18, .bwwidth18 { width: 18% !important; }

.bwwidthpercent19, .bwwidth19 { width: 19% !important; }

.bwwidthpercent20, .bwwidth20 { width: 20% !important; }

.bwwidthpercent21, .bwwidth21 { width: 21% !important; }

.bwwidthpercent22, .bwwidth22 { width: 22% !important; }

.bwwidthpercent23, .bwwidth23 { width: 23% !important; }

.bwwidthpercent24, .bwwidth24 { width: 24% !important; }

.bwwidthpercent25, .bwwidth25 { width: 25% !important; }

.bwwidthpercent26, .bwwidth26 { width: 26% !important; }

.bwwidthpercent27, .bwwidth27 { width: 27% !important; }

.bwwidthpercent28, .bwwidth28 { width: 28% !important; }

.bwwidthpercent29, .bwwidth29 { width: 29% !important; }

.bwwidthpercent30, .bwwidth30 { width: 30% !important; }

.bwwidthpercent31, .bwwidth31 { width: 31% !important; }

.bwwidthpercent32, .bwwidth32 { width: 32% !important; }

.bwwidthpercent33, .bwwidth33 { width: 33% !important; }

.bwwidthpercent34, .bwwidth34 { width: 34% !important; }

.bwwidthpercent35, .bwwidth35 { width: 35% !important; }

.bwwidthpercent36, .bwwidth36 { width: 36% !important; }

.bwwidthpercent37, .bwwidth37 { width: 37% !important; }

.bwwidthpercent38, .bwwidth38 { width: 38% !important; }

.bwwidthpercent39, .bwwidth39 { width: 39% !important; }

.bwwidthpercent40, .bwwidth40 { width: 40% !important; }

.bwwidthpercent41, .bwwidth41 { width: 41% !important; }

.bwwidthpercent42, .bwwidth42 { width: 42% !important; }

.bwwidthpercent43, .bwwidth43 { width: 43% !important; }

.bwwidthpercent44, .bwwidth44 { width: 44% !important; }

.bwwidthpercent45, .bwwidth45 { width: 45% !important; }

.bwwidthpercent46, .bwwidth46 { width: 46% !important; }

.bwwidthpercent47, .bwwidth47 { width: 47% !important; }

.bwwidthpercent48, .bwwidth48 { width: 48% !important; }

.bwwidthpercent49, .bwwidth49 { width: 49% !important; }

.bwwidthpercent50, .bwwidth50 { width: 50% !important; }

.bwwidthpercent51, .bwwidth51 { width: 51% !important; }

.bwwidthpercent52, .bwwidth52 { width: 52% !important; }

.bwwidthpercent53, .bwwidth53 { width: 53% !important; }

.bwwidthpercent54, .bwwidth54 { width: 54% !important; }

.bwwidthpercent55, .bwwidth55 { width: 55% !important; }

.bwwidthpercent56, .bwwidth56 { width: 56% !important; }

.bwwidthpercent57, .bwwidth57 { width: 57% !important; }

.bwwidthpercent58, .bwwidth58 { width: 58% !important; }

.bwwidthpercent59, .bwwidth59 { width: 59% !important; }

.bwwidthpercent60, .bwwidth60 { width: 60% !important; }

.bwwidthpercent61, .bwwidth61 { width: 61% !important; }

.bwwidthpercent62, .bwwidth62 { width: 62% !important; }

.bwwidthpercent63, .bwwidth63 { width: 63% !important; }

.bwwidthpercent64, .bwwidth64 { width: 64% !important; }

.bwwidthpercent65, .bwwidth65 { width: 65% !important; }

.bwwidthpercent66, .bwwidth66 { width: 66% !important; }

.bwwidthpercent67, .bwwidth67 { width: 67% !important; }

.bwwidthpercent68, .bwwidth68 { width: 68% !important; }

.bwwidthpercent69, .bwwidth69 { width: 69% !important; }

.bwwidthpercent70, .bwwidth70 { width: 70% !important; }

.bwwidthpercent71, .bwwidth71 { width: 71% !important; }

.bwwidthpercent72, .bwwidth72 { width: 72% !important; }

.bwwidthpercent73, .bwwidth73 { width: 73% !important; }

.bwwidthpercent74, .bwwidth74 { width: 74% !important; }

.bwwidthpercent75, .bwwidth75 { width: 75% !important; }

.bwwidthpercent76, .bwwidth76 { width: 76% !important; }

.bwwidthpercent77, .bwwidth77 { width: 77% !important; }

.bwwidthpercent78, .bwwidth78 { width: 78% !important; }

.bwwidthpercent79, .bwwidth79 { width: 79% !important; }

.bwwidthpercent80, .bwwidth80 { width: 80% !important; }

.bwwidthpercent81, .bwwidth81 { width: 81% !important; }

.bwwidthpercent82, .bwwidth82 { width: 82% !important; }

.bwwidthpercent83, .bwwidth83 { width: 83% !important; }

.bwwidthpercent84, .bwwidth84 { width: 84% !important; }

.bwwidthpercent85, .bwwidth85 { width: 85% !important; }

.bwwidthpercent86, .bwwidth86 { width: 86% !important; }

.bwwidthpercent87, .bwwidth87 { width: 87% !important; }

.bwwidthpercent88, .bwwidth88 { width: 88% !important; }

.bwwidthpercent89, .bwwidth89 { width: 89% !important; }

.bwwidthpercent90, .bwwidth90 { width: 90% !important; }

.bwwidthpercent91, .bwwidth91 { width: 91% !important; }

.bwwidthpercent92, .bwwidth92 { width: 92% !important; }

.bwwidthpercent93, .bwwidth93 { width: 93% !important; }

.bwwidthpercent94, .bwwidth94 { width: 94% !important; }

.bwwidthpercent95, .bwwidth95 { width: 95% !important; }

.bwwidthpercent96, .bwwidth96 { width: 96% !important; }

.bwwidthpercent97, .bwwidth97 { width: 97% !important; }

.bwwidthpercent98, .bwwidth98 { width: 98% !important; }

.bwwidthpercent99, .bwwidth99 { width: 99% !important; }

.bwwidthpercent100, .bwwidth100 { width: 100% !important; }

.prntblns tr td:first-child, .prntblns tr td:first-child p { white-space: n=
ormal !important; }

p.prnews_p { margin: 0px !important; }

.prngen14 { border-width: 0.08em !important; border-bottom-style: solid !im=
portant; border-bottom-color: black !important; text-align: right !importan=
t; border-left-style: initial !important; border-left-color: initial !impor=
tant; padding-left: 0px !important; padding-right: 0px !important; vertical=
-align: bottom !important; border-top-style: initial !important; border-top=
-color: initial !important; border-right-style: initial !important; border-=
right-color: initial !important; }

.prngen21 { border-width: 0.08em !important; border-style: initial !importa=
nt; border-color: initial !important; text-align: left !important; padding-=
left: 0px !important; padding-right: 0px !important; vertical-align: bottom=
 !important; }

.prngen4 { white-space: normal; border-width: 0.08em !important; border-sty=
le: initial !important; border-color: initial !important; text-align: left =
!important; padding-left: 0px !important; padding-right: 0px !important; ve=
rtical-align: bottom !important; }

.prngen19 { border-bottom: 0.17em double black; text-align: right !importan=
t; border-left: 0.08em !important; padding-left: 0px !important; padding-ri=
ght: 0px !important; vertical-align: bottom !important; border-top: 0.08em =
!important; border-right: 0.08em !important; }

.prngen16 { border-bottom: 0.17em double black; text-align: right !importan=
t; border-left: 0.08em !important; padding-left: 0px !important; padding-ri=
ght: 0px !important; vertical-align: bottom !important; border-top: black !=
important; border-right: 0.08em !important; }

.prngen6 { border-width: 0.08em !important; border-bottom-style: initial !i=
mportant; border-bottom-color: initial !important; text-align: right !impor=
tant; border-left-style: solid !important; border-left-color: black !import=
ant; padding-left: 0px !important; padding-right: 0px !important; vertical-=
align: bottom !important; border-top-style: initial !important; border-top-=
color: initial !important; border-right-style: initial !important; border-r=
ight-color: initial !important; }

.prngen9 { text-align: center; border-width: 0.08em !important; border-bott=
om-style: solid !important; border-bottom-color: black !important; border-l=
eft-style: initial !important; border-left-color: initial !important; paddi=
ng-left: 0px !important; padding-right: 0px !important; vertical-align: bot=
tom !important; border-top-style: initial !important; border-top-color: ini=
tial !important; border-right-style: initial !important; border-right-color=
: initial !important; }

.prngen13 { border-width: 0.08em !important; border-style: initial !importa=
nt; border-color: initial !important; text-align: right !important; padding=
-left: 0px !important; padding-right: 0px !important; vertical-align: botto=
m !important; }

.prngen2 { border-width: 0.08em !important; border-style: initial !importan=
t; border-color: initial !important; padding-left: 0px !important; padding-=
right: 0px !important; vertical-align: bottom !important; }

.prngen12 { border-width: 0.08em !important; border-bottom-style: solid !im=
portant; border-bottom-color: black !important; text-align: right !importan=
t; border-left-style: initial !important; border-left-color: initial !impor=
tant; padding-left: 0px !important; padding-right: 0px !important; vertical=
-align: bottom !important; border-top-style: initial !important; border-top=
-color: initial !important; border-right-style: initial !important; border-=
right-color: initial !important; }

.prngen3 { border-width: 0.08em !important; border-style: initial !importan=
t; border-color: initial !important; text-align: right !important; padding-=
left: 0px !important; padding-right: 0px !important; vertical-align: bottom=
 !important; }

.prngen8 { text-align: center; border-width: 0.08em !important; border-bott=
om-style: initial !important; border-bottom-color: initial !important; bord=
er-left-style: initial !important; border-left-color: initial !important; p=
adding-left: 0px !important; padding-right: 0px !important; vertical-align:=
 bottom !important; border-top-style: solid !important; border-top-color: b=
lack !important; border-right-style: initial !important; border-right-color=
: initial !important; }

.prngen10 { text-align: center; border-width: 0.08em !important; border-sty=
le: initial !important; border-color: initial !important; padding-left: 0px=
 !important; padding-right: 0px !important; vertical-align: bottom !importa=
nt; }

.prngen23 { border-width: 0.08em !important; border-bottom-style: solid !im=
portant; border-bottom-color: black !important; text-align: right !importan=
t; border-left-style: initial !important; border-left-color: initial !impor=
tant; padding-left: 0px !important; padding-right: 0px !important; vertical=
-align: bottom !important; border-top-style: solid !important; border-top-c=
olor: black !important; border-right-style: initial !important; border-righ=
t-color: initial !important; }

.prngen24 { border-width: 0.08em !important; border-bottom-style: solid !im=
portant; border-bottom-color: black !important; text-align: right !importan=
t; border-left-style: initial !important; border-left-color: initial !impor=
tant; padding-left: 0px !important; padding-right: 0px !important; vertical=
-align: bottom !important; border-top-style: solid !important; border-top-c=
olor: black !important; border-right-style: initial !important; border-righ=
t-color: initial !important; }

.prngen18 { border-width: 0.08em !important; border-style: solid !important=
; border-color: black !important; text-align: center !important; padding-le=
ft: 0px !important; padding-right: 0px !important; vertical-align: bottom !=
important; }

.prngen20 { border-width: 0.08em !important; border-style: initial !importa=
nt; border-color: initial !important; text-align: right !important; padding=
-left: 0px !important; padding-right: 0px !important; vertical-align: top !=
important; }

.prngen22 { border-bottom: 0.08em solid black !important; text-align: right=
 !important; border-left: 0.08em !important; padding-left: 0px !important; =
padding-right: 0px !important; vertical-align: bottom !important; border-to=
p: black !important; border-right: 0.08em !important; }

.prngen17 { border-bottom: 0.17em double black !important; text-align: righ=
t !important; border-left: 0.08em !important; padding-left: 0px !important;=
 padding-right: 0px !important; vertical-align: bottom !important; border-t=
op: black !important; border-right: 0.08em !important; }

.prngen15 { border-width: 0.08em 0.08em 0.17em !important; border-bottom-st=
yle: double !important; border-bottom-color: black !important; text-align: =
right !important; border-left-style: initial !important; border-left-color:=
 initial !important; padding-left: 0px !important; padding-right: 0px !impo=
rtant; vertical-align: bottom !important; border-top-style: initial !import=
ant; border-top-color: initial !important; border-right-style: initial !imp=
ortant; border-right-color: initial !important; }

.prngen5 { border-width: 0.08em !important; border-bottom-style: solid !imp=
ortant; border-bottom-color: black !important; text-align: center !importan=
t; border-left-style: initial !important; border-left-color: initial !impor=
tant; padding-left: 0px !important; padding-right: 0px !important; vertical=
-align: bottom !important; border-top-style: initial !important; border-top=
-color: initial !important; border-right-style: initial !important; border-=
right-color: initial !important; }

.prngen7 { border-width: 0.08em !important; border-style: initial !importan=
t; border-color: initial !important; text-align: center !important; padding=
-left: 0px !important; padding-right: 0px !important; vertical-align: botto=
m !important; }

.prnpr8 { padding-right: 0.67em !important; }

.prntblns { border-width: 0.08em !important; border-style: initial !importa=
nt; border-color: initial !important; }

.prnvab { vertical-align: bottom !important; }

.prnpl6 { padding-left: 0.5em !important; }

.prnbls { border-left: 0.08em solid black !important; }

.prnbb1 { border-bottom: 0.08em !important; }

.prnbr1 { border-right: 0.08em !important; }

.prnbt1 { border-top: 0.08em !important; }

.prntac { text-align: center !important; }

.gnw_heading { font: 16px Arial; text-align: center; }

.gnw_subhead { font: 12px Arial; text-align: center; }

.gnw_colhead { font: 12px Arial; text-align: center; }

.gnw_colhead_uline { border-bottom: 1pt solid black; font: 12px Arial; text=
-align: center; }

.gnw_colhead_dline { border-bottom: 2.5pt double black; font: 12px Arial; t=
ext-align: center; }

.gnw_label { font: 12px Arial; text-align: left; vertical-align: bottom; }

.gnw_label_uline { border-bottom: 1pt solid black; font: 12px Arial; text-a=
lign: left; vertical-align: bottom; }

.gnw_label_uline_i10 { border-bottom: 1pt solid black; font: 12px Arial; te=
xt-align: right; vertical-align: bottom; }

.gnw_label_uline_i15 { border-bottom: 1pt solid black; font: 12px Arial; te=
xt-align: right; vertical-align: bottom; }

.gnw_label_uline_i20 { border-bottom: 1pt solid black; font: 12px Arial; te=
xt-align: right; vertical-align: bottom; }

.gnw_label_uline_i25 { border-bottom: 1pt solid black; font: 12px Arial; te=
xt-align: right; vertical-align: bottom; }

.gnw_label_uline_i30 { border-bottom: 1pt solid black; font: 12px Arial; te=
xt-align: right; vertical-align: bottom; }

.gnw_label_ulinetop { border-top: 1pt solid black; font: 12px Arial; text-a=
lign: left; vertical-align: bottom; }

.gnw_label_dline { border-bottom: 2.5pt double black; font: 12px Arial; tex=
t-align: left; vertical-align: bottom; }

.gnw_label_i10 { font: 12px Arial; padding-left: 10px; text-align: left; ve=
rtical-align: bottom; }

.gnw_label_i15 { font: 12px Arial; padding-left: 15px; text-align: left; ve=
rtical-align: bottom; }

.gnw_label_i20 { font: 12px Arial; padding-left: 20px; text-align: left; ve=
rtical-align: bottom; }

.gnw_label_i25 { font: 12px Arial; padding-left: 25px; text-align: left; ve=
rtical-align: bottom; }

.gnw_label_i30 { font: 12px Arial; padding-left: 30px; text-align: left; ve=
rtical-align: bottom; }

.gnw_num { font: 12px Arial; text-align: right; vertical-align: bottom; whi=
te-space: nowrap; }

.gnw_num_uline { border-bottom: 1pt solid black; font: 12px Arial; text-ali=
gn: right; vertical-align: bottom; white-space: nowrap; }

.gnw_num_ulinetop { border-top: 1pt solid black; font: 12px Arial; text-ali=
gn: right; vertical-align: bottom; white-space: nowrap; }

.gnw_num_dline { border-bottom: 2.5pt double black; font: 12px Arial; text-=
align: right; vertical-align: bottom; white-space: nowrap; }

.gnw_num_dlinetop { border-top: 2.5pt double black; font: 12px Arial; text-=
align: right; vertical-align: bottom; white-space: nowrap; }

.gnw_data { font: 12px Arial; text-align: left; vertical-align: bottom; whi=
te-space: nowrap; }

.gnw_data_uline { border-bottom: 1pt solid black; font: 12px Arial; text-al=
ign: left; vertical-align: bottom; }

.gnw_data_dline { border-bottom: 2.5pt double black; font: 12px Arial; text=
-align: left; vertical-align: bottom; }

.gnw_news_media_box { border-color: rgb(169, 169, 169); border-style: solid=
; border-width: 1px; margin: 15px 6px 6px; }

.gnw_media_caption { font-family: Verdana, Arial, Helvetica, Geneva, Swiss,=
 SunSans-Regular; font-size: 8pt; }

.gnw_media_bgcolor { background-color: transparent; }

.gnw_table { border-collapse: separate; border-spacing: 6px; }

.gnw_videotitle { color: rgb(29, 82, 150); font: bold 12px Arial; }

.gnw_border_top_solid { border-top: 1px solid black !important; }

.gnw_border_right_solid { border-right: 1px solid black !important; }

.gnw_border_bottom_solid { border-bottom: 1px solid black !important; }

.gnw_border_left_solid { border-left: 1px solid black !important; }

.gnw_border_top_double { border-top: 3px double black !important; }

.gnw_border_right_double { border-right: 3px double black !important; }

.gnw_border_bottom_double { border-bottom: 3px double black !important; }

.gnw_border_left_double { border-left: 3px double black !important; }

.gnw_table_border_collapse { border-collapse: collapse !important; }

.gnw_table_border_collapse td { padding-left: 3px !important; padding-right=
: 3px !important; }

.gnw_align_left { text-align: left !important; }

.gnw_align_center { text-align: center !important; }

.gnw_align_right { text-align: right !important; }

.gnw_align_justify { text-align: justify !important; }

.gnw_vertical_align_top { vertical-align: top !important; }

.gnw_vertical_align_middle { vertical-align: middle !important; }

.gnw_vertical_align_bottom { vertical-align: bottom !important; }

.gnw_padding_left_none { padding-left: 0px !important; }

.gnw_padding_right_none { padding-right: 0px !important; }

.gnw_table_border_collapse td.gnw_heading, .gnw_heading { font: 16px Arial;=
 text-align: center; }

.gnw_table_border_collapse td.gnw_subhead, .gnw_subhead { font: 12px Arial;=
 text-align: center; }

.gnw_table_border_collapse td.gnw_colhead, .gnw_colhead { font: 12px Arial;=
 text-align: center; }

.gnw_table_border_collapse td.gnw_colhead_uline, .gnw_colhead_uline { font:=
 12px Arial; text-align: center; border-bottom: 1pt solid black; }

.gnw_table_border_collapse td.gnw_colhead_dline, .gnw_colhead_dline { font:=
 12px Arial; text-align: center; border-bottom: 2.5pt double black; }

.gnw_table_border_collapse td.gnw_label, .gnw_label { font: 12px Arial; ver=
tical-align: bottom; text-align: left; }

.gnw_table_border_collapse td.gnw_label_uline, .gnw_label_uline { font: 12p=
x Arial; vertical-align: bottom; text-align: left; border-bottom: 1pt solid=
 black; }

.gnw_table_border_collapse td.gnw_label_uline_i10, .gnw_label_uline_i10 { f=
ont: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: 1=
pt solid black; padding-left: 10px; }

.gnw_table_border_collapse td.gnw_label_uline_i15, .gnw_label_uline_i15 { f=
ont: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: 1=
pt solid black; padding-left: 15px; }

.gnw_table_border_collapse td.gnw_label_uline_i20, .gnw_label_uline_i20 { f=
ont: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: 1=
pt solid black; padding-left: 20px; }

.gnw_table_border_collapse td.gnw_label_uline_i25, .gnw_label_uline_i25 { f=
ont: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: 1=
pt solid black; padding-left: 25px; }

.gnw_table_border_collapse td.gnw_label_uline_i30, .gnw_label_uline_i30 { f=
ont: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: 1=
pt solid black; padding-left: 30px; }

.gnw_table_border_collapse td.gnw_label_dline_i10, .gnw_label_dline_i10 { f=
ont: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: 2=
.5pt double black; padding-left: 10px; }

.gnw_table_border_collapse td.gnw_label_dline_i15, .gnw_label_dline_i15 { f=
ont: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: 2=
.5pt double black; padding-left: 15px; }

.gnw_table_border_collapse td.gnw_label_dline_i20, .gnw_label_dline_i20 { f=
ont: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: 2=
.5pt double black; padding-left: 20px; }

.gnw_table_border_collapse td.gnw_label_dline_i25, .gnw_label_dline_i25 { f=
ont: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: 2=
.5pt double black; padding-left: 25px; }

.gnw_table_border_collapse td.gnw_label_dline_i30, .gnw_label_dline_i30 { f=
ont: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: 2=
.5pt double black; padding-left: 30px; }

.gnw_table_border_collapse td.gnw_label_ulinetop, .gnw_label_ulinetop { fon=
t: 12px Arial; vertical-align: bottom; text-align: left; border-top: 1pt so=
lid black; }

.gnw_table_border_collapse td.gnw_label_dline, .gnw_label_dline { font: 12p=
x Arial; vertical-align: bottom; text-align: left; border-bottom: 2.5pt dou=
ble black; }

.gnw_table_border_collapse td.gnw_label_i10, .gnw_label_i10 { font: 12px Ar=
ial; vertical-align: bottom; text-align: left; padding-left: 10px; }

.gnw_table_border_collapse td.gnw_label_i15, .gnw_label_i15 { font: 12px Ar=
ial; vertical-align: bottom; text-align: left; padding-left: 15px; }

.gnw_table_border_collapse td.gnw_label_i20, .gnw_label_i20 { font: 12px Ar=
ial; vertical-align: bottom; text-align: left; padding-left: 20px; }

.gnw_table_border_collapse td.gnw_label_i25, .gnw_label_i25 { font: 12px Ar=
ial; vertical-align: bottom; text-align: left; padding-left: 25px; }

.gnw_table_border_collapse td.gnw_label_i30, .gnw_label_i30 { font: 12px Ar=
ial; vertical-align: bottom; text-align: left; padding-left: 30px; }

.gnw_table_border_collapse td.gnw_num, .gnw_num { font: 12px Arial; vertica=
l-align: bottom; text-align: right; white-space: nowrap; }

.gnw_table_border_collapse td.gnw_num_uline, .gnw_num_uline { font: 12px Ar=
ial; vertical-align: bottom; text-align: right; white-space: nowrap; border=
-bottom: 1pt solid black; }

.gnw_table_border_collapse td.gnw_num_ulinetop, .gnw_num_ulinetop { font: 1=
2px Arial; vertical-align: bottom; text-align: right; white-space: nowrap; =
border-top: 1pt solid black; }

.gnw_table_border_collapse td.gnw_num_dline, .gnw_num_dline { font: 12px Ar=
ial; vertical-align: bottom; text-align: right; white-space: nowrap; border=
-bottom: 2.5pt double black; }

.gnw_table_border_collapse td.gnw_num_dlinetop, .gnw_num_dlinetop { font: 1=
2px Arial; vertical-align: bottom; text-align: right; white-space: nowrap; =
border-top: 2.5pt double black; }

.gnw_table_border_collapse td.gnw_data, .gnw_data { font: 12px Arial; verti=
cal-align: bottom; text-align: left; white-space: nowrap; }

.gnw_table_border_collapse td.gnw_data_uline, .gnw_data_uline { font: 12px =
Arial; vertical-align: bottom; text-align: left; border-bottom: 1pt solid b=
lack; }

.gnw_table_border_collapse td.gnw_data_dline, .gnw_data_dline { font: 12px =
Arial; vertical-align: bottom; text-align: left; border-bottom: 2.5pt doubl=
e black; }

.gnw_news_media_box { margin: 15px 6px 6px; border-width: 1px; border-color=
: rgb(169, 169, 169); border-style: solid; }

.gnw_table_border_collapse td.gnw_media_caption, .gnw_media_caption { font-=
size: 8pt; font-family: Verdana, Arial, Helvetica, Geneva, Swiss, SunSans-R=
egular; }

.gnw_media_bgcolor { background-color: transparent; }

.gnw_table { border-collapse: separate; border-spacing: 6px; }

.gnw_table_border_collapse td.gnw_videotitle, .gnw_videotitle { font: bold =
12px Arial; color: rgb(29, 82, 150); }

.gnw_border_top_solid { border-top: 1px solid black !important; }

.gnw_border_right_solid { border-right: 1px solid black !important; }

.gnw_border_bottom_solid { border-bottom: 1px solid black !important; }

.gnw_border_left_solid { border-left: 1px solid black !important; }

.gnw_border_top_double { border-top: 3px double black !important; }

.gnw_border_right_double { border-right: 3px double black !important; }

.gnw_border_bottom_double { border-bottom: 3px double black !important; }

.gnw_border_left_double { border-left: 3px double black !important; }

.gnw_table_border_collapse { border-collapse: collapse !important; }

.gnw_table_border_collapse td { font-size: 12px; }

.gnw_align_left { text-align: left !important; }

.gnw_align_center { text-align: center !important; }

.gnw_align_right { text-align: right !important; }

.gnw_align_justify { text-align: justify !important; }

.gnw_vertical_align_top { vertical-align: top !important; }

.gnw_vertical_align_middle { vertical-align: middle !important; }

.gnw_vertical_align_bottom { vertical-align: bottom !important; }

.gnw_padding_left_none { padding-left: 0px !important; }

.gnw_padding_right_none { padding-right: 0px !important; }

[role=3D"tooltip"] { width: 300px; height: auto; background: rgb(255, 255, =
255); text-align: left; border: 1px solid rgb(204, 204, 204); padding: 5px;=
 color: rgb(102, 102, 102); font-size: 16px; }

.block--attribution-block__fundamentals-legend__nasdaq p { width: 50%; }

.md-download { text-align: right; }

.market-data-filter-form input { margin: 1em 0em 1.42857em; }

body .container { background: inherit; }

.nir-mean-value-rating .mean-recommendation, .nir-mean-value-rating h3 { di=
splay: inline-block; font-size: 20px; }

.nir-mean-value-rating .clearfix p { font-size: 16px; }

.nir-mean-value-rating h3 { margin-left: 25px; }

.block--search-form { clear: both; }

.region.region-content .block--search-form .form-no-label { margin: 10px 0p=
x; }

.region.region-content .block--search-form h2 { border-bottom: 0px; font-si=
ze: 20px; text-transform: capitalize; font-weight: bold; }

.region.region-content .block-search-form form::after, .region.region-conte=
nt .view-search form::after { display: none; }

.region.region-content .block-search-form form input[type=3D"search"], .reg=
ion.region-content .view-search form input[type=3D"text"], .region.region-c=
ontent input:not([type=3D"submit"]) { border-radius: 0px; background: rgb(2=
49, 249, 249); border: 1px solid rgb(204, 204, 204); box-shadow: rgba(0, 0,=
 0, 0.1) 1px 1px 1px inset; padding: 2px; }

.region.region-content .block-search-form form input[type=3D"search"], .reg=
ion.region-content .view-search form input[type=3D"text"] { width: 35%; }

input#edit-submit, input#edit-submit:hover, .region.region-content .block-s=
earch-form form input[type=3D"submit"], .region.region-content .view-search=
 form input[type=3D"submit"] { background-color: rgb(238, 238, 238); border=
-radius: 0px; font-size: inherit; color: inherit; text-shadow: none; font-w=
eight: inherit; padding: 2px 10px; box-shadow: none; border: 1px solid rgb(=
161, 161, 161); }

form#contact-message-nir-document-request-form label { margin: 5px 0px; dis=
play: block; }

.region.region-content .block-search-form form input[type=3D"submit"], .reg=
ion.region-content .view-search form input[type=3D"submit"] { left: 36%; te=
xt-indent: 1px; }

details#edit-field-nir-address-0 summary { display: inline-block; }

legend { border-bottom: 0px; }

.contact-form textarea { border-radius: 0px; }

div.address-container-inline > .form-item { width: 100%; margin: 10px 0px; =
}

form#views-exposed-form-widget-sec-filings-table label { display: block; }

.views-field-field-nir-sec-pdf a::before { padding-right: 0px; }

.node--nir-sec-filing--full h2 { border-bottom: 0px; }

.historical-price-lookup-form .form-submit, .stock-price-calculator-form .f=
orm-submit { margin-top: 1.1em; }

.nir-node--5921 h2 { border-bottom: 0px; }

table.nirtable thead tr th, table.nirtable thead tr td, .nir-node--5896 tab=
le thead tr td { background-color: rgb(241, 241, 241); color: rgb(80, 81, 8=
6); }

table.nirtable thead tr th a, .nir-node--5896 table thead tr td span { colo=
r: inherit !important; }

table.nirtable thead tr th, table.nirtable thead tr td, table.nirtable tbod=
y tr td, .block--system-main-block--5911 table tr td, .nir-node--5896 table=
 thead tr td, .nir-node--5896 table tbody tr td { padding: 5px 3px; }

table.nirtable tbody tr td, .block--system-main-block--5911 table tr td, .n=
ir-node--5896 table tbody tr td { border-bottom: 0px; }

table.nirtable tbody tr:nth-child(2n+1), .nir-node--5896 table tbody tr:nth=
-child(2n+1) { background-color: rgb(241, 241, 241); }

.view-id-widget_sec_filings table.nirtable thead th { background: rgb(255, =
255, 255); }

.tablesort { display: none; }

table.nirtable tbody tr:nth-child(2n), .nir-node--5896 table tbody tr:nth-c=
hild(2n) { background-color: rgb(241, 241, 241); }

time.datetime, .field--name-field-nir-person-company { font-style: normal; =
}

@media screen and (-ms-high-contrast:active), (-ms-high-contrast:none) {
  .block-search-form form input[type=3D"submit"], .view-search form input[t=
ype=3D"submit"] { width: 10%; }
}

.view-widget-news.view-display-id-widget_news_ul .item-list, .field--name-f=
ield-nir-document .field__item, .view-widget-assets table .item-list ul, .v=
iew-empty, .node--type-nir-event .node--type-nir-asset .field--name-field-n=
ir-document .field__item { margin: 0px; }

.view-widget-assets .item-list ul li, .view-widget-events .item-list ul li,=
 .view-widget-news.view-display-id-widget_news_ul .item-list ul li, .view-w=
idget-people .item-list > ul > li { padding: 0px; border: 0px; margin: 0px;=
 }

.view-widget-news.view-display-id-widget_news_ul .item-list ul li:first-chi=
ld, .quote-wrap { border: 0px; }

.view-widget-events h3 { margin-bottom: 0px; }

span.ndqicon__cob_after::after, span.ndqicon__calculator_after::after, .ndq=
icon__member a::before, span.ndqicon__member::before, .ndqicon__chairperson=
 a::before, span.ndqicon__chairperson::before, .ndqicon__cob a::before, spa=
n.ndqicon__cob::before, .ndqicon__calculator::before, span.ndqicon__calcula=
tor::before { color: rgb(0, 0, 0); }

@media screen and (max-width: 767px) {
  .collapse-table-wide tbody tr td::before { position: static; left: 0px; f=
loat: left; width: 40%; }
  .nir-node--5921 .collapse-table-wide tbody tr td::before { width: 65%; }
  iframe.nir-stock-chart { width: 100% !important; }
  td.views-field.views-field-field-nir-sec-description p { width: 100%; dis=
play: inline-block; }
}

@media (min-width: 1024px) {
  .view-widget-news.view-display-id-widget_news_ul .has-news-supp .col:nth-=
child(1) { width: 100%; margin-right: 0px; }
}

.region.region-content ul li.side-menu__item { display: inline-block; line-=
height: 12px; float: none; }

.region.region-content ul li.side-menu__item a.is-active { color: rgb(68, 6=
8, 68); }

.region.region-content nav[role=3D"navigation"] ul.side-menu { margin-botto=
m: 10px; }

.region.region-content ul li.side-menu__item a::after { content: "|"; paddi=
ng-left: 4px; }

.region.region-content ul li.side-menu__item:last-child a::after { content:=
 ""; }

.block-nir-attribution-block { padding: 0px; }

.block-nir-attribution-block > p, .block-attribution-block__stock-info-attr=
ibution__thomson-reuters p { font-size: 11px !important; color: rgb(153, 15=
3, 153) !important; }

.view-widget-assets table td h4 { margin: 0px; }

.block-attribution-block__stock-info-attribution__thomson-reuters p { margi=
n-top: 20px !important; }

.file--application-pdf a::before, .view-widget-sec-filings .views-field-fie=
ld-nir-sec-pdf a::before, .view-widget-sec-filings .html-link a::before, .v=
iew-widget-sec-filings .file-link a::before, .market-data-file-download-csv=
::before, .external-link::before, .field--name-field-nir-ext-document a::be=
fore, .html-link a::before, .asset-link a::before, .file--mime-text-csv a::=
before, .file--mime-text-csv.file--text a::before, .market-data-file-downlo=
ad-csv::before, .file--mime-image-jpeg a::before, .file--mime-image-jpg a::=
before, .view-widget-news.view-display-id-table .html-link a::before, .view=
-widget-news.view-display-id-table .file-link a::before, .file--mime-applic=
ation-rtf a::before, .file--xls a::before, .file--x-office-spreadsheet a::b=
efore, .market-data-file-download-xls::before { font-size: 22px; }

form table tbody tr, form table tbody { border: 0px; }

.faq-acc-dl dt, .acc-wrap .acc-title { cursor: pointer; position: relative;=
 border-bottom: 2px solid rgb(218, 218, 218); margin-bottom: 10px; backgrou=
nd: inherit; padding: 10px; }

.faq-acc-dl dd, .acc-body { padding: 10px; margin: 0px 0px 20px; }

.acc-body .content:first-child { padding-top: 0px; }

.faq-acc-dl dt.opened::before, .faq-acc-dl dt { color: rgb(69, 69, 69); }

.faq-acc-dl dt.opened, .faq-acc-dl dt:hover { color: rgb(203, 81, 14); }

.block-views-blockwidget-bundled-content-block-1 .show-all { width: 11%; fl=
oat: right; }

.block-content--nir-faq .show-all { width: 9%; float: right; }

.block-content--nir-faq a.show-all::after { color: rgb(69, 69, 69); }

@media screen and (min-width: 992px) {
  input#edit-nir-email-alerts-signup-email, input#edit-nir-email-alerts-uns=
ubscribe-email { width: 40%; }
  form#contact-message-nir-document-request-form { width: 50%; }
}

body { font-size: 100%; }

.messages--error, .messages.error { border-color: rgb(204, 0, 0); }

article h1 { font-size: 0px; }

.option1_16 { background: url("/sites/g/files/knoqqb12671/themes/site/nir_p=
id1175/client/images/option1_16.png") no-repeat scroll; }

h2 { display: inline-block; margin-bottom: 2px; padding-bottom: 8px; font-s=
ize: 30px; font-style: normal; font-weight: normal; text-rendering: optimiz=
elegibility; font-family: Montserrat, sans-serif; color: rgb(137, 140, 141)=
 !important; }

.button { text-transform: uppercase; letter-spacing: 3px; border: 1px solid=
 rgb(255, 255, 255); background-color: rgb(0, 169, 183) !important; color: =
rgb(255, 255, 255) !important; padding: 10px 22px 10px 25px !important; fon=
t-weight: 600 !important; font-size: 15px !important; }

.nir-widget--label { display: inline-block; margin-bottom: 2px; padding-bot=
tom: 8px; font-size: 30px; font-style: normal; font-weight: normal; text-re=
ndering: optimizelegibility; font-family: Montserrat, sans-serif; color: rg=
b(137, 140, 141) !important; }

.menu--ir ul.menu.side-menu li a { font-weight: bold; font-size: 11px; }

.menu--ir ul.menu.side-menu, .item-list ul { margin: 0px; }

.menu--ir ul.menu.side-menu li { line-height: 18px; }

.menu--ir { margin-top: 35px; }

.stock-quote { padding: 0px; margin: 0px; }

span.ccbnLnk { float: right; display: inline-block; }

.nir-node--5806 .views-field.views-field-field-nir-news-date, .nir-node--58=
06 .views-field.views-field-field-nir-news-title { display: inline-block; f=
loat: left; }

.nir-node--5806 .views-field.views-field-field-nir-news-date { width: 14% !=
important; font-weight: bold; }

.nir-node--5806 .views-field.views-field-field-nir-news-title { width: 85%;=
 font-size: 12px; font-weight: normal; }

.nir-node--5806 .views-field.views-field-field-nir-news-title a { font-size=
: 12px; font-weight: normal; }

.nir-node--5806 .block-views-blockwidget-events-block-1 { margin: 30px 0px;=
 }

.nir-node--5806 .block-nir-assets.block-nir-assets__widget { margin-bottom:=
 30px; }

.file-link a { font-weight: normal; }

nav#block-nir-pid1175-tools { margin-top: 20px; }

nav#block-nir-pid1175-tools ul li a { font-weight: bold; padding-left: 40px=
; }

.historical-lookup th, .historical-lookup td { text-align: center !importan=
t; }

form#historical-price-lookup-form { margin-bottom: 20px; }

table.historical-lookup tr:first-child { font-weight: normal; }

.block-views-blockwidget-news-widget-news-ul a.summary-toggle.nir-news-widg=
et-summary-toggle-title { display: none; }

.block-views-blockwidget-news-widget-news-ul .summary-hidden { display: blo=
ck; margin-top: 3px !important; }

.view-widget-news.view-display-id-widget_news_ul .views-field-field-nir-new=
s-title { font-weight: bold; font-size: inherit; }

.view-widget-news.view-display-id-widget_news_ul .has-news-supp .col:nth-ch=
ild(2) { width: auto; float: left; margin: 0px; padding-bottom: 20px; }

#ocontent .region.region-content .block-search-form h2 { font-size: 12px; m=
argin: 0px; }

.nir-node--5846 .block-views-blockwidget-people-widget-assets-ul ul li, .ni=
r-node--5841 .block-views-blockwidget-people-widget-assets-ul ul li { paddi=
ng: 0px 0px 20px !important; }

table.striped-odd.collapse-table.nirtable.commiteetable thead tr td, table.=
striped-odd.collapse-table.nirtable.commiteetable thead tr th { background:=
 rgb(255, 255, 255); text-align: center; }

table.striped-odd.collapse-table.nirtable.commiteetable thead tr th a { bac=
kground: rgb(255, 255, 255); color: rgb(117, 141, 131) !important; }

table.striped-odd.collapse-table.nirtable.commiteetable tbody tr td { font-=
weight: bold; }

th#view-field-nir-sec-form-table-column { width: 50px; }

th#view-field-nir-sec-description-table-column { width: 50%; }

form#views-exposed-form-widget-sec-filings-table { margin: 20px 0px; }

.pager__items { margin-left: 0px; }

.pager__current-item, .pager .is-active, .pager-current { background-color:=
 rgb(238, 238, 238); }

.faq-acc-dl dt.opened, .faq-acc-dl .acc-title.opened, .acc-wrap dt.opened, =
.acc-wrap .acc-title.opened, .faq-acc-dl dt:hover, .faq-acc-dl .acc-title:h=
over, .acc-wrap dt:hover, .acc-wrap .acc-title:hover, .faq-acc-dl dt, .acc-=
wrap .acc-title { background: none; color: inherit; font-weight: bold; bord=
er: 0px; padding: 0px; margin: 15px 0px 10px; }

.faq-acc-dl dt.opened::before, .faq-acc-dl .acc-title.opened::before, .acc-=
wrap dt.opened::before, .acc-wrap .acc-title.opened::before, .faq-acc-dl dt=
::before, .faq-acc-dl .acc-title::before, .acc-wrap dt::before, .acc-wrap .=
acc-title::before { display: none; }

.acc-content-wrap { border: 1px solid rgb(230, 230, 230); overflow: auto; p=
adding: 5px; }

.acc-content-wrap span.views-label.views-label-field-nir-tags, .acc-content=
-wrap .webcast-link a::before, .normal-webcast-link a::before, .acc-content=
-wrap .html-link a::before, .asset-link a::before, a.show-all { display: no=
ne; }

.view-widget-bundled-content .views-field-field-nir-bundle-content ul div {=
 line-height: inherit; }

#ocontent h1 { margin-top: 10px; }

.nir-node--5951 .block-block-content table tr td, .nir-node--5951 .block-bl=
ock-content table:last-child tr:first-child td { font-weight: bold; }

.nir-node--5951 .block-block-content table tr td a { font-weight: normal; b=
ackground: url("/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client/i=
mages/toolkit_rss_t.gif") no-repeat; padding-left: 25px; display: block; ma=
rgin-bottom: 10px; margin-top: 10px; }

.nir-node--5951 .block-block-content table:nth-child(1) tr td, .nir-node--5=
951 .block-block-content table:last-child tr td { font-weight: normal; }

.nir-node--6031 .block-views-blockwidget-events-block-1 h4 { display: none;=
 }

table#edit-nir-email-alerts-signup-alerts, .g-recaptcha { margin-top: 20px;=
 }

table#edit-nir-email-alerts-signup-alerts tbody td { background: rgb(255, 2=
55, 255); }

.nir-node--5806 .form.views-exposed-form .form-actions { margin: 0px; }

.nir-node--6846 .node--promoted h1 + .ccbnLnk + .ccbnLnk { text-align: righ=
t; }

.nir-node--6846 .node--promoted h1 + .ccbnLnk { background: url("/sites/g/f=
iles/knoqqb12671/themes/site/nir_pid1175/client/images/toolkit_print_t.gif"=
) no-repeat; padding-left: 20px; }

.nir-node--6846 .field__item { font-size: 12px; font-weight: bold; }

.nir-node--6031 td[align=3D"center"] { text-align: left; }

.nir-node--6031 .block-views-blockwidget-events-block-1 ul li > table { mar=
gin: 10px 0px; }

.nir-node--6031 .block-views-blockwidget-events-block-1 td table tbody tr.c=
cbnBgTblTxt:nth-child(2) > td { padding: 20px 0px; }

.nir-node--6031 .block-views-blockwidget-events-block-1 td table tbody tr.c=
cbnBgTblTxt:nth-child(3) > td .ccbnBgTblTxt td > div { padding: 0px 0px 20p=
x; }

.ccbn-event-summary-heading h2 { background: url("/sites/g/files/knoqqb1267=
1/themes/site/nir_pid1175/client/images/icon-microphone-16.png") no-repeat;=
 padding-left: 25px; line-height: 22px; margin: 0px 0px 13px; font-size: 18=
px; font-weight: normal; }

.ccbn-event-option { border: 1px solid rgb(239, 239, 239); margin-bottom: 5=
px; padding: 5px; }

.ccbn-event-details { background: url("/sites/g/files/knoqqb12671/themes/si=
te/nir_pid1175/client/images/bg-toolbar-content-gradient.png") 0px 0px repe=
at scroll rgb(239, 239, 240); }

.ccbn-event-details-header { padding: 5px; }

.ccbn-event-details-content { padding: 5px; }

.webcast-link a { font-weight: normal; }

.block--header--nir-events__widget .node--nir-event--nir-widget-list.node--=
type-nir-event td:first-child { width: 5%; }

.block--header--nir-events__widget .nir-widgets--event--title { margin: 0px=
; }

.block--nir-email-alerts-signup-block h2::after { content: url("/sites/g/fi=
les/knoqqb12671/themes/site/nir_pid1175/client/images/icon_emailAlert.gif")=
; padding-left: 6px; }

.nir-node--5816 .nir-widgets--field-container { margin-bottom: 13px; }

.nir-node--5816 .nir-widget--form form { margin-bottom: 10px; }

.nir-node--5816 .nir-widget--field.nir-widget--news--headline a, .nir-node-=
-6031 .field-nir-event-title a { font-weight: bold; }

.nir-widget--event--location-notes { clear: both; }

.view-widget-bundled-content .views-field-field-nir-bundle-body, .view-widg=
et-bundled-content .views-field-field-nir-bundle-content { width: 100%; }

.filesize { display: none; }

.view-widget-bundled-content .views-field-field-nir-bundle-content ul div {=
 line-height: 25px; }

.personal { font-weight: bold !important; }

.RedAster { color: rgb(204, 0, 0) !important; }

.option { display: inline !important; }

form#contact-message-nir-document-request-form label { margin: 12px 0px; }

.block-content--nir-lp-block--8236 { margin-bottom: 20px; }

.nir-node--5866 .form-checkbox { position: relative; top: 10px; }

.nir-node--type-nir-event .node--nir-asset--asset-link { margin-bottom: 10p=
x; }

.node--type-nir-event .location-info { font-style: normal; }

.nir-node--type-nir-sec-filing .node__content h2 { font-size: 16px; }

.nir-node--type-person .node-right h3 { font-size: 12px; }

.nir-node--type-person .field.committee-composition ul { margin: 0px; }

.nir-node--type-person .field--name-field-nir-person-bio { margin-bottom: 1=
0px; }

.about, .product { display: none; }

.abouto { background: url("/sites/g/files/knoqqb12671/themes/site/nir_pid11=
75/client/images/other-about.jpg") no-repeat; }

.producto { background: url("/sites/g/files/knoqqb12671/themes/site/nir_pid=
1175/client/images/other-product.jpg") no-repeat; }

.about { background: url("/sites/g/files/knoqqb12671/themes/site/nir_pid117=
5/client/images/about-abouto.jpg") no-repeat; width: 306px; height: 177px; =
}

.product { background: url("/sites/g/files/knoqqb12671/themes/site/nir_pid1=
175/client/images/other-producto.jpg") no-repeat; width: 306px; height: 177=
px; }

.product ul li a, .about ul li a { color: rgb(255, 255, 255); text-decorati=
on: none; font-weight: bold; font-size: 12px; font-family: Arial, Helvetica=
, sans-serif; }

.product ul li, .about ul li { list-style-type: none; margin-left: 0px; }

.about ul li :hover { background: url("/sites/g/files/knoqqb12671/themes/si=
te/nir_pid1175/client/images/aboutnavback.png") no-repeat; display: block; =
}

.product ul li :hover { background: url("/sites/g/files/knoqqb12671/themes/=
site/nir_pid1175/client/images/candidatenavback.png") no-repeat; display: b=
lock; }

.nir-node--5806 span.ccbnLnk { float: none !important; }

.region.region-content .view-search form input[type=3D"text"] { width: 100%=
 !important; }

.region.region-content .view-search form input[type=3D"submit"] { left: 32%=
 !important; }

.block--system-menu-blockevents-and-presentations--5826 li a.is-active { fo=
nt-size: 12px; line-height: 16px; color: rgb(80, 81, 86) !important; text-d=
ecoration: none !important; }

.nir-node--type-nir-sec-filing .field--name-field-nir-sec-issuer { display:=
 none !important; }

.nir-node--5866 .js-form-type-checkbox label { position: relative !importan=
t; top: 6px !important; }

.search .view-empty { clear: both; }

.region.region-content ul li.side-menu__item a.is-active { color: rgb(68, 6=
8, 68) !important; }

.chosen-container-single .chosen-single div b { background: none !important=
; }

.region.region-content .block-search-form form input[type=3D"submit"], .reg=
ion.region-content .view-search form input[type=3D"submit"] { width: 15% !i=
mportant; }

.nir-node--5816 span.ccbnLnk { float: left !important; }

.nir-node--5986 a.show-all { display: block; }

.nir-node--5986 .view-grouping-content .acc-body { border: 1px solid rgb(23=
0, 230, 230); }

header ul#menu-main-nav li ul li.side-menu__item { margin: 0px; }

.sidebarNav .block--system-menu-blockir ul li { background: transparent; wi=
dth: 100%; }

.sidebarNav .block--system-menu-blockir ul li a.is-active { font-weight: 60=
0; color: rgb(0, 169, 183); }

.sidebarNav .block--system-menu-blockir { margin: 0px; }

.sidebarNav .block--system-menu-blockir ul li ul { margin-top: 3px; margin-=
bottom: -3px; }

.sidebarNav .block--system-menu-blockir ul li ul li { padding-left: 0px; }

.sidebarNav .block--system-menu-blockir ul li a::after { display: none; }

.sidebarNav .block--system-menu-blockir ul li a { line-height: 19.6px; font=
-size: 16px; }

.sidebarNav .block--system-menu-blockir ul li ul li { margin: 0px; }

.sidebarNav .block--system-menu-blockir ul li ul { display: block; position=
: relative; top: 0px; }

.sidebarNav .block--system-menu-blockir ul li a:hover { background: transpa=
rent; color: rgb(0, 169, 183); }

.sidebarNav .block--system-menu-blockir ul li ul li { margin: 0px; }

div.ccbnPopover { display: none; visibility: visible !important; }

div.ccbnPopover:hover { display: block !important; }

.block--header--nir-events__widget--5806 .node--nir-event--nir-widget-list.=
node--type-nir-event td:first-child { width: auto; }

.mainContent .webcast-link { margin: 0px; }

.mainContent .webcast-link a::before { display: none; }

.mainContent .webcast-link a { color: rgb(23, 121, 186); }

.mainContent .webcast-link a:hover, .mainContent .webcast-link a:focus { co=
lor: rgb(20, 104, 160); }

.mainContent .webcast-link a:visited { color: rgb(0, 169, 183); }

span.ccbnLnk.eventToolTip a:hover { color: rgb(21, 196, 211); }

a.help:hover, a.help:focus, a.help:visited { color: rgb(0, 169, 183); text-=
decoration: none; }

.block--nir-events__widget--5806 td a:hover { text-decoration: none; }

article.node--type-nir_landing_page h1 { display: none; }

.block-content--nir-lp-block--8226 span.ccbnTxt { margin-top: -10px; displa=
y: inline-block; }

.block-content--nir-lp-block--8226 { display: inline-block; margin-bottom: =
65px; }

.block-attribution-block__stock-info-attribution__thomson-reuters p { posit=
ion: absolute; left: 10px; top: -10px; font-style: italic; display: block; =
font-family: Montserrat, sans-serif; font-weight: 300; color: rgb(51, 51, 5=
1); font-size: 14px !important; }

.block-attribution-block__stock-info-attribution__thomson-reuters { positio=
n: relative; display: inline-block; width: 100%; }

.block-attribution-block__stock-info-attribution__thomson-reuters { positio=
n: relative; display: inline-block; width: 100%; }

.block--nir-news__widget--5806 { margin-top: 60px; }

.block--nir-news__widget--5806 .nir-widget--label { margin-bottom: 22px; }

.block--nir-news__widget--5806 { margin-top: 60px; }

.nir-node--5806 .col-md-6.radix-layouts-secondcolumn1, .nir-node--5806 .col=
-md-6.radix-layouts-secondcolumn2 { margin-top: 70px; }

.block--nir-events__widget--5806 .nir-widget--content { display: inline-blo=
ck; width: 100%; margin-bottom: 10px; }

.block-content--nir-lp-block--8491 { display: inline-block; margin-top: 60p=
x; width: 100%; }

form.nir-email-alerts-signup-form table.nirtable thead tr th, form.nir-emai=
l-alerts-signup-form table.nirtable thead { background: transparent !import=
ant; }

input#edit-submit { border: none; }

ul.footerNav li a { line-height: 25.6px; padding-left: 0px; }

ul.footerNav li { background: transparent; display: inline-block; width: 10=
0%; }

ul.footerNav li a:hover { background: transparent; text-decoration: none; c=
olor: rgb(21, 196, 211); }

div.socialMedia ul li { margin-right: 1px; }

footer { padding-bottom: 99px; }

div.socialMedia ul { position: relative; left: -2px; }

.sidebarNav nav.block--system-menu-blocktools#block-nir-pid1175-tools ul li=
 a { font-weight: normal; text-transform: capitalize; line-height: 25.6px; =
padding-left: 0px; }

.sidebarNav nav.block--system-menu-blocktools#block-nir-pid1175-tools ul li=
 { display: inline-block; width: 100%; border: none; margin: 0px; }

.sidebarNav nav.block--system-menu-blocktools ul li a:hover { background: t=
ransparent; }

.sidebarNav nav.block--system-menu-blocktools ul li:last-child { border: no=
ne !important; }

.sidebarNav nav#block-nir-pid1175-tools ul li { background-color: transpare=
nt; background-repeat: no-repeat; background-position: left center; backgro=
und-size: 30px; padding: 5px 0px 5px 40px; display: inline-block !important=
; }

.sidebarNav nav#block-nir-pid1175-tools ul li:nth-child(1) { background-ima=
ge: url("/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client/images/p=
rintIcon_2x.png"); }

.sidebarNav nav#block-nir-pid1175-tools ul li:nth-child(2) { background-ima=
ge: url("/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client/images/r=
ssIcon_2x.png"); }

.sidebarNav nav#block-nir-pid1175-tools ul li:nth-child(3) { background-ima=
ge: url("/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client/images/a=
lertIcon_2x.png"); }

.sidebarNav nav#block-nir-pid1175-tools ul li:nth-child(4) { background-ima=
ge: url("/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client/images/s=
heeticon_2x.png"); }

.sidebarNav nav#block-nir-pid1175-tools ul li:nth-child(5) { background-ima=
ge: url("/sites/g/files/knoqqb12671/themes/site/nir_pid1175/client/images/t=
oolkit_emailPg_t.gif"); }

.sidebarNav nav#block-nir-pid1175-tools ul { margin-left: 30px; margin-top:=
 20px; margin-bottom: 16px; display: inline-block; width: 100%; }

div.home-quote { padding-bottom: 80px; }

input#edit-nir-email-alerts-signup-email { width: 300px; }

.quote-wrapper .irContent tr.ccbnOutline td table tr.ccbnBgTblTtl td { padd=
ing-top: 3px; padding-left: 7px; }

.quote-wrapper .irContent tr.ccbnOutline td table tr td { padding-top: 9px;=
 padding-left: 7px; padding-bottom: 9px; }

body.nir-node--6126 .block-nir-stock-chart .nir-stock-chart { height: 565px=
 !important; }

.historical-price-lookup-form .form-item, .stock-price-calculator-form .for=
m-item { margin: 0px 20px 0px 0px; }

.nir-node--5921 h2.table-title { margin: 20px 0px 10px; }

div.region.region-content .block--search-form h2 { font-size: 16px; padding=
: 0px; margin: 0px; color: rgb(68, 68, 68) !important; }

div.region.region-content .block--search-form form { margin-top: -10px; }

.block--nir-news__widget--5816 article.node--nir-news--nir-widget-list { ma=
rgin: 25px 0px; }

.block--nir-news__widget--5816 .nir-widget--field.nir-widget--news--teaser =
p { margin: 0px; }

.block--nir-news__widget--5816 .nir-widget--field.nir-widget--news--read-mo=
re { display: inline-block; }

.block--nir-news__widget--5816 a:hover { text-decoration: none; }

nav.pager ul li.is-active a { color: rgb(68, 68, 68); cursor: unset; }

nav.pager ul li.is-active { padding: 0px; background: transparent; }

nav.pager ul li { padding: 0px; background: transparent; }

nav.pager ul li a:hover { background: transparent; }

.nir-node--type-nir-news article.node--nir-news--full .printLnk a.ccbnTblLn=
k::before { content: "=EE=80=97"; speak: none; line-height: 1; -webkit-font=
-smoothing: antialiased; font-size: 22px; vertical-align: middle; font-fami=
ly: ndqfonticons !important; font-style: normal !important; font-weight: no=
rmal !important; font-variant: normal !important; text-transform: none !imp=
ortant; }

.nir-node--type-nir-news article.node--nir-news--full h1.pressTitle, .nir-n=
ode--type-nir-news article.node--nir-news--full h1.pressTitle .field__item =
{ display: inline-block; margin-bottom: 2px; padding-bottom: 8px; font-size=
: 30px; font-style: normal; font-weight: normal; text-rendering: optimizele=
gibility; font-family: Montserrat, sans-serif; text-transform: none; line-h=
eight: 45px; letter-spacing: 0px; color: rgb(137, 140, 141) !important; }

.nir-node--type-nir-news article.node--nir-news--full .ccbnLnk.backLnk { fl=
oat: right; }

a:hover { text-decoration: none; }

.region.region-content nav.block--system-menu-blockevents-and-presentations=
 ul li a { font-size: 16px; }

.region.region-content nav.block--system-menu-blockevents-and-presentations=
 ul li, .region.region-content nav.block--system-menu-blockevents-and-prese=
ntations ul li a { background: transparent; padding: 0px; }

div.region.region-content ul li.side-menu__item a::after { padding-right: 4=
px; color: rgb(68, 68, 68); }

.region.region-content nav.block--system-menu-blockevents-and-presentations=
 ul { margin: 5px 0px 0px 1px; }

.nir-node--6031.nir-node--type-nir-landing-page article.node--nir-event--ni=
r-widget-list { margin: 60px 0px; }

.nir-node--type-nir-landing-page article.node--nir-event--nir-widget-list .=
asset-link { margin: 0px; }

.nir-node--type-nir-landing-page article.node--nir-event--nir-widget-list .=
field--name-field-nir-news-title a { font-size: 16px; font-weight: 400; }

.nir-widget--event--section-title.nir-widget--event--section-title--locatio=
n { display: inline-block; vertical-align: top; }

.nir-widget--event--section-title.nir-widget--event--section-title--locatio=
n label { font-weight: bold; font-size: 16px; }

.nir-widget--field.nir-widget--event--location-notes .field--name-field-nir=
-event-loc-address { display: inline-block; margin-top: 1px; }

.nir-node--type-nir-event .ccbn-event-summary-heading h2 { font-family: Mon=
tserrat, sans-serif; font-size: 40px; line-height: 56px; color: rgb(68, 68,=
 68) !important; }

a.ccbn-inlay-trigger { font-weight: bold; }

.ccbn-event-details-content { display: none; }

a.ccbn-inlay-trigger { background: url("/sites/g/files/knoqqb12671/themes/s=
ite/nir_pid1175/client/images/sprite-inlay-toggle.png") left -16px no-repea=
t scroll transparent; color: rgb(0, 169, 183); font-weight: bold; padding-l=
eft: 20px; text-decoration: none; }

a.ccbn-inlay-trigger.ccbn-inlay-trigger-expand { background-position: left =
3px; }

div.ccbn-event-details-header { padding-left: 0px; }

.mainContent .ccbn-event-options .webcast-link a, .mainContent .ccbn-event-=
options .webcast-link a:visited, .nir-node--5986 .mainContent .webcast-link=
 a, .nir-node--5986 .mainContent .webcast-link a:visited { color: rgb(0, 16=
9, 183); }

.mainContent .ccbn-event-options .webcast-link a:hover, .nir-node--5986 .ma=
inContent .webcast-link a:hover { color: rgb(21, 196, 211); }

.ccbn-event-option.ccbn-event-option-webcast h3 { margin: 0px; }

.block--nir-assets__widget--6116 { border: 1px solid rgb(241, 241, 241); }

.block--nir-assets__widget--6116 .nir-widget--label { background: rgb(248, =
248, 248); padding: 8px 10px 10px; font-family: Roboto, sans-serif; font-si=
ze: 16px; font-weight: bold; display: inline-block; width: 99.4%; margin: 1=
px; color: rgb(10, 10, 10) !important; }

.nir-node--6116 .col-md-6.radix-layouts-column1 { margin-right: 4%; }

.nir-node--6116 .col-md-6.radix-layouts-column1, .nir-node--6116 .col-md-6.=
radix-layouts-column2 { width: 48%; }

.nir-node--6116 .mainContent table.assetTable td.leftAsset a { font-size: 0=
px; }

.nir-node--6116 .mainContent table.assetTable td.rightAsset a::before { dis=
play: none; }

.nir-node--6116 .mainContent table.assetTable td.leftAsset { width: 25px; }

.nir-node--6116 .mainContent table.assetTable td { padding: 5px; }

.nir-node--6116 .mainContent table.assetTable { margin: 0px; }

.nir-node--6116 .mainContent table.assetTable tr:nth-child(2n) { background=
-color: rgb(241, 241, 241); }

.block--nir-assets__widget--6116 .nir-widget--content article.node--nir-ass=
et--nir-widget-list { display: none; }

.nir-node--6116 .mainContent table.assetTable { border-spacing: unset; }

.nir-node--6116 .mainContent table.assetTable td.rightAsset { border-right:=
 1px solid rgb(255, 255, 255); border-bottom: 1px solid rgb(255, 255, 255);=
 }

.nir-node--6116 .mainContent table.assetTable td.leftAsset { border-right: =
1px solid rgb(255, 255, 255); border-left: 1px solid rgb(255, 255, 255); bo=
rder-bottom: 1px solid rgb(255, 255, 255); }

div table.striped-odd.collapse-table.nirtable.commiteetable thead tr th, di=
v table.striped-odd.collapse-table.nirtable.commiteetable thead tr td { bac=
kground: rgb(248, 248, 248); }

div table.striped-odd.collapse-table.nirtable.commiteetable thead tr th a, =
div table.striped-odd.collapse-table.nirtable.commiteetable thead tr th a:v=
isited { background: transparent; color: rgb(0, 169, 183) !important; }

div table.striped-odd.collapse-table.nirtable.commiteetable thead tr th a:h=
over { color: rgb(21, 196, 211) !important; }

div table.striped-odd.collapse-table.nirtable.commiteetable tbody tr:nth-ch=
ild(2n) td { background: rgb(241, 241, 241); }

a:focus { text-decoration: none; }

.nir-node--type-person .node-right h3 { font-size: 16px; color: rgb(68, 68,=
 68); font-family: Roboto, sans-serif; font-weight: bold; letter-spacing: 0=
px; }

.nir-node--type-person span.back { float: right; width: 100%; text-align: r=
ight; margin-bottom: 40px; }

form#views-exposed-form-widget-sec-filings-table .form-item { margin-top: 0=
px; margin-bottom: 20px; }

form#views-exposed-form-widget-sec-filings-table .form-item label { font-we=
ight: bold; font-size: 16px; }

div.view-id-widget_sec_filings table.nirtable thead tr th a { color: rgb(68=
, 68, 68) !important; }

div.view-id-widget_sec_filings table.nirtable thead tr th { background: rgb=
(248, 248, 248); }

div.view-id-widget_sec_filings table.nirtable thead tr th:first-child { bor=
der: none; }

div.view-id-widget_sec_filings table.nirtable thead tr th { border-left: 1p=
x solid rgb(255, 255, 255); padding: 8px 10px; }

div.view-id-widget_sec_filings table.nirtable tr:nth-child(2n) td { border-=
left: 1px solid rgb(255, 255, 255); }

div.view-id-widget_sec_filings table.nirtable tr:nth-child(2n) td:first-chi=
ld { border: none; }

div.view-id-widget_sec_filings table.nirtable tr:nth-child(2n) td { backgro=
und: rgb(241, 241, 241); }

div.view-id-widget_sec_filings table.nirtable thead tr th:nth-child(5) { wi=
dth: 25%; }

div.view-id-widget_sec_filings table.nirtable thead tr th:nth-child(4) { wi=
dth: 20%; }

div.view-id-widget_sec_filings table.nirtable thead tr th:nth-child(3) { wi=
dth: 25%; }

div.view-id-widget_sec_filings table.nirtable thead tr th:nth-child(2) { wi=
dth: 14% !important; }

div.view-id-widget_sec_filings table.nirtable thead tr th:first-child { wid=
th: 16%; }

.chosen-container-multi .chosen-choices input { color: rgb(68, 68, 68) !imp=
ortant; }

.chosen-container-multi .chosen-choices { background: transparent; }

.block--nir-assets__widget--5881 article.node--nir-asset--nir-widget-list {=
 margin-bottom: 10px; }

div.acc-wrap .acc-title, div.acc-wrap .acc-title.opened, div.acc-wrap .acc-=
title:hover, div.acc-wrap .acc-title.opened:hover { display: inline-block; =
margin-bottom: 2px; padding-bottom: 8px; font-size: 30px; font-style: norma=
l; font-weight: normal; text-rendering: optimizelegibility; font-family: Mo=
ntserrat, sans-serif; color: rgb(137, 140, 141) !important; }

.block--views-blockwidget-bundled-content-block-1--5986 .item-list ul li { =
border-bottom: 1px solid rgb(241, 241, 241); margin-bottom: 20px; }

body.nir-node--5986 a.show-all { display: none; }

form.contact-message-nir-document-request-form .js-form-type-checkbox { mar=
gin: 0px; }

form.contact-message-nir-document-request-form .form-item { margin: 0px; }

form.contact-message-nir-document-request-form .form-item label { font-size=
: 16px; font-weight: bold; }

.contact-form input[type=3D"text"], .contact-form input[type=3D"search"], .=
contact-form input[type=3D"tel"], .contact-form input[type=3D"url"], .conta=
ct-form input[type=3D"email"], .contact-form input[type=3D"password"], .con=
tact-form input[type=3D"date"], .contact-form input[type=3D"time"], .contac=
t-form input[type=3D"number"], .contact-form input[type=3D"datalist"], form=
.contact-form textarea { width: 300px; }

body.nir-node--5951 .block-block-content table tr td a { background: none; =
padding-left: 0px; }

body.nir-node--5951 .block-block-content table tr td span.ccbnTtl { padding=
: 0px; }

form.nir-email-alerts-signup-form .js-form-type-email label { font-size: 16=
px; font-weight: bold; }

.block--nir-news__widget--5816 .nir-widget--form label { font-family: Robot=
o, sans-serif; color: rgb(68, 68, 68); font-size: 16px; font-weight: bold; =
}

.search .region.region-content .view-search form input[type=3D"submit"] { d=
isplay: inline-block; position: relative; margin: 0px; width: 15% !importan=
t; left: 0px !important; }

.search form.views-exposed-form .form-item { margin: 0px 10px 0px 0px; }

.search .region.region-content .view-search form { margin-bottom: 20px; }

.search hr.underLine { display: none; }

.nir-node--5911 .block-attribution-block__stock-info-attribution__thomson-r=
euters p { font-family: Roboto, sans-serif; font-style: normal; position: r=
elative; top: 0px; left: 0px; color: rgb(153, 153, 153) !important; font-si=
ze: 11px !important; }

.nir-node--6031 .nir-widget--event--section-title--supporting-materials lab=
el { font-weight: bold; font-size: 16px; line-height: 24px; font-family: Ro=
boto, sans-serif; }

@media screen and (max-width: 768px) {
  form.nir-email-alerts-signup-form .form-item, form.nir-email-alerts-signu=
p-form .form-item label { margin: 0px; display: inline-block; }
  form.nir-email-alerts-signup-form table td .form-item input[type=3D"check=
box"] { display: inline-block; margin-right: 5px; position: relative; top: =
2px; }
  form.nir-email-alerts-signup-form .form-item-nir-email-alerts-signup-emai=
l label { float: left; }
  body.nir-node--6126 .block-nir-stock-chart .nir-stock-chart { height: 575=
px !important; }
  table.nirtable tbody tr { margin: 0px; }
  .historical-price-lookup-form .form-item label, .stock-price-calculator-f=
orm .form-item label { width: 100%; display: inline-block; margin-right: 0p=
x; margin-top: 0px; }
  .block--nir-news__widget--5816 form label { display: inline-block; width:=
 100%; margin: 0px; }
  .region.region-content .block-search-form form input[type=3D"search"], .r=
egion.region-content .view-search form input[type=3D"text"] { width: 100%; =
}
  .region.region-content .block-search-form form input[type=3D"submit"], .r=
egion.region-content .view-search form input[type=3D"submit"] { display: in=
line-block; position: relative; left: 0px; width: auto !important; }
  .region.region-content .block--search-form .form-no-label { display: inli=
ne-block; width: 100%; }
  .nir-node--6116 .col-md-6.radix-layouts-column1, .nir-node--6116 .col-md-=
6.radix-layouts-column2 { width: 100%; }
  .nir-node--6116 .grid-padding-x > .cell { padding-right: 0px; }
  form#contact-message-nir-document-request-form label { float: left; width=
: 100%; }
  .search .region.region-content .view-search form input[type=3D"submit"] {=
 margin: 20px 0px 0px; width: auto !important; }
}

.search .view-search .views-exposed-form #edit-actions { margin: 0px; }

.nir-node--11 .node--nir-system--full h1.field__item::before { content: "";=
 }

.nir-node--5921 .historical-price-lookup-form .form-item { margin: 0px; flo=
at: none; }

.nir-node--6031 .block--nir-events__widget article .field-nir-event-assets-=
ref .field--name-field-nir-news-title a::before, .nir-node--type-nir-event =
.field--name-field-nir-news-title a::before { display: inline-block; line-h=
eight: 1; color: rgb(68, 68, 68); content: "=EE=80=95" !important; font-fam=
ily: ndqfonticons !important; font-style: normal !important; font-weight: n=
ormal !important; font-variant: normal !important; text-transform: none !im=
portant; }

.nir-node--type-nir-event .field--name-field-nir-news-title a { font-size: =
16px; font-weight: 400; }

.nir-node--6031 .field--name-field-nir-event-loc-desc { display: inline-blo=
ck; }

.eventToolTipData { position: absolute; visibility: hidden; overflow: auto;=
 width: 300px; height: auto; background: rgb(255, 255, 255); text-align: le=
ft; border: 1px solid rgb(0, 0, 0); top: 0px; left: 0px; padding: 5px; z-in=
dex: 999; margin-top: 8px; }

.visibleText { visibility: visible !important; }

.file--mime-application-rtf a::before { content: "=EE=80=89"; color: rgb(0,=
 81, 148); font-size: 22px; }

.file--mime-application-vnd-ms-excel a::before { content: "=EE=80=9F"; colo=
r: rgb(112, 168, 31); font-size: 22px; }

.file--mime-application-pdf a::before { content: "=EE=80=88"; color: rgb(22=
3, 0, 0); font-size: 22px; }

.file--mime-application-xml a::before { color: rgb(123, 65, 189); font-size=
: 22px; content: "=EE=80=A0" !important; }

#main-nav .investors-active { color: rgb(51, 51, 51) !important; }

@media only screen and (max-width: 639px) {
  .block--nir-events__widget--6031 .nir-widget--event--location-notes { dis=
play: flex; }
  .block--nir-events__widget--6031 .nir-widget--event--section-title--locat=
ion label { margin: 0px 10px 0px 0px; }
  .js-form-item > label { margin-top: 0px !important; margin-left: 5px; }
}

@media only screen and (max-width: 639px) {
  .block--nir-events__widget--6031 .nir-widget--event--location-notes { dis=
play: flex; }
  .block--nir-events__widget--6031 .nir-widget--event--section-title--locat=
ion label { margin: 0px 10px 0px 0px; }
  .js-form-item > label { margin-top: 0px !important; margin-left: 5px; }
}

@media (max-width: 900px) and (min-width: 768px) {
  .block--market-data-block__historical-price-lookup .historical-lookup tbo=
dy tr td { display: flex; justify-content: center; }
  .view-widget-sec-filings tbody tr td { display: flex; justify-content: ce=
nter; flex-direction: row; }
}

@media (max-width: 768px) and (min-width: 768px) {
  .view-widget-sec-filings tbody tr td { display: flex; justify-content: ce=
nter; flex-direction: row; }
}

.nir-node--5826 article.clearfix.node.node--nir-event--nir-widget-list { ma=
rgin-bottom: 25px; }

.add-outlook a::before, .add-gcal a::before { height: auto; width: auto; }

.p-lastname { margin-right: -3px; }

.nir-node--5806 div.block-region-secondcolumn2 .nir-widget--list article.no=
de--view-mode-nir-widget-list { margin-bottom: 15px; }

.view-widget-bundled-content .views-field-field-nir-tags { display: none; }

.stock-quote { padding: 0px; }

.node--nir-sec-filing--full .field--name-field-nir-sec-issuer { display: no=
ne !important; }

span.tablesort, span.filesize { display: none; }

.view-widget-assets table .item-list ul { margin: 0px; }

.view-widget-assets table.nirtable tr td .field__item { margin: 0px; }

.nir-widget .nir-widget--field { margin: 0px; }

div table.nirtable tbody tr td .field__item .file a { display: inline-block=
; position: relative; padding-left: 30px; }

div table.nirtable tbody tr td .field__item .file a::before { position: abs=
olute; left: 0px; top: 0px; }

div table.dataTable thead .sorting, div table.dataTable thead .sorting_desc=
 { background-image: none; }

.field--name-field-nir-person-company, .view-widget-assets table tbody .vie=
ws-field-field-nir-asset-date { font-style: normal; }

div.block-nir-attribution-block { padding: 0px; }

table.nirtable tbody tr:nth-child(2n+1) { background: transparent; }

table.nirtable tbody tr:nth-child(2n) { background: transparent; }

h2 { border: none; }

.node--type-nir-event .location-info { font-style: normal; }

body.nir-node--type-nir-sec-filing article.node--nir-sec-filing--full .node=
__content h2 { margin: 20px 0px 0px; }

.chosen-container-single .chosen-single { border-radius: 0px; background: t=
ransparent; box-shadow: none; }

.gnw_table_border_collapse td.gnw_heading, .gnw_heading { font: 16px Arial;=
 text-align: center; }

.gnw_table_border_collapse td.gnw_subhead, .gnw_subhead { font: 12px Arial;=
 text-align: center; }

.gnw_table_border_collapse td.gnw_colhead, .gnw_colhead { font: 12px Arial;=
 text-align: center; }

.gnw_table_border_collapse td.gnw_colhead_uline, .gnw_colhead_uline { font:=
 12px Arial; text-align: center; border-bottom: 1pt solid black; }

.gnw_table_border_collapse td.gnw_colhead_dline, .gnw_colhead_dline { font:=
 12px Arial; text-align: center; border-bottom: 2.5pt double black; }

.gnw_table_border_collapse td.gnw_label, .gnw_label { font: 12px Arial; ver=
tical-align: bottom; text-align: left; }

.gnw_table_border_collapse td.gnw_label_uline, .gnw_label_uline { font: 12p=
x Arial; vertical-align: bottom; text-align: left; border-bottom: 1pt solid=
 black; }

.gnw_table_border_collapse td.gnw_label_uline_i10, .gnw_label_uline_i10 { f=
ont: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: 1=
pt solid black; padding-left: 10px; }

.gnw_table_border_collapse td.gnw_label_uline_i15, .gnw_label_uline_i15 { f=
ont: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: 1=
pt solid black; padding-left: 15px; }

.gnw_table_border_collapse td.gnw_label_uline_i20, .gnw_label_uline_i20 { f=
ont: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: 1=
pt solid black; padding-left: 20px; }

.gnw_table_border_collapse td.gnw_label_uline_i25, .gnw_label_uline_i25 { f=
ont: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: 1=
pt solid black; padding-left: 25px; }

.gnw_table_border_collapse td.gnw_label_uline_i30, .gnw_label_uline_i30 { f=
ont: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: 1=
pt solid black; padding-left: 30px; }

.gnw_table_border_collapse td.gnw_label_dline_i10, .gnw_label_dline_i10 { f=
ont: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: 2=
.5pt double black; padding-left: 10px; }

.gnw_table_border_collapse td.gnw_label_dline_i15, .gnw_label_dline_i15 { f=
ont: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: 2=
.5pt double black; padding-left: 15px; }

.gnw_table_border_collapse td.gnw_label_dline_i20, .gnw_label_dline_i20 { f=
ont: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: 2=
.5pt double black; padding-left: 20px; }

.gnw_table_border_collapse td.gnw_label_dline_i25, .gnw_label_dline_i25 { f=
ont: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: 2=
.5pt double black; padding-left: 25px; }

.gnw_table_border_collapse td.gnw_label_dline_i30, .gnw_label_dline_i30 { f=
ont: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: 2=
.5pt double black; padding-left: 30px; }

.gnw_table_border_collapse td.gnw_label_ulinetop, .gnw_label_ulinetop { fon=
t: 12px Arial; vertical-align: bottom; text-align: left; border-top: 1pt so=
lid black; }

.gnw_table_border_collapse td.gnw_label_dline, .gnw_label_dline { font: 12p=
x Arial; vertical-align: bottom; text-align: left; border-bottom: 2.5pt dou=
ble black; }

.gnw_table_border_collapse td.gnw_label_i10, .gnw_label_i10 { font: 12px Ar=
ial; vertical-align: bottom; text-align: left; padding-left: 10px; }

.gnw_table_border_collapse td.gnw_label_i15, .gnw_label_i15 { font: 12px Ar=
ial; vertical-align: bottom; text-align: left; padding-left: 15px; }

.gnw_table_border_collapse td.gnw_label_i20, .gnw_label_i20 { font: 12px Ar=
ial; vertical-align: bottom; text-align: left; padding-left: 20px; }

.gnw_table_border_collapse td.gnw_label_i25, .gnw_label_i25 { font: 12px Ar=
ial; vertical-align: bottom; text-align: left; padding-left: 25px; }

.gnw_table_border_collapse td.gnw_label_i30, .gnw_label_i30 { font: 12px Ar=
ial; vertical-align: bottom; text-align: left; padding-left: 30px; }

.gnw_table_border_collapse td.gnw_num, .gnw_num { font: 12px Arial; vertica=
l-align: bottom; text-align: right; white-space: nowrap; }

.gnw_table_border_collapse td.gnw_num_uline, .gnw_num_uline { font: 12px Ar=
ial; vertical-align: bottom; text-align: right; white-space: nowrap; border=
-bottom: 1pt solid black; }

.gnw_table_border_collapse td.gnw_num_ulinetop, .gnw_num_ulinetop { font: 1=
2px Arial; vertical-align: bottom; text-align: right; white-space: nowrap; =
border-top: 1pt solid black; }

.gnw_table_border_collapse td.gnw_num_dline, .gnw_num_dline { font: 12px Ar=
ial; vertical-align: bottom; text-align: right; white-space: nowrap; border=
-bottom: 2.5pt double black; }

.gnw_table_border_collapse td.gnw_num_dlinetop, .gnw_num_dlinetop { font: 1=
2px Arial; vertical-align: bottom; text-align: right; white-space: nowrap; =
border-top: 2.5pt double black; }

.gnw_table_border_collapse td.gnw_data, .gnw_data { font: 12px Arial; verti=
cal-align: bottom; text-align: left; white-space: nowrap; }

.gnw_table_border_collapse td.gnw_data_uline, .gnw_data_uline { font: 12px =
Arial; vertical-align: bottom; text-align: left; border-bottom: 1pt solid b=
lack; }

.gnw_table_border_collapse td.gnw_data_dline, .gnw_data_dline { font: 12px =
Arial; vertical-align: bottom; text-align: left; border-bottom: 2.5pt doubl=
e black; }

.gnw_news_media_box { margin: 15px 6px 6px; border-width: 1px; border-color=
: rgb(169, 169, 169); border-style: solid; }

.gnw_table_border_collapse td.gnw_media_caption, .gnw_media_caption { font-=
size: 8pt; font-family: Verdana, Arial, Helvetica, Geneva, Swiss, SunSans-R=
egular; }

.gnw_media_bgcolor { background-color: transparent; }

.gnw_table { border-collapse: separate; border-spacing: 6px; }

.gnw_table_border_collapse td.gnw_videotitle, .gnw_videotitle { font: bold =
12px Arial; color: rgb(29, 82, 150); }

.gnw_border_top_solid { border-top: 1px solid black !important; }

.gnw_border_right_solid { border-right: 1px solid black !important; }

.gnw_border_bottom_solid { border-bottom: 1px solid black !important; }

.gnw_border_left_solid { border-left: 1px solid black !important; }

.gnw_border_top_double { border-top: 3px double black !important; }

.gnw_border_right_double { border-right: 3px double black !important; }

.gnw_border_bottom_double { border-bottom: 3px double black !important; }

.gnw_border_left_double { border-left: 3px double black !important; }

.gnw_table_border_collapse { border-collapse: collapse !important; }

.gnw_table_border_collapse td { font-size: 12px; }

.gnw_align_left { text-align: left !important; }

.gnw_align_center { text-align: center !important; }

.gnw_align_right { text-align: right !important; }

.gnw_align_justify { text-align: justify !important; }

.gnw_vertical_align_top { vertical-align: top !important; }

.gnw_vertical_align_middle { vertical-align: middle !important; }

.gnw_vertical_align_bottom { vertical-align: bottom !important; }

.gnw_padding_left_none { padding-left: 0px !important; }

.gnw_padding_right_none { padding-right: 0px !important; }

.xn-content td { white-space: normal; padding-left: 0px !important; padding=
-right: 0px !important; }

.xn-content td * { }

.prntblns { width: auto; }

.prntblns td { padding-left: 0px !important; padding-right: 0px !important;=
 white-space: normal !important; }

.prntblns tr td:first-child, .prntblns tr td:first-child p { white-space: n=
ormal !important; }

p.prnews_p { margin: 0px !important; }

.bwbodyimg { float: left; padding: 0px 20px 0px 0px; }

.bwbodyimgcaption { font-size: 85%; }

.bwtextaligncenter, .bwalignc { text-align: center; }

.bwtextalignleft, .bwalignl { text-align: left; }

.bwtextalignright, .bwalignr { text-align: right; }

.bwverticalaligntop, .bwvertalignt { vertical-align: top; }

.bwverticalalignmiddle, .bwvertalignm { vertical-align: middle; }

.bwverticalalignbottom, .bwvertalignb { vertical-align: bottom; }

.bwtablefigurealign, .bwfigurealign { text-align: right; vertical-align: bo=
ttom; }

.bwtabletextalign, .bwtxtalign { text-align: left; vertical-align: bottom; =
}

.bwwhitespacenowrap, .bwnowrap { white-space: nowrap; }

.bwsinglebottomborder, .bwsinglebottom { border-bottom: 1pt solid black; }

.bwdoublebottomborder, .bwdoublebottom { border-bottom: 2.25pt double black=
; }

.bwsingletopborder, .bwsingletop { border-top: 1pt solid black; }

.bwdoubletopborder, .bwdoubletop { border-top: 2.25pt double black; }

.bwcellpaddingleft0, .bwpadl0 { padding-left: 0px; }

.bwcellpaddingleft1, .bwpadl1 { padding-left: 5px; }

.bwcellpaddingleft2, .bwpadl2 { padding-left: 10px; }

.bwcellpaddingleft3, .bwpadl3 { padding-left: 15px; }

.bwcellpaddingleft4, .bwpadl4 { padding-left: 20px; }

.bwcellpaddingleft5, .bwpadl5 { padding-left: 25px; }

.bwcellpaddingleft6, .bwpadl6 { padding-left: 30px; }

.bwcellpaddingleft7, .bwpadl7 { padding-left: 35px; }

.bwcellpaddingleft8, .bwpadl8 { padding-left: 40px; }

.bwcellpaddingleft9, .bwpadl9 { padding-left: 45px; }

.bwcellpaddingleft10, .bwpadl10 { padding-left: 50px; }

.bwcellpaddingleft11, .bwpadl11 { padding-left: 55px; }

.bwcellpaddingleft12, .bwpadl12 { padding-left: 60px; }

.bwcellpaddingleft13, .bwpadl13 { padding-left: 65px; }

.bwcellpaddingleft14, .bwpadl14 { padding-left: 70px; }

.bwcellpaddingleft15, .bwpadl15 { padding-left: 75px; }

.bwcellpaddingleft16, .bwpadl16 { padding-left: 80px; }

.bwcellpaddingleft17, .bwpadl17 { padding-left: 85px; }

.bwcellpaddingleft18, .bwpadl18 { padding-left: 90px; }

.bwcellpaddingleft19, .bwpadl19 { padding-left: 95px; }

.bwcellpaddingleft20, .bwpadl20 { padding-left: 100px; }

.bwcellpaddingright0, .bwpadr0 { padding-right: 0px; }

.bwcellpaddingright1, .bwpadr1 { padding-right: 5px; }

.bwcellpaddingright2, .bwpadr2 { padding-right: 10px; }

.bwcellpaddingright3, .bwpadr3 { padding-right: 15px; }

.bwcellpaddingright4, .bwpadr4 { padding-right: 20px; }

.bwcellpaddingright5, .bwpadr5 { padding-right: 25px; }

.bwcellpaddingright6, .bwpadr6 { padding-right: 30px; }

.bwcellpaddingright7, .bwpadr7 { padding-right: 35px; }

.bwcellpaddingright8, .bwpadr8 { padding-right: 40px; }

.bwcellpaddingright9, .bwpadr9 { padding-right: 45px; }

.bwcellpaddingright10, .bwpadr10 { padding-right: 50px; }

.bwcellpaddingtop1, .bwpadt1 { padding-top: 10px; }

.bwcellpaddingtop2, .bwpadt2 { padding-top: 20px; }

.bwcellpaddingtop3, .bwpadt3 { padding-top: 30px; }

.bwcellpaddingtop4, .bwpadt4 { padding-top: 40px; }

.bwcellpaddingtop5, .bwpadt5 { padding-top: 50px; }

.bwcellpaddingtop6, .bwpadt6 { padding-top: 60px; }

.bwcellpaddingtop7, .bwpadt7 { padding-top: 70px; }

.bwcellpaddingtop8, .bwpadt8 { padding-top: 80px; }

.bwcellpaddingtop9, .bwpadt9 { padding-top: 90px; }

.bwcellpaddingtop10, .bwpadt10 { padding-top: 100px; }

.bwcellpaddingtop11, .bwpadt11 { padding-top: 110px; }

.bwcellpaddingtop12, .bwpadt12 { padding-top: 120px; }

.bwcellpaddingtop13, .bwpadt13 { padding-top: 130px; }

.bwcellpaddingtop14, .bwpadt14 { padding-top: 140px; }

.bwcellpaddingtop15, .bwpadt15 { padding-top: 150px; }

.bwcellpaddingtop16, .bwpadt16 { padding-top: 160px; }

.bwcellpaddingtop17, .bwpadt17 { padding-top: 170px; }

.bwcellpaddingtop18, .bwpadt18 { padding-top: 180px; }

.bwcellpaddingtop19, .bwpadt19 { padding-top: 190px; }

.bwcellpaddingtop20, .bwpadt20 { padding-top: 200px; }

.bwcellpaddingbottom1, .bwpadb1 { padding-bottom: 2px; }

.bwcellpaddingbottom2, .bwpadb2 { padding-bottom: 3px; }

.bwcellpaddingbottom3, .bwpadb3 { padding-bottom: 4px; }

.bwunderlinestyle, .bwuline { text-decoration: underline; }

.bwdoubleunderlinestyle, .bwdbluline { text-decoration: underline; border-b=
ottom: 1px solid black; }

.bwcolorred, .bwred { color: red; }

.bwcolorblack, .bwblack { color: black; }

.bwmarginleft1, .bwmarginl1 { margin-left: 30px; }

.bwmarginleft2, .bwmarginl2 { margin-left: 60px; }

.bwmarginleft3, .bwmarginl3 { margin-left: 90px; }

.bwmarginleft4, .bwmarginl4 { margin-left: 120px; }

.bwmarginleft5, .bwmarginl5 { margin-left: 150px; }

.bwmarginleft6, .bwmarginl6 { margin-left: 180px; }

.bwmarginleft7, .bwmarginl7 { margin-left: 210px; }

.bwmarginleft8, .bwmarginl8 { margin-left: 240px; }

.bwmarginleft9, .bwmarginl9 { margin-left: 270px; }

.bwmarginleft10, .bwmarginl10 { margin-left: 300px; }

.bwhangingindent, .bwhangindent { text-indent: -30px; }

.bwparagraphindent, .bwpindent { text-indent: 30px; }

.bwliststylenone, .bwlistnone { list-style-image: none; list-style-type: no=
ne; }

.bwliststyledisc, .bwlistdisc { list-style-type: disc; }

.bwliststylesquare, .bwlistsquare { list-style-type: square; }

.bwliststylecircle, .bwlistcircle { list-style-type: circle; }

.bwliststyledecimal, .bwlistdecimal { list-style-type: decimal; }

.bwliststyleloweralpha, .bwlistlowalpha { list-style-type: lower-alpha; }

.bwliststyleupperalpha, .bwlistupalpha { list-style-type: upper-alpha; }

.bwliststylelowerroman, .bwlistlowroman { list-style-type: lower-roman; }

.bwliststyleupperroman, .bwlistuproman { list-style-type: upper-roman; }

.bwlistitemmarginbottom, .bwlistitemmargb { margin-bottom: 10px; }

.bwcellparagraphmargin, .bwcellpmargin { margin-bottom: 0px; margin-top: 0p=
x; }

.bwtablebottommargin, .bwtablemarginb { margin-bottom: 10px; }

.bwblockaligncenter, .bwblockalignc { margin-left: auto; margin-right: auto=
; }

.bwblockalignleft, .bwblockalignl { margin-left: 0px; margin-right: auto; }

.bwblockalignright, .bwblockalignr { margin-left: auto; margin-right: 0px; =
}

.bwwidthpercent1, .bwwidth1 { width: 1%; }

.bwwidthpercent2, .bwwidth2 { width: 2%; }

.bwwidthpercent3, .bwwidth3 { width: 3%; }

.bwwidthpercent4, .bwwidth4 { width: 4%; }

.bwwidthpercent5, .bwwidth5 { width: 5%; }

.bwwidthpercent6, .bwwidth6 { width: 6%; }

.bwwidthpercent7, .bwwidth7 { width: 7%; }

.bwwidthpercent8, .bwwidth8 { width: 8%; }

.bwwidthpercent9, .bwwidth9 { width: 9%; }

.bwwidthpercent10, .bwwidth10 { width: 10%; }

.bwwidthpercent11, .bwwidth11 { width: 11%; }

.bwwidthpercent12, .bwwidth12 { width: 12%; }

.bwwidthpercent13, .bwwidth13 { width: 13%; }

.bwwidthpercent14, .bwwidth14 { width: 14%; }

.bwwidthpercent15, .bwwidth15 { width: 15%; }

.bwwidthpercent16, .bwwidth16 { width: 16%; }

.bwwidthpercent17, .bwwidth17 { width: 17%; }

.bwwidthpercent18, .bwwidth18 { width: 18%; }

.bwwidthpercent19, .bwwidth19 { width: 19%; }

.bwwidthpercent20, .bwwidth20 { width: 20%; }

.bwwidthpercent21, .bwwidth21 { width: 21%; }

.bwwidthpercent22, .bwwidth22 { width: 22%; }

.bwwidthpercent23, .bwwidth23 { width: 23%; }

.bwwidthpercent24, .bwwidth24 { width: 24%; }

.bwwidthpercent25, .bwwidth25 { width: 25%; }

.bwwidthpercent26, .bwwidth26 { width: 26%; }

.bwwidthpercent27, .bwwidth27 { width: 27%; }

.bwwidthpercent28, .bwwidth28 { width: 28%; }

.bwwidthpercent29, .bwwidth29 { width: 29%; }

.bwwidthpercent30, .bwwidth30 { width: 30%; }

.bwwidthpercent31, .bwwidth31 { width: 31%; }

.bwwidthpercent32, .bwwidth32 { width: 32%; }

.bwwidthpercent33, .bwwidth33 { width: 33%; }

.bwwidthpercent34, .bwwidth34 { width: 34%; }

.bwwidthpercent35, .bwwidth35 { width: 35%; }

.bwwidthpercent36, .bwwidth36 { width: 36%; }

.bwwidthpercent37, .bwwidth37 { width: 37%; }

.bwwidthpercent38, .bwwidth38 { width: 38%; }

.bwwidthpercent39, .bwwidth39 { width: 39%; }

.bwwidthpercent40, .bwwidth40 { width: 40%; }

.bwwidthpercent41, .bwwidth41 { width: 41%; }

.bwwidthpercent42, .bwwidth42 { width: 42%; }

.bwwidthpercent43, .bwwidth43 { width: 43%; }

.bwwidthpercent44, .bwwidth44 { width: 44%; }

.bwwidthpercent45, .bwwidth45 { width: 45%; }

.bwwidthpercent46, .bwwidth46 { width: 46%; }

.bwwidthpercent47, .bwwidth47 { width: 47%; }

.bwwidthpercent48, .bwwidth48 { width: 48%; }

.bwwidthpercent49, .bwwidth49 { width: 49%; }

.bwwidthpercent50, .bwwidth50 { width: 50%; }

.bwwidthpercent51, .bwwidth51 { width: 51%; }

.bwwidthpercent52, .bwwidth52 { width: 52%; }

.bwwidthpercent53, .bwwidth53 { width: 53%; }

.bwwidthpercent54, .bwwidth54 { width: 54%; }

.bwwidthpercent55, .bwwidth55 { width: 55%; }

.bwwidthpercent56, .bwwidth56 { width: 56%; }

.bwwidthpercent57, .bwwidth57 { width: 57%; }

.bwwidthpercent58, .bwwidth58 { width: 58%; }

.bwwidthpercent59, .bwwidth59 { width: 59%; }

.bwwidthpercent60, .bwwidth60 { width: 60%; }

.bwwidthpercent61, .bwwidth61 { width: 61%; }

.bwwidthpercent62, .bwwidth62 { width: 62%; }

.bwwidthpercent63, .bwwidth63 { width: 63%; }

.bwwidthpercent64, .bwwidth64 { width: 64%; }

.bwwidthpercent65, .bwwidth65 { width: 65%; }

.bwwidthpercent66, .bwwidth66 { width: 66%; }

.bwwidthpercent67, .bwwidth67 { width: 67%; }

.bwwidthpercent68, .bwwidth68 { width: 68%; }

.bwwidthpercent69, .bwwidth69 { width: 69%; }

.bwwidthpercent70, .bwwidth70 { width: 70%; }

.bwwidthpercent71, .bwwidth71 { width: 71%; }

.bwwidthpercent72, .bwwidth72 { width: 72%; }

.bwwidthpercent73, .bwwidth73 { width: 73%; }

.bwwidthpercent74, .bwwidth74 { width: 74%; }

.bwwidthpercent75, .bwwidth75 { width: 75%; }

.bwwidthpercent76, .bwwidth76 { width: 76%; }

.bwwidthpercent77, .bwwidth77 { width: 77%; }

.bwwidthpercent78, .bwwidth78 { width: 78%; }

.bwwidthpercent79, .bwwidth79 { width: 79%; }

.bwwidthpercent80, .bwwidth80 { width: 80%; }

.bwwidthpercent81, .bwwidth81 { width: 81%; }

.bwwidthpercent82, .bwwidth82 { width: 82%; }

.bwwidthpercent83, .bwwidth83 { width: 83%; }

.bwwidthpercent84, .bwwidth84 { width: 84%; }

.bwwidthpercent85, .bwwidth85 { width: 85%; }

.bwwidthpercent86, .bwwidth86 { width: 86%; }

.bwwidthpercent87, .bwwidth87 { width: 87%; }

.bwwidthpercent88, .bwwidth88 { width: 88%; }

.bwwidthpercent89, .bwwidth89 { width: 89%; }

.bwwidthpercent90, .bwwidth90 { width: 90%; }

.bwwidthpercent91, .bwwidth91 { width: 91%; }

.bwwidthpercent92, .bwwidth92 { width: 92%; }

.bwwidthpercent93, .bwwidth93 { width: 93%; }

.bwwidthpercent94, .bwwidth94 { width: 94%; }

.bwwidthpercent95, .bwwidth95 { width: 95%; }

.bwwidthpercent96, .bwwidth96 { width: 96%; }

.bwwidthpercent97, .bwwidth97 { width: 97%; }

.bwwidthpercent98, .bwwidth98 { width: 98%; }

.bwwidthpercent99, .bwwidth99 { width: 99%; }

.bwwidthpercent100, .bwwidth100 { width: 100%; }

.xn-content table, table.gnw_table, table.bwtablemarginb, .hugin pre, table=
.hugin, .yom-mod table, .node--nir-news--full .node__content table { overfl=
ow: auto; display: block; max-width: 100%; }

.xn-content td *, .gnw_table *, .bwtablemarginb *, table.hugin *, .yom-mod =
table *, .node--nir-news--full .node__content table * { }

.node--nir-news--full .node__content pre { overflow: auto; display: block; =
}

.node--nir-news--full .node__content a { overflow-wrap: break-word; word-br=
eak: break-word; hyphens: auto; }

@media only screen and (max-width: 768px) {
  .xn-content td *, .gnw_table *, .bwtablemarginb *, table.hugin *, .yom-mo=
d table *, .node--nir-news--full .node__content table * { font-size: 11px !=
important; }
}

@media only screen and (max-width: 468px) {
  .xn-content td *, .gnw_table *, .bwtablemarginb *, table.hugin *, .yom-mo=
d table *, .node--nir-news--full .node__content table * { font-size: 9px !i=
mportant; }
  .xn-content td a, .gnw_table a, .bwtablemarginb a, table.hugin a, .yom-mo=
d table a, .node--nir-news--full .node__content table a { overflow-wrap: br=
eak-word; word-break: break-word; hyphens: auto; }
}

.nir-node--6126 .block-nir-stock-chart .nir-stock-chart { border-right: 1px=
 solid rgb(153, 153, 153); border-bottom: 1px solid rgb(153, 153, 153); hei=
ght: 456px !important; }

.back { float: right; }

.node--nir-news--full h1 > .field--name-field-nir-news-title { font-size: 1=
2px; color: rgb(80, 81, 86); display: inline-block; font-weight: bold; line=
-height: 16px; }

.nir-node--5816 .nir-widget--news--headline { margin-top: 0px; margin-botto=
m: 0px; }

.nir-node--5816 .nir-widget--news--date-time { margin-bottom: 0px; }

.nir-node--5816 .nir-widget--news--teaser, .nir-node--5816 .nir-widget--new=
s--read-more { margin: 0px; }

.nir-node--6031 .nir-widget--event--section-title--supporting-materials { f=
loat: left; width: 90px; }

.nir-node--6031 .field-nir-event-assets-ref { float: left; width: 88%; }

.nir-node--5986 .acc-body .html-link a::before { display: none; }
------MultipartBoundary--OyEh8n7b4Lw6tzistt7cxFCRw1zMtvVQlXOUlVtdJx----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: https://investor.xenon-pharma.com/sites/g/files/knoqqb12671/files/css/css_1BYDXkiJUITULboGN1B4U4lCfcXnJ5FvdU8omlFmO4s.css?delta=0&language=en&theme=nir_pid1175&include=eJyVjsEKAjEMRH-oWPYgfk5I27CGTZMljYJ_b3cvInjxNrx5DKPs0NE3CmgYCEWsbrkTKjhV6510cjaFekePpD99VJTXCPCp6goF_Q99QGARStWccvPHjnJpjGJrGtOingsOOqeOkI_A1XR8kHD57sNM5osT7tyW5XbN9iR3bvQGCmRfGw

@charset "utf-8";

.ui-helper-hidden { display: none; }

.ui-helper-hidden-accessible { border: 0px; clip: rect(0px, 0px, 0px, 0px);=
 height: 1px; margin: -1px; overflow: hidden; padding: 0px; position: absol=
ute; width: 1px; }

.ui-helper-reset { margin: 0px; padding: 0px; border: 0px; outline: 0px; li=
ne-height: 1.3; text-decoration: none; font-size: 100%; list-style: none; }

.ui-helper-clearfix::before, .ui-helper-clearfix::after { content: ""; disp=
lay: table; border-collapse: collapse; }

.ui-helper-clearfix::after { clear: both; }

.ui-helper-zfix { width: 100%; height: 100%; top: 0px; left: 0px; position:=
 absolute; opacity: 0; }

.ui-front { z-index: 100; }

.ui-state-disabled { cursor: default !important; pointer-events: none; }

.ui-icon { display: inline-block; vertical-align: middle; margin-top: -0.25=
em; position: relative; text-indent: -99999px; overflow: hidden; background=
-repeat: no-repeat; }

.ui-widget-icon-block { left: 50%; margin-left: -8px; display: block; }

.ui-widget-overlay { position: fixed; top: 0px; left: 0px; width: 100%; hei=
ght: 100%; }

.ui-controlgroup { vertical-align: middle; display: inline-block; }

.ui-controlgroup > .ui-controlgroup-item { float: left; margin-left: 0px; m=
argin-right: 0px; }

.ui-controlgroup > .ui-controlgroup-item:focus, .ui-controlgroup > .ui-cont=
rolgroup-item.ui-visual-focus { z-index: 9999; }

.ui-controlgroup-vertical > .ui-controlgroup-item { display: block; float: =
none; width: 100%; margin-top: 0px; margin-bottom: 0px; text-align: left; }

.ui-controlgroup-vertical .ui-controlgroup-item { box-sizing: border-box; }

.ui-controlgroup .ui-controlgroup-label { padding: 0.4em 1em; }

.ui-controlgroup .ui-controlgroup-label span { font-size: 80%; }

.ui-controlgroup-horizontal .ui-controlgroup-label + .ui-controlgroup-item =
{ border-left: none; }

.ui-controlgroup-vertical .ui-controlgroup-label + .ui-controlgroup-item { =
border-top: none; }

.ui-controlgroup-horizontal .ui-controlgroup-label.ui-widget-content { bord=
er-right: none; }

.ui-controlgroup-vertical .ui-controlgroup-label.ui-widget-content { border=
-bottom: none; }

.ui-controlgroup-vertical .ui-spinner-input { width: calc(100% - 2.4em); }

.ui-controlgroup-vertical .ui-spinner .ui-spinner-up { border-top-style: so=
lid; }

.ui-checkboxradio-label .ui-icon-background { box-shadow: rgb(204, 204, 204=
) 1px 1px 1px inset; border-radius: 0.12em; border: none; }

.ui-checkboxradio-radio-label .ui-icon-background { width: 16px; height: 16=
px; border-radius: 1em; overflow: visible; border: none; }

.ui-checkboxradio-radio-label.ui-checkboxradio-checked .ui-icon, .ui-checkb=
oxradio-radio-label.ui-checkboxradio-checked:hover .ui-icon { background-im=
age: none; width: 8px; height: 8px; border-width: 4px; border-style: solid;=
 }

.ui-checkboxradio-disabled { pointer-events: none; }

.ui-resizable { position: relative; }

.ui-resizable-handle { position: absolute; font-size: 0.1px; display: block=
; touch-action: none; }

.ui-resizable-disabled .ui-resizable-handle, .ui-resizable-autohide .ui-res=
izable-handle { display: none; }

.ui-resizable-n { cursor: n-resize; height: 7px; width: 100%; top: -5px; le=
ft: 0px; }

.ui-resizable-s { cursor: s-resize; height: 7px; width: 100%; bottom: -5px;=
 left: 0px; }

.ui-resizable-e { cursor: e-resize; width: 7px; right: -5px; top: 0px; heig=
ht: 100%; }

.ui-resizable-w { cursor: w-resize; width: 7px; left: -5px; top: 0px; heigh=
t: 100%; }

.ui-resizable-se { cursor: se-resize; width: 12px; height: 12px; right: 1px=
; bottom: 1px; }

.ui-resizable-sw { cursor: sw-resize; width: 9px; height: 9px; left: -5px; =
bottom: -5px; }

.ui-resizable-nw { cursor: nw-resize; width: 9px; height: 9px; left: -5px; =
top: -5px; }

.ui-resizable-ne { cursor: ne-resize; width: 9px; height: 9px; right: -5px;=
 top: -5px; }

.ui-button { padding: 0.4em 1em; display: inline-block; position: relative;=
 line-height: normal; margin-right: 0.1em; cursor: pointer; vertical-align:=
 middle; text-align: center; user-select: none; overflow: visible; }

.ui-button, .ui-button:link, .ui-button:visited, .ui-button:hover, .ui-butt=
on:active { text-decoration: none; }

.ui-button-icon-only { width: 2em; box-sizing: border-box; text-indent: -99=
99px; white-space: nowrap; }

input.ui-button.ui-button-icon-only { text-indent: 0px; }

.ui-button-icon-only .ui-icon { position: absolute; top: 50%; left: 50%; ma=
rgin-top: -8px; margin-left: -8px; }

.ui-button.ui-icon-notext .ui-icon { padding: 0px; width: 2.1em; height: 2.=
1em; text-indent: -9999px; white-space: nowrap; }

input.ui-button.ui-icon-notext .ui-icon { width: auto; height: auto; text-i=
ndent: 0px; white-space: normal; padding: 0.4em 1em; }

.progress { position: relative; }

.progress__track { min-width: 100px; max-width: 100%; height: 16px; margin-=
top: 5px; border: 1px solid; background-color: rgb(255, 255, 255); }

.progress__bar { width: 3%; min-width: 3%; max-width: 100%; height: 16px; b=
ackground-color: rgb(0, 0, 0); }

.progress__description, .progress__percentage { overflow: hidden; margin-to=
p: 0.2em; color: rgb(85, 85, 85); font-size: 0.875em; }

.progress__description { float: left; }

[dir=3D"rtl"] .progress__description { float: right; }

.progress__percentage { float: right; }

[dir=3D"rtl"] .progress__percentage { float: left; }

.progress--small .progress__track { height: 7px; }

.progress--small .progress__bar { height: 7px; background-size: 20px 20px; =
}

.ajax-progress { display: inline-block; padding: 1px 5px 2px; }

[dir=3D"rtl"] .ajax-progress { float: right; }

.ajax-progress-throbber .throbber { display: inline; padding: 1px 6px 2px; =
background: url("/core/misc/throbber-active.gif") 0px center no-repeat tran=
sparent; }

.ajax-progress-throbber .message { display: inline; padding: 1px 5px 2px; }

tr .ajax-progress-throbber .throbber { margin: 0px 2px; }

.ajax-progress-bar { width: 16em; }

.ajax-progress-fullscreen { position: fixed; z-index: 1261; top: 48.5%; lef=
t: 49%; width: 24px; height: 24px; padding: 4px; opacity: 0.9; border-radiu=
s: 7px; background-color: rgb(35, 35, 35); background-image: url("/core/mis=
c/loading-small.gif"); background-repeat: no-repeat; background-position: c=
enter center; }

[dir=3D"rtl"] .ajax-progress-fullscreen { right: 49%; left: auto; }

.text-align-left { text-align: left; }

.text-align-right { text-align: right; }

.text-align-center { text-align: center; }

.text-align-justify { text-align: justify; }

.align-left { float: left; }

.align-right { float: right; }

.align-center { display: block; margin-right: auto; margin-left: auto; }

.fieldgroup { padding: 0px; border-width: 0px; }

.container-inline div, .container-inline label { display: inline-block; }

.container-inline .details-wrapper { display: block; }

.container-inline .hidden { display: none; }

.clearfix::after { display: table; clear: both; content: ""; }

.js details:not([open]) .details-wrapper { display: none; }

.hidden { display: none; }

.visually-hidden { overflow: hidden; clip: rect(1px, 1px, 1px, 1px); width:=
 1px; height: 1px; overflow-wrap: normal; position: absolute !important; }

.visually-hidden.focusable:active, .visually-hidden.focusable:focus { overf=
low: visible; clip: auto; width: auto; height: auto; position: static !impo=
rtant; }

.invisible { visibility: hidden; }

.item-list__comma-list, .item-list__comma-list li { display: inline; }

.item-list__comma-list { margin: 0px; padding: 0px; }

.item-list__comma-list li::after { content: ", "; }

.item-list__comma-list li:last-child::after { content: ""; }

.js .js-hide { display: none; }

.js-show { display: none; }

.js .js-show { display: block; }

@media (scripting: enabled) {
  .js-hide.js-hide { display: none; }
  .js-show { display: block; }
}

.nowrap { white-space: nowrap; }

.position-container { position: relative; }

.reset-appearance { margin: 0px; padding: 0px; border: 0px none; background=
: transparent; line-height: inherit; appearance: none; }

.resize-none { resize: none; }

.resize-vertical { min-height: 2em; resize: vertical; }

.resize-horizontal { max-width: 100%; resize: horizontal; }

.resize-both { max-width: 100%; min-height: 2em; resize: both; }

.system-status-counter__status-icon { display: inline-block; width: 25px; h=
eight: 25px; vertical-align: middle; }

.system-status-counter__status-icon::before { display: block; width: 100%; =
height: 100%; content: ""; background-repeat: no-repeat; background-positio=
n: center 2px; background-size: 16px; }

.system-status-counter__status-icon--error::before { background-image: url(=
"/core/misc/icons/e32700/error.svg"); }

.system-status-counter__status-icon--warning::before { background-image: ur=
l("/core/misc/icons/e29700/warning.svg"); }

.system-status-counter__status-icon--checked::before { background-image: ur=
l("/core/misc/icons/73b355/check.svg"); }

.system-status-report-counters__item { width: 100%; margin-bottom: 0.5em; p=
adding: 0.5em 0px; text-align: center; white-space: nowrap; background-colo=
r: rgba(0, 0, 0, 0.063); }

@media screen and (min-width: 60em) {
  .system-status-report-counters { display: flex; flex-wrap: wrap; justify-=
content: space-between; }
  .system-status-report-counters__item--half-width { width: 49%; }
  .system-status-report-counters__item--third-width { width: 33%; }
}

.system-status-general-info__item { margin-top: 1em; padding: 0px 1em 1em; =
border: 1px solid rgb(204, 204, 204); }

.system-status-general-info__item-title { border-bottom: 1px solid rgb(204,=
 204, 204); }

.tablesort { display: inline-block; width: 16px; height: 16px; background-s=
ize: 100%; }

.tablesort--asc { background-image: url("/core/misc/icons/787878/twistie-do=
wn.svg"); }

.tablesort--desc { background-image: url("/core/misc/icons/787878/twistie-u=
p.svg"); }

.ui-dialog ~ .ck-body-wrapper { --ck-z-panel: 1261; }

#toolbar-administration, #toolbar-administration * { box-sizing: border-box=
; }

#toolbar-administration { font-size: small; line-height: 1; margin: 0px; pa=
dding: 0px; vertical-align: baseline; }

@media print {
  #toolbar-administration { display: none; }
}

.nir-toolbar li, .nir-toolbar .item-list, .nir-toolbar .item-list li, .nir-=
toolbar .menu-item, .nir-toolbar .menu-item--expanded { list-style-type: no=
ne; list-style-image: none; }

.nir-toolbar .menu-item { padding-top: 0px; }

.nir-toolbar .toolbar-bar .toolbar-tab, .nir-toolbar .menu-item { display: =
block; }

.nir-toolbar .toolbar-bar .toolbar-tab.hidden { display: none; }

.nir-toolbar a { display: block; line-height: 1; }

.nir-toolbar .toolbar-bar, .nir-toolbar .toolbar-tray { position: relative;=
 z-index: 1250; }

body.toolbar-fixed .toolbar-oriented, .toolbar-oriented .toolbar-bar, .tool=
bar-oriented .toolbar-tray { left: 0px; right: 0px; top: 0px; }

.toolbar-oriented .toolbar-bar { z-index: 502; }

body.toolbar-tray-open.toolbar-fixed.toolbar-vertical .toolbar-oriented { b=
ottom: 0px; width: 15rem; }

.nir-toolbar .toolbar-bar .toolbar-tab, .nir-toolbar .toolbar-tray-horizont=
al li { float: left; }

[dir=3D"rtl"] .nir-toolbar .toolbar-bar .toolbar-tab, [dir=3D"rtl"] .nir-to=
olbar .toolbar-tray-horizontal li { float: right; }

@media only screen {
  .nir-toolbar .toolbar-bar .toolbar-tab, .nir-toolbar .toolbar-tray-horizo=
ntal li { float: none; }
  [dir=3D"rtl"] .nir-toolbar .toolbar-bar .toolbar-tab, [dir=3D"rtl"] .nir-=
toolbar .toolbar-tray-horizontal li { float: none; }
}

@media (min-width: 16.5em) {
  .nir-toolbar .toolbar-bar .toolbar-tab, .nir-toolbar .toolbar-tray-horizo=
ntal li { float: left; }
  [dir=3D"rtl"] .nir-toolbar .toolbar-bar .toolbar-tab, [dir=3D"rtl"] .nir-=
toolbar .toolbar-tray-horizontal li { float: right; }
}

.toolbar-oriented .toolbar-bar .toolbar-tab, .toolbar-oriented .toolbar-tra=
y-horizontal li { float: left; }

[dir=3D"rtl"] .toolbar-oriented .toolbar-bar .toolbar-tab, [dir=3D"rtl"] .t=
oolbar-oriented .toolbar-tray-horizontal li { float: right; }

.nir-toolbar .toolbar-tray { display: none; z-index: 501; }

.toolbar-oriented .toolbar-tray-vertical { left: -100%; width: 15rem; }

[dir=3D"rtl"] .toolbar-oriented .toolbar-tray-vertical { left: auto; right:=
 -100%; }

.nir-toolbar .toolbar-tray-vertical > .toolbar-lining { min-height: 100%; }

.nir-toolbar .toolbar-tray-vertical > .toolbar-lining::before { width: 100%=
; }

.toolbar-oriented .toolbar-tray-vertical > .toolbar-lining::before { bottom=
: 0px; content: ""; display: block; left: 0px; position: fixed; top: 0px; w=
idth: 14rem; z-index: -1; }

[dir=3D"rtl"] .nir-toolbar .toolbar-tray-vertical > .toolbar-lining::before=
 { left: auto; right: 0px; }

.nir-toolbar .toolbar-bar .toolbar-tab > .toolbar-icon { position: relative=
; z-index: 502; }

.toolbar-oriented .toolbar-tray-horizontal .menu-item ul { display: none; }

body.toolbar-fixed .nir-toolbar .toolbar-tray-horizontal { position: fixed;=
 }

.nir-toolbar .toolbar-tray-vertical.is-active, body.toolbar-fixed .nir-tool=
bar .toolbar-tray-vertical { height: 100%; overflow: hidden auto; position:=
 fixed; }

.nir-toolbar .toolbar-tray.is-active { display: block; }

.toolbar-oriented .toolbar-tray-vertical.is-active { left: 0px; }

[dir=3D"rtl"] .toolbar-oriented .toolbar-tray-vertical.is-active { left: au=
to; right: 0px; }

body.toolbar-tray-open.toolbar-vertical.toolbar-fixed { margin-left: 15rem;=
 }

@media print {
  body.toolbar-tray-open.toolbar-vertical.toolbar-fixed { margin-left: 0px;=
 }
}

[dir=3D"rtl"] body.toolbar-tray-open.toolbar-vertical.toolbar-fixed { margi=
n-left: auto; margin-right: 15rem; }

@media print {
  [dir=3D"rtl"] body.toolbar-tray-open.toolbar-vertical.toolbar-fixed { mar=
gin-right: 0px; }
}

.nir-toolbar .toolbar-tray .toolbar-toggle-orientation { display: none; }

.toolbar-oriented .toolbar-tray .toolbar-toggle-orientation { display: bloc=
k; }

.toolbar-oriented .toolbar-tray-horizontal .toolbar-toggle-orientation { bo=
ttom: 0px; position: absolute; right: 0px; top: auto; }

[dir=3D"rtl"] .toolbar-oriented .toolbar-tray-horizontal .toolbar-toggle-or=
ientation { left: 0px; right: auto; }

.toolbar-oriented .toolbar-tray-vertical .toolbar-toggle-orientation { floa=
t: right; width: 100%; }

[dir=3D"rtl"] .toolbar-oriented .toolbar-tray-vertical .toolbar-toggle-orie=
ntation { float: left; }

#block-nasdaq-admin-primary-local-tasks { display: none; }

.nir-toolbar .toolbar-menu, [dir=3D"rtl"] .nir-toolbar .toolbar-menu { list=
-style: none; margin: 0px; padding: 0px; }

.nir-toolbar .toolbar-box { display: block; line-height: 1em; position: rel=
ative; width: auto; }

.nir-toolbar .toolbar-tray-horizontal .toolbar-menu .toolbar-handle, .nir-t=
oolbar .toolbar-tray-horizontal .toolbar-menu ul, .nir-toolbar .toolbar-tra=
y-vertical .toolbar-menu ul { display: none; }

.nir-toolbar .toolbar-tray-vertical li.open > ul { display: block; }

.nir-toolbar .toolbar-tray-vertical .toolbar-handle + a { margin-right: 3em=
; }

[dir=3D"rtl"] .nir-toolbar .toolbar-tray-vertical .toolbar-handle + a { mar=
gin-left: 3em; margin-right: 0px; }

.nir-toolbar .toolbar-tray .menu-item--active-trail > .toolbar-box a, .nir-=
toolbar .toolbar-tray a.is-active { color: rgb(0, 0, 0); font-weight: bold;=
 }

@media screen and (max-width: 319px) {
  .nir-toolbar .toolbar-tray-vertical.is-active { width: 100%; }
}

.nir-toolbar .level-2 > ul { background-color: rgb(250, 250, 250); border-b=
ottom-color: rgb(204, 204, 204); border-top-color: rgb(229, 229, 229); }

.nir-toolbar .level-3 > ul { background-color: rgb(245, 245, 245); border-b=
ottom-color: rgb(197, 197, 197); border-top-color: rgb(221, 221, 221); }

.nir-toolbar .level-4 > ul { background-color: rgb(238, 238, 238); border-b=
ottom-color: rgb(187, 187, 187); border-top-color: rgb(213, 213, 213); }

.nir-toolbar .level-5 > ul { background-color: rgb(229, 229, 229); border-b=
ottom-color: rgb(181, 181, 181); border-top-color: rgb(204, 204, 204); }

.nir-toolbar .level-6 > ul { background-color: rgb(238, 238, 238); border-b=
ottom-color: rgb(170, 170, 170); border-top-color: rgb(197, 197, 197); }

.nir-toolbar .level-7 > ul { background-color: rgb(250, 250, 250); border-b=
ottom-color: rgb(181, 181, 181); border-top-color: rgb(204, 204, 204); }

.nir-toolbar .level-8 > ul { background-color: rgb(221, 221, 221); border-b=
ottom-color: rgb(204, 204, 204); border-top-color: rgb(221, 221, 221); }

.nir-toolbar .toolbar-handle:hover { cursor: pointer; }

.nir-toolbar .toolbar-icon.toolbar-handle { bottom: 0px; display: block; he=
ight: 100%; padding: 0px; position: absolute; right: 0px; top: 0px; z-index=
: 1; }

[dir=3D"rtl"] .nir-toolbar .toolbar-icon.toolbar-handle { left: 0px; paddin=
g: 0px; right: auto; }

.ui-widget { font-family: Arial, Helvetica, sans-serif; font-size: 1em; }

.ui-widget .ui-widget { font-size: 1em; }

.ui-widget input, .ui-widget select, .ui-widget textarea, .ui-widget button=
 { font-family: Arial, Helvetica, sans-serif; font-size: 1em; }

.ui-widget.ui-widget-content { border: 1px solid rgb(197, 197, 197); }

.ui-widget-content { border: 1px solid rgb(221, 221, 221); background: rgb(=
255, 255, 255); color: rgb(51, 51, 51); }

.ui-widget-content a { color: rgb(51, 51, 51); }

.ui-widget-header { border: 1px solid rgb(221, 221, 221); background: rgb(2=
33, 233, 233); color: rgb(51, 51, 51); font-weight: bold; }

.ui-widget-header a { color: rgb(51, 51, 51); }

.ui-state-default, .ui-widget-content .ui-state-default, .ui-widget-header =
.ui-state-default, .ui-button, html .ui-button.ui-state-disabled:hover, htm=
l .ui-button.ui-state-disabled:active { border: 1px solid rgb(197, 197, 197=
); background: rgb(246, 246, 246); font-weight: normal; color: rgb(69, 69, =
69); }

.ui-state-default a, .ui-state-default a:link, .ui-state-default a:visited,=
 a.ui-button, a:link.ui-button, a:visited.ui-button, .ui-button { color: rg=
b(69, 69, 69); text-decoration: none; }

.ui-state-hover, .ui-widget-content .ui-state-hover, .ui-widget-header .ui-=
state-hover, .ui-state-focus, .ui-widget-content .ui-state-focus, .ui-widge=
t-header .ui-state-focus, .ui-button:hover, .ui-button:focus { border: 1px =
solid rgb(204, 204, 204); background: rgb(237, 237, 237); font-weight: norm=
al; color: rgb(43, 43, 43); }

.ui-state-hover a, .ui-state-hover a:hover, .ui-state-hover a:link, .ui-sta=
te-hover a:visited, .ui-state-focus a, .ui-state-focus a:hover, .ui-state-f=
ocus a:link, .ui-state-focus a:visited, a.ui-button:hover, a.ui-button:focu=
s { color: rgb(43, 43, 43); text-decoration: none; }

.ui-visual-focus { box-shadow: rgb(94, 158, 214) 0px 0px 3px 1px; }

.ui-state-active, .ui-widget-content .ui-state-active, .ui-widget-header .u=
i-state-active, a.ui-button:active, .ui-button:active, .ui-button.ui-state-=
active:hover { border: 1px solid rgb(0, 62, 255); background: rgb(0, 127, 2=
55); font-weight: normal; color: rgb(255, 255, 255); }

.ui-icon-background, .ui-state-active .ui-icon-background { border: rgb(0, =
62, 255); background-color: rgb(255, 255, 255); }

.ui-state-active a, .ui-state-active a:link, .ui-state-active a:visited { c=
olor: rgb(255, 255, 255); text-decoration: none; }

.ui-state-highlight, .ui-widget-content .ui-state-highlight, .ui-widget-hea=
der .ui-state-highlight { border: 1px solid rgb(218, 213, 94); background: =
rgb(255, 250, 144); color: rgb(119, 118, 32); }

.ui-state-checked { border: 1px solid rgb(218, 213, 94); background: rgb(25=
5, 250, 144); }

.ui-state-highlight a, .ui-widget-content .ui-state-highlight a, .ui-widget=
-header .ui-state-highlight a { color: rgb(119, 118, 32); }

.ui-state-error, .ui-widget-content .ui-state-error, .ui-widget-header .ui-=
state-error { border: 1px solid rgb(241, 168, 153); background: rgb(253, 22=
3, 223); color: rgb(95, 63, 63); }

.ui-state-error a, .ui-widget-content .ui-state-error a, .ui-widget-header =
.ui-state-error a { color: rgb(95, 63, 63); }

.ui-state-error-text, .ui-widget-content .ui-state-error-text, .ui-widget-h=
eader .ui-state-error-text { color: rgb(95, 63, 63); }

.ui-priority-primary, .ui-widget-content .ui-priority-primary, .ui-widget-h=
eader .ui-priority-primary { font-weight: bold; }

.ui-priority-secondary, .ui-widget-content .ui-priority-secondary, .ui-widg=
et-header .ui-priority-secondary { opacity: 0.7; font-weight: normal; }

.ui-state-disabled, .ui-widget-content .ui-state-disabled, .ui-widget-heade=
r .ui-state-disabled { opacity: 0.35; background-image: none; }

.ui-state-disabled .ui-icon { }

.ui-icon { width: 16px; height: 16px; }

.ui-icon, .ui-widget-content .ui-icon { background-image: url("/core/assets=
/vendor/jquery.ui/themes/base/images/ui-icons_444444_256x240.png"); }

.ui-widget-header .ui-icon { background-image: url("/core/assets/vendor/jqu=
ery.ui/themes/base/images/ui-icons_444444_256x240.png"); }

.ui-state-hover .ui-icon, .ui-state-focus .ui-icon, .ui-button:hover .ui-ic=
on, .ui-button:focus .ui-icon { background-image: url("/core/assets/vendor/=
jquery.ui/themes/base/images/ui-icons_555555_256x240.png"); }

.ui-state-active .ui-icon, .ui-button:active .ui-icon { background-image: u=
rl("/core/assets/vendor/jquery.ui/themes/base/images/ui-icons_ffffff_256x24=
0.png"); }

.ui-state-highlight .ui-icon, .ui-button .ui-state-highlight.ui-icon { back=
ground-image: url("/core/assets/vendor/jquery.ui/themes/base/images/ui-icon=
s_777620_256x240.png"); }

.ui-state-error .ui-icon, .ui-state-error-text .ui-icon { background-image:=
 url("/core/assets/vendor/jquery.ui/themes/base/images/ui-icons_cc0000_256x=
240.png"); }

.ui-button .ui-icon { background-image: url("/core/assets/vendor/jquery.ui/=
themes/base/images/ui-icons_777777_256x240.png"); }

.ui-icon-blank.ui-icon-blank.ui-icon-blank { background-image: none; }

.ui-icon-caret-1-n { background-position: 0px 0px; }

.ui-icon-caret-1-ne { background-position: -16px 0px; }

.ui-icon-caret-1-e { background-position: -32px 0px; }

.ui-icon-caret-1-se { background-position: -48px 0px; }

.ui-icon-caret-1-s { background-position: -65px 0px; }

.ui-icon-caret-1-sw { background-position: -80px 0px; }

.ui-icon-caret-1-w { background-position: -96px 0px; }

.ui-icon-caret-1-nw { background-position: -112px 0px; }

.ui-icon-caret-2-n-s { background-position: -128px 0px; }

.ui-icon-caret-2-e-w { background-position: -144px 0px; }

.ui-icon-triangle-1-n { background-position: 0px -16px; }

.ui-icon-triangle-1-ne { background-position: -16px -16px; }

.ui-icon-triangle-1-e { background-position: -32px -16px; }

.ui-icon-triangle-1-se { background-position: -48px -16px; }

.ui-icon-triangle-1-s { background-position: -65px -16px; }

.ui-icon-triangle-1-sw { background-position: -80px -16px; }

.ui-icon-triangle-1-w { background-position: -96px -16px; }

.ui-icon-triangle-1-nw { background-position: -112px -16px; }

.ui-icon-triangle-2-n-s { background-position: -128px -16px; }

.ui-icon-triangle-2-e-w { background-position: -144px -16px; }

.ui-icon-arrow-1-n { background-position: 0px -32px; }

.ui-icon-arrow-1-ne { background-position: -16px -32px; }

.ui-icon-arrow-1-e { background-position: -32px -32px; }

.ui-icon-arrow-1-se { background-position: -48px -32px; }

.ui-icon-arrow-1-s { background-position: -65px -32px; }

.ui-icon-arrow-1-sw { background-position: -80px -32px; }

.ui-icon-arrow-1-w { background-position: -96px -32px; }

.ui-icon-arrow-1-nw { background-position: -112px -32px; }

.ui-icon-arrow-2-n-s { background-position: -128px -32px; }

.ui-icon-arrow-2-ne-sw { background-position: -144px -32px; }

.ui-icon-arrow-2-e-w { background-position: -160px -32px; }

.ui-icon-arrow-2-se-nw { background-position: -176px -32px; }

.ui-icon-arrowstop-1-n { background-position: -192px -32px; }

.ui-icon-arrowstop-1-e { background-position: -208px -32px; }

.ui-icon-arrowstop-1-s { background-position: -224px -32px; }

.ui-icon-arrowstop-1-w { background-position: -240px -32px; }

.ui-icon-arrowthick-1-n { background-position: 1px -48px; }

.ui-icon-arrowthick-1-ne { background-position: -16px -48px; }

.ui-icon-arrowthick-1-e { background-position: -32px -48px; }

.ui-icon-arrowthick-1-se { background-position: -48px -48px; }

.ui-icon-arrowthick-1-s { background-position: -64px -48px; }

.ui-icon-arrowthick-1-sw { background-position: -80px -48px; }

.ui-icon-arrowthick-1-w { background-position: -96px -48px; }

.ui-icon-arrowthick-1-nw { background-position: -112px -48px; }

.ui-icon-arrowthick-2-n-s { background-position: -128px -48px; }

.ui-icon-arrowthick-2-ne-sw { background-position: -144px -48px; }

.ui-icon-arrowthick-2-e-w { background-position: -160px -48px; }

.ui-icon-arrowthick-2-se-nw { background-position: -176px -48px; }

.ui-icon-arrowthickstop-1-n { background-position: -192px -48px; }

.ui-icon-arrowthickstop-1-e { background-position: -208px -48px; }

.ui-icon-arrowthickstop-1-s { background-position: -224px -48px; }

.ui-icon-arrowthickstop-1-w { background-position: -240px -48px; }

.ui-icon-arrowreturnthick-1-w { background-position: 0px -64px; }

.ui-icon-arrowreturnthick-1-n { background-position: -16px -64px; }

.ui-icon-arrowreturnthick-1-e { background-position: -32px -64px; }

.ui-icon-arrowreturnthick-1-s { background-position: -48px -64px; }

.ui-icon-arrowreturn-1-w { background-position: -64px -64px; }

.ui-icon-arrowreturn-1-n { background-position: -80px -64px; }

.ui-icon-arrowreturn-1-e { background-position: -96px -64px; }

.ui-icon-arrowreturn-1-s { background-position: -112px -64px; }

.ui-icon-arrowrefresh-1-w { background-position: -128px -64px; }

.ui-icon-arrowrefresh-1-n { background-position: -144px -64px; }

.ui-icon-arrowrefresh-1-e { background-position: -160px -64px; }

.ui-icon-arrowrefresh-1-s { background-position: -176px -64px; }

.ui-icon-arrow-4 { background-position: 0px -80px; }

.ui-icon-arrow-4-diag { background-position: -16px -80px; }

.ui-icon-extlink { background-position: -32px -80px; }

.ui-icon-newwin { background-position: -48px -80px; }

.ui-icon-refresh { background-position: -64px -80px; }

.ui-icon-shuffle { background-position: -80px -80px; }

.ui-icon-transfer-e-w { background-position: -96px -80px; }

.ui-icon-transferthick-e-w { background-position: -112px -80px; }

.ui-icon-folder-collapsed { background-position: 0px -96px; }

.ui-icon-folder-open { background-position: -16px -96px; }

.ui-icon-document { background-position: -32px -96px; }

.ui-icon-document-b { background-position: -48px -96px; }

.ui-icon-note { background-position: -64px -96px; }

.ui-icon-mail-closed { background-position: -80px -96px; }

.ui-icon-mail-open { background-position: -96px -96px; }

.ui-icon-suitcase { background-position: -112px -96px; }

.ui-icon-comment { background-position: -128px -96px; }

.ui-icon-person { background-position: -144px -96px; }

.ui-icon-print { background-position: -160px -96px; }

.ui-icon-trash { background-position: -176px -96px; }

.ui-icon-locked { background-position: -192px -96px; }

.ui-icon-unlocked { background-position: -208px -96px; }

.ui-icon-bookmark { background-position: -224px -96px; }

.ui-icon-tag { background-position: -240px -96px; }

.ui-icon-home { background-position: 0px -112px; }

.ui-icon-flag { background-position: -16px -112px; }

.ui-icon-calendar { background-position: -32px -112px; }

.ui-icon-cart { background-position: -48px -112px; }

.ui-icon-pencil { background-position: -64px -112px; }

.ui-icon-clock { background-position: -80px -112px; }

.ui-icon-disk { background-position: -96px -112px; }

.ui-icon-calculator { background-position: -112px -112px; }

.ui-icon-zoomin { background-position: -128px -112px; }

.ui-icon-zoomout { background-position: -144px -112px; }

.ui-icon-search { background-position: -160px -112px; }

.ui-icon-wrench { background-position: -176px -112px; }

.ui-icon-gear { background-position: -192px -112px; }

.ui-icon-heart { background-position: -208px -112px; }

.ui-icon-star { background-position: -224px -112px; }

.ui-icon-link { background-position: -240px -112px; }

.ui-icon-cancel { background-position: 0px -128px; }

.ui-icon-plus { background-position: -16px -128px; }

.ui-icon-plusthick { background-position: -32px -128px; }

.ui-icon-minus { background-position: -48px -128px; }

.ui-icon-minusthick { background-position: -64px -128px; }

.ui-icon-close { background-position: -80px -128px; }

.ui-icon-closethick { background-position: -96px -128px; }

.ui-icon-key { background-position: -112px -128px; }

.ui-icon-lightbulb { background-position: -128px -128px; }

.ui-icon-scissors { background-position: -144px -128px; }

.ui-icon-clipboard { background-position: -160px -128px; }

.ui-icon-copy { background-position: -176px -128px; }

.ui-icon-contact { background-position: -192px -128px; }

.ui-icon-image { background-position: -208px -128px; }

.ui-icon-video { background-position: -224px -128px; }

.ui-icon-script { background-position: -240px -128px; }

.ui-icon-alert { background-position: 0px -144px; }

.ui-icon-info { background-position: -16px -144px; }

.ui-icon-notice { background-position: -32px -144px; }

.ui-icon-help { background-position: -48px -144px; }

.ui-icon-check { background-position: -64px -144px; }

.ui-icon-bullet { background-position: -80px -144px; }

.ui-icon-radio-on { background-position: -96px -144px; }

.ui-icon-radio-off { background-position: -112px -144px; }

.ui-icon-pin-w { background-position: -128px -144px; }

.ui-icon-pin-s { background-position: -144px -144px; }

.ui-icon-play { background-position: 0px -160px; }

.ui-icon-pause { background-position: -16px -160px; }

.ui-icon-seek-next { background-position: -32px -160px; }

.ui-icon-seek-prev { background-position: -48px -160px; }

.ui-icon-seek-end { background-position: -64px -160px; }

.ui-icon-seek-start { background-position: -80px -160px; }

.ui-icon-seek-first { background-position: -80px -160px; }

.ui-icon-stop { background-position: -96px -160px; }

.ui-icon-eject { background-position: -112px -160px; }

.ui-icon-volume-off { background-position: -128px -160px; }

.ui-icon-volume-on { background-position: -144px -160px; }

.ui-icon-power { background-position: 0px -176px; }

.ui-icon-signal-diag { background-position: -16px -176px; }

.ui-icon-signal { background-position: -32px -176px; }

.ui-icon-battery-0 { background-position: -48px -176px; }

.ui-icon-battery-1 { background-position: -64px -176px; }

.ui-icon-battery-2 { background-position: -80px -176px; }

.ui-icon-battery-3 { background-position: -96px -176px; }

.ui-icon-circle-plus { background-position: 0px -192px; }

.ui-icon-circle-minus { background-position: -16px -192px; }

.ui-icon-circle-close { background-position: -32px -192px; }

.ui-icon-circle-triangle-e { background-position: -48px -192px; }

.ui-icon-circle-triangle-s { background-position: -64px -192px; }

.ui-icon-circle-triangle-w { background-position: -80px -192px; }

.ui-icon-circle-triangle-n { background-position: -96px -192px; }

.ui-icon-circle-arrow-e { background-position: -112px -192px; }

.ui-icon-circle-arrow-s { background-position: -128px -192px; }

.ui-icon-circle-arrow-w { background-position: -144px -192px; }

.ui-icon-circle-arrow-n { background-position: -160px -192px; }

.ui-icon-circle-zoomin { background-position: -176px -192px; }

.ui-icon-circle-zoomout { background-position: -192px -192px; }

.ui-icon-circle-check { background-position: -208px -192px; }

.ui-icon-circlesmall-plus { background-position: 0px -208px; }

.ui-icon-circlesmall-minus { background-position: -16px -208px; }

.ui-icon-circlesmall-close { background-position: -32px -208px; }

.ui-icon-squaresmall-plus { background-position: -48px -208px; }

.ui-icon-squaresmall-minus { background-position: -64px -208px; }

.ui-icon-squaresmall-close { background-position: -80px -208px; }

.ui-icon-grip-dotted-vertical { background-position: 0px -224px; }

.ui-icon-grip-dotted-horizontal { background-position: -16px -224px; }

.ui-icon-grip-solid-vertical { background-position: -32px -224px; }

.ui-icon-grip-solid-horizontal { background-position: -48px -224px; }

.ui-icon-gripsmall-diagonal-se { background-position: -64px -224px; }

.ui-icon-grip-diagonal-se { background-position: -80px -224px; }

.ui-corner-all, .ui-corner-top, .ui-corner-left, .ui-corner-tl { border-top=
-left-radius: 3px; }

.ui-corner-all, .ui-corner-top, .ui-corner-right, .ui-corner-tr { border-to=
p-right-radius: 3px; }

.ui-corner-all, .ui-corner-bottom, .ui-corner-left, .ui-corner-bl { border-=
bottom-left-radius: 3px; }

.ui-corner-all, .ui-corner-bottom, .ui-corner-right, .ui-corner-br { border=
-bottom-right-radius: 3px; }

.ui-widget-overlay { background: rgb(170, 170, 170); opacity: 0.3; }

.ui-widget-shadow { box-shadow: rgb(102, 102, 102) 0px 0px 5px; }

.nir-mean-recommendation-chart .rating .scale { border-bottom: 1px solid bl=
ack; height: 1px; float: left; width: 80%; margin-left: 10%; }

.nir-mean-recommendation-chart .rating { margin-top: 10px; }

.nir-mean-recommendation-chart .rating .scale .rating-box { float: left; wi=
dth: 25%; height: 11px; margin-top: -5px; border-left: 1px solid black; }

.nir-mean-recommendation-chart .rating .scale .rating-box.last { border-rig=
ht: 1px solid black; }

.nir-mean-recommendation-chart .rating .scale-labels { float: left; width: =
100%; margin-top: 10px; }

.nir-mean-recommendation-chart .rating .scale-labels .rating-box { float: l=
eft; width: 20%; text-align: center; }

.nir-mean-recommendation-chart .wrapper-arrow .rating-arrow-box { backgroun=
d: black; color: white; border-radius: 6px; padding: 1.5px 6px; text-align:=
 center; }

.nir-mean-recommendation-chart .wrapper-arrow .rating-arrow { border-width:=
 7px; border-style: solid; border-color: black transparent transparent; bor=
der-image: initial; }

.nir-mean-recommendation-chart .wrapper-arrow { float: left; margin-left: 3=
0%; transform: translateX(calc(-50% + 0.5px)); position: relative; display:=
 flex; flex-direction: column; align-items: center; }

.lfg-screen-reader-only { border: 0px !important; clip: rect(1px, 1px, 1px,=
 1px) !important; clip-path: inset(50%) !important; height: 1px !important;=
 margin: -1px !important; overflow: hidden !important; padding: 0px !import=
ant; position: absolute !important; width: 1px !important; white-space: now=
rap !important; }

.lfg-screen-reader-only-focusable:focus, .lfg-screen-reader-only-focusable:=
active { clip: auto !important; clip-path: none !important; height: auto !i=
mportant; margin: auto !important; overflow: visible !important; width: aut=
o !important; white-space: normal !important; }

table.nirtable.analyst-ratings-table caption { background-color: transparen=
t; color: inherit; border-bottom: none; font-size: 1em; margin-top: 0px; cl=
ear: both; }

table.nirtable.estimates-analyst-forecasts caption { display: table-caption=
; }

.nir-toolbar { font-family: "Source Sans Pro", "Lucida Grande", Verdana, sa=
ns-serif; font-size: 0.8125rem; -webkit-tap-highlight-color: rgba(0, 0, 0, =
0); }

.nir-toolbar .toolbar-item { cursor: pointer; padding: 1em 1.3333em; line-h=
eight: 1em; text-decoration: none; }

.nir-toolbar .toolbar-item:hover, .nir-toolbar .toolbar-item:focus { text-d=
ecoration: underline; }

.nir-toolbar .toolbar-bar { background-color: rgb(15, 15, 15); box-shadow: =
rgba(0, 0, 0, 0.333) -1px 0px 3px 1px; color: rgb(221, 221, 221); }

[dir=3D"rtl"] .nir-toolbar .toolbar-bar { box-shadow: rgba(0, 0, 0, 0.333) =
1px 0px 3px 1px; }

.nir-toolbar .toolbar-bar .toolbar-item { color: rgb(255, 255, 255); }

.nir-toolbar .toolbar-bar .nir-toolbar-tab > .toolbar-item { font-weight: b=
old; }

.nir-toolbar .toolbar-bar .nir-toolbar-tab > .toolbar-item:hover, .nir-tool=
bar .toolbar-bar .nir-toolbar-tab > .toolbar-item:focus { background-image:=
 linear-gradient(rgba(255, 255, 255, 0.125) 20%, transparent 200%); }

.nir-toolbar .toolbar-bar .nir-toolbar-tab > .toolbar-item.is-active { back=
ground-image: linear-gradient(rgba(255, 255, 255, 0.25) 20%, transparent 20=
0%); }

.nir-toolbar .toolbar-tray { background-color: rgb(255, 255, 255); }

.nir-toolbar .toolbar-tray-horizontal > .toolbar-lining { padding-right: 5e=
m; }

[dir=3D"rtl"] .nir-toolbar .toolbar-tray-horizontal > .toolbar-lining { pad=
ding-right: 0px; padding-left: 5em; }

.nir-toolbar .toolbar-tray-vertical { background-color: rgb(245, 245, 245);=
 border-right: 1px solid rgb(170, 170, 170); box-shadow: rgba(0, 0, 0, 0.33=
3) -1px 0px 5px 2px; }

[dir=3D"rtl"] .nir-toolbar .toolbar-tray-vertical { border-left: 1px solid =
rgb(170, 170, 170); border-right: 0px none; box-shadow: rgba(0, 0, 0, 0.333=
) 1px 0px 5px 2px; }

.nir-toolbar .toolbar-tray-horizontal { border-bottom: 1px solid rgb(170, 1=
70, 170); box-shadow: rgba(0, 0, 0, 0.333) -2px 1px 3px 1px; }

[dir=3D"rtl"] .nir-toolbar .toolbar-tray-horizontal { box-shadow: rgba(0, 0=
, 0, 0.333) 2px 1px 3px 1px; }

.nir-toolbar .toolbar-tray-horizontal .toolbar-tray { background-color: rgb=
(245, 245, 245); }

.toolbar-tray a { color: rgb(86, 86, 86); cursor: pointer; padding: 1em 1.3=
333em; text-decoration: none; }

.toolbar-tray a:hover, .toolbar-tray a:active, .toolbar-tray a:focus, .tool=
bar-tray a.is-active { color: rgb(0, 0, 0); text-decoration: underline; }

.nir-toolbar .toolbar-menu { background-color: rgb(255, 255, 255); }

.nir-toolbar .toolbar-tray-horizontal .menu-item + .menu-item { border-left=
: 1px solid rgb(221, 221, 221); }

[dir=3D"rtl"] .nir-toolbar .toolbar-tray-horizontal .menu-item + .menu-item=
 { border-left: 0px none; border-right: 1px solid rgb(221, 221, 221); }

.nir-toolbar .toolbar-tray-horizontal .menu-item:last-child { border-right:=
 1px solid rgb(221, 221, 221); }

[dir=3D"rtl"] .nir-toolbar .toolbar-tray-horizontal .menu-item:last-child {=
 border-left: 1px solid rgb(221, 221, 221); }

.nir-toolbar .toolbar-tray-vertical .menu-item + .menu-item { border-top: 1=
px solid rgb(221, 221, 221); }

.nir-toolbar .toolbar-tray-vertical .menu-item:last-child { border-bottom: =
1px solid rgb(221, 221, 221); }

.nir-toolbar .toolbar-tray-vertical .menu-item .menu-item { border: 0px non=
e; }

.nir-toolbar .toolbar-tray-vertical .toolbar-menu ul ul { border-bottom: 1p=
x solid rgb(221, 221, 221); border-top: 1px solid rgb(221, 221, 221); }

.nir-toolbar .toolbar-tray-vertical .menu-item:last-child > ul { border-bot=
tom: 0px; }

.nir-toolbar .toolbar-tray-vertical .toolbar-menu .toolbar-menu .toolbar-me=
nu .toolbar-menu { margin-left: 0.25em; }

[dir=3D"rtl"] .nir-toolbar .toolbar-tray-vertical .toolbar-menu .toolbar-me=
nu .toolbar-menu .toolbar-menu { margin-left: 0px; margin-right: 0.25em; }

.nir-toolbar .toolbar-menu .toolbar-menu a { color: rgb(67, 67, 67); }

.nir-toolbar .toolbar-toggle-orientation { background-color: rgb(245, 245, =
245); padding: 0px; height: 100%; }

.nir-toolbar .toolbar-tray-horizontal .toolbar-toggle-orientation { border-=
left: 1px solid rgb(201, 201, 201); }

[dir=3D"rtl"] .nir-toolbar .toolbar-tray-horizontal .toolbar-toggle-orienta=
tion { border-left: 0px none; border-right: 1px solid rgb(201, 201, 201); }

.nir-toolbar .toolbar-toggle-orientation > .toolbar-lining { float: right; =
}

[dir=3D"rtl"] .nir-toolbar .toolbar-toggle-orientation > .toolbar-lining { =
float: left; }

.nir-toolbar .toolbar-toggle-orientation button { cursor: pointer; display:=
 inline-block; }

.nir-toolbar .toolbar-icon { padding-left: 2.75em; position: relative; }

[dir=3D"rtl"] .nir-toolbar .toolbar-icon { padding-left: 1.3333em; padding-=
right: 2.75em; }

.nir-toolbar .toolbar-icon::before { background-attachment: scroll; backgro=
und-color: transparent; background-position: center center; background-repe=
at: no-repeat; background-size: 100%; content: ""; display: block; height: =
100%; left: 0.6667em; position: absolute; top: 0px; width: 20px; }

[dir=3D"rtl"] .nir-toolbar .toolbar-icon::before { left: auto; right: 0.666=
7em; }

.nir-toolbar button.toolbar-icon { background-color: transparent; border: 0=
px; font-size: 1em; }

.nir-toolbar .toolbar-menu ul .toolbar-icon { padding-left: 1.3333em; }

[dir=3D"rtl"] .nir-toolbar .toolbar-menu ul .toolbar-icon { padding-left: 0=
px; padding-right: 1.3333em; }

.nir-toolbar .toolbar-menu ul a.toolbar-icon::before { display: none; }

.nir-toolbar .toolbar-tray-vertical .toolbar-menu ul a { padding-left: 2.75=
em; }

[dir=3D"rtl"] .nir-toolbar .toolbar-tray-vertical .toolbar-menu ul a { padd=
ing-left: 0px; padding-right: 2.75em; }

.nir-toolbar .toolbar-tray-vertical .toolbar-menu ul ul a { padding-left: 3=
.75em; }

[dir=3D"rtl"] .nir-toolbar .toolbar-tray-vertical .toolbar-menu ul ul a { p=
adding-left: 0px; padding-right: 3.75em; }

.nir-toolbar .toolbar-tray-vertical .toolbar-menu a { padding-left: 2.75em;=
 padding-right: 4em; }

[dir=3D"rtl"] .nir-toolbar .toolbar-tray-vertical .toolbar-menu a { padding=
-left: 4em; padding-right: 2.75em; }

.toolbar-bar .toolbar-icon-menu::before { background-image: url("/core/misc=
/icons/bebebe/hamburger.svg"); }

.toolbar-bar .toolbar-icon-menu:active::before, .toolbar-bar .toolbar-icon-=
menu.is-active::before { background-image: url("/core/misc/icons/ffffff/ham=
burger.svg"); }

.toolbar-bar .toolbar-icon-help::before { background-image: url("/core/misc=
/icons/bebebe/questionmark-disc.svg"); }

.toolbar-bar .toolbar-icon-help:active::before, .toolbar-bar .toolbar-icon-=
help.is-active::before { background-image: url("/core/misc/icons/ffffff/que=
stionmark-disc.svg"); }

.toolbar-icon-system-admin-content::before { background-image: url("/core/m=
isc/icons/787878/file.svg"); }

.toolbar-icon-system-admin-content:active::before, .toolbar-icon-system-adm=
in-content.is-active::before { background-image: url("/core/misc/icons/0000=
00/file.svg"); }

.toolbar-icon-system-admin-structure::before { background-image: url("/core=
/misc/icons/787878/orgchart.svg"); }

.toolbar-icon-system-admin-structure:active::before, .toolbar-icon-system-a=
dmin-structure.is-active::before { background-image: url("/core/misc/icons/=
000000/orgchart.svg"); }

.toolbar-icon-system-themes-page::before { background-image: url("/core/mis=
c/icons/787878/paintbrush.svg"); }

.toolbar-icon-system-themes-page:active::before, .toolbar-icon-system-theme=
s-page.is-active::before { background-image: url("/core/misc/icons/000000/p=
aintbrush.svg"); }

.toolbar-icon-entity-user-collection::before { background-image: url("/core=
/misc/icons/787878/people.svg"); }

.toolbar-icon-entity-user-collection:active::before, .toolbar-icon-entity-u=
ser-collection.is-active::before { background-image: url("/core/misc/icons/=
000000/people.svg"); }

.toolbar-icon-system-modules-list::before { background-image: url("/core/mi=
sc/icons/787878/puzzlepiece.svg"); }

.toolbar-icon-system-modules-list:active::before, .toolbar-icon-system-modu=
les-list.is-active::before { background-image: url("/core/misc/icons/000000=
/puzzlepiece.svg"); }

.toolbar-icon-system-admin-config::before { background-image: url("/core/mi=
sc/icons/787878/wrench.svg"); }

.toolbar-icon-system-admin-config:active::before, .toolbar-icon-system-admi=
n-config.is-active::before { background-image: url("/core/misc/icons/000000=
/wrench.svg"); }

.toolbar-icon-system-admin-reports::before { background-image: url("/core/m=
isc/icons/787878/barchart.svg"); }

.toolbar-icon-system-admin-reports:active::before, .toolbar-icon-system-adm=
in-reports.is-active::before { background-image: url("/core/misc/icons/0000=
00/barchart.svg"); }

.toolbar-icon-help-main::before { background-image: url("/core/misc/icons/7=
87878/questionmark-disc.svg"); }

.toolbar-icon-help-main:active::before, .toolbar-icon-help-main.is-active::=
before { background-image: url("/core/misc/icons/000000/questionmark-disc.s=
vg"); }

@media only screen and (min-width: 16.5em) {
  .nir-toolbar .toolbar-bar .toolbar-tab > .toolbar-icon { margin-left: 0px=
; margin-right: 0px; padding-left: 0px; padding-right: 0px; text-indent: -9=
999px; width: 4em; }
  .nir-toolbar .toolbar-bar .toolbar-tab > .toolbar-icon::before { backgrou=
nd-size: 42%; left: 0px; width: 100%; }
  .no-svg .nir-toolbar .toolbar-bar .toolbar-tab > .toolbar-icon::before { =
background-size: auto; }
  [dir=3D"rtl"] .nir-toolbar .toolbar-bar .toolbar-tab > .toolbar-icon::bef=
ore { left: auto; right: 0px; }
}

@media only screen and (min-width: 36em) {
  .nir-toolbar .toolbar-bar .toolbar-tab > .toolbar-icon { background-posit=
ion: left center; padding-left: 2.75em; padding-right: 1.3333em; text-inden=
t: 0px; width: auto; }
  [dir=3D"rtl"] .nir-toolbar .toolbar-bar .toolbar-tab > .toolbar-icon { ba=
ckground-position: right center; padding-left: 1.3333em; padding-right: 2.7=
5em; }
  .nir-toolbar .toolbar-bar .toolbar-tab > .toolbar-icon::before { backgrou=
nd-size: 100%; left: 0.6667em; width: 20px; }
  .no-svg .nir-toolbar .toolbar-bar .toolbar-tab > .toolbar-icon::before { =
background-size: auto; }
  [dir=3D"rtl"] .nir-toolbar .toolbar-bar .toolbar-tab > .toolbar-icon::bef=
ore { left: 0px; right: 0.6667em; }
}

.toolbar-tab a:focus { outline: none; text-decoration: underline; }

.toolbar-lining button:focus { outline: none; }

.toolbar-tray-horizontal a:focus, .toolbar-box a:focus { outline: none; bac=
kground-color: rgb(245, 245, 245); }

.toolbar-box a:hover:focus { text-decoration: underline; }

.nir-toolbar .toolbar-icon.toolbar-handle:focus { outline: none; background=
-color: rgb(245, 245, 245); }

.nir-toolbar .toolbar-icon.toolbar-handle { width: 4em; text-indent: -9999p=
x; }

.nir-toolbar .toolbar-icon.toolbar-handle::before { left: 1.6667em; }

[dir=3D"rtl"] .nir-toolbar .toolbar-icon.toolbar-handle::before { left: aut=
o; right: 1.6667em; }

.nir-toolbar .toolbar-icon.toolbar-handle::before { background-image: url("=
/core/misc/icons/5181c6/chevron-disc-down.svg"); }

.nir-toolbar .toolbar-icon.toolbar-handle.open::before { background-image: =
url("/core/misc/icons/787878/chevron-disc-up.svg"); }

.nir-toolbar .toolbar-menu .toolbar-menu .toolbar-icon.toolbar-handle::befo=
re { background-image: url("/core/misc/icons/5181c6/twistie-down.svg"); bac=
kground-size: 75%; }

.nir-toolbar .toolbar-menu .toolbar-menu .toolbar-icon.toolbar-handle.open:=
:before { background-image: url("/core/misc/icons/787878/twistie-up.svg"); =
background-size: 75%; }

.nir-toolbar .toolbar-icon-escape-admin::before { background-image: url("/c=
ore/misc/icons/bebebe/chevron-disc-left.svg"); }

[dir=3D"rtl"] .nir-toolbar .toolbar-icon-escape-admin::before { background-=
image: url("/core/misc/icons/bebebe/chevron-disc-right.svg"); }

.nir-toolbar .toolbar-toggle-orientation button { height: 39px; padding: 0p=
x; text-indent: -999em; width: 39px; }

.nir-toolbar .toolbar-toggle-orientation button::before { left: 0px; right:=
 0px; margin: 0px auto; }

[dir=3D"rtl"] .nir-toolbar .toolbar-toggle-orientation .toolbar-icon { padd=
ing: 0px; }

.nir-toolbar .toolbar-toggle-orientation [value=3D"vertical"]::before { bac=
kground-image: url("/core/misc/icons/bebebe/push-left.svg"); }

.nir-toolbar .toolbar-toggle-orientation [value=3D"vertical"]:hover::before=
, .nir-toolbar .toolbar-toggle-orientation [value=3D"vertical"]:focus::befo=
re { background-image: url("/core/misc/icons/787878/push-left.svg"); }

[dir=3D"rtl"] .nir-toolbar .toolbar-toggle-orientation [value=3D"vertical"]=
::before { background-image: url("/core/misc/icons/bebebe/push-right.svg");=
 }

[dir=3D"rtl"] .nir-toolbar .toolbar-toggle-orientation [value=3D"vertical"]=
:hover::before, [dir=3D"rtl"] .nir-toolbar .toolbar-toggle-orientation [val=
ue=3D"vertical"]:focus::before { background-image: url("/core/misc/icons/78=
7878/push-right.svg"); }

.nir-toolbar .toolbar-toggle-orientation [value=3D"horizontal"]::before { b=
ackground-image: url("/core/misc/icons/bebebe/push-up.svg"); }

.nir-toolbar .toolbar-toggle-orientation [value=3D"horizontal"]:hover::befo=
re, .nir-toolbar .toolbar-toggle-orientation [value=3D"horizontal"]:focus::=
before { background-image: url("/core/misc/icons/787878/push-up.svg"); }
------MultipartBoundary--OyEh8n7b4Lw6tzistt7cxFCRw1zMtvVQlXOUlVtdJx----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: cid:css-9e6a5f14-919f-423f-a6e5-8c6c4e9316bf@mhtml.blink

@charset "utf-8";

.ck.ck-datatables-form { padding: var(--ck-spacing-large); display: grid; g=
rid-template-columns: repeat(2, 1fr); grid-template-rows: repeat(3, 1fr); c=
olumn-gap: 0px; row-gap: var(--ck-spacing-standard); }

.ck.ck-datatables-form .ck.ck-labeled-field-view:nth-of-type(1) { grid-area=
: 1 / 1 / 2 / 3; }

.ck.ck-datatables-form .ck.ck-labeled-field-view:nth-of-type(2) { grid-area=
: 2 / 1 / 3 / 3; }

.ck.ck-datatables-form .ck.ck-labeled-field-view:nth-of-type(3) { grid-area=
: 3 / 1 / 4 / 3; }

.ck.ck-datatables-form .ck.ck-labeled-field-view:nth-of-type(4) { grid-area=
: 4 / 1 / 5 / 3; }

.ck.ck-datatables-form .ck.ck-labeled-field-view:nth-of-type(5) { grid-area=
: 5 / 1 / 6 / 3; }

.ck.ck-datatables-form .ck.ck-switchbutton:nth-of-type(1) { grid-area: 6 / =
1 / 7 / 3; }

.ck.ck-datatables-form .ck.ck-dropdown { grid-area: 7 / 1 / 8 / 3; }

.ck.ck-datatables-form .ck.ck-labeled-field-view:nth-of-type(6) { grid-area=
: 8 / 1 / 9 / 3; }

.ck.ck-datatables-form .ck-button:nth-of-type(2) { grid-area: 9 / 1 / 10 / =
2; }

.ck.ck-datatables-form .ck-button:nth-of-type(3) { grid-area: 9 / 2 / 10 / =
3; }
------MultipartBoundary--OyEh8n7b4Lw6tzistt7cxFCRw1zMtvVQlXOUlVtdJx----
Content-Type: text/css
Content-Transfer-Encoding: quoted-printable
Content-Location: cid:css-7144c8f9-7436-42a7-8f90-d2c6afc77f4b@mhtml.blink

@charset "utf-8";

.ck .ck-placeholder, .ck.ck-placeholder { position: relative; }

.ck .ck-placeholder::before, .ck.ck-placeholder::before { content: attr(dat=
a-placeholder); left: 0px; pointer-events: none; position: absolute; right:=
 0px; }

.ck.ck-read-only .ck-placeholder::before { display: none; }

.ck.ck-reset_all .ck-placeholder { position: relative; }

.ck .ck-placeholder::before, .ck.ck-placeholder::before { color: var(--ck-c=
olor-engine-placeholder-text); cursor: text; }

.ck.ck-editor__editable span[data-ck-unsafe-element] { display: none; }

.ck-hidden { display: none !important; }

.ck-reset_all :not(.ck-reset_all-excluded *), .ck.ck-reset, .ck.ck-reset_al=
l { box-sizing: border-box; height: auto; position: static; width: auto; }

:root { --ck-z-default: 1; --ck-z-panel: calc(var(--ck-z-default) + 999); -=
-ck-z-dialog: 9999; }

.ck-transitions-disabled, .ck-transitions-disabled * { transition: none !im=
portant; }

:root { --ck-powered-by-line-height: 10px; --ck-powered-by-padding-vertical=
: 2px; --ck-powered-by-padding-horizontal: 4px; --ck-powered-by-text-color:=
 #4f4f4f; --ck-powered-by-border-radius: var(--ck-border-radius); --ck-powe=
red-by-background: #fff; --ck-powered-by-border-color: var(--ck-color-focus=
-border); }

.ck.ck-balloon-panel.ck-powered-by-balloon { --ck-border-radius: var(--ck-p=
owered-by-border-radius); background: var(--ck-powered-by-background); box-=
shadow: none; min-height: unset; z-index: calc(var(--ck-z-panel) - 1); }

.ck.ck-balloon-panel.ck-powered-by-balloon .ck.ck-powered-by { line-height:=
 var(--ck-powered-by-line-height); }

.ck.ck-balloon-panel.ck-powered-by-balloon .ck.ck-powered-by a { align-item=
s: center; cursor: pointer; display: flex; filter: grayscale(80%); line-hei=
ght: var(--ck-powered-by-line-height); opacity: 0.66; padding: var(--ck-pow=
ered-by-padding-vertical) var(--ck-powered-by-padding-horizontal); }

.ck.ck-balloon-panel.ck-powered-by-balloon .ck.ck-powered-by .ck-powered-by=
__label { color: var(--ck-powered-by-text-color); cursor: pointer; font-siz=
e: 7.5px; font-weight: 700; letter-spacing: -0.2px; line-height: normal; ma=
rgin-right: 4px; padding-left: 2px; text-transform: uppercase; }

.ck.ck-balloon-panel.ck-powered-by-balloon .ck.ck-powered-by .ck-icon { cur=
sor: pointer; display: block; }

.ck.ck-balloon-panel.ck-powered-by-balloon .ck.ck-powered-by:hover a { filt=
er: grayscale(0); opacity: 1; }

.ck.ck-balloon-panel.ck-powered-by-balloon[class*=3D"position_inside"] { bo=
rder-color: transparent; }

.ck.ck-balloon-panel.ck-powered-by-balloon[class*=3D"position_border"] { bo=
rder-top-style: ; border-top-width: ; border-right-style: ; border-right-wi=
dth: ; border-bottom-style: ; border-bottom-width: ; border-left-style: ; b=
order-left-width: ; border-image-source: ; border-image-slice: ; border-ima=
ge-width: ; border-image-outset: ; border-image-repeat: ; border-color: var=
(--ck-powered-by-border-color); }

:root { --ck-color-base-foreground: #fafafa; --ck-color-base-background: #f=
ff; --ck-color-base-border: #ccced1; --ck-color-base-action: #53a336; --ck-=
color-base-focus: #6cb5f9; --ck-color-base-text: #333; --ck-color-base-acti=
ve: #2977ff; --ck-color-base-active-focus: #0d65ff; --ck-color-base-error: =
#db3700; --ck-color-focus-border-coordinates: 218,81.8%,56.9%; --ck-color-f=
ocus-border: hsl(var(--ck-color-focus-border-coordinates)); --ck-color-focu=
s-outer-shadow: #cae1fc; --ck-color-focus-disabled-shadow: rgba(119,186,248=
,.3); --ck-color-focus-error-shadow: rgba(255,64,31,.3); --ck-color-text: v=
ar(--ck-color-base-text); --ck-color-shadow-drop: rgba(0,0,0,.15); --ck-col=
or-shadow-drop-active: rgba(0,0,0,.2); --ck-color-shadow-inner: rgba(0,0,0,=
.1); --ck-color-button-default-background: transparent; --ck-color-button-d=
efault-hover-background: #f0f0f0; --ck-color-button-default-active-backgrou=
nd: #f0f0f0; --ck-color-button-default-disabled-background: transparent; --=
ck-color-button-on-background: #f0f7ff; --ck-color-button-on-hover-backgrou=
nd: #dbecff; --ck-color-button-on-active-background: #dbecff; --ck-color-bu=
tton-on-disabled-background: #f0f2f4; --ck-color-button-on-color: #2977ff; =
--ck-color-button-action-background: var(--ck-color-base-action); --ck-colo=
r-button-action-hover-background: #4d9d30; --ck-color-button-action-active-=
background: #4d9d30; --ck-color-button-action-disabled-background: #7ec365;=
 --ck-color-button-action-text: var(--ck-color-base-background); --ck-color=
-button-save: #008a00; --ck-color-button-cancel: #db3700; --ck-color-switch=
-button-off-background: #939393; --ck-color-switch-button-off-hover-backgro=
und: #7d7d7d; --ck-color-switch-button-on-background: var(--ck-color-button=
-action-background); --ck-color-switch-button-on-hover-background: #4d9d30;=
 --ck-color-switch-button-inner-background: var(--ck-color-base-background)=
; --ck-color-switch-button-inner-shadow: rgba(0,0,0,.1); --ck-color-dropdow=
n-panel-background: var(--ck-color-base-background); --ck-color-dropdown-pa=
nel-border: var(--ck-color-base-border); --ck-color-dialog-background: var(=
--ck-custom-background); --ck-color-dialog-form-header-border: var(--ck-cus=
tom-border); --ck-color-input-background: var(--ck-color-base-background); =
--ck-color-input-border: var(--ck-color-base-border); --ck-color-input-erro=
r-border: var(--ck-color-base-error); --ck-color-input-text: var(--ck-color=
-base-text); --ck-color-input-disabled-background: #f2f2f2; --ck-color-inpu=
t-disabled-border: var(--ck-color-base-border); --ck-color-input-disabled-t=
ext: #757575; --ck-color-list-background: var(--ck-color-base-background); =
--ck-color-list-button-hover-background: var(--ck-color-button-default-hove=
r-background); --ck-color-list-button-on-background: var(--ck-color-button-=
on-color); --ck-color-list-button-on-background-focus: var(--ck-color-butto=
n-on-color); --ck-color-list-button-on-text: var(--ck-color-base-background=
); --ck-color-panel-background: var(--ck-color-base-background); --ck-color=
-panel-border: var(--ck-color-base-border); --ck-color-toolbar-background: =
var(--ck-color-base-background); --ck-color-toolbar-border: var(--ck-color-=
base-border); --ck-color-tooltip-background: var(--ck-color-base-text); --c=
k-color-tooltip-text: var(--ck-color-base-background); --ck-color-engine-pl=
aceholder-text: #707070; --ck-color-upload-bar-background: #6cb5f9; --ck-co=
lor-link-default: #0000f0; --ck-color-link-selected-background: rgba(31,176=
,255,.1); --ck-color-link-fake-selection: rgba(31,176,255,.3); --ck-color-h=
ighlight-background: #ff0; --ck-color-light-red: #fcc; --ck-disabled-opacit=
y: .5; --ck-focus-outer-shadow-geometry: 0 0 0 3px; --ck-focus-outer-shadow=
: var(--ck-focus-outer-shadow-geometry) var(--ck-color-focus-outer-shadow);=
 --ck-focus-disabled-outer-shadow: var(--ck-focus-outer-shadow-geometry) va=
r(--ck-color-focus-disabled-shadow); --ck-focus-error-outer-shadow: var(--c=
k-focus-outer-shadow-geometry) var(--ck-color-focus-error-shadow); --ck-foc=
us-ring: 1px solid var(--ck-color-focus-border); --ck-font-size-base: 13px;=
 --ck-line-height-base: 1.84615; --ck-font-face: Helvetica,Arial,Tahoma,Ver=
dana,Sans-Serif; --ck-font-size-tiny: 0.7em; --ck-font-size-small: 0.75em; =
--ck-font-size-normal: 1em; --ck-font-size-big: 1.4em; --ck-font-size-large=
: 1.8em; --ck-ui-component-min-height: 2.3em; }

.ck-reset_all :not(.ck-reset_all-excluded *), .ck.ck-reset, .ck.ck-reset_al=
l { overflow-wrap: break-word; background: transparent; border: 0px; margin=
: 0px; padding: 0px; text-decoration: none; transition: none; vertical-alig=
n: middle; }

.ck-reset_all :not(.ck-reset_all-excluded *), .ck.ck-reset_all { border-col=
lapse: collapse; color: var(--ck-color-text); cursor: auto; float: none; fo=
nt: normal normal normal var(--ck-font-size-base)/var(--ck-line-height-base=
) var(--ck-font-face); text-align: left; white-space: nowrap; }

.ck-reset_all .ck-rtl :not(.ck-reset_all-excluded *) { text-align: right; }

.ck-reset_all iframe:not(.ck-reset_all-excluded *) { vertical-align: inheri=
t; }

.ck-reset_all textarea:not(.ck-reset_all-excluded *) { white-space: pre-wra=
p; }

.ck-reset_all input[type=3D"password"]:not(.ck-reset_all-excluded *), .ck-r=
eset_all input[type=3D"text"]:not(.ck-reset_all-excluded *), .ck-reset_all =
textarea:not(.ck-reset_all-excluded *) { cursor: text; }

.ck-reset_all input[type=3D"password"][disabled]:not(.ck-reset_all-excluded=
 *), .ck-reset_all input[type=3D"text"][disabled]:not(.ck-reset_all-exclude=
d *), .ck-reset_all textarea[disabled]:not(.ck-reset_all-excluded *) { curs=
or: default; }

.ck-reset_all fieldset:not(.ck-reset_all-excluded *) { border: 2px groove r=
gb(223, 222, 227); padding: 10px; }

.ck[dir=3D"rtl"], .ck[dir=3D"rtl"] .ck { text-align: right; }

:root { --ck-border-radius: 2px; --ck-inner-shadow: 2px 2px 3px var(--ck-co=
lor-shadow-inner) inset; --ck-drop-shadow: 0 1px 2px 1px var(--ck-color-sha=
dow-drop); --ck-drop-shadow-active: 0 3px 6px 1px var(--ck-color-shadow-dro=
p-active); --ck-spacing-unit: 0.6em; --ck-spacing-large: calc(var(--ck-spac=
ing-unit)*1.5); --ck-spacing-standard: var(--ck-spacing-unit); --ck-spacing=
-medium: calc(var(--ck-spacing-unit)*0.8); --ck-spacing-small: calc(var(--c=
k-spacing-unit)*0.5); --ck-spacing-tiny: calc(var(--ck-spacing-unit)*0.3); =
--ck-spacing-extra-tiny: calc(var(--ck-spacing-unit)*0.16); }

.ck.ck-label { display: block; }

.ck.ck-voice-label { display: none; }

.ck.ck-label { font-weight: 700; }

:root { --ck-accessibility-help-dialog-max-width: 600px; --ck-accessibility=
-help-dialog-max-height: 400px; --ck-accessibility-help-dialog-border-color=
: #ccced1; --ck-accessibility-help-dialog-code-background-color: #ededed; -=
-ck-accessibility-help-dialog-kbd-shadow-color: #9c9c9c; }

.ck.ck-accessibility-help-dialog .ck-accessibility-help-dialog__content { b=
order: 1px solid transparent; max-height: var(--ck-accessibility-help-dialo=
g-max-height); max-width: var(--ck-accessibility-help-dialog-max-width); ov=
erflow: auto; padding: var(--ck-spacing-large); user-select: text; }

.ck.ck-accessibility-help-dialog .ck-accessibility-help-dialog__content:foc=
us { border: var(--ck-focus-ring); box-shadow: var(--ck-focus-outer-shadow)=
,0 0; outline: none; }

.ck.ck-accessibility-help-dialog .ck-accessibility-help-dialog__content {
  & * { white-space: normal; }
}

.ck.ck-accessibility-help-dialog .ck-accessibility-help-dialog__content .ck=
-label { display: none; }

.ck.ck-accessibility-help-dialog .ck-accessibility-help-dialog__content h3 =
{ font-size: 1.2em; font-weight: 700; }

.ck.ck-accessibility-help-dialog .ck-accessibility-help-dialog__content h4 =
{ font-size: 1em; font-weight: 700; }

.ck.ck-accessibility-help-dialog .ck-accessibility-help-dialog__content h3,=
 .ck.ck-accessibility-help-dialog .ck-accessibility-help-dialog__content h4=
, .ck.ck-accessibility-help-dialog .ck-accessibility-help-dialog__content p=
, .ck.ck-accessibility-help-dialog .ck-accessibility-help-dialog__content t=
able { margin: 1em 0px; }

.ck.ck-accessibility-help-dialog .ck-accessibility-help-dialog__content dl =
{ border-bottom: none; border-top: 1px solid var(--ck-accessibility-help-di=
alog-border-color); display: grid; grid-template-columns: 2fr 1fr; }

.ck.ck-accessibility-help-dialog .ck-accessibility-help-dialog__content dl =
dd, .ck.ck-accessibility-help-dialog .ck-accessibility-help-dialog__content=
 dl dt { border-bottom: 1px solid var(--ck-accessibility-help-dialog-border=
-color); padding: 0.4em 0px; }

.ck.ck-accessibility-help-dialog .ck-accessibility-help-dialog__content dl =
dt { grid-column-start: 1; }

.ck.ck-accessibility-help-dialog .ck-accessibility-help-dialog__content dl =
dd { grid-column-start: 2; text-align: right; }

.ck.ck-accessibility-help-dialog .ck-accessibility-help-dialog__content cod=
e, .ck.ck-accessibility-help-dialog .ck-accessibility-help-dialog__content =
kbd { background: var(--ck-accessibility-help-dialog-code-background-color)=
; border-radius: 2px; display: inline-block; font-size: 0.9em; line-height:=
 1; padding: 0.4em; text-align: center; vertical-align: middle; }

.ck.ck-accessibility-help-dialog .ck-accessibility-help-dialog__content cod=
e { font-family: monospace; }

.ck.ck-accessibility-help-dialog .ck-accessibility-help-dialog__content kbd=
 { box-shadow: 0 1px 1px var(--ck-accessibility-help-dialog-kbd-shadow-colo=
r); margin: 0px 1px; min-width: 1.8em; }

.ck.ck-accessibility-help-dialog .ck-accessibility-help-dialog__content kbd=
 + kbd { margin-left: 2px; }

.ck.ck-icon { vertical-align: middle; }

:root { --ck-icon-size: calc(var(--ck-line-height-base)*var(--ck-font-size-=
normal)); }

.ck.ck-icon { font-size: 0.833335em; height: var(--ck-icon-size); width: va=
r(--ck-icon-size); will-change: transform; }

.ck.ck-icon, .ck.ck-icon * { cursor: inherit; }

.ck.ck-icon.ck-icon_inherit-color, .ck.ck-icon.ck-icon_inherit-color * { co=
lor: inherit; }

.ck.ck-icon.ck-icon_inherit-color :not([fill]) { fill: currentcolor; }

.ck.ck-button, a.ck.ck-button { align-items: center; display: inline-flex; =
position: relative; user-select: none; }

[dir=3D"ltr"] .ck.ck-button, [dir=3D"ltr"] a.ck.ck-button { justify-content=
: left; }

[dir=3D"rtl"] .ck.ck-button, [dir=3D"rtl"] a.ck.ck-button { justify-content=
: right; }

.ck.ck-button .ck-button__label, a.ck.ck-button .ck-button__label { display=
: none; }

.ck.ck-button.ck-button_with-text .ck-button__label, a.ck.ck-button.ck-butt=
on_with-text .ck-button__label { display: inline-block; }

.ck.ck-button:not(.ck-button_with-text), a.ck.ck-button:not(.ck-button_with=
-text) { justify-content: center; }

.ck.ck-button, a.ck.ck-button { background: var(--ck-color-button-default-b=
ackground); }

.ck.ck-button:not(.ck-disabled):hover, a.ck.ck-button:not(.ck-disabled):hov=
er { background: var(--ck-color-button-default-hover-background); }

.ck.ck-button:not(.ck-disabled):active, a.ck.ck-button:not(.ck-disabled):ac=
tive { background: var(--ck-color-button-default-active-background); }

.ck.ck-button.ck-disabled, a.ck.ck-button.ck-disabled { background: var(--c=
k-color-button-default-disabled-background); }

.ck.ck-button, a.ck.ck-button { border-radius: 0px; }

.ck-rounded-corners .ck.ck-button, .ck-rounded-corners a.ck.ck-button, .ck.=
ck-button.ck-rounded-corners, a.ck.ck-button.ck-rounded-corners { border-ra=
dius: var(--ck-border-radius); }

.ck.ck-button, a.ck.ck-button { appearance: none; border: 1px solid transpa=
rent; cursor: default; font-size: inherit; line-height: 1; min-height: var(=
--ck-ui-component-min-height); min-width: var(--ck-ui-component-min-height)=
; padding: var(--ck-spacing-tiny); text-align: center; transition: box-shad=
ow 0.2s ease-in-out, border 0.2s ease-in-out; vertical-align: middle; white=
-space: nowrap; }

.ck.ck-button:active, .ck.ck-button:focus, a.ck.ck-button:active, a.ck.ck-b=
utton:focus { border: var(--ck-focus-ring); box-shadow: var(--ck-focus-oute=
r-shadow),0 0; outline: none; }

.ck.ck-button .ck-button__icon use, .ck.ck-button .ck-button__icon use *, a=
.ck.ck-button .ck-button__icon use, a.ck.ck-button .ck-button__icon use * {=
 color: inherit; }

.ck.ck-button .ck-button__label, a.ck.ck-button .ck-button__label { color: =
inherit; cursor: inherit; font-size: inherit; font-weight: inherit; vertica=
l-align: middle; }

[dir=3D"ltr"] .ck.ck-button .ck-button__label, [dir=3D"ltr"] a.ck.ck-button=
 .ck-button__label { text-align: left; }

[dir=3D"rtl"] .ck.ck-button .ck-button__label, [dir=3D"rtl"] a.ck.ck-button=
 .ck-button__label { text-align: right; }

.ck.ck-button .ck-button__keystroke, a.ck.ck-button .ck-button__keystroke {=
 color: inherit; }

[dir=3D"ltr"] .ck.ck-button .ck-button__keystroke, [dir=3D"ltr"] a.ck.ck-bu=
tton .ck-button__keystroke { margin-left: var(--ck-spacing-large); }

[dir=3D"rtl"] .ck.ck-button .ck-button__keystroke, [dir=3D"rtl"] a.ck.ck-bu=
tton .ck-button__keystroke { margin-right: var(--ck-spacing-large); }

.ck.ck-button .ck-button__keystroke, a.ck.ck-button .ck-button__keystroke {=
 opacity: 0.5; }

.ck.ck-button.ck-disabled:active, .ck.ck-button.ck-disabled:focus, a.ck.ck-=
button.ck-disabled:active, a.ck.ck-button.ck-disabled:focus { box-shadow: v=
ar(--ck-focus-disabled-outer-shadow),0 0; }

.ck.ck-button.ck-disabled .ck-button__icon, .ck.ck-button.ck-disabled .ck-b=
utton__label, a.ck.ck-button.ck-disabled .ck-button__icon, a.ck.ck-button.c=
k-disabled .ck-button__label { opacity: var(--ck-disabled-opacity); }

.ck.ck-button.ck-disabled .ck-button__keystroke, a.ck.ck-button.ck-disabled=
 .ck-button__keystroke { opacity: 0.3; }

.ck.ck-button.ck-button_with-text, a.ck.ck-button.ck-button_with-text { pad=
ding: var(--ck-spacing-tiny) var(--ck-spacing-standard); }

[dir=3D"ltr"] .ck.ck-button.ck-button_with-text .ck-button__icon, [dir=3D"l=
tr"] a.ck.ck-button.ck-button_with-text .ck-button__icon { margin-left: cal=
c(var(--ck-spacing-small)*-1); margin-right: var(--ck-spacing-small); }

[dir=3D"rtl"] .ck.ck-button.ck-button_with-text .ck-button__icon, [dir=3D"r=
tl"] a.ck.ck-button.ck-button_with-text .ck-button__icon { margin-left: var=
(--ck-spacing-small); margin-right: calc(var(--ck-spacing-small)*-1); }

.ck.ck-button.ck-button_with-keystroke .ck-button__label, a.ck.ck-button.ck=
-button_with-keystroke .ck-button__label { flex-grow: 1; }

.ck.ck-button.ck-on, a.ck.ck-button.ck-on { background: var(--ck-color-butt=
on-on-background); }

.ck.ck-button.ck-on:not(.ck-disabled):hover, a.ck.ck-button.ck-on:not(.ck-d=
isabled):hover { background: var(--ck-color-button-on-hover-background); }

.ck.ck-button.ck-on:not(.ck-disabled):active, a.ck.ck-button.ck-on:not(.ck-=
disabled):active { background: var(--ck-color-button-on-active-background);=
 }

.ck.ck-button.ck-on.ck-disabled, a.ck.ck-button.ck-on.ck-disabled { backgro=
und: var(--ck-color-button-on-disabled-background); }

.ck.ck-button.ck-on, a.ck.ck-button.ck-on { color: var(--ck-color-button-on=
-color); }

.ck.ck-button.ck-button-save, a.ck.ck-button.ck-button-save { color: var(--=
ck-color-button-save); }

.ck.ck-button.ck-button-cancel, a.ck.ck-button.ck-button-cancel { color: va=
r(--ck-color-button-cancel); }

.ck.ck-button-action, a.ck.ck-button-action { background: var(--ck-color-bu=
tton-action-background); }

.ck.ck-button-action:not(.ck-disabled):hover, a.ck.ck-button-action:not(.ck=
-disabled):hover { background: var(--ck-color-button-action-hover-backgroun=
d); }

.ck.ck-button-action:not(.ck-disabled):active, a.ck.ck-button-action:not(.c=
k-disabled):active { background: var(--ck-color-button-action-active-backgr=
ound); }

.ck.ck-button-action.ck-disabled, a.ck.ck-button-action.ck-disabled { backg=
round: var(--ck-color-button-action-disabled-background); }

.ck.ck-button-action, a.ck.ck-button-action { color: var(--ck-color-button-=
action-text); }

.ck.ck-button-bold, a.ck.ck-button-bold { font-weight: 700; }

.ck.ck-button.ck-switchbutton .ck-button__toggle, .ck.ck-button.ck-switchbu=
tton .ck-button__toggle .ck-button__toggle__inner { display: block; }

:root { --ck-switch-button-toggle-width: 2.6153846154em; --ck-switch-button=
-toggle-inner-size: calc(1.07692em + 1px); --ck-switch-button-translation: =
calc(var(--ck-switch-button-toggle-width) - var(--ck-switch-button-toggle-i=
nner-size) - 2px); --ck-switch-button-inner-hover-shadow: 0 0 0 5px var(--c=
k-color-switch-button-inner-shadow); }

.ck.ck-button.ck-switchbutton, .ck.ck-button.ck-switchbutton.ck-on:active, =
.ck.ck-button.ck-switchbutton.ck-on:focus, .ck.ck-button.ck-switchbutton.ck=
-on:hover, .ck.ck-button.ck-switchbutton:active, .ck.ck-button.ck-switchbut=
ton:focus, .ck.ck-button.ck-switchbutton:hover { background: transparent; c=
olor: inherit; }

[dir=3D"ltr"] .ck.ck-button.ck-switchbutton .ck-button__label { margin-righ=
t: calc(var(--ck-spacing-large)*2); }

[dir=3D"rtl"] .ck.ck-button.ck-switchbutton .ck-button__label { margin-left=
: calc(var(--ck-spacing-large)*2); }

.ck.ck-button.ck-switchbutton .ck-button__toggle { border-radius: 0px; }

.ck-rounded-corners .ck.ck-button.ck-switchbutton .ck-button__toggle, .ck.c=
k-button.ck-switchbutton .ck-button__toggle.ck-rounded-corners { border-rad=
ius: var(--ck-border-radius); }

[dir=3D"ltr"] .ck.ck-button.ck-switchbutton .ck-button__toggle { margin-lef=
t: auto; }

[dir=3D"rtl"] .ck.ck-button.ck-switchbutton .ck-button__toggle { margin-rig=
ht: auto; }

.ck.ck-button.ck-switchbutton .ck-button__toggle { background: var(--ck-col=
or-switch-button-off-background); border: 1px solid transparent; transition=
: background 0.4s, box-shadow 0.2s ease-in-out, outline 0.2s ease-in-out; w=
idth: var(--ck-switch-button-toggle-width); }

.ck.ck-button.ck-switchbutton .ck-button__toggle .ck-button__toggle__inner =
{ border-radius: 0px; }

.ck-rounded-corners .ck.ck-button.ck-switchbutton .ck-button__toggle .ck-bu=
tton__toggle__inner, .ck.ck-button.ck-switchbutton .ck-button__toggle .ck-b=
utton__toggle__inner.ck-rounded-corners { border-radius: calc(var(--ck-bord=
er-radius)*.5); }

.ck.ck-button.ck-switchbutton .ck-button__toggle .ck-button__toggle__inner =
{ background: var(--ck-color-switch-button-inner-background); height: var(-=
-ck-switch-button-toggle-inner-size); transition: 0.3s; width: var(--ck-swi=
tch-button-toggle-inner-size); }

.ck.ck-button.ck-switchbutton .ck-button__toggle:hover { background: var(--=
ck-color-switch-button-off-hover-background); }

.ck.ck-button.ck-switchbutton .ck-button__toggle:hover .ck-button__toggle__=
inner { box-shadow: var(--ck-switch-button-inner-hover-shadow); }

.ck.ck-button.ck-switchbutton.ck-disabled .ck-button__toggle { opacity: var=
(--ck-disabled-opacity); }

.ck.ck-button.ck-switchbutton:focus { border-color: transparent; box-shadow=
: none; outline: none; }

.ck.ck-button.ck-switchbutton:focus .ck-button__toggle { box-shadow: 0 0 0 =
1px var(--ck-color-base-background),0 0 0 5px var(--ck-color-focus-outer-sh=
adow); outline: var(--ck-focus-ring); outline-offset: 1px; }

.ck.ck-button.ck-switchbutton.ck-on .ck-button__toggle { background: var(--=
ck-color-switch-button-on-background); }

.ck.ck-button.ck-switchbutton.ck-on .ck-button__toggle:hover { background: =
var(--ck-color-switch-button-on-hover-background); }

[dir=3D"ltr"] .ck.ck-button.ck-switchbutton.ck-on .ck-button__toggle .ck-bu=
tton__toggle__inner { transform: translateX(var( --ck-switch-button-transla=
tion )); }

[dir=3D"rtl"] .ck.ck-button.ck-switchbutton.ck-on .ck-button__toggle .ck-bu=
tton__toggle__inner { transform: translateX(calc(var( --ck-switch-button-tr=
anslation )*-1)); }

.ck.ck-collapsible.ck-collapsible_collapsed > .ck-collapsible__children { d=
isplay: none; }

:root { --ck-collapsible-arrow-size: calc(var(--ck-icon-size)*0.5); }

.ck.ck-collapsible > .ck.ck-button { border-radius: 0px; color: inherit; fo=
nt-weight: 700; padding: var(--ck-list-button-padding); width: 100%; }

.ck.ck-collapsible > .ck.ck-button:focus { background: transparent; }

.ck.ck-collapsible > .ck.ck-button:active, .ck.ck-collapsible > .ck.ck-butt=
on:hover:not(:focus), .ck.ck-collapsible > .ck.ck-button:not(:focus) { back=
ground: transparent; border-color: transparent; box-shadow: none; }

.ck.ck-collapsible > .ck.ck-button > .ck-icon { margin-right: var(--ck-spac=
ing-medium); width: var(--ck-collapsible-arrow-size); }

.ck.ck-collapsible > .ck-collapsible__children { padding: var(--ck-spacing-=
medium) var(--ck-spacing-large) var(--ck-spacing-large); }

.ck.ck-collapsible.ck-collapsible_collapsed > .ck.ck-button .ck-icon { tran=
sform: rotate(-90deg); }

.ck.ck-color-grid { display: grid; }

:root { --ck-color-grid-tile-size: 24px; --ck-color-color-grid-check-icon: =
#166fd4; }

.ck.ck-color-grid { gap: 5px; padding: 8px; }

.ck.ck-color-grid__tile { border: 0px; height: var(--ck-color-grid-tile-siz=
e); min-height: var(--ck-color-grid-tile-size); min-width: var(--ck-color-g=
rid-tile-size); padding: 0px; transition: box-shadow 0.2s; width: var(--ck-=
color-grid-tile-size); }

.ck.ck-color-grid__tile.ck-disabled { cursor: unset; transition: unset; }

.ck.ck-color-grid__tile.ck-color-selector__color-tile_bordered { box-shadow=
: 0 0 0 1px var(--ck-color-base-border); }

.ck.ck-color-grid__tile .ck.ck-icon { color: var(--ck-color-color-grid-chec=
k-icon); display: none; }

.ck.ck-color-grid__tile.ck-on { box-shadow: inset 0 0 0 1px var(--ck-color-=
base-background),0 0 0 2px var(--ck-color-base-text); }

.ck.ck-color-grid__tile.ck-on .ck.ck-icon { display: block; }

.ck.ck-color-grid__tile.ck-on, .ck.ck-color-grid__tile:focus:not(.ck-disabl=
ed), .ck.ck-color-grid__tile:hover:not(.ck-disabled) { border: 0px; }

.ck.ck-color-grid__tile:focus:not(.ck-disabled), .ck.ck-color-grid__tile:ho=
ver:not(.ck-disabled) { box-shadow: inset 0 0 0 1px var(--ck-color-base-bac=
kground),0 0 0 2px var(--ck-color-focus-border); }

.ck.ck-color-grid__label { padding: 0 var(--ck-spacing-standard); }

.ck.ck-labeled-field-view > .ck.ck-labeled-field-view__input-wrapper { disp=
lay: flex; position: relative; }

.ck.ck-labeled-field-view .ck.ck-label { display: block; position: absolute=
; }

:root { --ck-labeled-field-view-transition: .1s cubic-bezier(0,0,0.24,0.95)=
; --ck-labeled-field-empty-unfocused-max-width: 100% - 2 * var(--ck-spacing=
-medium); --ck-labeled-field-label-default-position-x: var(--ck-spacing-med=
ium); --ck-labeled-field-label-default-position-y: calc(var(--ck-font-size-=
base)*0.6); --ck-color-labeled-field-label-background: var(--ck-color-base-=
background); }

.ck.ck-labeled-field-view { border-radius: 0px; }

.ck-rounded-corners .ck.ck-labeled-field-view, .ck.ck-labeled-field-view.ck=
-rounded-corners { border-radius: var(--ck-border-radius); }

.ck.ck-labeled-field-view > .ck.ck-labeled-field-view__input-wrapper { widt=
h: 100%; }

.ck.ck-labeled-field-view > .ck.ck-labeled-field-view__input-wrapper > .ck.=
ck-label { top: 0px; }

[dir=3D"ltr"] .ck.ck-labeled-field-view > .ck.ck-labeled-field-view__input-=
wrapper > .ck.ck-label { left: 0px; transform: translate(var(--ck-spacing-m=
edium),-6px) scale(.75); transform-origin: 0px 0px; }

[dir=3D"rtl"] .ck.ck-labeled-field-view > .ck.ck-labeled-field-view__input-=
wrapper > .ck.ck-label { right: 0px; transform: translate(calc(var(--ck-spa=
cing-medium)*-1),-6px) scale(.75); transform-origin: 100% 0px; }

.ck.ck-labeled-field-view > .ck.ck-labeled-field-view__input-wrapper > .ck.=
ck-label { background: var(--ck-color-labeled-field-label-background); font=
-weight: 400; line-height: normal; max-width: 100%; overflow: hidden; paddi=
ng: 0 calc(var(--ck-font-size-tiny)*.5); pointer-events: none; text-overflo=
w: ellipsis; transition: transform var(--ck-labeled-field-view-transition),=
padding var(--ck-labeled-field-view-transition),background var(--ck-labeled=
-field-view-transition); }

.ck.ck-labeled-field-view.ck-error .ck-input:not([readonly]) + .ck.ck-label=
, .ck.ck-labeled-field-view.ck-error > .ck.ck-labeled-field-view__input-wra=
pper > .ck.ck-label { color: var(--ck-color-base-error); }

.ck.ck-labeled-field-view .ck-labeled-field-view__status { font-size: var(-=
-ck-font-size-small); margin-top: var(--ck-spacing-small); white-space: nor=
mal; }

.ck.ck-labeled-field-view .ck-labeled-field-view__status.ck-labeled-field-v=
iew__status_error { color: var(--ck-color-base-error); }

.ck.ck-labeled-field-view.ck-disabled > .ck.ck-labeled-field-view__input-wr=
apper > .ck.ck-label, .ck.ck-labeled-field-view.ck-labeled-field-view_empty=
:not(.ck-labeled-field-view_focused) > .ck.ck-labeled-field-view__input-wra=
pper > .ck.ck-label { color: var(--ck-color-input-disabled-text); }

[dir=3D"ltr"] .ck.ck-labeled-field-view.ck-disabled.ck-labeled-field-view_e=
mpty:not(.ck-labeled-field-view_placeholder) > .ck.ck-labeled-field-view__i=
nput-wrapper > .ck.ck-label, [dir=3D"ltr"] .ck.ck-labeled-field-view.ck-lab=
eled-field-view_empty:not(.ck-labeled-field-view_focused):not(.ck-labeled-f=
ield-view_placeholder):not(.ck-error) > .ck.ck-labeled-field-view__input-wr=
apper > .ck.ck-label { transform: translate(var(--ck-labeled-field-label-de=
fault-position-x),var(--ck-labeled-field-label-default-position-y)) scale(1=
); }

[dir=3D"rtl"] .ck.ck-labeled-field-view.ck-disabled.ck-labeled-field-view_e=
mpty:not(.ck-labeled-field-view_placeholder) > .ck.ck-labeled-field-view__i=
nput-wrapper > .ck.ck-label, [dir=3D"rtl"] .ck.ck-labeled-field-view.ck-lab=
eled-field-view_empty:not(.ck-labeled-field-view_focused):not(.ck-labeled-f=
ield-view_placeholder):not(.ck-error) > .ck.ck-labeled-field-view__input-wr=
apper > .ck.ck-label { transform: translate(calc(var(--ck-labeled-field-lab=
el-default-position-x)*-1),var(--ck-labeled-field-label-default-position-y)=
) scale(1); }

.ck.ck-labeled-field-view.ck-disabled.ck-labeled-field-view_empty:not(.ck-l=
abeled-field-view_placeholder) > .ck.ck-labeled-field-view__input-wrapper >=
 .ck.ck-label, .ck.ck-labeled-field-view.ck-labeled-field-view_empty:not(.c=
k-labeled-field-view_focused):not(.ck-labeled-field-view_placeholder):not(.=
ck-error) > .ck.ck-labeled-field-view__input-wrapper > .ck.ck-label { backg=
round: transparent; max-width: calc(var(--ck-labeled-field-empty-unfocused-=
max-width)); padding: 0px; }

.ck.ck-labeled-field-view > .ck.ck-labeled-field-view__input-wrapper > .ck-=
dropdown > .ck.ck-button { background: transparent; }

.ck.ck-labeled-field-view.ck-labeled-field-view_empty > .ck.ck-labeled-fiel=
d-view__input-wrapper > .ck-dropdown > .ck-button > .ck-button__label { opa=
city: 0; }

.ck.ck-labeled-field-view.ck-labeled-field-view_empty:not(.ck-labeled-field=
-view_focused):not(.ck-labeled-field-view_placeholder) > .ck.ck-labeled-fie=
ld-view__input-wrapper > .ck-dropdown + .ck-label { max-width: calc(var(--c=
k-labeled-field-empty-unfocused-max-width) - var(--ck-dropdown-arrow-size) =
- var(--ck-spacing-standard)); }

:root { --ck-input-width: 18em; --ck-input-text-width: var(--ck-input-width=
); }

.ck.ck-input { border-radius: 0px; }

.ck-rounded-corners .ck.ck-input, .ck.ck-input.ck-rounded-corners { border-=
radius: var(--ck-border-radius); }

.ck.ck-input { background: var(--ck-color-input-background); border: 1px so=
lid var(--ck-color-input-border); min-height: var(--ck-ui-component-min-hei=
ght); min-width: var(--ck-input-width); padding: var(--ck-spacing-extra-tin=
y) var(--ck-spacing-medium); transition: box-shadow 0.1s ease-in-out, borde=
r 0.1s ease-in-out; }

.ck.ck-input:focus { border: var(--ck-focus-ring); box-shadow: var(--ck-foc=
us-outer-shadow),0 0; outline: none; }

.ck.ck-input[readonly] { background: var(--ck-color-input-disabled-backgrou=
nd); border: 1px solid var(--ck-color-input-disabled-border); color: var(--=
ck-color-input-disabled-text); }

.ck.ck-input[readonly]:focus { box-shadow: var(--ck-focus-disabled-outer-sh=
adow),0 0; }

.ck.ck-input.ck-error { animation: 0.3s ease 0s 1 normal both running ck-in=
put-shake; border-color: var(--ck-color-input-error-border); }

.ck.ck-input.ck-error:focus { box-shadow: var(--ck-focus-error-outer-shadow=
),0 0; }

@keyframes ck-input-shake {=20
  20% { transform: translateX(-2px); }
  40% { transform: translateX(2px); }
  60% { transform: translateX(-1px); }
  80% { transform: translateX(1px); }
}

.ck-textarea { overflow-x: hidden; }

:root { --ck-dropdown-max-width: 75vw; }

.ck.ck-dropdown { display: inline-block; position: relative; }

.ck.ck-dropdown .ck-dropdown__arrow { pointer-events: none; z-index: var(--=
ck-z-default); }

.ck.ck-dropdown .ck-button.ck-dropdown__button { width: 100%; }

.ck.ck-dropdown .ck-dropdown__panel { display: none; max-width: var(--ck-dr=
opdown-max-width); position: absolute; z-index: var(--ck-z-panel); }

.ck.ck-dropdown .ck-dropdown__panel.ck-dropdown__panel-visible { display: i=
nline-block; }

.ck.ck-dropdown .ck-dropdown__panel.ck-dropdown__panel_n, .ck.ck-dropdown .=
ck-dropdown__panel.ck-dropdown__panel_ne, .ck.ck-dropdown .ck-dropdown__pan=
el.ck-dropdown__panel_nme, .ck.ck-dropdown .ck-dropdown__panel.ck-dropdown_=
_panel_nmw, .ck.ck-dropdown .ck-dropdown__panel.ck-dropdown__panel_nw { bot=
tom: 100%; }

.ck.ck-dropdown .ck-dropdown__panel.ck-dropdown__panel_s, .ck.ck-dropdown .=
ck-dropdown__panel.ck-dropdown__panel_se, .ck.ck-dropdown .ck-dropdown__pan=
el.ck-dropdown__panel_sme, .ck.ck-dropdown .ck-dropdown__panel.ck-dropdown_=
_panel_smw, .ck.ck-dropdown .ck-dropdown__panel.ck-dropdown__panel_sw { bot=
tom: auto; top: 100%; }

.ck.ck-dropdown .ck-dropdown__panel.ck-dropdown__panel_ne, .ck.ck-dropdown =
.ck-dropdown__panel.ck-dropdown__panel_se { left: 0px; }

.ck.ck-dropdown .ck-dropdown__panel.ck-dropdown__panel_nw, .ck.ck-dropdown =
.ck-dropdown__panel.ck-dropdown__panel_sw { right: 0px; }

.ck.ck-dropdown .ck-dropdown__panel.ck-dropdown__panel_n, .ck.ck-dropdown .=
ck-dropdown__panel.ck-dropdown__panel_s { left: 50%; transform: translateX(=
-50%); }

.ck.ck-dropdown .ck-dropdown__panel.ck-dropdown__panel_nmw, .ck.ck-dropdown=
 .ck-dropdown__panel.ck-dropdown__panel_smw { left: 75%; transform: transla=
teX(-75%); }

.ck.ck-dropdown .ck-dropdown__panel.ck-dropdown__panel_nme, .ck.ck-dropdown=
 .ck-dropdown__panel.ck-dropdown__panel_sme { left: 25%; transform: transla=
teX(-25%); }

.ck.ck-toolbar .ck-dropdown__panel { z-index: calc(var(--ck-z-panel) + 1); =
}

:root { --ck-dropdown-arrow-size: calc(var(--ck-icon-size)*0.5); }

.ck.ck-dropdown { font-size: inherit; }

.ck.ck-dropdown .ck-dropdown__arrow { width: var(--ck-dropdown-arrow-size);=
 }

[dir=3D"ltr"] .ck.ck-dropdown .ck-dropdown__arrow { margin-left: var(--ck-s=
pacing-standard); right: var(--ck-spacing-standard); }

[dir=3D"rtl"] .ck.ck-dropdown .ck-dropdown__arrow { left: var(--ck-spacing-=
standard); margin-right: var(--ck-spacing-small); }

.ck.ck-dropdown.ck-disabled .ck-dropdown__arrow { opacity: var(--ck-disable=
d-opacity); }

[dir=3D"ltr"] .ck.ck-dropdown .ck-button.ck-dropdown__button:not(.ck-button=
_with-text) { padding-left: var(--ck-spacing-small); }

[dir=3D"rtl"] .ck.ck-dropdown .ck-button.ck-dropdown__button:not(.ck-button=
_with-text) { padding-right: var(--ck-spacing-small); }

.ck.ck-dropdown .ck-button.ck-dropdown__button .ck-button__label { overflow=
: hidden; text-overflow: ellipsis; width: 7em; }

.ck.ck-dropdown .ck-button.ck-dropdown__button.ck-disabled .ck-button__labe=
l { opacity: var(--ck-disabled-opacity); }

.ck.ck-dropdown .ck-button.ck-dropdown__button.ck-on { border-bottom-left-r=
adius: 0px; border-bottom-right-radius: 0px; }

.ck.ck-dropdown .ck-button.ck-dropdown__button.ck-dropdown__button_label-wi=
dth_auto .ck-button__label { width: auto; }

.ck.ck-dropdown .ck-button.ck-dropdown__button.ck-off:active, .ck.ck-dropdo=
wn .ck-button.ck-dropdown__button.ck-on:active { box-shadow: none; }

.ck.ck-dropdown .ck-button.ck-dropdown__button.ck-off:active:focus, .ck.ck-=
dropdown .ck-button.ck-dropdown__button.ck-on:active:focus { box-shadow: va=
r(--ck-focus-outer-shadow),0 0; }

.ck.ck-dropdown__panel { border-radius: 0px; }

.ck-rounded-corners .ck.ck-dropdown__panel, .ck.ck-dropdown__panel.ck-round=
ed-corners { border-radius: var(--ck-border-radius); }

.ck.ck-dropdown__panel { background: var(--ck-color-dropdown-panel-backgrou=
nd); border: 1px solid var(--ck-color-dropdown-panel-border); bottom: 0px; =
box-shadow: var(--ck-drop-shadow),0 0; min-width: 100%; }

.ck.ck-dropdown__panel.ck-dropdown__panel_se { border-top-left-radius: 0px;=
 }

.ck.ck-dropdown__panel.ck-dropdown__panel_sw { border-top-right-radius: 0px=
; }

.ck.ck-dropdown__panel.ck-dropdown__panel_ne { border-bottom-left-radius: 0=
px; }

.ck.ck-dropdown__panel.ck-dropdown__panel_nw { border-bottom-right-radius: =
0px; }

.ck.ck-dropdown__panel:focus { outline: none; }

.ck.ck-toolbar { align-items: center; display: flex; flex-flow: row; user-s=
elect: none; }

.ck.ck-toolbar > .ck-toolbar__items { align-items: center; display: flex; f=
lex-flow: wrap; flex-grow: 1; }

.ck.ck-toolbar .ck.ck-toolbar__separator { display: inline-block; }

.ck.ck-toolbar .ck.ck-toolbar__separator:first-child, .ck.ck-toolbar .ck.ck=
-toolbar__separator:last-child { display: none; }

.ck.ck-toolbar .ck-toolbar__line-break { flex-basis: 100%; }

.ck.ck-toolbar.ck-toolbar_grouping > .ck-toolbar__items { flex-wrap: nowrap=
; }

.ck.ck-toolbar.ck-toolbar_vertical > .ck-toolbar__items { flex-direction: c=
olumn; }

.ck.ck-toolbar.ck-toolbar_floating > .ck-toolbar__items { flex-wrap: nowrap=
; }

.ck.ck-toolbar > .ck.ck-toolbar__grouped-dropdown > .ck-dropdown__button .c=
k-dropdown__arrow { display: none; }

.ck.ck-toolbar { border-radius: 0px; }

.ck-rounded-corners .ck.ck-toolbar, .ck.ck-toolbar.ck-rounded-corners { bor=
der-radius: var(--ck-border-radius); }

.ck.ck-toolbar { background: var(--ck-color-toolbar-background); border: 1p=
x solid var(--ck-color-toolbar-border); padding: 0 var(--ck-spacing-small);=
 }

.ck.ck-toolbar .ck.ck-toolbar__separator { align-self: stretch; background:=
 var(--ck-color-toolbar-border); margin-bottom: var(--ck-spacing-small); ma=
rgin-top: var(--ck-spacing-small); min-width: 1px; width: 1px; }

.ck.ck-toolbar .ck-toolbar__line-break { height: 0px; }

.ck.ck-toolbar > .ck-toolbar__items > :not(.ck-toolbar__line-break) { margi=
n-right: var(--ck-spacing-small); }

.ck.ck-toolbar > .ck-toolbar__items:empty + .ck.ck-toolbar__separator { dis=
play: none; }

.ck.ck-toolbar > .ck-toolbar__items > :not(.ck-toolbar__line-break), .ck.ck=
-toolbar > .ck.ck-toolbar__grouped-dropdown { margin-bottom: var(--ck-spaci=
ng-small); margin-top: var(--ck-spacing-small); }

.ck.ck-toolbar.ck-toolbar_vertical { padding: 0px; }

.ck.ck-toolbar.ck-toolbar_vertical > .ck-toolbar__items > .ck { border-radi=
us: 0px; margin: 0px; width: 100%; }

.ck.ck-toolbar.ck-toolbar_compact { padding: 0px; }

.ck.ck-toolbar.ck-toolbar_compact > .ck-toolbar__items > * { margin: 0px; }

.ck.ck-toolbar.ck-toolbar_compact > .ck-toolbar__items > :not(:first-child)=
:not(:last-child) { border-radius: 0px; }

.ck.ck-toolbar > .ck.ck-toolbar__grouped-dropdown > .ck.ck-button.ck-dropdo=
wn__button { padding-left: var(--ck-spacing-tiny); }

.ck.ck-toolbar .ck-toolbar__nested-toolbar-dropdown > .ck-dropdown__panel {=
 min-width: auto; }

.ck.ck-toolbar .ck-toolbar__nested-toolbar-dropdown > .ck-button > .ck-butt=
on__label { max-width: 7em; width: auto; }

.ck.ck-toolbar:focus { outline: none; }

.ck-toolbar-container .ck.ck-toolbar { border: 0px; }

.ck.ck-toolbar[dir=3D"rtl"] > .ck-toolbar__items > .ck, [dir=3D"rtl"] .ck.c=
k-toolbar > .ck-toolbar__items > .ck { margin-right: 0px; }

.ck.ck-toolbar[dir=3D"rtl"]:not(.ck-toolbar_compact) > .ck-toolbar__items >=
 .ck, [dir=3D"rtl"] .ck.ck-toolbar:not(.ck-toolbar_compact) > .ck-toolbar__=
items > .ck { margin-left: var(--ck-spacing-small); }

.ck.ck-toolbar[dir=3D"rtl"] > .ck-toolbar__items > .ck:last-child, [dir=3D"=
rtl"] .ck.ck-toolbar > .ck-toolbar__items > .ck:last-child { margin-left: 0=
px; }

.ck.ck-toolbar.ck-toolbar_compact[dir=3D"rtl"] > .ck-toolbar__items > .ck:f=
irst-child, [dir=3D"rtl"] .ck.ck-toolbar.ck-toolbar_compact > .ck-toolbar__=
items > .ck:first-child { border-bottom-left-radius: 0px; border-top-left-r=
adius: 0px; }

.ck.ck-toolbar.ck-toolbar_compact[dir=3D"rtl"] > .ck-toolbar__items > .ck:l=
ast-child, [dir=3D"rtl"] .ck.ck-toolbar.ck-toolbar_compact > .ck-toolbar__i=
tems > .ck:last-child { border-bottom-right-radius: 0px; border-top-right-r=
adius: 0px; }

.ck.ck-toolbar.ck-toolbar_grouping[dir=3D"rtl"] > .ck-toolbar__items:not(:e=
mpty):not(:only-child), .ck.ck-toolbar[dir=3D"rtl"] > .ck.ck-toolbar__separ=
ator, [dir=3D"rtl"] .ck.ck-toolbar.ck-toolbar_grouping > .ck-toolbar__items=
:not(:empty):not(:only-child), [dir=3D"rtl"] .ck.ck-toolbar > .ck.ck-toolba=
r__separator { margin-left: var(--ck-spacing-small); }

.ck.ck-toolbar[dir=3D"ltr"] > .ck-toolbar__items > .ck:last-child, [dir=3D"=
ltr"] .ck.ck-toolbar > .ck-toolbar__items > .ck:last-child { margin-right: =
0px; }

.ck.ck-toolbar.ck-toolbar_compact[dir=3D"ltr"] > .ck-toolbar__items > .ck:f=
irst-child, [dir=3D"ltr"] .ck.ck-toolbar.ck-toolbar_compact > .ck-toolbar__=
items > .ck:first-child { border-bottom-right-radius: 0px; border-top-right=
-radius: 0px; }

.ck.ck-toolbar.ck-toolbar_compact[dir=3D"ltr"] > .ck-toolbar__items > .ck:l=
ast-child, [dir=3D"ltr"] .ck.ck-toolbar.ck-toolbar_compact > .ck-toolbar__i=
tems > .ck:last-child { border-bottom-left-radius: 0px; border-top-left-rad=
ius: 0px; }

.ck.ck-toolbar.ck-toolbar_grouping[dir=3D"ltr"] > .ck-toolbar__items:not(:e=
mpty):not(:only-child), .ck.ck-toolbar[dir=3D"ltr"] > .ck.ck-toolbar__separ=
ator, [dir=3D"ltr"] .ck.ck-toolbar.ck-toolbar_grouping > .ck-toolbar__items=
:not(:empty):not(:only-child), [dir=3D"ltr"] .ck.ck-toolbar > .ck.ck-toolba=
r__separator { margin-right: var(--ck-spacing-small); }

.ck.ck-list { display: flex; flex-direction: column; user-select: none; }

.ck.ck-list .ck-list__item, .ck.ck-list .ck-list__separator { display: bloc=
k; }

.ck.ck-list .ck-list__item > :focus { position: relative; z-index: var(--ck=
-z-default); }

:root { --ck-list-button-padding: calc(var(--ck-line-height-base)*0.11*var(=
--ck-font-size-base)) calc(var(--ck-line-height-base)*0.4*var(--ck-font-siz=
e-base)); }

.ck.ck-list { border-radius: 0px; }

.ck-rounded-corners .ck.ck-list, .ck.ck-list.ck-rounded-corners { border-ra=
dius: var(--ck-border-radius); }

.ck.ck-list { background: var(--ck-color-list-background); list-style-type:=
 none; }

.ck.ck-list__item { cursor: default; min-width: 12em; }

.ck.ck-list__item > .ck-button { border-radius: 0px; min-height: unset; wid=
th: 100%; }

[dir=3D"ltr"] .ck.ck-list__item > .ck-button { text-align: left; }

[dir=3D"rtl"] .ck.ck-list__item > .ck-button { text-align: right; }

.ck.ck-list__item > .ck-button { padding: var(--ck-list-button-padding); }

.ck.ck-list__item > .ck-button:active { box-shadow: none; }

.ck.ck-list__item > .ck-button.ck-on { background: var(--ck-color-list-butt=
on-on-background); color: var(--ck-color-list-button-on-text); }

.ck.ck-list__item > .ck-button.ck-on:active { box-shadow: none; }

.ck.ck-list__item > .ck-button.ck-on:hover:not(.ck-disabled) { background: =
var(--ck-color-list-button-on-background-focus); }

.ck.ck-list__item > .ck-button.ck-on:focus:not(.ck-switchbutton):not(.ck-di=
sabled) { border-color: var(--ck-color-base-background); }

.ck.ck-list__item > .ck-button:hover:not(.ck-disabled) { background: var(--=
ck-color-list-button-hover-background); }

.ck.ck-list__item > .ck-switchbutton.ck-on { background: var(--ck-color-lis=
t-background); color: inherit; }

.ck.ck-list__item > .ck-switchbutton.ck-on:hover:not(.ck-disabled) { backgr=
ound: var(--ck-color-list-button-hover-background); color: inherit; }

.ck-list .ck-list__group {
  padding-top: var(--ck-spacing-medium);
  :not(.ck-hidden) ~ & { border-top: 1px solid var(--ck-color-base-border);=
 }
}

.ck-list .ck-list__group > .ck-label { font-size: 11px; font-weight: 700; p=
adding: var(--ck-spacing-medium) var(--ck-spacing-medium) 0 var(--ck-spacin=
g-medium); }

.ck.ck-list__separator { background: var(--ck-color-base-border); height: 1=
px; width: 100%; }

.ck.ck-splitbutton { font-size: inherit; }

.ck.ck-splitbutton .ck-splitbutton__action:focus { z-index: calc(var(--ck-z=
-default) + 1); }

:root { --ck-color-split-button-hover-background: #ebebeb; --ck-color-split=
-button-hover-border: #b3b3b3; }

[dir=3D"ltr"] .ck.ck-splitbutton.ck-splitbutton_open > .ck-splitbutton__act=
ion, [dir=3D"ltr"] .ck.ck-splitbutton:hover > .ck-splitbutton__action { bor=
der-bottom-right-radius: unset; border-top-right-radius: unset; }

[dir=3D"rtl"] .ck.ck-splitbutton.ck-splitbutton_open > .ck-splitbutton__act=
ion, [dir=3D"rtl"] .ck.ck-splitbutton:hover > .ck-splitbutton__action { bor=
der-bottom-left-radius: unset; border-top-left-radius: unset; }

.ck.ck-splitbutton > .ck-splitbutton__arrow { min-width: unset; }

[dir=3D"ltr"] .ck.ck-splitbutton > .ck-splitbutton__arrow { border-bottom-l=
eft-radius: unset; border-top-left-radius: unset; }

[dir=3D"rtl"] .ck.ck-splitbutton > .ck-splitbutton__arrow { border-bottom-r=
ight-radius: unset; border-top-right-radius: unset; }

.ck.ck-splitbutton > .ck-splitbutton__arrow svg { width: var(--ck-dropdown-=
arrow-size); }

.ck.ck-splitbutton > .ck-splitbutton__arrow:not(:focus) { border-bottom-wid=
th: 0px; border-top-width: 0px; }

.ck.ck-splitbutton.ck-splitbutton_open > .ck-button:not(.ck-on):not(.ck-dis=
abled):not(:hover), .ck.ck-splitbutton:hover > .ck-button:not(.ck-on):not(.=
ck-disabled):not(:hover) { background: var(--ck-color-split-button-hover-ba=
ckground); }

.ck.ck-splitbutton.ck-splitbutton_open > .ck-splitbutton__arrow:not(.ck-dis=
abled)::after, .ck.ck-splitbutton:hover > .ck-splitbutton__arrow:not(.ck-di=
sabled)::after { background-color: var(--ck-color-split-button-hover-border=
); content: ""; height: 100%; position: absolute; width: 1px; }

.ck.ck-splitbutton.ck-splitbutton_open > .ck-splitbutton__arrow:focus::afte=
r, .ck.ck-splitbutton:hover > .ck-splitbutton__arrow:focus::after { --ck-co=
lor-split-button-hover-border: var(--ck-color-focus-border); }

[dir=3D"ltr"] .ck.ck-splitbutton.ck-splitbutton_open > .ck-splitbutton__arr=
ow:not(.ck-disabled)::after, [dir=3D"ltr"] .ck.ck-splitbutton:hover > .ck-s=
plitbutton__arrow:not(.ck-disabled)::after { left: -1px; }

[dir=3D"rtl"] .ck.ck-splitbutton.ck-splitbutton_open > .ck-splitbutton__arr=
ow:not(.ck-disabled)::after, [dir=3D"rtl"] .ck.ck-splitbutton:hover > .ck-s=
plitbutton__arrow:not(.ck-disabled)::after { right: -1px; }

.ck.ck-splitbutton.ck-splitbutton_open { border-radius: 0px; }

.ck-rounded-corners .ck.ck-splitbutton.ck-splitbutton_open, .ck.ck-splitbut=
ton.ck-splitbutton_open.ck-rounded-corners { border-radius: var(--ck-border=
-radius); }

.ck-rounded-corners .ck.ck-splitbutton.ck-splitbutton_open > .ck-splitbutto=
n__action, .ck.ck-splitbutton.ck-splitbutton_open.ck-rounded-corners > .ck-=
splitbutton__action { border-bottom-left-radius: 0px; }

.ck-rounded-corners .ck.ck-splitbutton.ck-splitbutton_open > .ck-splitbutto=
n__arrow, .ck.ck-splitbutton.ck-splitbutton_open.ck-rounded-corners > .ck-s=
plitbutton__arrow { border-bottom-right-radius: 0px; }

:root { --ck-toolbar-dropdown-max-width: 60vw; }

.ck.ck-toolbar-dropdown > .ck-dropdown__panel { max-width: var(--ck-toolbar=
-dropdown-max-width); width: max-content; }

.ck.ck-toolbar-dropdown > .ck-dropdown__panel .ck-button:focus { z-index: c=
alc(var(--ck-z-default) + 1); }

.ck.ck-toolbar-dropdown .ck-toolbar { border: 0px; }

.ck.ck-dropdown > .ck-dropdown__panel > .ck-list { border-radius: 0px; }

.ck-rounded-corners .ck.ck-dropdown > .ck-dropdown__panel > .ck-list, .ck.c=
k-dropdown > .ck-dropdown__panel > .ck-list.ck-rounded-corners { border-top=
-right-radius: ; border-bottom-right-radius: ; border-bottom-left-radius: ;=
 border-top-left-radius: 0px; }

.ck.ck-dropdown > .ck-dropdown__panel > .ck-list .ck-list__item:first-child=
 > .ck-button { border-radius: 0px; }

.ck-rounded-corners .ck.ck-dropdown > .ck-dropdown__panel > .ck-list .ck-li=
st__item:first-child > .ck-button, .ck.ck-dropdown > .ck-dropdown__panel > =
.ck-list .ck-list__item:first-child > .ck-button.ck-rounded-corners { borde=
r-top-right-radius: ; border-bottom-left-radius: 0px; border-bottom-right-r=
adius: 0px; border-top-left-radius: 0px; }

.ck.ck-dropdown > .ck-dropdown__panel > .ck-list .ck-list__item:last-child =
> .ck-button { border-radius: 0px; }

.ck-rounded-corners .ck.ck-dropdown > .ck-dropdown__panel > .ck-list .ck-li=
st__item:last-child > .ck-button, .ck.ck-dropdown > .ck-dropdown__panel > .=
ck-list .ck-list__item:last-child > .ck-button.ck-rounded-corners { border-=
bottom-right-radius: ; border-bottom-left-radius: ; border-top-left-radius:=
 0px; border-top-right-radius: 0px; }

.color-picker-hex-input { width: max-content; }

.color-picker-hex-input .ck.ck-input { min-width: unset; }

.ck.ck-color-picker__row { display: flex; flex-flow: row; justify-content: =
space-between; margin: var(--ck-spacing-large) 0 0; width: unset; }

.ck.ck-color-picker__row .ck.ck-labeled-field-view { padding-top: unset; }

.ck.ck-color-picker__row .ck.ck-input-text { width: unset; }

.ck.ck-color-picker__row .ck-color-picker__hash-view { padding-right: var(-=
-ck-spacing-medium); padding-top: var(--ck-spacing-tiny); }

.ck.ck-color-selector .ck-color-grids-fragment .ck-button.ck-color-selector=
__color-picker, .ck.ck-color-selector .ck-color-grids-fragment .ck-button.c=
k-color-selector__remove-color { align-items: center; display: flex; }

[dir=3D"rtl"] .ck.ck-color-selector .ck-color-grids-fragment .ck-button.ck-=
color-selector__color-picker, [dir=3D"rtl"] .ck.ck-color-selector .ck-color=
-grids-fragment .ck-button.ck-color-selector__remove-color { justify-conten=
t: flex-start; }

.ck.ck-color-selector .ck-color-picker-fragment .ck.ck-color-selector_actio=
n-bar { display: flex; flex-direction: row; justify-content: space-around; =
}

.ck.ck-color-selector .ck-color-picker-fragment .ck.ck-color-selector_actio=
n-bar .ck-button-cancel, .ck.ck-color-selector .ck-color-picker-fragment .c=
k.ck-color-selector_action-bar .ck-button-save { flex: 1 1 0%; }

.ck.ck-color-selector .ck-color-grids-fragment .ck-button.ck-color-selector=
__color-picker, .ck.ck-color-selector .ck-color-grids-fragment .ck-button.c=
k-color-selector__remove-color { width: 100%; }

.ck.ck-color-selector .ck-color-grids-fragment .ck-button.ck-color-selector=
__color-picker { border-bottom-left-radius: 0px; border-bottom-right-radius=
: 0px; padding: calc(var(--ck-spacing-standard)/2) var(--ck-spacing-standar=
d); }

.ck.ck-color-selector .ck-color-grids-fragment .ck-button.ck-color-selector=
__color-picker:not(:focus) { border-top: 1px solid var(--ck-color-base-bord=
er); }

[dir=3D"ltr"] .ck.ck-color-selector .ck-color-grids-fragment .ck-button.ck-=
color-selector__color-picker .ck.ck-icon { margin-right: var(--ck-spacing-s=
tandard); }

[dir=3D"rtl"] .ck.ck-color-selector .ck-color-grids-fragment .ck-button.ck-=
color-selector__color-picker .ck.ck-icon { margin-left: var(--ck-spacing-st=
andard); }

.ck.ck-color-selector .ck-color-grids-fragment label.ck.ck-color-grid__labe=
l { font-weight: unset; }

.ck.ck-color-selector .ck-color-picker-fragment .ck.ck-color-picker { paddi=
ng: 8px; }

.ck.ck-color-selector .ck-color-picker-fragment .ck.ck-color-picker .hex-co=
lor-picker { height: 100px; min-width: 180px; }

.ck.ck-color-selector .ck-color-picker-fragment .ck.ck-color-picker .hex-co=
lor-picker::part(saturation) { border-radius: var(--ck-border-radius) var(-=
-ck-border-radius) 0 0; }

.ck.ck-color-selector .ck-color-picker-fragment .ck.ck-color-picker .hex-co=
lor-picker::part(hue) { border-radius: 0 0 var(--ck-border-radius) var(--ck=
-border-radius); }

.ck.ck-color-selector .ck-color-picker-fragment .ck.ck-color-picker .hex-co=
lor-picker::part(hue-pointer), .ck.ck-color-selector .ck-color-picker-fragm=
ent .ck.ck-color-picker .hex-color-picker::part(saturation-pointer) { heigh=
t: 15px; width: 15px; }

.ck.ck-color-selector .ck-color-picker-fragment .ck.ck-color-selector_actio=
n-bar { padding: 0px 8px 8px; }

.ck.ck-form__header { align-items: center; display: flex; flex-flow: row; j=
ustify-content: space-between; }

.ck.ck-form__header h2.ck-form__header__label { flex-grow: 1; }

:root { --ck-form-header-height: 44px; }

.ck.ck-form__header { border-bottom: 1px solid var(--ck-color-base-border);=
 height: var(--ck-form-header-height); line-height: var(--ck-form-header-he=
ight); padding: var(--ck-spacing-small) var(--ck-spacing-large); }

[dir=3D"ltr"] .ck.ck-form__header > .ck-icon { margin-right: var(--ck-spaci=
ng-medium); }

[dir=3D"rtl"] .ck.ck-form__header > .ck-icon { margin-left: var(--ck-spacin=
g-medium); }

.ck.ck-form__header .ck-form__header__label { --ck-font-size-base: 15px; fo=
nt-weight: 700; }

.ck.ck-dialog .ck.ck-dialog__actions { display: flex; justify-content: flex=
-end; padding: var(--ck-spacing-large); }

.ck.ck-dialog .ck.ck-dialog__actions > * + * { margin-left: var(--ck-spacin=
g-large); }

.ck.ck-dialog-overlay { inset: 0px; overscroll-behavior: none; position: fi=
xed; user-select: none; }

.ck.ck-dialog-overlay.ck-dialog-overlay__transparent { animation: auto ease=
 0s 1 normal none running none; background: none; pointer-events: none; }

.ck.ck-dialog { overscroll-behavior: none; position: absolute; width: fit-c=
ontent; }

.ck.ck-dialog .ck.ck-form__header { flex-shrink: 0; }

.ck.ck-dialog .ck.ck-form__header .ck-form__header__label { cursor: grab; }

.ck.ck-dialog-overlay.ck-dialog-overlay__transparent .ck.ck-dialog { pointe=
r-events: all; }

:root { --ck-dialog-overlay-background-color: rgba(0,0,0,.5); --ck-dialog-d=
rop-shadow: 0px 0px 6px 2px rgba(0,0,0,.15); --ck-dialog-max-width: 100vw; =
--ck-dialog-max-height: 90vh; --ck-color-dialog-background: var(--ck-color-=
base-background); --ck-color-dialog-form-header-border: var(--ck-color-base=
-border); }

.ck.ck-dialog-overlay { animation: 0.3s ease 0s 1 normal none running ck-di=
alog-fade-in; background: var(--ck-dialog-overlay-background-color); z-inde=
x: var(--ck-z-dialog); }

.ck.ck-dialog { border-radius: 0px; }

.ck-rounded-corners .ck.ck-dialog, .ck.ck-dialog.ck-rounded-corners { borde=
r-radius: var(--ck-border-radius); }

.ck.ck-dialog { --ck-drop-shadow: var(--ck-dialog-drop-shadow); background:=
 var(--ck-color-dialog-background); border: 1px solid var(--ck-color-base-b=
order); box-shadow: var(--ck-drop-shadow),0 0; max-height: var(--ck-dialog-=
max-height); max-width: var(--ck-dialog-max-width); }

.ck.ck-dialog .ck.ck-form__header { border-bottom: 1px solid var(--ck-color=
-dialog-form-header-border); }

@keyframes ck-dialog-fade-in {=20
  0% { background: transparent; }
  100% { background: var(--ck-dialog-overlay-background-color); }
}

:root { --ck-balloon-panel-arrow-z-index: calc(var(--ck-z-default) - 3); }

.ck.ck-balloon-panel { display: none; position: absolute; z-index: var(--ck=
-z-panel); }

.ck.ck-balloon-panel.ck-balloon-panel_with-arrow::after, .ck.ck-balloon-pan=
el.ck-balloon-panel_with-arrow::before { content: ""; position: absolute; }

.ck.ck-balloon-panel.ck-balloon-panel_with-arrow::before { z-index: var(--c=
k-balloon-panel-arrow-z-index); }

.ck.ck-balloon-panel.ck-balloon-panel_with-arrow::after { z-index: calc(var=
(--ck-balloon-panel-arrow-z-index) + 1); }

.ck.ck-balloon-panel[class*=3D"arrow_n"]::before { z-index: var(--ck-balloo=
n-panel-arrow-z-index); }

.ck.ck-balloon-panel[class*=3D"arrow_n"]::after { z-index: calc(var(--ck-ba=
lloon-panel-arrow-z-index) + 1); }

.ck.ck-balloon-panel[class*=3D"arrow_s"]::before { z-index: var(--ck-balloo=
n-panel-arrow-z-index); }

.ck.ck-balloon-panel[class*=3D"arrow_s"]::after { z-index: calc(var(--ck-ba=
lloon-panel-arrow-z-index) + 1); }

.ck.ck-balloon-panel.ck-balloon-panel_visible { display: block; }

:root { --ck-balloon-border-width: 1px; --ck-balloon-arrow-offset: 2px; --c=
k-balloon-arrow-height: 10px; --ck-balloon-arrow-half-width: 8px; --ck-ball=
oon-arrow-drop-shadow: 0 2px 2px var(--ck-color-shadow-drop); }

.ck.ck-balloon-panel { border-radius: 0px; }

.ck-rounded-corners .ck.ck-balloon-panel, .ck.ck-balloon-panel.ck-rounded-c=
orners { border-radius: var(--ck-border-radius); }

.ck.ck-balloon-panel { background: var(--ck-color-panel-background); border=
: var(--ck-balloon-border-width) solid var(--ck-color-panel-border); box-sh=
adow: var(--ck-drop-shadow),0 0; min-height: 15px; }

.ck.ck-balloon-panel.ck-balloon-panel_with-arrow::after, .ck.ck-balloon-pan=
el.ck-balloon-panel_with-arrow::before { border-style: solid; height: 0px; =
width: 0px; }

.ck.ck-balloon-panel[class*=3D"arrow_n"]::after, .ck.ck-balloon-panel[class=
*=3D"arrow_n"]::before { border-width: 0 var(--ck-balloon-arrow-half-width)=
 var(--ck-balloon-arrow-height) var(--ck-balloon-arrow-half-width); }

.ck.ck-balloon-panel[class*=3D"arrow_n"]::before { border-color: transparen=
t transparent var(--ck-color-panel-border) transparent; margin-top: calc(va=
r(--ck-balloon-border-width)*-1); }

.ck.ck-balloon-panel[class*=3D"arrow_n"]::after { border-color: transparent=
 transparent var(--ck-color-panel-background) transparent; margin-top: calc=
(var(--ck-balloon-arrow-offset) - var(--ck-balloon-border-width)); }

.ck.ck-balloon-panel[class*=3D"arrow_s"]::after, .ck.ck-balloon-panel[class=
*=3D"arrow_s"]::before { border-width: var(--ck-balloon-arrow-height) var(-=
-ck-balloon-arrow-half-width) 0 var(--ck-balloon-arrow-half-width); }

.ck.ck-balloon-panel[class*=3D"arrow_s"]::before { border-color: var(--ck-c=
olor-panel-border) transparent transparent; filter: drop-shadow(var(--ck-ba=
lloon-arrow-drop-shadow)); margin-bottom: calc(var(--ck-balloon-border-widt=
h)*-1); }

.ck.ck-balloon-panel[class*=3D"arrow_s"]::after { border-color: var(--ck-co=
lor-panel-background) transparent transparent transparent; margin-bottom: c=
alc(var(--ck-balloon-arrow-offset) - var(--ck-balloon-border-width)); }

.ck.ck-balloon-panel[class*=3D"arrow_e"]::after, .ck.ck-balloon-panel[class=
*=3D"arrow_e"]::before { border-width: var(--ck-balloon-arrow-half-width) 0=
 var(--ck-balloon-arrow-half-width) var(--ck-balloon-arrow-height); }

.ck.ck-balloon-panel[class*=3D"arrow_e"]::before { border-color: transparen=
t transparent transparent var(--ck-color-panel-border); margin-right: calc(=
var(--ck-balloon-border-width)*-1); }

.ck.ck-balloon-panel[class*=3D"arrow_e"]::after { border-color: transparent=
 transparent transparent var(--ck-color-panel-background); margin-right: ca=
lc(var(--ck-balloon-arrow-offset) - var(--ck-balloon-border-width)); }

.ck.ck-balloon-panel[class*=3D"arrow_w"]::after, .ck.ck-balloon-panel[class=
*=3D"arrow_w"]::before { border-width: var(--ck-balloon-arrow-half-width) v=
ar(--ck-balloon-arrow-height) var(--ck-balloon-arrow-half-width) 0; }

.ck.ck-balloon-panel[class*=3D"arrow_w"]::before { border-color: transparen=
t var(--ck-color-panel-border) transparent transparent; margin-left: calc(v=
ar(--ck-balloon-border-width)*-1); }

.ck.ck-balloon-panel[class*=3D"arrow_w"]::after { border-color: transparent=
 var(--ck-color-panel-background) transparent transparent; margin-left: cal=
c(var(--ck-balloon-arrow-offset) - var(--ck-balloon-border-width)); }

.ck.ck-balloon-panel.ck-balloon-panel_arrow_n::after, .ck.ck-balloon-panel.=
ck-balloon-panel_arrow_n::before { left: 50%; margin-left: calc(var(--ck-ba=
lloon-arrow-half-width)*-1); top: calc(var(--ck-balloon-arrow-height)*-1); =
}

.ck.ck-balloon-panel.ck-balloon-panel_arrow_nw::after, .ck.ck-balloon-panel=
.ck-balloon-panel_arrow_nw::before { left: calc(var(--ck-balloon-arrow-half=
-width)*2); top: calc(var(--ck-balloon-arrow-height)*-1); }

.ck.ck-balloon-panel.ck-balloon-panel_arrow_ne::after, .ck.ck-balloon-panel=
.ck-balloon-panel_arrow_ne::before { right: calc(var(--ck-balloon-arrow-hal=
f-width)*2); top: calc(var(--ck-balloon-arrow-height)*-1); }

.ck.ck-balloon-panel.ck-balloon-panel_arrow_s::after, .ck.ck-balloon-panel.=
ck-balloon-panel_arrow_s::before { bottom: calc(var(--ck-balloon-arrow-heig=
ht)*-1); left: 50%; margin-left: calc(var(--ck-balloon-arrow-half-width)*-1=
); }

.ck.ck-balloon-panel.ck-balloon-panel_arrow_sw::after, .ck.ck-balloon-panel=
.ck-balloon-panel_arrow_sw::before { bottom: calc(var(--ck-balloon-arrow-he=
ight)*-1); left: calc(var(--ck-balloon-arrow-half-width)*2); }

.ck.ck-balloon-panel.ck-balloon-panel_arrow_se::after, .ck.ck-balloon-panel=
.ck-balloon-panel_arrow_se::before { bottom: calc(var(--ck-balloon-arrow-he=
ight)*-1); right: calc(var(--ck-balloon-arrow-half-width)*2); }

.ck.ck-balloon-panel.ck-balloon-panel_arrow_sme::after, .ck.ck-balloon-pane=
l.ck-balloon-panel_arrow_sme::before { bottom: calc(var(--ck-balloon-arrow-=
height)*-1); margin-right: calc(var(--ck-balloon-arrow-half-width)*2); righ=
t: 25%; }

.ck.ck-balloon-panel.ck-balloon-panel_arrow_smw::after, .ck.ck-balloon-pane=
l.ck-balloon-panel_arrow_smw::before { bottom: calc(var(--ck-balloon-arrow-=
height)*-1); left: 25%; margin-left: calc(var(--ck-balloon-arrow-half-width=
)*2); }

.ck.ck-balloon-panel.ck-balloon-panel_arrow_nme::after, .ck.ck-balloon-pane=
l.ck-balloon-panel_arrow_nme::before { margin-right: calc(var(--ck-balloon-=
arrow-half-width)*2); right: 25%; top: calc(var(--ck-balloon-arrow-height)*=
-1); }

.ck.ck-balloon-panel.ck-balloon-panel_arrow_nmw::after, .ck.ck-balloon-pane=
l.ck-balloon-panel_arrow_nmw::before { left: 25%; margin-left: calc(var(--c=
k-balloon-arrow-half-width)*2); top: calc(var(--ck-balloon-arrow-height)*-1=
); }

.ck.ck-balloon-panel.ck-balloon-panel_arrow_e::after, .ck.ck-balloon-panel.=
ck-balloon-panel_arrow_e::before { margin-top: calc(var(--ck-balloon-arrow-=
half-width)*-1); right: calc(var(--ck-balloon-arrow-height)*-1); top: 50%; =
}

.ck.ck-balloon-panel.ck-balloon-panel_arrow_w::after, .ck.ck-balloon-panel.=
ck-balloon-panel_arrow_w::before { left: calc(var(--ck-balloon-arrow-height=
)*-1); margin-top: calc(var(--ck-balloon-arrow-half-width)*-1); top: 50%; }

.ck.ck-balloon-panel.ck-tooltip { --ck-balloon-border-width: 0px; --ck-ball=
oon-arrow-offset: 0px; --ck-balloon-arrow-half-width: 4px; --ck-balloon-arr=
ow-height: 4px; --ck-tooltip-text-padding: 4px; --ck-color-panel-background=
: var(--ck-color-tooltip-background); padding: 0 var(--ck-spacing-medium); =
z-index: calc(var(--ck-z-dialog) + 100); }

.ck.ck-balloon-panel.ck-tooltip .ck-tooltip__text { color: var(--ck-color-t=
ooltip-text); font-size: 0.9em; line-height: 1.5; }

.ck.ck-balloon-panel.ck-tooltip.ck-tooltip_multi-line .ck-tooltip__text { d=
isplay: inline-block; max-width: 200px; padding: var(--ck-tooltip-text-padd=
ing) 0; white-space: break-spaces; }

.ck.ck-balloon-panel.ck-tooltip { box-shadow: none; }

.ck.ck-balloon-panel.ck-tooltip::before { display: none; }

.ck.ck-aria-live-announcer { left: -10000px; position: absolute; top: -1000=
0px; }

:root { --ck-color-editable-blur-selection: #d9d9d9; }

.ck.ck-editor__editable:not(.ck-editor__nested-editable) { border-radius: 0=
px; }

.ck-rounded-corners .ck.ck-editor__editable:not(.ck-editor__nested-editable=
), .ck.ck-editor__editable.ck-rounded-corners:not(.ck-editor__nested-editab=
le) { border-radius: var(--ck-border-radius); }

.ck.ck-editor__editable.ck-focused:not(.ck-editor__nested-editable) { borde=
r: var(--ck-focus-ring); box-shadow: var(--ck-inner-shadow),0 0; outline: n=
one; }

.ck.ck-editor__editable_inline { border: 1px solid transparent; overflow: a=
uto; padding: 0 var(--ck-spacing-standard); }

.ck.ck-editor__editable_inline[dir=3D"ltr"] { text-align: left; }

.ck.ck-editor__editable_inline[dir=3D"rtl"] { text-align: right; }

.ck.ck-editor__editable_inline > :first-child { margin-top: var(--ck-spacin=
g-large); }

.ck.ck-editor__editable_inline > :last-child { margin-bottom: var(--ck-spac=
ing-large); }

.ck.ck-editor__editable_inline.ck-blurred ::selection { background: var(--c=
k-color-editable-blur-selection); }

.ck.ck-balloon-panel.ck-toolbar-container[class*=3D"arrow_n"]::after { bord=
er-bottom-color: var(--ck-color-panel-background); }

.ck.ck-balloon-panel.ck-toolbar-container[class*=3D"arrow_s"]::after { bord=
er-top-color: var(--ck-color-panel-background); }

.ck .ck-balloon-rotator__navigation { align-items: center; display: flex; j=
ustify-content: center; }

.ck .ck-balloon-rotator__content .ck-toolbar { justify-content: center; }

.ck .ck-balloon-rotator__navigation { background: var(--ck-color-toolbar-ba=
ckground); border-bottom: 1px solid var(--ck-color-toolbar-border); padding=
: 0 var(--ck-spacing-small); }

.ck .ck-balloon-rotator__navigation > * { margin-bottom: var(--ck-spacing-s=
mall); margin-right: var(--ck-spacing-small); margin-top: var(--ck-spacing-=
small); }

.ck .ck-balloon-rotator__navigation .ck-balloon-rotator__counter { margin-l=
eft: var(--ck-spacing-small); margin-right: var(--ck-spacing-standard); }

.ck .ck-balloon-rotator__content .ck.ck-annotation-wrapper { box-shadow: no=
ne; }

.ck .ck-fake-panel { position: absolute; z-index: calc(var(--ck-z-panel) - =
1); }

.ck .ck-fake-panel div { position: absolute; }

.ck .ck-fake-panel div:first-child { z-index: 2; }

.ck .ck-fake-panel div:nth-child(2) { z-index: 1; }

:root { --ck-balloon-fake-panel-offset-horizontal: 6px; --ck-balloon-fake-p=
anel-offset-vertical: 6px; }

.ck .ck-fake-panel div { background: var(--ck-color-panel-background); bord=
er: 1px solid var(--ck-color-panel-border); border-radius: var(--ck-border-=
radius); box-shadow: var(--ck-drop-shadow),0 0; height: 100%; min-height: 1=
5px; width: 100%; }

.ck .ck-fake-panel div:first-child { margin-left: var(--ck-balloon-fake-pan=
el-offset-horizontal); margin-top: var(--ck-balloon-fake-panel-offset-verti=
cal); }

.ck .ck-fake-panel div:nth-child(2) { margin-left: calc(var(--ck-balloon-fa=
ke-panel-offset-horizontal)*2); margin-top: calc(var(--ck-balloon-fake-pane=
l-offset-vertical)*2); }

.ck .ck-fake-panel div:nth-child(3) { margin-left: calc(var(--ck-balloon-fa=
ke-panel-offset-horizontal)*3); margin-top: calc(var(--ck-balloon-fake-pane=
l-offset-vertical)*3); }

.ck .ck-balloon-panel_arrow_s + .ck-fake-panel, .ck .ck-balloon-panel_arrow=
_se + .ck-fake-panel, .ck .ck-balloon-panel_arrow_sw + .ck-fake-panel { --c=
k-balloon-fake-panel-offset-vertical: -6px; }

.ck.ck-sticky-panel .ck-sticky-panel__content_sticky { position: fixed; top=
: 0px; z-index: var(--ck-z-panel); }

.ck.ck-sticky-panel .ck-sticky-panel__content_sticky_bottom-limit { positio=
n: absolute; top: auto; }

.ck.ck-sticky-panel .ck-sticky-panel__content_sticky { border-top-left-radi=
us: 0px; border-top-right-radius: 0px; border-width: 0px 1px 1px; box-shado=
w: var(--ck-drop-shadow),0 0; }

.ck.ck-search > .ck-labeled-field-view > .ck-labeled-field-view__input-wrap=
per > .ck-icon { position: absolute; top: 50%; transform: translateY(-50%);=
 }

[dir=3D"ltr"] .ck.ck-search > .ck-labeled-field-view > .ck-labeled-field-vi=
ew__input-wrapper > .ck-icon { left: var(--ck-spacing-medium); }

[dir=3D"rtl"] .ck.ck-search > .ck-labeled-field-view > .ck-labeled-field-vi=
ew__input-wrapper > .ck-icon { right: var(--ck-spacing-medium); }

.ck.ck-search > .ck-labeled-field-view .ck-search__reset { position: absolu=
te; top: 50%; transform: translateY(-50%); }

.ck.ck-search > .ck-search__results > .ck-search__info > span:first-child {=
 display: block; }

.ck.ck-search > .ck-search__results > .ck-search__info:not(.ck-hidden) ~ * =
{ display: none; }

:root { --ck-search-field-view-horizontal-spacing: calc(var(--ck-icon-size)=
 + var(--ck-spacing-medium)); }

.ck.ck-search > .ck-labeled-field-view .ck-input { width: 100%; }

.ck.ck-search > .ck-labeled-field-view.ck-search__query_with-icon { --ck-la=
beled-field-label-default-position-x: var(--ck-search-field-view-horizontal=
-spacing); }

.ck.ck-search > .ck-labeled-field-view.ck-search__query_with-icon > .ck-lab=
eled-field-view__input-wrapper > .ck-icon { opacity: 0.5; pointer-events: n=
one; }

.ck.ck-search > .ck-labeled-field-view.ck-search__query_with-icon .ck-input=
 { width: 100%; }

[dir=3D"ltr"] .ck.ck-search > .ck-labeled-field-view.ck-search__query_with-=
icon .ck-input, [dir=3D"rtl"] .ck.ck-search > .ck-labeled-field-view.ck-sea=
rch__query_with-icon .ck-input:not(.ck-input-text_empty) { padding-left: va=
r(--ck-search-field-view-horizontal-spacing); }

.ck.ck-search > .ck-labeled-field-view.ck-search__query_with-reset { --ck-l=
abeled-field-empty-unfocused-max-width: 100% - 2 * var(--ck-search-field-vi=
ew-horizontal-spacing); }

.ck.ck-search > .ck-labeled-field-view.ck-search__query_with-reset.ck-label=
ed-field-view_empty { --ck-labeled-field-empty-unfocused-max-width: 100% - =
var(--ck-search-field-view-horizontal-spacing) - var(--ck-spacing-medium); =
}

.ck.ck-search > .ck-labeled-field-view.ck-search__query_with-reset .ck-sear=
ch__reset { background: none; min-height: auto; min-width: auto; opacity: 0=
.5; padding: 0px; }

[dir=3D"ltr"] .ck.ck-search > .ck-labeled-field-view.ck-search__query_with-=
reset .ck-search__reset { right: var(--ck-spacing-medium); }

[dir=3D"rtl"] .ck.ck-search > .ck-labeled-field-view.ck-search__query_with-=
reset .ck-search__reset { left: var(--ck-spacing-medium); }

.ck.ck-search > .ck-labeled-field-view.ck-search__query_with-reset .ck-sear=
ch__reset:hover { opacity: 1; }

.ck.ck-search > .ck-labeled-field-view.ck-search__query_with-reset .ck-inpu=
t { width: 100%; }

[dir=3D"ltr"] .ck.ck-search > .ck-labeled-field-view.ck-search__query_with-=
reset .ck-input:not(.ck-input-text_empty), [dir=3D"rtl"] .ck.ck-search > .c=
k-labeled-field-view.ck-search__query_with-reset .ck-input { padding-right:=
 var(--ck-search-field-view-horizontal-spacing); }

.ck.ck-search > .ck-search__results { min-width: 100%; }

.ck.ck-search > .ck-search__results > .ck-search__info { padding: var(--ck-=
spacing-medium) var(--ck-spacing-large); width: 100%; }

.ck.ck-search > .ck-search__results > .ck-search__info * { white-space: nor=
mal; }

.ck.ck-search > .ck-search__results > .ck-search__info > span:first-child {=
 font-weight: 700; }

.ck.ck-search > .ck-search__results > .ck-search__info > span:last-child { =
margin-top: var(--ck-spacing-medium); }

.ck.ck-autocomplete { position: relative; }

.ck.ck-autocomplete > .ck-search__results { position: absolute; z-index: va=
r(--ck-z-panel); }

.ck.ck-autocomplete > .ck-search__results.ck-search__results_n { bottom: 10=
0%; }

.ck.ck-autocomplete > .ck-search__results.ck-search__results_s { bottom: au=
to; top: 100%; }

.ck.ck-autocomplete > .ck-search__results { border-radius: 0px; }

.ck-rounded-corners .ck.ck-autocomplete > .ck-search__results, .ck.ck-autoc=
omplete > .ck-search__results.ck-rounded-corners { border-radius: var(--ck-=
border-radius); }

.ck.ck-autocomplete > .ck-search__results { background: var(--ck-color-base=
-background); border: 1px solid var(--ck-color-dropdown-panel-border); box-=
shadow: var(--ck-drop-shadow),0 0; max-height: 200px; min-width: auto; over=
flow-y: auto; }

.ck.ck-autocomplete > .ck-search__results.ck-search__results_n { border-bot=
tom-left-radius: 0px; border-bottom-right-radius: 0px; margin-bottom: -1px;=
 }

.ck.ck-autocomplete > .ck-search__results.ck-search__results_s { border-top=
-left-radius: 0px; border-top-right-radius: 0px; margin-top: -1px; }

.ck.ck-highlighted-text mark { background: var(--ck-color-highlight-backgro=
und); font-size: inherit; font-weight: inherit; line-height: inherit; verti=
cal-align: initial; }

.ck.ck-spinner-container { display: block; position: relative; }

.ck.ck-spinner { left: 0px; margin: 0px auto; position: absolute; right: 0p=
x; top: 50%; transform: translateY(-50%); z-index: 1; }

:root { --ck-toolbar-spinner-size: 18px; }

.ck.ck-spinner-container { animation: 1.5s linear 0s infinite normal none r=
unning rotate; }

.ck.ck-spinner, .ck.ck-spinner-container { height: var(--ck-toolbar-spinner=
-size); width: var(--ck-toolbar-spinner-size); }

.ck.ck-spinner { border-right-color: ; border-right-style: ; border-right-w=
idth: ; border-bottom-color: ; border-bottom-style: ; border-bottom-width: =
; border-left-color: ; border-left-style: ; border-left-width: ; border-ima=
ge-source: ; border-image-slice: ; border-image-width: ; border-image-outse=
t: ; border-image-repeat: ; border-radius: 50%; border-top: 2px solid trans=
parent; }

@keyframes rotate {=20
  100% { transform: rotate(1turn); }
}

.ck.ck-block-toolbar-button { position: absolute; z-index: var(--ck-z-defau=
lt); }

:root { --ck-color-block-toolbar-button: var(--ck-color-text); --ck-block-t=
oolbar-button-size: var(--ck-font-size-normal); }

.ck.ck-block-toolbar-button { color: var(--ck-color-block-toolbar-button); =
font-size: var(--ck-block-toolbar-size); }

.ck.ck-menu-bar__menu > .ck-menu-bar__menu__button > .ck-menu-bar__menu__bu=
tton__arrow { pointer-events: none; z-index: var(--ck-z-default); }

.ck.ck-menu-bar__menu > .ck-menu-bar__menu__button { padding: var(--ck-list=
-button-padding); width: 100%; }

.ck.ck-menu-bar__menu > .ck-menu-bar__menu__button > .ck-button__label { fl=
ex-grow: 1; overflow: hidden; text-overflow: ellipsis; }

.ck.ck-menu-bar__menu > .ck-menu-bar__menu__button.ck-disabled > .ck-button=
__label { opacity: var(--ck-disabled-opacity); }

[dir=3D"ltr"] .ck.ck-menu-bar__menu > .ck-menu-bar__menu__button:not(.ck-bu=
tton_with-text) { padding-left: var(--ck-spacing-small); }

[dir=3D"rtl"] .ck.ck-menu-bar__menu > .ck-menu-bar__menu__button:not(.ck-bu=
tton_with-text) { padding-right: var(--ck-spacing-small); }

.ck.ck-menu-bar__menu.ck-menu-bar__menu_top-level > .ck-menu-bar__menu__but=
ton { min-height: unset; padding: var(--ck-spacing-small) var(--ck-spacing-=
medium); }

.ck.ck-menu-bar__menu.ck-menu-bar__menu_top-level > .ck-menu-bar__menu__but=
ton .ck-button__label { line-height: unset; width: unset; }

.ck.ck-menu-bar__menu.ck-menu-bar__menu_top-level > .ck-menu-bar__menu__but=
ton.ck-on { border-bottom-left-radius: 0px; border-bottom-right-radius: 0px=
; }

.ck.ck-menu-bar__menu.ck-menu-bar__menu_top-level > .ck-menu-bar__menu__but=
ton .ck-icon { display: none; }

.ck.ck-menu-bar__menu:not(.ck-menu-bar__menu_top-level) .ck-menu-bar__menu_=
_button { border-radius: 0px; }

.ck.ck-menu-bar__menu:not(.ck-menu-bar__menu_top-level) .ck-menu-bar__menu_=
_button:focus { border-color: transparent; box-shadow: none; }

.ck.ck-menu-bar__menu:not(.ck-menu-bar__menu_top-level) .ck-menu-bar__menu_=
_button:focus:not(.ck-on) { background: var(--ck-color-button-default-hover=
-background); }

.ck.ck-menu-bar__menu:not(.ck-menu-bar__menu_top-level) .ck-menu-bar__menu_=
_button:not(:has(.ck-button__icon)) > .ck-button__label { margin-left: calc=
(var(--ck-icon-size) - var(--ck-spacing-small)); }

.ck.ck-menu-bar__menu:not(.ck-menu-bar__menu_top-level) .ck-menu-bar__menu_=
_button > .ck-menu-bar__menu__button__arrow { width: var(--ck-dropdown-arro=
w-size); }

[dir=3D"ltr"] .ck.ck-menu-bar__menu:not(.ck-menu-bar__menu_top-level) .ck-m=
enu-bar__menu__button > .ck-menu-bar__menu__button__arrow { transform: rota=
te(-90deg); }

[dir=3D"rtl"] .ck.ck-menu-bar__menu:not(.ck-menu-bar__menu_top-level) .ck-m=
enu-bar__menu__button > .ck-menu-bar__menu__button__arrow { transform: rota=
te(90deg); }

.ck.ck-menu-bar__menu:not(.ck-menu-bar__menu_top-level) .ck-menu-bar__menu_=
_button.ck-disabled > .ck-menu-bar__menu__button__arrow { opacity: var(--ck=
-disabled-opacity); }

[dir=3D"ltr"] .ck.ck-menu-bar__menu:not(.ck-menu-bar__menu_top-level) .ck-m=
enu-bar__menu__button > .ck-menu-bar__menu__button__arrow { margin-left: va=
r(--ck-spacing-standard); right: var(--ck-spacing-standard); }

[dir=3D"rtl"] .ck.ck-menu-bar__menu:not(.ck-menu-bar__menu_top-level) .ck-m=
enu-bar__menu__button > .ck-menu-bar__menu__button__arrow { left: var(--ck-=
spacing-standard); margin-right: var(--ck-spacing-small); }

:root { --ck-menu-bar-menu-item-min-width: 18em; }

.ck.ck-menu-bar__menu .ck.ck-menu-bar__menu__item { min-width: var(--ck-men=
u-bar-menu-item-min-width); }

:root { --ck-menu-bar-menu-max-width: 75vw; --ck-menu-bar-nested-menu-horiz=
ontal-offset: 5px; }

.ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel { max-width: var(--ck-=
menu-bar-menu-max-width); position: absolute; z-index: var(--ck-z-panel); }

.ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-menu-bar__menu__pan=
el_position_ne, .ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-men=
u-bar__menu__panel_position_nw { bottom: 100%; }

.ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-menu-bar__menu__pan=
el_position_se, .ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-men=
u-bar__menu__panel_position_sw { bottom: auto; top: 100%; }

.ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-menu-bar__menu__pan=
el_position_ne, .ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-men=
u-bar__menu__panel_position_se { left: 0px; }

.ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-menu-bar__menu__pan=
el_position_nw, .ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-men=
u-bar__menu__panel_position_sw { right: 0px; }

.ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-menu-bar__menu__pan=
el_position_en, .ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-men=
u-bar__menu__panel_position_es { left: calc(100% - var(--ck-menu-bar-nested=
-menu-horizontal-offset)); }

.ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-menu-bar__menu__pan=
el_position_es { top: 0px; }

.ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-menu-bar__menu__pan=
el_position_en { bottom: 0px; }

.ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-menu-bar__menu__pan=
el_position_wn, .ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-men=
u-bar__menu__panel_position_ws { right: calc(100% - var(--ck-menu-bar-neste=
d-menu-horizontal-offset)); }

.ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-menu-bar__menu__pan=
el_position_ws { top: 0px; }

.ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-menu-bar__menu__pan=
el_position_wn { bottom: 0px; }

:root { --ck-menu-bar-menu-panel-max-width: 75vw; }

.ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel { border-radius: 0px; =
}

.ck-rounded-corners .ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel, .=
ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-rounded-corners { bo=
rder-radius: var(--ck-border-radius); }

.ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel { background: var(--ck=
-color-dropdown-panel-background); border: 1px solid var(--ck-color-dropdow=
n-panel-border); bottom: 0px; box-shadow: var(--ck-drop-shadow),0 0; height=
: fit-content; max-width: var(--ck-menu-bar-menu-panel-max-width); }

.ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-menu-bar__menu__pan=
el_position_es, .ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-men=
u-bar__menu__panel_position_se { border-top-left-radius: 0px; }

.ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-menu-bar__menu__pan=
el_position_sw, .ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-men=
u-bar__menu__panel_position_ws { border-top-right-radius: 0px; }

.ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-menu-bar__menu__pan=
el_position_en, .ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-men=
u-bar__menu__panel_position_ne { border-bottom-left-radius: 0px; }

.ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-menu-bar__menu__pan=
el_position_nw, .ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel.ck-men=
u-bar__menu__panel_position_wn { border-bottom-right-radius: 0px; }

.ck.ck-menu-bar__menu > .ck.ck-menu-bar__menu__panel:focus { outline: none;=
 }

.ck.ck-menu-bar__menu { display: block; font-size: inherit; position: relat=
ive; }

.ck.ck-menu-bar__menu.ck-menu-bar__menu_top-level { max-width: 100%; }

.ck.ck-menu-bar__menu .ck-button.ck-menu-bar__menu__item__button { border-r=
adius: 0px; }

.ck.ck-menu-bar__menu .ck-button.ck-menu-bar__menu__item__button > .ck-spin=
ner-container, .ck.ck-menu-bar__menu .ck-button.ck-menu-bar__menu__item__bu=
tton > .ck-spinner-container .ck-spinner { --ck-toolbar-spinner-size: 20px;=
 }

.ck.ck-menu-bar__menu .ck-button.ck-menu-bar__menu__item__button > .ck-spin=
ner-container { margin-left: calc(var(--ck-spacing-small)*-1); margin-right=
: var(--ck-spacing-small); }

.ck.ck-menu-bar__menu .ck-button.ck-menu-bar__menu__item__button:focus { bo=
rder-color: transparent; box-shadow: none; }

.ck.ck-menu-bar__menu .ck-button.ck-menu-bar__menu__item__button:focus:not(=
.ck-on) { background: var(--ck-color-button-default-hover-background); }

.ck.ck-menu-bar__menu.ck-menu-bar__menu_top-level > .ck-menu-bar__menu__pan=
el > ul > .ck-menu-bar__menu__item > .ck-menu-bar__menu__item__button:not(:=
has(.ck-button__icon)) > .ck-button__label { margin-left: calc(var(--ck-ico=
n-size) - var(--ck-spacing-small)); }

.ck.ck-menu-bar { background: var(--ck-color-base-background); border: 1px =
solid var(--ck-color-toolbar-border); display: flex; flex-wrap: wrap; gap: =
var(--ck-spacing-small); justify-content: flex-start; padding: var(--ck-spa=
cing-small); width: 100%; }

.ck .ck-widget .ck-widget__type-around__button { display: block; overflow: =
hidden; position: absolute; z-index: var(--ck-z-default); }

.ck .ck-widget .ck-widget__type-around__button svg { left: 50%; position: a=
bsolute; top: 50%; z-index: calc(var(--ck-z-default) + 2); }

.ck .ck-widget .ck-widget__type-around__button.ck-widget__type-around__butt=
on_before { left: min(10%, 30px); top: calc(var(--ck-widget-outline-thickne=
ss)*-.5); transform: translateY(-50%); }

.ck .ck-widget .ck-widget__type-around__button.ck-widget__type-around__butt=
on_after { bottom: calc(var(--ck-widget-outline-thickness)*-.5); right: min=
(10%, 30px); transform: translateY(50%); }

.ck .ck-widget.ck-widget_selected > .ck-widget__type-around > .ck-widget__t=
ype-around__button::after, .ck .ck-widget > .ck-widget__type-around > .ck-w=
idget__type-around__button:hover::after { content: ""; display: block; left=
: 1px; position: absolute; top: 1px; z-index: calc(var(--ck-z-default) + 1)=
; }

.ck .ck-widget > .ck-widget__type-around > .ck-widget__type-around__fake-ca=
ret { display: none; left: 0px; position: absolute; right: 0px; }

.ck .ck-widget:hover > .ck-widget__type-around > .ck-widget__type-around__f=
ake-caret { left: calc(var(--ck-widget-outline-thickness)*-1); right: calc(=
var(--ck-widget-outline-thickness)*-1); }

.ck .ck-widget.ck-widget_type-around_show-fake-caret_before > .ck-widget__t=
ype-around > .ck-widget__type-around__fake-caret { display: block; top: cal=
c(var(--ck-widget-outline-thickness)*-1 - 1px); }

.ck .ck-widget.ck-widget_type-around_show-fake-caret_after > .ck-widget__ty=
pe-around > .ck-widget__type-around__fake-caret { bottom: calc(var(--ck-wid=
get-outline-thickness)*-1 - 1px); display: block; }

.ck.ck-editor__editable.ck-read-only .ck-widget__type-around, .ck.ck-editor=
__editable.ck-restricted-editing_mode_restricted .ck-widget__type-around, .=
ck.ck-editor__editable.ck-widget__type-around_disabled .ck-widget__type-aro=
und { display: none; }

:root { --ck-widget-type-around-button-size: 20px; --ck-color-widget-type-a=
round-button-active: var(--ck-color-focus-border); --ck-color-widget-type-a=
round-button-hover: var(--ck-color-widget-hover-border); --ck-color-widget-=
type-around-button-blurred-editable: var(--ck-color-widget-blurred-border);=
 --ck-color-widget-type-around-button-radar-start-alpha: 0; --ck-color-widg=
et-type-around-button-radar-end-alpha: .3; --ck-color-widget-type-around-bu=
tton-icon: var(--ck-color-base-background); }

.ck .ck-widget .ck-widget__type-around__button { background: var(--ck-color=
-widget-type-around-button); border-radius: 100px; height: var(--ck-widget-=
type-around-button-size); opacity: 0; pointer-events: none; transition: opa=
city var(--ck-widget-handler-animation-duration) var(--ck-widget-handler-an=
imation-curve),background var(--ck-widget-handler-animation-duration) var(-=
-ck-widget-handler-animation-curve); width: var(--ck-widget-type-around-but=
ton-size); }

.ck .ck-widget .ck-widget__type-around__button svg { height: 8px; margin-to=
p: 1px; transform: translate(-50%, -50%); transition: transform 0.5s; width=
: 10px; }

.ck .ck-widget .ck-widget__type-around__button svg * { stroke-dasharray: 10=
; stroke-dashoffset: 0; fill: none; stroke: var(--ck-color-widget-type-arou=
nd-button-icon); stroke-width: 1.5px; stroke-linecap: round; stroke-linejoi=
n: round; }

.ck .ck-widget .ck-widget__type-around__button svg line { stroke-dasharray:=
 7; }

.ck .ck-widget .ck-widget__type-around__button:hover { animation: 1s ease 0=
s infinite normal none running ck-widget-type-around-button-sonar; }

.ck .ck-widget .ck-widget__type-around__button:hover svg polyline { animati=
on: 2s linear 0s 1 normal none running ck-widget-type-around-arrow-dash; }

.ck .ck-widget .ck-widget__type-around__button:hover svg line { animation: =
2s linear 0s 1 normal none running ck-widget-type-around-arrow-tip-dash; }

.ck .ck-widget.ck-widget_selected > .ck-widget__type-around > .ck-widget__t=
ype-around__button, .ck .ck-widget:hover > .ck-widget__type-around > .ck-wi=
dget__type-around__button { opacity: 1; pointer-events: auto; }

.ck .ck-widget:not(.ck-widget_selected) > .ck-widget__type-around > .ck-wid=
get__type-around__button { background: var(--ck-color-widget-type-around-bu=
tton-hover); }

.ck .ck-widget.ck-widget_selected > .ck-widget__type-around > .ck-widget__t=
ype-around__button, .ck .ck-widget > .ck-widget__type-around > .ck-widget__=
type-around__button:hover { background: var(--ck-color-widget-type-around-b=
utton-active); }

.ck .ck-widget.ck-widget_selected > .ck-widget__type-around > .ck-widget__t=
ype-around__button::after, .ck .ck-widget > .ck-widget__type-around > .ck-w=
idget__type-around__button:hover::after { background: linear-gradient(135de=
g, rgba(255, 255, 255, 0), rgba(255, 255, 255, 0.3)); border-radius: 100px;=
 height: calc(var(--ck-widget-type-around-button-size) - 2px); width: calc(=
var(--ck-widget-type-around-button-size) - 2px); }

.ck .ck-widget.ck-widget_with-selection-handle > .ck-widget__type-around > =
.ck-widget__type-around__button_before { margin-left: 20px; }

.ck .ck-widget .ck-widget__type-around__fake-caret { animation: 1s linear 0=
s infinite normal forwards running ck-widget-type-around-fake-caret-pulse; =
background: var(--ck-color-base-text); height: 1px; outline: rgba(255, 255,=
 255, 0.5) solid 1px; pointer-events: none; }

.ck .ck-widget.ck-widget_selected.ck-widget_type-around_show-fake-caret_aft=
er, .ck .ck-widget.ck-widget_selected.ck-widget_type-around_show-fake-caret=
_before { outline-color: transparent; }

.ck .ck-widget.ck-widget_type-around_show-fake-caret_after.ck-widget_select=
ed:hover, .ck .ck-widget.ck-widget_type-around_show-fake-caret_before.ck-wi=
dget_selected:hover { outline-color: var(--ck-color-widget-hover-border); }

.ck .ck-widget.ck-widget_type-around_show-fake-caret_after > .ck-widget__ty=
pe-around > .ck-widget__type-around__button, .ck .ck-widget.ck-widget_type-=
around_show-fake-caret_before > .ck-widget__type-around > .ck-widget__type-=
around__button { opacity: 0; pointer-events: none; }

.ck .ck-widget.ck-widget_type-around_show-fake-caret_after.ck-widget_select=
ed.ck-widget_with-resizer > .ck-widget__resizer, .ck .ck-widget.ck-widget_t=
ype-around_show-fake-caret_after.ck-widget_with-selection-handle.ck-widget_=
selected:hover > .ck-widget__selection-handle, .ck .ck-widget.ck-widget_typ=
e-around_show-fake-caret_after.ck-widget_with-selection-handle.ck-widget_se=
lected > .ck-widget__selection-handle, .ck .ck-widget.ck-widget_type-around=
_show-fake-caret_before.ck-widget_selected.ck-widget_with-resizer > .ck-wid=
get__resizer, .ck .ck-widget.ck-widget_type-around_show-fake-caret_before.c=
k-widget_with-selection-handle.ck-widget_selected:hover > .ck-widget__selec=
tion-handle, .ck .ck-widget.ck-widget_type-around_show-fake-caret_before.ck=
-widget_with-selection-handle.ck-widget_selected > .ck-widget__selection-ha=
ndle { opacity: 0; }

.ck[dir=3D"rtl"] .ck-widget.ck-widget_with-selection-handle .ck-widget__typ=
e-around > .ck-widget__type-around__button_before { margin-left: 0px; margi=
n-right: 20px; }

.ck-editor__nested-editable.ck-editor__editable_selected .ck-widget.ck-widg=
et_selected > .ck-widget__type-around > .ck-widget__type-around__button, .c=
k-editor__nested-editable.ck-editor__editable_selected .ck-widget:hover > .=
ck-widget__type-around > .ck-widget__type-around__button { opacity: 0; poin=
ter-events: none; }

.ck-editor__editable.ck-blurred .ck-widget.ck-widget_selected > .ck-widget_=
_type-around > .ck-widget__type-around__button:not(:hover) { background: va=
r(--ck-color-widget-type-around-button-blurred-editable); }

.ck-editor__editable.ck-blurred .ck-widget.ck-widget_selected > .ck-widget_=
_type-around > .ck-widget__type-around__button:not(:hover) svg * { stroke: =
rgb(153, 153, 153); }

@keyframes ck-widget-type-around-arrow-dash {=20
  0% { stroke-dashoffset: 10; }
  20%, 100% { stroke-dashoffset: 0; }
}

@keyframes ck-widget-type-around-arrow-tip-dash {=20
  0%, 20% { stroke-dashoffset: 7; }
  40%, 100% { stroke-dashoffset: 0; }
}

@keyframes ck-widget-type-around-button-sonar {=20
  0% { box-shadow: 0 0 0 0 hsla(var(--ck-color-focus-border-coordinates),va=
r(--ck-color-widget-type-around-button-radar-start-alpha)); }
  50% { box-shadow: 0 0 0 5px hsla(var(--ck-color-focus-border-coordinates)=
,var(--ck-color-widget-type-around-button-radar-end-alpha)); }
  100% { box-shadow: 0 0 0 5px hsla(var(--ck-color-focus-border-coordinates=
),var(--ck-color-widget-type-around-button-radar-start-alpha)); }
}

@keyframes ck-widget-type-around-fake-caret-pulse {=20
  0% { opacity: 1; }
  49% { opacity: 1; }
  50% { opacity: 0; }
  99% { opacity: 0; }
  100% { opacity: 1; }
}

:root { --ck-color-resizer: var(--ck-color-focus-border); --ck-color-resize=
r-tooltip-background: #262626; --ck-color-resizer-tooltip-text: #f2f2f2; --=
ck-resizer-border-radius: var(--ck-border-radius); --ck-resizer-tooltip-off=
set: 10px; --ck-resizer-tooltip-height: calc(var(--ck-spacing-small)*2 + 10=
px); }

.ck .ck-widget, .ck .ck-widget.ck-widget_with-selection-handle { position: =
relative; }

.ck .ck-widget.ck-widget_with-selection-handle .ck-widget__selection-handle=
 { position: absolute; }

.ck .ck-widget.ck-widget_with-selection-handle .ck-widget__selection-handle=
 .ck-icon { display: block; }

.ck .ck-widget.ck-widget_with-selection-handle.ck-widget_selected > .ck-wid=
get__selection-handle, .ck .ck-widget.ck-widget_with-selection-handle:hover=
 > .ck-widget__selection-handle { visibility: visible; }

.ck .ck-size-view { background: var(--ck-color-resizer-tooltip-background);=
 border: 1px solid var(--ck-color-resizer-tooltip-text); border-radius: var=
(--ck-resizer-border-radius); color: var(--ck-color-resizer-tooltip-text); =
display: block; font-size: var(--ck-font-size-tiny); height: var(--ck-resiz=
er-tooltip-height); line-height: var(--ck-resizer-tooltip-height); padding:=
 0 var(--ck-spacing-small); }

.ck .ck-size-view.ck-orientation-above-center, .ck .ck-size-view.ck-orienta=
tion-bottom-left, .ck .ck-size-view.ck-orientation-bottom-right, .ck .ck-si=
ze-view.ck-orientation-top-left, .ck .ck-size-view.ck-orientation-top-right=
 { position: absolute; }

.ck .ck-size-view.ck-orientation-top-left { left: var(--ck-resizer-tooltip-=
offset); top: var(--ck-resizer-tooltip-offset); }

.ck .ck-size-view.ck-orientation-top-right { right: var(--ck-resizer-toolti=
p-offset); top: var(--ck-resizer-tooltip-offset); }

.ck .ck-size-view.ck-orientation-bottom-right { bottom: var(--ck-resizer-to=
oltip-offset); right: var(--ck-resizer-tooltip-offset); }

.ck .ck-size-view.ck-orientation-bottom-left { bottom: var(--ck-resizer-too=
ltip-offset); left: var(--ck-resizer-tooltip-offset); }

.ck .ck-size-view.ck-orientation-above-center { left: 50%; top: calc(var(--=
ck-resizer-tooltip-height)*-1); transform: translate(-50%); }

:root { --ck-widget-outline-thickness: 3px; --ck-widget-handler-icon-size: =
16px; --ck-widget-handler-animation-duration: 200ms; --ck-widget-handler-an=
imation-curve: ease; --ck-color-widget-blurred-border: #dedede; --ck-color-=
widget-hover-border: #ffc83d; --ck-color-widget-editable-focus-background: =
var(--ck-color-base-background); --ck-color-widget-drag-handler-icon-color:=
 var(--ck-color-base-background); }

.ck .ck-widget { outline-color: transparent; outline-style: solid; outline-=
width: var(--ck-widget-outline-thickness); transition: outline-color var(--=
ck-widget-handler-animation-duration) var(--ck-widget-handler-animation-cur=
ve); }

.ck .ck-widget.ck-widget_selected, .ck .ck-widget.ck-widget_selected:hover =
{ outline: var(--ck-widget-outline-thickness) solid var(--ck-color-focus-bo=
rder); }

.ck .ck-widget:hover { outline-color: var(--ck-color-widget-hover-border); =
}

.ck .ck-editor__nested-editable { border: 1px solid transparent; }

.ck .ck-editor__nested-editable.ck-editor__nested-editable_focused, .ck .ck=
-editor__nested-editable:focus { background-color: var(--ck-color-widget-ed=
itable-focus-background); border: var(--ck-focus-ring); box-shadow: var(--c=
k-inner-shadow),0 0; outline: none; }

.ck .ck-widget.ck-widget_with-selection-handle .ck-widget__selection-handle=
 { background-color: transparent; border-radius: var(--ck-border-radius) va=
r(--ck-border-radius) 0 0; box-sizing: border-box; left: calc(0px - var(--c=
k-widget-outline-thickness)); opacity: 0; padding: 4px; top: 0px; transform=
: translateY(-100%); transition: background-color var(--ck-widget-handler-a=
nimation-duration) var(--ck-widget-handler-animation-curve),visibility var(=
--ck-widget-handler-animation-duration) var(--ck-widget-handler-animation-c=
urve),opacity var(--ck-widget-handler-animation-duration) var(--ck-widget-h=
andler-animation-curve); }

.ck .ck-widget.ck-widget_with-selection-handle .ck-widget__selection-handle=
 .ck-icon { color: var(--ck-color-widget-drag-handler-icon-color); height: =
var(--ck-widget-handler-icon-size); width: var(--ck-widget-handler-icon-siz=
e); }

.ck .ck-widget.ck-widget_with-selection-handle .ck-widget__selection-handle=
 .ck-icon .ck-icon__selected-indicator { opacity: 0; transition: opacity .3=
s var(--ck-widget-handler-animation-curve); }

.ck .ck-widget.ck-widget_with-selection-handle .ck-widget__selection-handle=
:hover .ck-icon .ck-icon__selected-indicator { opacity: 1; }

.ck .ck-widget.ck-widget_with-selection-handle:hover > .ck-widget__selectio=
n-handle { background-color: var(--ck-color-widget-hover-border); opacity: =
1; }

.ck .ck-widget.ck-widget_with-selection-handle.ck-widget_selected:hover > .=
ck-widget__selection-handle, .ck .ck-widget.ck-widget_with-selection-handle=
.ck-widget_selected > .ck-widget__selection-handle { background-color: var(=
--ck-color-focus-border); opacity: 1; }

.ck .ck-widget.ck-widget_with-selection-handle.ck-widget_selected:hover > .=
ck-widget__selection-handle .ck-icon .ck-icon__selected-indicator, .ck .ck-=
widget.ck-widget_with-selection-handle.ck-widget_selected > .ck-widget__sel=
ection-handle .ck-icon .ck-icon__selected-indicator { opacity: 1; }

.ck[dir=3D"rtl"] .ck-widget.ck-widget_with-selection-handle .ck-widget__sel=
ection-handle { left: auto; right: calc(0px - var(--ck-widget-outline-thick=
ness)); }

.ck.ck-editor__editable.ck-read-only .ck-widget { transition: none; }

.ck.ck-editor__editable.ck-read-only .ck-widget:not(.ck-widget_selected) { =
--ck-widget-outline-thickness: 0px; }

.ck.ck-editor__editable.ck-read-only .ck-widget.ck-widget_with-selection-ha=
ndle .ck-widget__selection-handle, .ck.ck-editor__editable.ck-read-only .ck=
-widget.ck-widget_with-selection-handle .ck-widget__selection-handle:hover =
{ background: var(--ck-color-widget-blurred-border); }

.ck.ck-editor__editable.ck-blurred .ck-widget.ck-widget_selected, .ck.ck-ed=
itor__editable.ck-blurred .ck-widget.ck-widget_selected:hover { outline-col=
or: var(--ck-color-widget-blurred-border); }

.ck.ck-editor__editable.ck-blurred .ck-widget.ck-widget_selected.ck-widget_=
with-selection-handle:hover > .ck-widget__selection-handle, .ck.ck-editor__=
editable.ck-blurred .ck-widget.ck-widget_selected.ck-widget_with-selection-=
handle:hover > .ck-widget__selection-handle:hover, .ck.ck-editor__editable.=
ck-blurred .ck-widget.ck-widget_selected.ck-widget_with-selection-handle > =
.ck-widget__selection-handle, .ck.ck-editor__editable.ck-blurred .ck-widget=
.ck-widget_selected.ck-widget_with-selection-handle > .ck-widget__selection=
-handle:hover { background: var(--ck-color-widget-blurred-border); }

.ck.ck-editor__editable blockquote > .ck-widget.ck-widget_with-selection-ha=
ndle:first-child, .ck.ck-editor__editable > .ck-widget.ck-widget_with-selec=
tion-handle:first-child { margin-top: calc(1em + var(--ck-widget-handler-ic=
on-size)); }

.ck .ck-widget_with-resizer { position: relative; }

.ck .ck-widget__resizer { display: none; left: 0px; pointer-events: none; p=
osition: absolute; top: 0px; }

.ck-focused .ck-widget_with-resizer.ck-widget_selected > .ck-widget__resize=
r { display: block; }

.ck .ck-widget__resizer__handle { pointer-events: all; position: absolute; =
}

.ck .ck-widget__resizer__handle.ck-widget__resizer__handle-bottom-right, .c=
k .ck-widget__resizer__handle.ck-widget__resizer__handle-top-left { cursor:=
 nwse-resize; }

.ck .ck-widget__resizer__handle.ck-widget__resizer__handle-bottom-left, .ck=
 .ck-widget__resizer__handle.ck-widget__resizer__handle-top-right { cursor:=
 nesw-resize; }

:root { --ck-resizer-size: 10px; --ck-resizer-offset: calc(var(--ck-resizer=
-size)/-2 - 2px); --ck-resizer-border-width: 1px; }

.ck .ck-widget__resizer { outline: 1px solid var(--ck-color-resizer); }

.ck .ck-widget__resizer__handle { background: var(--ck-color-focus-border);=
 border: var(--ck-resizer-border-width) solid #fff; border-radius: var(--ck=
-resizer-border-radius); height: var(--ck-resizer-size); width: var(--ck-re=
sizer-size); }

.ck .ck-widget__resizer__handle.ck-widget__resizer__handle-top-left { left:=
 var(--ck-resizer-offset); top: var(--ck-resizer-offset); }

.ck .ck-widget__resizer__handle.ck-widget__resizer__handle-top-right { righ=
t: var(--ck-resizer-offset); top: var(--ck-resizer-offset); }

.ck .ck-widget__resizer__handle.ck-widget__resizer__handle-bottom-right { b=
ottom: var(--ck-resizer-offset); right: var(--ck-resizer-offset); }

.ck .ck-widget__resizer__handle.ck-widget__resizer__handle-bottom-left { bo=
ttom: var(--ck-resizer-offset); left: var(--ck-resizer-offset); }

.ck.ck-editor__editable .ck.ck-clipboard-drop-target-position { display: in=
line; pointer-events: none; position: relative; }

.ck.ck-editor__editable .ck.ck-clipboard-drop-target-position span { positi=
on: absolute; width: 0px; }

.ck.ck-editor__editable .ck-widget:-webkit-drag > .ck-widget__selection-han=
dle, .ck.ck-editor__editable .ck-widget:-webkit-drag > .ck-widget__type-aro=
und { display: none; }

.ck.ck-clipboard-drop-target-line { pointer-events: none; position: absolut=
e; }

:root { --ck-clipboard-drop-target-dot-width: 12px; --ck-clipboard-drop-tar=
get-dot-height: 8px; --ck-clipboard-drop-target-color: var(--ck-color-focus=
-border); }

.ck.ck-editor__editable .ck.ck-clipboard-drop-target-position span { backgr=
ound: var(--ck-clipboard-drop-target-color); border: 1px solid var(--ck-cli=
pboard-drop-target-color); bottom: calc(var(--ck-clipboard-drop-target-dot-=
height)*-.5); margin-left: -1px; top: calc(var(--ck-clipboard-drop-target-d=
ot-height)*-.5); }

.ck.ck-editor__editable .ck.ck-clipboard-drop-target-position span::after {=
 border-color: var(--ck-clipboard-drop-target-color) transparent transparen=
t transparent; border-style: solid; border-width: calc(var(--ck-clipboard-d=
rop-target-dot-height)) calc(var(--ck-clipboard-drop-target-dot-width)*.5) =
0 calc(var(--ck-clipboard-drop-target-dot-width)*.5); content: ""; display:=
 block; height: 0px; left: 50%; position: absolute; top: calc(var(--ck-clip=
board-drop-target-dot-height)*-.5); transform: translateX(-50%); width: 0px=
; }

.ck.ck-editor__editable .ck-widget.ck-clipboard-drop-target-range { outline=
: var(--ck-widget-outline-thickness) solid var(--ck-clipboard-drop-target-c=
olor) !important; }

.ck.ck-editor__editable .ck-widget:-webkit-drag { zoom: 0.6; outline: none =
!important; }

.ck.ck-clipboard-drop-target-line { background: var(--ck-clipboard-drop-tar=
get-color); border: 1px solid var(--ck-clipboard-drop-target-color); height=
: 0px; margin-top: -1px; }

.ck.ck-clipboard-drop-target-line::before { border-style: solid; content: "=
"; height: 0px; position: absolute; top: calc(var(--ck-clipboard-drop-targe=
t-dot-width)*-.5); width: 0px; }

[dir=3D"ltr"] .ck.ck-clipboard-drop-target-line::before { border-color: tra=
nsparent transparent transparent var(--ck-clipboard-drop-target-color); bor=
der-width: calc(var(--ck-clipboard-drop-target-dot-width)*.5) 0 calc(var(--=
ck-clipboard-drop-target-dot-width)*.5) var(--ck-clipboard-drop-target-dot-=
height); left: -1px; }

[dir=3D"rtl"] .ck.ck-clipboard-drop-target-line::before { border-color: tra=
nsparent var(--ck-clipboard-drop-target-color) transparent transparent; bor=
der-width: calc(var(--ck-clipboard-drop-target-dot-width)*.5) var(--ck-clip=
board-drop-target-dot-height) calc(var(--ck-clipboard-drop-target-dot-width=
)*.5) 0; right: -1px; }
------MultipartBoundary--OyEh8n7b4Lw6tzistt7cxFCRw1zMtvVQlXOUlVtdJx------
